sentence_id,doc_id,section,sent_index,text,start_char,end_char
med:pmid:40689605:sec:title:sent:0,med:pmid:40689605,title,0,Angiotensin-neprilysin inhibition in acute decompensated heart failure: a meta-analysis of randomized controlled trials.,0,120
med:pmid:40689605:sec:introduction:sent:1,med:pmid:40689605,introduction,1,Angiotensin receptor - neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction.,0,155
med:pmid:40689605:sec:introduction:sent:2,med:pmid:40689605,introduction,2,"However, their efficacy and safety after stabilization of acute decompensation (ADHF) remain unclear.",156,257
med:pmid:40689605:sec:introduction:sent:3,med:pmid:40689605,introduction,3,This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF.,258,398
med:pmid:40689605:sec:methods:sent:4,med:pmid:40689605,methods,4,"Meta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, WOS, Embase, and CENTRAL up to November 2024.",399,535
med:pmid:40689605:sec:methods:sent:5,med:pmid:40689605,methods,5,Risk ratios (RR) and standardized mean differences (SMD) with 95% confidence intervals (CI) were used.,536,638
med:pmid:40689605:sec:results:sent:6,med:pmid:40689605,results,6,"Three RCTs (1,741 patients) were included.",639,698
med:pmid:40689605:sec:results:sent:7,med:pmid:40689605,results,7,"ARNI use after ADHF stabilization significantly reduced HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57-0.88; <i>p</i> < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57-0.93; <i>p</i> = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64-1.00; <i>p</i> = 0.048), and NT-proBNP at 4 weeks (SMD: -0.24; 95% CI: -0.34 to -0.14; <i>p</i> < 0.0001) and 8 weeks (SMD: -0.21; 95% CI: -0.31 to -0.10; <i>p</i> = 0.0001).",699,1136
med:pmid:40689605:sec:results:sent:8,med:pmid:40689605,results,8,"However, ARNI increased symptomatic hypotension risk (RR: 1.33; 95% CI: 1.04-1.71; <i>p</i> = 0.024).",1137,1238
med:pmid:40689605:sec:conclusion:sent:9,med:pmid:40689605,conclusion,9,"initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.",1239,1424
med:pmid:40689605:sec:conclusion:sent:10,med:pmid:40689605,conclusion,10,<h4>Protocol registration</h4> PROSPERO: CRD42024618027.,1425,1481
med:pmid:40101251:sec:title:sent:0,med:pmid:40101251,title,0,Heart Health Hub virtual care program for newly diagnosed heart failure patients.,0,81
med:pmid:40101251:sec:introduction:sent:1,med:pmid:40101251,introduction,1,The Heart Health Hub (HHH) is a virtual model of care for patients with newly diagnosed heart failure.,0,112
med:pmid:40101251:sec:introduction:sent:2,med:pmid:40101251,introduction,2,A program pilot commenced in April 2020 and aimed to achieve acceptable titration rates for heart failure medications while improving patient access to services.,113,274
med:pmid:40101251:sec:introduction:sent:3,med:pmid:40101251,introduction,3,"This study aimed to investigate whether the virtual HHH service could deliver feasible, safe and acceptable titration outcomes.",275,402
med:pmid:40101251:sec:methods:sent:4,med:pmid:40101251,methods,4,A single-arm observational cohort study design was adopted.,402,468
med:pmid:40101251:sec:methods:sent:5,med:pmid:40101251,methods,5,Eligible heart failure patients currently receiving care could consent to be enrolled in the pilot virtual HHH program based on pre-defined inclusion and exclusion criteria.,469,642
med:pmid:40101251:sec:results:sent:6,med:pmid:40101251,results,6,"on patient demographics, clinical characteristics and heart failure medication titration rates were obtained from routine health system databases and patient notes.",643,812
med:pmid:40101251:sec:results:sent:7,med:pmid:40101251,results,7,Patient satisfaction data were collected using a Likert-scale questionnaire.,813,889
med:pmid:40101251:sec:results:sent:8,med:pmid:40101251,results,8,Overall health service use and costs for each patient were obtained from health system databases for a period of 12 months following enrolment in the virtual HHH program.,890,1060
med:pmid:40101251:sec:results:sent:9,med:pmid:40101251,results,9,A total of 89 heart failure patients were included in the evaluation.,1060,1136
med:pmid:40101251:sec:results:sent:10,med:pmid:40101251,results,10,"Of these, 95% reached titration to either guideline-recommended target doses or maximum tolerated doses for both angiotensin-converting enzyme inhibitor/angiotensin receptor blockers/angiotensin and angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and beta-blockers combined.",1137,1421
med:pmid:40101251:sec:results:sent:11,med:pmid:40101251,results,11,"The mean number of days to achieve titration ranged from 20.2 days for mineralocorticoid receptor antagonist drugs, between 27.5 to 32.3 days for ACEI/ARB/ARNI drugs and 41.0 days for beta-blockers; 70 (79%) patients completed the satisfaction survey at least once, with more than 98% of survey questions receiving a positive response.",1422,1757
med:pmid:40101251:sec:results:sent:12,med:pmid:40101251,results,12,"The average monthly equipment and consumables cost per patient was $277 in year 2021/22.ConclusionThis study provides evidence that a virtual model of care for newly diagnosed heart failure patients was feasible, safe and acceptable, with high titration rates, relatively rapid times to titration, strong patient satisfaction outcomes and relatively low equipment costs.",1758,2128
med:pmid:41455057:sec:title:sent:0,med:pmid:41455057,title,0,A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA.,0,129
med:pmid:41455057:sec:abstract:sent:1,med:pmid:41455057,abstract,1,"The renin-angiotensin system (RAS) plays a pivotal role in the pathophysiology of several conditions such as hypertension, heart failure and chronic kidney disease.",0,164
med:pmid:41455057:sec:abstract:sent:2,med:pmid:41455057,abstract,2,"In the last fifty years different therapeutic strategies, including angiotensin converting enzyme inhibitors (ACEi), type 1 angiotensin II receptor blockers (ARBs) and angiotensin receptor neprilysin inhibitors (ARNi), have been developed to counteract this neurohormonal dysregulation.",165,451
med:pmid:41455057:sec:abstract:sent:3,med:pmid:41455057,abstract,3,"However, all these therapeutic strategies have a relatively short-term action and they need to be administered orally once or more times every day to achieve the therapeutic purposes with a risk of poor therapeutic adherence.",452,677
med:pmid:41455057:sec:abstract:sent:4,med:pmid:41455057,abstract,4,"More recently, the search for a new effective strategy to provide a long-term control of hypertension was recently boosted by the availability of novel technologies, such as the angiotensinogen suppression in the liver realized through the silencing of RNA with zilebesiran, a small interfering RNA (siRNA) agent.",677,990
med:pmid:41455057:sec:abstract:sent:5,med:pmid:41455057,abstract,5,The purpose of this article is to review the available data on Zilebesiran and to discuss in detail potential advantages in the clinical use as well as the still unresolved potential risks.,990,1179
med:pmid:41408894:sec:title:sent:0,med:pmid:41408894,title,0,Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry.,0,112
med:pmid:41408894:sec:introduction:sent:1,med:pmid:41408894,introduction,1,"Despite guideline recommendations, guideline-directed medical therapy (GDMT) remains underused and underdosed in patients with heart failure (HF) across the ejection fraction (EF) spectrum.",0,203
med:pmid:41408894:sec:introduction:sent:2,med:pmid:41408894,introduction,2,"The aim of this study was to evaluate GDMT use, dosing, and implementation in a contemporary, nationwide HF cohort.",204,319
med:pmid:41408894:sec:results:sent:3,med:pmid:41408894,results,3,"The OPTIPHARM-HF (NCT06192524) is a prospective, multicentre, observational study enrolling adult patients with HF, across 32 Italian HF centres.",320,494
med:pmid:41408894:sec:results:sent:4,med:pmid:41408894,results,4,"Clinical characteristics, medical therapy prevalence and change after first visit have been assessed in patients with reduced (HFrEF: EF ≤40%), mildly reduced (HFmrEF: EF 40-49%), and preserved EF (HFpEF: EF ≥50%).",495,709
med:pmid:41408894:sec:results:sent:5,med:pmid:41408894,results,5,"From September 2022 to December 2024, 3054 patients (mean age 69 ± 12 years, 25% female) were enrolled: 56% with HFrEF, 21% with HFmrEF, and 23% with HFpEF.",710,866
med:pmid:41408894:sec:results:sent:6,med:pmid:41408894,results,6,"Among HFrEF, prescription frequencies were: 90% for beta-blockers; 19% for angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB); 61% for angiotensin receptor-neprilysin inhibitors (ARNI); 72% for mineralocorticoid receptor antagonists (MRA); and 69% for sodium-glucose co-transporter 2 inhibitors (SGLT2i).",867,1207
med:pmid:41408894:sec:results:sent:7,med:pmid:41408894,results,7,Less than 60% achieved ≥50% of target doses.,1208,1252
med:pmid:41408894:sec:results:sent:8,med:pmid:41408894,results,8,Quadruple therapy was received by 47% of the patients.,1253,1307
med:pmid:41408894:sec:results:sent:9,med:pmid:41408894,results,9,"After first visit, there was an increase in prescription of all classes of drugs, and titration to quadruple therapy was attained in 64% (p < 0.001).",1308,1457
med:pmid:41408894:sec:results:sent:10,med:pmid:41408894,results,10,"Among HFmrEF, 88% were on beta-blockers, 34% on ACEi/ARB, 49% on ARNI, 63% on MRA, and 59% on SGLT2i.",1458,1559
med:pmid:41408894:sec:results:sent:11,med:pmid:41408894,results,11,"In the HFpEF group, 76% were on beta-blockers, 49% on ACEi/ARB, 18% on ARNI, 49% on MRA and 40% on SGLT2i.",1560,1666
med:pmid:41408894:sec:results:sent:12,med:pmid:41408894,results,12,"After the first visit, SGLT2i prescription significantly increased both in HFmrEF (74%, p < 0.001) and HFpEF (54%, p < 0.001).",1667,1793
med:pmid:41408894:sec:conclusion:sent:13,med:pmid:41408894,conclusion,13,Use of GDMT remains suboptimal across the EF spectrum although the adoption of quadruple GDMT in HFrEF and of SGLT2i in HFmrEF and HFpEF increased in recent years.,1794,1978
med:pmid:41379379:sec:title:sent:0,med:pmid:41379379,title,0,Victoria and Victor: event-driven lessons for integrating vericiguat into practice and reducing residual risk in HFrEF.,0,119
med:pmid:41379379:sec:abstract:sent:1,med:pmid:41379379,abstract,1,"Chronic heart failure with reduced ejection fraction (HFrEF) is a progressive syndrome associated with substantial residual morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT) - angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) [1].",0,472
med:pmid:41379379:sec:abstract:sent:2,med:pmid:41379379,abstract,2,"Consequently, the need for novel therapeutic strategies has led to the exploration of new drug classes and pathways.",473,589
med:pmid:41379379:sec:abstract:sent:3,med:pmid:41379379,abstract,3,"In HF, impaired nitric-oxide (NO) signaling, reduced soluble guanylate cyclase (sGC) responsiveness/abundance, and downstream attenuation of cyclic guanosine monophosphate (cGMP) contribute to disease progression [2].",590,807
med:pmid:41379379:sec:abstract:sent:4,med:pmid:41379379,abstract,4,"Vericiguat-an oral sGC stimulator-sensitizes sGC to endogenous NO and directly stimulates the enzyme, thereby restoring cGMP signaling in vascular smooth muscle and cardiomyocytes.",808,988
med:pmid:40910162:sec:title:sent:0,med:pmid:40910162,title,0,Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction.,0,89
med:pmid:40910162:sec:introduction:sent:1,med:pmid:40910162,introduction,1,"Although the effects of various combinations of treatments on mortality and morbidity outcomes in heart failure with reduced ejection fraction (HFrEF) have been evaluated, the impact on quality of life is unknown.",0,233
med:pmid:40910162:sec:introduction:sent:2,med:pmid:40910162,introduction,2,This study evaluated and compared the composite impact of pharmacological therapies on quality of life in HFrEF using a frequentist network meta-analysis and systematic review methodology.,234,422
med:pmid:40910162:sec:methods:sent:3,med:pmid:40910162,methods,3,"We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials for randomized controlled trials published between January 1, 2021 and August 10, 2024.",423,607
med:pmid:40910162:sec:methods:sent:4,med:pmid:40910162,methods,4,We included all contemporary and efficacious HFrEF therapies used in adults.,608,684
med:pmid:40910162:sec:methods:sent:5,med:pmid:40910162,methods,5,"The primary outcome was change in quality of life measured through the Kansas City Cardiomyopathy Questionnaire and the Minnesota Living with Heart Failure Questionnaire, expressed as mean difference (MD).",685,890
med:pmid:40910162:sec:results:sent:6,med:pmid:40910162,results,6,We identified 41 randomized controlled trials representing 41 145 patients (76.5% male).,891,996
med:pmid:40910162:sec:results:sent:7,med:pmid:40910162,results,7,"The trials had a median of 276 participants (105-464), a mean left ventricular ejection fraction of 28%, and a median follow-up time of 5 months (3-8).",997,1148
med:pmid:40910162:sec:results:sent:8,med:pmid:40910162,results,8,"A combination of angiotensin receptor blocker/neprilysin inhibitors (ARNi)+β-blockers (BB)+sodium-glucose cotransporter 2 inhibitors (SGLT2i; MD, +5.3 [+0.4, +10.3]) was the most effective at improving quality of life followed by ARNi+BB+mineralocorticoid receptor antagonists (MRA)+SGLT2i (MD, +7.1 [-1.0 to +15.2]), ACE inhibitor+BB+MRA+SGLT2i (MD, +5.3 [-2.6, to +13.3]), and ACE inhibitor+BB+MRA+ivabradine (MD, +5.2 [-3.1 to +13.6]), which were not statistically significant.",1149,1629
med:pmid:40910162:sec:results:sent:9,med:pmid:40910162,results,9,"Individually, the most effective treatments for improving quality of life were SGLT2i (MD, +3.4 [+1.4 to +5.30]), ivabradine (MD, +3.3 [+0.1 to +6.4]), ARNi (MD, +2.6 [-3.2 to +8.5]), and MRA (MD, +1.8 [-4.8 to +8.4]).",1630,1848
med:pmid:40910162:sec:conclusion:sent:10,med:pmid:40910162,conclusion,10,A composite of ARNi+BB+SGLT2i or ARNi+BB+MRA+SGLT2i was the most effective at improving quality of life in patients with HFrEF.,1849,1997
med:pmid:40105368:sec:title:sent:0,med:pmid:40105368,title,0,OPTIHEART: determinants and prognostic importance of optimal medical treatment in patients with heart failure with reduced ejection fraction discharged from a heart failure clinic from 2018 to 2020.,0,198
med:pmid:40105368:sec:introduction:sent:1,med:pmid:40105368,introduction,1,Heart failure (HF) is an increasing health problem globally.,0,80
med:pmid:40105368:sec:introduction:sent:2,med:pmid:40105368,introduction,2,"Profound sex-related differences have been observed regarding the cause, treatment, and prognosis of HF.",81,185
med:pmid:40105368:sec:introduction:sent:3,med:pmid:40105368,introduction,3,To assess baseline predictors for achieving optimal medical treatment (OMT) and the prognostic importance of OMT for male and female patients who have attended a HF clinical program (HFCP).,186,388
med:pmid:40105368:sec:methods:sent:4,med:pmid:40105368,methods,4,"OPTIHEART was a retrospective study that included 870 consecutive patients with left ventricular ejection fraction (LVEF)≤40% discharged from HFCP in 2018, 2019 or 2020 and followed in registers for a mean of 1083(SD 11.3) days.",389,634
med:pmid:40105368:sec:methods:sent:5,med:pmid:40105368,methods,5,"OMT was defined as receiving an angiotensin-converting-enzyme-inhibitor (ACEi), angiotensin-receptor blocker (ARB) or angiotensin-II-receptor blocker and nephrylisin-inhibitor (ARNI) AND a betablocker (BB) both in doses ≥ 50% of target doses.",635,877
med:pmid:40105368:sec:results:sent:6,med:pmid:40105368,results,6,"Achieving OMT was associated with male sex (OR: 2.05 95%CI 1.44-2.97; <i>p</i> < 0.0001) independently of younger age, higher diastolic blood pressure (DBP), and lower creatinine.",878,1074
med:pmid:40105368:sec:results:sent:7,med:pmid:40105368,results,7,"A lower rate of 5-point MACE was associated with achieved OMT (HR: 0.67 95%CI 0.50-0.90; <i>p</i> = 0.007) independently of female sex (HR: 0.64 95%CI 0.48-0.84; <i>p</i> = 0.002), younger age, never smoking and NYHA ≤ 2.",1075,1296
med:pmid:40105368:sec:results:sent:8,med:pmid:40105368,results,8,"The beneficial effect of OMT was insignificantly more pronounced in patients with male sex, older age, higher creatinine, lower DBP, and body mass index ≤25kg/m<sup>2</sup>.",1297,1470
med:pmid:40105368:sec:conclusion:sent:9,med:pmid:40105368,conclusion,9,"OMT was more frequently achieved in patients with male sex independently of age, DBP, and creatinine.",1471,1592
med:pmid:40105368:sec:conclusion:sent:10,med:pmid:40105368,conclusion,10,"Achieving OMT was associated with less 5-point MACE independently of female sex, younger age, never smoking and NYHA ≤ 2.",1593,1714
med:pmid:39687932:sec:title:sent:0,med:pmid:39687932,title,0,"Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction.",0,155
med:pmid:39687932:sec:introduction:sent:1,med:pmid:39687932,introduction,1,Much remains to be learned about patients with heart failure with improved ejection fraction (HFimpEF).,0,123
med:pmid:39687932:sec:introduction:sent:2,med:pmid:39687932,introduction,2,"This study sheds light on the characteristics and clinical outcomes of HFimpEF patients, including the consequences of halting guideline-directed medical therapy (GDMT).",124,312
med:pmid:39687932:sec:methods:sent:3,med:pmid:39687932,methods,3,This retrospective study was conducted on patients diagnosed with heart failure with reduced ejection fraction (HFrEF) who underwent a second echocardiogram at least 6 months apart between January 2009 and February 2023.,313,550
med:pmid:39687932:sec:methods:sent:4,med:pmid:39687932,methods,4,"The primary outcomes were major adverse cardiovascular events (MACEs), including all-cause mortality and heart failure hospitalization.",551,686
med:pmid:39687932:sec:methods:sent:5,med:pmid:39687932,methods,5,The second outcome was recurrent HFrEF.,687,726
med:pmid:39687932:sec:results:sent:6,med:pmid:39687932,results,6,"Of 4,560 HFrEF patients were included, 3,289 (72.1%) achieved HFimpEF within a median follow-up period of 3.4 years (IQR: 1.8 - 5.9 years).",727,883
med:pmid:39687932:sec:results:sent:7,med:pmid:39687932,results,7,"Among these HFimpEF patients, recurrent HFrEF was observed in 941 (28.6%) patients during a median follow-up period of 2.3 years (IQR: 0.8-4.6 years).",884,1034
med:pmid:39687932:sec:results:sent:8,med:pmid:39687932,results,8,"The proportion of patients who halted GDMT was 70.4%, 53.2%, 59.8% and 63.8% for MRA, beta-blockers, ACEI/ARB/ARNI and SGLT-2 inhibitors.",1035,1172
med:pmid:39687932:sec:results:sent:9,med:pmid:39687932,results,9,"Multivariable Cox analysis revealed ischemic heart disease, chronic kidney disease, coronary heart disease, lower left ventricular ejection fraction, larger left ventricular diastolic dimension and non-use GDMT are associated with recurrent HFrEF.",1173,1420
med:pmid:39687932:sec:results:sent:10,med:pmid:39687932,results,10,Individuals without GDMT use exhibited lower chances of persistently recovering ejection fraction and high risks of MACEs compared to those who continue use.,1421,1578
med:pmid:39687932:sec:conclusion:sent:11,med:pmid:39687932,conclusion,11,HFimpEF is a common condition across all clinical follow-ups.,1579,1661
med:pmid:39687932:sec:conclusion:sent:12,med:pmid:39687932,conclusion,12,"Prevalent discontinuation of GDMT medications may contribute significantly to recurrent HFrEF, placing patients at a higher risk for poor prognosis.",1662,1810
med:pmid:41377094:sec:title:sent:0,med:pmid:41377094,title,0,Impact of socio-demographic and ethnic determinants in guideline-directed medical therapy implementation during heart failure hospitalization.,0,142
med:pmid:41377094:sec:introduction:sent:1,med:pmid:41377094,introduction,1,To assess for the first time the impact of socio-demographic variables on prescription of guideline-directed medical therapy (GDMT) after an episode of heart failure (HF) decompensation in the Italian healthcare system.,0,233
med:pmid:41377094:sec:results:sent:2,med:pmid:41377094,results,2,"Utilizing 'GENERATOR-HF DataMart', a cross-sectional analysis was performed.",234,339
med:pmid:41377094:sec:results:sent:3,med:pmid:41377094,results,3,We included patients with HF and reduced ejection fraction discharged between January 2019 and July 2024.,340,445
med:pmid:41377094:sec:results:sent:4,med:pmid:41377094,results,4,"The degree of GDMT implementation across the different socio-demographic variables (i.e. patient's age, sex, marital status, nationality, place of residence, and educational level) was evaluated through the modified optimal medical therapy (mOMT) score (i.e. a ratio between the number of pillars actually prescribed and the number of pillars that could be prescribed on the basis of each specific contraindication).",446,862
med:pmid:41377094:sec:results:sent:5,med:pmid:41377094,results,5,A multivariable logistic regression model was also fitted to assess the association between the socio-demographic variables and the prescription of each pillar and loop diuretics.,863,1042
med:pmid:41377094:sec:results:sent:6,med:pmid:41377094,results,6,1730 patients (median age: 72 years; 24% females) were included.,1043,1107
med:pmid:41377094:sec:results:sent:7,med:pmid:41377094,results,7,"The mOMT score was significantly lower in elderly patients, but comparable across other pre-specified socio-demographic categories.",1108,1239
med:pmid:41377094:sec:results:sent:8,med:pmid:41377094,results,8,"In multivariable regression analysis, older age was the only independent socio-demographic predictor of under-prescription both overall and for ACEi/ARB/ARNI (OR0.70; 95% CI 0.55-0.89), beta-blockers (OR0.59; 95% CI 0.41-0.84) and SGLT2i (OR0.66, 95% CI 0.47-0.93), while also associated with a loop diuretics use (OR1.56; 95% CI 1.13-2.17).",1240,1581
med:pmid:41377094:sec:results:sent:9,med:pmid:41377094,results,9,A higher mOMT score was significantly associated with a reduced incidence of early adverse events (i.e. 30-day all-cause death and urgent re-admissions) (4.1% vs. 8.5%; <i>P</i> = 0.001).,1582,1769
med:pmid:41377094:sec:conclusion:sent:10,med:pmid:41377094,conclusion,10,"Older age was the only independent predictor of under-prescription of GDMT and enhanced use of loop diuretics, whereas no discrepancies were found across the other socio-demographic subgroups.",1770,1982
med:pmid:41303015:sec:title:sent:0,med:pmid:41303015,title,0,Assessment of Pharmacotherapy Modifications During the Treatment of Episodes of Acutely Decompensated Heart Failure: The HEROES Study.,0,134
med:pmid:41303015:sec:introduction:sent:1,med:pmid:41303015,introduction,1,</b> Urgent hospitalization due to acutely decompensated heart failure (ADHF) is an unfavorable event in the trajectory of this disease.,0,161
med:pmid:41303015:sec:introduction:sent:2,med:pmid:41303015,introduction,2,Patient condition during decompensation frequently limits opportunities to implement and optimize guideline-directed medical therapy (GDMT).,162,302
med:pmid:41303015:sec:introduction:sent:3,med:pmid:41303015,introduction,3,"To define the tasks of post-hospital care, it is essential to gain knowledge regarding the extent of GDMT implementation on the day of discharge after ADHF episodes.",303,468
med:pmid:41303015:sec:introduction:sent:4,med:pmid:41303015,introduction,4,"The purpose of this analisis was to evaluate GDMT changes during hospitalization due to ADHF, with a particular emphasis on patients with reduced ejection fraction.",469,633
med:pmid:41303015:sec:introduction:sent:5,med:pmid:41303015,introduction,5,<b>Methods:</b> The analysis was conducted in a group of 262 patients hospitalized due to ADHF and with known left ventricular ejection fraction (LVEF).,634,786
med:pmid:41303015:sec:introduction:sent:6,med:pmid:41303015,introduction,6,"The HEROES study was a prospective, multi-center, observational study.",787,857
med:pmid:41303015:sec:introduction:sent:7,med:pmid:41303015,introduction,7,"<b>Results:</b> The mean age in the study group (196 men and 66 women) was 67.6 ± 14.6 years, with a mean LVEF of 33.9 ± 14.8%.",858,985
med:pmid:41303015:sec:introduction:sent:8,med:pmid:41303015,introduction,8,Six patients died during hospitalization.,986,1027
med:pmid:41303015:sec:introduction:sent:9,med:pmid:41303015,introduction,9,"In the analysis for the whole group (regardless of ejection fraction [EF]), ARNI (angiotensin receptor-neprilysin inhibitor)/ACEI (angiotensin-converting enzyme inhibitor)/ARB (angiotensin receptor blocker) use increased from 63.3% of the subjects at admission to 81.3% at discharge, beta-blocker use increased from 70.6% to 92.6%, MRA (mineralocorticoid receptor antagonist) use increased from 43.1% to 75.8%, and SGLT2i (sodium-glucose co-transporter 2 inhibitor) use increased from 30.1% to 75.0%.",1028,1528
med:pmid:41303015:sec:introduction:sent:10,med:pmid:41303015,introduction,10,"ARNI/ACEI/ARB therapy was optimized in 48.4% of the subjects, with optimization rates of 37.9%, 40.2%, and 44.1% for beta-blockers, MRAs, and SGLT2is, respectively.",1529,1693
med:pmid:41303015:sec:introduction:sent:11,med:pmid:41303015,introduction,11,"However, only 38 (22.0%) patients reached the level of treatment corresponding to ""SGLT2i and ARNI/ACEI/ARB and betablocker and MRA in doses ≥ 50%"".",1694,1842
med:pmid:41303015:sec:introduction:sent:12,med:pmid:41303015,introduction,12,"<b>Conclusions:</b> In patients hospitalized due to ADHF in the HEROES study, the use of GDMT at discharge was significantly higher than at admission.",1843,1993
med:pmid:41303015:sec:introduction:sent:13,med:pmid:41303015,introduction,13,"In patients with reduced ejection fraction, GDMTs from all drug classes were prescribed to over 80% of patients.",1994,2106
med:pmid:41303015:sec:introduction:sent:14,med:pmid:41303015,introduction,14,"However, an insufficient number of patients attained high doses of GDMT, which emphasizes the need for effective dose up-titration in outpatient settings.",2107,2261
med:pmid:41296625:sec:title:sent:0,med:pmid:41296625,title,0,Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis.,0,110
med:pmid:41296625:sec:introduction:sent:1,med:pmid:41296625,introduction,1,Transthyretin cardiac amyloidosis (ATTR-CA) typically manifests with heart failure.,0,103
med:pmid:41296625:sec:introduction:sent:2,med:pmid:41296625,introduction,2,Discontinuing beta-blockers and avoiding angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) in patients with ATTR-CA has been recommended.,104,273
med:pmid:41296625:sec:methods:sent:3,med:pmid:41296625,methods,3,We investigated the prescription of neurohormonal therapies and their relationship with all-cause mortality in a multicenter cohort.,274,423
med:pmid:41296625:sec:results:sent:4,med:pmid:41296625,results,4,"Patients (n = 926) had a median age of 79 years (interquartile range 74-83), 90% were men, 17% had a left ventricular ejection fraction (LVEF) 40% or less, and 27% were in New York Heart Association (NYHA) class III/IV.",424,660
med:pmid:41296625:sec:results:sent:5,med:pmid:41296625,results,5,"At diagnosis, 60% of patients were on beta-blockers, 58% on ACEi/ARB/ARNI, and 35% on MRA.",661,751
med:pmid:41296625:sec:results:sent:6,med:pmid:41296625,results,6,"Patients on beta-blockers had more often NYHA class III/IV, a greater burden of comorbidities, and lower LVEF, and those on ACEi/ARB/ARNI had more comorbidities.",752,913
med:pmid:41296625:sec:results:sent:7,med:pmid:41296625,results,7,"Nonetheless, the survival of patients on beta-blockers or ACEi/ARB/ARNI was not significantly shorter over a 2.5-year follow-up (1.6-3.8) (P = 0.577 and P = 0.977, respectively), and patients on both drugs did not have a worse outcome than those not receiving any neurohormonal drug (P = 0.575).",914,1209
med:pmid:41296625:sec:results:sent:8,med:pmid:41296625,results,8,"During the entire follow-up, the number of neurohormonal drugs remained unchanged in 54%, decreased in 27%, and increased in 19%.",1210,1339
med:pmid:41296625:sec:results:sent:9,med:pmid:41296625,results,9,"Patients with a number of neurohormonal drugs either unchanged or increased had a lower risk of mortality (odds ratio 0.71, 95% confidence interval 0.53-0.95, P = 0.023).",1340,1510
med:pmid:41296625:sec:conclusion:sent:10,med:pmid:41296625,conclusion,10,ATTRwt-CA patients on beta-blockers or ACEi/ARB/ARNI at diagnosis did not have a shorter survival.,1511,1629
med:pmid:41296625:sec:conclusion:sent:11,med:pmid:41296625,conclusion,11,Beta-blockers were discontinued less often than were ACEi/ARB/ARNI.,1630,1697
med:pmid:41296625:sec:conclusion:sent:12,med:pmid:41296625,conclusion,12,"There was no sign of better outcomes in patients discontinuing these therapies, or worse outcomes in those starting them.",1698,1819
med:pmid:41287294:sec:title:sent:0,med:pmid:41287294,title,0,[The influence of two-way referral model on treatment and prognosis of patients with chronic heart failure].,0,108
med:pmid:41287294:sec:abstract:sent:1,med:pmid:41287294,abstract,1,<b>Objective:</b> To explore the impact of the two-way referral model on compliance and prognosis in patients with heart failure.,0,129
med:pmid:41287294:sec:abstract:sent:2,med:pmid:41287294,abstract,2,<b>Methods:</b> This bidirectional cohort study enrolled chronic heart failure (CHF) patients treated at Qilu Hospital of Shandong University or designated primary hospitals between March 2018 and March 2022.,130,338
med:pmid:41287294:sec:abstract:sent:3,med:pmid:41287294,abstract,3,Patients were categorized into two groups based on referral status: two-way referral group (participating in the referral model with≥1 follow-up visit at primary hospitals) and the core hospital group (receiving treatment and follow-up exclusively at Qilu Hospital).,339,605
med:pmid:41287294:sec:abstract:sent:4,med:pmid:41287294,abstract,4,Baseline clinical characteristics were collected and compared between groups.,606,683
med:pmid:41287294:sec:abstract:sent:5,med:pmid:41287294,abstract,5,"Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate.",684,1055
med:pmid:41287294:sec:abstract:sent:6,med:pmid:41287294,abstract,6,"Secondary endpoints encompassed changes from baseline in left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDd), and N-terminal pro-brain natriuretic peptide (NT-proBNP), plus cardiovascular mortality and heart failure rehospitalization.",1056,1329
med:pmid:41287294:sec:abstract:sent:7,med:pmid:41287294,abstract,7,"Generalized linear mixed models analyzed longitudinal trends in LVEF, LVEDd, and NT-proBNP levels.",1330,1428
med:pmid:41287294:sec:abstract:sent:8,med:pmid:41287294,abstract,8,"Kaplan-Meier curves and Cox regression evaluated LVEF recovery rates, supplemented by subgroup analyses.",1429,1533
med:pmid:41287294:sec:abstract:sent:9,med:pmid:41287294,abstract,9,Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients.,1534,1696
med:pmid:41287294:sec:abstract:sent:10,med:pmid:41287294,abstract,10,"<b>Results:</b> A total of 357 patients were enrolled, aged 53 (41, 63) years, including 256 males (71.7%).",1697,1804
med:pmid:41287294:sec:abstract:sent:11,med:pmid:41287294,abstract,11,157 patients were in the two-way referral group and 200 patients in the core hospital-treated group.,1805,1905
med:pmid:41287294:sec:abstract:sent:12,med:pmid:41287294,abstract,12,"Compared with the core hospital-treated group, the two-way referral group had lower baseline LVEF (28 (22, 34)% vs. 31 (23, 36)%, <i>P</i>=0.021) and systolic blood pressure (116 (104, 125) mmHg vs. 121 (109, 134) mmHg (1 mmHg=0.133 kPa), <i>P</i>=0.010).",1906,2161
med:pmid:41287294:sec:abstract:sent:13,med:pmid:41287294,abstract,13,"The 12-month follow-up rate of the two-way referral group was higher than the core hospital-treated group (73.8% vs. 56.0%, <i>P</i>=0.004).",2162,2302
med:pmid:41287294:sec:abstract:sent:14,med:pmid:41287294,abstract,14,"No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all <i>P</i>>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups.",2303,2585
med:pmid:41287294:sec:abstract:sent:15,med:pmid:41287294,abstract,15,"Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, <i>P</i>=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, <i>P</i>=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all <i>P</i>>0.05).",2586,2945
med:pmid:41287294:sec:abstract:sent:16,med:pmid:41287294,abstract,16,"Both groups showed improved NT-proBNP, LVEDd, and LVEF from baseline (all <i>P</i><0.001) with no significant difference in trends between groups (all <i>P</i>>0.05).",2946,3112
med:pmid:41287294:sec:abstract:sent:17,med:pmid:41287294,abstract,17,"There was no significant difference in the composite incidence (7.6% vs. 6.5%, <i>P</i>=0.674) and cumulative incidence (log-rank <i>P</i>=0.684) of cardiovascular death and heart failure rehospitalization at 12 months between two groups.",3113,3351
med:pmid:41287294:sec:abstract:sent:18,med:pmid:41287294,abstract,18,"<b>Conclusion:</b> The two-way referral model demonstrates advantages in improving medication adherence, drug utilization rates, and targetdoseachievement rates among CHF patients.",3352,3532
med:pmid:41287294:sec:abstract:sent:19,med:pmid:41287294,abstract,19,"This model not only promotes cardiac functional recovery but also reduces risks of cardiovascular mortality and heart failure rehospitalization, achieving comparable therapeutic and management outcomes to those observed in core hospital-treated patients.",3533,3787
med:pmid:41249923:sec:title:sent:0,med:pmid:41249923,title,0,Effectiveness of quality improvement interventions in improving cardiovascular disease-related outcomes in primary and tertiary care: A systematic review and meta-analyses.,0,172
med:pmid:41249923:sec:introduction:sent:1,med:pmid:41249923,introduction,1,Quality improvement strategies are increasingly being used across all healthcare settings to improve patient outcomes.,0,138
med:pmid:41249923:sec:introduction:sent:2,med:pmid:41249923,introduction,2,"However, the effectiveness of QI interventions in improving the care of cardiovascular (CVD) disease remains unclear.",139,256
med:pmid:41249923:sec:introduction:sent:3,med:pmid:41249923,introduction,3,"More evidence is needed to determine whether QI interventions can improve CVD medication use, manage risk factors, and enhance clinical outcomes.",257,402
med:pmid:41249923:sec:introduction:sent:4,med:pmid:41249923,introduction,4,"Therefore, this study aimed to systematically assess the effectiveness of QI interventions in improving CVD-related outcomes in both primary and tertiary healthcare services.",403,577
med:pmid:41249923:sec:methods:sent:5,med:pmid:41249923,methods,5,"Six databases (Medline, Embase, PsycINFO, CENTRAL, CINAHL, and Scopus) were systematically searched for randomised and cluster randomised controlled trials from inception to 21st January 2025.",578,787
med:pmid:41249923:sec:methods:sent:6,med:pmid:41249923,methods,6,"Studies were included if they were randomised trials, included people with CVD, implemented a QI intervention focused on improving CVD care in either primary care services and hospitals, and measured at least one of the following outcomes: prescribed guideline-recommended CVD medications, risk factors, and clinical events.",788,1112
med:pmid:41249923:sec:methods:sent:7,med:pmid:41249923,methods,7,Three authors independently screened articles and extracted data from eligible studies.,1113,1200
med:pmid:41249923:sec:methods:sent:8,med:pmid:41249923,methods,8,A random-effects model was used to estimate the pooled effects.,1201,1264
med:pmid:41249923:sec:results:sent:9,med:pmid:41249923,results,9,"Eighteen studies involving 438,285 individuals with CVD (72% male, pooled mean age [standard deviation]: 61.7 [12.8]).",1265,1400
med:pmid:41249923:sec:results:sent:10,med:pmid:41249923,results,10,"Commonly identified QI strategies were feedback reports (83%), decision support tools (72%), and QI teams (50%).",1401,1513
med:pmid:41249923:sec:results:sent:11,med:pmid:41249923,results,11,"Meta-analyses showed compared to usual care, QI interventions significantly improved lipid-lowering medications prescriptions (OR: 1.46, [95% CI: 1.08, 1.99]), reduced the rate of major cardiovascular events (MACE) (OR: 0.84, 95% CI: 0.71, 0.98) and total mortality (OR: 0.87, [95% CI: 0.77, 0.98]).",1514,1813
med:pmid:41249923:sec:results:sent:12,med:pmid:41249923,results,12,"Sensitivity analyses excluding one study showed significant improvements in ACEi/ARB/ARNI prescriptions (OR: 1.36, [95% CI: 1.10, 1.69]).",1814,1951
med:pmid:41249923:sec:results:sent:13,med:pmid:41249923,results,13,"Risk of bias analysis demonstrated significant improvements for lipid-lowering medications (OR: 1.63, [95% CI: 1.34, 2.00]), ACE/ARB/ARNI (OR: 1.90, [95% CI: 1.34, 2.71]) and beta-blockers (OR: 1.24, [95% CI:0.95, 1.61]).",1952,2173
med:pmid:41249923:sec:results:sent:14,med:pmid:41249923,results,14,"Subgroup analyses showed significant improvements in ACEi/ARB/ARNI (OR:1.35, [95% CI: 1.03, 1.77)]) and beta-blockers (OR:1.48, [95% CI: 1.31, 1.68)]) prescriptions along with reduced total mortality (OR: 0.86, [95% CI: 0.76, 0.98]) in hospitals.",2174,2420
med:pmid:41249923:sec:results:sent:15,med:pmid:41249923,results,15,"Lipid-lowering medication prescriptions improved in both primary care (OR: 1.58, [95% CI: 1.03, 2.40]) and hospitals (OR: 1.37, [95% CI: 1.08, 1.72]).",2421,2571
med:pmid:41249923:sec:results:sent:16,med:pmid:41249923,results,16,"In another subgroup analyses, shorter follow-up periods were associated with improvement in ACEi/ARB/ARNI (OR:1.38, [95% CI: 1.08, 1.77]), beta-blockers (OR: 1.45, [95% CI: 1.28, 1.61]) prescriptions and total mortality (OR: 0.86, [95% CI: 0.75, 0.99]).",2572,2825
med:pmid:41249923:sec:results:sent:17,med:pmid:41249923,results,17,"Longer follow-ups were more effective in reducing MACE (OR: 0.75, [95% CI: 0.63, 0.90]).",2826,2914
med:pmid:41249923:sec:conclusion:sent:18,med:pmid:41249923,conclusion,18,"QI interventions can effectively improve lipid-lowering medication prescriptions, reduce MACE, and lower total mortality in CVD management.",2915,3074
med:pmid:41249923:sec:methods:sent:19,med:pmid:41249923,methods,19,"are particularly effective in hospital settings and with shorter follow-up periods for medication prescriptions, while longer follow-ups benefit MACE reduction.",3075,3249
med:pmid:41249923:sec:methods:sent:20,med:pmid:41249923,methods,20,"These findings highlight the potential of QI interventions to improve CVD management in both primary care services and hospitals, though tailored QI strategies may be needed for optimal effectiveness.",3250,3450
med:pmid:41249923:sec:methods:sent:21,med:pmid:41249923,methods,21,Further studies are needed to fully evaluate the effectiveness of diverse QI interventions in healthcare.,3451,3556
med:pmid:41249923:sec:methods:sent:22,med:pmid:41249923,methods,22,<h4>Systematic review registration</h4> PROSPERO registration number: CRD42021249907.,3557,3642
med:pmid:41151613:sec:title:sent:0,med:pmid:41151613,title,0,[Heart failure in Germany: epidemiology and recent developments].,0,65
med:pmid:41151613:sec:abstract:sent:1,med:pmid:41151613,abstract,1,"Heart failure is the leading single cause of hospitalisation in Germany and places a heavy clinical and psychosocial burden on patients, families, and caregivers.",0,162
med:pmid:41151613:sec:abstract:sent:2,med:pmid:41151613,abstract,2,"Since 2021, evidence‑based management of heart failure with reduced ejection fraction (HFrEF) has centred on four pharmacological ""pillars"": β‑blockers, sacubitril/valsartan (or an ACE inhibitor), mineralocorticoid‑receptor antagonists, and sodium-glucose co‑transporter‑2 (SGLT‑2) inhibitors.",163,456
med:pmid:41151613:sec:abstract:sent:3,med:pmid:41151613,abstract,3,"While these agents improve survival and quality of life, they also predispose to adverse effects - most notably electrolyte disturbances.",457,594
med:pmid:41151613:sec:abstract:sent:4,med:pmid:41151613,abstract,4,Hypo‑ or hyperkalaemia can precipitate malignant arrhythmias and therefore demands vigilant monitoring.,595,698
med:pmid:41151613:sec:abstract:sent:5,med:pmid:41151613,abstract,5,Iron deficiency is equally prevalent in the heart‑failure population; randomised trials have primarily tested intravenous iron(III)‑carboxymaltose and iron(III)‑derisomaltose to correct this deficit.,699,898
med:pmid:41151613:sec:abstract:sent:6,med:pmid:41151613,abstract,6,"This review summarises the most recent epidemiological data for heart failure in Germany and Europe, outlines current guideline‑directed therapies, and highlights key treatment‑related complications clinicians must anticipate and manage.",899,1136
med:pmid:41084891:sec:title:sent:0,med:pmid:41084891,title,0,Implementation of recommendations regarding pharmacotherapy optimization in patients with heart failure with reduced ejection fraction undergoing scheduled hospitalization: the HEROES study.,0,190
med:pmid:41084891:sec:introduction:sent:1,med:pmid:41084891,introduction,1,Optimization of guideline‑directed medical therapy (GDMT) to improve the prognosis of patients with heart failure (HF) is one of the main goals of chronic care.,0,182
med:pmid:41084891:sec:introduction:sent:2,med:pmid:41084891,introduction,2,"We aimed to assess implementation of the recommendations regarding GDMT optimization in HF patients undergoing scheduled hospitalization, with particular emphasis on the patients with reduced left ventricular ejection fraction (LVEF).",183,437
med:pmid:41084891:sec:methods:sent:3,med:pmid:41084891,methods,3,"Our analysis included 412 patients with known LVEF (mean [SD] age, 66.7 [13.5] y; 297 men) admitted for elective hospitalization, representing a subset of 1422 participants of the HEROES study (Heart Failure Observational Study of the Polish Cardiac Society).",438,727
med:pmid:41084891:sec:methods:sent:4,med:pmid:41084891,methods,4,Recruitment across 41 Polish centers took place from April 2022 to May 2024.,728,804
med:pmid:41084891:sec:results:sent:5,med:pmid:41084891,results,5,Mean (SD) LVEF in the study group was 34.9% (14.4%).,805,874
med:pmid:41084891:sec:results:sent:6,med:pmid:41084891,results,6,The patients with HF with reduced LVEF (HFrEF) constituted 69.7% (n = 287) of the whole group.,875,969
med:pmid:41084891:sec:results:sent:7,med:pmid:41084891,results,7,"In this subgroup, the use of angiotensin receptor‑neprilysin inhibitor (ARNI) / angiotensin‑converting enzyme inhibitor (ACEI) / angiotensin receptor blocker (ARB) increased from 81.5% of the patients at admission to 88.9% at discharge, of β‑blocker from 85% to 94.4%, of mineralocorticoid receptor antagonist (MRA) from 69.7% to 86.1%, and of sodium‑glucose cotransporter 2 inhibitor (SGLT2i) from 59.2% to 83.6%.",970,1384
med:pmid:41084891:sec:results:sent:8,med:pmid:41084891,results,8,"ARNI/ACEI/ARB therapy was optimized in 36.2% of the participants, while the rates of optimization were 24.7%, 27.2%, and 24.4% for β‑blockers, MRA, and SGLT2i, respectively.",1385,1558
med:pmid:41084891:sec:results:sent:9,med:pmid:41084891,results,9,"However, only 64 patients (22.3%) attained the 4‑pillar GDMT of SGLT2i, ARNI/ACEI/ARB, β‑blockers, and MRA at doses equal to or above 50% of the target dose.",1559,1716
med:pmid:41084891:sec:conclusion:sent:10,med:pmid:41084891,conclusion,10,"In the Polish multicenter HEROES registry, over 80% of the patients with HFrEF were discharged on 4‑pillar GDMT.",1717,1850
med:pmid:41084891:sec:conclusion:sent:11,med:pmid:41084891,conclusion,11,"Nevertheless, the attainment of target high‑dose GDMT remained suboptimal.",1851,1925
med:pmid:41084891:sec:conclusion:sent:12,med:pmid:41084891,conclusion,12,These findings provide new insights into the variability of GDMT implementation at the national level and underline the need for strategies to improve dosing optimization.,1926,2097
med:pmid:41016569:sec:title:sent:0,med:pmid:41016569,title,0,Early sacubitril/valsartan therapy reduces ventricular remodeling and cardiac events in patients with acute anterior myocardial infarction.,0,139
med:pmid:41016569:sec:introduction:sent:1,med:pmid:41016569,introduction,1,To compare the effects of early angiotensin receptor-neprilysin inhibitor (ARNI) versus angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy on left ventricular remodeling and heart failure progression in patients with acute anterior wall myocardial infarction.,0,316
med:pmid:41016569:sec:methods:sent:2,med:pmid:41016569,methods,2,Patients were stratified by treatment into ARNI (n = 97) and ACEI/ARB (n = 71) groups.,317,420
med:pmid:41016569:sec:methods:sent:3,med:pmid:41016569,methods,3,"Baseline characteristics, cardiac ultrasound data (baseline, 0-3 months, 6-12 months), and major adverse cardiac events (MACEs) were analyzed.",421,563
med:pmid:41016569:sec:results:sent:4,med:pmid:41016569,results,4,The ARNI group demonstrated significantly greater improvements in left ventricular end-diastolic diameter and relative wall thickness versus the ACEI/ARB group.,564,741
med:pmid:41016569:sec:results:sent:5,med:pmid:41016569,results,5,"Subgroup analyses (target-dose achievers, emergency reperfusion recipients, left ventricular ejection fraction ≥50 % patients) consistently showed better improvements with ARNI.",742,919
med:pmid:41016569:sec:results:sent:6,med:pmid:41016569,results,6,"ARNI therapy also significantly reduced MACEs risk (HR = 0.392, 95 % CI: 0.194-0.791, P = 0.009).",920,1017
med:pmid:41016569:sec:conclusion:sent:7,med:pmid:41016569,conclusion,7,"Compared with ACEI/ARB, ARNI demonstrated enhanced preservation of cardiac function, attenuation of adverse ventricular remodeling, and maintenance of ventricular geometry following myocardial infarction.",1018,1242
med:pmid:41016569:sec:conclusion:sent:8,med:pmid:41016569,conclusion,8,"Additionally, ARNI was associated with a reduction in major adverse cardiac events and improved survival outcomes.",1243,1357
med:pmid:40993994:sec:title:sent:0,med:pmid:40993994,title,0,Contemporary implementation of guideline-directed medical and device therapies in heart failure: Insights from the Central/Eastern Europe Quality of Care Centres Survey.,0,169
med:pmid:40993994:sec:introduction:sent:1,med:pmid:40993994,introduction,1,"The Central/Eastern Europe (CEE) Quality of Care Centres (QCC) Survey evaluated the implementation of guideline-directed medical therapies (GDMT) and device use at discharge after heart failure (HF) hospitalization in CEE, where GDMT underutilization remains a concern.",0,283
med:pmid:40993994:sec:results:sent:2,med:pmid:40993994,results,2,"Between March 2024 and January 2025, 2251 patients (mean age 70.0 years, 60.4% male) were enrolled at discharge from 21 centres across 12 CEE countries.",284,465
med:pmid:40993994:sec:results:sent:3,med:pmid:40993994,results,3,"The patient population included HF with reduced ejection fraction (HFrEF) (55.5%), HF with mildly reduced ejection fraction (15.3%) and HF with preserved ejection fraction (27.9%).",466,646
med:pmid:40993994:sec:results:sent:4,med:pmid:40993994,results,4,"In the total population, from admission to discharge there was a increase in the use of angiotensin receptor-neprilysin inhibitor (ARNI) (17.1% to 34.3%), beta-blockers (69.4% to 92.4%), mineralocorticoid receptor antagonists (MRA) (44.0% to 82.1%) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) (30.8% to 79.9%), with a reduction in angiotensin-converting enzyme inhibitor (ACEI) use (all p < 0.05).",647,1056
med:pmid:40993994:sec:results:sent:5,med:pmid:40993994,results,5,"Similar trends were observed across HF phenotypes, including HFrEF (increased use of ARNI, 26.3% to 55.1%, beta-blockers, 69.8% to 95.3%, MRA 49.5% to 89.0%, and SGLT2I 36.2% to 79.8%, and lower ACEI use, all p < 0.05).",1057,1276
med:pmid:40993994:sec:results:sent:6,med:pmid:40993994,results,6,"At discharge, 53.5% of patients received quadruple therapy (63.9% with HFrEF), while ≥50% target doses of titratable drugs were achieved in 18.8% (17.8% in HFrEF).",1277,1440
med:pmid:40993994:sec:results:sent:7,med:pmid:40993994,results,7,"Predictors of GDMT underuse included older age, lower education, living alone, non-ischaemic HF, higher ejection fraction, chronic kidney disease, hypotension, hyperkalaemia, prolonged hospitalization, and residual oedema.",1441,1663
med:pmid:40993994:sec:results:sent:8,med:pmid:40993994,results,8,"Among eligible HFrEF patients, 21.3% were discharged with, or referred for implantable cardioverter-defibrillator, and 17.4% for cardiac resynchronization therapy.",1664,1827
med:pmid:40993994:sec:conclusion:sent:9,med:pmid:40993994,conclusion,9,"The CEE-QCC Survey highlights substantial in-hospital GDMT implementation and up-titration, though device use remains limited.",1828,1975
med:pmid:40993994:sec:conclusion:sent:10,med:pmid:40993994,conclusion,10,Targeted strategies are needed to enhance guideline implementation and ensure optimal HF care across the CEE region.,1976,2092
med:pmid:40849246:sec:title:sent:0,med:pmid:40849246,title,0,[Translated article] Cost-utility of sacubitril/valsartan in heart failure with reduced ejection fraction in Spain.,0,115
med:pmid:40849246:sec:introduction:sent:1,med:pmid:40849246,introduction,1,"Heart failure is an increasingly common syndrome with a rising prevalence, which associates significant costs, mainly related to hospitalization.",0,167
med:pmid:40849246:sec:introduction:sent:2,med:pmid:40849246,introduction,2,"In fact, heart failure is the most frequent diagnosis in hospital discharges in Spain.",168,254
med:pmid:40849246:sec:introduction:sent:3,med:pmid:40849246,introduction,3,To analyze the economic impact of new treatments for heart failure with reduced ejection fraction such as sacubitril/valsartan in out-patient and in-patient setting.,255,439
med:pmid:40849246:sec:introduction:sent:4,med:pmid:40849246,introduction,4,<h4>Material and methods</h4> The present economic evaluation study was carried out by developing a Markov model.,440,553
med:pmid:40849246:sec:introduction:sent:5,med:pmid:40849246,introduction,5,"Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator.",554,683
med:pmid:40849246:sec:introduction:sent:6,med:pmid:40849246,introduction,6,"Total costs, years of life gained, quality-adjusted life years, and incremental cost-effectiveness ratio and incremental cost-utility ratio were analyzed.",684,838
med:pmid:40849246:sec:results:sent:7,med:pmid:40849246,results,7,were obtained from the PARADIGM-HF and PIONEER-HF studies.,839,902
med:pmid:40849246:sec:results:sent:8,med:pmid:40849246,results,8,"The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost-utility ratio below €20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved.",903,1298
med:pmid:40849246:sec:conclusion:sent:9,med:pmid:40849246,conclusion,9,This study shows that starting sacubitril/valsartan from hospital admission for heart failure is cost-effective from the perspective of the National Health Service in Spain.,1299,1492
med:pmid:40839760:sec:title:sent:0,med:pmid:40839760,title,0,Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.,0,180
med:pmid:40839760:sec:introduction:sent:1,med:pmid:40839760,introduction,1,To investigate the EQ-5D-3L Level Sum Score (LSS) in patients with heart failure (HF) and reduced (HFrEF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and the effect of sacubitril/valsartan on this score using patient-level data from the PARADIGM-HF and PARAGON-HF trials.,0,306
med:pmid:40839760:sec:results:sent:2,med:pmid:40839760,results,2,The LSS was calculated by summing the three levels (1-3) for each of the five domains (minimum sum score = 5; maximum sum score = 15).,307,470
med:pmid:40839760:sec:results:sent:3,med:pmid:40839760,results,3,Patient characteristics and outcomes were compared across LSS tertiles (T1-T3) at baseline.,471,562
med:pmid:40839760:sec:results:sent:4,med:pmid:40839760,results,4,Cox models were used to evaluate the primary endpoint [first HF hospitalization or cardiovascular death (CVD)] according to tertiles of LSS.,563,703
med:pmid:40839760:sec:results:sent:5,med:pmid:40839760,results,5,Changes in LSS severity at 8 months were analysed using ordinal logistic regression models to estimate the effect of sacubitril/valsartan vs. enalapril or valsartan.,704,869
med:pmid:40839760:sec:results:sent:6,med:pmid:40839760,results,6,"Of 13 195 patients, 12 974 had a baseline LSS.",870,916
med:pmid:40839760:sec:results:sent:7,med:pmid:40839760,results,7,"Compared to lower LSS, patients with higher (worse) scores were older, more often women and White, and had more comorbidities and more severe HF.",917,1062
med:pmid:40839760:sec:results:sent:8,med:pmid:40839760,results,8,"At 8 months, patients assigned to sacubitril/valsartan experienced more improvement and less worsening of LSS vs. the comparator: OR:1.16 (95%CI: 1.08-1.24).",1063,1220
med:pmid:40839760:sec:results:sent:9,med:pmid:40839760,results,9,Sacubitril/valsartan also reduced the risk of the primary outcome across LSS tertiles: T1: HR: 0.87 (95%CI: 0.75-1.00); T2: 0.80 (95%CI: 0.71-0.90); T3: 0.87 (95%CI: 0.77-0.97); Pinteraction = 0.59.,1221,1419
med:pmid:40839760:sec:results:sent:10,med:pmid:40839760,results,10,"Higher LSS was independently associated with a greater risk of the primary endpoint, and the achieved LSS at 8 months may be more strongly associated with subsequent outcomes.",1420,1595
med:pmid:40839760:sec:conclusion:sent:11,med:pmid:40839760,conclusion,11,Sacubitril/valsartan significantly reduced the risk of HF events and improved health status across the LSS spectrum in HFrEF and HFmrEF/HFpEF.,1596,1758
med:pmid:40839760:sec:conclusion:sent:12,med:pmid:40839760,conclusion,12,<h4>Clinical trial registration</h4> https://www.clinicaltrials.gov.,1759,1827
med:pmid:40839760:sec:conclusion:sent:13,med:pmid:40839760,conclusion,13,"Unique identifiers: NCT01920711 (PARAGON-HF), NCT01035255 (PARADIGM-HF).",1828,1900
med:pmid:40788620:sec:title:sent:0,med:pmid:40788620,title,0,Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registry.,0,100
med:pmid:40788620:sec:introduction:sent:1,med:pmid:40788620,introduction,1,Patients with heart failure (HF) at high risk for hyperkalaemia are underrepresented in prospective HF registries.,0,128
med:pmid:40788620:sec:introduction:sent:2,med:pmid:40788620,introduction,2,"The CARE-HK in HF registry sought to characterize prospectively the clinical profile, management, and outcomes for patients with HF at high risk of hyperkalaemia.",129,291
med:pmid:40788620:sec:results:sent:3,med:pmid:40788620,results,3,CARE-HK in HF was a multinational prospective registry of outpatients with HF (regardless of left ventricular ejection fraction [LVEF]) treated with an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and either receiving or potential candidate for a mineralocorticoid receptor antagonist (MRA).,292,697
med:pmid:40788620:sec:results:sent:4,med:pmid:40788620,results,4,"All patients were at increased risk of hyperkalaemia, defined as hyperkalaemia at baseline, prior hyperkalaemia, or estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m<sup>2</sup>.",698,888
med:pmid:40788620:sec:results:sent:5,med:pmid:40788620,results,5,"included frequency of hyperkalaemic events (defined by clinician report with associated potassium value), achievement of renin-angiotensin system inhibitor (RASi) optimization (defined as ≥50% target doses for ACEI/ARB/ARNI and MRA), medication changes following hyperkalaemic episodes, and clinical events.",889,1205
med:pmid:40788620:sec:results:sent:6,med:pmid:40788620,results,6,"Overall, 2558 patients from 111 sites across nine countries were included.",1206,1280
med:pmid:40788620:sec:results:sent:7,med:pmid:40788620,results,7,"Median (25th-75th) age was 73 (65-80) years, 32% were women, 61% had LVEF ≤40%, and 40% had prior laboratory evidence of hyperkalaemia.",1281,1416
med:pmid:40788620:sec:results:sent:8,med:pmid:40788620,results,8,"Median baseline eGFR and serum potassium were 44 (33-60) ml/min/1.73 m<sup>2</sup> and 5.0 (4.4-5.3) mEq/L, respectively.",1417,1538
med:pmid:40788620:sec:results:sent:9,med:pmid:40788620,results,9,"Over a median follow-up of 12.3 (9.4-18.1) months, 29% of patients had a hyperkalaemic event, and 7% had multiple events.",1539,1660
med:pmid:40788620:sec:results:sent:10,med:pmid:40788620,results,10,"In characterizing treatment prescribed for most of follow-up, 29% of patients received optimal RASi/MRA therapy, 69% received suboptimal RASi/MRA therapy, and 3% received no RASi/MRA.",1661,1844
med:pmid:40788620:sec:results:sent:11,med:pmid:40788620,results,11,"In the 30 days following the first hyperkalaemic event, RASi/MRA was down-titrated or discontinued in 3.6% of cases.",1845,1961
med:pmid:40788620:sec:results:sent:12,med:pmid:40788620,results,12,"Potassium binder use was low (patiromer 9.1%, sodium zirconium cyclosilicate 5.9%).",1962,2045
med:pmid:40788620:sec:results:sent:13,med:pmid:40788620,results,13,"Compared with patients without a hyperkalaemic event, patients experiencing a hyperkalaemic event had similar risk of all-cause mortality (hazard ratio [HR] 1.22, 95% confidence interval [CI] 0.92-1.62, p = 0.16) and a higher risk of subsequent hospitalization (HR 1.59, 95% CI 1.35-1.86, p < 0.001).",2046,2346
med:pmid:40788620:sec:conclusion:sent:14,med:pmid:40788620,conclusion,14,"In this contemporary multinational prospective registry of patients with HF at high risk for hyperkalaemia, hyperkalaemic events were common but infrequently associated with RASi/MRA modification or potassium binder use.",2347,2588
med:pmid:40788620:sec:conclusion:sent:15,med:pmid:40788620,conclusion,15,"Fewer than one in three patients received optimal RASi/MRA therapy for the majority of follow-up, and hyperkalaemic events were associated with higher risk of adverse clinical outcomes.",2589,2774
med:pmid:40788620:sec:conclusion:sent:16,med:pmid:40788620,conclusion,16,<h4>Clinical trial registration</h4> ClinicalTrials.gov NCT04864795.,2775,2843
med:pmid:41136931:sec:title:sent:0,med:pmid:41136931,title,0,Evaluation of prescribing adherence to guideline-directed medical therapy in patients with chronic heart failure: a retrospective study at the National Heart Centre in Oman.,0,173
med:pmid:41136931:sec:introduction:sent:1,med:pmid:41136931,introduction,1,Guideline-directed medical therapy (GDMT) improves survival and quality of life in patients with heart failure with reduced ejection fraction (HFrEF).,0,170
med:pmid:41136931:sec:introduction:sent:2,med:pmid:41136931,introduction,2,"However, real-world adherence to these guidelines remains suboptimal.",171,240
med:pmid:41136931:sec:introduction:sent:3,med:pmid:41136931,introduction,3,This study aimed to evaluate prescribing adherence to GDMT in HFrEF patients using a global guideline adherence scoring tool.,241,366
med:pmid:41136931:sec:methods:sent:4,med:pmid:41136931,methods,4,This retrospective study included adult patients with HFrEF (left ventricular ejection fraction ≤ 40%) attending the Heart Failure Clinic at the National Heart Centre in Oman between January and June 2022.,367,589
med:pmid:41136931:sec:methods:sent:5,med:pmid:41136931,methods,5,GDMT adherence was assessed based on 2021 European Society of Cardiology guidelines.,590,674
med:pmid:41136931:sec:methods:sent:6,med:pmid:41136931,methods,6,"Adherence levels were categorized as good (all indicated GDMT at ≥ 50% of target dose), moderate (more than half at ≥ 50%), or poor (less than half or < 50%).",675,833
med:pmid:41136931:sec:methods:sent:7,med:pmid:41136931,methods,7,Descriptive statistics and chi-square tests were used to identify associations.,834,913
med:pmid:41136931:sec:results:sent:8,med:pmid:41136931,results,8,"Of the 259 patients included (mean age 57 ± 13.6 years, 70% male), 71% had good adherence, 22% moderate, and 7% poor.",914,1048
med:pmid:41136931:sec:results:sent:9,med:pmid:41136931,results,9,"Target dose attainment varied by drug class: 78% for beta-blockers, 63% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine.",1049,1178
med:pmid:41136931:sec:results:sent:10,med:pmid:41136931,results,10,"Suboptimal GDMT (< 50% target dose) was significantly associated with hypertension (P = 0.004), dilated cardiomyopathy (P = 0.015), chronic kidney disease (P = 0.001), and older age (P = 0.004).",1179,1373
med:pmid:41136931:sec:conclusion:sent:11,med:pmid:41136931,conclusion,11,Prescribing adherence to GDMT in Oman is consistent with international data.,1374,1470
med:pmid:41136931:sec:conclusion:sent:12,med:pmid:41136931,conclusion,12,"Suboptimal titration was significantly linked to older age and comorbidities, suggesting that perceived frailty and clinical complexity may influence physician prescribing patterns.",1471,1652
med:pmid:41136931:sec:conclusion:sent:13,med:pmid:41136931,conclusion,13,"Efforts to improve individualized, patient-centered GDMT titration are warranted.",1653,1734
med:pmid:40769236:sec:title:sent:0,med:pmid:40769236,title,0,"Metabolic syndrome, ischemic heart disease, and heart failure: insights from the Colombian Heart Failure Registry (RECOLFACA).",0,126
med:pmid:40769236:sec:introduction:sent:1,med:pmid:40769236,introduction,1,"Ischemic heart disease (IHD) is still a leading cause of morbidity and mortality worldwide, with major implications for healthcare systems, especially in low- and middle-income countries.",0,207
med:pmid:40769236:sec:introduction:sent:2,med:pmid:40769236,introduction,2,"Effective metabolic control and risk factor management, including evidence-based pharmacological therapies such as statins, ACE inhibitors (ACEIs), and angiotensin receptor-neprilysin inhibitors (ARNIs), are essential for reducing adverse outcomes.",208,456
med:pmid:40769236:sec:introduction:sent:3,med:pmid:40769236,introduction,3,"However, gaps persist in the implementation of these therapies, particularly in resource-limited regions.",457,562
med:pmid:40769236:sec:introduction:sent:4,med:pmid:40769236,introduction,4,"To evaluate metabolic control and the use of evidence-based therapies in patients with IHD enrolled in the Colombian Heart Failure Registry (RECOLFACA), and to identify barriers to optimal treatment implementation.",563,796
med:pmid:40769236:sec:methods:sent:5,med:pmid:40769236,methods,5,"This cross-sectional study analyzed demographic, clinical, and biochemical data, as well as medication usage, from patients with confirmed IHD.",797,957
med:pmid:40769236:sec:methods:sent:6,med:pmid:40769236,methods,6,Descriptive and inferential statistical analyses were performed to identify treatment patterns and associated factors.,958,1076
med:pmid:40769236:sec:results:sent:7,med:pmid:40769236,results,7,"Among 2,528 patients with heart failure (HF), 1,123 had IHD.",1077,1154
med:pmid:40769236:sec:results:sent:8,med:pmid:40769236,results,8,"Statins were prescribed to 73.6% (827), antiplatelets to 66.3% (745), and ARNIs to only 10.1% (114), despite guideline recommendations.",1155,1290
med:pmid:40769236:sec:results:sent:9,med:pmid:40769236,results,9,"Statin use was notably low among patients with chronic kidney disease (CKD) (18.1%), diabetes mellitus type 2 (15.8%), and both conditions combined (3.2%).",1291,1446
med:pmid:40769236:sec:conclusion:sent:10,med:pmid:40769236,conclusion,10,"Despite robust evidence supporting their efficacy, the use of statins, ACEIs, and ARNIs remains suboptimal in Colombia.",1447,1587
med:pmid:40769236:sec:conclusion:sent:11,med:pmid:40769236,conclusion,11,"Addressing barriers to access, adherence, and healthcare delivery is crucial to improve outcomes and align clinical practices with international standards.",1588,1743
med:pmid:40769236:sec:conclusion:sent:12,med:pmid:40769236,conclusion,12,These findings highlight the need for targeted interventions and future studies to evaluate strategies that enhance access to and adherence with guideline-directed therapies.,1744,1918
med:pmid:40679772:sec:title:sent:0,med:pmid:40679772,title,0,Comparative effectiveness of the Beers Criteria (2023) versus the STOPP (v3) in detecting potentially inappropriate medications in older adults with heart failure: a retrospective cross-sectional study.,0,202
med:pmid:40679772:sec:introduction:sent:1,med:pmid:40679772,introduction,1,The American Geriatrics Society (AGS) Beers Criteria and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP)/Screening Tool to Alert to Right Treatment (START) criteria are extensively utilized in identifying potentially inappropriate medications (PIMs) among older adults.,0,324
med:pmid:40679772:sec:introduction:sent:2,med:pmid:40679772,introduction,2,"Older adults with heart failure (HF) confront the dual challenge of polypharmacy and inadequate adherence to evidence-based medications, which further complicates their medication management and clinical outcomes.",325,538
med:pmid:40679772:sec:introduction:sent:3,med:pmid:40679772,introduction,3,To assess the effectiveness of the AGS Beers (2023) Criteria and the STOPP (v3) criteria in identifying PIMs among older adults with HF and to analyze patterns of polypharmacy and evidence-based medications.,539,759
med:pmid:40679772:sec:introduction:sent:4,med:pmid:40679772,introduction,4,"<h4>Method</h4> This retrospective study was conducted at a tertiary academic medical center in China and involved 1578 outpatients aged ≥ 65 years with HF who received at least one outpatient prescription between January 1 and December 31, 2023.",760,1006
med:pmid:40679772:sec:results:sent:5,med:pmid:40679772,results,5,"on demographics, comorbidities, and prescribed medications were extracted from the hospital's electronic medical record (EMR) system.",1007,1145
med:pmid:40679772:sec:results:sent:6,med:pmid:40679772,results,6,PIMs were identified with the AGS Beers (2023) Criteria and the STOPP (v3) criteria.,1146,1230
med:pmid:40679772:sec:results:sent:7,med:pmid:40679772,results,7,The data were analyzed using descriptive statistics in Microsoft Excel.,1231,1302
med:pmid:40679772:sec:results:sent:8,med:pmid:40679772,results,8,"Polypharmacy and hyperpolypharmacy were prevalent among the patients, affecting 65.3% and 15.7% of the cohort, respectively.",1303,1444
med:pmid:40679772:sec:results:sent:9,med:pmid:40679772,results,9,"PIMs were identified in 75.5% of patients (1192/1578), with a total of 2128 PIM cases observed according to the Beers Criteria, with the most common PIM being rivaroxaban (32.3%).",1445,1624
med:pmid:40679772:sec:results:sent:10,med:pmid:40679772,results,10,"The STOPP (v3) criteria identified PIMs in 28.9% of patients (n = 471), with the most frequent PIMs being statin use in frail patients aged ≥ 85 years (26.8%) and prolonged use of proton-pump inhibitors (16.6%).",1625,1836
med:pmid:40679772:sec:results:sent:11,med:pmid:40679772,results,11,"Among all patients in our study, 61.6% received either an angiotensin-converting enzyme inhibitor, angiotensin-II receptor blocker, or angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI); 57.0% were prescribed β-blockers; and 32.6% used a sodium-glucose cotransporter 2 inhibitor.",1837,2123
med:pmid:40679772:sec:conclusion:sent:12,med:pmid:40679772,conclusion,12,"While the Beers Criteria identified a greater number of PIMs in this study, both tools have differing strengths in detecting medication-related risks.",2124,2294
med:pmid:40679772:sec:conclusion:sent:13,med:pmid:40679772,conclusion,13,Their combined use may provide a more holistic assessment of prescribing appropriateness.,2295,2384
med:pmid:40679772:sec:conclusion:sent:14,med:pmid:40679772,conclusion,14,"The widespread use of PIMs in older adults with HF, coupled with the frequent underuse of beneficial therapies, calls for systematic interventions.",2385,2532
med:pmid:40679772:sec:conclusion:sent:15,med:pmid:40679772,conclusion,15,"Pharmacist-led interventions and electronic decision-support systems that integrate evidence-based prescribing, deprescribing, and regular medication reviews are crucial for optimizing therapeutic outcomes in older adults with HF.",2533,2763
med:pmid:40470816:sec:title:sent:0,med:pmid:40470816,title,0,Cardiac resynchronization therapy for enabling guideline-directed medical therapy optimization in heart failure.,0,112
med:pmid:40470816:sec:introduction:sent:1,med:pmid:40470816,introduction,1,We aimed to assess whether cardiac resynchronization therapy (CRT) might serve as an enabler for guideline-directed medical therapy (GDMT) optimization.,0,166
med:pmid:40470816:sec:results:sent:2,med:pmid:40470816,results,2,Patients with heart failure with reduced ejection fraction (HFrEF) enrolled in the Swedish Heart Failure Registry between January 2009 and August 2022 were considered.,167,363
med:pmid:40470816:sec:results:sent:3,med:pmid:40470816,results,3,"Patients receiving a CRT close to the index registration were the cases, whereas controls had not received a CRT despite having an indication.",364,506
med:pmid:40470816:sec:results:sent:4,med:pmid:40470816,results,4,"Overall, 1543 (25%) HFrEF cases and 4537 (75%) controls were analysed in the intention-to-treat analysis.",507,612
med:pmid:40470816:sec:results:sent:5,med:pmid:40470816,results,5,"At baseline, beta-blockers, angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNi), mineralocorticoid receptor antagonist (MRA) and loop diuretic use was 84% versus 86%, 89% versus 88%, 57% versus 46% and 62% versus 59% in patients receiving versus not receiving CRT, respectively.",613,974
med:pmid:40470816:sec:results:sent:6,med:pmid:40470816,results,6,"At 1.5-year follow-up, patients receiving a CRT more likely experienced an improved use/dose of beta-blocker therapy (46% vs. 35%) and decreased loop diuretic use/dose (30% vs. 24%) versus controls.",975,1173
med:pmid:40470816:sec:results:sent:7,med:pmid:40470816,results,7,"These associations were consistent after adjustments (odds ratio [OR] 1.83, 95% confidence interval [CI] 1.58-2.13, and OR 1.26, 95% CI 1.07-1.48, respectively), and confirmed in the per-protocol analysis (i.e. after excluding controls who received a CRT during follow-up).",1174,1447
med:pmid:40470816:sec:results:sent:8,med:pmid:40470816,results,8,"A significant association between CRT and the likelihood of ACEi/ARB/ARNi and MRA optimization (OR 1.22, 95% CI 1.04-1.44, and OR 1.25, 95% CI 1.05-1.50, respectively) was observed in the per-protocol analysis.",1448,1658
med:pmid:40470816:sec:conclusion:sent:9,med:pmid:40470816,conclusion,9,"In this large nationwide real-world population with HFrEF, CRT implantation was associated with enabled use/dose of heart failure GDMT and decreased loop diuretic need (use/dose).",1659,1859
med:pmid:41070303:sec:title:sent:0,med:pmid:41070303,title,0,The efficacy and safety of left bundle branch pacing combined with sacubitril/valsartan or enalapril in the treatment of elderly coronary heart disease with chronic heart failure.,0,179
med:pmid:41070303:sec:introduction:sent:1,med:pmid:41070303,introduction,1,Left bundle branch pacing (LBBP) is the best alternative to biventricular pacing (BiVP) and cardiac resynchronization therapy (CRT).,0,151
med:pmid:41070303:sec:introduction:sent:2,med:pmid:41070303,introduction,2,This study compares the efficacy and safety of LBBP combined with sacubitril/valsartan and LBBP combined with enalapril in treating elderly coronary heart disease (CHD) patients with chronic heart failure (CHF).,152,363
med:pmid:41070303:sec:methods:sent:3,med:pmid:41070303,methods,3,This retrospective observational study included clinical records of elderly CHD patients with CHF who received LBBP treatment at The Affiliated Hospital of Northwest University from January 2022 to August 2024.,364,595
med:pmid:41070303:sec:methods:sent:4,med:pmid:41070303,methods,4,"Based on the postoperative treatment regimen, patients were divided into the LBBP & sacubitril/valsartan and the LBBP & enalapril groups.",596,733
med:pmid:41070303:sec:methods:sent:5,med:pmid:41070303,methods,5,"Levels of left ventricular end diastolic diameter (LVEDd), left ventricular ejection fraction (LVEF), QRS duration, N-terminal B-type natriuretic peptide precursor (NT proBNP), soluble growth stimulating gene 2 protein (sSt2), matrix metalloproteinase-9 (MMP-9) and the occurrence of adverse events were compared between two groups before and after treatment.",734,1093
med:pmid:41070303:sec:results:sent:6,med:pmid:41070303,results,6,A total of 111 patients met the inclusion criteria.,1094,1162
med:pmid:41070303:sec:results:sent:7,med:pmid:41070303,results,7,"Of them, 53 patients comprised the LBBP & sacubitril/valsartan group and 58 patients comprised the LBBP & enalapril group.",1163,1285
med:pmid:41070303:sec:results:sent:8,med:pmid:41070303,results,8,"After treatment, levels of LVEDd, LVEF, NT proBNP, sSt2 and MMP-9 in the LBBP & sacubitril/valsartan group were significantly improved compared to those in the LBBP & enalapril group (all P<0.05).",1286,1482
med:pmid:41070303:sec:results:sent:9,med:pmid:41070303,results,9,There was no statistically significant difference in the occurrence of adverse events between the two groups (both P>0.05).,1483,1606
med:pmid:41070303:sec:conclusion:sent:10,med:pmid:41070303,conclusion,10,LBBP combined with sacubitril/valsartan is more effective in treating elderly CHD with CHF than LBBP combined with enalapril.,1607,1753
med:pmid:41049960:sec:title:sent:0,med:pmid:41049960,title,0,Underutilization of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: A Retrospective Study in Rural Appalachia.,0,146
med:pmid:41049960:sec:introduction:sent:1,med:pmid:41049960,introduction,1,"Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) includes a combination of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/angiotensin receptor neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor agonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",0,396
med:pmid:41049960:sec:introduction:sent:2,med:pmid:41049960,introduction,2,"Despite mortality benefits, implementation remains suboptimal.",397,459
med:pmid:41049960:sec:methods:sent:3,med:pmid:41049960,methods,3,This was a retrospective observational study conducted in three outpatient Internal Medicine and Cardiology clinics within the East Tennessee State University Health system.,459,643
med:pmid:41049960:sec:methods:sent:4,med:pmid:41049960,methods,4,Adults aged ≥18 years with ejection fraction (EF) ≤40% and at least one outpatient follow-up between December 2022 and November 2023 were included.,644,791
med:pmid:41049960:sec:methods:sent:5,med:pmid:41049960,methods,5,"Patients with contraindications to GDMT, end-stage renal disease, or limited life expectancy were excluded.",792,899
med:pmid:41049960:sec:methods:sent:6,med:pmid:41049960,methods,6,"GDMT use and dosing (none, <50%, ≥50 to <100%, 100% target dose) for beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i were assessed.",899,1029
med:pmid:41049960:sec:methods:sent:7,med:pmid:41049960,methods,7,Descriptive statistics and logistic regression models were used to examine patient characteristics and treatment patterns.,1030,1152
med:pmid:41049960:sec:results:sent:8,med:pmid:41049960,results,8,"Among 236 eligible patients, only 16.5%, 10.2%, 31.4%, and 42.8% were receiving target doses of beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i, respectively.",1153,1326
med:pmid:41049960:sec:results:sent:9,med:pmid:41049960,results,9,"Quadruple therapy was prescribed in just 21.2% of patients, and fewer than 1% achieved target dosing for all four medication classes.",1327,1460
med:pmid:41049960:sec:results:sent:10,med:pmid:41049960,results,10,"MRA use was strikingly low, with 58.9% of patients not on therapy despite its well-established mortality benefit and relative affordability.",1461,1601
med:pmid:41049960:sec:results:sent:11,med:pmid:41049960,results,11,Multivariable regression analysis revealed several notable associations.,1602,1674
med:pmid:41049960:sec:results:sent:12,med:pmid:41049960,results,12,"Increasing age was linked to lower odds of ACEI/ARB/ARNI use, while higher systolic blood pressure (SBP) favored treatment.",1675,1798
med:pmid:41049960:sec:results:sent:13,med:pmid:41049960,results,13,"MRA use was more likely among patients with lower SBP, non-ischemic cardiomyopathy, obesity, and absence of atrial fibrillation (AF), with obesity and absence of AF being associated with achieving >50% of the target dose.",1799,2020
med:pmid:41049960:sec:results:sent:14,med:pmid:41049960,results,14,"SGLT2i therapy was more common in younger patients with lower ejection fraction and lower SBP, with type 2 diabetes mellitus being the strongest predictor for both initiation and dose optimization.",2021,2218
med:pmid:41049960:sec:conclusion:sent:15,med:pmid:41049960,conclusion,15,These findings highlight a significant gap in GDMT implementation.,2218,2298
med:pmid:41049960:sec:conclusion:sent:16,med:pmid:41049960,conclusion,16,"Despite favorable patient profiles and a high cost-benefit ratio, MRA use remains limited in this cohort.",2299,2404
med:pmid:41049960:sec:conclusion:sent:17,med:pmid:41049960,conclusion,17,Targeted interventions to support GDMT initiation and optimization in eligible patients may help reduce disparities in heart failure care.,2405,2543
med:pmid:41007826:sec:title:sent:0,med:pmid:41007826,title,0,Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis.,0,189
med:pmid:41007826:sec:introduction:sent:1,med:pmid:41007826,introduction,1,"Angiotensin receptor-neprilysin inhibitor (ARNI) has a well-established advantage over angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction, the advantage of ARNI has not been clearly proven.",0,435
med:pmid:41007826:sec:introduction:sent:2,med:pmid:41007826,introduction,2,The efficacy of ARNI is compared with that of ACEI/ARB therapy in patients with their first AMI in terms of improvement of post-infarction LV systolic function.,436,596
med:pmid:41007826:sec:introduction:sent:3,med:pmid:41007826,introduction,3,<b>Methods</b>: The study was conducted as a retrospective one-center cross-sectional analysis.,597,692
med:pmid:41007826:sec:introduction:sent:4,med:pmid:41007826,introduction,4,"Overall, 1473 pts (990 M, median age 71 [64; 77]) with AMI (their first AMI, complete coronary revascularization, no prior coronary revascularization or history of HF) hospitalized in 2022-2024 were enrolled in a retrospective cross-sectional analysis.",693,945
med:pmid:41007826:sec:introduction:sent:5,med:pmid:41007826,introduction,5,The study population was categorized into pts receiving ARNI and ACEI/ARB.,946,1020
med:pmid:41007826:sec:introduction:sent:6,med:pmid:41007826,introduction,6,"Then, based on the ARNI subgroup, matching that included age, sex, and LV ejection fraction (LVEF) was performed by using the 1:1 nearest neighbor method without returning.",1021,1193
med:pmid:41007826:sec:introduction:sent:7,med:pmid:41007826,introduction,7,"Finally, two groups (ARNI vs. ACEI/ARB) of 30 pts were obtained and analyzed at baseline and at a 6-week follow-up.",1194,1309
med:pmid:41007826:sec:introduction:sent:8,med:pmid:41007826,introduction,8,"The improvement of post-infarction LV systolic function was obtained in terms of LVEF, ΔLVEF, and relative ΔLVEF values (ΔLVEF/baseline LVEF).",1310,1452
med:pmid:41007826:sec:introduction:sent:9,med:pmid:41007826,introduction,9,"<b>Results</b>: The comparison of baseline characteristics revealed borderline lower initial LVEF (30 vs. 36%, <i>p</i> = 0.076) and a higher frequency of SGLT-2 inhibitor use (70% vs. 36.7%, <i>p</i> = 0.01) in the ARNI subgroup.",1453,1683
med:pmid:41007826:sec:introduction:sent:10,med:pmid:41007826,introduction,10,"At the 6-week follow-up, in both subgroups, a significant improvement in the median LVEF values was achieved-from a median LVEF value of 30% (27.3; 38) to 37% (30; 43; <i>p</i> = 0.0008) in the ARNI subgroup and from a median LVEF value of 36% (33; 39) to 45% (42; 52; <i>p</i> < 0.0001) in the ACEI/ARB subgroup.",1684,1997
med:pmid:41007826:sec:introduction:sent:11,med:pmid:41007826,introduction,11,"The median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), <i>p</i> = 0.018].",1998,2125
med:pmid:41007826:sec:introduction:sent:12,med:pmid:41007826,introduction,12,"Similarly, the median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), <i>p</i> = 0.047].",2126,2275
med:pmid:41007826:sec:introduction:sent:13,med:pmid:41007826,introduction,13,"The vast majority of patients, particularly in the ARNI group (99.7%), were treated with the lowest available dose of the drug.",2276,2403
med:pmid:41007826:sec:introduction:sent:14,med:pmid:41007826,introduction,14,"<b>Conclusions</b>: Our current experience in ARNI therapy after AMI is promising; however, it is limited to a small group of patients with severe impairment of LV systolic function.",2404,2586
med:pmid:41007826:sec:introduction:sent:15,med:pmid:41007826,introduction,15,"Regardless of the significant improvement in the baseline LVEF observed in patients receiving both ACEI/ARB and ARNI at the 6-week follow-up, the absolute and relative increases in the LVEF were higher in subjects treated with ACEI/ARB.",2587,2823
med:pmid:41007826:sec:introduction:sent:16,med:pmid:41007826,introduction,16,"However, the clinical benefits of ARNI therapy may emerge more gradually, and its advantages could become more apparent over a longer follow-up period.",2824,2975
med:pmid:41007826:sec:introduction:sent:17,med:pmid:41007826,introduction,17,The clinical efficacy of early use of ARNI in the setting of AMI needs further evaluation.,2976,3066
med:pmid:40981086:sec:title:sent:0,med:pmid:40981086,title,0,Prescription Patterns of Sacubitril/Valsartan in an Outpatient Population Diagnosed with Heart Failure with Reduced Ejection Fraction After a Recent Hospitalization.,0,165
med:pmid:40981086:sec:abstract:sent:1,med:pmid:40981086,abstract,1,<b>Background</b>: Sacubitril/Valsartan is a first-line treatment for heart failure with reduced ejection fraction (HFrEF) according to international guidelines.,0,161
med:pmid:40981086:sec:abstract:sent:2,med:pmid:40981086,abstract,2,"However, achieving the target doses of guideline-directed medical therapy (GDMT) remains a challenge in clinical practice and its efficacy at suboptimal dose (<200 mg/day) versus angiotensin-converting enzyme (ACE) inhibitors remains debated.",162,404
med:pmid:40981086:sec:abstract:sent:3,med:pmid:40981086,abstract,3,Our objective was to evaluate the titration of Sacubitril/Valsartan within 3 months of hospital discharge in patients with HFrEF.,405,534
med:pmid:40981086:sec:abstract:sent:4,med:pmid:40981086,abstract,4,"<b>Methods</b>: A cross-sectional study was conducted in a secondary care hospital in Geneva, Switzerland.",535,641
med:pmid:40981086:sec:abstract:sent:5,med:pmid:40981086,abstract,5,"Patients hospitalized between 2020 and 2022 with HFrEF, discharged with Sacubitril/Valsartan, were included.",642,750
med:pmid:40981086:sec:abstract:sent:6,med:pmid:40981086,abstract,6,Physicians managing patients discharged with a Sacubitril/Valsartan dose of less than 200 mg/day were contacted and asked to complete a structured 7-item questionnaire regarding dose adjustments within the first 3 months following hospital discharge.,751,1001
med:pmid:40981086:sec:abstract:sent:7,med:pmid:40981086,abstract,7,"The primary outcome was the proportion of patients who did not achieve GDMT doses of Sacubitril/Valsartan, along with reasons for inadequate titration.",1002,1153
med:pmid:40981086:sec:abstract:sent:8,med:pmid:40981086,abstract,8,"<b>Results</b>: Overall, 30 patients out of 79 (38%, 95% confidence interval [27-49%]) had not been titrated to an effective dose of Sacubitril/Valsartan 3 months after hospitalization.",1154,1339
med:pmid:40981086:sec:abstract:sent:9,med:pmid:40981086,abstract,9,"Of these thirty patients, the primary reason for not titrating cited by their practitioners (<i>n</i> = 27) was that titration was perceived to be within the cardiologist's scope of responsibility (15/27, 56%).",1340,1550
med:pmid:40981086:sec:abstract:sent:10,med:pmid:40981086,abstract,10,"While most physicians (66%) knew the target doses for Sacubitril/Valsartan, 83% of them were unaware that the clinical benefit of sacubitril/valsartan at doses below 50% of the target compared to ACE inhibitors remains uncertain and is not well supported by current evidence.",1551,1826
med:pmid:40981086:sec:abstract:sent:11,med:pmid:40981086,abstract,11,"<b>Conclusions</b>: In this cohort, more than a third of patients with HFrEF were not titrated to guideline-recommended target doses of sacubitril/valsartan within 3 months of hospital discharge.",1827,2022
med:pmid:40981086:sec:abstract:sent:12,med:pmid:40981086,abstract,12,"This finding raises questions about the clinical and economic value of initiating sacubitril/valsartan without subsequent dose optimization, especially given the uncertainty surrounding the efficacy of suboptimal dosing compared to ACE inhibitors.",2023,2270
med:pmid:40916703:sec:title:sent:0,med:pmid:40916703,title,0,Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.,0,142
med:pmid:40916703:sec:introduction:sent:1,med:pmid:40916703,introduction,1,"The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC).",0,432
med:pmid:40916703:sec:introduction:sent:2,med:pmid:40916703,introduction,2,We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.,433,539
med:pmid:40916703:sec:results:sent:3,med:pmid:40916703,results,3,"PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.",540,790
med:pmid:40916703:sec:results:sent:4,med:pmid:40916703,results,4,Participants were randomized 1:1 to sacubitril/valsartan (97/103 mg bid) or enalapril (10 mg bid).,791,889
med:pmid:40916703:sec:results:sent:5,med:pmid:40916703,results,5,"Enrolled participants (mean age: 64.2 years, 42.0% women) had a baseline LVEF of 29.8% (NYHA class II: 61.7%; NHYA class III/IV: 38.2%).",890,1026
med:pmid:40916703:sec:results:sent:6,med:pmid:40916703,results,6,"History included hypertension (40.5%), atrial fibrillation/flutter (32.5%), ventricular arrhythmia (24.7%) and stroke (12.5%).",1027,1153
med:pmid:40916703:sec:results:sent:7,med:pmid:40916703,results,7,"The majority of patients had cardiac conduction abnormalities and 46.0% had conventional pacemaker, cardiac resynchronization therapy or implantable cardioverter-defibrillator.",1154,1330
med:pmid:40916703:sec:results:sent:8,med:pmid:40916703,results,8,"Mean systolic blood pressure was 118 mmHg, and median NT-proBNP level was 1730 pg/ml.",1331,1416
med:pmid:40916703:sec:conclusion:sent:9,med:pmid:40916703,conclusion,9,"Baseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies.",1417,1767
med:pmid:40916703:sec:conclusion:sent:10,med:pmid:40916703,conclusion,10,"These findings reinforce the need for dedicated heart failure treatments in this neglected subpopulation, particularly in Latin America where Chagas disease remains a significant public health issue.",1768,1967
med:pmid:40908036:sec:title:sent:0,med:pmid:40908036,title,0,Drug treatment of chronic heart failure with reduced ejection fraction.,0,71
med:pmid:40908036:sec:abstract:sent:1,med:pmid:40908036,abstract,1,"Heart failure (HF) is a progressive clinical syndrome characterised by insufficient cardiac output due to structural and functional abnormalities of the heart, which can then lead to breathlessness, fatigue and fluid overload.",0,226
med:pmid:40908036:sec:abstract:sent:2,med:pmid:40908036,abstract,2,"HF has an associated high morbidity and mortality rate as well as a significant impact on healthcare resources; for example, in the UK, it accounts for 5% of National Health Service (NHS) emergency admissions.",227,436
med:pmid:40908036:sec:abstract:sent:3,med:pmid:40908036,abstract,3,"This review focuses on pharmacological treatment of chronic HF with reduced ejection fraction (HFrEF), which affects approximately 60% of patients with HF.",437,592
med:pmid:40908036:sec:abstract:sent:4,med:pmid:40908036,abstract,4,Patient outcomes are determined by early diagnosis and individualised treatment.,593,673
med:pmid:40908036:sec:abstract:sent:5,med:pmid:40908036,abstract,5,"The cornerstone of HFrEF management consists of four key medication classes: ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",674,935
med:pmid:40908036:sec:abstract:sent:6,med:pmid:40908036,abstract,6,These medications constitute the four pillars of HfrEF treatment.,936,1001
med:pmid:40908036:sec:abstract:sent:7,med:pmid:40908036,abstract,7,Each class has a distinct mechanism that when used together synergistically enhances patient outcomes.,1002,1104
med:pmid:40908036:sec:abstract:sent:8,med:pmid:40908036,abstract,8,In this review we discuss drug treatment options and key considerations in the management of people with chronic HFrEF.,1105,1224
med:pmid:40908036:sec:abstract:sent:9,med:pmid:40908036,abstract,9,"The review also highlights the importance of medication management, addressing complications and promoting lifestyle modifications.",1225,1356
med:pmid:39497472:sec:title:sent:0,med:pmid:39497472,title,0,Angiotensin-Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor/Neprilysin Inhibitor Initiation in the Inpatient Setting.,0,142
med:pmid:39497472:sec:introduction:sent:1,med:pmid:39497472,introduction,1,The 2022 AHA-ACC HFSA Guideline for Management of Heart Failure recommend initiating an angiotensin receptor/neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) who can tolerate an angiotensin-converting enzyme inhibitor (ACEi).,0,294
med:pmid:39497472:sec:introduction:sent:2,med:pmid:39497472,introduction,2,"The manufacturer recommends initiating a 36-hour washout period when switching from ACEi to ARNI due to an increased risk of adverse effects, including angioedema.",295,458
med:pmid:39497472:sec:introduction:sent:3,med:pmid:39497472,introduction,3,This study investigated the adherence to the washout period when transitioning from ACEi to ARNI at a community hospital.,459,580
med:pmid:39497472:sec:introduction:sent:4,med:pmid:39497472,introduction,4,The primary objective was to assess the rate of adherence to the 36-hour washout when transitioning patients from ACEi to ARNI.,581,728
med:pmid:39497472:sec:introduction:sent:5,med:pmid:39497472,introduction,5,"Secondary outcomes included heart failure exacerbation readmission rates within 90 days and the rate of adverse effects (angioedema, hypotension, acute kidney injury, and hyperkalemia).",729,914
med:pmid:39497472:sec:methods:sent:6,med:pmid:39497472,methods,6,"This was a retrospective cohort study including patients with HFrEF who were transitioned from ACEi to ARNI during their hospital stay between March 1, 2016 and December 31, 2022.",915,1111
med:pmid:39497472:sec:methods:sent:7,med:pmid:39497472,methods,7,Patients were excluded if they did not receive an ACEi or ARNI during their admission or if they had an ejection fraction >40%.,1112,1239
med:pmid:39497472:sec:methods:sent:8,med:pmid:39497472,methods,8,Pearson chi-square was used to analyze categorical data.,1240,1296
med:pmid:39497472:sec:results:sent:9,med:pmid:39497472,results,9,"Of 33 patients included in this study, 67% received the full 36-hour washout period when transitioning from ACEi to ARNI.",1297,1435
med:pmid:39497472:sec:results:sent:10,med:pmid:39497472,results,10,There were no significant differences between the rates of hospital readmissions or adverse effects between the groups.,1436,1555
med:pmid:39497472:sec:results:sent:11,med:pmid:39497472,results,11,No patients experienced hyperkalemia or angioedema.,1556,1607
med:pmid:39497472:sec:conclusion:sent:12,med:pmid:39497472,conclusion,12,This is the first study to our knowledge to describe real-world prescribing practices when transitioning patients from ACEi to ARNI for the treatment of HFrEF.,1608,1801
med:pmid:39497472:sec:conclusion:sent:13,med:pmid:39497472,conclusion,13,"Larger, multicenter studies are needed to provide more data on prescribing practices outside this single center.",1802,1914
med:pmid:39497472:sec:conclusion:sent:14,med:pmid:39497472,conclusion,14,Future research should also include pharmacist's role in adhering to the recommended washout.,1915,2008
med:pmid:40869719:sec:title:sent:0,med:pmid:40869719,title,0,"Heart Failure Readmission Prevention Strategies-A Comparative Review of Medications, Devices, and Other Interventions.",0,118
med:pmid:40869719:sec:abstract:sent:1,med:pmid:40869719,abstract,1,"Heart failure readmissions remain a major challenge for healthcare systems, contributing significantly to morbidity, mortality, and increased healthcare costs.",0,159
med:pmid:40869719:sec:abstract:sent:2,med:pmid:40869719,abstract,2,"Despite advancements in medical and device-based therapies, rehospitalization rates remain high, particularly within the first 30 days of discharge.",160,308
med:pmid:40869719:sec:abstract:sent:3,med:pmid:40869719,abstract,3,This review aims to evaluate the primary factors associated with HF readmissions and discuss evidence-based strategies to reduce these rates.,309,450
med:pmid:40869719:sec:abstract:sent:4,med:pmid:40869719,abstract,4,"The review examines the efficacy of pharmacological therapies and their impact on readmission rates, highlighting key interventions such as diuretics, beta-blockers, ACE inhibitors, ARBs, ARNIs, SGLT2 inhibitors, and intravenous iron supplementation.",451,701
med:pmid:40869719:sec:abstract:sent:5,med:pmid:40869719,abstract,5,"Additionally, device-based interventions, including CardioMEMS, LVADs, CRT-P/D, ICDs, Furoscix, and the ReDS vest, are critically evaluated for their role in the early detection and management of decompensation.",702,913
med:pmid:40869719:sec:abstract:sent:6,med:pmid:40869719,abstract,6,"Non-pharmacological strategies are also underscored, such as dietary modifications, exercise, cardiac rehabilitation, and structured follow-up programs.",914,1066
med:pmid:40869719:sec:abstract:sent:7,med:pmid:40869719,abstract,7,"By synthesizing current evidence, this review provides a comprehensive analysis of heart failure readmission factors and proposes multidisciplinary, patient-centered strategies to improve outcomes and reduce hospitalizations.",1067,1292
med:pmid:40835081:sec:title:sent:0,med:pmid:40835081,title,0,Clinical and Epidemiological Profile of Heart Failure Patients With Chagas Disease: Insights From the SEPE-HF Registry.,0,119
med:pmid:40835081:sec:abstract:sent:1,med:pmid:40835081,abstract,1,"Chagas cardiomyopathy (Ch-CMP) represents a unique and understudied phenotype of heart failure (HF) in endemic regions, with distinct clinical, electrocardiographic, and therapeutic characteristics compared to non-Chagas HF.",0,224
med:pmid:40835081:sec:abstract:sent:2,med:pmid:40835081,abstract,2,"In this retrospective cohort of 417 patients hospitalized for decompensated HF at a tertiary center in Brazil, 155 (37.1%) had confirmed Ch-CMP.",225,369
med:pmid:40835081:sec:abstract:sent:3,med:pmid:40835081,abstract,3,"Chagas patients were younger (mean age 67.5 vs 67.7 years, p = 0.86), had lower BMI (28.65 vs 25.40, p < 0.001), and a higher proportion of males (50.9% vs 47.7%, p = 0.56).",370,543
med:pmid:40835081:sec:abstract:sent:4,med:pmid:40835081,abstract,4,"Comorbidities were less frequent in the Chagas group, including hypertension (49.6% vs 70.1%, p = 0.001) and ischemic heart disease (3.2% vs 16.6%, p = 0.001).",544,703
med:pmid:40835081:sec:abstract:sent:5,med:pmid:40835081,abstract,5,"Electrocardiographic abnormalities were more prevalent among Chagas patients, such as right bundle branch block (17.6% vs 9%, p = 0.015), atrial fibrillation (37.9% vs 23%, p = 0.001), and pacemaker rhythms (22.2% vs 3.7%, p = 0.001).",704,938
med:pmid:40835081:sec:abstract:sent:6,med:pmid:40835081,abstract,6,"Systolic dysfunction (LVEF < 40%) was more common in Chagas (59.4% vs 27.1%, p = 0.001).",939,1027
med:pmid:40835081:sec:abstract:sent:7,med:pmid:40835081,abstract,7,"Despite these differences, cardiovascular inhospital mortality did not significantly differ (8.4% vs 5.2%, p = 0.279).",1028,1146
med:pmid:40835081:sec:abstract:sent:8,med:pmid:40835081,abstract,8,"The use of guideline-directed medical therapy at discharge was suboptimal in both groups, but even lower in Chagas patients, particularly for beta-blockers (52% vs 64%, p = 0.02) and ACEi/ARB/ARNi (54% vs 68%, p = 0.01).",1147,1367
med:pmid:40835081:sec:abstract:sent:9,med:pmid:40835081,abstract,9,"Loop diuretics were used in only 64% of the entire cohort; among those not requiring diuretics, arrhythmias and infections were the leading causes of admission, atrial fibrillation in 22 patients, and infection in 21.",1368,1585
med:pmid:40835081:sec:abstract:sent:10,med:pmid:40835081,abstract,10,"In conclusion, Chagas cardiomyopathy remains a major contributor to HF hospitalizations in endemic regions, with a unique arrhythmogenic and vasodilated profile, lower prevalence of traditional risk factors, and concerning therapeutic gaps at discharge that merit targeted intervention.",1586,1872
med:pmid:40755965:sec:title:sent:0,med:pmid:40755965,title,0,Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis.,0,124
med:pmid:40755965:sec:introduction:sent:1,med:pmid:40755965,introduction,1,"Classical renin-angiotensin system inhibitors (RASI), such as angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), have long been the foundation of treatment for patients with cardiovascular disease (CVD) and chronic kidney disease (CKD).",0,294
med:pmid:40755965:sec:introduction:sent:2,med:pmid:40755965,introduction,2,"The development of angiotensin receptor neprilysin inhibitors (ARNI) has introduced a valuable therapeutic option for patients with heart failure with reduced ejection fraction (HFrEF), reducing the risk of major cardiovascular events and becoming an essential component of treatment for this population.",295,599
med:pmid:40755965:sec:introduction:sent:3,med:pmid:40755965,introduction,3,"However, their effects on renal outcomes remain uncertain.",600,658
med:pmid:40755965:sec:methods:sent:4,med:pmid:40755965,methods,4,We conducted a systematic review and meta-analysis to compare the renal effects of ARNI and RASI.,659,773
med:pmid:40755965:sec:methods:sent:5,med:pmid:40755965,methods,5,"Relevant studies were searched in the following databases from inception to 30 December 2024: MEDLINE (PubMed), Embase and Scopus.",774,904
med:pmid:40755965:sec:methods:sent:6,med:pmid:40755965,methods,6,"The primary outcomes assessed were: a ≥50% reduction in estimated glomerular filtration rate (eGFR) or progression to end-stage renal disease (ESRD), a composite measure of worsening renal function (serum creatinine increase of ≥0.5 mg/dL from baseline and a 25% decline in eGFR) and renal impairment (an increase of at least 0.3 mg/dL in creatinine levels).",905,1263
med:pmid:40755965:sec:methods:sent:7,med:pmid:40755965,methods,7,"Additionally, a subgroup analysis of renal impairment in patients with HFrEF was performed.",1264,1355
med:pmid:40755965:sec:methods:sent:8,med:pmid:40755965,methods,8,Secondary outcomes included hyperkalemia.,1356,1397
med:pmid:40755965:sec:results:sent:9,med:pmid:40755965,results,9,Our results suggested a 31% reduction in renal impairment with ARNI treatment compared with RASI and a 37% reduction in the odds of ≥50% decline in eGFR or ESRD.,1398,1576
med:pmid:40755965:sec:results:sent:10,med:pmid:40755965,results,10,"However, the pooled analysis for worsening renal function and hyperkalemia showed no apparent difference between ARNI and RASI.",1577,1704
med:pmid:40755965:sec:results:sent:11,med:pmid:40755965,results,11,A subgroup analysis on a population with a reduced ejection fraction suggested a 37% lower odds of renal impairment with ARNI when compared with RASI.,1705,1855
med:pmid:40755965:sec:results:sent:12,med:pmid:40755965,results,12,This study represents the largest and first systematic review and meta-analysis with clearly defined renal outcomes.,1856,1972
med:pmid:40755965:sec:conclusion:sent:13,med:pmid:40755965,conclusion,13,"Given that ARNI has been explored for indications beyond heart failure, further randomized controlled trials are needed to understand its renal effects better.",1973,2152
med:pmid:40755965:sec:conclusion:sent:14,med:pmid:40755965,conclusion,14,"Future research should determine whether ARNI provides a benefit in a purely CKD population or in a cardio-renal population, given that CVD is the leading cause of mortality in CKD patients.",2153,2343
med:pmid:40542996:sec:title:sent:0,med:pmid:40542996,title,0,Novel Potassium Binders in Reduction of Hyperkalemia and Optimization of RAAS Inhibitors Treatment in Patients with Chronic Kidney Disease or Heart Failure: A Systematic Review and Meta-analysis.,0,195
med:pmid:40542996:sec:introduction:sent:1,med:pmid:40542996,introduction,1,Renin-angiotensin-aldosterone system inhibitors (RAASi) and its combination therapy are essential supportive treatments for patients with chronic kidney disease (CKD) and heart failure (HF).,0,210
med:pmid:40542996:sec:introduction:sent:2,med:pmid:40542996,introduction,2,"Hyperkalemia (HK) is the major safety concern associated with the treatments, which often leads to RAASi dose reduction or discontinuation, thereby compromising cardiovascular protective effects.",211,406
med:pmid:40542996:sec:introduction:sent:3,med:pmid:40542996,introduction,3,"Although novel potassium binders (NPBs) are recommended by current guidelines for the treatment of HK, systematic evidence is needed to guide their use in RAASi optimization and HK management.",407,599
med:pmid:40542996:sec:introduction:sent:4,med:pmid:40542996,introduction,4,A systematic review and meta-analysis was conducted to evaluate the incidence of HK in patients with CKD or HF who received RAASi and the efficacy of NPBs in RAASi optimization.,600,777
med:pmid:40542996:sec:methods:sent:5,med:pmid:40542996,methods,5,"PubMed, Medline, Embase, and the Cochrane Library were searched from January 1, 2011 to December 31, 2023.",778,901
med:pmid:40542996:sec:methods:sent:6,med:pmid:40542996,methods,6,Any studies of adult patients with CKD or HF who received RAASi were included in systematic review of HK incidence and risk factors (part 1).,902,1043
med:pmid:40542996:sec:methods:sent:7,med:pmid:40542996,methods,7,Randomized controlled trials (RCTs) of NPBs in patients with CKD or HF were included in meta-analysis on the efficacy of novel potassium binders (NPBs) (part 2).,1044,1205
med:pmid:40542996:sec:methods:sent:8,med:pmid:40542996,methods,8,The primary outcome was optimization of RAASi therapy with NPBs.,1206,1270
med:pmid:40542996:sec:methods:sent:9,med:pmid:40542996,methods,9,A pooled analysis was conducted in part 1.,1271,1313
med:pmid:40542996:sec:methods:sent:10,med:pmid:40542996,methods,10,Network meta-analyses using a random-effects model were performed in part 2.,1314,1390
med:pmid:40542996:sec:results:sent:11,med:pmid:40542996,results,11,"A total of 83 studies (24 with CKD, 54 with HF, and 5 with CKD and HF) were included in part 1 and 8 RCTs (2 with CKD, 4 with HF, and 2 with CKD and HF) were included in part 2.",1391,1585
med:pmid:40542996:sec:results:sent:12,med:pmid:40542996,results,12,The pooled HK incidence was 10.7% overall at any criteria and in all patients who received RAASi.,1586,1683
med:pmid:40542996:sec:results:sent:13,med:pmid:40542996,results,13,"The highest incidence of HK was observed with the combination of angiotensin converting enzyme inhibitor (ACEi)/angiotensin ii receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitor (ARNi)+ mineralocorticoid receptor antagonists (MRAs) (24.4%), followed by the triple therapy ACEi/ARB/ARNi+ sodium glucose cotransporter-2 inhibitor (SGLT2i)+MRA (10.9%), and ACEi/ARB/ARNi + SGLT2i (2.2%).",1684,2084
med:pmid:40542996:sec:results:sent:14,med:pmid:40542996,results,14,"Novel potassium binders improved RAASi optimization by 38% compared with placebo (risk ratio, 1.38; 95% CI, 1.16-1.65).",2085,2204
med:pmid:40542996:sec:results:sent:15,med:pmid:40542996,results,15,"Additionally, NPBs decreased the incidence of HK by 28% and reduced the level of potassium by 0.71 mEq/L. The CKD population showed a higher optimization rate than the HF population (84% vs 29%).",2205,2400
med:pmid:40542996:sec:conclusion:sent:16,med:pmid:40542996,conclusion,16,"The RAASi treatment was associated with high prevalence of HK, especially in bigeminal and triple therapy.",2401,2527
med:pmid:40542996:sec:conclusion:sent:17,med:pmid:40542996,conclusion,17,"The NPBs were effective in RAASi optimization and HK management, especially among the CKD population.",2528,2629
med:pmid:40450497:sec:title:sent:0,med:pmid:40450497,title,0,Effects of Sacubitril/Valsartan on Renal Function in Adults With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.,0,150
med:pmid:40450497:sec:introduction:sent:1,med:pmid:40450497,introduction,1,We systematically evaluated sacubitril/valsartan (S/V) effects on the renal outcomes of patients with acute or chronic heart failure (HF) receiving angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).,0,258
med:pmid:40450497:sec:introduction:sent:2,med:pmid:40450497,introduction,2,<h4>Method</h4> Five (5) databases were searched for randomised controlled trials (RCTs) comparing S/V vs ACEI or ARB in adult patients with HF until 2 September 2023.,259,426
med:pmid:40450497:sec:introduction:sent:3,med:pmid:40450497,introduction,3,Doubling of the serum creatinine (sCr) level was the primary outcome.,427,496
med:pmid:40450497:sec:introduction:sent:4,med:pmid:40450497,introduction,4,"Worsening or decline in renal function (WDRF), >50% decline of estimated glomerular filtration rate (eGFR), and hyperkalaemia (serum K+ >5.5 mmol/L) were secondary outcomes.",497,670
med:pmid:40450497:sec:introduction:sent:5,med:pmid:40450497,introduction,5,"Inverse variance random-effects meta-analyses were performed, and the effects of S/V on outcomes were described using relative risks (RRs) and their 95% confidence intervals (CIs).",671,851
med:pmid:40450497:sec:introduction:sent:6,med:pmid:40450497,introduction,6,Subgroup analyses were performed according to the type of HF (chronic vs acute) and left ventricular ejection fraction (<40% vs >40 %).,852,987
med:pmid:40450497:sec:introduction:sent:7,med:pmid:40450497,introduction,7,The GRADE approach was used to rate the certainty of evidence (CoE).,988,1056
med:pmid:40450497:sec:results:sent:8,med:pmid:40450497,results,8,"Eight (8) RCTs (n=15,859) were included: four on chronic HF and four on acute HF.",1057,1155
med:pmid:40450497:sec:results:sent:9,med:pmid:40450497,results,9,"Median (interquartile range [IQR]) age was 68.4 (63.8-72.7) years in chronic, and 62 (57.1-70.9) years in acute patients, and 34.1% were female.",1156,1300
med:pmid:40450497:sec:results:sent:10,med:pmid:40450497,results,10,The median (IQR) follow-up was 29.5 (12-108) weeks in chronic and 22 (8-54) weeks in acute patients.,1301,1401
med:pmid:40450497:sec:results:sent:11,med:pmid:40450497,results,11,"In comparison to ACEI or ARB, S/V likely reduced doubling sCr (RR 0.77; 95% CI 0.72 to 0.83; moderate CoE), may have resulted in little to no difference of WDRF (RR 0.88; 95% CI 0.72 to 1.08; low CoE), and had little to no effect on both >50% decline of eGFR (RR 0.65; 95% CI 0.37 to 1.17; very low CoE) and hyperkalaemia (RR 1.01; 95% CI 0.81 to 1.25; very low CoE) but the evidence was very uncertain.",1402,1805
med:pmid:40450497:sec:conclusion:sent:12,med:pmid:40450497,conclusion,12,"In adults with HF, S/V likely reduced doubling sCr compared to ACEI or ARB but may have little to no effect on WDRF, a >50% decline in eGFR, and hyperkalaemia.",1806,1986
med:pmid:40397431:sec:title:sent:0,med:pmid:40397431,title,0,Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study.,0,120
med:pmid:40397431:sec:introduction:sent:1,med:pmid:40397431,introduction,1,To evaluate the risk of incident dementia associated with sacubitril/valsartan in patients with heart failure (HF) in South Korea.,0,144
med:pmid:40397431:sec:results:sent:2,med:pmid:40397431,results,2,We conducted a retrospective cohort study using the National Health Insurance Database in South Korea.,145,276
med:pmid:40397431:sec:results:sent:3,med:pmid:40397431,results,3,Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included.,277,532
med:pmid:40397431:sec:results:sent:4,med:pmid:40397431,results,4,"The primary outcome was incident dementia, categorized into Alzheimer's dementia and vascular dementia.",533,636
med:pmid:40397431:sec:results:sent:5,med:pmid:40397431,results,5,"Follow-up began after 1 year from the prescription date, to accommodate dementia onset latency, until the earliest occurrence of dementia, death, or end of study period (March 2023).",637,819
med:pmid:40397431:sec:results:sent:6,med:pmid:40397431,results,6,"After 1:4 propensity score matching, the hazard ratio (HR) with 95% confidence interval (CI) for dementia was estimated using a Cox proportional hazards model.",820,979
med:pmid:40397431:sec:results:sent:7,med:pmid:40397431,results,7,"Among 7085 sacubitril/valsartan users and 359 153 ACEI/ARB users, 6930 sacubitril/valsartan users [mean (SD) age, 61.7 (14.6) years; 70.9% male] were matched on propensity score to 27 720 ACEI/ARB users [mean (SD) age, 61.7 (15.8) years; 71.1% male].",980,1230
med:pmid:40397431:sec:results:sent:8,med:pmid:40397431,results,8,"During a mean follow-up of 2.2 and 2.3 years, dementia occurred in 200 (2.9%) sacubitril/valsartan users and 980 (3.5%) ACEI/ARB users, respectively.",1231,1380
med:pmid:40397431:sec:results:sent:9,med:pmid:40397431,results,9,Sacubitril/valsartan showed a 16% lower risk of dementia compared with ACEI/ARB (HR 0.84; 95% CI 0.72-0.98).,1381,1489
med:pmid:40397431:sec:results:sent:10,med:pmid:40397431,results,10,"However, of 1180 cases of incident dementia, 1079 (91.4%) were categorized as Alzheimer's dementia and statistical significance was not reached in this main group.",1490,1653
med:pmid:40397431:sec:conclusion:sent:11,med:pmid:40397431,conclusion,11,"Despite plausible biological mechanisms, no association between sacubitril/valsartan and an increased risk of dementia was observed in patients with HF.",1654,1826
med:pmid:40353367:sec:title:sent:0,med:pmid:40353367,title,0,Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF.,0,145
med:pmid:40353367:sec:introduction:sent:1,med:pmid:40353367,introduction,1,The PANORAMA-HF trial demonstrated significant N-terminal pro-B-type natriuretic peptide (NT-proBNP) reductions in paediatric patients with left ventricular systolic dysfunction with sacubitril/valsartan or enalapril treatment over 52 weeks.,0,255
med:pmid:40353367:sec:introduction:sent:2,med:pmid:40353367,introduction,2,This post hoc analysis aims to correlate changes in NT-proBNP levels with clinical outcomes in PANORAMA-HF patients receiving either sacubitril/valsartan or enalapril.,256,423
med:pmid:40353367:sec:introduction:sent:3,med:pmid:40353367,introduction,3,"Additionally, NT-proBNP reductions in the paediatric population were compared with a subset of adult heart failure with reduced ejection fraction (HFrEF) patients from the PARADIGM-HF trial.",424,614
med:pmid:40353367:sec:results:sent:4,med:pmid:40353367,results,4,This post hoc analysis utilized data from Part 2 of the PANORAMA-HF trial.,615,718
med:pmid:40353367:sec:results:sent:5,med:pmid:40353367,results,5,"Associations between baseline NT-proBNP levels, changes post-baseline and the risk of HF clinical events in paediatric patients on sacubitril/valsartan or enalapril were assessed.",719,898
med:pmid:40353367:sec:results:sent:6,med:pmid:40353367,results,6,"The paediatric HF population from PANORAMA-HF was categorized into age groups (AG): AG1 (aged 6 to <18 years), AG2a (aged 2 to <6 years) and AG3a (aged 1 month to <2 years).",899,1072
med:pmid:40353367:sec:results:sent:7,med:pmid:40353367,results,7,The Cox proportional hazard model evaluated the relationship between NT-proBNP and clinical outcomes.,1073,1174
med:pmid:40353367:sec:discussion:sent:8,med:pmid:40353367,discussion,8,"of 361 paediatric patients (sacubitril/valsartan, n = 179; enalapril, n = 182) demonstrated overall higher baseline NT-proBNP levels in younger AGs.",1175,1332
med:pmid:40353367:sec:discussion:sent:9,med:pmid:40353367,discussion,9,"At Week 52, both treatment groups exhibited reduced NT-proBNP levels across all AGs.",1333,1417
med:pmid:40353367:sec:discussion:sent:10,med:pmid:40353367,discussion,10,"Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children.",1418,1569
med:pmid:40353367:sec:discussion:sent:11,med:pmid:40353367,discussion,11,Strong associations between NT-proBNP levels and HF clinical outcomes were observed in paediatric populations in PANORAMA-HF and in adult DCM patients with HFrEF in PARADIGM-HF.,1570,1747
med:pmid:40353367:sec:discussion:sent:12,med:pmid:40353367,discussion,12,"Doubling of NT-proBNP levels was associated with a ≥1.7-fold increased risk of HF clinical events, while halving of the levels correlated with a 52% reduction in the risk of clinical events.",1748,1938
med:pmid:40353367:sec:conclusion:sent:13,med:pmid:40353367,conclusion,13,"This is the first prospective, randomized large-scale study to demonstrate a strong correlation between NT-proBNP levels and risks of HF clinical events in paediatric patients with HF.",1939,2144
med:pmid:40302030:sec:title:sent:0,med:pmid:40302030,title,0,Prescription of guideline-directed medical therapy in heart failure: impact on mortality and readmission.,0,105
med:pmid:40302030:sec:introduction:sent:1,med:pmid:40302030,introduction,1,The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy (angiotensin-converting enzyme inhibitor [ACEI]/angiotensin receptor blocker [ARB]/angiotensin receptor-neprilysin inhibitor [ARNI]; beta-blocker (BB); mineralocorticoid receptor antagonist [MRA]; sodium-glucose co-transporter 2 inhibitor [SGLT2i]) in patients with heart failure and reduced ejection fraction (HFrEF).,0,442
med:pmid:40302030:sec:introduction:sent:2,med:pmid:40302030,introduction,2,We investigated if the use of this combined treatment (as opposed to the outdated two-drug ACEI/ARB and BB therapy) yields a favourable outcome regarding mortality and readmission and evaluated whether an increase in adoption of the newly endorsed therapy can already be observed in clinical routine.,443,743
med:pmid:40302030:sec:results:sent:3,med:pmid:40302030,results,3,We included anonymous data from all patients who were insured at Germany's largest health insurer (Allgemeine Ortskrankenkasse [AOK]) and had a claims record for hospitalization (2019-2021) with the main diagnosis of HF.,744,993
med:pmid:40302030:sec:results:sent:4,med:pmid:40302030,results,4,"Mortality and readmission within 91-365 days following the index stay were analysed, and the impact of medication on outcome was compared.",994,1132
med:pmid:40302030:sec:results:sent:5,med:pmid:40302030,results,5,"315 342 cases of hospitalization due to HF were included (median 80 years [IQR 72-86], 53.7% female).",1133,1234
med:pmid:40302030:sec:results:sent:6,med:pmid:40302030,results,6,"HF drug prescription rates were as follows: ACEI 46.3%, ARB 31.8%, ARNI 12.1%, BB 80.9%, MRA 35.6%, SGLT2i 7.3%.",1235,1347
med:pmid:40302030:sec:results:sent:7,med:pmid:40302030,results,7,Treatment combinations were prescribed in 35.9% (two-drug) and 3.7% (four-drug).,1348,1428
med:pmid:40302030:sec:results:sent:8,med:pmid:40302030,results,8,"Total mortality was 18.0%, all-cause readmission 32.0%, and HF readmission 16.0%.",1429,1510
med:pmid:40302030:sec:results:sent:9,med:pmid:40302030,results,9,Mortality risk was significantly lower (adjusted HR = 0.92 [95% CI 0.86-0.97]) with the four- versus two-drug treatment.,1511,1631
med:pmid:40302030:sec:results:sent:10,med:pmid:40302030,results,10,Kaplan-Meier survival was 88.2% for the four-drug therapy [95% CI: 87.6%-88.8%] and 83.1% for the two-drug therapy [95% CI: 82.9%-83.3%]).,1632,1770
med:pmid:40302030:sec:results:sent:11,med:pmid:40302030,results,11,Similar benefits were visible for the readmission rates due to all causes (HR = 0.76 [0.73-0.80]) and readmission due to HF (HR = 0.90 [0.85-0.95]).,1771,1919
med:pmid:40302030:sec:conclusion:sent:12,med:pmid:40302030,conclusion,12,Our study suggests that the newly recommended four-drug therapy may lead to lower mortality and readmission rates compared to the outdated two-drug therapy.,1920,2097
med:pmid:40302030:sec:conclusion:sent:13,med:pmid:40302030,conclusion,13,"However, the overall adoption of the four-drug therapy remains limited.",2098,2169
med:pmid:40232857:sec:title:sent:0,med:pmid:40232857,title,0,Early prescription of quadruple therapy in acute decompensated heart failure with reduced ejection fraction: A propensity score-matched analysis.,0,145
med:pmid:40232857:sec:introduction:sent:1,med:pmid:40232857,introduction,1,The optimal timing for prescribing guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) during acute decompensated heart failure (ADHF) remains uncertain.,0,227
med:pmid:40232857:sec:introduction:sent:2,med:pmid:40232857,introduction,2,This study evaluated the real-world impact of early in-hospital quadruple GDMT prescription in ADHF patients with HFrEF.,228,348
med:pmid:40232857:sec:results:sent:3,med:pmid:40232857,results,3,"In this retrospective cohort study using the Institutional aCute descompensAted heaRt failUre regiStry (ICARUS), we analysed 2051 HFrEF patients (71% male, median age 68 years) hospitalized for ADHF between June 2022 and March 2024.",349,610
med:pmid:40232857:sec:results:sent:4,med:pmid:40232857,results,4,"Early quadruple therapy was defined as the prescription of beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) within 48 h of admission.",611,950
med:pmid:40232857:sec:results:sent:5,med:pmid:40232857,results,5,"Among included patients, 898 (43.8%) received early quadruple therapy.",951,1021
med:pmid:40232857:sec:results:sent:6,med:pmid:40232857,results,6,"Using optimal full matching propensity score methodology, early quadruple therapy was associated with lower 30 day mortality/rehospitalization [relative risk (RR) 0.73; 95% confidence interval (CI) 0.55-0.97, P = 0.028], reduced in-hospital mortality (RR 0.29; 95% CI 0.15-0.56, P < 0.001) and shorter hospital stay (β = -2.65 days; 95% CI -3.67 to -1.63, P < 0.001).",1022,1389
med:pmid:40232857:sec:results:sent:7,med:pmid:40232857,results,7,"Patients receiving early quadruple therapy showed higher rates of GDMT continuation at discharge (RR 3.82; 95% CI 3.01-4.86, P < 0.001).",1390,1526
med:pmid:40232857:sec:conclusion:sent:8,med:pmid:40232857,conclusion,8,"In this HFrEF cohort, early initiation of comprehensive GDMT during ADHF hospitalization was associated with improved clinical outcomes.",1527,1684
med:pmid:40232857:sec:conclusion:sent:9,med:pmid:40232857,conclusion,9,Future randomized trials including patients across the full spectrum of ejection fraction are needed to validate these findings and determine their applicability to other heart failure phenotypes.,1685,1881
med:pmid:39792134:sec:title:sent:0,med:pmid:39792134,title,0,Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF.,0,134
med:pmid:39792134:sec:introduction:sent:1,med:pmid:39792134,introduction,1,"Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.",0,341
med:pmid:39792134:sec:results:sent:2,med:pmid:39792134,results,2,"This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status.",342,650
med:pmid:39792134:sec:results:sent:3,med:pmid:39792134,results,3,The primary endpoint was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8.,651,803
med:pmid:39792134:sec:results:sent:4,med:pmid:39792134,results,4,"Secondary analyses included a win-ratio analysis of the hierarchical outcome of (i) cardiovascular death; (ii) HF hospitalizations; (iii) urgent HF visits; and (iv) time-averaged proportional change in NT-proBNP from baseline to weeks 4 and 8, in addition to safety outcomes.",804,1079
med:pmid:39792134:sec:results:sent:5,med:pmid:39792134,results,5,"Among 466 patients, 107 (23%) were ACEi/ARB naïve at the time of randomization.",1080,1159
med:pmid:39792134:sec:results:sent:6,med:pmid:39792134,results,6,"NT-proBNP favoured Sac/Val irrespective of ACEi/ARB status (naïve: 0.76, 95% confidence interval [CI] 0.51-1.13; users: 0.88, 95% CI 0.74-1.05; p<sub>interaction</sub> = 0.52).",1160,1336
med:pmid:39792134:sec:results:sent:7,med:pmid:39792134,results,7,The win ratio of the hierarchical outcome was 1.13 (95% CI 0.86-1.49) for ACEi/ARB users and 1.38 (95% CI 0.81-2.37) for ACEi/ARB naïve (p<sub>interaction</sub> = 0.51).,1337,1506
med:pmid:39792134:sec:results:sent:8,med:pmid:39792134,results,8,"Safety endpoints showed non-significant interactions by ACEi/ARB status, with odds ratio of 1.79 (95% CI 0.68-4.72) and 0.71 (95% CI 0.29-1.78) for symptomatic hypotension and worsening renal function, respectively for ACEi/ARB naïve.",1507,1741
med:pmid:39792134:sec:conclusion:sent:9,med:pmid:39792134,conclusion,9,"In HF with EF >40% stabilized after worsening HF, safety and efficacy were similar irrespective of ACEi/ARB status at baseline, supporting early initiation irrespective of prior ACEi/ARB use.",1742,1953
med:pmid:40660106:sec:title:sent:0,med:pmid:40660106,title,0,"Discrepancy between clinical guidelines and real-world management of heart failure with reduced ejection fraction at University Medical Center Ho Chi Minh City, Vietnam.",0,169
med:pmid:40660106:sec:introduction:sent:1,med:pmid:40660106,introduction,1,"Although guideline-directed medical therapy (GDMT) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF), multiple real-world studies - such as CHAMP-HF (USA) and ASIAN-HF (Asia-Pacific) - have reported that a large proportion of patients fail to reach target doses.",0,320
med:pmid:40660106:sec:introduction:sent:2,med:pmid:40660106,introduction,2,"This global gap between recommendations and practice highlights the need to better understand country-specific barriers, particularly in low- and middle-income settings such as Vietnam.",321,506
med:pmid:40660106:sec:methods:sent:3,med:pmid:40660106,methods,3,"This cross-sectional study included adult outpatients diagnosed with HFrEF who had received at least three months of continuous therapy at the Heart Failure Clinic, University Medical Center Ho Chi Minh City, between February and August 2023, and aimed to (1) determine the prevalence of use, (2) evaluate typical dosages, and (3) examine the sequence of initiation of foundational therapies in this population.",507,935
med:pmid:40660106:sec:results:sent:4,med:pmid:40660106,results,4,"Among 181 patients, 98.9% were prescribed at least one foundational drug class, and 74.6% received all four classes.",936,1070
med:pmid:40660106:sec:results:sent:5,med:pmid:40660106,results,5,Patients who did not receive all four therapies were typically older females with higher systolic blood pressure and reduced renal function.,1071,1211
med:pmid:40660106:sec:results:sent:6,med:pmid:40660106,results,6,"SGLT2 inhibitors and MRAs had the highest rates of target dose achievement, whereas ARNI and beta-blockers were more frequently underdosed.",1212,1351
med:pmid:40660106:sec:results:sent:7,med:pmid:40660106,results,7,"Dose escalation was commonly limited by hypotension, advanced age, renal impairment, and low body weight.",1352,1457
med:pmid:40660106:sec:results:sent:8,med:pmid:40660106,results,8,"Notably, 82% of patients were initiated on three or four drug classes concurrently at the start of treatment, most commonly including RAS inhibitors, MRAs, and beta-blockers, with a preference for ARNI over ACE inhibitors or ARBs.",1458,1688
med:pmid:40660106:sec:discussion:sent:9,med:pmid:40660106,discussion,9,Foundational therapies were widely prescribed and frequently initiated concurrently in the management of HFrEF at a tertiary care hospital in Vietnam.,1689,1863
med:pmid:40660106:sec:discussion:sent:10,med:pmid:40660106,discussion,10,"However, achieving target doses remains a challenge, highlighting the gap between clinical guidelines and real-world practice due to factors such as low blood pressure, advanced age, and renal dysfunction.",1864,2069
med:pmid:40543460:sec:title:sent:0,med:pmid:40543460,title,0,Implementing a Cardiology Quality Incentive Program to Improve Guideline-Directed Medical Therapy.,0,98
med:pmid:40543460:sec:introduction:sent:1,med:pmid:40543460,introduction,1,"Adherence to guideline-directed medical therapy (GDMT) is central to quality-improvement programs, although the impact of financial incentive programs has been mixed.",0,186
med:pmid:40543460:sec:introduction:sent:2,med:pmid:40543460,introduction,2,"The purpose of this study was to the impact of a cardiovascular population health initiative that integrates financial incentives, robust data infrastructure, and electronic health record clinical decision support on improving GDMT for cardiovascular disease (CVD).",187,472
med:pmid:40543460:sec:methods:sent:3,med:pmid:40543460,methods,3,The program was implemented across 15 ambulatory clinics with 54 cardiologists in an academic health system.,473,598
med:pmid:40543460:sec:methods:sent:4,med:pmid:40543460,methods,4,"Individualized CVD patient panels were created for each provider, and providers received quarterly performance and incentive reports.",599,732
med:pmid:40543460:sec:methods:sent:5,med:pmid:40543460,methods,5,"Quality metrics included antiplatelet and statin or proprotein convertase subtilisin/kexin type 9 inhibitor therapy for atherosclerotic cardiovascular disease prevention, blood pressure control, and GDMT for heart failure with reduced ejection fraction (HFrEF; specified beta blockers; ACEI, ARB, or ARNI; mineralocorticoid receptor antagonist).",733,1078
med:pmid:40543460:sec:methods:sent:6,med:pmid:40543460,methods,6,"An interrupted time series analysis evaluated monthly, 1-year, and 2-year changes in the odds of adhering to each specific metric associated with the implementation of the cardiovascular population health program.",1079,1292
med:pmid:40543460:sec:results:sent:7,med:pmid:40543460,results,7,"After the intervention, the composite HFrEF therapy metric improved significantly (2-year odds ratio [OR]: 2.285; 95% confidence interval [CI]: 1.653-3.158; P < 0.001).",1293,1478
med:pmid:40543460:sec:results:sent:8,med:pmid:40543460,results,8,"Individual metrics also improved, including mineralocorticoid receptor antagonist (2-year OR: 3.039; 95% CI: 2.520-3.663; P < 0.001); specified beta blockers (2-year OR: 1.430; 95% CI: 1.129-1.810; P = 0.003); angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or angiotensin receptor-neprilysin inhibitor therapy for HFrEF (2-year OR: 1.228; 95% CI: 1.001-1.505; P = 0.049); statin or proprotein convertase subtilisin/kexin type 9 inhibitor therapy for atherosclerotic cardiovascular disease (2-year OR: 1.146; 95% CI: 1.092-1.202; P < 0.001); and blood pressure control (2-year OR: 1.496; 95% CI: 1.444-1.550; P < 0.001).",1479,2122
med:pmid:40543460:sec:conclusion:sent:9,med:pmid:40543460,conclusion,9,Our program was associated with sustained improvements in GDMT adherence for CVD.,2123,2225
med:pmid:40543460:sec:conclusion:sent:10,med:pmid:40543460,conclusion,10,It may serve as a scalable model for enhancing the quality of cardiovascular care.,2226,2308
med:pmid:40319618:sec:title:sent:0,med:pmid:40319618,title,0,Cost-Effectiveness Analysis of Angiotensin Receptor Neprilysin Inhibitor Compared With Angiotensin-Converting Enzyme Inhibitor Among Patients With Heart Failure With Reduced Ejection Fraction in Malaysia.,0,204
med:pmid:40319618:sec:introduction:sent:1,med:pmid:40319618,introduction,1,This study compared the costs and effectiveness of angiotensin receptor neprilysin inhibitor (ARNI) with angiotensin-converting enzyme inhibitor (ACEI) for the heart failure with reduced ejection fraction population from the Malaysian Ministry of Health's perspective.,0,288
med:pmid:40319618:sec:methods:sent:2,med:pmid:40319618,methods,2,"A 3-state Markov model, with a monthly cycle, was constructed to estimate the lifetime healthcare costs, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) of ARNI and ACEI.",289,511
med:pmid:40319618:sec:methods:sent:3,med:pmid:40319618,methods,3,The monthly baseline risks for all-cause mortality and heart failure (HF) hospitalization were estimated from the PARADIGM-HF trial and age-adjusted to the Malaysian population.,512,689
med:pmid:40319618:sec:methods:sent:4,med:pmid:40319618,methods,4,The treatment effects were obtained from the PARADIGM-HF trial.,690,753
med:pmid:40319618:sec:methods:sent:5,med:pmid:40319618,methods,5,"All-cause mortality risks from hospitalization, utility values, and costs were derived from local studies.",754,860
med:pmid:40319618:sec:methods:sent:6,med:pmid:40319618,methods,6,All costs were adjusted to 2023.,861,893
med:pmid:40319618:sec:methods:sent:7,med:pmid:40319618,methods,7,The ICER was compared with Malaysian Ringgit (RM) 55 426 per QALY (one gross domestic product per capita).,894,1000
med:pmid:40319618:sec:results:sent:8,med:pmid:40319618,results,8,"Despite ARNI being more expensive compared with ACEI, it gained more QALYs, resulting in an ICER of RM46 498 per QALY.",1001,1136
med:pmid:40319618:sec:results:sent:9,med:pmid:40319618,results,9,"One-way sensitivity analyses found that the key model drivers were the relative treatment effects on cardiovascular mortality, duration of treatment effects, and time horizon.",1137,1312
med:pmid:40319618:sec:results:sent:10,med:pmid:40319618,results,10,Probabilistic sensitivity analysis estimated that ARNI is 66% cost-effective at the cost-effectiveness threshold of RM55 426 per QALY.,1313,1447
med:pmid:40319618:sec:results:sent:11,med:pmid:40319618,results,11,Subgroup analysis showed that ICER increased with age.,1448,1502
med:pmid:40319618:sec:results:sent:12,med:pmid:40319618,results,12,Scenario analysis demonstrated that initiation of ARNI alongside sodium-glucose cotransporter-2 inhibitor (SGLT-2i) produces more favorable ICER and ARNI without SGLT-2i.,1503,1673
med:pmid:40319618:sec:conclusion:sent:13,med:pmid:40319618,conclusion,13,"At the cost-effectiveness threshold of RM55 426 per QALY, ARNI is cost-effective compared with ACEI for the heart failure with reduced ejection fraction population.",1674,1859
med:pmid:40319618:sec:conclusion:sent:14,med:pmid:40319618,conclusion,14,Expanding patient access to ARNI is likely to improve health outcomes cost-effectively.,1860,1947
med:pmid:40188960:sec:title:sent:0,med:pmid:40188960,title,0,Angiography-derived index of microcirculatory resistance as a novel tool to assess coronary microvascular dysfunction in patients with diabetic cardiomyopathy.,0,159
med:pmid:40188960:sec:abstract:sent:1,med:pmid:40188960,abstract,1,"<h4>Backgrounds</h4> Coronary microvascular dysfunction (CMD) has been proposed as a major mechanism and a potential therapeutic target for diabetic cardiomyopathy (DbCM); however, it has not been fully investigated in a clinical setting.",0,238
med:pmid:40188960:sec:abstract:sent:2,med:pmid:40188960,abstract,2,The angiography-derived index of microcirculatory resistance (AMR) is a novel non-invasive measurement of CMD that exhibits promising clinical applications.,239,395
med:pmid:40188960:sec:methods:sent:3,med:pmid:40188960,methods,3,AMR was measured in hospitalized patients with DbCM and in control patients.,396,489
med:pmid:40188960:sec:methods:sent:4,med:pmid:40188960,methods,4,"The incidence, clinical characteristics, risk factors, and effects of pharmacological interventions on CMD were investigated.",490,615
med:pmid:40188960:sec:results:sent:5,med:pmid:40188960,results,5,AMR was significantly higher in patients who met the DbCM-2B diagnostic criteria.,616,714
med:pmid:40188960:sec:results:sent:6,med:pmid:40188960,results,6,"The independent risk factors for abnormal AMR included diabetes, body mass index (BMI), and N-terminal pro-brain natriuretic peptide (NT-pro-BNP).",715,861
med:pmid:40188960:sec:results:sent:7,med:pmid:40188960,results,7,"Patients with elevated NT-pro-BNP had high AMR, and those grouped by medication indicated that ACEI/ARB, sacubitril/valsartan, and trimetazidine might lower AMR in patients with elevated NT-pro-BNP.",862,1060
med:pmid:40188960:sec:conclusion:sent:8,med:pmid:40188960,conclusion,8,The DbCM-2B diagnostic criteria demonstrated a strong correlation with CMD.,1061,1157
med:pmid:40188960:sec:conclusion:sent:9,med:pmid:40188960,conclusion,9,"ACEI/ARB, sacubitril/valsartan, and trimetazidine might improve CMD in patients with DbCM.",1158,1248
med:pmid:40540017:sec:title:sent:0,med:pmid:40540017,title,0,Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy.,0,80
med:pmid:40540017:sec:abstract:sent:1,med:pmid:40540017,abstract,1,This study seeks to understand cardiac medication use in a large cohort of males with Duchenne Muscular Dystrophy (DMD) followed prospectively with focus on current practices and adherence to consensus directed medical therapy (CDMT).,0,234
med:pmid:40540017:sec:abstract:sent:2,med:pmid:40540017,abstract,2,DMD patients have been enrolled in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Dystrophinopathy Registry since 2021.,235,374
med:pmid:40540017:sec:abstract:sent:3,med:pmid:40540017,abstract,3,Cardiac medication use was analyzed at enrollment and most recent follow-up.,375,451
med:pmid:40540017:sec:abstract:sent:4,med:pmid:40540017,abstract,4,CDMT was defined as concurrent use of angiotensin-converting-enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) /angiotensin receptor-neprilysin inhibitor (ARNI) plus beta-blocker (BB) plus mineralocorticoid receptor antagonist (MRA).,452,697
med:pmid:40540017:sec:abstract:sent:5,med:pmid:40540017,abstract,5,Two hundred sixty-five males with DMD (median age 17.5 (IQR 14.5-21.5) years) were prospectively followed; median follow-up was 11.5 (IQR 6.2-15.6) months.,698,853
med:pmid:40540017:sec:abstract:sent:6,med:pmid:40540017,abstract,6,"At most recent follow-up, 153 patients (57.7%) had decreased LV systolic function, 67 (25.3% of the cohort) had moderate or severe dysfunction.",854,997
med:pmid:40540017:sec:abstract:sent:7,med:pmid:40540017,abstract,7,"For patients with moderate or severe dysfunction, CDMT was used for 49/67 (73.1%) at most recent follow-up, similar to 36/51 (70.6%) at enrollment (p = 0.92).",998,1156
med:pmid:40540017:sec:abstract:sent:8,med:pmid:40540017,abstract,8,"Target doses of CDMT were achieved for 27% of males on ACEi/ARB/ARNI, 28% on BB, and 23% on MRA.",1157,1253
med:pmid:40540017:sec:abstract:sent:9,med:pmid:40540017,abstract,9,Initial analysis of a prospective registry of males with DMD showed that ~ 30% of patients with moderate or severe LV dysfunction were not on CDMT at most recent follow-up and the majority did not reach target dosing.,1254,1471
med:pmid:40540017:sec:abstract:sent:10,med:pmid:40540017,abstract,10,"Further understanding regarding the optimal combination of cardiac medications for DMD cardiomyopathy is needed, as is a better understanding of the barriers to CDMT optimization given increasing cardiac causes of death for DMD patients.",1472,1709
med:pmid:40418165:sec:title:sent:0,med:pmid:40418165,title,0,Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis.,0,115
med:pmid:40418165:sec:introduction:sent:1,med:pmid:40418165,introduction,1,ST-segment elevation myocardial infarction (STEMI) is responsible for high morbidity and mortality rates globally.,0,134
med:pmid:40418165:sec:introduction:sent:2,med:pmid:40418165,introduction,2,"Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs.",135,362
med:pmid:40418165:sec:introduction:sent:3,med:pmid:40418165,introduction,3,This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI.,363,460
med:pmid:40418165:sec:methods:sent:4,med:pmid:40418165,methods,4,Randomized controlled trials (RCTs) were pooled from PubMed and Cochrane databases.,461,561
med:pmid:40418165:sec:methods:sent:5,med:pmid:40418165,methods,5,A random-effects model calculated risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs).,562,687
med:pmid:40418165:sec:results:sent:6,med:pmid:40418165,results,6,"Five trials (<i>n</i> = 4,915) were included.",688,750
med:pmid:40418165:sec:results:sent:7,med:pmid:40418165,results,7,"ARNIs significantly reduced major adverse cardiovascular events (MACE) (RR: 0.66, 95% CI [0.50, 0.86]; <i>p</i> = 0.002) and hospitalizations for heart failure (HHF) (RR: 0.67, 95% CI [0.49, 0.92]; <i>p</i> = 0.01).",751,966
med:pmid:40418165:sec:results:sent:8,med:pmid:40418165,results,8,"ARNIs also improved left ventricular ejection fraction (LVEF) (WMD: 2.60, 95% CI[1.53, 3.68]; <i>p</i> < 0.00001) and lowered NT-proBNP levels (WMD: -268.89, 95% CI[-422.35, -115.42]; <i>p</i> = 0.0006).",967,1170
med:pmid:40418165:sec:results:sent:9,med:pmid:40418165,results,9,"No significant differences were observed in recurrent myocardial infarction, cardiovascular death, or safety outcomes - except for hypotension, which was significantly more common with ARNI use.",1171,1365
med:pmid:40418165:sec:conclusion:sent:10,med:pmid:40418165,conclusion,10,"ARNI therapy reduces MACE, HHF, and NT-proBNP levels and improves LVEF in patients with STEMI without increasing safety risks, except for hypotension.",1366,1537
med:pmid:40418165:sec:conclusion:sent:11,med:pmid:40418165,conclusion,11,Further RCTs are needed to confirm these findings.,1538,1588
med:pmid:40268473:sec:title:sent:0,med:pmid:40268473,title,0,Effects of Sacubitril/Valsartan on Myocardial Tissue in Heart Failure With Left Ventricular Ejection Fraction Below 50.,0,119
med:pmid:40268473:sec:introduction:sent:1,med:pmid:40268473,introduction,1,The effects of sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor [ARNI]) on myocardial tissue in heart failure (HF) with left ventricular ejection fraction (LVEF) <50% remain unclear.,0,217
med:pmid:40268473:sec:results:sent:2,med:pmid:40268473,results,2,Sixty-four HF outpatients with LVEF <50% were randomized to ARNI (switching from an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [ACEi/ARB] to ARNI) or control (continuing with ACEi/ARB).,218,458
med:pmid:40268473:sec:results:sent:3,med:pmid:40268473,results,3,"Left ventricular (LV) structure and myocardial tissue, including changes in LV extracellular volume fraction (ECV), were evaluated before and after the 9-month program using cardiac magnetic resonance imaging.",459,668
med:pmid:40268473:sec:results:sent:4,med:pmid:40268473,results,4,The primary endpoint was changes in ECV.,669,709
med:pmid:40268473:sec:results:sent:5,med:pmid:40268473,results,5,"Secondary endpoints were changes in LVEF, LV volume and mass, and extra- and intracellular mass.",710,806
med:pmid:40268473:sec:results:sent:6,med:pmid:40268473,results,6,Fifty-nine patients completed the 9-month intervention.,807,862
med:pmid:40268473:sec:results:sent:7,med:pmid:40268473,results,7,ARNI decreased systolic blood pressure from the first month.,863,923
med:pmid:40268473:sec:results:sent:8,med:pmid:40268473,results,8,"The ARNI group showed significant reductions in LV volume, LV mass, and extra- and intracellular mass from baseline to 9 months, but there was no change in LVEF, or in ECV (31.6±5.0% vs. 31.9±5.0%, respectively; P=0.795).",924,1145
med:pmid:40268473:sec:results:sent:9,med:pmid:40268473,results,9,"In the control group, there was no change in systolic blood pressure, LV volume, LV mass, ECV, or extra- and intracellular mass.",1146,1274
med:pmid:40268473:sec:results:sent:10,med:pmid:40268473,results,10,"There was no significant difference in the change in ECV between the ARNI and control groups (0.3±5.1% vs. 1.2±4.1%, respectively; P=0.461), whereas the change in extracellular mass was greater in the ARNI group (P=0.025).",1275,1497
med:pmid:40268473:sec:conclusion:sent:11,med:pmid:40268473,conclusion,11,"ARNI reduced LV volume and mass, resulting from decreases in both extra- and intracellular mass, without changing ECV.",1498,1637
med:pmid:40268473:sec:conclusion:sent:12,med:pmid:40268473,conclusion,12,This suggests ARNI has potential to improve LV tissue characteristics in HF patients with LVEF <50%.,1638,1738
med:pmid:39888167:sec:title:sent:0,med:pmid:39888167,title,0,Real-world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure.,0,128
med:pmid:39888167:sec:introduction:sent:1,med:pmid:39888167,introduction,1,"Large-scale, real-world data on early initiation of sacubitril/valsartan in patients newly diagnosed (de novo) with HF with reduced ejection fraction (HFrEF) are limited.",0,184
med:pmid:39888167:sec:introduction:sent:2,med:pmid:39888167,introduction,2,We examined the effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum® dataset in the United States.,185,456
med:pmid:39888167:sec:methods:sent:3,med:pmid:39888167,methods,3,This retrospective cohort study included adult patients with de novo HFrEF (diagnosed ≤30 days) with left ventricular ejection fraction (LVEF) ≤40% who were first prescribed with sacubitril/valsartan or ACEi/ARB from 1 January 2016 to 31 March 2020.,457,723
med:pmid:39888167:sec:methods:sent:4,med:pmid:39888167,methods,4,The primary endpoint (all-cause hospitalization) and secondary endpoints were analysed in propensity score-matched cohorts.,724,847
med:pmid:39888167:sec:results:sent:5,med:pmid:39888167,results,5,A cohort of 3290 patients with de novo HFrEF who were prescribed with sacubitril/valsartan and a propensity-matched cohort of 6580 patients who were prescribed with ACEi/ARB were analysed.,848,1053
med:pmid:39888167:sec:results:sent:6,med:pmid:39888167,results,6,"Overall, the mean (SD) age of patients was 63 (14) years, 34% were women, and baseline characteristics were balanced across treatment groups.",1054,1195
med:pmid:39888167:sec:results:sent:7,med:pmid:39888167,results,7,"Hypertension (67%), diabetes (33%) and chronic kidney disease (28%) were highly prevalent comorbidities.",1196,1300
med:pmid:39888167:sec:results:sent:8,med:pmid:39888167,results,8,"Patients in the sacubitril/valsartan cohort when compared with the ACEi/ARB cohort had lower annual rates of all-cause hospitalizations [incidence rate ratio (IRR): 0.81, 95% confidence interval (CI): 0.75-0.89, P < 0.001], cardiovascular (CV) hospitalizations (IRR: 0.80, 95% CI: 0.73-0.87, P < 0.001) and HF hospitalizations (IRR: 0.86, 95% CI: 0.78-0.95, P = 0.002).",1301,1670
med:pmid:39888167:sec:conclusion:sent:9,med:pmid:39888167,conclusion,9,"Among patients with de novo HFrEF, sacubitril/valsartan (compared with that of ACEi/ARB) was associated with fewer all-cause, CV and HF hospitalizations.",1671,1845
med:pmid:39888167:sec:conclusion:sent:10,med:pmid:39888167,conclusion,10,"These findings are consistent with clinical trial evidence suggesting potential benefits of early initiation of sacubitril/valsartan in patients with HFrEF, including those soon after diagnosis.",1846,2040
med:pmid:39829077:sec:title:sent:0,med:pmid:39829077,title,0,Guideline-directed medical therapy rates in heart failure patients with reduced ejection fraction in a diverse cohort.,0,118
med:pmid:39829077:sec:introduction:sent:1,med:pmid:39829077,introduction,1,Guideline-directed medical therapy (GDMT) is recommended for all patients with heart failure with reduced ejection fraction (HFrEF).,0,146
med:pmid:39829077:sec:introduction:sent:2,med:pmid:39829077,introduction,2,"Despite this, little data exist describing GDMT use in diverse, real-world populations including the use of vasodilators, prescribed primarily to Black populations.",147,311
med:pmid:39829077:sec:introduction:sent:3,med:pmid:39829077,introduction,3,"We sought, among a diverse population of HFrEF patients, to determine (1) GDMT use rates and target dosing by medication class and (2) predictors of GDMT use and target dosing by medication class.",312,508
med:pmid:39829077:sec:methods:sent:4,med:pmid:39829077,methods,4,"We utilized electronic health records (EHRs) from Kaiser Permanente (KP) Mid-Atlantic States, a large integrated health system.",509,653
med:pmid:39829077:sec:methods:sent:5,med:pmid:39829077,methods,5,Included patients had heart failure and left ventricular ejection fraction (EF) of ≤40% between 2015 and 2021.,654,764
med:pmid:39829077:sec:methods:sent:6,med:pmid:39829077,methods,6,"GDMT was defined by five medication classes-angiotensin-converting enzyme (ACE) inhibitors (ACEis)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), sodium-glucose cotransporter 2 inhibitors (SGLT2is) and vasodilators (Black patients only).",765,1112
med:pmid:39829077:sec:methods:sent:7,med:pmid:39829077,methods,7,Proportions of patients on GDMT and target dose rates were examined.,1113,1181
med:pmid:39829077:sec:methods:sent:8,med:pmid:39829077,methods,8,"Logistic regression determined, within each class, predictors of medication use and being at ≥80% of the target dose.",1182,1299
med:pmid:39829077:sec:results:sent:9,med:pmid:39829077,results,9,A total of 3154 patients were included.,1300,1356
med:pmid:39829077:sec:results:sent:10,med:pmid:39829077,results,10,"Among the 93.8% on some form of GDMT, 82.8%, 81.4%, 23.5%, 3.6% and 13.4% were on ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators (Black patients only), respectively.",1357,1529
med:pmid:39829077:sec:results:sent:11,med:pmid:39829077,results,11,"Among treated patients, 45.8%, 21.4%, 77.6%, 100% and 14.7% were treated at ≥80% of the target dose for ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators, respectively.",1530,1702
med:pmid:39829077:sec:results:sent:12,med:pmid:39829077,results,12,"Overall, increasing age, higher EF, atrial fibrillation/flutter, chronic obstructive pulmonary disease (COPD), prior stroke and dementia were associated with decreased odds of GDMT use.",1703,1888
med:pmid:39829077:sec:results:sent:13,med:pmid:39829077,results,13,"Conversely, higher body mass index (BMI), Black race, higher glomerular filtration rate (GFR), recent echo and cardiac defibrillator were associated with increased odds of GDMT use.",1889,2070
med:pmid:39829077:sec:results:sent:14,med:pmid:39829077,results,14,"Among treated, higher BMI, higher systolic blood pressure, haemoglobin A1C ≥ 6.5% and cardiac defibrillator were associated with higher odds of being at ≥80% of the target dose.",2071,2248
med:pmid:39829077:sec:conclusion:sent:15,med:pmid:39829077,conclusion,15,"Our study using real-world data from a diverse health system demonstrated gaps in GDMT use among patients with HFrEF, specifically older patients with more comorbidities.",2249,2440
med:pmid:40486108:sec:title:sent:0,med:pmid:40486108,title,0,Impact of the angiotensin receptor-neprilysin inhibitor on chronic heart failure due to adult congenital heart disease: A systematic review and meta-analysis.,0,158
med:pmid:40486108:sec:introduction:sent:1,med:pmid:40486108,introduction,1,"Heart failure (HF) is a significant complication in adults with congenital heart disease (ACHD), often requiring advanced therapeutic strategies.",0,165
med:pmid:40486108:sec:introduction:sent:2,med:pmid:40486108,introduction,2,Angiotensin receptor-neprilysin inhibitors (ARNIs) have emerged as a promising alternative to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in HF management.,166,367
med:pmid:40486108:sec:introduction:sent:3,med:pmid:40486108,introduction,3,"However, their safety and efficacy in ACHD-related HF remain unclear.",368,437
med:pmid:40486108:sec:introduction:sent:4,med:pmid:40486108,introduction,4,This systematic review and meta-analysis aim to evaluate the impact of ARNIs on functional and safety outcomes in this unique patient population.,438,583
med:pmid:40486108:sec:methods:sent:5,med:pmid:40486108,methods,5,"We conducted a systematic review and meta-analysis of published studies assessing the use of ARNIs in ACHD patients with HF, comparing them to ACEIs/ARBs.",584,755
med:pmid:40486108:sec:methods:sent:6,med:pmid:40486108,methods,6,The primary outcome was the change in New York Heart Association (NYHA) functional class (FC).,756,850
med:pmid:40486108:sec:methods:sent:7,med:pmid:40486108,methods,7,"Additionally, we assessed the safety profile of ARNIs in this population.",851,924
med:pmid:40486108:sec:results:sent:8,med:pmid:40486108,results,8,Our meta-analysis included 14 studies encompassing 305 patients.,925,1006
med:pmid:40486108:sec:results:sent:9,med:pmid:40486108,results,9,"Substituting ACEIs/ARBs with ARNIs significantly improved the NYHA functional class (log odds ratio [log OR] 0.67, 95% CI 0.15-1.19; <i>p</i> = 0.01).",1007,1157
med:pmid:40486108:sec:results:sent:10,med:pmid:40486108,results,10,"ARNI therapy was associated with a notable reduction in systolic blood pressure (mean difference [MD] -0.49, 95% CI -0.70 to -0.29, <i>p</i> < 0.001) and an increase in serum creatinine levels (MD 0.30, 95% CI 0.10-0.49, <i>p</i> < 0.001).",1158,1397
med:pmid:40486108:sec:results:sent:11,med:pmid:40486108,results,11,"However, no significant change in serum potassium levels was observed (MD 0.00, 95% CI -0.61-0.61, <i>p</i> = 0.99).",1398,1514
med:pmid:40486108:sec:conclusion:sent:12,med:pmid:40486108,conclusion,12,The addition of ARNIs to standard HF therapy may enhance functional outcomes in ACHD patients.,1515,1630
med:pmid:40486108:sec:conclusion:sent:13,med:pmid:40486108,conclusion,13,"However, the increased risk of hypotension and elevated serum creatinine levels necessitates careful monitoring.",1631,1743
med:pmid:40486108:sec:conclusion:sent:14,med:pmid:40486108,conclusion,14,Further research is essential to better define the role of ARNIs in managing ACHD-related HF.,1744,1837
med:pmid:40486108:sec:conclusion:sent:15,med:pmid:40486108,conclusion,15,<h4>Registration</h4> URL: https://www.crd.york.ac.uk/prospero; Unique identifier: CRD42024591442.,1838,1936
med:pmid:40389107:sec:title:sent:0,med:pmid:40389107,title,0,Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the PREMIER Study.,0,91
med:pmid:40389107:sec:introduction:sent:1,med:pmid:40389107,introduction,1,This study investigated the effect of uptitration of sacubitril/valsartan (Sac/Val) compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level within current guideline-directed medical therapy in acute heart failure (AHF).,0,341
med:pmid:40389107:sec:results:sent:2,med:pmid:40389107,results,2,This was the secondary analysis in the Program Angiotensin-Neprilysin Inhibition in Admitted Patients with Worsening Heart Failure (PREMIER) study.,342,518
med:pmid:40389107:sec:results:sent:3,med:pmid:40389107,results,3,"AHF patients were allocated to switch to Sac/Val or ACEIs/ARBs, and the Sac/Val group was divided into Sac/Val with or without uptitration group (Sac/Val >24/26 mg or ≤24/26 mg twice daily at week 8).",519,719
med:pmid:40389107:sec:results:sent:4,med:pmid:40389107,results,4,The primary endpoint was the proportional change in geometric means of NT-proBNP levels at week 8.,720,818
med:pmid:40389107:sec:results:sent:5,med:pmid:40389107,results,5,"A total of 376 patients were included, consistent with the primary analysis in PREMIER.",819,906
med:pmid:40389107:sec:results:sent:6,med:pmid:40389107,results,6,"The percent changes in the NT-proBNP level were -51% (Sac/Val with uptitration), -39% (Sac/Val without uptitration), and -32% (ACEIs/ARBs).",907,1046
med:pmid:40389107:sec:results:sent:7,med:pmid:40389107,results,7,"Their group ratios adjusted for baseline characteristics were 0.72 (Sac/Val with uptitration vs. ACEIs/ARBs, 95% confidence interval [CI], 0.59 to 0.89; P = .002) and 0.93 (Sac/Val without uptitration vs. ACEIs/ARBs, 95% CI, 0.76 to 1.13; P = .47).",1047,1295
med:pmid:40389107:sec:results:sent:8,med:pmid:40389107,results,8,"However, the Sac/Val without uptitration group yielded a greater NT-proBNP reduction than the ACEI/ARB group (adjusted ratio of change 0.72, 95% CI, 0.55 to 0.94; P = .016) in the subgroup of reduced ejection fraction.",1296,1514
med:pmid:40389107:sec:results:sent:9,med:pmid:40389107,results,9,There were no adverse events associated with Sac/Val uptitration.,1515,1580
med:pmid:40389107:sec:conclusion:sent:10,med:pmid:40389107,conclusion,10,"Uptitration of Sac/Val therapy yielded a greater NT-proBNP level reduction in AHF patients, but Sac/Val therapy without uptitration also reduced NT-proBNP levels in a subgroup with reduced ejection fraction compared with ACEI/ARB therapy.",1581,1840
med:pmid:40265590:sec:title:sent:0,med:pmid:40265590,title,0,Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HF.,0,158
med:pmid:40265590:sec:introduction:sent:1,med:pmid:40265590,introduction,1,"Women with heart failure (HF) ejection fraction appeared to respond more favorably to sacubitril/valsartan, compared with valsartan, than men in PARAGON-HF (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction), driven by a greater reduction in total (first and recurrent) HF hospitalizations.",0,366
med:pmid:40265590:sec:introduction:sent:2,med:pmid:40265590,introduction,2,Sex-specific efficacy and safety of sacubitril/valsartan in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) remain unreported.,367,571
med:pmid:40265590:sec:results:sent:3,med:pmid:40265590,results,3,This post hoc analysis of PARADIGM-HF examined sex-based outcomes in patients with HF and reduced ejection fraction randomized to sacubitril/valsartan or enalapril.,572,765
med:pmid:40265590:sec:results:sent:4,med:pmid:40265590,results,4,The primary end point was a composite of cardiovascular death or HF hospitalization.,766,850
med:pmid:40265590:sec:results:sent:5,med:pmid:40265590,results,5,"Secondary and exploratory efficacy outcomes, biomarker changes, and safety outcomes were also assessed.",851,954
med:pmid:40265590:sec:results:sent:6,med:pmid:40265590,results,6,"Among 8399 participants, 1832 (21.8%) were women.",955,1004
med:pmid:40265590:sec:results:sent:7,med:pmid:40265590,results,7,"Women were older, had worse New York Heart Association functional class and Kansas City Cardiomyopathy Questionnaire scores, more symptoms of HF, and lower estimated glomerular filtration rate, yet had lower rates of HF hospitalization (and other worsening of HF) and cardiovascular death than men.",1005,1303
med:pmid:40265590:sec:results:sent:8,med:pmid:40265590,results,8,"Compared with enalapril, sacubitril/valsartan reduced the risk of the primary end point to a similar extent in both sexes: hazard ratios, 0.76 (95% CI, 0.62-0.94) in women and 0.80 (95% CI, 0.73-0.89) in men (<i>P</i>-interaction=0.62).",1304,1540
med:pmid:40265590:sec:results:sent:9,med:pmid:40265590,results,9,were consistent for the individual components of the primary outcome.,1541,1618
med:pmid:40265590:sec:results:sent:10,med:pmid:40265590,results,10,"The rate ratio for total HF hospitalizations was 0.66 (95% CI, 0.48-0.89) in women and 0.80 (95% CI, 0.69-0.94) in men (<i>P</i>-interaction=0.25).",1619,1766
med:pmid:40265590:sec:results:sent:11,med:pmid:40265590,results,11,Randomized treatment discontinuation and adverse effects of interest were similar in women and men.,1767,1866
med:pmid:40265590:sec:conclusion:sent:12,med:pmid:40265590,conclusion,12,"In PARADIGM-HF, sacubitril/valsartan, compared with enalapril, reduced the risk of HF hospitalizations, death from cardiovascular causes, and death from any cause similarly in women and men with HF with reduced ejection fraction.",1867,2117
med:pmid:40265590:sec:conclusion:sent:13,med:pmid:40265590,conclusion,13,"In addition, sacubitril/valsartan was safe and well tolerated, irrespective of sex.",2118,2201
med:pmid:40265590:sec:conclusion:sent:14,med:pmid:40265590,conclusion,14,<h4>Registration</h4> URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01035255.,2202,2292
med:pmid:39563094:sec:title:sent:0,med:pmid:39563094,title,0,Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF.,0,165
med:pmid:39563094:sec:introduction:sent:1,med:pmid:39563094,introduction,1,"Beta-blockers may inhibit neprilysin activity and conversely, neprilysin inhibition may have a sympatho-inhibitory action.",0,136
med:pmid:39563094:sec:introduction:sent:2,med:pmid:39563094,introduction,2,"Consequently, sacubitril/valsartan may have a greater effect in patients not receiving a beta-blocker compared to those treated with a beta-blocker.",137,285
med:pmid:39563094:sec:results:sent:3,med:pmid:39563094,results,3,We examined the effect of sacubitril/valsartan compared to enalapril on outcomes according to background beta-blocker treatment in the 8399 patients with heart failure with reduced ejection fraction enrolled in PARADIGM-HF.,286,538
med:pmid:39563094:sec:results:sent:4,med:pmid:39563094,results,4,The primary outcome was time to first heart failure hospitalization or cardiovascular death.,539,631
med:pmid:39563094:sec:results:sent:5,med:pmid:39563094,results,5,"Compared to the 7811 patients taking a beta-blocker, the 588 patients not receiving a beta-blocker were older, more frequently female, but had a similar mean left ventricular ejection fraction and New York Heart Association class distribution, with little difference in N-terminal pro-B-type natriuretic peptide.",632,944
med:pmid:39563094:sec:results:sent:6,med:pmid:39563094,results,6,Patients not taking beta-blockers had a higher rate of the primary endpoint than those taking beta-blockers.,945,1053
med:pmid:39563094:sec:results:sent:7,med:pmid:39563094,results,7,"The benefit of sacubitril/valsartan on the primary endpoint was evident in both the no beta-blocker subgroup (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.45-0.82) and the beta-blocker subgroup (HR 0.82, 95% CI 0.75-0.90; p-interaction = 0.06).",1054,1308
med:pmid:39563094:sec:results:sent:8,med:pmid:39563094,results,8,The respective HRs for cardiovascular death were 0.47 (95% CI 0.32-0.69) versus 0.84 (95% CI 0.75-0.95; p-interaction <0.01) and for HF hospitalization 0.76 (95% CI 0.51-1.12) versus 0.80 (95% CI 0.71-0.90; p-interaction = 0.73).,1309,1538
med:pmid:39563094:sec:results:sent:9,med:pmid:39563094,results,9,"For all-cause death, the HR in the no beta-blocker group was 0.50 (95% CI 0.36-0.71) compared to 0.89 (95% CI 0.80-0.99) in the beta-blocker group (p-interaction <0.01).",1539,1708
med:pmid:39563094:sec:results:sent:10,med:pmid:39563094,results,10,Safety outcomes related to sacubitril/valsartan versus enalapril did not differ according to background beta-blocker use.,1709,1830
med:pmid:39563094:sec:conclusion:sent:11,med:pmid:39563094,conclusion,11,"Sacubitril/valsartan may be more effective than enalapril in reducing the risk of death in patients not treated with a beta-blocker compared to those treated with a beta-blocker, but is effective regardless of beta-blocker use.",1831,2078
med:pmid:39563094:sec:conclusion:sent:12,med:pmid:39563094,conclusion,12,<h4>Clinical trial registration</h4> ClinicalTrials.gov NCT01035255.,2079,2147
med:pmid:40718065:sec:title:sent:0,med:pmid:40718065,title,0,Pharmacological treatment of patients with chronic heart failure.,0,65
med:pmid:40718065:sec:title:sent:1,med:pmid:40718065,title,1,Subanalysis of an Ecuadorian registry.,66,104
med:pmid:40718065:sec:introduction:sent:2,med:pmid:40718065,introduction,2,Introduction.,0,35
med:pmid:40718065:sec:introduction:sent:3,med:pmid:40718065,introduction,3,"In Ecuador, there is limited data on the treatment of patients with heart failure (HF).",36,123
med:pmid:40718065:sec:introduction:sent:4,med:pmid:40718065,introduction,4,This study aimed to determine the rate of use of prognosis-modifying drugs and their association with prognosis.,124,255
med:pmid:40718065:sec:methods:sent:5,med:pmid:40718065,methods,5,"A retrospective observational study was conducted on patients with chronic HF included in the ""Los Ceibos"" registry between January 2017 and December 2022.",256,442
med:pmid:40718065:sec:methods:sent:6,med:pmid:40718065,methods,6,Patients were followed for a median of 2.28 years (interquartile range [IQR]: 1.25-3.49).,443,532
med:pmid:40718065:sec:results:sent:7,med:pmid:40718065,results,7,A total of 711 patients diagnosed with HF were included.,533,606
med:pmid:40718065:sec:results:sent:8,med:pmid:40718065,results,8,"Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs).",607,911
med:pmid:40718065:sec:results:sent:9,med:pmid:40718065,results,9,"Among patients with HFrEF, those receiving triple therapy (ACEI/ARB/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014).",912,1078
med:pmid:40718065:sec:results:sent:10,med:pmid:40718065,results,10,"In patients with Heart Failure with preserved Ejection Fraction (HFpEF), no mortality differences were observed according to the number of medications used (log-rank p=0.720).",1079,1254
med:pmid:40718065:sec:results:sent:11,med:pmid:40718065,results,11,MRA use was not associated with a prognostic benefit in HFpEF (p>0.05).,1255,1326
med:pmid:40718065:sec:results:sent:12,med:pmid:40718065,results,12,Patients receiving triple therapy with ARNI + BB + MRA had better survival during follow-up compared to any other drug combination (log-rank p=0.027).,1327,1477
med:pmid:40718065:sec:conclusion:sent:13,med:pmid:40718065,conclusion,13,A high rate of ACEI/ARB/ARNI and BB use was observed.,1478,1552
med:pmid:40718065:sec:conclusion:sent:14,med:pmid:40718065,conclusion,14,"The use of triple therapy, particularly the combination of ARNI + BB + MRA, was associated with improved prognosis in patients with HFrEF over a four-year follow-up period.",1553,1725
med:pmid:40718065:sec:conclusion:sent:15,med:pmid:40718065,conclusion,15,No prognostic benefit of MRA use was observed in patients with HFpEF.,1726,1795
med:pmid:40385266:sec:title:sent:0,med:pmid:40385266,title,0,Initial outcomes of novel guideline-directed pharmacotherapy for systemic right heart failure in adults with congenital heart disease.,0,134
med:pmid:40385266:sec:introduction:sent:1,med:pmid:40385266,introduction,1,"The combination therapy of angiotensin-converting enzyme inhibitors (ACEi) or alternatively angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and recently sodium-glucose co-transporter 2 inhibitors (SGLT2is) has been hailed as a breakthrough in heart failure treatment for patients with structurally normal hearts, with international guidelines recommending these as first-line therapies (""fantastic four"").",0,497
med:pmid:40385266:sec:introduction:sent:2,med:pmid:40385266,introduction,2,"However, specific recommendations for adult with congenital heart disease (ACHD) and systemic right ventricle (sRV), who are at heightened risk for heart failure, are largely based on clinical experience or position statements, lacking robust clinical trial data.",498,761
med:pmid:40385266:sec:introduction:sent:3,med:pmid:40385266,introduction,3,This study aims to evaluate the effectiveness and tolerability of these medications in ACHD patients with sRV.,762,872
med:pmid:40385266:sec:methods:sent:4,med:pmid:40385266,methods,4,"This retrospective single-center cohort study included 21 adult patients with sRV and signs of heart failure [6 with d-transposition of the great arteries (d-TGA) post-atrial switch, 7 with congenitally corrected transposition of the great arteries (cc-TGA), and 8 with univentricular right heart in Fontan circulation].",873,1210
med:pmid:40385266:sec:methods:sent:5,med:pmid:40385266,methods,5,"Changes in functional New York Heart Association (NYHA) class, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, sRV function, and renal function were assessed before and after initiating or escalating heart failure pharmacotherapy with ARNi and/or SGLT2i.",1211,1479
med:pmid:40385266:sec:methods:sent:6,med:pmid:40385266,methods,6,The median follow-up was 15 months (1.24 years).,1480,1528
med:pmid:40385266:sec:results:sent:7,med:pmid:40385266,results,7,"The combination therapy was well tolerated among all patients, with no interruptions in therapy and no adverse effects such as hyperkalemia, renal dysfunction, or significant hypotension reported.",1529,1742
med:pmid:40385266:sec:results:sent:8,med:pmid:40385266,results,8,"Among the 21 patients with follow-up data, 12 were treated with the full combination of guideline-directed therapy, including ARNi and SGLT2i.",1743,1885
med:pmid:40385266:sec:results:sent:9,med:pmid:40385266,results,9,"NYHA class improved in 62.0% of patients (P=0.001), and the median NT-proBNP level decreased from 870 (range, 593-1,774) to 373 (range, 189-743) ng/L (P=0.001).",1886,2046
med:pmid:40385266:sec:results:sent:10,med:pmid:40385266,results,10,"However, no significant change in ventricular function was detected by echocardiography.",2047,2135
med:pmid:40385266:sec:conclusion:sent:11,med:pmid:40385266,conclusion,11,Our preliminary findings suggest that in ACHD patients with a sRV the new guideline-directed heart failure pharmacotherapy regimen is well tolerated and leads to improvements in NYHA class and reductions in NT-proBNP levels.,2136,2381
med:pmid:40385266:sec:conclusion:sent:12,med:pmid:40385266,conclusion,12,"Further randomized studies are needed to confirm these promising results and to explore the effects of SGLT2i, either alone or in combination, in this patient population.",2382,2552
med:pmid:40295134:sec:title:sent:0,med:pmid:40295134,title,0,"Evaluation of the efficacy of angiotensin receptor-neprilysin inhibitor in patients with aortic stenosis undergoing transcatheter aortic valve implantation: protocol for a randomised, open-label, controlled study.",0,213
med:pmid:40295134:sec:introduction:sent:1,med:pmid:40295134,introduction,1,"There are a substantial number of patients developing heart failure after transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS), even though AS has been successfully treated.",0,221
med:pmid:40295134:sec:introduction:sent:2,med:pmid:40295134,introduction,2,"The purpose of this randomised controlled trial was to determine whether the addition of an angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, is superior to conventional medications in lowering N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients undergoing TAVI for AS.",222,534
med:pmid:40295134:sec:introduction:sent:3,med:pmid:40295134,introduction,3,"<h4>Methods and analysis</h4> The study design is a prospective, single-centre, open-label, randomised, parallel-group, two-arm study, in which participants will be randomised in a 1:1 ratio to receive either conventional medications plus ARNI or conventional medications only.",535,812
med:pmid:40295134:sec:introduction:sent:4,med:pmid:40295134,introduction,4,"In the ARNI group, if a patient was on an ACE inhibitor or angiotensin II receptor blocker before TAVI, it will be switched to ARNI 100 mg/day (50 mg two times per day) on the first postoperative day.",813,1013
med:pmid:40295134:sec:introduction:sent:5,med:pmid:40295134,introduction,5,"If not, candesartan 4 mg/day will be started 1-2 days before TAVI, and switched to ARNI 100 mg/day on the first postoperative day.",1014,1144
med:pmid:40295134:sec:introduction:sent:6,med:pmid:40295134,introduction,6,"As the patient has tolerability to ARNI, dosage will be increased stepwise to 400 mg/day 2-4 weeks apart.",1145,1250
med:pmid:40295134:sec:introduction:sent:7,med:pmid:40295134,introduction,7,ARNI will be continued until at least 6-month follow-up.,1251,1307
med:pmid:40295134:sec:introduction:sent:8,med:pmid:40295134,introduction,8,"In the control group, the patient will receive conventional medications.",1308,1380
med:pmid:40295134:sec:introduction:sent:9,med:pmid:40295134,introduction,9,The primary endpoint is the serum NT-proBNP value at 6-month follow-up after TAVI.,1381,1463
med:pmid:40295134:sec:introduction:sent:10,med:pmid:40295134,introduction,10,Each group includes 42 patients (84 total patients).,1464,1516
med:pmid:40295134:sec:introduction:sent:11,med:pmid:40295134,introduction,11,<h4>Ethics and dissemination</h4> Ethical approval for this study has been obtained from the Chiba University Hospital Certified Clinical Research Review Board (CRB3180015).,1517,1690
med:pmid:40295134:sec:introduction:sent:12,med:pmid:40295134,introduction,12,The study is ongoing.,1691,1712
med:pmid:40295134:sec:results:sent:13,med:pmid:40295134,results,13,from this study will be disseminated through peer-reviewed publications and conference presentations.,1713,1823
med:pmid:40295134:sec:results:sent:14,med:pmid:40295134,results,14,<h4>Trial registration number</h4> This trial has been registered on the Japan Registry of Clinical Trials: jRCT1031220344.,1824,1947
med:pmid:40283370:sec:title:sent:0,med:pmid:40283370,title,0,Sacubitril/Valsartan Improves Hemodynamic Parameters of Pulmonary and Systemic Circulation in Patients Awaiting Heart Transplantation.,0,134
med:pmid:40283370:sec:introduction:sent:1,med:pmid:40283370,introduction,1,Heart transplantation (HTX) is the definitive treatment for advanced heart failure (AdHF).,0,120
med:pmid:40283370:sec:introduction:sent:2,med:pmid:40283370,introduction,2,The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) has been shown to reduce heart failure (HF) hospitalizations and mortality when compared to conventionally administered HF medications (i.e. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)).,121,436
med:pmid:40283370:sec:introduction:sent:3,med:pmid:40283370,introduction,3,"Nevertheless, limited data are available on the hemodynamic (HD) effects of ARNI in patients with AdHF.",437,540
med:pmid:40283370:sec:introduction:sent:4,med:pmid:40283370,introduction,4,"Therefore, the aim of the present study was to compare echocardiographic, laboratory, and HD parameters relevant to HF before and after switching to ARNI in patients with AdHF awaiting HTX.",541,730
med:pmid:40283370:sec:introduction:sent:5,med:pmid:40283370,introduction,5,"<b>Methods</b>: A retrospective analysis was conducted utilizing available data on HD parameters, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, data on kidney function, HF therapy, and comorbidities.",731,945
med:pmid:40283370:sec:introduction:sent:6,med:pmid:40283370,introduction,6,"The study cohort comprised 13 AdHF patients (3 women, 10 men; mean age 56.4 ± 9 years) of whom 53.8% presented with non-ischemic and 46.2% with ischemic etiology.",946,1108
med:pmid:40283370:sec:introduction:sent:7,med:pmid:40283370,introduction,7,All patients were awaiting heart transplantation (HTX) and were transitioned to ARNI therapy between 2018 and 2021.,1109,1224
med:pmid:40283370:sec:introduction:sent:8,med:pmid:40283370,introduction,8,"<b>Results</b>: After switching to ARNI, we observed significant improvements: in left ventricular ejection fraction (LVEF: 27.27 ± 1.04% vs. 23.65 ± 1.02%, <i>p</i> = 0.03; data are given as mean ± SEM after vs. before ARNI therapy, respectively), cardiac output (CO: 4.90 ± 0.35 L/min vs. 3.83 ± 0.24 L/min, <i>p</i> = 0.013), and stroke volume (SV: 70.9 ± 5.9 mL vs. 55.5 ± 4.12 mL, <i>p</i> = 0.013).",1225,1629
med:pmid:40283370:sec:introduction:sent:9,med:pmid:40283370,introduction,9,"Significant reductions in systemic vascular resistance (SVR: 1188 ± 79.8 vs. 1600 ± 100 DS/cm<sup>5</sup>, <i>p</i> = 0.004) and pulmonary vascular resistance (PVR: 232.5 ± 34.8 vs. 278.9 ± 31.7 DS/cm<sup>5</sup>, <i>p</i> = 0.04) were also noted.",1630,1877
med:pmid:40283370:sec:introduction:sent:10,med:pmid:40283370,introduction,10,"Central venous pressure (CVP), pulmonary arterial systolic and diastolic pressures (PAPs and PAPd), pulmonary capillary wedge pressure (PCWP), and NT-proBNP levels did not exhibit significant changes upon ARNI administration.",1878,2103
med:pmid:40283370:sec:introduction:sent:11,med:pmid:40283370,introduction,11,"<b>Conclusions</b>: Early transition to ARNI therapy offers significant benefits for invasively measured hemodynamic parameters in patients with AdHF, potentially aiding in the stabilization and improvement of this vulnerable patient population.",2104,2349
med:pmid:40266448:sec:title:sent:0,med:pmid:40266448,title,0,Association of Angiotensin Receptor-Neprilysin Inhibitors Use and Better Cardiorenal Outcomes in Patients With Heart Failure and Acute Kidney Disease.,0,150
med:pmid:40266448:sec:introduction:sent:1,med:pmid:40266448,introduction,1,Angiotensin receptor-neprilysin inhibitors (ARNi) have been shown to improve cardiovascular outcomes in heart failure (HF) patients.,0,149
med:pmid:40266448:sec:introduction:sent:2,med:pmid:40266448,introduction,2,"However, their impact on HF patients with concurrent acute kidney disease (AKD) remains underexplored.",150,252
med:pmid:40266448:sec:introduction:sent:3,med:pmid:40266448,introduction,3,This study investigated the outcomes of ARNi compared to angiotensin-converting enzyme inhibitors (ACEi) in HF patients with AKD.,253,382
med:pmid:40266448:sec:methods:sent:4,med:pmid:40266448,methods,4,"The study included 20,009 hospitalized HF and AKD patients who underwent dialysis during hospitalization, recovered from dialysis within 90 days after discharge, and were followed until November 30, 2022, using data from TriNetX. The study period began in July 2015, coinciding with the availability of ARNi in the market.",383,722
med:pmid:40266448:sec:methods:sent:5,med:pmid:40266448,methods,5,Propensity score matching (1:1) was applied to balance ARNi and ACEi groups.,723,799
med:pmid:40266448:sec:methods:sent:6,med:pmid:40266448,methods,6,"Adjusted hazard ratios (aHR) with 95% confidence intervals (CI) were calculated to assess the risks of mortality, major adverse kidney events (MAKE), readmission and major adverse cardiac events (MACE).",800,1002
med:pmid:40266448:sec:methods:sent:7,med:pmid:40266448,methods,7,The follow-up period was conducted with a maximum duration of 5 years.,1003,1073
med:pmid:40266448:sec:results:sent:8,med:pmid:40266448,results,8,"A total of 20,009 AKD patients (mean [SD] age, 59.1 [12.2] years) were enrolled, of whom 21.9% received ARNi, with a median follow-up of 2.3 years.",1074,1238
med:pmid:40266448:sec:results:sent:9,med:pmid:40266448,results,9,"After matching, 4391 patients (mean age, 58.6 years; male, 67.9%) were identified in both the ARNi and control groups.",1239,1357
med:pmid:40266448:sec:results:sent:10,med:pmid:40266448,results,10,"ARNi users exhibited a significantly lower risk of mortality (aHR, 0.32, 95% CI 0.13-0.80, p = 0.01), MAKE (aHR, 0.58, 95% CI 0.51-0.66, p < 0.01 ), and readmission (aHR, 0.61, 95% CI 0.55-0.68, p <0.01) versus controls.",1358,1578
med:pmid:40266448:sec:results:sent:11,med:pmid:40266448,results,11,"However, no significant difference in the risk of MACE was observed between the two groups (aHR, 0.94, 95% CI 0.82-1.09, p = 0.78).",1579,1710
med:pmid:40266448:sec:results:sent:12,med:pmid:40266448,results,12,"Subgroup analysis revealed ARNi users, when concomitantly treated with mineralocorticoids, diuretics, or beta-blockers had significantly lower risks of mortality, readmission, and MAKE than the control group.",1711,1919
med:pmid:40266448:sec:results:sent:13,med:pmid:40266448,results,13,"In addition, ARNi significantly reduced mortality and MAKE in patients with GFR 30-60 mL/min/1.73 m<sup>2</sup>, irrespective of proteinuria status.",1920,2068
med:pmid:40266448:sec:results:sent:14,med:pmid:40266448,results,14,"However, no significant benefit was observed in patients with GFR <30 mL/min/1.73 m<sup>2</sup>.",2069,2165
med:pmid:40266448:sec:conclusion:sent:15,med:pmid:40266448,conclusion,15,"In HF patients with AKD, ARNi was associated with reduced all-cause mortality, MAKE, and readmission risks compared to ACEi, particularly with concurrent mineralocorticoids, diuretics, or beta-blockers.",2166,2389
med:pmid:40266448:sec:conclusion:sent:16,med:pmid:40266448,conclusion,16,Future research is necessary to further investigate the impact of ARNi on outcomes in patients with HF and AKD.,2390,2501
med:pmid:40261428:sec:title:sent:0,med:pmid:40261428,title,0,Heart failure burden and care among cardiology inpatients: insights from the Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study.,0,132
med:pmid:40261428:sec:introduction:sent:1,med:pmid:40261428,introduction,1,Heart failure (HF) burden and care varies significantly across different countries.,0,100
med:pmid:40261428:sec:introduction:sent:2,med:pmid:40261428,introduction,2,We aimed to illustrate the clinical characteristics and HF-related care among cardiology inpatients in Greece.,101,211
med:pmid:40261428:sec:methods:sent:3,med:pmid:40261428,methods,3,We collected information about all cardiology inpatients on the 3rd of March 2022.,212,311
med:pmid:40261428:sec:methods:sent:4,med:pmid:40261428,methods,4,The current analysis focuses on acute or chronic HF.,312,364
med:pmid:40261428:sec:results:sent:5,med:pmid:40261428,results,5,"Among a total of 923 participants, 280 (30%) concerned cases of acute HF whereas 351 patients (38%), (median age 79 ± 12 years, male gender 63.8%) had a history of chronic HF, with their majority presenting with multiple comorbidities and previous HF hospitalizations.",365,650
med:pmid:40261428:sec:results:sent:6,med:pmid:40261428,results,6,173 (49%) of chronic HF participants had reduced LVEF.,651,705
med:pmid:40261428:sec:results:sent:7,med:pmid:40261428,results,7,"Ischemic heart disease was the predominant HF etiology (182, 51.9%).",706,774
med:pmid:40261428:sec:results:sent:8,med:pmid:40261428,results,8,"Prior to the index admission, chronic HF cases were receiving diuretics, beta blockers, ACEi/ARBs, ARNI, MRAs, and SGLT2i at 79.8%, 74.4%, 43.3%, 10.8%, 40.7%, and 14%, respectively.",775,957
med:pmid:40261428:sec:results:sent:9,med:pmid:40261428,results,9,"Independent predictors of lower prescription rates of Guideline Directed Medical Therapy (GDMT) included advanced age (p < 0.001), chronic kidney disease (RASi OR 0.392, p = 0.008, MRA OR 0.523 p = 0.097), and lack of follow-up in dedicated HF clinics (p = 0.006).",958,1222
med:pmid:40261428:sec:results:sent:10,med:pmid:40261428,results,10,No regional differences with regards to GDMT were identified.,1223,1284
med:pmid:40261428:sec:conclusion:sent:11,med:pmid:40261428,conclusion,11,"In this nation-wide real-world snapshot study, patients with chronic and acute HF accounted for a significant proportion of cardiology inpatients, while ischemic heart disease was the leading HF cause.",1285,1506
med:pmid:40261428:sec:conclusion:sent:12,med:pmid:40261428,conclusion,12,GDMT and device therapy can be improved.,1507,1547
med:pmid:40261428:sec:conclusion:sent:13,med:pmid:40261428,conclusion,13,"Follow-up in dedicated HF units was related with increased prescription rates of GDMT, whereas this was not affected by geographical region.",1548,1688
med:pmid:40091512:sec:title:sent:0,med:pmid:40091512,title,0,Factors associated with the use of guideline-directed medical therapy in patients with left ventricular assist device.,0,118
med:pmid:40091512:sec:introduction:sent:1,med:pmid:40091512,introduction,1,Societal guidelines have recently supported the use of guideline-directed medical therapy (GDMT) in patients with left ventricular assist device (LVAD) to promote ventricular recovery.,0,198
med:pmid:40091512:sec:introduction:sent:2,med:pmid:40091512,introduction,2,We sought to characterize patient factors associated with use of GDMT in durable LVAD recipients.,199,296
med:pmid:40091512:sec:results:sent:3,med:pmid:40091512,results,3,"We performed a retrospective analysis of patients with a HeartMate 3 (HM3) LVAD at our institution, including comprehensive data from the past 12 months.",297,479
med:pmid:40091512:sec:results:sent:4,med:pmid:40091512,results,4,"The GDMT score (0-8) factored in doses of beta-blocker (BB), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB), mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), angiotensin receptor-neprilysin inhibitor (ARNI), isosorbide dinitrate/hydralazine (ISDN/HYD).",480,812
med:pmid:40091512:sec:results:sent:5,med:pmid:40091512,results,5,"Our cohort consisted of 270 patients (mean age 63 years, 77% male).",813,880
med:pmid:40091512:sec:results:sent:6,med:pmid:40091512,results,6,"Median GDMT score was 3 ± 1.7, and 155 patients (57.4%) had a score of 3 or lower.",881,963
med:pmid:40091512:sec:results:sent:7,med:pmid:40091512,results,7,"Prescription rates were 50% for BB, 74.1% for ACEi/ARB/ARNI, 14.8% for SGLT2i, 47% for MRA, and 19.6% for ISDN/HYD.",964,1079
med:pmid:40091512:sec:results:sent:8,med:pmid:40091512,results,8,"On univariable logistic regression, increasing age, right ventricular dysfunction, estimated glomerular filtration rate <60 ml/min/1.7 3 m<sup>2</sup>, and destination therapy strategy were associated with a GDMT score below the median.",1080,1316
med:pmid:40091512:sec:results:sent:9,med:pmid:40091512,results,9,Only age remained a significant predictor after adjustment.,1317,1376
med:pmid:40091512:sec:results:sent:10,med:pmid:40091512,results,10,"In multivariable analysis for individual drugs, right ventricular dysfunction was linked to non-use of BB, and age and Black race were associated with non-use of MRA and use of ISDN/HYD, but no significant predictors were identified for other therapies.",1377,1630
med:pmid:40091512:sec:conclusion:sent:11,med:pmid:40091512,conclusion,11,"While advancing age is associated with lower use of GDMT in HM3 recipients, other patient factors do not adequately explain low prescription rates.",1631,1798
med:pmid:40091512:sec:conclusion:sent:12,med:pmid:40091512,conclusion,12,This highlights significant opportunity to improve the use of GDMT in LVAD patients.,1799,1883
med:pmid:38811344:sec:title:sent:0,med:pmid:38811344,title,0,Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis.,0,117
med:pmid:38811344:sec:introduction:sent:1,med:pmid:38811344,introduction,1,"Angiotensin receptor neprilysin inhibitors (ARNIs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs) are the cornerstones in treating heart failure with reduced ejection fraction (HFrEF).",0,314
med:pmid:38811344:sec:introduction:sent:2,med:pmid:38811344,introduction,2,Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) are included in HFrEF treatment guidelines.,315,411
med:pmid:38811344:sec:introduction:sent:3,med:pmid:38811344,introduction,3,"However, the effect of SGLT-2i and the five drugs on HFrEF have not yet been systematically evaluated.",412,514
med:pmid:38811344:sec:methods:sent:4,med:pmid:38811344,methods,4,"PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) from inception dates to September 23, 2022.",515,670
med:pmid:38811344:sec:methods:sent:5,med:pmid:38811344,methods,5,Additional trials from previous relevant reviews and references were also included.,671,754
med:pmid:38811344:sec:methods:sent:6,med:pmid:38811344,methods,6,"The primary outcomes were changes in left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter/dimension (LVEDD), left ventricular end-systolic diameter/dimension (LVESD), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV), left ventricular end-systolic volume index (LVESVI), and left ventricular end-diastolic volume index (LVEDVI).",755,1159
med:pmid:38811344:sec:methods:sent:7,med:pmid:38811344,methods,7,"Secondary outcomes were New York Heart Association (NYHA) class, 6-min walking distance (6MWD), B-type natriuretic peptide (BNP) level, and N-terminal pro-BNP (NT-proBNP) level.",1160,1337
med:pmid:38811344:sec:methods:sent:8,med:pmid:38811344,methods,8,The effect sizes were presented as the mean difference (MD) with 95% confidence interval (CI).,1338,1432
med:pmid:38811344:sec:results:sent:9,med:pmid:38811344,results,9,"We included 68 RCTs involving 16,425 patients.",1433,1496
med:pmid:38811344:sec:results:sent:10,med:pmid:38811344,results,10,"Compared with placebo, ARNI + BB + MRA + SGLT-2i was the most effective combination to improve LVEF (15.63%, 95% CI: 9.91% to 21.68%).",1497,1631
med:pmid:38811344:sec:results:sent:11,med:pmid:38811344,results,11,"ARNI + BB + MRA + SGLT-2i (5.83%, 95% CI: 0.53% to 11.14%) and ARNI + BB + MRA (3.83%, 95% CI: 0.72% to 6.90%) were superior to the traditional golden triangle ACEI + BB + MRA in improving LVEF.",1632,1826
med:pmid:38811344:sec:results:sent:12,med:pmid:38811344,results,12,"ACEI + BB + MRA + SGLT-2i was better than ACEI + BB + MRA (-8.05 mL/m 2 , 95% CI: -14.88 to -1.23 mL/m 2 ) and ACEI + BB + SGLT-2i (-18.94 mL/m 2 , 95% CI: -36.97 to -0.61 mL/m 2 ) in improving LVEDVI.",1827,2028
med:pmid:38811344:sec:results:sent:13,med:pmid:38811344,results,13,"ACEI + BB + MRA + SGLT-2i (-3254.21 pg/mL, 95% CI: -6242.19 to -560.47 pg/mL) was superior to ARB + BB + MRA in reducing NT-proBNP.",2029,2160
med:pmid:38811344:sec:conclusion:sent:14,med:pmid:38811344,conclusion,14,Adding SGLT-2i to ARNI/ACEI + BB + MRA is beneficial for reversing cardiac remodeling.,2161,2268
med:pmid:38811344:sec:conclusion:sent:15,med:pmid:38811344,conclusion,15,"The new quadruple drug ""ARNI + BB + MRA + SGLT-2i"" is superior to the golden triangle ""ACEI + BB + MRA"" in improving LVEF.",2269,2391
med:pmid:38811344:sec:conclusion:sent:16,med:pmid:38811344,conclusion,16,<h4>Registration</h4> PROSPERO; No.,2392,2427
med:pmid:38811344:sec:conclusion:sent:17,med:pmid:38811344,conclusion,17,CRD42022354792.,2428,2443
med:pmid:40063170:sec:title:sent:0,med:pmid:40063170,title,0,Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure with reduced ejection fraction.,0,139
med:pmid:40063170:sec:introduction:sent:1,med:pmid:40063170,introduction,1,Heart failure (HF) is a significant global health issue.,0,76
med:pmid:40063170:sec:introduction:sent:2,med:pmid:40063170,introduction,2,Appropriate and timely treatment at target doses significantly reduces mortality and enhances quality of life.,77,187
med:pmid:40063170:sec:introduction:sent:3,med:pmid:40063170,introduction,3,"However, studies indicate suboptimal pharmacotherapy among patients.",188,256
med:pmid:40063170:sec:introduction:sent:4,med:pmid:40063170,introduction,4,This study aims to assess the medical treatment of patients with heart failure and reduced ejection fraction (HFrEF) and their adherence to the American Heart Association (AHA) guidelines.,257,445
med:pmid:40063170:sec:introduction:sent:5,med:pmid:40063170,introduction,5,"The study was designed as a cross-sectional analysis in the cardiac department of Razi Hospital in Birjand from March 20, 2020, to March 11, 2023, focusing on patients with left ventricular ejection fraction less than or equal to 40%.",446,680
med:pmid:40063170:sec:results:sent:6,med:pmid:40063170,results,6,were extracted from patients' medical records.,681,732
med:pmid:40063170:sec:results:sent:7,med:pmid:40063170,results,7,"Medications were classified according to the four-pillar therapy recommended by the AHA, including β-blockers, ARNI, ACE inhibitors/ARBs, SGLT2, and MRAs.",733,887
med:pmid:40063170:sec:results:sent:8,med:pmid:40063170,results,8,Patients were grouped based on their treatment regimens.,888,944
med:pmid:40063170:sec:results:sent:9,med:pmid:40063170,results,9,"The percentage of achieved target doses for each medication was categorized as follows: 0-25%, 25-50%, 50-99%, and 100%.",945,1065
med:pmid:40063170:sec:methods:sent:10,med:pmid:40063170,methods,10,was conducted using SPSS version 22.,1066,1123
med:pmid:40063170:sec:results:sent:11,med:pmid:40063170,results,11,"The study included patients with a mean age of 66 ± 13.7 years, of whom 278 (69%) were male.",1124,1233
med:pmid:40063170:sec:results:sent:12,med:pmid:40063170,results,12,"The mean ejection fraction was 26.8 ± 9.6%, and the most prevalent comorbidity was coronary artery disease (CAD) observed in 68.0% of patients.",1234,1377
med:pmid:40063170:sec:results:sent:13,med:pmid:40063170,results,13,The in-hospital mortality rate was 5%.,1378,1416
med:pmid:40063170:sec:results:sent:14,med:pmid:40063170,results,14,"The results revealed that only 20% were on quadruple therapy, while 10% received none of the recommended medications.",1417,1534
med:pmid:40063170:sec:results:sent:15,med:pmid:40063170,results,15,"The prescription rates for key medications were as follows: β-blockers 76.4%, ACE inhibitors/ARBs 71.6%, MRA 63.3%, SGLT2I 33.5%, and ARNI 0%.",1535,1677
med:pmid:40063170:sec:results:sent:16,med:pmid:40063170,results,16,"Notably, 94.8% of prescribed SGLT2I doses met the target dose, while 84.4% of β-blocker prescriptions and 61.8% of ACEI/ARB prescriptions were below 75% of the target dose.",1678,1850
med:pmid:40063170:sec:conclusion:sent:17,med:pmid:40063170,conclusion,17,"The findings reveal significant gaps in the prescription of essential therapies, including MRAs and ARNIs, which are crucial for managing myocardial dysfunction.",1851,2032
med:pmid:40063170:sec:conclusion:sent:18,med:pmid:40063170,conclusion,18,Addressing these gaps underscores the necessity for ongoing education and training for healthcare providers in heart failure management.,2033,2169
med:pmid:39983618:sec:title:sent:0,med:pmid:39983618,title,0,Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A Randomized Controlled Trial.,0,187
med:pmid:39983618:sec:introduction:sent:1,med:pmid:39983618,introduction,1,"In patients with bone marrow transplantation (BMT) for hematologic malignancies, evidence for prevention of cancer therapy-related cardiac dysfunction (CTRCD) remains limited.",0,195
med:pmid:39983618:sec:introduction:sent:2,med:pmid:39983618,introduction,2,The authors investigated whether early initiation of sacubitril/valsartan or enalapril could be helpful to prevent CTRCD in patients undergoing BMT.,196,364
med:pmid:39983618:sec:methods:sent:3,med:pmid:39983618,methods,3,"We randomized 90 patients with preserved left ventricular ejection fraction (LVEF) after BMT to sacubitril/valsartan, enalapril, or no cardioprotective medication (controls).",365,556
med:pmid:39983618:sec:methods:sent:4,med:pmid:39983618,methods,4,"The primary endpoints included i) LVEF, ii) LV global longitudinal strain (GLS), iii) myocardial wasted work (GWW), and work efficiency (GWE) by speckle tracking echocardiography.",557,736
med:pmid:39983618:sec:methods:sent:5,med:pmid:39983618,methods,5,Secondary endpoints included changes in LV volumes.,737,788
med:pmid:39983618:sec:results:sent:6,med:pmid:39983618,results,6,Patients treated with sacubitril/valsartan or enalapril for 6 months did not show a deterioration of LV GLS or LVEF (P > 0.05).,789,933
med:pmid:39983618:sec:results:sent:7,med:pmid:39983618,results,7,"Conversely, controls showed impaired LV GLS (-20.9% ± 2.1% vs -18.8% ± 2.6%, P = 0.001) and reduced LVEF (P = 0.045) at 6 months post-BMT.",934,1072
med:pmid:39983618:sec:results:sent:8,med:pmid:39983618,results,8,"The percent improvement of GWW and GWE was greater in the sacubitril/valsartan compared to enalapril or control group (P = 0.044 and P = 0.011, respectively) at 6 months.",1073,1243
med:pmid:39983618:sec:results:sent:9,med:pmid:39983618,results,9,"Conversely, in controls, GWW increased (80.7 ± 60.6 vs 115.3 ± 52.1 mm Hg%, P = 0.045), and GWE was compromised (P = 0.030) at 6 months post-BMT.",1244,1389
med:pmid:39983618:sec:results:sent:10,med:pmid:39983618,results,10,"Among the 3 treatment groups, only sacubitril/valsartan group showed a reduction in LV end-diastolic and systolic volume compared to baseline (102.3 ± 26.9 vs 93.2 ± 18.9 mL, P = 0.042 and 44.5 ± 15.4 vs 39.1 ± 10.1 mL, P = 0.012, respectively).",1390,1635
med:pmid:39983618:sec:conclusion:sent:11,med:pmid:39983618,conclusion,11,Treatment with sacubitril/valsartan or enalapril prevented deterioration of myocardial function at 6 months in patients with hematologic malignancies treated with BMT.,1636,1824
med:pmid:39983618:sec:conclusion:sent:12,med:pmid:39983618,conclusion,12,"Moreover, sacubitril/valsartan showed a more favorable effect on myocardial work indices. (",1825,1916
med:pmid:39983618:sec:conclusion:sent:13,med:pmid:39983618,conclusion,13,Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation; NCT04092309).,1916,2041
med:pmid:39970741:sec:title:sent:0,med:pmid:39970741,title,0,Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials.,0,107
med:pmid:39970741:sec:introduction:sent:1,med:pmid:39970741,introduction,1,Sacubitril/valsartan (SAV) is crucial for managing heart failure (HF).,0,90
med:pmid:39970741:sec:introduction:sent:2,med:pmid:39970741,introduction,2,Randomized clinical trials have shown SAV's superiority over angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) in reducing N-terminal pro-B-type natriuretic peptide levels.,91,302
med:pmid:39970741:sec:introduction:sent:3,med:pmid:39970741,introduction,3,"However, results for cardiovascular (CV) mortality, HF rehospitalization, and all-cause mortality have been mixed.",303,417
med:pmid:39970741:sec:introduction:sent:4,med:pmid:39970741,introduction,4,This study aimed to determine hard endpoints among the population with HF treated with SAV vs ACEI/ARBs and conduct a comprehensive risk-benefit analysis of the safety profile for SAV vs ACEI/ARB.,418,634
med:pmid:39970741:sec:methods:sent:5,med:pmid:39970741,methods,5,"We queried PubMed, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials for randomized clinical trials from inception to November 2023.",635,805
med:pmid:39970741:sec:methods:sent:6,med:pmid:39970741,methods,6,"We included studies that compared SAV to ACEI or ARBs and reported hard endpoints, including all-cause mortality, CV mortality, and HF rehospitalizations.",806,960
med:pmid:39970741:sec:methods:sent:7,med:pmid:39970741,methods,7,"Random effect model was used, and categorical values were analyzed using risk ratios (RRs) and 95% CI.",961,1063
med:pmid:39970741:sec:methods:sent:8,med:pmid:39970741,methods,8,The I<sup>2</sup> test was used to assess between-study heterogeneity.,1064,1134
med:pmid:39970741:sec:methods:sent:9,med:pmid:39970741,methods,9,Publication bias was assessed via funnel plots and the Egger test.,1135,1201
med:pmid:39970741:sec:methods:sent:10,med:pmid:39970741,methods,10,This study was registered in PROSPERO (CRD42024497661).,1202,1257
med:pmid:39970741:sec:results:sent:11,med:pmid:39970741,results,11,"The study included a total of 14 trials (n = 25,167).",1258,1328
med:pmid:39970741:sec:results:sent:12,med:pmid:39970741,results,12,"SAV reduced all-cause mortality in the population with an ejection fraction (EF) ≤40% (RR: 0.88; 95% CI: 0.81-0.94; P = 0.0006), but not in those with EF >40% (RR: 0.97; 95% 0.85-1.11; P = 0.67).",1329,1524
med:pmid:39970741:sec:results:sent:13,med:pmid:39970741,results,13,There was no difference in CV mortality across EF spectrums (RR: 0.9; 95% CI: 0.79-1.03; P = 0.13).,1525,1624
med:pmid:39970741:sec:results:sent:14,med:pmid:39970741,results,14,HF readmission was lower in the SAV-treated group regardless of EF (RR: 0.85; 95% CI: 0.79-0.91; P = 0.00001).,1625,1735
med:pmid:39970741:sec:conclusion:sent:15,med:pmid:39970741,conclusion,15,"The SAV-treated group, across all EF spectrum, was less likely to be rehospitalized than the ACEI/ARB-treated group.",1736,1873
med:pmid:39970741:sec:conclusion:sent:16,med:pmid:39970741,conclusion,16,"However, all-cause mortality reduction was only noted in the SAV group with EF <40%.",1874,1958
med:pmid:39970741:sec:conclusion:sent:17,med:pmid:39970741,conclusion,17,No reduction in CV-related mortality was observed across the EF spectrum.,1959,2032
med:pmid:39939202:sec:title:sent:0,med:pmid:39939202,title,0,A Comparison of Prescribing Guideline-Advocated Treatment for Heart Failure at Discharge from Cardiology and Non-Cardiology Wards.,0,130
med:pmid:39939202:sec:introduction:sent:1,med:pmid:39939202,introduction,1,Adherence to heart failure (HF) management guidelines is important to optimise clinical outcomes but can be variable in practice.,0,149
med:pmid:39939202:sec:introduction:sent:2,med:pmid:39939202,introduction,2,This study compared prescribing guideline-advocated pharmacological and non-pharmacological management of HF between patients discharged from cardiology and non-cardiology wards.,150,328
med:pmid:39939202:sec:introduction:sent:3,med:pmid:39939202,introduction,3,<h4>Method</h4> A retrospective audit of electronic medical records was undertaken of patients discharged from cardiology (n=100) or non-cardiology wards (n=100) of a tertiary hospital with a primary diagnosis of HF.,329,545
med:pmid:39939202:sec:introduction:sent:4,med:pmid:39939202,introduction,4,Non-pharmacological management was quantified from documentation in medical records.,546,630
med:pmid:39939202:sec:introduction:sent:5,med:pmid:39939202,introduction,5,Drug prescription was determined based on patients' discharge summaries.,631,703
med:pmid:39939202:sec:introduction:sent:6,med:pmid:39939202,introduction,6,Comparisons between wards were conducted using Student's t-tests or Mann-Whitney U tests for continuous data and chi square tests or Fisher's tests for categorical data.,704,873
med:pmid:39939202:sec:introduction:sent:7,med:pmid:39939202,introduction,7,Binary logistic regression modelling was applied.,874,923
med:pmid:39939202:sec:results:sent:8,med:pmid:39939202,results,8,"Patients discharged from non-cardiology wards were older and had a higher incidence of hypertension, ischaemic heart disease, and renal insufficiency than those discharged from cardiology wards.",924,1135
med:pmid:39939202:sec:results:sent:9,med:pmid:39939202,results,9,"The prescription of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)/angiotensin receptor neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists at any dose (52% vs 80%; p<0.01, 25% vs 52%; p<0.01, respectively) were lower in non-cardiology than in cardiology wards, but there was no difference between wards for beta blockers.",1136,1521
med:pmid:39939202:sec:results:sent:10,med:pmid:39939202,results,10,Referral to cardiac rehabilitation (4% vs 28%; p<0.01) before discharge was significantly lower in non-cardiology wards.,1522,1642
med:pmid:39939202:sec:results:sent:11,med:pmid:39939202,results,11,Increased age was associated with less likelihood of the prescription of ACEIs/ARBs/ARNIs and mineralocorticoid receptor antagonists at any dose and ≥50% target dose.,1643,1809
med:pmid:39939202:sec:results:sent:12,med:pmid:39939202,results,12,Better renal function was a predictor for ACEIs/ARBs/ARNIs at any dose and ≥50% target dose.,1810,1902
med:pmid:39939202:sec:results:sent:13,med:pmid:39939202,results,13,Discharge ward was not in itself an independent predictor of drug prescription at any dose or for any drug class.,1903,2016
med:pmid:39939202:sec:conclusion:sent:14,med:pmid:39939202,conclusion,14,Prescription rates with key components of pharmacological and non-pharmacological HF management were lower in non-cardiology than in cardiology wards.,2017,2188
med:pmid:39939202:sec:conclusion:sent:15,med:pmid:39939202,conclusion,15,"For pharmacological management, this appeared related to higher patient complexity rather than the ward.",2189,2293
med:pmid:39939202:sec:conclusion:sent:16,med:pmid:39939202,conclusion,16,"Quality improvement programs to strengthen adherence to guideline-advocated treatment is warranted to optimise care, especially for higher complexity admitted to a non-cardiology ward.",2294,2478
med:pmid:39661383:sec:title:sent:0,med:pmid:39661383,title,0,Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure.,0,106
med:pmid:39661383:sec:abstract:sent:1,med:pmid:39661383,abstract,1,"<h4>Importance</h4> Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less.",0,199
med:pmid:39661383:sec:introduction:sent:2,med:pmid:39661383,introduction,2,To describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF.,200,328
med:pmid:39661383:sec:introduction:sent:3,med:pmid:39661383,introduction,3,"<h4>Design, setting, and participants</h4> Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, hospitalized patients with HFrEF at 614 participating hospitals were identified.",329,530
med:pmid:39661383:sec:introduction:sent:4,med:pmid:39661383,introduction,4,"Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at discharge were evaluated across 3 time periods.",531,699
med:pmid:39661383:sec:introduction:sent:5,med:pmid:39661383,introduction,5,Adjusted logistic regression and piecewise logistic regression were used to evaluate the impact of publication dates on ARNI prescription rates.,700,844
med:pmid:39661383:sec:introduction:sent:6,med:pmid:39661383,introduction,6,<h4>Exposures</h4> ARNI prescribing patterns in hospitalized patients with HFrEF.,845,926
med:pmid:39661383:sec:introduction:sent:7,med:pmid:39661383,introduction,7,"<h4>Main outcomes and measures</h4> Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022).",927,1784
med:pmid:39661383:sec:results:sent:8,med:pmid:39661383,results,8,"A total of 114 333 hospitalized patients (mean [IQR] age, 67.0 [57.0-78.0] years; 74 765 male [65.4%]) were included in this study.",1785,1933
med:pmid:39661383:sec:results:sent:9,med:pmid:39661383,results,9,"Rates of ARNI prescribed at discharge increased from 1.1% (27 of 2451) during July 7, 2015, to September 30, 2015, to 55.4% (1957 of 3536) during October 1, 2022, to December 31, 2022.",1934,2118
med:pmid:39661383:sec:results:sent:10,med:pmid:39661383,results,10,"ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711).",2119,2334
med:pmid:39661383:sec:results:sent:11,med:pmid:39661383,results,11,"In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge.",2335,2699
med:pmid:39661383:sec:conclusion:sent:12,med:pmid:39661383,conclusion,12,"Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased.",2700,2970
med:pmid:39661383:sec:conclusion:sent:13,med:pmid:39661383,conclusion,13,"Overall prescription of ARNI at discharge was 55.4% in eligible patients at the end of the study, suggesting remaining opportunity for continued improvement in ARNI prescription.",2971,3149
med:pmid:39318024:sec:title:sent:0,med:pmid:39318024,title,0,Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey.,0,120
med:pmid:39318024:sec:title:sent:1,med:pmid:39318024,title,1,A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC.,121,232
med:pmid:39318024:sec:introduction:sent:2,med:pmid:39318024,introduction,2,"Real-world data show that guidelines are insufficiently implemented, and particularly guideline-directed medical therapies (GDMT) are underused in patients with heart failure and reduced ejection fraction (HFrEF) in clinical practice.",0,248
med:pmid:39318024:sec:introduction:sent:3,med:pmid:39318024,introduction,3,"The Council for Cardiology Practice and the Heart Failure Association of the European Society of Cardiology (ESC) developed a survey aiming to (i) evaluate the perspectives of the cardiology community on the 2021 ESC heart failure (HF) guidelines, (ii) pinpoint disparities in disease management, and (iii) propose strategies to enhance adherence to HF guidelines.",249,613
med:pmid:39318024:sec:results:sent:4,med:pmid:39318024,results,4,A 22-question survey regarding the diagnosis and treatment of HFrEF was delivered between March and June 2022.,614,753
med:pmid:39318024:sec:results:sent:5,med:pmid:39318024,results,5,"Of 457 physicians, 54% were general cardiologists, 19.4% were HF specialists, 18.9% other cardiac specialists, and 7.7% non-cardiac specialists.",754,898
med:pmid:39318024:sec:results:sent:6,med:pmid:39318024,results,6,"For diagnosis, 52.1% employed echocardiography and natriuretic peptides (NPs), 33.2% primarily used echocardiography, and 14.7% predominantly relied on NPs.",899,1055
med:pmid:39318024:sec:results:sent:7,med:pmid:39318024,results,7,"The first drug class initiated in HFrEF was angiotensin-converting enzyme inhibitors/angiotensin receptor-neprilysin inhibitor (ACEi/ARNi) (91.2%), beta-blockers (BB) (73.8%), mineralocorticoid receptor antagonists (MRAs) (53.4%), and sodium-glucose cotransporter 2 (SGLT2) inhibitors (48.1%).",1056,1349
med:pmid:39318024:sec:results:sent:8,med:pmid:39318024,results,8,"The combination ACEi/ARNi + MRA+ BB was preferred by 39.3% of physicians, ACEi/ARNi + SGLT2 inhibitors + BB by 33.3%, and ACEi/ARNi + BB by 22.2%.",1350,1496
med:pmid:39318024:sec:results:sent:9,med:pmid:39318024,results,9,"The time required to initiate and optimize GDMT was estimated to be <1 month by 8.3%, 1-3 months by 52%, 3-6 months by 31.8%, and >6 months by 7.9%.",1497,1645
med:pmid:39318024:sec:results:sent:10,med:pmid:39318024,results,10,"Compared to general cardiologists, HF specialists/academic cardiologists reported lower estimated time-to-initiation, and more commonly preferred a parallel initiation of GDMT rather than a sequential approach.",1646,1856
med:pmid:39318024:sec:conclusion:sent:11,med:pmid:39318024,conclusion,11,"Participants generally followed diagnostic and treatment guidelines, but variations in HFrEF management across care settings or HF specialties were noted.",1857,2031
med:pmid:39318024:sec:conclusion:sent:12,med:pmid:39318024,conclusion,12,The survey may raise awareness and promote standardized HF care.,2032,2096
med:pmid:39284545:sec:title:sent:0,med:pmid:39284545,title,0,Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril/valsartan or enalapril: Results from the PARALLEL-HF study.,0,188
med:pmid:39284545:sec:introduction:sent:1,med:pmid:39284545,introduction,1,"The PARALLEL-HF trial showed that treatment with sacubitril/valsartan resulted in more symptomatic hypotension versus enalapril in Japanese patients with heart failure (HF) and reduced ejection fraction, similar to PARADIGM-HF.",0,247
med:pmid:39284545:sec:introduction:sent:2,med:pmid:39284545,introduction,2,Use of sacubitril/valsartan in these patients may be limited by concerns regarding hypotension.,248,343
med:pmid:39284545:sec:methods:sent:3,med:pmid:39284545,methods,3,"This post-hoc analysis characterized hypotension-related adverse events (AEs) and their effects on efficacy using data from PARALLEL-HF, in which patients received sacubitril/valsartan 200 mg twice daily or enalapril 10 mg twice daily.",344,596
med:pmid:39284545:sec:results:sent:4,med:pmid:39284545,results,4,"Of 223 patients, 28.2 % experienced hypotension-related AEs and incidence was higher with sacubitril/valsartan versus enalapril (hazard ratio, 2.2; 95 % CI, 1.3-3.8; p = 0.0027).",597,792
med:pmid:39284545:sec:results:sent:5,med:pmid:39284545,results,5,"However, reduction in mean systolic blood pressure from baseline to study end did not significantly differ (sacubitril/valsartan: -2.2 mmHg vs enalapril: -1.3 mmHg; p = 0.6895).",793,970
med:pmid:39284545:sec:results:sent:6,med:pmid:39284545,results,6,"Patients who experienced hypotension-related AEs had lower mean body mass index, higher median N-terminal pro-brain natriuretic peptide at randomization, and more frequent history of stroke.",971,1161
med:pmid:39284545:sec:results:sent:7,med:pmid:39284545,results,7,"Hypotension-related AEs leading to treatment discontinuation were not significantly different for sacubitril/valsartan versus enalapril (3.4 % vs 6.9 %, p = 0.5957).",1162,1327
med:pmid:39284545:sec:results:sent:8,med:pmid:39284545,results,8,Reduction in risk of cardiovascular death or HF hospitalization was similar with sacubitril/valsartan versus enalapril in patients with or without hypotension-related AEs.,1328,1499
med:pmid:39284545:sec:conclusion:sent:9,med:pmid:39284545,conclusion,9,"Incidence of hypotension-related AEs was higher in the sacubitril/valsartan versus enalapril group but did not affect risk of cardiovascular death or HF hospitalization, which was similar between treatment groups.",1500,1734
med:pmid:40115097:sec:title:sent:0,med:pmid:40115097,title,0,A heart failure center model helped to promote the standardized management and improve the prognosis of patients.,0,113
med:pmid:40115097:sec:introduction:sent:1,med:pmid:40115097,introduction,1,Heart failure (HF) is the end stage of various heart disease.,0,81
med:pmid:40115097:sec:introduction:sent:2,med:pmid:40115097,introduction,2,"An increasing number of HF centers have emerged in China, which aimed to facilitate standardized, multidisciplinary, and scientific management for HF patients.",82,241
med:pmid:40115097:sec:introduction:sent:3,med:pmid:40115097,introduction,3,The study aimed to observe whether the establishment of HF center has positive effect on standardized management and prognosis of HF patients.,242,384
med:pmid:40115097:sec:methods:sent:4,med:pmid:40115097,methods,4,"A before and after study was performed by randomly collecting a total of 300 cases of medical records and follow-up data in the HF database of our hospital (Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University).",385,639
med:pmid:40115097:sec:methods:sent:5,med:pmid:40115097,methods,5,"Referring to the certification date (December 2020) of our center, 150 cases were selected into the center group (January 2021-December 2022, after certification) and 150 cases in the control group (January 2019-December 2020, before certification).",640,889
med:pmid:40115097:sec:methods:sent:6,med:pmid:40115097,methods,6,"Statistical comparison between two groups was performed, which focused on indicators of standardized management [proportion of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiography performed in the diagnosis of HF, application ratio of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), β-blockers in heart failure with reduced ejection fraction (HFrEF) patients, 1 week, 1 month, 3 months and 1 year follow-up rate] and clinical prognosis indicators (NT-proBNP level, 6-minute walking distance test, heart function grading, shorter average duration in hospital) at discharge, review of relevant indicators after 1 year, readmission rate and incidence of main adverse cardiovascular and cerebrovascular events (MACCEs) in 1 year.",890,1721
med:pmid:40115097:sec:results:sent:7,med:pmid:40115097,results,7,"Compared to the control group, the proportion of patients using NT-proBNP (94.7% <i>vs.</i> 87.3%, P=0.03), echocardiography (88.7% <i>vs.</i> 78.7%, P=0.02), the ratio of patients using ACEI/ARB/ARNI (87.0% <i>vs.</i> 72.2%, P=0.03) and β-blocker (82.7% <i>vs.</i> 66.7%, P=0.03) before discharge, and the follow-up rate of each period after discharge (1 week, 90.7% <i>vs.</i> 80.0%, P=0.01; 1 month, 84.7% <i>vs.</i> 72.0%, P=0.01; 3 months, 76.7% <i>vs.</i> 64.0%, P=0.02; 1 year, 88.0% <i>vs.</i> 79.3%, P=0.04) was higher in the center group.",1722,2287
med:pmid:40115097:sec:results:sent:8,med:pmid:40115097,results,8,"Treated with standardized management, patients in the center group had a lower NT-proBNP level (1,760±934 <i>vs.</i> 2,279±1,085 pg/mL, P<0.001), a further 6-minute walking test distance (364±117 <i>vs.</i> 330±135 m, P=0.02), better cardiac function classification (2.1±0.6 <i>vs.</i> 2.3±0.7, P=0.01) and shorter average duration (7.3±2.5 <i>vs.</i> 8.9±2.1 days, P<0.001) in hospital at discharge.",2288,2688
med:pmid:40115097:sec:results:sent:9,med:pmid:40115097,results,9,"1 year later, the corresponding indicators are still better than the control group, and the readmission rate (8.7% <i>vs.</i> 16.0%, P=0.02) and incidence of MACCE (4.7% <i>vs.</i> 11.3%, P=0.03) were lower.",2689,2896
med:pmid:40115097:sec:conclusion:sent:10,med:pmid:40115097,conclusion,10,"The HF center model can standardize the management and improve the prognosis of patients with HF, it should be promoted actively.",2897,3047
med:pmid:39922597:sec:title:sent:0,med:pmid:39922597,title,0,Temporal trends in guideline-recommended medical therapy after an acute heart failure decompensation event: an observational analysis from Generator Heart Failure DataMart.,0,172
med:pmid:39922597:sec:introduction:sent:1,med:pmid:39922597,introduction,1,"To evaluate the trend of prescription of the four foundational therapies, and their impact on 30-day urgent re-admissions and all-cause death in patients with heart failure and reduced ejection fraction (HFrEF) following an acute decompensation event.",0,271
med:pmid:39922597:sec:introduction:sent:2,med:pmid:39922597,introduction,2,<h4>Design</h4> Retrospective.,272,302
med:pmid:39922597:sec:introduction:sent:3,med:pmid:39922597,introduction,3,<h4>Setting</h4> One tertiary referral centre.,303,349
med:pmid:39922597:sec:introduction:sent:4,med:pmid:39922597,introduction,4,"<h4>Participants</h4> 999 consecutively patients admitted with a primary diagnosis of HFrEF between January 2020 and June 2023 were identified through a validated, high-performance technology infrastructure based on artificial intelligence.",350,590
med:pmid:39922597:sec:introduction:sent:5,med:pmid:39922597,introduction,5,"The entire cohort was divided into three time periods based on two time points: September 2021 (ie, the release of the latest European guidelines) and January 2022 (ie, reimbursement for sodium-glucose cotransporter 2 (SGLT2) inhibitors).",591,829
med:pmid:39922597:sec:introduction:sent:6,med:pmid:39922597,introduction,6,<h4>Primary and secondary outcome measures</h4> Trends and predictors of the prescription of each of the four foundational therapies and of the composite of all-cause death and rehospitalisation for urgent causes at 30 days.,830,1054
med:pmid:39922597:sec:results:sent:7,med:pmid:39922597,results,7,"Among the 999 included patients, β-blockers were prescribed in 93% of patients, ACE inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin-neprilysin receptor inhibitor (ARNi) in 73%, mineralocorticoid receptor antagonist in 30% and SGLT2 inhibitors in 18%.",1055,1338
med:pmid:39922597:sec:results:sent:8,med:pmid:39922597,results,8,"Over time, an increase in the prescription rate occurred only for SGLT2 inhibitors (3% vs 10% vs 32%, p<0.001), whereas the rate of the composite of all-cause death and rehospitalisation for urgent causes at 30 days remained stable (9.9% vs 10.3% vs 8.4%; p=ns).",1339,1601
med:pmid:39922597:sec:results:sent:9,med:pmid:39922597,results,9,"In multivariate analysis, the use of ACEi/ARB/ARNi was associated with a lower risk of 30-day all-cause death and urgent rehospitalisation (adjusted OR 0.38; 95% CI 0.24 to 0.59; p<0.01).",1602,1789
med:pmid:39922597:sec:results:sent:10,med:pmid:39922597,results,10,"Conversely, the prescription of furosemide at discharge (adjusted OR 2.25; 95% CI 95% 1.29 to 3.94; p<0.01) and a previous genitourinary infection (adjusted OR 4.02; 95% CI 1.67 to 9.68; p<0.01) were associated with higher risk of 30-day all-cause death and urgent rehospitalisation.",1790,2073
med:pmid:39922597:sec:conclusion:sent:11,med:pmid:39922597,conclusion,11,"In our study, early adoption of guideline-recommended medical therapy is still limited, with a significant rise in SGLT2i prescriptions after January 2022 and a lower risk of the composite of all-cause death and urgent readmissions at 30 days restricted to the use of ACEi/ARB/ARNi.",2074,2377
med:pmid:39571389:sec:title:sent:0,med:pmid:39571389,title,0,Development and validation of a machine learning model to predict the risk of readmission within one year in HFpEF patients: Short title: Prediction of HFpEF readmission.,0,170
med:pmid:39571389:sec:introduction:sent:1,med:pmid:39571389,introduction,1,Heart failure with preserved ejection fraction (HFpEF) is associated with elevated rates of readmission and mortality.,0,138
med:pmid:39571389:sec:introduction:sent:2,med:pmid:39571389,introduction,2,Accurate prediction of readmission risk is essential for optimizing healthcare resources and enhancing patient outcomes.,139,259
med:pmid:39571389:sec:methods:sent:3,med:pmid:39571389,methods,3,"We conducted a retrospective cohort study utilizing HFpEF patient data from two institutions: the First Affiliated Hospital Zhejiang University School of Medicine for model development and internal validation, and the Affiliated Hospital of Xuzhou Medical University for external validation.",260,568
med:pmid:39571389:sec:methods:sent:4,med:pmid:39571389,methods,4,A machine learning (ML) model was developed and validated using 53 variables to predict the risk of readmission within one year.,569,697
med:pmid:39571389:sec:methods:sent:5,med:pmid:39571389,methods,5,"The model's performance was assessed using several metrics, including the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, F1 score, model training time, model prediction time and brier score.",698,939
med:pmid:39571389:sec:methods:sent:6,med:pmid:39571389,methods,6,"SHAP (SHapley Additive exPlanations) analysis was employed to enhance model interpretability, and a dynamic nomogram was constructed to visualize the predictive model.",940,1107
med:pmid:39571389:sec:results:sent:7,med:pmid:39571389,results,7,"Among the 766 HFpEF patients included in the study, 203 (26.5%) were readmitted within one year.",1108,1221
med:pmid:39571389:sec:results:sent:8,med:pmid:39571389,results,8,"The LightGBM model exhibited the highest predictive performance, with an AUC of 0.88 (95% confidence interval (CI):0.84-0.91), an accuracy of 0.79, a sensitivity of 0.81, and a specificity of 0.78.",1222,1419
med:pmid:39571389:sec:results:sent:9,med:pmid:39571389,results,9,"Key predictors included the E/e' ratio, NYHA classification, LVEF, age, BNP levels, MLR, history of atrial fibrillation (AF), use of ACEI/ARB/ARNI, and history of myocardial infarction (MI).",1420,1610
med:pmid:39571389:sec:results:sent:10,med:pmid:39571389,results,10,"External validation also demonstrated strong predictive performance, with an AUC of 0.87 (95%CI:0.83-0.91).",1611,1718
med:pmid:39571389:sec:conclusion:sent:11,med:pmid:39571389,conclusion,11,"The LightGBM model exhibited robust performance in predicting one-year readmission risk among HFpEF patients, providing a valuable tool for clinicians to identify high-risk individuals and implement timely interventions.",1719,1960
med:pmid:39327768:sec:title:sent:0,med:pmid:39327768,title,0,Guideline-directed medical therapy implementation during hospitalization for cardiogenic shock.,0,95
med:pmid:39327768:sec:introduction:sent:1,med:pmid:39327768,introduction,1,"Despite significant morbidity and mortality, recent advances in cardiogenic shock (CS) management have been associated with increased survival.",0,157
med:pmid:39327768:sec:introduction:sent:2,med:pmid:39327768,introduction,2,"However, little is known regarding the management of patients who survive CS with heart failure (HF) with reduced left ventricular ejection fraction (LVEF, HFrEF), and the utilization of guideline-directed medical therapy (GDMT) in these patients has not been well described.",158,433
med:pmid:39327768:sec:introduction:sent:3,med:pmid:39327768,introduction,3,"To fill this gap, we investigated the use of GDMT during an admission for CS and short-term outcomes using the Inova single-centre shock registry.",434,580
med:pmid:39327768:sec:methods:sent:4,med:pmid:39327768,methods,4,We investigated the implementation of GDMT for patients who survived an admission for CS with HFrEF using data from our single-centre shock registry from January 2017 to December 2019.,581,782
med:pmid:39327768:sec:methods:sent:5,med:pmid:39327768,methods,5,"Baseline characteristics, discharge clinical status, data on GDMT utilization and 30 day, 6 month and 12 month patient outcomes were collected by retrospective chart review.",783,956
med:pmid:39327768:sec:results:sent:6,med:pmid:39327768,results,6,"Among 520 patients hospitalized for CS during the study period, 185 (35.6%) had HFrEF upon survival to discharge.",957,1087
med:pmid:39327768:sec:results:sent:7,med:pmid:39327768,results,7,"The median age was 64 years [interquartile range (IQR) 56, 70], 72% (n = 133) were male, 22% (n = 40) were Black and 7% (n = 12) were Hispanic.",1088,1231
med:pmid:39327768:sec:results:sent:8,med:pmid:39327768,results,8,"Forty-one per cent of patients (n = 76) presented with shock related to acute myocardial infarction (AMI), while 59% (n = 109) had HF-related CS (HF-CS).",1232,1385
med:pmid:39327768:sec:results:sent:9,med:pmid:39327768,results,9,"The median length of hospital stay was 12 days (IQR 7, 18).",1386,1445
med:pmid:39327768:sec:results:sent:10,med:pmid:39327768,results,10,"At discharge, the proportions of patients on beta-blockers, angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs)/angiotensin receptor/neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs) were 78% (n = 144), 58% (n = 107) and 55% (n = 101), respectively.",1446,1759
med:pmid:39327768:sec:results:sent:11,med:pmid:39327768,results,11,Utilization of three-drug GDMT was 33.0% (n = 61).,1760,1810
med:pmid:39327768:sec:results:sent:12,med:pmid:39327768,results,12,Ten per cent of CS survivors with HFrEF (n = 19) were not prescribed any component of GDMT at discharge.,1811,1915
med:pmid:39327768:sec:results:sent:13,med:pmid:39327768,results,13,Multivariable logistic regression adjusted for baseline GDMT use revealed that patients with lower LVEF and those who transferred to our centre from an outside hospital were more likely to experience GDMT addition (P < 0.05).,1916,2141
med:pmid:39327768:sec:results:sent:14,med:pmid:39327768,results,14,"Patients prescribed at least one additional class of GDMT during admission had higher odds of 6 month and 1 year survival (P < 0.01): On average, 6 month survival odds were 7.1 times greater [confidence interval (CI) 1.9, 28.5] and 1 year survival odds were 6.0 times greater than those who did not have at least one GDMT added (CI 1.9, 20.5).",2142,2485
med:pmid:39327768:sec:conclusion:sent:15,med:pmid:39327768,conclusion,15,Most patients who survived CS admission with HFrEF in this single-centre CS registry were not prescribed all classes or goal doses of GDMT at hospital discharge.,2486,2668
med:pmid:39327768:sec:conclusion:sent:16,med:pmid:39327768,conclusion,16,These findings highlight an urgent need to augment multidisciplinary efforts to enhance the post-discharge medical management and outcomes of patients who survive CS with HFrEF.,2669,2846
med:pmid:41126807:sec:title:sent:0,med:pmid:41126807,title,0,Quality of Care among Post-discharge Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) at the Outpatient Department (OPD) of a Tertiary Center.,0,160
med:pmid:41126807:sec:abstract:sent:1,med:pmid:41126807,abstract,1,"<h4>Background and objective</h4> Physician adherence to the recommended management of patients with heart failure with reduced ejection fraction (HFrEF) at the outpatient setting is crucial to reduce the burden of subsequent rehospitalization, morbidity, and mortality.",0,270
med:pmid:41126807:sec:abstract:sent:2,med:pmid:41126807,abstract,2,Recently updated guidelines recommend early and rapid titration to optimal doses of medications in the first 2 to 6 weeks of discharge.,271,406
med:pmid:41126807:sec:abstract:sent:3,med:pmid:41126807,abstract,3,"In the absence of local data, our study evaluates physician adherence to guideline-recommended treatment in this setting.",407,528
med:pmid:41126807:sec:methods:sent:4,med:pmid:41126807,methods,4,This is a retrospective cross-sectional study among post-discharge HFrEF patients at the outpatient department from December 2022 to May 2023 with a follow-up within three months.,529,725
med:pmid:41126807:sec:methods:sent:5,med:pmid:41126807,methods,5,Clinical profile and treatment were extracted from medical records.,726,793
med:pmid:41126807:sec:methods:sent:6,med:pmid:41126807,methods,6,"Adherence to the 2021 ESC Guidelines Class I recommendations, among eligible patients, is measured as quality indicators.",794,915
med:pmid:41126807:sec:results:sent:7,med:pmid:41126807,results,7,are presented using descriptive statistics.,916,964
med:pmid:41126807:sec:results:sent:8,med:pmid:41126807,results,8,A total of 99 patients were included in the study.,965,1032
med:pmid:41126807:sec:results:sent:9,med:pmid:41126807,results,9,"Overall, adherence to prescription of beta-blockers (94.8%), ACEI/ARNI/ARBs (88.5%), and diuretics (100%) were high.",1033,1149
med:pmid:41126807:sec:results:sent:10,med:pmid:41126807,results,10,"Prescription of mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) were 67% and 57.3%, respectively.",1150,1299
med:pmid:41126807:sec:results:sent:11,med:pmid:41126807,results,11,"Over three months of follow-up, improvement in the quality of care was demonstrated with ACEI/ARNI/ARBs (81.8% to 90.9%), MRA (68.7 to 81.2%), and SGLT2i (58% to 67.7%).",1300,1469
med:pmid:41126807:sec:results:sent:12,med:pmid:41126807,results,12,Beta-blocker use is consistently high at 97%.,1470,1515
med:pmid:41126807:sec:results:sent:13,med:pmid:41126807,results,13,"In the 3<sup>rd</sup> month post-discharge, titration to optimal doses was achieved in only 26.4%, 15%, and 6.25% for those on beta-blockers, ACEI/ARNI/ARB, and MRA, respectively.",1516,1695
med:pmid:41126807:sec:results:sent:14,med:pmid:41126807,results,14,"For non-pharmacologic management, referral to HF specialty was made in 30% and cardiac rehabilitation in 22.2%.",1696,1807
med:pmid:41126807:sec:conclusion:sent:15,med:pmid:41126807,conclusion,15,"Among patients with HFrEF seen at the outpatient, there is good physician adherence to betablockers, ACEI/ARNI/ARBs, and diuretics.",1808,1959
med:pmid:41126807:sec:conclusion:sent:16,med:pmid:41126807,conclusion,16,"MRA and SGLT2i prescription, referral to HF specialty and cardiac rehabilitation, and up-titration to optimal doses of oral medications for HF need improvement.",1960,2120
med:pmid:41126807:sec:conclusion:sent:17,med:pmid:41126807,conclusion,17,"Hospital pathway development and regular performance evaluation will improve initiation, maintenance, and up-titration of appropriate treatment.",2121,2265
med:pmid:41080832:sec:title:sent:0,med:pmid:41080832,title,0,Angiotensin-Neprilysin Inhibitor Therapy: A Retrospective Chart Study.,0,70
med:pmid:41080832:sec:abstract:sent:1,med:pmid:41080832,abstract,1,<i>Background:</i> Guideline-directed medical therapy in patients with systolic heart failure (HF) has demonstrated improvement in morbidity and mortality rates.,0,161
med:pmid:41080832:sec:abstract:sent:2,med:pmid:41080832,abstract,2,The FDA approved sacubitril/valsartan in 2015 to reduce the risk of cardiovascular death and hospitalization for HF.,162,278
med:pmid:41080832:sec:abstract:sent:3,med:pmid:41080832,abstract,3,<i>Objective:</i> The purpose of this study was to evaluate the change in loop diuretic dose and the clinical outcomes of angiotensin receptor-neprilysin inhibitor (ARNI) therapy within a 90-day follow-up period.,279,491
med:pmid:41080832:sec:abstract:sent:4,med:pmid:41080832,abstract,4,<i>Methods:</i> A retrospective chart review of 110 HF patients on concomitant ARNI and loop diuretic therapy at New York University Langone Health was conducted.,492,654
med:pmid:41080832:sec:abstract:sent:5,med:pmid:41080832,abstract,5,The primary endpoint was a change in loop diuretic dose.,655,711
med:pmid:41080832:sec:abstract:sent:6,med:pmid:41080832,abstract,6,"Six secondary endpoints, including dose conversion from ACEi or ARB to ARNI therapy, were assessed.",712,811
med:pmid:41080832:sec:abstract:sent:7,med:pmid:41080832,abstract,7,"<i>Results:</i> Of the 110 HF patients, 72 did not receive diuretic dose adjustments, yet 40 (55.56%) experienced laboratory-dependent dehydration.",812,959
med:pmid:41080832:sec:abstract:sent:8,med:pmid:41080832,abstract,8,"Fifty-six percent of patients experienced an improvement in systolic blood pressure, and 52 percent experienced a decrease in diastolic blood pressure.",960,1111
med:pmid:41080832:sec:abstract:sent:9,med:pmid:41080832,abstract,9,"Sixty percent of patients experienced an improvement in EF, with a median increase of 10.00% over a 90-day follow-up.",1112,1229
med:pmid:41080832:sec:abstract:sent:10,med:pmid:41080832,abstract,10,"A significant negative correlation between patients' age and absolute change in EF was identified (r= -0.28; p < 0.05), indicating that the increase in EF was stronger for younger patients.",1230,1419
med:pmid:41080832:sec:abstract:sent:11,med:pmid:41080832,abstract,11,"Eighteen hospitalizations occurred within a 90-day follow-up, with only 4 patients being admitted for heart failure exacerbation.",1420,1549
med:pmid:41080832:sec:abstract:sent:12,med:pmid:41080832,abstract,12,<i>Conclusion and Relevance:</i> This study examines the real-world effects of ARNI therapy in patients with systolic heart failure.,1550,1682
med:pmid:41080832:sec:abstract:sent:13,med:pmid:41080832,abstract,13,"Optimization of HF medications, including ARNI therapy, remains an important factor for achieving the maximum benefits in heart failure management.",1683,1830
med:pmid:41080832:sec:abstract:sent:14,med:pmid:41080832,abstract,14,ARNI therapy requires careful monitoring to ensure effective diuresis in symptomatic heart failure patients while avoiding adverse events.,1831,1969
med:pmid:41080832:sec:abstract:sent:15,med:pmid:41080832,abstract,15,Future studies should address diuretic dose adjustment in conjunction with the administration of ARNI and sodium-glucose cotransporter-2 inhibitors.,1970,2118
med:pmid:41079587:sec:title:sent:0,med:pmid:41079587,title,0,Early sacubitril/valsartan use associated with reduced atrial fibrillation risk in patients with acute myocardial infarction complicated by mitral regurgitation: a retrospective cohort study.,0,191
med:pmid:41079587:sec:introduction:sent:1,med:pmid:41079587,introduction,1,Patients with acute myocardial infarction (AMI) complicated by mitral regurgitation (MR) experience a substantially elevated risk of atrial fibrillation (AF).,0,178
med:pmid:41079587:sec:introduction:sent:2,med:pmid:41079587,introduction,2,Evidence remains limited regarding whether early administration of sacubitril/valsartan confers additional protection against new-onset AF in this high-risk population to traditional ACEI/ARB therapy.,179,379
med:pmid:41079587:sec:introduction:sent:3,med:pmid:41079587,introduction,3,To evaluate the impact of early sacubitril/valsartan therapy on the 1-year cumulative incidence of AF in patients with AMI complicated by MR.,380,540
med:pmid:41079587:sec:methods:sent:4,med:pmid:41079587,methods,4,"In this single-center retrospective cohort, 1,065 in-patients with AMI complicated by MR (June 2021-December 2023) were categorized by discharge prescription into the Sacubitril/Valsartan group (<i>n</i> = 427) or the ACEI/ARB group (<i>n</i> = 638).The primary endpoint was new-onset AF within 1 year.",541,860
med:pmid:41079587:sec:methods:sent:5,med:pmid:41079587,methods,5,Cumulative incidence was estimated using the cumulative incidence function (CIF) and compared with Gray's test.,861,972
med:pmid:41079587:sec:methods:sent:6,med:pmid:41079587,methods,6,Associations were evaluated using Fine-Gray subdistribution hazard models [subdistribution hazard ratios (sHR)] and multivariable Cox proportional hazards models [hazard ratios (HR)].,973,1156
med:pmid:41079587:sec:methods:sent:7,med:pmid:41079587,methods,7,"To mitigate confounding, 1:1 propensity score matching (PSM) was performed, and analyses were repeated in the matched cohort.",1157,1282
med:pmid:41079587:sec:methods:sent:8,med:pmid:41079587,methods,8,Prespecified subgroup analyses were performed to assess treatment-effect consistency.,1283,1368
med:pmid:41079587:sec:results:sent:9,med:pmid:41079587,results,9,"Despite a higher baseline risk profile in the Sacubitril/Valsartan group, the 1-year cumulative incidence of AF was lower than in the ACEI/ARB group (CIF 10.8% vs. 17.9%; Gray's test <i>P</i> = 0.002).",1369,1587
med:pmid:41079587:sec:results:sent:10,med:pmid:41079587,results,10,"In competing-risk analysis, sacubitril/valsartan was associated with a reduced risk of AF (sHR = 0.56; 95% CI 0.39-0.81; <i>P</i> = 0.002), concordant with the multivariable Cox model (HR = 0.55; 95% CI 0.38-0.81; <i>P</i> = 0.003).",1588,1820
med:pmid:41079587:sec:results:sent:11,med:pmid:41079587,results,11,"After PSM, the association persisted in both the competing-risk analysis (sHR = 0.63; 95% CI 0.40-0.94; <i>P</i> = 0.025) and the Cox model (HR = 0.63; 95% CI 0.41-0.96; <i>P</i> = 0.030).",1821,2009
med:pmid:41079587:sec:results:sent:12,med:pmid:41079587,results,12,Subgroup analyses demonstrated consistent benefits across all prespecified strata.,2010,2092
med:pmid:41079587:sec:conclusion:sent:13,med:pmid:41079587,conclusion,13,"Early sacubitril/valsartan use was associated with reduced 1-year AF risk vs. ACEI/ARB in AMI complicated by MR, suggesting a potential role in this population; prospective trials are needed to confirm causality.",2093,2325
med:pmid:41079061:sec:title:sent:0,med:pmid:41079061,title,0,Price and Affordability of Heart Failure Guideline Directed Medical Therapy in Venezuela: A Cross Sectional Observational Study.,0,128
med:pmid:41079061:sec:introduction:sent:1,med:pmid:41079061,introduction,1,"Heart failure (HF) impacts over 56 million people worldwide, with significantly higher mortality rates in low and low-middle-income countries (LIC/LMICs).",0,174
med:pmid:41079061:sec:introduction:sent:2,med:pmid:41079061,introduction,2,"Despite the effectiveness of guideline-directed medical therapy (GDMT) for HF with reduced ejection fraction (HFrEF), its use remains limited in LIC/LMICs due to limited availability and affordability.",175,376
med:pmid:41079061:sec:introduction:sent:3,med:pmid:41079061,introduction,3,"These barriers are particularly pressing in Venezuela's context, as the country faces an ongoing crisis.",377,481
med:pmid:41079061:sec:introduction:sent:4,med:pmid:41079061,introduction,4,Describe price and affordability of HF Guideline Directed Medical Therapy at optimal dosages in Venezuela.,482,607
med:pmid:41079061:sec:methods:sent:5,med:pmid:41079061,methods,5,"We conducted a cross-sectional analysis from December 2023 to January 2024, surveying prices of HF GDMT medications across 13 major pharmacy networks in Venezuela.",608,788
med:pmid:41079061:sec:methods:sent:6,med:pmid:41079061,methods,6,"Medications analyzed included ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose co-transporter 2 inhibitors (SGLT2i).",789,1052
med:pmid:41079061:sec:methods:sent:7,med:pmid:41079061,methods,7,"Affordability was defined and calculated using the World Health Organization/Health Action International (WHO/HAI) methodology, comparing the median costs of one month of HF GDMT at optimal dosages to the lowest-paid government worker's (LPGW) daily wages.",1053,1309
med:pmid:41079061:sec:methods:sent:8,med:pmid:41079061,methods,8,"Other comparisons of price affordability were made against the mean daily salary of managers, professional and non-professional workers in the country.",1310,1461
med:pmid:41079061:sec:results:sent:9,med:pmid:41079061,results,9,"The most expensive medication regime for HF in Venezuela was ARNI-based GDMT with a median monthly cost of 393.81USD, followed by ARB-based GDMT and ACEi-based GDMT costing $100.88USD and $82.23USD respectively.",1462,1690
med:pmid:41079061:sec:results:sent:10,med:pmid:41079061,results,10,meaning LPGW and elderly receiving retirement stipends would need between 506 to 2421 paid work days to cover one month of treatment at optimal dosages.,1691,1843
med:pmid:41079061:sec:conclusion:sent:11,med:pmid:41079061,conclusion,11,Based on the WHO/HAI methodology all HF GDMT regimens were deemed unaffordable in Venezuela.,1844,1956
med:pmid:41079061:sec:conclusion:sent:12,med:pmid:41079061,conclusion,12,Similar affordability challenges exist in other LIC/LMICs countries highlighting the need for global advocacy and policy action to address financial barriers to access guideline-based heart failure care.,1957,2160
med:pmid:40873622:sec:title:sent:0,med:pmid:40873622,title,0,Effects of angiotensin receptor-neprilysin inhibition on myocardial energy metabolism and prognosis in patients with acute myocardial infarction complicated by heart failure.,0,174
med:pmid:40873622:sec:introduction:sent:1,med:pmid:40873622,introduction,1,This study aims to evaluate the effects of angiotensin receptor-neprilysin inhibitor (ARNI) on myocardial energy metabolism and prognosis in patients with acute myocardial infarction (AMI) complicated by heart failure (HF).,0,242
med:pmid:40873622:sec:methods:sent:2,med:pmid:40873622,methods,2,"A retrospective analysis was conducted on data from 244 inpatients admitted to our center, who were diagnosed with AMI complicated by HF.",243,397
med:pmid:40873622:sec:methods:sent:3,med:pmid:40873622,methods,3,"Among these patients, 210 completed a 1-year follow-up.",398,453
med:pmid:40873622:sec:methods:sent:4,med:pmid:40873622,methods,4,"According to the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/ARNI, the 210 patients were divided into the ARNI group (107 cases, 51.0%) and the non-ARNI (ACEI/ARB) group (103 cases, 49.0%).",454,690
med:pmid:40873622:sec:methods:sent:5,med:pmid:40873622,methods,5,The main outcome measures were the changes in myocardial energy expenditure (MEE) and prognostic indicators after 1-year follow-up.,691,822
med:pmid:40873622:sec:results:sent:6,med:pmid:40873622,results,6,"ARNI significantly reduced MEE after 1 year compared with the ACEI/ARB [(129.61 ± 40.81) kcal/min vs. (154.49 ± 47.58) kcal/min, <i>P</i> < 0.01].",823,986
med:pmid:40873622:sec:results:sent:7,med:pmid:40873622,results,7,The MEE level in the HFrEF group was significantly higher than that in the HFmrEF group (<i>P</i> < 0.05).,987,1093
med:pmid:40873622:sec:results:sent:8,med:pmid:40873622,results,8,"The ARNI group showed significantly lower rates of heart failure (23.0% vs. 43.4%, <i>P</i> = 0.001), recurrent myocardial infarction (9.8% vs. 22.1%, <i>P</i> = 0.009), and renal function deterioration (5.7% vs. 13.1%, <i>P</i> = 0.049) than those in the non-ARNI group.",1094,1365
med:pmid:40873622:sec:results:sent:9,med:pmid:40873622,results,9,"ROC analysis identified an MEE (kcal/min) cutoff value of 178, with 85% sensitivity and 64% specificity for the prediction of cardiac death (AUC = 0.74, <i>P</i> = 0.007).",1366,1537
med:pmid:40873622:sec:results:sent:10,med:pmid:40873622,results,10,"During the 1-year follow-up, patients with MEE over 178 kcal/min were associated with increased risk of all-cause death compared with those with MEE below 178 kcal/min.",1538,1706
med:pmid:40873622:sec:conclusion:sent:11,med:pmid:40873622,conclusion,11,ARNI significantly reduced MEE compared with ACEI/ARB.,1707,1781
med:pmid:40873622:sec:conclusion:sent:12,med:pmid:40873622,conclusion,12,MEE was significantly associated with the severity of left ventricular systolic dysfunction and long-term prognosis.,1782,1898
med:pmid:40873622:sec:conclusion:sent:13,med:pmid:40873622,conclusion,13,An MEE value over 178 kcal/min was a powerful predictor of cardiac death and linked with increased risk of 1-year all-cause mortality in patients with AMI complicated by HF.,1899,2072
med:pmid:40791946:sec:title:sent:0,med:pmid:40791946,title,0,"Clinical characteristics, management approaches, and outcomes of patients with heart failure: the Jordan Heart Failure Registry.",0,128
med:pmid:40791946:sec:introduction:sent:1,med:pmid:40791946,introduction,1,Heart failure (HF) is a complex clinical syndrome with diverse etiologies and pathophysiological mechanisms.,0,128
med:pmid:40791946:sec:introduction:sent:2,med:pmid:40791946,introduction,2,"While chronic HF has gained substantial understanding, acute HF remains less elucidated.",129,217
med:pmid:40791946:sec:introduction:sent:3,med:pmid:40791946,introduction,3,"This study aimed to analyze the data from the Jordanian Heart Failure Registry (JoHFR) to assess the clinical characteristics, management approaches, and outcomes of patients with HF.",218,401
med:pmid:40791946:sec:methods:sent:4,med:pmid:40791946,methods,4,"The study included data from 21 healthcare centers from private sector clinics and hospitals and public secondary and tertiary university hospitals across Jordan from July 1, 2021, to February 28, 2023.",402,621
med:pmid:40791946:sec:methods:sent:5,med:pmid:40791946,methods,5,"It included patients above the age of 18 with chronic HF, acute decompensated HF <i>de novo</i>, or acute on top of chronic HF.",622,749
med:pmid:40791946:sec:results:sent:6,med:pmid:40791946,results,6,"encompassed patient demographics, comorbidities, medications, clinical presentation, laboratory findings, echocardiograms, and outcomes.",750,891
med:pmid:40791946:sec:results:sent:7,med:pmid:40791946,results,7,"A total of 2,151 patients were enrolled.",892,949
med:pmid:40791946:sec:results:sent:8,med:pmid:40791946,results,8,More than half (58.0%) of the study cohort were males.,950,1004
med:pmid:40791946:sec:results:sent:9,med:pmid:40791946,results,9,"The mean age of patients was 66 years, with almost half of the patients (45.5%) aged 70 or older.",1005,1102
med:pmid:40791946:sec:results:sent:10,med:pmid:40791946,results,10,"Chronic HF accounted for 71% of cases, while acute HF constituted 29% of cases.",1103,1182
med:pmid:40791946:sec:results:sent:11,med:pmid:40791946,results,11,Obesity was identified in 36.6% of the cohort.,1183,1229
med:pmid:40791946:sec:results:sent:12,med:pmid:40791946,results,12,Hypertension (80.7%) and a history of atherosclerotic cardiovascular disease (ASCVD) (80.6%) were the most prevalent comorbidities.,1230,1361
med:pmid:40791946:sec:results:sent:13,med:pmid:40791946,results,13,Beta-blockers were the most commonly prescribed medications (67.4%).,1362,1430
med:pmid:40791946:sec:results:sent:14,med:pmid:40791946,results,14,"RAAS inhibitors including ACE inhibitors (18.1%), ARBs (25.2%), and ARNI (10.8%), were also frequently used.",1431,1539
med:pmid:40791946:sec:results:sent:15,med:pmid:40791946,results,15,"Dyspnea (85.9%) was the most common presenting symptom, and elevated B-type natriuretic peptide levels were well utilized and observed in most patients (96.7%).",1540,1700
med:pmid:40791946:sec:results:sent:16,med:pmid:40791946,results,16,"Left ventricular ejection fraction (LVEF) was ≤40% in 58.8%, 41%-49% in 11.4%, and ≥50% in 29.7% of patients, with a mean (SD) of 38.1% (12.7%).",1701,1845
med:pmid:40791946:sec:results:sent:17,med:pmid:40791946,results,17,The in-hospital mortality rate in our registry stood at 9.6%.,1846,1907
med:pmid:40791946:sec:conclusion:sent:18,med:pmid:40791946,conclusion,18,The Jordan Heart Failure Registry (JoHFR) presents the unique characteristics of both chronic and acute HF patients in Jordan and highlights areas for improving patient care and adherence to international guidelines.,1908,2144
med:pmid:40791946:sec:conclusion:sent:19,med:pmid:40791946,conclusion,19,These findings should guide healthcare policymakers and practitioners in the country to enhance the quality of management of HF patients and implement interventions to reduce the burden of comorbidities accompanying HF.,2145,2364
med:pmid:40727001:sec:title:sent:0,med:pmid:40727001,title,0,Machine Learning-Driven Prediction of One-Year Readmission in HFrEF Patients: The Key Role of Inflammation.,0,107
med:pmid:40727001:sec:introduction:sent:1,med:pmid:40727001,introduction,1,Heart failure with reduced ejection fraction (HFrEF) is a global health issue with high morbidity and frequent hospitalizations.,0,148
med:pmid:40727001:sec:introduction:sent:2,med:pmid:40727001,introduction,2,Predicting one-year readmission risk is crucial for optimizing treatment and reducing costs.,149,241
med:pmid:40727001:sec:methods:sent:3,med:pmid:40727001,methods,3,"We conducted a single-center retrospective study on adult HFrEF patients admitted to the Cardiovascular Department of the First Affiliated Hospital, Zhejiang University School of Medicine on January 2020 and March 2023.",242,478
med:pmid:40727001:sec:methods:sent:4,med:pmid:40727001,methods,4,"Feature selection was performed using LASSO regression, with inflammatory biomarkers (PLR, MLR, NLR, SII, SIRI) prioritized.",479,603
med:pmid:40727001:sec:methods:sent:5,med:pmid:40727001,methods,5,"Seven machine learning (ML) algorithms were trained and validated using a 7:3 dataset split; the metrics of the model included the area under the curve (AUC), accuracy, sensitivity, specificity, F1 score, and Brier score.",604,825
med:pmid:40727001:sec:methods:sent:6,med:pmid:40727001,methods,6,SHapley Additive exPlanations (SHAP) analysis provided model interpretability.,826,904
med:pmid:40727001:sec:methods:sent:7,med:pmid:40727001,methods,7,A network-based dynamic nomogram was developed to visualize predictive models.,905,983
med:pmid:40727001:sec:results:sent:8,med:pmid:40727001,results,8,"This study included 733 patients, of whom 231 (31.5%) were readmitted within one year.",984,1087
med:pmid:40727001:sec:results:sent:9,med:pmid:40727001,results,9,"LASSO regression showed that the key predictors included age, BNP, New York Heart Association (NYHA) class, LVEF, PLR, MLR, AF history, and ACEI/ARB/ARNI usage.",1088,1248
med:pmid:40727001:sec:results:sent:10,med:pmid:40727001,results,10,"The Random Forest (RF) model performed best, with an AUC of 0.89 (95% confidence interval (CI): 0.86-0.93), an accuracy of 0.83, a sensitivity of 0.87, and a specificity of 0.80.",1249,1427
med:pmid:40727001:sec:results:sent:11,med:pmid:40727001,results,11,"SHAP analysis showed that BNP was the most influential feature, followed by NYHA class and LVEF, which were also important predictors.",1428,1562
med:pmid:40727001:sec:results:sent:12,med:pmid:40727001,results,12,"In addition, MLR and PLR also played an important role in prediction, once again confirming the important predictive role of MLR and PLR as inflammatory indicators for readmission within one year in HFrEF patients.",1563,1777
med:pmid:40727001:sec:conclusion:sent:13,med:pmid:40727001,conclusion,13,"The ML-based RF model effectively predicted one-year readmission in HFrEF patients, with inflammation indicators playing an important role.",1778,1937
med:pmid:40727001:sec:conclusion:sent:14,med:pmid:40727001,conclusion,14,"Integrating such models into clinical practice could improve risk stratification, reduce readmissions, and enhancing patient outcomes.",1938,2072
med:pmid:40575771:sec:title:sent:0,med:pmid:40575771,title,0,Heart failure medication treatment and prognosis: a retrospective cross-sectional study.,0,88
med:pmid:40575771:sec:introduction:sent:1,med:pmid:40575771,introduction,1,"Heart failure (HF) is a significant global public health concern and the leading cause of morbidity and mortality worldwide, imposing a substantial economic burden on society.",0,194
med:pmid:40575771:sec:introduction:sent:2,med:pmid:40575771,introduction,2,Guideline-directed medical therapy (GDMT) refers to the standardized pharmacological treatment for specific diseases based on recommendations from authoritative clinical guidelines and evidence from large-scale randomized clinical trials.,195,433
med:pmid:40575771:sec:introduction:sent:3,med:pmid:40575771,introduction,3,GDMT serves as the cornerstone of drug therapy for heart failure patients.,434,508
med:pmid:40575771:sec:introduction:sent:4,med:pmid:40575771,introduction,4,This study describes hospitalized HF patients and focuses on drug prescription and readmission rates.,509,610
med:pmid:40575771:sec:methods:sent:5,med:pmid:40575771,methods,5,This study is a retrospective cross-sectional study with data from HF patients obtained from the Second Affiliated Hospital of Chongqing Medical University between January 2016 and June 2021.,611,819
med:pmid:40575771:sec:methods:sent:6,med:pmid:40575771,methods,6,Patients were considered to have received GDMT if they were prescribed any guideline-recommended medication.,820,928
med:pmid:40575771:sec:methods:sent:7,med:pmid:40575771,methods,7,Multilevel logistic regression was used to obtain the relationship between medication and readmission rates.,929,1037
med:pmid:40575771:sec:methods:sent:8,med:pmid:40575771,methods,8,The odds ratios (ORs) and 95% confidence intervals (CIs) have been reported.,1038,1114
med:pmid:40575771:sec:results:sent:9,med:pmid:40575771,results,9,"In this study, a total of 5,356 HF patients (51.0% female; average age 77 years) were included.",1115,1227
med:pmid:40575771:sec:results:sent:10,med:pmid:40575771,results,10,"Among these patients, the most commonly used medications were mineralocorticoid receptor antagonists (MRA) (69.3%), Beta-blockers (54.2%), and lipid-lowering agents (46.0%).",1228,1401
med:pmid:40575771:sec:results:sent:11,med:pmid:40575771,results,11,"Currently, GDMT recommendations mainly include five types of drugs: diuretics, angiotensin receptor-neprilysin inhibitors (ARNIs), renin-angiotensin system inhibitors (ACEIs/ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i).",1402,1701
med:pmid:40575771:sec:results:sent:12,med:pmid:40575771,results,12,"Among them, the utilization rates of ARNIs, SGLT-2i, triple therapy, and quadruple therapy are relatively low, accounting for 12.7%, 8.1%, 33.2%, and 3.75% respectively.",1702,1871
med:pmid:40575771:sec:results:sent:13,med:pmid:40575771,results,13,"The usage rates of these drugs are gradually increasing, especially after pharmacists participate in clinical decision-making and assist doctors in selecting therapeutic drugs, leading to a significant increase in the utilization rates of guideline-recommended drugs.",1872,2139
med:pmid:40575771:sec:results:sent:14,med:pmid:40575771,results,14,"Additionally, a multivariate logistic regression analysis of all drugs recommended by GDMT showed that ARBs (OR 0.681, CI 0.511-0.908), ARNIs (OR 0.191, CI 0.089-0.406), anticoagulants (OR 0.578, CI 0.403-0.829), tolvaptan (OR 0.340, CI 0.124-0.929), and SGLT-2i (OR 0.238, CI 0.058-0.969) significantly reduced the readmission rate of patients.",2140,2485
med:pmid:40575771:sec:results:sent:15,med:pmid:40575771,results,15,"Further subgroup analysis showed that the efficacy of the drugs varied slightly depending on the type of HF, but was consistent with guideline recommendations and clinical study results.",2486,2672
med:pmid:40575771:sec:conclusion:sent:16,med:pmid:40575771,conclusion,16,"In our hospital, the utilization rate of guideline-recommended drugs is gradually increasing, especially after pharmacists participate in rational drug use in clinical practice, the rate of increase is more significant, which is more in line with GDMT recommendations.",2673,2961
med:pmid:40575771:sec:conclusion:sent:17,med:pmid:40575771,conclusion,17,"Additionally, despite some limitations in our study, most of the guideline-recommended drugs show good therapeutic effects.",2962,3085
med:pmid:40575771:sec:conclusion:sent:18,med:pmid:40575771,conclusion,18,"And, we found that drugs such as SGLT-2i and ivabradine, despite their low usage rates, also demonstrate good therapeutic effects, providing significant implications for clinical decision-making.",3086,3281
med:pmid:40463763:sec:title:sent:0,med:pmid:40463763,title,0,Impact of Angiotensin Receptor-Neprilysin Inhibitor Therapy on Cardiac Remodeling in Patients with Heart Failure and Reduced Ejection Fraction.,0,143
med:pmid:40463763:sec:introduction:sent:1,med:pmid:40463763,introduction,1,Cardiac remodeling in response to hemodynamic and neurohormonal factors is the primary driver of heart failure progression.,0,143
med:pmid:40463763:sec:introduction:sent:2,med:pmid:40463763,introduction,2,Angiotensin receptor-neprilysin inhibitor (ARNI) has superior beneficial effects on mortality and quality of life compared to angiotensin-converting enzyme inhibitor (ACEI).,144,317
med:pmid:40463763:sec:introduction:sent:3,med:pmid:40463763,introduction,3,Speckle-tracking echocardiography can detect early subtle changes in cardiac structure in numerous cardiac diseases.,318,434
med:pmid:40463763:sec:introduction:sent:4,med:pmid:40463763,introduction,4,"The study was conducted to evaluate the possible impact of ARNI therapy compared to ACEI on cardiac remodeling using echocardiographic parameters, including global longitudinal strain (GLS) in heart failure with reduced left ventricular ejection fraction (HFrEF) patients.",435,707
med:pmid:40463763:sec:methods:sent:5,med:pmid:40463763,methods,5,"This prospective observational study included eighty recently diagnosed HFrEF patients with left ventricular ejection fraction (LVEF) ≤35%, prescribed the four pillars of guideline-directed medical therapy, and uptitrated to the maximally tolerated doses.",708,980
med:pmid:40463763:sec:methods:sent:6,med:pmid:40463763,methods,6,"The study included two groups: the ARNI group included forty patients prescribed ARNI, and the ACEI group included forty patients prescribed ACEI.",981,1127
med:pmid:40463763:sec:methods:sent:7,med:pmid:40463763,methods,7,"All patients underwent two- and three-dimensional (2D and 3D) echocardiography to assess baseline parameters, including indexed left ventricular (LV) volumes and 2D and 3D GLS, at baseline and after a 6-month follow-up period.",1128,1354
med:pmid:40463763:sec:results:sent:8,med:pmid:40463763,results,8,Both groups had no significant differences regarding demographic data and echocardiographic findings at baseline.,1355,1485
med:pmid:40463763:sec:results:sent:9,med:pmid:40463763,results,9,"After a 6-month follow-up period, there was a significant reduction in LV-indexed volumes in the ARNI group (<i>P</i> < 0.001) and indexed left atrial volumes (<i>P</i> = 0.013) compared to the ACEI group.",1486,1691
med:pmid:40463763:sec:results:sent:10,med:pmid:40463763,results,10,"There was a significant improvement in the ARNI group regarding LVEF (<i>P</i> = 0.011), 2D GLS (<i>P</i> < 0.001), and 3D GLS compared to the ACEI group, but no significant change in the LV mass index.",1692,1894
med:pmid:40463763:sec:results:sent:11,med:pmid:40463763,results,11,"Multivariate regression analysis showed that the use of ARNI, absence of diabetes mellitus, and a higher baseline GLS (above-9.1%) are independent predictors for the occurrence of reverse remodeling (defined as an increase in LVEF ≥5%).",1895,2131
med:pmid:40463763:sec:conclusion:sent:12,med:pmid:40463763,conclusion,12,"The inclusion of ARNI in the pharmacotherapy of HFrEF patients is an independent predictor of LV reverse remodeling, as observed in a significant improvement in both 2D and 3D volumetric echocardiographic parameters, improved LVEF and longitudinal LV systolic function, represented in 2D and 3D GLS.",2132,2451
med:pmid:40463763:sec:conclusion:sent:13,med:pmid:40463763,conclusion,13,Baseline 3D GLS and not LVEF or 2D GLS can help predict the occurrence of reverse remodeling in HFrEF patients.,2452,2563
med:pmid:40332281:sec:title:sent:0,med:pmid:40332281,title,0,Adherence to Guideline-Directed Medical Therapy Target in patients with heart failure and reduced ejection fraction: a cross-sectional study.,0,141
med:pmid:40332281:sec:introduction:sent:1,med:pmid:40332281,introduction,1,Heart failure with reduced ejection fraction (HFrEF) represents a compelling cause of hospital morbidity and mortality in Brazil.,0,149
med:pmid:40332281:sec:introduction:sent:2,med:pmid:40332281,introduction,2,"There is low adherence to guideline-directed medical therapy (GDMT), which in turn, can result in higher morbidity and mortality.",150,279
med:pmid:40332281:sec:introduction:sent:3,med:pmid:40332281,introduction,3,The present study aims to evaluate adherence to GDMT in patients with HFrEF in a Brazilian University hospital service.,280,419
med:pmid:40332281:sec:introduction:sent:4,med:pmid:40332281,introduction,4,"<h4>Design and settings</h4> Observational, cross-sectional, single-center study conducted at the Hospital Universitário Professor Edgard Santos (HUPES), Salvador, BA, Brazil.",420,595
med:pmid:40332281:sec:methods:sent:5,med:pmid:40332281,methods,5,The study was conducted with convenience sampling at the cardiology outpatient clinic of a university hospital service.,596,732
med:pmid:40332281:sec:methods:sent:6,med:pmid:40332281,methods,6,Patients with left ventricular ejection fraction (LVEF) < 40% who had reverse remodeling were excluded.,733,836
med:pmid:40332281:sec:results:sent:7,med:pmid:40332281,results,7,"289 patients were included, with mean age 63 years, 54.7% were male, 56,4% mixed-race and 27,7% had Chagasic cardiomyopathy.",837,978
med:pmid:40332281:sec:results:sent:8,med:pmid:40332281,results,8,"93.1% were prescribed ACEi, ARB or ARNi, 95.8% betablockers, 69.2% spironolactone and 8% the combination hydralazine/isosorbide-dinitrate.",979,1117
med:pmid:40332281:sec:results:sent:9,med:pmid:40332281,results,9,"71,7% were using enalapril, losartan or ARNi above 50% of GDMT target doses; 81,2% were using beta-blockers and 100% were using spironolactone.",1118,1261
med:pmid:40332281:sec:results:sent:10,med:pmid:40332281,results,10,"Only 21,2% were prescribed GDMT target doses of enalapril, losartan or ARNi and 52,3% of beta-blockers.",1262,1365
med:pmid:40332281:sec:results:sent:11,med:pmid:40332281,results,11,"98,5% of spironolactone prescriptions reached GDMT target doses.",1366,1430
med:pmid:40332281:sec:conclusion:sent:12,med:pmid:40332281,conclusion,12,"We found high frequencies of prescription of GDMT for HFrEF, considering the therapeutic goals recommended by cardiology guidelines, but, prescription of target doses were low in ACEi, ARB or ARNi and beta-blockers.",1431,1667
med:pmid:40255655:sec:title:sent:0,med:pmid:40255655,title,0,Inflammation-Driven Prognosis in Advanced Heart Failure: A Machine Learning-Based Risk Prediction Model for One-Year Mortality.,0,127
med:pmid:40255655:sec:introduction:sent:1,med:pmid:40255655,introduction,1,"To develop a machine learning (ML)-based prediction model focused on the one-year mortality risk in patients with advanced heart failure (AdHF), aiming to improve prediction accuracy by integrating inflammatory biomarkers and clinical parameters, assist clinical decision-making, and enhance patient outcomes.",0,329
med:pmid:40255655:sec:methods:sent:2,med:pmid:40255655,methods,2,A retrospective cohort study.,330,376
med:pmid:40255655:sec:results:sent:3,med:pmid:40255655,results,3,were obtained from the electronic medical records system of the Affiliated Hospital of Xuzhou Medical University.,377,495
med:pmid:40255655:sec:results:sent:4,med:pmid:40255655,results,4,AdHF patients admitted to the ICU and cardiology department from January 2015 to December 2023 were included with a one-year follow-up.,496,631
med:pmid:40255655:sec:results:sent:5,med:pmid:40255655,results,5,52 variables potentially affecting prognosis were incorporated.,632,695
med:pmid:40255655:sec:results:sent:6,med:pmid:40255655,results,6,The LASSO algorithm was used for feature selection and dimensionality reduction.,696,776
med:pmid:40255655:sec:results:sent:7,med:pmid:40255655,results,7,were split into training and validation sets.,777,827
med:pmid:40255655:sec:results:sent:8,med:pmid:40255655,results,8,Seven ML algorithms were applied to build and evaluate models.,828,890
med:pmid:40255655:sec:results:sent:9,med:pmid:40255655,results,9,The SHAP method was used for model analysis and a dynamic nomogram was created.,891,970
med:pmid:40255655:sec:results:sent:10,med:pmid:40255655,results,10,The study included 715 AdHF patients.,971,1025
med:pmid:40255655:sec:results:sent:11,med:pmid:40255655,results,11,"The random forest (RF) model performed best, with an area under the curve (AUC) of 0.83 (95% confidence interval: 0.77-0.88), an accuracy of 0.72, a sensitivity of 0.74, and an F1 score of 0.73.",1026,1220
med:pmid:40255655:sec:results:sent:12,med:pmid:40255655,results,12,"Key predictors of one-year mortality risk included Beta blockers, ACEI/ARB/ARNI, BNP, CRP, NLR, AF, MI, NYHA class, and age.",1221,1345
med:pmid:40255655:sec:results:sent:13,med:pmid:40255655,results,13,"SHAP analysis revealed that elevated CRP, NLR, and age were associated with increased risk, while Beta blockers, ACEI/ARB/ARNI, and lower BNP values were associated with reduced risk.",1346,1529
med:pmid:40255655:sec:results:sent:14,med:pmid:40255655,results,14,An online dynamic nomogram was developed to provide personalized risk predictions based on patient-specific conditions.,1530,1649
med:pmid:40255655:sec:conclusion:sent:15,med:pmid:40255655,conclusion,15,"A successful ML-based prediction model was developed to accurately predict the one-year mortality risk in AdHF patients, with inflammation-driven factors being significant.",1650,1842
med:pmid:40255655:sec:conclusion:sent:16,med:pmid:40255655,conclusion,16,The RF model integrating clinical features and inflammatory markers showed excellent performance and could assist clinical decision-making.,1843,1982
med:pmid:40255655:sec:conclusion:sent:17,med:pmid:40255655,conclusion,17,"Future research should conduct larger, multi-center, and prospective studies to further validate these findings.",1983,2095
med:pmid:39864551:sec:title:sent:0,med:pmid:39864551,title,0,Sacubitril/valsartan role in patients with resistant hypertension: a systematic review.,0,87
med:pmid:39864551:sec:introduction:sent:1,med:pmid:39864551,introduction,1,"Sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor (ARNI), shows promising result in treating resistant hypertension (RH) but lacks comprehensive evaluation.",0,193
med:pmid:39864551:sec:introduction:sent:2,med:pmid:39864551,introduction,2,We performed a systematic review to assess and compare the efficacy of ARNI in managing RH.,194,285
med:pmid:39864551:sec:methods:sent:3,med:pmid:39864551,methods,3,"We conducted a systematic search on multiple databases such as Cochrane, ProQuest, PubMed, and Google Scholar.",286,413
med:pmid:39864551:sec:methods:sent:4,med:pmid:39864551,methods,4,Studies comparing the effects of ARNI on blood pressure in adult RH patients were included in the review.,414,519
med:pmid:39864551:sec:results:sent:5,med:pmid:39864551,results,5,"extraction and synthesis followed PRISMA guidelines, and the risk of bias was assessed using Cochrane tools.",520,633
med:pmid:39864551:sec:results:sent:6,med:pmid:39864551,results,6,"The primary outcome is to determine the effect of ARNI on blood pressure in RH patients, and the secondary outcome was to assess the safety of ARNI in RH patients.",634,797
med:pmid:39864551:sec:results:sent:7,med:pmid:39864551,results,7,Four studies involving 915 RH patients were included in the systematic review.,798,893
med:pmid:39864551:sec:results:sent:8,med:pmid:39864551,results,8,The sacubitril/valsartan dose used ranged between 100 and 400 mg/day.,894,963
med:pmid:39864551:sec:results:sent:9,med:pmid:39864551,results,9,"All studies reported a statistically significant reduction in blood pressure, with 24-h blood pressure reduction ranging from 15.8/6.5 to 16.6/9.3 mmHg and office systolic blood pressure reduction ranging from 24.7 to 10.3 mmHg.",964,1192
med:pmid:39864551:sec:results:sent:10,med:pmid:39864551,results,10,"Additionally, two studies reported improvements in cardiac remodeling and left ventricular function associated with sacubitril/valsartan.",1193,1330
med:pmid:39864551:sec:results:sent:11,med:pmid:39864551,results,11,"The most common adverse events were hypotension and elevated serum potassium levels, though these were minimal and did not require discontinuation of ARNI therapy.",1331,1494
med:pmid:39864551:sec:conclusion:sent:12,med:pmid:39864551,conclusion,12,"Sacubitril/valsartan is a promising alternative to ARB or ACEi in managing RH, offering superior blood pressure reductions and potential benefits in reversing cardiac remodeling, while maintaining a favorable safety profile with minimal risk of serious adverse events.",1495,1783
med:pmid:39719408:sec:title:sent:0,med:pmid:39719408,title,0,Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HF.,0,225
med:pmid:39719408:sec:introduction:sent:1,med:pmid:39719408,introduction,1,The importance of nutritional status is underappreciated in patients with heart failure (HF).,0,113
med:pmid:39719408:sec:introduction:sent:2,med:pmid:39719408,introduction,2,"This study aimed to describe the range of the prognostic nutrition index (PNI), and the clinical characteristics and outcomes according to PNI, in patients with HF with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF).",114,357
med:pmid:39719408:sec:introduction:sent:3,med:pmid:39719408,introduction,3,The primary outcome was the composite of HF hospitalization or cardiovascular death.,358,442
med:pmid:39719408:sec:results:sent:4,med:pmid:39719408,results,4,Individual patient data from the PARAGON-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blocker] Global Outcomes in HFpEF) and PARADIGM-HF (Prospective Comparison of ARNI With ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in HF) trials were used to examine patient characteristics and outcomes according to quartiles of PNI.,443,914
med:pmid:39719408:sec:results:sent:5,med:pmid:39719408,results,5,"Cox regression was used to analyze clinical outcomes, and multivariable fractional polynomial interaction analysis to examine the effects of sacubitril-valsartan, according to PNI.",915,1095
med:pmid:39719408:sec:results:sent:6,med:pmid:39719408,results,6,"Patients with lower PNI (poorer nutrition) were older, frailer, and had more comorbidities and worse HF status, with greater congestion.",1096,1232
med:pmid:39719408:sec:results:sent:7,med:pmid:39719408,results,7,"Patients with lower PNI had biomarker abnormalities indicating inflammation, bone marrow suppression, and increased collagen turnover, among other physiologic perturbations.",1233,1406
med:pmid:39719408:sec:results:sent:8,med:pmid:39719408,results,8,"Lower PNI was associated with worse outcomes; that is, the rate of the primary end point among patients in the first quartile was 11.31 (10.20-12.54) compared with 7.09 (6.17-8.14) per 100 person-years in the fourth quartile.",1407,1632
med:pmid:39719408:sec:results:sent:9,med:pmid:39719408,results,9,These associations persisted after adjustment for other prognostic variables.,1633,1710
med:pmid:39719408:sec:results:sent:10,med:pmid:39719408,results,10,PNI did not modify the effects of sacubitril-valsartan in HFrEF although sacubitril/valsartan seemed to have a greater benefit in patients with HFpEF with a higher PNI.,1711,1879
med:pmid:39719408:sec:conclusion:sent:11,med:pmid:39719408,conclusion,11,"Nutritional status, assessed using PNI, is an independent predictor of poor outcomes in HF.",1880,1992
med:pmid:39719408:sec:conclusion:sent:12,med:pmid:39719408,conclusion,12,"Evaluation of nutritional status in clinical practice, the causes of undernutrition, and whether undernutrition should be a therapeutic target, are all worthy of further investigation in HF.",1993,2183
med:pmid:39439294:sec:title:sent:0,med:pmid:39439294,title,0,Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials.,0,132
med:pmid:39439294:sec:introduction:sent:1,med:pmid:39439294,introduction,1,"Resting heart rate (HR) is a strong risk marker in patients with heart failure (HF), but the clinical implications of visit-to-visit changes in HR (ΔHR) are less well established.",0,193
med:pmid:39439294:sec:introduction:sent:2,med:pmid:39439294,introduction,2,We aimed to explore the association between ΔHR and subsequent outcomes in a pooled dataset of two well-characterized cohorts of patients with HF across the full range of left ventricular ejection fraction (LVEF).,194,407
med:pmid:39439294:sec:results:sent:3,med:pmid:39439294,results,3,"PARADIGM-HF and PARAGON-HF were randomized trials testing sacubitril/valsartan versus enalapril or valsartan, respectively, in patients with HF and LVEF ≤40% (PARADIGM-HF) or LVEF ≥45% (PARAGON-HF).",408,635
med:pmid:39439294:sec:results:sent:4,med:pmid:39439294,results,4,We analysed the association between ΔHR from the preceding visit with the primary endpoint of HF hospitalization (HFH) or cardiovascular death using covariate-adjusted Cox proportional hazards models.,636,836
med:pmid:39439294:sec:results:sent:5,med:pmid:39439294,results,5,"A total of 13 194 patients (mean age 67 ± 11 years, 67% men, mean LVEF 40 ± 15%) were included.",837,932
med:pmid:39439294:sec:results:sent:6,med:pmid:39439294,results,6,"Over a median follow-up of 2.5 years, 3114 patients experienced a first HFH or cardiovascular death event (10.4 events per 100 patient-years).",933,1075
med:pmid:39439294:sec:results:sent:7,med:pmid:39439294,results,7,"An increase in HR from the preceding visit, compared with no change, was associated with a higher risk (hazard ratio 1.12; 95% confidence interval [CI] 1.10-1.15; p < 0.001 per 5 bpm increase).",1076,1269
med:pmid:39439294:sec:results:sent:8,med:pmid:39439294,results,8,"Conversely, a drop in HR was associated with a lower risk (hazard ratio 0.97; 95% CI 0.94-1.00; p = 0.044 per 5 bpm drop).",1270,1392
med:pmid:39439294:sec:results:sent:9,med:pmid:39439294,results,9,The prognostic implications of ΔHR were consistent across the range of LVEF and observed regardless of β-blocker use or presence of a permanent pacemaker.,1393,1547
med:pmid:39439294:sec:results:sent:10,med:pmid:39439294,results,10,Visit-to-visit increases in HR were especially prognostic in patients without atrial fibrillation (p<sub>interaction</sub> = 0.006).,1548,1680
med:pmid:39439294:sec:conclusion:sent:11,med:pmid:39439294,conclusion,11,"Across a broad spectrum of patients with chronic HF, increases in HR from a preceding visit independently predicted clinical outcomes.",1681,1835
med:pmid:39439294:sec:conclusion:sent:12,med:pmid:39439294,conclusion,12,The detection of notable increases in HR between outpatient visits may help identify patients at heightened risk of adverse events.,1836,1967
med:pmid:39439294:sec:conclusion:sent:13,med:pmid:39439294,conclusion,13,"<h4>Clinical trial registration</h4> ClinicalTrials.gov NCT01035255 (PARADIGM-HF), NCT01920711 (PARAGON-HF).",1968,2076
med:pmid:39387766:sec:title:sent:0,med:pmid:39387766,title,0,Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials.,0,107
med:pmid:39387766:sec:introduction:sent:1,med:pmid:39387766,introduction,1,"Mechanisms of disease pathobiology, prognosis, and potentially treatment responses might vary by race in patients with heart failure (HF).",0,158
med:pmid:39387766:sec:introduction:sent:2,med:pmid:39387766,introduction,2,The authors aimed to examine the safety and efficacy of sacubitril/valsartan among patients with HF by self-reported race.,159,301
med:pmid:39387766:sec:methods:sent:3,med:pmid:39387766,methods,3,"PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) were global, randomized clinical trials testing sacubitril/valsartan against a renin-angiotensin system inhibitor (RASi) (enalapril or valsartan, respectively) in patients with HF and left ventricular ejection fraction ≤40% (PARADIGM-HF) or left ventricular ejection fraction ≥45% (PARAGON-HF).",302,851
med:pmid:39387766:sec:methods:sent:4,med:pmid:39387766,methods,4,"Patients with self-reported race were categorized as White, Asian, or Black.",852,928
med:pmid:39387766:sec:methods:sent:5,med:pmid:39387766,methods,5,"We assessed the composite of first HF hospitalization or cardiovascular death, its components, and angioedema across races.",929,1052
med:pmid:39387766:sec:results:sent:6,med:pmid:39387766,results,6,"Among 12,097 participants, 9,451 (78.1%) were White, 2,116 (17.5%) were Asian, and 530 (4.4%) were Black.",1053,1175
med:pmid:39387766:sec:results:sent:7,med:pmid:39387766,results,7,"Over a median follow-up of 2.5 years, Black (adjusted HR: 1.68; 95% CI: 1.42-1.98) and Asian patients (adjusted HR: 1.32; 95% CI: 1.18-1.47) experienced higher risks of the primary outcome compared with White patients.",1176,1394
med:pmid:39387766:sec:results:sent:8,med:pmid:39387766,results,8,"Treatment effects of sacubitril/valsartan vs RASi on the primary endpoint were consistent among White (HR: 0.84; 95% CI: 0.77-0.91), Asian (HR: 0.92; 95% CI: 0.78-1.10), and Black patients (HR: 0.79; 95% CI: 0.58-1.07; P<sub>interaction</sub> = 0.58).",1395,1646
med:pmid:39387766:sec:results:sent:9,med:pmid:39387766,results,9,Rates of severe angioedema were higher with sacubitril/valsartan vs RASi (White: 0.2% vs 0.1%; Black: 1.5% vs 0.0%; Asian: 0.1% vs 0.1%).,1647,1784
med:pmid:39387766:sec:conclusion:sent:10,med:pmid:39387766,conclusion,10,"In a pooled experience of 2 global trials, Black and Asian patients exhibited a higher risk of cardiovascular events than White patients.",1785,1943
med:pmid:39387766:sec:conclusion:sent:11,med:pmid:39387766,conclusion,11,The benefits of sacubitril/valsartan were consistent across races.,1944,2010
med:pmid:39387766:sec:conclusion:sent:12,med:pmid:39387766,conclusion,12,Risks of severe angioedema were low but numerically higher with sacubitril/valsartan. (,2011,2098
med:pmid:39387766:sec:conclusion:sent:13,med:pmid:39387766,conclusion,13,Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255; Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).,2098,2360
med:pmid:39816068:sec:title:sent:0,med:pmid:39816068,title,0,&lt;i&gt;ACE&lt;/i&gt; inhibitors versus angiotensin receptor-neprilysin inhibitors for &lt;i&gt;HFrEF&lt;/i&gt; management: A prospective cohort study from Indonesia.,0,167
med:pmid:39816068:sec:abstract:sent:1,med:pmid:39816068,abstract,1,Previous studies have reported that angiotensin receptor-neprilysin inhibitors (ARNI) are superior to angiotensin-converting enzyme inhibitors (ACEI) in treating heart failure with reduced ejection fraction (HFrEF).,0,215
med:pmid:39816068:sec:abstract:sent:2,med:pmid:39816068,abstract,2,"Unfortunately, previously published studies predominantly focused on Western populations, while the data remains insufficient in developing countries.",216,366
med:pmid:39816068:sec:abstract:sent:3,med:pmid:39816068,abstract,3,The aim of this study was to compare the efficacies of ARNI and ACEI on patients with HFrEF in Indonesia.,367,472
med:pmid:39816068:sec:abstract:sent:4,med:pmid:39816068,abstract,4,"A prospective cohort study was conducted among heart failure patients at Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia.",473,597
med:pmid:39816068:sec:abstract:sent:5,med:pmid:39816068,abstract,5,Both ACEI and ARNI each consisted of 40 subjects receiving standard treatment for heart failure.,598,694
med:pmid:39816068:sec:abstract:sent:6,med:pmid:39816068,abstract,6,"Left ventricular ejection fraction (LVEF), quality of life (QoL), suppression of tumorigenicity 2 (ST2), and troponin T were measured upon admission and at the end of the follow-up.",695,876
med:pmid:39816068:sec:abstract:sent:7,med:pmid:39816068,abstract,7,"In addition, the occurrence of major adverse cardiac events (MACE) was observed during 6 months of follow-up.",877,986
med:pmid:39816068:sec:abstract:sent:8,med:pmid:39816068,abstract,8,Paired <i>t</i>-test was used to compare the outcomes of ACEI and ARNI.,987,1058
med:pmid:39816068:sec:abstract:sent:9,med:pmid:39816068,abstract,9,The results revealed that KKCQ score and LVEF were improved in both ARNI and ACEI groups (each with <i>p</i><0.001).,1059,1175
med:pmid:39816068:sec:abstract:sent:10,med:pmid:39816068,abstract,10,A higher KCCQ overall score was observed in the ARNI group in contrast to the ACEI group (<i>p</i>=0.01).,1176,1281
med:pmid:39816068:sec:abstract:sent:11,med:pmid:39816068,abstract,11,ARNI demonstrated superior results in improving the ejection fraction as compared with ACEI (<i>p</i>=0.001).,1282,1391
med:pmid:39816068:sec:abstract:sent:12,med:pmid:39816068,abstract,12,"Troponin T and ST2 levels exhibited no significant difference between the two groups (<i>p</i>=0.07 and 0.286, respectively).",1392,1517
med:pmid:39816068:sec:abstract:sent:13,med:pmid:39816068,abstract,13,MACE-associated mortality (<i>p</i>=0.696) and rehospitalization (<i>p</i>=0.955) were identical between both groups.,1518,1635
med:pmid:39816068:sec:abstract:sent:14,med:pmid:39816068,abstract,14,"In conclusion, ARNI was more efficacious than ACEI in improving the quality of life and left ventricular ejection fraction of patients with HFrEF.",1636,1782
med:pmid:39816068:sec:abstract:sent:15,med:pmid:39816068,abstract,15,"However, the efficacy was not significantly different in reducing the risk of MACE.",1783,1866
med:pmid:39622578:sec:title:sent:0,med:pmid:39622578,title,0,Effect of optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan (Entresto) and dapaglifloziN on left Ventricular reverse remodelling as demonstrated by cardiac magnetic resonance (CMR) Imaging: the ENVI study.,0,232
med:pmid:39622578:sec:introduction:sent:1,med:pmid:39622578,introduction,1,Heart failure with reduced ejection fraction (HFrEF) guidelines recommend 'four pillars' of medical therapy and device therapy if left ventricular ejection fraction (LVEF) remains ≤35% after 3 months optimum medical therapy.,0,246
med:pmid:39622578:sec:introduction:sent:2,med:pmid:39622578,introduction,2,"We conducted the first study to examine the effects of optimisation to contemporary medical therapy on cardiac reverse remodelling, as demonstrated by cardiac magnetic resonance imaging (CMR).We hypothesised a proportion of patients would undergo beneficial remodelling and LVEF improvement above the threshold for complex device prescription after 6 months.",246,604
med:pmid:39622578:sec:methods:sent:3,med:pmid:39622578,methods,3,"HFrEF patients with symptomatic LVEF≤35% despite ACE inhibitor/beta blocker/mineralocorticoid receptor antagonist therapy, and qualified for sacubitril/valsartan switchover were recruited to this single centre prospective study.",605,850
med:pmid:39622578:sec:methods:sent:4,med:pmid:39622578,methods,4,CMR was performed at baseline and at follow-up.,850,897
med:pmid:39622578:sec:methods:sent:5,med:pmid:39622578,methods,5,"Clinical, volumetric and outcome data were collected and compared.",898,964
med:pmid:39622578:sec:results:sent:6,med:pmid:39622578,results,6,"Between June 2021 and August 2022, 49 patients were recruited.",965,1044
med:pmid:39622578:sec:results:sent:7,med:pmid:39622578,results,7,"The majority (80%) were male, mean age 63±14 years.",1045,1096
med:pmid:39622578:sec:results:sent:8,med:pmid:39622578,results,8,35 (71%) had non-ischaemic cardiomyopathy.,1097,1139
med:pmid:39622578:sec:results:sent:9,med:pmid:39622578,results,9,2 (4%) patients died and 47 were followed up for a median of 7.4 months.,1140,1212
med:pmid:39622578:sec:results:sent:10,med:pmid:39622578,results,10,There were no heart failure hospitalisations.,1213,1258
med:pmid:39622578:sec:results:sent:11,med:pmid:39622578,results,11,Significant reductions were seen in median indexed left atrial volume: 54 mL/m<sup>2</sup> (41-72) to 39 mL/m<sup>2</sup> (30-60) (p<0.001); indexed left ventricular end-diastolic volume: 109 mL/m<sup>2</sup> (74-125) to 76 mL/m<sup>2</sup> (58-102) (p<0.001); indexed left ventricular end-systolic volume: 74mL/m<sup>2</sup> (50-92) to 43 mL/m<sup>2</sup> (27-58) (p<0.001) and mean indexed left ventricular mass: 72±13 g/m<sup>2</sup> to 62±13 g/m<sup>2</sup> (p<0.001).Median LVEF increased by 12 points from 31% to 43% (p<0.001).,1258,1791
med:pmid:39622578:sec:results:sent:12,med:pmid:39622578,results,12,29 (59%) patients improved to LVEF>35%.,1792,1831
med:pmid:39622578:sec:results:sent:13,med:pmid:39622578,results,13,13 (27%) patients improved to LVEF≥50%.Median N-terminal pro B type natriuretic peptide (NTproBNP) reduced from 883 ng/L (293-2043) to 429 ng/L (171-1421) (p<0.001).,1832,1997
med:pmid:39622578:sec:conclusion:sent:14,med:pmid:39622578,conclusion,14,Optimisation to contemporary HFrEF medical therapy results in beneficial cardiac reverse remodelling and significant improvements in LVEF and NTproBNP at 6 months as demonstrated by CMR.,1998,2205
med:pmid:39622578:sec:conclusion:sent:15,med:pmid:39622578,conclusion,15,59% of our cohort no longer met complex device indications.,2206,2265
med:pmid:39622578:sec:conclusion:sent:16,med:pmid:39622578,conclusion,16,"Guidelines suggest re-assessment of LVEF at 3 months, but our data suggests a longer period is required.",2266,2370
med:pmid:39622578:sec:conclusion:sent:17,med:pmid:39622578,conclusion,17,<h4>Trial registration number</h4> NCT05348226.,2371,2418
med:pmid:39620289:sec:title:sent:0,med:pmid:39620289,title,0,Clinical Management Strategies of Cardiologists in Heart Failure with Reduced Ejection Fraction in Türkiye.,0,107
med:pmid:39620289:sec:introduction:sent:1,med:pmid:39620289,introduction,1,Integrating heart failure (HF) guideline recommendations into clinical practice takes time and is often suboptimal in real-life settings.,0,156
med:pmid:39620289:sec:introduction:sent:2,med:pmid:39620289,introduction,2,Physician-related factors may be significant barriers to the adoption of these guidelines.,157,247
med:pmid:39620289:sec:introduction:sent:3,med:pmid:39620289,introduction,3,This survey aims to assess the current opinions of cardiologists practicing in Türkiye regarding the management of heart failure with reduced ejection fraction (HFrEF).,248,416
med:pmid:39620289:sec:methods:sent:4,med:pmid:39620289,methods,4,The survey comprised 22 questions and was published on the SurveyMonkey platform.,417,515
med:pmid:39620289:sec:results:sent:5,med:pmid:39620289,results,5,A total of 177 cardiologists (mean age: 39.5 years; 73.3% male) participated in the survey.,516,624
med:pmid:39620289:sec:results:sent:6,med:pmid:39620289,results,6,"Of these, 38.7% worked in a training and research hospital, and 10.2% were specialists in HF.",625,718
med:pmid:39620289:sec:results:sent:7,med:pmid:39620289,results,7,The threshold EF value to define HFrEF was ≤ 40% for 80.1% of the cardiologists.,719,799
med:pmid:39620289:sec:results:sent:8,med:pmid:39620289,results,8,"While 52.6% of physicians considered angiotensin receptor-neprilysin inhibitor (ARNi) treatment the most effective medication for HF, 62.7% would initiate HF treatment with an angiotensin-converting enzyme inhibitor (ACEi) instead of ARNi due to reimbursement and cost issues.",800,1076
med:pmid:39620289:sec:results:sent:9,med:pmid:39620289,results,9,More than half of the cardiologists (52.3%) stated that adding another class of HF medication is more important than up-titrating those already prescribed.,1077,1232
med:pmid:39620289:sec:results:sent:10,med:pmid:39620289,results,10,"Although 69.5% of the study participants indicated prescribing all four classes of HF medications during the initial hospitalization is feasible, most cardiologists preferred a sequential approach starting with ACEi/ARNi, followed by beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).",1233,1584
med:pmid:39620289:sec:conclusion:sent:11,med:pmid:39620289,conclusion,11,This survey highlights significant discrepancies between guideline recommendations and the real-life clinical practice of cardiologists in Türkiye.,1585,1752
med:pmid:39620289:sec:conclusion:sent:12,med:pmid:39620289,conclusion,12,These results suggest that there is a need for organized action by healthcare providers to improve the implementation of guideline recommendations.,1753,1900
med:pmid:39455534:sec:title:sent:0,med:pmid:39455534,title,0,ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.,0,228
med:pmid:39455534:sec:introduction:sent:1,med:pmid:39455534,introduction,1,"The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in regulating blood pressure (BP), with dysregulation of RAAS resulting in hypertension and potentially heart failure (HF), myocardial infarction (MI), cardio-renal syndrome, and stroke.",0,277
med:pmid:39455534:sec:introduction:sent:2,med:pmid:39455534,introduction,2,"RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), have advantages beyond BP control.",278,428
med:pmid:39455534:sec:introduction:sent:3,med:pmid:39455534,introduction,3,"However, differences between these two drug classes need to be considered when choosing a therapy for preventing cardiovascular events.",429,564
med:pmid:39455534:sec:methods:sent:4,med:pmid:39455534,methods,4,"A panel of 36 Egyptian cardiologists developed consensus statements on RAAS inhibitors for primary and secondary prevention of cardiovascular outcomes and stroke, using a modified three-step Delphi process.",565,788
med:pmid:39455534:sec:results:sent:5,med:pmid:39455534,results,5,The consensus statements highlight the importance of effective BP control and the role of RAAS blockade for prevention and management of various cardiovascular diseases.,789,975
med:pmid:39455534:sec:results:sent:6,med:pmid:39455534,results,6,"ACEis and ARBs differ in their mode of action and, thus, clinical effects.",976,1050
med:pmid:39455534:sec:results:sent:7,med:pmid:39455534,results,7,"On the basis of available evidence, the consensus group recommended the following: ACEis should be considered as first choice (in preference to ARBs) to reduce the risk of MI, for primary prevention of HF, and for secondary prevention of stroke.",1051,1296
med:pmid:39455534:sec:results:sent:8,med:pmid:39455534,results,8,ACEis and ARBs show equivalent efficacy for the primary prevention of stroke.,1297,1374
med:pmid:39455534:sec:results:sent:9,med:pmid:39455534,results,9,"Evidence also favors the preferential use of ACEis in patients with type 2 diabetes, for BP control, for the primary prevention of diabetic kidney disease, and to reduce the risk of major cardiovascular and renal outcomes.",1375,1597
med:pmid:39455534:sec:results:sent:10,med:pmid:39455534,results,10,"Treatment with an ACEi should be started within 24 h of ST segment elevation MI (and continued long term) in patients with HF, left ventricular systolic dysfunction, and/or diabetes.",1598,1780
med:pmid:39455534:sec:results:sent:11,med:pmid:39455534,results,11,"Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group.",1781,1954
med:pmid:39455534:sec:results:sent:12,med:pmid:39455534,results,12,ARBs are indicated as alternatives in patients who cannot tolerate ACEis.,1955,2028
med:pmid:39455534:sec:results:sent:13,med:pmid:39455534,results,13,"ACEis may be associated with cough development, but the incidence tends to be overestimated, and the risk can be reduced by use of a lipophilic ACEi or combining the ACEi with a calcium channel blocker.",2029,2231
med:pmid:39455534:sec:conclusion:sent:14,med:pmid:39455534,conclusion,14,"RAAS blockade is an essential component of hypertension therapy; however, the protective effects provided by ACEis are superior to those of ARBs.",2232,2397
med:pmid:39455534:sec:conclusion:sent:15,med:pmid:39455534,conclusion,15,"Therefore, an ACEi is indicated in almost all cases, unless not tolerated.",2398,2472
med:pmid:39412629:sec:title:sent:0,med:pmid:39412629,title,0,A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients.,0,201
med:pmid:39412629:sec:introduction:sent:1,med:pmid:39412629,introduction,1,A systematic literature review and network meta-analysis was conducted on azilsartan medoxomil (AZL-M) versus other antihypertensive drugs' efficacy in hypertensive patients.,0,196
med:pmid:39412629:sec:methods:sent:2,med:pmid:39412629,methods,2,"The search utilized English platforms, from January 2000 until December 2023, resulting in 10,380 articles being screened.",197,336
med:pmid:39412629:sec:methods:sent:3,med:pmid:39412629,methods,3,"Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure.",337,774
med:pmid:39412629:sec:methods:sent:4,med:pmid:39412629,methods,4,Study design was randomized clinical trials.,775,819
med:pmid:39412629:sec:methods:sent:5,med:pmid:39412629,methods,5,Efficacy variables included absolute office systolic and diastolic blood pressure (BP) reductions.,820,918
med:pmid:39412629:sec:methods:sent:6,med:pmid:39412629,methods,6,"A total of 21 publications provided adequate data for analysis, of which 20 studies reported both systolic and diastolic BP and one study reported only the diastolic BP.",919,1088
med:pmid:39412629:sec:results:sent:7,med:pmid:39412629,results,7,"In 21 studies on systolic BP, against the common comparator placebo, the differences in systolic BP were significantly in favor of AZL-M, amlodipine, candesartan, irbesartan, nebivolol, nifedipine, olmesartan, sacubitril valsartan, telmisartan, and valsartan.",1089,1365
med:pmid:39412629:sec:results:sent:8,med:pmid:39412629,results,8,"The surface under the cumulative ranking curve (SUCRA) ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 93% being the best in all other included treatments.",1366,1551
med:pmid:39412629:sec:results:sent:9,med:pmid:39412629,results,9,"In 20 studies on diastolic BP, against the common comparator placebo, the differences in diastolic BP were significantly in favor of AZL-M, amlodipine, bisoprolol, nebivolol, olmesartan, sacubitril valsartan, telmisartan, and valsartan.",1552,1788
med:pmid:39412629:sec:results:sent:10,med:pmid:39412629,results,10,"The SUCRA ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 90% being the best in all other included treatments.",1789,1929
med:pmid:39412629:sec:conclusion:sent:11,med:pmid:39412629,conclusion,11,"AZL-M at 40 mg and 80 mg shows favorable efficacy compared to other anti-hypertensives, and the 80 mg dosage seemed to be the most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild-to-moderate hypertension.",1930,2221
med:pmid:39720381:sec:title:sent:0,med:pmid:39720381,title,0,Comparative Efficacy and Long-Term Outcomes of Beta-Blockers Alone or in Combination With Angiotensin-Converting Enzyme (ACE) Inhibitors in Chronic Heart Failure: A Systematic Review.,0,183
med:pmid:39720381:sec:abstract:sent:1,med:pmid:39720381,abstract,1,"This systematic review provides a comprehensive comparison of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors in the management of chronic heart failure (CHF), with a focus on their long-term efficacy and safety profiles.",0,238
med:pmid:39720381:sec:abstract:sent:2,med:pmid:39720381,abstract,2,"By synthesizing evidence from randomized controlled trials (RCTs) and clinical studies, the review highlights the significant benefits of both drug classes in reducing mortality and hospital readmissions, and improving patient outcomes.",239,475
med:pmid:39720381:sec:abstract:sent:3,med:pmid:39720381,abstract,3,"Beta-blockers, such as bisoprolol and carvedilol, demonstrated superior efficacy in reducing sudden cardiac death, particularly in patients with heart failure with reduced ejection fraction (HFrEF).",476,674
med:pmid:39720381:sec:abstract:sent:4,med:pmid:39720381,abstract,4,"Angiotensin-converting enzyme (ACE) inhibitors, including enalapril and lisinopril, effectively lowered overall cardiovascular mortality by targeting the renin-angiotensin-aldosterone system (RAAS) and preventing further cardiac remodeling.",675,915
med:pmid:39720381:sec:abstract:sent:5,med:pmid:39720381,abstract,5,"The findings of this review underscore the importance of utilizing these therapies, either alone or in combination, for optimal heart failure management.",916,1069
med:pmid:39720381:sec:abstract:sent:6,med:pmid:39720381,abstract,6,"Combining beta-blockers and ACE inhibitors, or integrating them with newer agents such as angiotensin receptor-neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs), provides an additive benefit, improving long-term survival and reducing heart failure-related hospitalizations.",1070,1373
med:pmid:39720381:sec:abstract:sent:7,med:pmid:39720381,abstract,7,"The review also identifies gaps in the current literature, suggesting that future research should focus on personalized treatment approaches, longer follow-up periods, and exploring novel therapeutic combinations for diverse heart failure populations.",1374,1625
med:pmid:39720381:sec:abstract:sent:8,med:pmid:39720381,abstract,8,This evidence reinforces the role of beta-blockers and ACE inhibitors as foundational therapies in CHF and offers actionable insights for clinicians to enhance patient care.,1626,1799
med:pmid:39602121:sec:title:sent:0,med:pmid:39602121,title,0,Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome.,0,105
med:pmid:39602121:sec:abstract:sent:1,med:pmid:39602121,abstract,1,<h4>Importance</h4> Individuals with type 2 diabetes (T2D) have high rates of mortality following myocardial infarction (MI).,0,125
med:pmid:39602121:sec:abstract:sent:2,med:pmid:39602121,abstract,2,Hospitalization is an opportunity to initiate or continue evidence-based treatment to reduce risk in individuals with T2D and acute coronary syndrome (ACS).,126,282
med:pmid:39602121:sec:introduction:sent:3,med:pmid:39602121,introduction,3,To determine patterns of evidence-based medication use during the period of transition from admission to discharge after hospitalization for MI or coronary revascularization among individuals with T2D and ACS.,283,511
med:pmid:39602121:sec:introduction:sent:4,med:pmid:39602121,introduction,4,"<h4>Design, setting, and participants</h4> This retrospective cohort study used data from the Centers for Medicare & Medicaid Services (CMS) for January 1, 2018, to June 30, 2020.",512,691
med:pmid:39602121:sec:introduction:sent:5,med:pmid:39602121,introduction,5,Medicare beneficiaries older than 18 years with T2D with a qualifying hospitalization were included.,692,792
med:pmid:39602121:sec:introduction:sent:6,med:pmid:39602121,introduction,6,"Individuals were followed before admission (90 days prior), at discharge (≤90 days), and after discharge (91-180 days after) from a hospitalization for MI or coronary revascularization.",793,978
med:pmid:39602121:sec:results:sent:7,med:pmid:39602121,results,7,analysis was performed in June 2023.,979,1020
med:pmid:39602121:sec:results:sent:8,med:pmid:39602121,results,8,"<h4>Exposures</h4> Demographic data (race, sex, rural vs urban location of care, and comorbidities) were abstracted from CMS data using Master Beneficiary and Summary Files and International Statistical Classification of Diseases, Tenth Revision codes.",1021,1273
med:pmid:39602121:sec:results:sent:9,med:pmid:39602121,results,9,"<h4>Main outcome and measures</h4> Medicare Part D prescription fill records were examined for the following agents: (1) angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); (2) β-blockers; (3) platelet adenosine diphosphate receptor inhibitors (P2Y12Is); (4) statins or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is); and (5) glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium glucose cotransporter 2 inhibitors (SGLT2Is).",1274,1819
med:pmid:39602121:sec:results:sent:10,med:pmid:39602121,results,10,Logistic regression analysis was used to examine the association between covariates and lack of prescription fills in the postdischarge period.,1820,1963
med:pmid:39602121:sec:results:sent:11,med:pmid:39602121,results,11,A total of 188 651 eligible Medicare beneficiaries with T2D and hospitalization for MI or coronary revascularization were identified.,1964,2114
med:pmid:39602121:sec:results:sent:12,med:pmid:39602121,results,12,"Their median age was 73.0 (IQR, 67.0-79.0) years, and more than half (111 982 [59.4%]) were men; 18 383 (9.7%) were Black and 153 461 (81.3%) were White.",2115,2268
med:pmid:39602121:sec:results:sent:13,med:pmid:39602121,results,13,"Not filling a cardiovascular medication after hospitalization was associated with not filling that medication at the time of discharge (adjusted risk ratio, 0.27 [95% CI, 0.27-0.28] for ACEIs, ARBs, or ARNIs; 0.24 [0.24-0.25] for β-blockers; 0.20 [0.19-0.20] for P2Y12Is; 0.31 [0.31-0.32] for statins or PCSK9Is; and 0.27 [0.26-0.28] for SGLT2Is or GLP-1RAs).",2269,2628
med:pmid:39602121:sec:conclusion:sent:14,med:pmid:39602121,conclusion,14,"In this cohort study of Medicare beneficiaries with T2D, longer-term medication use following hospitalization for MI was associated with medication use at the time of discharge.",2629,2841
med:pmid:39602121:sec:conclusion:sent:15,med:pmid:39602121,conclusion,15,These findings highlight the critical importance of this period to optimize preventive care for these high-risk individuals.,2842,2966
med:pmid:39602121:sec:conclusion:sent:16,med:pmid:39602121,conclusion,16,Further implementation science research is needed to develop strategies to improve use of these evidence-based medications.,2967,3090
med:pmid:39319469:sec:title:sent:0,med:pmid:39319469,title,0,"Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.",0,109
med:pmid:39319469:sec:introduction:sent:1,med:pmid:39319469,introduction,1,"Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction.",0,194
med:pmid:39319469:sec:introduction:sent:2,med:pmid:39319469,introduction,2,It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children.,195,289
med:pmid:39319469:sec:introduction:sent:3,med:pmid:39319469,introduction,3,"PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).",290,764
med:pmid:39319469:sec:methods:sent:4,med:pmid:39319469,methods,4,Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up.,765,960
med:pmid:39319469:sec:methods:sent:5,med:pmid:39319469,methods,5,"The primary end point of the study was to determine whether sacubitril/valsartan was superior to enalapril for the treatment of pediatric patients with HF attributable to systemic LVSD, assessed using a primary global rank end point consisting of ranking patients from worst to best on the basis of clinical events such as death, listing for urgent heart transplant, mechanical life support requirement, worsening HF, New York Heart Association (NYHA)/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory physical functioning domain.",961,1539
med:pmid:39319469:sec:methods:sent:6,med:pmid:39319469,methods,6,The change from baseline to 52 weeks in NT-proBNP (N-terminal pro-B-type natriuretic peptide) was an exploratory end point.,1540,1663
med:pmid:39319469:sec:results:sent:7,med:pmid:39319469,results,7,"A total of 375 children (mean age, 8.1±5.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188).",1664,1812
med:pmid:39319469:sec:results:sent:8,med:pmid:39319469,results,8,"At week 52, no significant difference was observed between the 2 treatment arms in the global rank end point (Mann-Whitney probability, 0.52 [95% CI, 0.47-0.58]; Mann-Whitney odds, 0.91 [95% CI, 0.72-1.14]; <i>P</i>=0.42).",1813,2035
med:pmid:39319469:sec:results:sent:9,med:pmid:39319469,results,9,"At week 52, clinically meaningful reductions were observed in both treatment arms in NYHA/Ross, PGIS, Patient Global Impression of Change, and NT-proBNP, without significant differences between groups.",2036,2237
med:pmid:39319469:sec:results:sent:10,med:pmid:39319469,results,10,"Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children.",2238,2423
med:pmid:39319469:sec:conclusion:sent:11,med:pmid:39319469,conclusion,11,"In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point.",2424,2633
med:pmid:39319469:sec:conclusion:sent:12,med:pmid:39319469,conclusion,12,"However, both treatment arms showed clinically meaningful improvements over 52 weeks.",2634,2719
med:pmid:39319469:sec:conclusion:sent:13,med:pmid:39319469,conclusion,13,<h4>Registration</h4> URL: https://www.clinicaltrials.gov; Unique identifier: NCT02678312.,2720,2810
med:pmid:39210725:sec:title:sent:0,med:pmid:39210725,title,0,Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.,0,159
med:pmid:39210725:sec:abstract:sent:1,med:pmid:39210725,abstract,1,<h4>Importance</h4> Sacubitril/valsartan is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalizations in patients with chronic HF.,0,165
med:pmid:39210725:sec:abstract:sent:2,med:pmid:39210725,abstract,2,"However, many of these patients are older and have multiple comorbidities that increase the risk of hospitalization for causes other than HF.",166,307
med:pmid:39210725:sec:introduction:sent:3,med:pmid:39210725,introduction,3,To assess the effects of sacubitril/valsartan on hospitalizations of any cause across the spectrum of left ventricular ejection fraction (LVEF).,308,471
med:pmid:39210725:sec:introduction:sent:4,med:pmid:39210725,introduction,4,"<h4>Design, setting, and participants</h4> This post hoc, participant-level, pooled analysis of the PARADIGM-HF (in patients with an LVEF ≤40%) and PARAGON-HF (in patients with an LVEF ≥45%) randomized clinical trials was conducted from February 5, 2024, to April 5, 2024.",472,744
med:pmid:39210725:sec:introduction:sent:5,med:pmid:39210725,introduction,5,"Participants with chronic HF, New York Heart Association classes II through IV symptoms, and elevated natriuretic peptides were randomized to treatment with either sacubitril/valsartan or a renin-angiotensin system inhibitor (RASi)-enalapril in the PARADIGM-HF trial or valsartan in the PARAGON-HF trial.",745,1049
med:pmid:39210725:sec:methods:sent:6,med:pmid:39210725,methods,6,Sacubitril/valsartan vs RASi (enalapril or valsartan).,1050,1126
med:pmid:39210725:sec:methods:sent:7,med:pmid:39210725,methods,7,"<h4>Main outcomes and measures</h4> The effects of sacubitril/valsartan on time to first investigator-reported all-cause and cause-specific hospitalizations were examined using Cox proportional hazards models, stratified by geographic region and trial.",1127,1379
med:pmid:39210725:sec:methods:sent:8,med:pmid:39210725,methods,8,Effect modification by LVEF as a continuous function was examined.,1380,1446
med:pmid:39210725:sec:results:sent:9,med:pmid:39210725,results,9,"Among 13 194 participants in the PARADIGM-HF and PARAGON-HF trials, mean (SD) patient age was 67 (11) years, 8883 patients (67.3%) were male, and mean (SD) LVEF was 40% (15%).",1447,1639
med:pmid:39210725:sec:results:sent:10,med:pmid:39210725,results,10,"Sacubitril/valsartan significantly reduced the risk of all-cause hospitalization (ACH) compared with RASi over a median (IQR) follow-up period of 2.5 (1.8-3.1) years (hazard ratio [HR], 0.92; 95% CI, 0.88-0.97; P = .002).",1640,1861
med:pmid:39210725:sec:results:sent:11,med:pmid:39210725,results,11,"The incidence rate of first ACH was 25 (95% CI, 24-26) per 100 patient-years in the sacubitril/valsartan arm and 27 (95% CI, 26-28) per 100 patient-years in the RASi arm.",1862,2032
med:pmid:39210725:sec:results:sent:12,med:pmid:39210725,results,12,"The absolute risk reduction (ARR) was 2.1 per 100 patient-years, corresponding to a number needed to treat (NNT) of 48 patient-years of treatment exposure to prevent 1 ACH.",2033,2205
med:pmid:39210725:sec:results:sent:13,med:pmid:39210725,results,13,Reductions in overall hospitalizations seemed primarily driven by lower rates of cardiac and pulmonary hospitalizations with sacubitril/valsartan.,2206,2352
med:pmid:39210725:sec:results:sent:14,med:pmid:39210725,results,14,Patients in the 2 treatment arms had similar rates of composite noncardiac hospitalizations.,2353,2445
med:pmid:39210725:sec:results:sent:15,med:pmid:39210725,results,15,"Treatment heterogeneity on ACH by LVEF was observed (P for interaction = .03), with benefits most apparent in patients with an LVEF less than 60% (HR, 0.91; 95% CI, 0.86-0.96), but not in patients with an LVEF of 60% or more (HR, 0.97; 95% CI, 0.86-1.09).",2446,2701
med:pmid:39210725:sec:conclusion:sent:16,med:pmid:39210725,conclusion,16,"In this post hoc pooled analysis of 13 194 patients with chronic HF in the PARADIGM-HF and PARAGON-HF randomized clinical trials, sacubitril/valsartan significantly reduced hospitalization for any reason, with benefits most apparent in patients with an LVEF below normal.",2702,3008
med:pmid:39210725:sec:conclusion:sent:17,med:pmid:39210725,conclusion,17,This reduction appeared to be principally driven by lower rates of cardiac and pulmonary hospitalizations.,3009,3115
med:pmid:39210725:sec:conclusion:sent:18,med:pmid:39210725,conclusion,18,<h4>Trial registrations</h4> ClinicalTrials.gov Identifiers: NCT01035255 (PARADIGM-HF) and NCT01920711 (PARAGON-HF).,3116,3232
med:pmid:37861303:sec:title:sent:0,med:pmid:37861303,title,0,Long-term outcomes of patients bridged to recovery with venoarterial extracorporeal life support.,0,97
med:pmid:37861303:sec:introduction:sent:1,med:pmid:37861303,introduction,1,Our study examines the long-term outcomes of patients discharged from the hospital without heart replacement therapy (HRT) after recovery from cardiogenic shock using venoarterial extracorporeal life support (VA-ECLS).,0,237
med:pmid:37861303:sec:methods:sent:2,med:pmid:37861303,methods,2,We retrospectively reviewed 615 cardiogenic shock patients who recovered from VA-ECLS at our institution between January 2015 and July 2021.,238,395
med:pmid:37861303:sec:methods:sent:3,med:pmid:37861303,methods,3,"Of those, 166 patients (27.0%) who recovered from VA-ECLS without HRT were included in this study.",396,494
med:pmid:37861303:sec:methods:sent:4,med:pmid:37861303,methods,4,"Baseline characteristics, discharge labs, vitals, electrocardiograms and echocardiograms were assessed.",495,598
med:pmid:37861303:sec:methods:sent:5,med:pmid:37861303,methods,5,Patients were contacted to determine vital status.,599,649
med:pmid:37861303:sec:methods:sent:6,med:pmid:37861303,methods,6,The primary outcome was post-discharge mortality.,650,699
med:pmid:37861303:sec:results:sent:7,med:pmid:37861303,results,7,"Of 166 patients, 158 patients (95.2%) had post-discharge follow-up, with a median time of follow-up of 2 years (IQR: [1 year, 4 years]).",700,853
med:pmid:37861303:sec:results:sent:8,med:pmid:37861303,results,8,"At discharge, the median ejection fraction (EF) was 52.5% (IQR: [32.5, 57.5]).",854,932
med:pmid:37861303:sec:results:sent:9,med:pmid:37861303,results,9,"At discharge, 92 patients (56%) were prescribed β-blockers, 28 (17%) were prescribed an ACE inhibitor, ARB or ARNI, and 50 (30%) were prescribed loop diuretics.",933,1093
med:pmid:37861303:sec:results:sent:10,med:pmid:37861303,results,10,"Kaplan-Meier analysis showed a 1-year survival rate of 85.6% (95% CI: [80.1%, 91.2%]) and a 5-year survival rate of 60.6% (95% CI: [49.9%, 71.3%]).",1094,1241
med:pmid:37861303:sec:results:sent:11,med:pmid:37861303,results,11,"A Cox regression model demonstrated that a history of congestive heart failure (CHF) was strongly predictive of increased mortality hazard (HR = 1.929; <i>p</i> = 0.036), while neither discharge EF nor etiology of VA-ECLS were associated with increased post-discharge mortality.",1242,1520
med:pmid:37861303:sec:conclusion:sent:12,med:pmid:37861303,conclusion,12,Patients discharged from the hospital after full myocardial recovery from VA-ECLS support without HRT should have close outpatient follow-up due to the risk of recurrent heart failure and increased mortality in these patients.,1521,1768
med:pmid:37043670:sec:title:sent:0,med:pmid:37043670,title,0,"Effects of Sacubitril/Valsartan on cardiac function, blood biochemistry and clinical efficacy in early ventricular remodeling after acute myocardial infarction.",0,160
med:pmid:37043670:sec:abstract:sent:1,med:pmid:37043670,abstract,1,Ventricular remodeling (VR) after acute ST-elevation myocardial infarction (STEMI) is an important predictor for medium- and long-term prognosis.,0,145
med:pmid:37043670:sec:abstract:sent:2,med:pmid:37043670,abstract,2,"This study focuses on the relevant indexes of VR in patients with AMI, in which, the intervention effects of sacubitril/valsartan and enalapril were compared, guiding the clinical treatment.",146,336
med:pmid:37043670:sec:abstract:sent:3,med:pmid:37043670,abstract,3,58 patients with acute STEMI treated with PCI were divided into research group and control group.,337,434
med:pmid:37043670:sec:abstract:sent:4,med:pmid:37043670,abstract,4,"UCG was performed at 1 week, 1 month and 3 months after MI, and the patients' indexes were collected to compare VR and adverse reactions in the two groups.",435,590
med:pmid:37043670:sec:abstract:sent:5,med:pmid:37043670,abstract,5,"The test results showed that there was no statistical difference in the baseline data of patients in the two groups, which were comparable.",591,730
med:pmid:37043670:sec:abstract:sent:6,med:pmid:37043670,abstract,6,"In the blood biochemical index examination, no statistical difference was found in cTnI and NT-proBNP between the two groups.",731,856
med:pmid:37043670:sec:abstract:sent:7,med:pmid:37043670,abstract,7,"At 1 week after operation, the levels of cTnI and NT-proBNP in research group were lower than those in the control group.",857,978
med:pmid:37043670:sec:abstract:sent:8,med:pmid:37043670,abstract,8,"In ECG examination, there was no statistical significance in the levels of LVEF, LVEDD and LVESD at admission between the two groups.",979,1112
med:pmid:37043670:sec:abstract:sent:9,med:pmid:37043670,abstract,9,"After 1 week, the results of LVEF, LVEDD, LVESD in the research group were higher than those in the control group.",1113,1227
med:pmid:37043670:sec:abstract:sent:10,med:pmid:37043670,abstract,10,The results of this study show that sacubitril/valsartan can be used in patients with AMI instead of enalapril.,1228,1339
med:pmid:37043670:sec:abstract:sent:11,med:pmid:37043670,abstract,11,"Sacubitril/valsartan improves cardiac function in patients with emergency percutaneous coronary intervention (PCI) for AMI, inhibits ventricular remodeling, and has a low incidence of adverse cardiac events and adverse drug reactions.",1340,1574
med:pmid:39320292:sec:title:sent:0,med:pmid:39320292,title,0,Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF.,0,128
med:pmid:39320292:sec:introduction:sent:1,med:pmid:39320292,introduction,1,Hypotension is an important clinical problem in heart failure (HF).,0,87
med:pmid:39320292:sec:introduction:sent:2,med:pmid:39320292,introduction,2,This study sought to examine the association between asymptomatic vs symptomatic hypotension and outcomes in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).,88,343
med:pmid:39320292:sec:methods:sent:3,med:pmid:39320292,methods,3,"In a post hoc analysis of PARADIGM-HF, the efficacy and safety of sacubitril/valsartan compared to enalapril were estimated using time-updated Cox proportional hazards models.",344,536
med:pmid:39320292:sec:methods:sent:4,med:pmid:39320292,methods,4,The primary outcome was cardiovascular death or HF hospitalization.,537,604
med:pmid:39320292:sec:results:sent:5,med:pmid:39320292,results,5,"Among 8,399 patients in PARADIGM-HF, 1,343 (16.0%) experienced only asymptomatic hypotension, and 936 (11.1%) experienced symptomatic hypotension at least once after randomization.",605,802
med:pmid:39320292:sec:results:sent:6,med:pmid:39320292,results,6,Patients with symptomatic hypotension were older and more frequently had cardiovascular comorbidities compared to those developing only asymptomatic hypotension.,803,964
med:pmid:39320292:sec:results:sent:7,med:pmid:39320292,results,7,"By contrast, left ventricular ejection fraction was lower in those with asymptomatic hypotension.",965,1062
med:pmid:39320292:sec:results:sent:8,med:pmid:39320292,results,8,Patients who experienced either type of hypotension were at higher risk for all outcomes examined.,1063,1161
med:pmid:39320292:sec:results:sent:9,med:pmid:39320292,results,9,"However, the effect of sacubitril/valsartan on the primary outcome was not diminished in patients experiencing hypotension compared to those who did not: the HR for sacubitril/valsartan vs enalapril was 0.80 (95% CI: 0.72-0.89) for no hypotension, 0.87 (95% CI: 0.70-1.08) for asymptomatic hypotension, and 0.51 (95% CI: 0.38-0.69) for symptomatic hypotension (P<sub>interaction</sub> = 0.01), and this was also true for cardiovascular and all-cause deaths.",1162,1619
med:pmid:39320292:sec:results:sent:10,med:pmid:39320292,results,10,The safety of sacubitril/valsartan vs enalapril was also maintained regardless of the occurrence of hypotension.,1620,1732
med:pmid:39320292:sec:results:sent:11,med:pmid:39320292,results,11,Discontinuation of randomized treatment was less common with sacubitril/valsartan vs enalapril in patients experiencing asymptomatic and symptomatic hypotension.,1733,1894
med:pmid:39320292:sec:conclusion:sent:12,med:pmid:39320292,conclusion,12,"Although both asymptomatic and symptomatic hypotension during treatment with sacubitril/valsartan or enalapril were associated with worse outcomes, the benefits of sacubitril/valsartan were maintained (or even enhanced) in patients experiencing hypotension.",1895,2173
med:pmid:39110471:sec:title:sent:0,med:pmid:39110471,title,0,Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials.,0,99
med:pmid:39110471:sec:abstract:sent:1,med:pmid:39110471,abstract,1,<h4>Importance</h4> Sudden death is a leading cause of death after acute myocardial infarction (AMI).,0,101
med:pmid:39110471:sec:abstract:sent:2,med:pmid:39110471,abstract,2,The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Infarction (VALIANT) trials enrolled patients with pulmonary congestion and/or left ventricular dysfunction after AMI.,102,379
med:pmid:39110471:sec:abstract:sent:3,med:pmid:39110471,abstract,3,Whether the prognosis in such patients has changed over time has not been examined.,380,463
med:pmid:39110471:sec:introduction:sent:4,med:pmid:39110471,introduction,4,To compare the rate of sudden death/resuscitated cardiac arrest (RCA) after AMI in the PARADISE-MI and VALIANT trials.,464,601
med:pmid:39110471:sec:introduction:sent:5,med:pmid:39110471,introduction,5,"<h4>Design, setting, and participants</h4> This was a secondary analysis of multicenter randomized clinical trials enrolling patients after AMI.",602,746
med:pmid:39110471:sec:introduction:sent:6,med:pmid:39110471,introduction,6,"In the primary analysis, the VALIANT cohort was restricted to patients with ""PARADISE-MI-like"" characteristics (eg, at least 1 augmenting risk factor and no history of heart failure).",747,930
med:pmid:39110471:sec:introduction:sent:7,med:pmid:39110471,introduction,7,The baseline characteristics of people in both trials were compared.,931,999
med:pmid:39110471:sec:introduction:sent:8,med:pmid:39110471,introduction,8,"The VALIANT trial enrolled from December 1998 to June 2001, and the PARADISE-MI trial enrolled between December 2016, and March 2020.",1000,1133
med:pmid:39110471:sec:introduction:sent:9,med:pmid:39110471,introduction,9,"The median follow-up in the VALIANT and PARADISE-MI trials was 24.7 and 22 months, respectively.",1134,1230
med:pmid:39110471:sec:introduction:sent:10,med:pmid:39110471,introduction,10,"People with AMI, complicated by pulmonary congestion and/or left ventricular dysfunction, were included in the analysis.",1231,1351
med:pmid:39110471:sec:introduction:sent:11,med:pmid:39110471,introduction,11,<h4>Exposure</h4> Sudden death after AMI.,1352,1393
med:pmid:39110471:sec:results:sent:12,med:pmid:39110471,results,12,"A total of 5661 patients were included in the PARADISE-MI cohort (mean [SD] age, 63.7 [11.5] years; 4298 male [75.9%]), 9617 were included in the VALIANT (PARADISE-MI-like) cohort (mean [SD] age, 66.1 [11.5] years; 6504 male [67.6%]), and 14 703 patients were included in the VALIANT (total) cohort (mean [SD] age, 64.8 [11.8] years; 10 133 male [68.9%]).",1394,1766
med:pmid:39110471:sec:results:sent:13,med:pmid:39110471,results,13,"In the PARADISE-MI-like cohort of the VALIANT trial, 707 of 9617 participants (7.4%) experienced sudden death/RCA.",1767,1881
med:pmid:39110471:sec:results:sent:14,med:pmid:39110471,results,14,A total of 148 of 5661 people (2.6%) in the PARADISE-MI trial experienced sudden death/RCA.,1882,1973
med:pmid:39110471:sec:results:sent:15,med:pmid:39110471,results,15,"Sudden death rates were highest in the first month after infarction in both trials: 19.3 (95% CI, 16.4-22.6) per 100 person-years in the VALIANT trial and 9.5 (95% CI, 7.0-12.7) per 100 person-years in the PARADISE-MI trial, and these rates declined steadily thereafter.",1974,2244
med:pmid:39110471:sec:results:sent:16,med:pmid:39110471,results,16,"Compared with the VALIANT cohort, people in the PARADISE-MI trial were more often treated with percutaneous coronary intervention for their qualifying AMI and received a β-blocker, statin, and mineralocorticoid receptor antagonist more frequently.",2245,2492
med:pmid:39110471:sec:conclusion:sent:17,med:pmid:39110471,conclusion,17,"After AMI, the risk of sudden death/RCA was highest in the first month, declining rapidly thereafter.",2493,2629
med:pmid:39110471:sec:results:sent:18,med:pmid:39110471,results,18,"revealed that compared with counterparts from 20 years ago, the rate of sudden death/RCA in patients with a reduced left ventricular ejection fraction and/or pulmonary congestion was 2- to 3-fold lower in people receiving contemporary management.",2630,2884
med:pmid:39110471:sec:methods:sent:19,med:pmid:39110471,methods,19,to further protect people in the highest risk first month after infarction are needed.,2885,2985
med:pmid:39110471:sec:methods:sent:20,med:pmid:39110471,methods,20,<h4>Trial registration</h4> ClinicalTrials.gov Identifier: NCT02924727.,2986,3057
med:pmid:38842957:sec:title:sent:0,med:pmid:38842957,title,0,Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to &lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;.,0,126
med:pmid:38842957:sec:introduction:sent:1,med:pmid:38842957,introduction,1,Sacubitril/valsartan is a foundational therapy for patients with heart failure.,0,99
med:pmid:38842957:sec:introduction:sent:2,med:pmid:38842957,introduction,2,"Although current U.S. Food and Drug Administration labeling does not provide guidance regarding initiation or continuation of sacubitril/valsartan in patients with worsening kidney function, guidelines identify estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m<sup>2</sup> as a contraindication to therapy.",100,418
med:pmid:38842957:sec:introduction:sent:3,med:pmid:38842957,introduction,3,This study aims to assess the safety and efficacy of continuing sacubitril/valsartan in patients with deterioration of kidney function below an eGFR of 30 mL/min/1.73 m<sup>2</sup>.,419,620
med:pmid:38842957:sec:methods:sent:4,med:pmid:38842957,methods,4,"The association between a deterioration in eGFR <30 mL/min/1.73 m<sup>2</sup>, efficacy and safety outcomes, and treatment with sacubitril/valsartan vs renin-angiotensin system inhibitor were evaluated using time updated Cox models in a post hoc parallel trial analyses of PARADIGM-HF and PARAGON-HF.",621,938
med:pmid:38842957:sec:results:sent:5,med:pmid:38842957,results,5,"Among 8,346 randomized patients in PARADIGM-HF and 4,746 in PARAGON-HF, 691 (8.3%) and 613 (12.9%), respectively, had an eGFR <30 mL/min/1.73 m<sup>2</sup> at least once in follow-up.",939,1139
med:pmid:38842957:sec:results:sent:6,med:pmid:38842957,results,6,Patients experiencing such deterioration were at higher risk of the primary outcome in both PARADIGM-HF and PARAGON-HF.,1140,1259
med:pmid:38842957:sec:results:sent:7,med:pmid:38842957,results,7,"However, the incidence of the primary outcome remained lower with sacubitril/valsartan vs renin-angiotensin system inhibitor, regardless of deterioration in kidney function in both PARADIGM-HF (P<sub>interaction</sub> = 0.50) and PARAGON-HF (P<sub>interaction</sub> = 0.64).",1260,1534
med:pmid:38842957:sec:results:sent:8,med:pmid:38842957,results,8,"Rates of key safety outcomes were higher among patients experiencing eGFR deterioration; however, rates were similar between treatment groups including among those who remained on treatment.",1535,1725
med:pmid:38842957:sec:conclusion:sent:9,med:pmid:38842957,conclusion,9,Patients experiencing deterioration of kidney function to a value below eGFR 30 mL/min/1.73 m<sup>2</sup> faced high risk of cardiovascular and kidney disease outcomes.,1726,1915
med:pmid:38842957:sec:conclusion:sent:10,med:pmid:38842957,conclusion,10,Continuation of sacubitril/valsartan was associated with persistent clinical benefit and no incremental safety risk.,1916,2032
med:pmid:38842957:sec:conclusion:sent:11,med:pmid:38842957,conclusion,11,"These data support continuation of sacubitril/valsartan for heart failure treatment even when eGFR declines below this threshold (PARADIGM-HF [Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure], NCT01035255; and PARAGON-HF [Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction], NCT01920711).",2033,2429
med:pmid:38330576:sec:title:sent:0,med:pmid:38330576,title,0,A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure.,0,168
med:pmid:38330576:sec:introduction:sent:1,med:pmid:38330576,introduction,1,"Heart failure is a common cardiovascular disease, and its prevalence is increasing year by year.",0,115
med:pmid:38330576:sec:introduction:sent:2,med:pmid:38330576,introduction,2,"For patients with heart failure combined with non-valvular reduced ejection fraction, drug therapy has always been a key treatment.",116,247
med:pmid:38330576:sec:introduction:sent:3,med:pmid:38330576,introduction,3,This study aimed to explore the clinical efficacy of sacubitril valsartan sodium and enalapril in such patients.,248,360
med:pmid:38330576:sec:methods:sent:4,med:pmid:38330576,methods,4,Study design: This study used a prospective observational design.,361,443
med:pmid:38330576:sec:methods:sent:5,med:pmid:38330576,methods,5,"From February 2020 to February 2022, we included 123 patients with non-valvular heart failure and reduced ejection fraction who were treated in Xingtai Third Hospital.",444,611
med:pmid:38330576:sec:methods:sent:6,med:pmid:38330576,methods,6,"Patients were divided into two groups according to the treatment plan: Group A (n=61) received enalapril, and Group B (n=62) received nifedipine.",612,757
med:pmid:38330576:sec:methods:sent:7,med:pmid:38330576,methods,7,All patients received conventional treatment.,758,803
med:pmid:38330576:sec:methods:sent:8,med:pmid:38330576,methods,8,We compared the efficacy of the two groups of patients 8 weeks after treatment.,804,883
med:pmid:38330576:sec:methods:sent:9,med:pmid:38330576,methods,9,"During the study, the laboratory indicators, echocardiographic indicators, cardiovascular markers, and possible adverse reactions of the two groups of patients before and after treatment were recorded.",884,1085
med:pmid:38330576:sec:results:sent:10,med:pmid:38330576,results,10,"After 8 weeks of treatment, the effective rate of group B was higher than group A (P < .05).",1086,1195
med:pmid:38330576:sec:results:sent:11,med:pmid:38330576,results,11,"There were no differences in the levels of total protein, total bilirubin, total cholesterol and serum creatinine between the two groups before and after treatment (P > .05).",1196,1370
med:pmid:38330576:sec:results:sent:12,med:pmid:38330576,results,12,"The serum creatinine level in the two groups after treatment was higher than that before treatment, and the level in group B was lower than that in group A (P < .05).",1371,1537
med:pmid:38330576:sec:results:sent:13,med:pmid:38330576,results,13,"There were no statistically significant differences in the levels of total protein, total bilirubin and total cholesterol between the two groups before and after treatment (P > .05), and there was no statistically significant difference in the level of serum creatinine between the two groups before treatment (P > .05), and the level of serum creatinine after treatment was higher than that before treatment, and the level of group B was lower than that of group A (P < .05).",1538,2014
med:pmid:38330576:sec:results:sent:14,med:pmid:38330576,results,14,"Before treatment, there was no significant difference in the levels of high-sensitive troponin T and n-terminal brain natriuretic peptide and cyclic guanosine phosphate between the two groups (P > .05).",2015,2217
med:pmid:38330576:sec:results:sent:15,med:pmid:38330576,results,15,"After treatment, the levels of high-sensitive troponin T and N-terminal brain natriuretic peptide in the two groups were lower than those before treatment, and those in group B were lower than those in group A. The level of cyclic guanosine phosphate in group A was lower than that before treatment, the level of cyclic guanosine phosphate in group B was higher than that before treatment, and the level of group B was higher than that of group A (P < .05).",2218,2675
med:pmid:38330576:sec:results:sent:16,med:pmid:38330576,results,16,"The incidence of adverse cardiovascular events in group B was lower than that in group A (P < .05).In this study, the effective rate of treatment group B was significantly higher than that of treatment group A, indicating that treatment group B had a better therapeutic effect.",2676,2953
med:pmid:38330576:sec:results:sent:17,med:pmid:38330576,results,17,"In addition, there were no significant differences between the two groups in a series of biochemical parameters, but it is worth noting that after treatment, the serum creatinine level of group B was significantly lower than that of group A, which may indicate that the treatment of group B is not only more effective but also Reduces the risk of certain adverse cardiovascular events.",2954,3339
med:pmid:38330576:sec:conclusion:sent:18,med:pmid:38330576,conclusion,18,The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction.,3340,3552
med:pmid:38330576:sec:conclusion:sent:19,med:pmid:38330576,conclusion,19,"Specifically, the drug significantly improved patients' kidney function, reduced cardiovascular marker levels, and reduced the incidence of adverse cardiovascular events.",3553,3723
med:pmid:38330576:sec:conclusion:sent:20,med:pmid:38330576,conclusion,20,These findings have important clinical implications for guiding treatment selection in patients with heart failure.,3724,3839
med:pmid:39404722:sec:title:sent:0,med:pmid:39404722,title,0,[Clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure with reduced left ventricular ejection fraction in various subgroups of standard therapy in the Russian Federation].,0,215
med:pmid:39404722:sec:introduction:sent:1,med:pmid:39404722,introduction,1,To evaluate the clinical and economic effectiveness of dapagliflozin in patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction (HFrEF) in the Russian Federation in various subgroups of standard therapy for CHF.,0,258
med:pmid:39404722:sec:methods:sent:2,med:pmid:39404722,methods,2,A clinical and economic analysis of the use of the drug dapagliflozin in addition to standard therapy was carried out in comparison with standard therapy in various subgroups of standard therapy for HFrEF using a modeling method.,259,519
med:pmid:39404722:sec:methods:sent:3,med:pmid:39404722,methods,3,Cost calculations were carried out in a mathematical model adapted to the healthcare conditions of the Russian Federation by using Russian cost indicators and characteristics of the patient population.,520,721
med:pmid:39404722:sec:results:sent:4,med:pmid:39404722,results,4,"The present study demonstrates that the addition of dapagliflozin is beneficial in terms of clinical and cost-effectiveness, regardless of the initial regimen (angiotensin receptor-neprilysin inhibitors [ARNI] or angiotensin-converting enzyme inhibitors [ACEi]/angiotensin II receptor blockers [ARB]) of standard drug therapy for HFrEF and in all cases leads to an increase in life expectancy, a decrease in the number of hospitalizations and emergency visits due to CHF, as well as cardiovascular mortality.",722,1247
med:pmid:39404722:sec:results:sent:5,med:pmid:39404722,results,5,"The obtained values of added value per additional year of life in all cases are significantly lower than the willingness-to-pay threshold, which indicates the clinical and economic effectiveness of the strategy of prescribing dapagliflozin as part of standard therapy for patients with HFrEF.",1248,1540
med:pmid:39404722:sec:results:sent:6,med:pmid:39404722,results,6,"In the case of adding dapagliflozin the values of the additional cost of an added year of life in the 3 considered standard therapy options (ARNI or ACEi/ARB, only ACEi/ARB and only ARNI) were 291,256, 279,571 and 338,374 rubles respectively.",1541,1783
med:pmid:39404722:sec:results:sent:7,med:pmid:39404722,results,7,"Thus, the scenario of using dapagliflozin with standard therapy, which included only ACEi/ARB, is characterized by the lowest additional cost and has the best clinical and economic characteristics.",1784,1981
med:pmid:39404722:sec:results:sent:8,med:pmid:39404722,results,8,"At the same time the scenario of use with standard therapy, which included only ARNI, is characterized by the highest value of the additional value of the added year of life.",1982,2156
med:pmid:39352849:sec:title:sent:0,med:pmid:39352849,title,0,[Cirrhotic cardiomyopathy – Clinically fact or academic curiosity?,0,66
med:pmid:39352849:sec:title:sent:1,med:pmid:39352849,title,1,Review.,67,74
med:pmid:39352849:sec:title:sent:2,med:pmid:39352849,title,2,Part 3: treatment],75,93
med:pmid:39352849:sec:abstract:sent:3,med:pmid:39352849,abstract,3,"Hepatic transplantation (HT) is the standard of care of end-stage liver disease with Cirrhotic Cardiomyopathy (CCM), but medical treatment with combination of diuretics and non-selective beta blockers are important before and after that.",0,237
med:pmid:39352849:sec:abstract:sent:4,med:pmid:39352849,abstract,4,"Owing to its particular pathophysiology unlike another etiologies of heart failure, in CCM angiotensin-converting enzyme inhibitors (ACEI), angiotensin II type I receptor blockers (ARB), and angiotensin receptor neprilysin inhibitor (ARNI) are not recommended.",238,498
med:pmid:39352849:sec:abstract:sent:5,med:pmid:39352849,abstract,5,Transjugular intrahepatic porto-systemic shunt (TIPS) has indications in CMM but its potential benefits and risks must be considered and more researh is necessary.,499,662
med:pmid:39352849:sec:abstract:sent:6,med:pmid:39352849,abstract,6,"HT is a demanding therapy but the most effective one, and showed improvement in QTc, diastolic and systolic dysfunction; in recent decades, in spite of more severe ill patients (more severe MELD score), survival has improved significantly due to better surgical techniques, intensive care, immunosupresive drugs, and images.",663,987
med:pmid:39264627:sec:title:sent:0,med:pmid:39264627,title,0,Kidney Outcomes Following Angiotensin Receptor-Neprilysin Inhibitor vs Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy for Thrombotic Microangiopathy.,0,179
med:pmid:39264627:sec:abstract:sent:1,med:pmid:39264627,abstract,1,"<h4>Importance</h4> Thrombotic microangiopathy (TMA) on kidney biopsy is a pattern of endothelial injury commonly seen in malignant hypertension (mHTN), but treatment strategies are not well established.",0,203
med:pmid:39264627:sec:introduction:sent:2,med:pmid:39264627,introduction,2,"To evaluate the kidney outcomes of angiotensin receptor-neprilysin inhibitor (ARNI), specifically sacubitril/valsartan, vs angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy for patients with mHTN-associated TMA.",204,477
med:pmid:39264627:sec:introduction:sent:3,med:pmid:39264627,introduction,3,"<h4>Design, setting, and participants</h4> This single-center cohort study enrolled consecutive patients in China diagnosed with mHTN-associated TMA through kidney biopsy from January 2008 to June 2023.",478,680
med:pmid:39264627:sec:introduction:sent:4,med:pmid:39264627,introduction,4,Follow-up was conducted until the conclusion of the study period.,681,746
med:pmid:39264627:sec:results:sent:5,med:pmid:39264627,results,5,were analyzed in September 2023.,747,784
med:pmid:39264627:sec:results:sent:6,med:pmid:39264627,results,6,<h4>Exposures</h4> Treatment with sacubitril/valsartan or ACEI/ARBs during hospitalization and after discharge.,785,896
med:pmid:39264627:sec:results:sent:7,med:pmid:39264627,results,7,"<h4>Main outcomes and measures</h4> The primary outcome was a composite of kidney recovery: a 50% decrease in serum creatinine level, decrease in serum creatinine levels to the reference range, or kidney survival free from dialysis for more than 1 month.",897,1151
med:pmid:39264627:sec:results:sent:8,med:pmid:39264627,results,8,"The secondary and tertiary outcomes were a 15% increase in the estimated glomerular filtration rate (eGFR) relative to baseline and kidney survival free from dialysis, respectively.",1152,1333
med:pmid:39264627:sec:results:sent:9,med:pmid:39264627,results,9,Propensity score matching (PSM) and Cox proportional hazards regression analysis were used to evaluate the association between sacubitril/valsartan and ACEI/ARB therapy with kidney recovery outcomes.,1334,1533
med:pmid:39264627:sec:results:sent:10,med:pmid:39264627,results,10,"Among the 217 patients (mean [SD] age, 35.9 [8.8] years; 188 men [86.6%]) included in the study, 66 (30.4%) received sacubitril/valsartan and 151 (69.6%) received ACEI/ARBs at baseline.",1534,1736
med:pmid:39264627:sec:results:sent:11,med:pmid:39264627,results,11,"Sacubitril/valsartan treatment was associated with shorter time to the primary outcome compared with ACEI/ARB treatment (20 of 63 [31.7%] vs 38 of 117 [32.5%]; adjusted hazard ratio [aHR], 1.85; 95% CI, 1.05-3.23).",1737,1951
med:pmid:39264627:sec:results:sent:12,med:pmid:39264627,results,12,"Sacubitril/valsartan treatment was independently associated with shorter time to a 15% increase in eGFR (15 of 46 [32.6%] vs 46 of 83 [55.4%]; aHR, 2.13; 95% CI, 1.09-4.17) and kidney survival free from dialysis (11 of 23 [47.8%] vs 16 of 57 [28.1%]; aHR, 2.63; 95% CI, 1.15-5.88) compared with ACEI/ARB treatment.",1952,2266
med:pmid:39264627:sec:results:sent:13,med:pmid:39264627,results,13,These differences remained significant in the PSM comparison.,2267,2328
med:pmid:39264627:sec:conclusion:sent:14,med:pmid:39264627,conclusion,14,"In this cohort study, sacubitril/valsartan treatment was associated with a potential kidney function benefit in patients with mHTN-associated TMA compared with ACEI/ARB treatment.",2329,2543
med:pmid:39264627:sec:conclusion:sent:15,med:pmid:39264627,conclusion,15,The findings suggested that sacubitril/valsartan could be a superior therapeutic approach for managing this serious condition in terms of kidney recovery.,2544,2698
med:pmid:39262640:sec:title:sent:0,med:pmid:39262640,title,0,Influenza Vaccination and Cardiovascular Events in Japanese Patients With Heart Failure　- Findings From the PARALLEL-HF Trial.,0,126
med:pmid:39262640:sec:introduction:sent:1,med:pmid:39262640,introduction,1,Influenza is associated with an increased risk for cardiovascular events in patients with heart failure (HF).,0,129
med:pmid:39262640:sec:introduction:sent:2,med:pmid:39262640,introduction,2,This study aimed to investigate the prevalence of influenza vaccination among Japanese patients with HF enrolled in the PARALLEL-HF (Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) trial and the association between receiving influenza vaccination and cardiovascular events including death or HF hospitalization.,130,520
med:pmid:39262640:sec:results:sent:3,med:pmid:39262640,results,3,"In PARALLEL-HF, in which 223 patients with HF and reduced ejection fraction (HFrEF) were randomized to the angiotensin-receptor neprilysin inhibitor (sacubitril/valsartan) or enalapril, 97 (43%) received influenza vaccination.",521,776
med:pmid:39262640:sec:results:sent:4,med:pmid:39262640,results,4,"Influenza vaccination tended to be associated, though statistically not significant, with a lower risk for all-cause death (adjusted hazard ratio [HR]: 0.67; 95% confidence interval [CI]: 0.32-1.39) and cardiopulmonary or influenza-related hospitalization or death (adjusted HR: 0.72; 95% CI: 0.46-1.11) in propensity score-adjusted models.",777,1117
med:pmid:39262640:sec:conclusion:sent:5,med:pmid:39262640,conclusion,5,The influenza vaccination rate in Japanese patients with HFrEF who were well managed on guideline-directed medical therapy was suboptimal despite recommendations from clinical practice guidelines.,1118,1335
med:pmid:39262640:sec:conclusion:sent:6,med:pmid:39262640,conclusion,6,"However, importantly, it could be associated with better clinical benefits.",1336,1411
med:pmid:39260836:sec:title:sent:0,med:pmid:39260836,title,0,Comparative effects of sacubitril/valsartan and ACEI/ARB on endothelial function and arterial stiffness in patients with heart failure: a protocol for systematic review and meta-analysis.,0,187
med:pmid:39260836:sec:introduction:sent:1,med:pmid:39260836,introduction,1,Heart failure (HF) is a complex syndrome that affects millions of people worldwide and leads to significant morbidity and mortality.,0,154
med:pmid:39260836:sec:introduction:sent:2,med:pmid:39260836,introduction,2,"Sacubitril/valsartan, a combination drug consisting of a neprilysin inhibitor and an angiotensin receptor blocker (ARB), has shown a greater improvement in the prognosis of HF than ACE inhibitors (ACEI) or ARB.",155,365
med:pmid:39260836:sec:introduction:sent:3,med:pmid:39260836,introduction,3,"Recent studies have found that ACEI/ARB or sacubitril/valsartan can increase flow-mediated dilation (FMD) and reduce pulse wave velocity (PWV), which are independent predictors of cardiovascular events and HF prognosis.",366,585
med:pmid:39260836:sec:introduction:sent:4,med:pmid:39260836,introduction,4,The purpose of this study is to assess and compare the effect of sacubitril/valsartan and ACEI/ARB on FMD and PWV using meta-analysis and further provide a reference for the role of sacubitril/valsartan in the treatment of HF.,586,812
med:pmid:39260836:sec:introduction:sent:5,med:pmid:39260836,introduction,5,"<h4>Methods and analysis</h4> Clinical randomised controlled trials investigating the effect of sacubitril/valsartan and/or ACEI/ARB on FMD and PWV in patients with HF will be searched in the relevant database, including PubMed, Web of Science, Embase, Cochrane Library and China's National Knowledge Infrastructure up to January 2024.",813,1148
med:pmid:39260836:sec:introduction:sent:6,med:pmid:39260836,introduction,6,The outcomes of interest are changes in endothelial function assessed by FMD and changes in arterial stiffness assessed by PWV.,1149,1276
med:pmid:39260836:sec:introduction:sent:7,med:pmid:39260836,introduction,7,The risk of bias was evaluated using the revised Cochrane risk of bias tool for randomised trials (RoB2.0).,1277,1384
med:pmid:39260836:sec:introduction:sent:8,med:pmid:39260836,introduction,8,"Review Manager V.5.3 software is used for meta-analysis data synthesis, sensitivity analysis, meta-regression analysis, subgroup analysis and risk of bias assessment.",1385,1551
med:pmid:39260836:sec:introduction:sent:9,med:pmid:39260836,introduction,9,"The reporting bias of studies will be evaluated using the funnel plot, in which symmetry will be assessed by Begg's and Egger's tests.",1552,1686
med:pmid:39260836:sec:introduction:sent:10,med:pmid:39260836,introduction,10,"The evidence quality of the included studies will be evaluated by the Grading of Recommendations Assessment, Development, and Evaluation.",1687,1824
med:pmid:39260836:sec:introduction:sent:11,med:pmid:39260836,introduction,11,<h4>Ethics and dissemination</h4> This study only analyses research data from the published literature and therefore does not require ethical approval.,1825,1976
med:pmid:39260836:sec:introduction:sent:12,med:pmid:39260836,introduction,12,We will submit the systematic review to a peer-reviewed journal.,1977,2041
med:pmid:39260836:sec:introduction:sent:13,med:pmid:39260836,introduction,13,<h4>Prospero registration number</h4> CRD42024538148.,2042,2095
med:pmid:39220717:sec:title:sent:0,med:pmid:39220717,title,0,Guideline-directed medical therapy prescribing patterns and in-hospital outcomes among heart failure patients during COVID-19.,0,126
med:pmid:39220717:sec:abstract:sent:1,med:pmid:39220717,abstract,1,"<h4>Study objective</h4> The association of prior to admission guideline-directed medical therapy (GDMT) use in patients hospitalized with Heart Failure with Reduced Ejection Fraction (HFrEF, ejection fraction ≤40 %) and Coronavirus Disease 2019 (COVID-19) with in-hospital outcomes has not been well studied.",0,309
med:pmid:39220717:sec:methods:sent:2,med:pmid:39220717,methods,2,"Using the American Heart Association's Get With The Guidelines Heart Failure Registry, we identified HFrEF patients presenting with acute decompensated heart failure (ADHF) and compared rates of GDMT prescription between those presenting prior to and during the pandemic.",310,649
med:pmid:39220717:sec:methods:sent:3,med:pmid:39220717,methods,3,"In a subgroup of patients with a concomitant COVID-19 diagnosis, we evaluated the association of prior to admission GDMT use with in-hospital mortality and severe COVID-19.",650,822
med:pmid:39220717:sec:results:sent:4,med:pmid:39220717,results,4,"23,899 patients were admitted with HFrEF during the pandemic (2/16/20-3/24/21) and 26,459 patients were admitted in the year prior (2/16/19-2/15/20).",823,989
med:pmid:39220717:sec:results:sent:5,med:pmid:39220717,results,5,"In this overall cohort, prior to admission ACEI/ARB/ARNI (45.6 % vs 48.1 %, p < 0.0001) and BB (56.9 % vs 62.4 %, p < 0.0001) use was lower among admitted HFrEF patients during the pandemic when compared to the year prior.",990,1212
med:pmid:39220717:sec:results:sent:6,med:pmid:39220717,results,6,"Rates of ACEI/ARB/ARNI, MRA, and triple therapy (ACE/ARB/ARNI + BB + MRA) prescription at discharge were higher during the pandemic compared to the year prior.",1213,1372
med:pmid:39220717:sec:results:sent:7,med:pmid:39220717,results,7,"Among a subgroup of those with HFrEF and COVID-19 (n = 333), prior to admission GDMT use was not associated with in-hospital mortality or severe COVID-19.",1373,1527
med:pmid:39220717:sec:conclusion:sent:8,med:pmid:39220717,conclusion,8,We found no association between prior to admission GDMT use and in-hospital mortality or severe COVID-19 among HFrEF patients admitted with ADHF and COVID-19.,1528,1706
med:pmid:39220717:sec:conclusion:sent:9,med:pmid:39220717,conclusion,9,GDMT prescription at discharge for HFrEF patients overall has remained either similar or improved during the pandemic.,1707,1825
med:pmid:39186181:sec:title:sent:0,med:pmid:39186181,title,0,Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020.,0,181
med:pmid:39186181:sec:introduction:sent:1,med:pmid:39186181,introduction,1,This study is aimed to compare the effectiveness of modern therapy including angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) with conventional heart failure treatment in the real world.,0,261
med:pmid:39186181:sec:introduction:sent:2,med:pmid:39186181,introduction,2,"Since ARNI and SGLT2i were introduced to treat heart failure (HF), its therapeutic regimen has modernized from previous treatment with beta-blocker (BB) and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) with mineralocorticoid receptor antagonist (MRA) as added-on in HF with reduced ejection fraction (HFrEF).",262,630
med:pmid:39186181:sec:introduction:sent:3,med:pmid:39186181,introduction,3,"However, a comparison between conventional and modern treatment strategies with drugs in combination has not been performed.",631,755
med:pmid:39186181:sec:methods:sent:4,med:pmid:39186181,methods,4,"This observational study (2013-2020), using the Swedish HF Registry, involved 20,849 HF patients.",756,870
med:pmid:39186181:sec:methods:sent:5,med:pmid:39186181,methods,5,"Patients received either conventional (BB, ACEi/ARB, with/without MRA, n = 20,140) or modern (BB, ACEi/ARB, MRA, SGLT2i or BB, ARNI, MRA with/without SGLT2i, n = 709) treatment at the index visit.",871,1067
med:pmid:39186181:sec:methods:sent:6,med:pmid:39186181,methods,6,The endpoints were all-cause and cardiovascular (CV) mortality.,1068,1131
med:pmid:39186181:sec:results:sent:7,med:pmid:39186181,results,7,"Modern HF therapy was associated with a significant 28% reduction in all-cause mortality (adjusted HR [aHR], 0.72 (0.54-0.96); p = 0.024) and a significant 62% reduction in CV mortality (aHR, 0.38 (0.21-0.68); p = 0.0013) compared to conventional HF treatment.",1132,1409
med:pmid:39186181:sec:results:sent:8,med:pmid:39186181,results,8,Similar results emerged in a sensitivity analysis using propensity score matching.,1410,1492
med:pmid:39186181:sec:results:sent:9,med:pmid:39186181,results,9,"The interaction analyses did not reveal any trends for EF (< 40% and ≥ 40%), sex, age (< 70 and ≥ 70 years), eGFR (< 60 and ≥ 60 ml/min/1.73 m<sup>2</sup>), and etiology of HF subgroups.",1493,1679
med:pmid:39186181:sec:conclusion:sent:10,med:pmid:39186181,conclusion,10,"In this nationwide study, modern HF therapy was associated with significantly reduced all-cause and CV mortality, regardless of EF, sex, age, eGFR, and etiology of HF.",1680,1867
med:pmid:39111953:sec:title:sent:0,med:pmid:39111953,title,0,Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.,0,119
med:pmid:39111953:sec:abstract:sent:1,med:pmid:39111953,abstract,1,"Chronic Chagas cardiomyopathy (CCC) has unique pathogenic and clinical features with worse prognosis than other causes of heart failure (HF), despite the fact that patients with CCC are often younger and have fewer comorbidities.",0,229
med:pmid:39111953:sec:abstract:sent:2,med:pmid:39111953,abstract,2,Patients with CCC were not adequately represented in any of the landmark HF studies that support current treatment guidelines.,230,356
med:pmid:39111953:sec:abstract:sent:3,med:pmid:39111953,abstract,3,"PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily added to standard of care treatment for HF.",357,661
med:pmid:39111953:sec:abstract:sent:4,med:pmid:39111953,abstract,4,The study aims to enroll approximately 900 patients with CCC and reduced ejection fraction at around 100 sites in Latin America.,662,790
med:pmid:39111953:sec:abstract:sent:5,med:pmid:39111953,abstract,5,"The primary outcome is a hierarchical composite of time from randomization to cardiovascular death, first HF hospitalization, or relative change from baseline to week 12 in NT-proBNP levels.",791,981
med:pmid:39111953:sec:abstract:sent:6,med:pmid:39111953,abstract,6,PARACHUTE-HF will provide new data on the treatment of this high-risk population. (,982,1065
med:pmid:39111953:sec:abstract:sent:7,med:pmid:39111953,abstract,7,"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC [PARACHUTE-HF]; NCT04023227).",1065,1229
med:pmid:38783593:sec:title:sent:0,med:pmid:38783593,title,0,Salt substitute recommendations for heart failure patients may influence guideline-directed medical therapies titration.,0,120
med:pmid:38783593:sec:introduction:sent:1,med:pmid:38783593,introduction,1,Reducing sodium intake is necessary for patients with chronic heart failure (CHF).,0,96
med:pmid:38783593:sec:introduction:sent:2,med:pmid:38783593,introduction,2,Salt substitutes (saltSubs) have become increasingly popular as recommendations by healthcare professionals (HCPs) as well as options for patients and their caregivers.,97,265
med:pmid:38783593:sec:introduction:sent:3,med:pmid:38783593,introduction,3,"However, their consumption is generally potassium based and remains poorly evaluated in CHF management.",266,369
med:pmid:38783593:sec:introduction:sent:4,med:pmid:38783593,introduction,4,Their impact on guideline-directed medical therapies (GDMTs) also remains unknown.,370,452
med:pmid:38783593:sec:introduction:sent:5,med:pmid:38783593,introduction,5,The primary objective of this study was to provide a description and estimate of HCP recommendations and reported use of saltSubs in France.,453,593
med:pmid:38783593:sec:introduction:sent:6,med:pmid:38783593,introduction,6,Secondary objectives were to identify if there was an association between these recommendations by HCPs and the use of GDMTs.,594,719
med:pmid:38783593:sec:results:sent:7,med:pmid:38783593,results,7,"A nationwide, questionnaire-based, cross-sectional, epidemiological study was conducted from September 2020 to July 2021.",720,870
med:pmid:38783593:sec:results:sent:8,med:pmid:38783593,results,8,"collection included baseline characteristics, the use and recommendations of saltSubs, and the use of GDMTs, which included (i) angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitors (ARNis), (ii) mineralocorticoid receptor antagonists (MRAs), and/or (iii) beta-blockers (BBs).",871,1234
med:pmid:38783593:sec:results:sent:9,med:pmid:38783593,results,9,"In total, 13% of HCPs advised saltSubs and 17% of patients and 22% of caregivers reported their consumption.",1235,1343
med:pmid:38783593:sec:results:sent:10,med:pmid:38783593,results,10,"CHF patients advised to take saltSubs did not differ in terms of left ventricular ejection fraction (EF) <40%, ischaemic origin, and New York Heart Association III-IV class, but were more recently hospitalized for acute HF (P = 0.004).",1344,1579
med:pmid:38783593:sec:results:sent:11,med:pmid:38783593,results,11,"HCPs who recommended saltSubs to patients were more likely to advise an anti-diabetic diet (P < 0.001), cholesterol-lowering diet (P < 0.001), and exercise (P = 0.018).",1580,1748
med:pmid:38783593:sec:results:sent:12,med:pmid:38783593,results,12,"In the overall population, ACEi/ARB/ARNi use was less frequent in case of saltSub recommendations (74% vs. 82%, P = 0.012).",1749,1872
med:pmid:38783593:sec:results:sent:13,med:pmid:38783593,results,13,"The concomitant prescription of none, one, two, or three GDMTs was less favourable in case of saltSub recommendations (P = 0.046).",1873,2003
med:pmid:38783593:sec:results:sent:14,med:pmid:38783593,results,14,There was no significant difference for the presence of MRA (56% vs. 58%) and/or BB (78% vs. 82%).,2004,2102
med:pmid:38783593:sec:results:sent:15,med:pmid:38783593,results,15,The under-prescription of ACEi/ARB/ARNi was found when patients had EF < 40% (P = 0.029) and/or EF ≥ 40% (P = 0.043).,2103,2220
med:pmid:38783593:sec:results:sent:16,med:pmid:38783593,results,16,"In the subgroup with left ventricular EF ≥ 40%, we found a higher thiazide use (P = 0.014) and a less frequent use of low EF GDMTs (P = 0.044) in case of being recommended saltSubs.",2221,2402
med:pmid:38783593:sec:conclusion:sent:17,med:pmid:38783593,conclusion,17,"Beyond the well-established risk for hyperkalaemia, our preliminary results suggest a potentially negative impact of saltSubs on GDMT use, especially for ACEis/ARBs/ARNis in CHF management.",2403,2613
med:pmid:38783593:sec:conclusion:sent:18,med:pmid:38783593,conclusion,18,saltSub recommendations and their availability from open sale outlets should be considered to avoid possible misuse or deference from GDMTs in the future.,2614,2768
med:pmid:38783593:sec:conclusion:sent:19,med:pmid:38783593,conclusion,19,Informed advice to consumers should also be considered from HCPs or pharmacists.,2769,2849
med:pmid:38639469:sec:title:sent:0,med:pmid:38639469,title,0,Treatment patterns of patients with worsening heart failure with reduced ejection fraction.,0,91
med:pmid:38639469:sec:introduction:sent:1,med:pmid:38639469,introduction,1,Patients with HFrEF and worsening HF events (WHFE) are at particularly high risk and urgently need disease-modifying therapy.,0,139
med:pmid:38639469:sec:introduction:sent:2,med:pmid:38639469,introduction,2,CHART-HF assessed treatment patterns and reasons for medication decisions among HFrEF patients with and without WHFE.,140,257
med:pmid:38639469:sec:results:sent:3,med:pmid:38639469,results,3,CHART-HF collected retrospective electronic medical records of outpatients with HF and EF < 45% between 2017-2019 from a nationwide panel of 238 cardiologists (458 patients) and the Geisinger Health System (GHS) medical record (1000 patients).,258,530
med:pmid:38639469:sec:results:sent:4,med:pmid:38639469,results,4,"The index visit in the WHFE cohort was the first outpatient cardiologist visit ≤6 months following the WHFE, and in the reference cohort was the last visit in a calendar year without WHFE.",531,719
med:pmid:38639469:sec:results:sent:5,med:pmid:38639469,results,5,Demographic characteristics were similar between patients with and without WHFE in both the nationwide panel and GHS.,720,837
med:pmid:38639469:sec:results:sent:6,med:pmid:38639469,results,6,"In the nationwide panel, the proportion of patients with versus without WHFE receiving ≥50% of guideline-recommended dose on index visit was 35% versus 40% for beta blocker, 74% versus 83% for ACEI/ARB/ARNI, and 48% versus 49% for MRA.",838,1073
med:pmid:38639469:sec:results:sent:7,med:pmid:38639469,results,7,"The proportion of patients receiving ≥50% of guideline-recommended dose was lower in the GHS: 29% versus 34% for beta-blocker, 16% versus 31% for ACEI/ARB/ARNI, and 18% versus 22% for MRA.",1074,1262
med:pmid:38639469:sec:results:sent:8,med:pmid:38639469,results,8,"For patients with and without WHFE, triple therapy on index date was 42% and 44% of patients from the nationwide panel, and 14% and 17% in the GHS.",1263,1410
med:pmid:38639469:sec:results:sent:9,med:pmid:38639469,results,9,"Comparing end of index clinic visit with 12-month follow-up in the GHS, the proportion of patients on no GDMT increased from 14% to 28% in the WHFE cohort and from 14 to 21% in the non-WHFE group.",1411,1607
med:pmid:38639469:sec:conclusion:sent:10,med:pmid:38639469,conclusion,10,"Major gaps in use of GDMT, particularly combination therapy, remain among US HFrEF patients.",1608,1721
med:pmid:38639469:sec:conclusion:sent:11,med:pmid:38639469,conclusion,11,These gaps persist during longitudinal follow-up and are particularly large among patients with recent WHFE.,1722,1830
med:pmid:38635062:sec:title:sent:0,med:pmid:38635062,title,0,Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial.,0,228
med:pmid:38635062:sec:abstract:sent:1,med:pmid:38635062,abstract,1,"Effects of angiotensin receptor/neprilysin inhibitors (ARNI) on ventricular remodeling in patients with heart failure, especially heart failure with reduced ejection fraction (HFrEF), are better than those of angiotensin-converting enzyme inhibitors (ACEI).",0,257
med:pmid:38635062:sec:abstract:sent:2,med:pmid:38635062,abstract,2,Acute myocardial infarction (AMI) complicated by mitral regurgitation exacerbates ventricular remodeling and increases the risk of heart failure.,258,403
med:pmid:38635062:sec:abstract:sent:3,med:pmid:38635062,abstract,3,There is limited evidence on the effects of early administration of ARNI in patients with AMI complicated by mitral regurgitation.,404,534
med:pmid:38635062:sec:abstract:sent:4,med:pmid:38635062,abstract,4,The aim of this trial was to examine the effectiveness and the safety of early administration of sacubitril/valsartan after coronary artery revascularization in patients with AMI complicated by moderate-to-severe mitral regurgitation.,535,769
med:pmid:38635062:sec:abstract:sent:5,med:pmid:38635062,abstract,5,"This was a randomized, single-blind, parallel-group, controlled trial.",770,840
med:pmid:38635062:sec:abstract:sent:6,med:pmid:38635062,abstract,6,"From June 2021 to June 2022, we enrolled 142 consecutive patients with AMI complicated by moderate-to-severe mitral regurgitation and followed them for 12 months.",841,1003
med:pmid:38635062:sec:abstract:sent:7,med:pmid:38635062,abstract,7,The patients received standard treatment for AMI and were randomly assigned to receive ARNI or benazepril.,1004,1110
med:pmid:38635062:sec:abstract:sent:8,med:pmid:38635062,abstract,8,"The primary efficacy end points were the differences in mitral regurgitant jet area (MRJA), mitral regurgitant volume (MRV), concentration of n-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular end-diastolic volume and end-systolic volume (LVEDV and LVESV) between groups and within groups at baseline, 1, 3, 6, and 12 months.",1111,1503
med:pmid:38635062:sec:abstract:sent:9,med:pmid:38635062,abstract,9,"Secondary end points included the rates of heart failure hospitalization, all-cause mortality, refractory angina, malignant arrhythmias, recurrent myocardial infarction, and stroke.",1504,1685
med:pmid:38635062:sec:abstract:sent:10,med:pmid:38635062,abstract,10,"Safety end points included the rates of hyperkalemia, renal dysfunction, hypotension, angioedema, and cough.",1686,1794
med:pmid:38635062:sec:abstract:sent:11,med:pmid:38635062,abstract,11,The ARNI group had significantly lower NT-proBNP levels than the benazepril group at 1 month and later (P < 0.001).,1795,1910
med:pmid:38635062:sec:abstract:sent:12,med:pmid:38635062,abstract,12,"MRJA and MRV significantly improved in the ARNI group compared with the benazepril group at 12 months (MRJA: - 3.21 ± 2.18 cm<sup>2</sup> vs. - 1.83 ± 2.81 cm<sup>2</sup>, P < 0.05; MRV: - 27.22 ± 15.22 mL vs. - 13.67 ± 21.02 mL, P < 0.001).",1911,2152
med:pmid:38635062:sec:abstract:sent:13,med:pmid:38635062,abstract,13,The ARNI group also showed significant reductions in LVEDV and LVESV (P < 0.05) and improvement in LVEF (P < 0.05).,2153,2268
med:pmid:38635062:sec:abstract:sent:14,med:pmid:38635062,abstract,14,"Secondary end point analysis showed a significantly higher rate of heart failure hospitalization in the benazepril group compared with the ARNI group (HR = 2.03, 95% CI 1.12-3.68, P = 0.021).",2269,2460
med:pmid:38635062:sec:abstract:sent:15,med:pmid:38635062,abstract,15,Safety end point analysis showed a higher rate of hypotension in the ARNI group (P < 0.05).,2461,2552
med:pmid:38635062:sec:abstract:sent:16,med:pmid:38635062,abstract,16,"Early use of sacubitril/valsartan after coronary artery revascularization in patients with AMI complicated by moderate-to-severe mitral regurgitation can significantly reduce mitral regurgitation, improve ventricular remodeling, and decrease heart failure hospitalization.",2553,2825
med:pmid:38635062:sec:abstract:sent:17,med:pmid:38635062,abstract,17,"Nevertheless, caution is needed to avoid hypotension.",2826,2879
med:pmid:38635062:sec:abstract:sent:18,med:pmid:38635062,abstract,18,"Chinese Clinical Trial Registry (ChiCTR2100054255) registered on December 11, 2021.",2880,2963
med:pmid:38597935:sec:title:sent:0,med:pmid:38597935,title,0,Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials.,0,222
med:pmid:38597935:sec:introduction:sent:1,med:pmid:38597935,introduction,1,The objective of this meta-analysis is to determine how sacubitril/valsartan (SV) compares to equivalent and sub-equivalent angiotensin receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEI) in patients with heart failure with reduced ejection fraction (HFrEF).,0,298
med:pmid:38597935:sec:methods:sent:2,med:pmid:38597935,methods,2,The databases of PubMed and EMBASE were used to identify those randomized controlled trials which compared SV to ARB/ACEI in patients with HFrEF.,299,461
med:pmid:38597935:sec:methods:sent:3,med:pmid:38597935,methods,3,"Only those trials that reported outcomes regarding total mortality, cardiovascular mortality, and worsening heart failure were considered.",462,600
med:pmid:38597935:sec:methods:sent:4,med:pmid:38597935,methods,4,Meta-analysis was performed separately in those patients receiving equivalent doses of ARB/ACEI and those receiving sub-equivalent doses.,601,738
med:pmid:38597935:sec:methods:sent:5,med:pmid:38597935,methods,5,Equivalent doses were SV 97/103 = valsartan 160 mg twice daily = enalapril 20 mg twice daily = ramipril 5 mg twice daily.,739,860
med:pmid:38597935:sec:methods:sent:6,med:pmid:38597935,methods,6,Meta-analyses were performed using Review Manager 5.4.,861,915
med:pmid:38597935:sec:results:sent:7,med:pmid:38597935,results,7,"Twelve randomized trials were identified involving 17,484 patients: 11,291 in the sub-equivalent group (8 trials) and 6193 in the equivalent group (4 trials).",916,1091
med:pmid:38597935:sec:results:sent:8,med:pmid:38597935,results,8,"Meta-analyses showed there were no statistical differences regarding the outcomes of total mortality, cardiovascular mortality, and worsening heart failure in the equivalent dosing group.",1092,1279
med:pmid:38597935:sec:results:sent:9,med:pmid:38597935,results,9,"However, SV reduced total mortality (risk ratio (RR) = 0.85, 95% confidence interval (CI) = 0.78-0.93, p < 0.001), cardiovascular mortality (RR = 0.81, 95% CI = 0.73-0.90, p ≤ 0.001) and worsening heart failure (RR = 0.77, 95% CI = 0.64-0.92, p = 0.005) in the sub-equivalent group.",1280,1562
med:pmid:38597935:sec:conclusion:sent:10,med:pmid:38597935,conclusion,10,"When compared to equivalent doses of ARB/ACEI, SV is not superior in reducing mortality and worsening heart failure.",1563,1699
med:pmid:38597935:sec:conclusion:sent:11,med:pmid:38597935,conclusion,11,SV is superior when compared to sub-equivalent doses of ACEI.,1700,1761
med:pmid:38513366:sec:title:sent:0,med:pmid:38513366,title,0,Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.,0,111
med:pmid:38513366:sec:introduction:sent:1,med:pmid:38513366,introduction,1,The study sought to comprehensively investigate the effect of heart failure (HF) pharmacotherapies in patients with HF with mildly reduced ejection fraction (HFmrEF).,0,180
med:pmid:38513366:sec:introduction:sent:2,med:pmid:38513366,introduction,2,"In the absence of randomized controlled trials, guideline recommendations concerning HF-related therapies in patients with HFmrEF are limited.",181,323
med:pmid:38513366:sec:results:sent:3,med:pmid:38513366,results,3,Consecutive patients hospitalized with HFmrEF were retrospectively included at one institution from 2016 to 2022.,324,466
med:pmid:38513366:sec:results:sent:4,med:pmid:38513366,results,4,"The prognostic value of treatment with beta-blockers (BB), angiotensin-converting enzyme inhibitors, receptor blockers, or receptor-neprilysin inhibitor (ACEi/ARB/ARNI), mineralocorticoid receptor antagonists (MRA), and sodium-glucose-linked transport protein 2 inhibitors (SGLT2i) was investigated for all-cause mortality at 30 months (a median follow-up) and HF-related rehospitalization.",467,857
med:pmid:38513366:sec:results:sent:5,med:pmid:38513366,results,5,A total of 2109 patients with HFmrEF were included.,858,909
med:pmid:38513366:sec:results:sent:6,med:pmid:38513366,results,6,"Treatment with BB [27.0 vs. 35.0%; hazard ratio (HR) = 0.737; 95% confidence interval (CI) 0.617-0.881; P = 0.001], ACEi/ARB/ARNI (25.9 vs. 37.6%; HR = 0.612; 95% CI 0.517-0.725; P = 0.001), and SGLT2i (11.9 vs. 29.5%; HR = 0.441; 95% CI 0.236-0.824; P = 0.010) was associated with a lower risk of 30-month all-cause mortality, which was still demonstrated after multivariable adjustment and propensity score matching.",910,1328
med:pmid:38513366:sec:results:sent:7,med:pmid:38513366,results,7,"In contrast, MRA treatment was not associated with long-term prognosis.",1329,1400
med:pmid:38513366:sec:results:sent:8,med:pmid:38513366,results,8,The risk of HF-related rehospitalization was not affected by HF pharmacotherapies.,1401,1483
med:pmid:38513366:sec:results:sent:9,med:pmid:38513366,results,9,"Finally, the lowest risk of long-term all-cause mortality was observed in patients with combined use of BB, ACEi/ARB/ARNI, and SGLT2i (HR = 0.456; 95% CI 0.227-0.916; P = 0.027).",1484,1662
med:pmid:38513366:sec:conclusion:sent:10,med:pmid:38513366,conclusion,10,"Beta-blockers, ACEi/ARB/ARNI, and SGLT2i were independently associated with a lower risk of all-cause mortality in patients with HFmrEF, specifically when applied as combined 'HF triple therapy'.",1663,1878
med:pmid:38513366:sec:conclusion:sent:11,med:pmid:38513366,conclusion,11,Randomized studies are needed to investigate the effect of HF-related pharmacotherapies in patients with HFmrEF.,1879,1991
med:pmid:39106509:sec:title:sent:0,med:pmid:39106509,title,0,[Chronic kidney disease and chronic heart failure: impact on prognosis and choice of pathogenetic therapy].,0,107
med:pmid:39106509:sec:introduction:sent:1,med:pmid:39106509,introduction,1,"To evaluate the impact of a decrease in glomerular filtration rate (GFR) on the prognosis of patients with chronic heart failure (CHF), to analyze real clinical practice regarding the frequency of prescribing pathogenetic therapy for CHF, achieving target dosages depending on the gradation of GFR in patients included in the CHF Register of the Tyumen region.",0,373
med:pmid:39106509:sec:methods:sent:2,med:pmid:39106509,methods,2,The analysis included medical data of 4077 patients (1662 men and 2415 women) with NYHA class I-IV CHF who underwent examination and treatment in medical organizations of the Tyumen region for the period from January 2020 to May 2023.,374,639
med:pmid:39106509:sec:methods:sent:3,med:pmid:39106509,methods,3,Criteria for inclusion in the register: proven heart failure.,640,701
med:pmid:39106509:sec:methods:sent:4,med:pmid:39106509,methods,4,Chronic kidney disease (CKD) was assessed by GFR calculated using the CKD-EPI formula (ml/min/1.73 m<sup>2</sup>).,702,816
med:pmid:39106509:sec:methods:sent:5,med:pmid:39106509,methods,5,The primary end point was defined as death from all causes.,817,876
med:pmid:39106509:sec:results:sent:6,med:pmid:39106509,results,6,"GFR<60 ml/min/1.73 m<sup>2</sup> was recorded in 34.6% of patients, more common in women (40.2 and 26.6%, respectively; <i>p</i><0.001).",877,1030
med:pmid:39106509:sec:results:sent:7,med:pmid:39106509,results,7,"When dividing patients into phenotypes according to LVEF, no statistically significant differences were found in the distribution of patients according to GFR.",1031,1190
med:pmid:39106509:sec:results:sent:8,med:pmid:39106509,results,8,In patients with HFrEF and HFpEF GFR<45 ml/min/1.73 m<sup>2</sup> was associated with an increased risk of meeting the endpoint.,1191,1319
med:pmid:39106509:sec:discussion:sent:9,med:pmid:39106509,discussion,9,"of prescribed pathogenetic therapy showed that in patients with HFrEF, the frequency of prescription of ACE inhibitors, â-blockers and MRA decreased (<i>p</i>=0.023, 006 and 0.01, respectively), and ARNI, on the contrary, increased with a decrease in GFR (<i>p</i>=0.026).",1320,1601
med:pmid:39106509:sec:discussion:sent:10,med:pmid:39106509,discussion,10,"In patients with HFpEF, a similar trend towards a decrease in the frequency of prescription of ACEIs and MCBs with a decrease in GFR (<i>p</i><0.001) remained, but it was compensated by an inversely proportional increase in the frequency of prescription of ARBs (<i>p</i><0.001).",1602,1881
med:pmid:39106509:sec:discussion:sent:11,med:pmid:39106509,discussion,11,100% of the target dosage is achieved in more than 90% of patients taking MRA across the entire LVEF range.,1882,1989
med:pmid:39106509:sec:discussion:sent:12,med:pmid:39106509,discussion,12,While for â-blockers and ARNI/ACE/ARB the percentage of patients receiving the full therapeutic dosage of drugs is significantly lower.,1990,2125
med:pmid:39106509:sec:discussion:sent:13,med:pmid:39106509,discussion,13,"When analyzing target dosages of pathogenetic drugs, gradations of achieved doses were distributed evenly throughout the entire range of GFR.",2126,2267
med:pmid:39106509:sec:conclusion:sent:14,med:pmid:39106509,conclusion,14,GFR<60 ml/min/1.73 m<sup>2</sup> occurs in every 3 patients with CHF across the entire range of LVEF.,2268,2389
med:pmid:39106509:sec:conclusion:sent:15,med:pmid:39106509,conclusion,15,"A decrease in GFR worsens the prognosis of patients with both HFrEF and HFpEF, increasing in direct proportion with the severity of the stage of CKD.",2390,2539
med:pmid:39106509:sec:conclusion:sent:16,med:pmid:39106509,conclusion,16,"Inclusion of patients in the monitoring program within the framework of the CHF service allows the treatment to be significantly brought closer to optimal drug therapy, at the same time, certain efforts are required to overcome difficulties with titration to target dosages.",2540,2814
med:pmid:39058824:sec:title:sent:0,med:pmid:39058824,title,0,Effect of sacubitril/valsartan on hospital readmissions in heart failure with reduced ejection fraction in Saudi Arabia: A multicenter retrospective cohort study.,0,162
med:pmid:39058824:sec:abstract:sent:1,med:pmid:39058824,abstract,1,Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) that has been shown in multiple clinical trials to have clinical benefits and is recommended by major clinical management guidelines as a first-line treatment for heart failure with reduced ejection fraction (HFrEF).,0,292
med:pmid:39058824:sec:abstract:sent:2,med:pmid:39058824,abstract,2,The most significant benefit that was observed in clinical trials is its effect in reducing hospital readmissions.,293,407
med:pmid:39058824:sec:abstract:sent:3,med:pmid:39058824,abstract,3,"However, little evidence supports its effectiveness in practice, especially in Saudi Arabia.",408,500
med:pmid:39058824:sec:abstract:sent:4,med:pmid:39058824,abstract,4,A multicenter retrospective cohort study was conducted using the patient medical records at 2 tertiary hospitals in Saudi Arabia.,501,630
med:pmid:39058824:sec:abstract:sent:5,med:pmid:39058824,abstract,5,Eligible patients were adults (≥18 years old) with a confirmed diagnosis of HFrEF who were discharged on either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) in addition to the other recommended therapy for HFrEF.,631,906
med:pmid:39058824:sec:abstract:sent:6,med:pmid:39058824,abstract,6,The primary endpoint was the all-cause 30-day readmission rate.,907,970
med:pmid:39058824:sec:abstract:sent:7,med:pmid:39058824,abstract,7,"The secondary endpoints included all-cause readmissions at 60-day, 90-day, and 12 months.",971,1060
med:pmid:39058824:sec:abstract:sent:8,med:pmid:39058824,abstract,8,"Additionally, 30-day, 60-day, and 90-day readmissions due to HF were evaluated.",1061,1140
med:pmid:39058824:sec:abstract:sent:9,med:pmid:39058824,abstract,9,"A total of 398 patients were included in our analysis; 199 (50.0%) received sacubitril/valsartan (group 1), and 199 (50.0%) received ACEI/ARB (group 2).",1141,1293
med:pmid:39058824:sec:abstract:sent:10,med:pmid:39058824,abstract,10,"Our results showed that all-cause 30-day readmissions in group 1 were significantly lower than in group 2 (7% vs 25.0%, RR 0.28, 95% Cl 0.16-0.49; P < .001).",1294,1451
med:pmid:39058824:sec:abstract:sent:11,med:pmid:39058824,abstract,11,"Additionally, the secondary outcomes showed significantly fewer 60-day, 90-day, and 12-month all-cause readmissions were identified in group 1 compared to group 2 (11% vs 30.7%, RR 0.36, 95% CI 0.23-0.56; P < .001), (11.6%.",1452,1675
med:pmid:39058824:sec:abstract:sent:12,med:pmid:39058824,abstract,12,"vs 32.6%, RR 0.35, 95% CI 0.23-0.55; P < .001) and (23.6% vs 51.2%, RR 0.46, 95% CI 0.35-0.62; P < .001), respectively.",1676,1795
med:pmid:39058824:sec:abstract:sent:13,med:pmid:39058824,abstract,13,"Furthermore, HF readmissions at 30-day, 60-day, and 90-day in group 1 were significantly lower than in group 2 (P < .05).",1796,1917
med:pmid:39058824:sec:abstract:sent:14,med:pmid:39058824,abstract,14,Sacubitril/valsartan for the treatment of HFrEF is associated with a significantly lower rate of all-cause readmission as well as HF readmissions compared to ACEI/ARB.,1918,2085
med:pmid:39058824:sec:abstract:sent:15,med:pmid:39058824,abstract,15,These benefits extend up to 12 months post-discharge.,2086,2139
med:pmid:39020009:sec:title:sent:0,med:pmid:39020009,title,0,Effects of angiotensin receptor-neprilysin inhibitor on ketone body metabolism in pre-heart failure/heart failure patients.,0,123
med:pmid:39020009:sec:abstract:sent:1,med:pmid:39020009,abstract,1,"Recently, a mild elevation of the blood ketone levels was found to exert multifaceted cardioprotective effects.",0,111
med:pmid:39020009:sec:abstract:sent:2,med:pmid:39020009,abstract,2,"To investigate the effect of angiotensin receptor neprilysin inhibitors (ARNIs) on the blood ketone body levels, 46 stable pre-heart failure (HF)/HF patients were studied, including 23 who switched from angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to ARNIs (ARNI group) and 23 who continued treatment with ACE inhibitors or ARBs (control group).",112,499
med:pmid:39020009:sec:abstract:sent:3,med:pmid:39020009,abstract,3,"At baseline, there were no significant differences in the total ketone body (TKB) levels between the two groups.",500,612
med:pmid:39020009:sec:abstract:sent:4,med:pmid:39020009,abstract,4,"Three months later, the TKB levels in the ARNI group were higher than the baseline values (baseline to 3 months: 71 [51, 122] to 92 [61, 270] μmol/L, P < 0.01).",613,773
med:pmid:39020009:sec:abstract:sent:5,med:pmid:39020009,abstract,5,"In the control group, no significant change was observed between the baseline and 3 months later.",774,871
med:pmid:39020009:sec:abstract:sent:6,med:pmid:39020009,abstract,6,"A multiple regression analysis demonstrated that the initiation of ARNI and an increase in the blood non-esterified fatty acid (NEFA) levels at 3 months increased the percentage changes in the TKB levels from baseline to 3 months (%ΔTKB level) (initiation of ARNI: P = 0.017, NEFA level at 3 months: P < 0.001).",872,1183
med:pmid:39020009:sec:abstract:sent:7,med:pmid:39020009,abstract,7,These results indicate that ARNI administration induces a mild elevation of the blood TKB levels in pre-HF/HF patients.,1184,1303
med:pmid:38904251:sec:title:sent:0,med:pmid:38904251,title,0,Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy.,0,128
med:pmid:38904251:sec:introduction:sent:1,med:pmid:38904251,introduction,1,Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined.,0,189
med:pmid:38904251:sec:results:sent:2,med:pmid:38904251,results,2,"We measured serum levels of 4123 unique proteins in 1117 patients with HFpEF enrolled in the PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial using a modified aptamer proteomic assay.",190,511
med:pmid:38904251:sec:results:sent:3,med:pmid:38904251,results,3,"Baseline circulating protein concentrations significantly associated with the primary end point and the timing and occurrence of total heart failure hospitalization and cardiovascular death were identified by recurrent events regression, accounting for multiple testing, adjusted for age, sex, treatment, and anticoagulant use, and compared with published analyses in 2515 patients with heart failure with reduced ejection fraction from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and ATMOSPHERE (Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-Mortality in Patients With Chronic Heart Failure) clinical trials.",512,1243
med:pmid:38904251:sec:results:sent:4,med:pmid:38904251,results,4,We identified 288 proteins that were robustly associated with the risk of heart failure hospitalization and cardiovascular death in patients with HFpEF.,1244,1396
med:pmid:38904251:sec:results:sent:5,med:pmid:38904251,results,5,"The baseline proteins most strongly related to outcomes included B2M (β-2 microglobulin), TIMP1 (tissue inhibitor of matrix metalloproteinase 1), SERPINA4 (serpin family A member 4), and SVEP1 (sushi, von Willebrand factor type A, EGF, and pentraxin domain containing 1).",1397,1668
med:pmid:38904251:sec:results:sent:6,med:pmid:38904251,results,6,"Overall, the protein-outcome associations in patients with HFpEF did not markedly differ as compared with patients with heart failure with reduced ejection fraction.",1669,1834
med:pmid:38904251:sec:results:sent:7,med:pmid:38904251,results,7,"A proteomic risk score derived in patients with HFpEF was not superior to a previous proteomic score derived in heart failure with reduced ejection fraction nor to clinical risk factors, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or high-sensitivity cardiac troponin.",1835,2114
med:pmid:38904251:sec:conclusion:sent:8,med:pmid:38904251,conclusion,8,"Numerous serum proteins linked to metabolic, coagulation, and extracellular matrix regulatory pathways were associated with worse HFpEF prognosis in the PARAGON-HF proteomic substudy.",2115,2319
med:pmid:38904251:sec:conclusion:sent:9,med:pmid:38904251,conclusion,9,Our results demonstrate substantial similarities among serum proteomic risk markers for heart failure hospitalization and cardiovascular death when comparing clinical trial participants with heart failure across the ejection fraction spectrum.,2320,2563
med:pmid:38904251:sec:conclusion:sent:10,med:pmid:38904251,conclusion,10,"<h4>Registration</h4> URL: https://www.clinicaltrials.gov; Unique Identifiers: NCT01920711, NCT01035255, NCT00853658.",2564,2681
med:pmid:38621576:sec:title:sent:0,med:pmid:38621576,title,0,"Association between visit frequency, continuity of care, and pharmacy fill adherence in heart failure patients.",0,111
med:pmid:38621576:sec:introduction:sent:1,med:pmid:38621576,introduction,1,"Despite advances in medical therapy for heart failure with reduced ejection fraction (HFrEF), major gaps in medication adherence to guideline-directed medical therapies (GDMT) remain.",0,203
med:pmid:38621576:sec:introduction:sent:2,med:pmid:38621576,introduction,2,Greater continuity of care may impact medication adherence and reduced hospitalizations.,204,292
med:pmid:38621576:sec:methods:sent:3,med:pmid:38621576,methods,3,"We conducted a cross-sectional study of adults with a diagnosis of HF and EF ≤40% with ≥2 outpatient encounters between January 1, 2017 and January 10, 2021, prescribed ≥1 of the following GDMT: 1) Beta Blocker, 2) Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker/Angiotensin Receptor Neprilysin Inhibitor, 3) Mineralocorticoid Receptor Antagonist, 4) Sodium Glucose Cotransporter-2 Inhibitor.",293,723
med:pmid:38621576:sec:methods:sent:4,med:pmid:38621576,methods,4,"Continuity of care was calculated using the Bice-Boxerman Continuity of Care Index (COC) and the Usual Provider of Care (UPC) index, categorized by quantile.",724,881
med:pmid:38621576:sec:methods:sent:5,med:pmid:38621576,methods,5,"The primary outcome was adherence to GDMT, defined as average proportion of days covered ≥80% over 1 year.",882,988
med:pmid:38621576:sec:methods:sent:6,med:pmid:38621576,methods,6,Secondary outcomes included all-cause and HF hospitalization at 1-year.,989,1060
med:pmid:38621576:sec:methods:sent:7,med:pmid:38621576,methods,7,"We performed multivariable logistic regression analyses adjusted for demographics, insurance status, comorbidity index, number of visits and neighborhood SES index.",1061,1225
med:pmid:38621576:sec:results:sent:8,med:pmid:38621576,results,8,"Overall, 3,971 individuals were included (mean age 72 years (SD 14), 71% male, 66% White race).",1226,1338
med:pmid:38621576:sec:results:sent:9,med:pmid:38621576,results,9,"In adjusted analyses, compared to individuals in the highest COC quartile, individuals in the third COC quartile had higher odds of GDMT adherence (OR 1.26, 95% CI 1.03-1.53, P = .024).",1339,1524
med:pmid:38621576:sec:results:sent:10,med:pmid:38621576,results,10,UPC tertile was not associated with adherence (all P > .05).,1525,1585
med:pmid:38621576:sec:results:sent:11,med:pmid:38621576,results,11,"Compared to the highest quantiles, the lowest UPC and COC quantiles had higher odds of all-cause (UPC: OR 1.53, 95%CI 1.23-1.91; COC: OR 2.54, 95%CI 1.94-3.34) and HF (UPC: OR 1.81, 95%CI 1.23-2.67; COC: OR 1.77, 95%CI 1.09-2.95) hospitalizations.",1586,1833
med:pmid:38621576:sec:conclusion:sent:12,med:pmid:38621576,conclusion,12,Continuity of care was not associated with GDMT adherence among patients with HFrEF but lower continuity of care was associated with increased all-cause and HF-hospitalizations.,1834,2032
med:pmid:38930091:sec:title:sent:0,med:pmid:38930091,title,0,"Contemporary Use of Sodium Glucose Co-Transporter 2 Inhibitors in Hospitalized Heart Failure Patients: A ""Real-World"" Experience.",0,129
med:pmid:38930091:sec:introduction:sent:1,med:pmid:38930091,introduction,1,The aim of this study was to examine the association between in-hospital initiation of sodium glucose co-transporter 2 inhibitors (SGLT2is) and outcomes in hospitalized heart failure (HHF) patients utilizing data from a Greek center.,0,263
med:pmid:38930091:sec:introduction:sent:2,med:pmid:38930091,introduction,2,"<b>Methods</b>: The present work was a single-center, retrospective, observational study of consecutive HF patients hospitalized in a tertiary center.",264,414
med:pmid:38930091:sec:introduction:sent:3,med:pmid:38930091,introduction,3,The study endpoint was all-cause mortality or HF rehospitalization.,415,482
med:pmid:38930091:sec:introduction:sent:4,med:pmid:38930091,introduction,4,Univariate and multivariate Cox proportional-hazard models were conducted to investigate the association between SGLT2i administration at discharge and the study endpoint.,483,654
med:pmid:38930091:sec:introduction:sent:5,med:pmid:38930091,introduction,5,"<b>Results</b>: Sample consisted of 171 patients, 55 of whom (32.2%) received SGLT2is at discharge.",655,754
med:pmid:38930091:sec:introduction:sent:6,med:pmid:38930091,introduction,6,"Overall, mean follow-up period was 6.1 months (SD = 4.8 months).",755,819
med:pmid:38930091:sec:introduction:sent:7,med:pmid:38930091,introduction,7,Patients who received SGLT2is at discharge had a 43% lower probability of the study endpoint compared to those who did not receive SGLT2is at discharge (HR = 0.57; 95% CI: 0.36-0.91; <i>p</i> = 0.018).,820,1021
med:pmid:38930091:sec:introduction:sent:8,med:pmid:38930091,introduction,8,"After adjusting for age, gender, smoking, hemoglobin (Hgb), use of SGLT2is at admission, use of Angiotensin-Converting Enzyme Inhibitors (ACEI-Is)/Angiotensin Receptor Blockers (ARBs) at discharge and Sacubitril/Valsartan at discharge, the aforementioned result remained significant (HR = 0.38; 95% CI: 0.19-0.73; <i>p</i> = 0.004).",1022,1354
med:pmid:38930091:sec:introduction:sent:9,med:pmid:38930091,introduction,9,The 55 patients who received SGLT2is at discharge were propensity score matched with the 116 patients who did not receive SGLT2is at discharge.,1355,1498
med:pmid:38930091:sec:introduction:sent:10,med:pmid:38930091,introduction,10,Receiving SGLT2is at discharge continued to be significantly associated with a lower probability of the study endpoint (HR= 0.43; 95% CI: 0.20-0.89; <i>p</i> = 0.024).,1499,1666
med:pmid:38930091:sec:introduction:sent:11,med:pmid:38930091,introduction,11,<b>Conclusions</b>: Initiation of SGLT2is in HHF patients may be associated with better outcomes.,1667,1764
med:pmid:38764991:sec:title:sent:0,med:pmid:38764991,title,0,Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction?,0,89
med:pmid:38764991:sec:title:sent:1,med:pmid:38764991,title,1,A Review of Randomized Comparative Trials.,90,132
med:pmid:38764991:sec:abstract:sent:2,med:pmid:38764991,abstract,2,<b>Background:</b> The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to enalapril in patients with reduced ejection fraction (HFrEF).,0,153
med:pmid:38764991:sec:abstract:sent:3,med:pmid:38764991,abstract,3,"Since its publication, several other randomized trials have compared SV to either an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in HFrEF which showed conflicting results regarding mortality, hospitalizations, and quality of life scoring.",154,433
med:pmid:38764991:sec:abstract:sent:4,med:pmid:38764991,abstract,4,<b>Objective:</b> To review randomized comparative trials of SV to either ACEI or ARB in patients with HFrEF.,434,543
med:pmid:38764991:sec:abstract:sent:5,med:pmid:38764991,abstract,5,<b>Methods:</b> PubMed and Embase databases were used to identify randomized comparative trials.,544,640
med:pmid:38764991:sec:abstract:sent:6,med:pmid:38764991,abstract,6,"The text terms sacubitril, angiotensin neprilysin, and LCZ696 were used for both searches.",641,731
med:pmid:38764991:sec:abstract:sent:7,med:pmid:38764991,abstract,7,"Meta-analysis, retrospective, adhoc, and cohort studies were excluded.",732,802
med:pmid:38764991:sec:abstract:sent:8,med:pmid:38764991,abstract,8,"<b>Results:</b> 1476 and 3983 citations were reviewed on PubMed and Embase, respectively.",803,892
med:pmid:38764991:sec:abstract:sent:9,med:pmid:38764991,abstract,9,"Of these, 11 randomized comparative trials to either ACEI or ARB were included for analysis.",893,985
med:pmid:38764991:sec:abstract:sent:10,med:pmid:38764991,abstract,10,The mortality/quality of life benefits of SV over enalapril in the PARADIGM HF were not corroborated in any of the other trials.,986,1114
med:pmid:38764991:sec:abstract:sent:11,med:pmid:38764991,abstract,11,The effect of hospitalizations for heart failure was inconsistent among trials.,1115,1194
med:pmid:38764991:sec:abstract:sent:12,med:pmid:38764991,abstract,12,Exercise tolerance was not improved with SV versus enalapril.,1195,1256
med:pmid:38764991:sec:abstract:sent:13,med:pmid:38764991,abstract,13,<b>Conclusion:</b> The results of the PARADIGM HF trial have largely not been confirmed in subsequent randomized comparative trials.,1257,1389
med:pmid:38588927:sec:title:sent:0,med:pmid:38588927,title,0,Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.,0,103
med:pmid:38588927:sec:introduction:sent:1,med:pmid:38588927,introduction,1,The Kidney Disease Improving Global Outcomes (KDIGO) classification integrates both estimated glomerular filtration rate and urine-albumin-creatinine ratio to stratify risk more comprehensively in patients with chronic kidney disease.,0,254
med:pmid:38588927:sec:introduction:sent:2,med:pmid:38588927,introduction,2,There are limited data assessing whether this classification system is associated with prognosis and treatment response in heart failure populations.,255,404
med:pmid:38588927:sec:introduction:sent:3,med:pmid:38588927,introduction,3,The aim of this study was to evaluate the relative treatment effects of sacubitril/valsartan across the KDIGO risk categories in patients with HFrEF.,405,574
med:pmid:38588927:sec:methods:sent:4,med:pmid:38588927,methods,4,PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) was a global randomized controlled trial evaluating sacubitril/valsartan vs enalapril in patients with heart failure with reduced ejection fraction (HFrEF).,575,874
med:pmid:38588927:sec:methods:sent:5,med:pmid:38588927,methods,5,"Patients were classified according to low, moderate, and high/very high KDIGO risk.",875,958
med:pmid:38588927:sec:methods:sent:6,med:pmid:38588927,methods,6,Treatment responses were assessed according to baseline KDIGO risk.,959,1026
med:pmid:38588927:sec:methods:sent:7,med:pmid:38588927,methods,7,The primary outcome was a composite of cardiovascular (CV) death or heart failure hospitalization.,1027,1125
med:pmid:38588927:sec:methods:sent:8,med:pmid:38588927,methods,8,A renal composite outcome was defined as sustained decline in estimated glomerular filtration rate by ≥40% or end-stage kidney disease.,1126,1261
med:pmid:38588927:sec:results:sent:9,med:pmid:38588927,results,9,"Among 1,910 (23% of total) participants with available data, 42%, 32%, and 26% were classified as low, moderate, and high/very high KDIGO risk, respectively.",1262,1436
med:pmid:38588927:sec:results:sent:10,med:pmid:38588927,results,10,"Patients in the highest KDIGO risk categories experienced the highest rates of the primary composite outcome (7.6 per 100 person-years [95% CI: 6.5-9.0 per 100 person-years], 9.4 per 100 person-years [95% CI: 7.9-11.2 per 100 person-years], and 14.9 per 100 person-years [95% CI: 12.7-17.6 per 100 person-years]; P < 0.001).",1437,1761
med:pmid:38588927:sec:results:sent:11,med:pmid:38588927,results,11,Sacubitril/valsartan had a similar safety profile and demonstrated consistent effects on the risk of both the primary outcome (P<sub>Interaction</sub> = 0.31) and the renal composite outcome (P<sub>Interaction</sub> = 0.50) across the spectrum of KDIGO risk.,1762,2020
med:pmid:38588927:sec:conclusion:sent:12,med:pmid:38588927,conclusion,12,One in 4 patients with HFrEF were classified as at least high KDIGO kidney risk; these individuals faced concordantly the highest risks of CV events.,2021,2191
med:pmid:38588927:sec:conclusion:sent:13,med:pmid:38588927,conclusion,13,Sacubitril/valsartan exhibited consistent CV and kidney protective benefits as well as safety across the spectrum of baseline kidney risk.,2192,2330
med:pmid:38588927:sec:conclusion:sent:14,med:pmid:38588927,conclusion,14,These data further support initiation of sacubitril/valsartan in HFrEF across a broad range of kidney risk. (,2331,2440
med:pmid:38588927:sec:conclusion:sent:15,med:pmid:38588927,conclusion,15,This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure [PARADIGM-HF]; NCT01035255).,2440,2615
med:pmid:36609948:sec:title:sent:0,med:pmid:36609948,title,0,Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.,0,134
med:pmid:36609948:sec:introduction:sent:1,med:pmid:36609948,introduction,1,Impaired renal function is frequently observed in patients with heart failure and reduced ejection fraction (HFrEF).,0,136
med:pmid:36609948:sec:introduction:sent:2,med:pmid:36609948,introduction,2,The differential effect of sacubitril/valsartan and angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEIs/ARBs) on the clinical and renal outcomes in patients with HFrEF and chronic kidney disease (CKD) remains unknown.,137,380
med:pmid:36609948:sec:introduction:sent:3,med:pmid:36609948,introduction,3,This study aimed to explore the differential effect of sacubitril/valsartan and ACEI/ARB on the clinical and renal outcomes as well as renal function over a 12-month follow-up period in HFrEF patients with and without CKD.,381,617
med:pmid:36609948:sec:methods:sent:4,med:pmid:36609948,methods,4,Patients with HfrEF (LVEF ≤35%) and NYHA class ≥II were enrolled from the Chang Gung Research Database between 2017 and 2020.,618,760
med:pmid:36609948:sec:methods:sent:5,med:pmid:36609948,methods,5,Baseline characteristics were compared between patients prescribed sacubitril/valsartan and ACEI/ARB.,761,862
med:pmid:36609948:sec:methods:sent:6,med:pmid:36609948,methods,6,"After propensity score matching, the following clinical and renal outcomes were compared between the two groups in patients with and without CKD over a 12-month follow-up period: acute kidney injury (AKI), emergent dialysis/renal death, HF hospitalization, cardiovascular mortality, and all-cause mortality.",863,1170
med:pmid:36609948:sec:results:sent:7,med:pmid:36609948,results,7,"This study enrolled 3735 HFrEF patients with a mean left ventricular EF of 27.56 ± 5.86%, who had been prescribed sacubitril/valsartan (N = 1708) or ACEI/ARB (N = 2027).",1171,1357
med:pmid:36609948:sec:results:sent:8,med:pmid:36609948,results,8,"After propensity score matching, the clinical and renal outcomes did not differ between the sacubitril/valsartan and ACEI/ARB groups in patients without CKD.",1358,1515
med:pmid:36609948:sec:results:sent:9,med:pmid:36609948,results,9,"In patients with CKD, the ACEI/ARB group had a significantly higher incidence of all-cause mortality than the sacubitril/valsartan group (14.89% vs. 10.50%; hazard ratio 1.46; 95% confidence interval 1.06-2.00; p = 0.02), and the incidence of AKI, HF hospitalization, and CV mortality did not differ between the two groups.",1516,1839
med:pmid:36609948:sec:conclusion:sent:10,med:pmid:36609948,conclusion,10,Sacubitril/valsartan had a lower all-cause mortality compared to ACEI/ARB in symptomatic HFrEF patients with CKD.,1840,1974
med:pmid:36609948:sec:conclusion:sent:11,med:pmid:36609948,conclusion,11,Further prospective randomized studies are warranted to confirm our findings.,1975,2052
med:pmid:38792317:sec:title:sent:0,med:pmid:38792317,title,0,Validation of a New Scoring Method to Assess the Efficacy of Rapid Initiation and Titration of Combination Pharmacotherapy for Patients Hospitalized with Acute Decompensated Heart Failure with Reduced and Mildly Reduced Ejection Fraction.,0,238
med:pmid:38792317:sec:abstract:sent:1,med:pmid:38792317,abstract,1,"<b>Background</b>: Despite the encouragement of early initiation and titration of guideline-directed medical therapy (GDMT) for the treatment of heart failure (HF), most patients do not receive an adequate type and dose of pharmacotherapy in the real world.",0,257
med:pmid:38792317:sec:abstract:sent:2,med:pmid:38792317,abstract,2,<b>Objectives</b>: This study aimed to determine the efficacy of titrating composite GDMT in patients with HF with reduced and mildly reduced ejection fraction and to identify patient conditions that may benefit from titration of GDMT.,258,493
med:pmid:38792317:sec:abstract:sent:3,med:pmid:38792317,abstract,3,"<b>Methods</b>: This was a two-center, retrospective study of consecutive patients hospitalized with acute decompensated heart failure (ADHF).",494,636
med:pmid:38792317:sec:abstract:sent:4,med:pmid:38792317,abstract,4,"Patients were classified into two groups according to a scoring scale determined by combination and doses of four types of HF agents (ACEis/ARBs/ARNis, BBs, MRAs, and SGLT2is) at discharge.",637,826
med:pmid:38792317:sec:abstract:sent:5,med:pmid:38792317,abstract,5,"A score of 5 or greater was defined as titrated GDMT, and a score of 4 or less was regarded as sub-optimal medical therapy (MT).",827,955
med:pmid:38792317:sec:abstract:sent:6,med:pmid:38792317,abstract,6,<b>Results</b>: A total of 979 ADHF patients were screened.,956,1015
med:pmid:38792317:sec:abstract:sent:7,med:pmid:38792317,abstract,7,"After 553 patients were excluded based on exclusion criteria, 426 patients (90 patients in the titrated GDMT group and 336 patients in the sub-optimal MT group) were enrolled for the analysis.",1016,1208
med:pmid:38792317:sec:abstract:sent:8,med:pmid:38792317,abstract,8,The median follow-up period was 612 (453-798) days.,1209,1260
med:pmid:38792317:sec:abstract:sent:9,med:pmid:38792317,abstract,9,"Following statistical adjustment using the propensity score weighting method, the 2-year composite endpoint (composite of cardiac death and HF rehospitalization) rate was significantly lower in the titrated GDMT group, at 19%, compared with the sub-optimal MT group: 31% (score 3-4 points) and 43% (score 0-2 points).",1261,1578
med:pmid:38792317:sec:abstract:sent:10,med:pmid:38792317,abstract,10,"Subgroup analysis indicated a marked benefit of titrated GDMT in particular patient subgroups: age < 80 years, BMI 19.0-24.9, eGFR > 20 mL/min/1.73 m<sup>2</sup>, and serum potassium level ≤ 5.5 mmol/L. <b>Conclusions</b>: Prompt initiation and dose adjustment of multiple HF medications, with careful monitoring of the patient's physiologic and laboratory values, is a prerequisite for improving the prognosis of patients with heart failure.",1579,2021
med:pmid:38573461:sec:title:sent:0,med:pmid:38573461,title,0,"Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany.",0,181
med:pmid:38573461:sec:introduction:sent:1,med:pmid:38573461,introduction,1,Data are limited regarding guideline-directed medical therapy (GDMT) treatment patterns in patients with worsening heart failure (HF).,0,154
med:pmid:38573461:sec:methods:sent:2,med:pmid:38573461,methods,2,We used administrative claims databases in Germany and the USA to conduct a retrospective cohort study of patients with worsening HF.,155,305
med:pmid:38573461:sec:methods:sent:3,med:pmid:38573461,methods,3,"Two cohorts of patients with prevalent HF and a HF hospitalization (HFH) from 2016 to 2019, alive at discharge (N = 75,140 USA; N = 47,003 Germany) were identified.",306,470
med:pmid:38573461:sec:methods:sent:4,med:pmid:38573461,methods,4,Index date was the first HFH during the study period.,471,524
med:pmid:38573461:sec:methods:sent:5,med:pmid:38573461,methods,5,One-year HF rehospitalization and mortality rates were calculated and a composite endpoint of both outcomes assessed using Kaplan-Meier estimation.,525,672
med:pmid:38573461:sec:methods:sent:6,med:pmid:38573461,methods,6,We evaluated HF medication patterns in the 6 months before and after the index date.,673,757
med:pmid:38573461:sec:methods:sent:7,med:pmid:38573461,methods,7,New users of a HF medication (at discharge/after index HFH) were followed for 1 year to evaluate persistence (no treatment gaps > 2 months) RESULTS: One-year HF rehospitalization rates were 36.2% (USA) and 47.7% (Germany).,758,980
med:pmid:38573461:sec:methods:sent:8,med:pmid:38573461,methods,8,"One year mortality rates were 30.0% (USA) and 23.0% (Germany), and the composite endpoint (mortality/HF rehospitalization) was reached in 55.1 % (USA) and 56.6% (Germany).",981,1152
med:pmid:38573461:sec:methods:sent:9,med:pmid:38573461,methods,9,Kaplan-Meier plots showed the risk for the composite endpoint was high in the early post discharge period.,1153,1259
med:pmid:38573461:sec:methods:sent:10,med:pmid:38573461,methods,10,"Comparison of patterns pre- and postindex HFH showed some increase in use of mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitor (ARNI), and triple therapy; use of angiotensin-converting enzyme (ACE) inhibitor/ angiotensin receptor blocker (ARB) plus beta-blockers remained constant/slightly declined; < 20% patients received triple therapy (ACE inhibitor/ARB plus beta-blocker plus MRA).",1260,1685
med:pmid:38573461:sec:methods:sent:11,med:pmid:38573461,methods,11,A third of patients were new users; 1 year persistence rates were often low.,1686,1762
med:pmid:38573461:sec:conclusion:sent:12,med:pmid:38573461,conclusion,12,"Morbidity, mortality, and rehospitalization risk is high among patients with worsening HF; uptake and continuation of GDMT is suboptimal.",1763,1921
med:pmid:39076544:sec:title:sent:0,med:pmid:39076544,title,0,An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease.,0,101
med:pmid:39076544:sec:abstract:sent:1,med:pmid:39076544,abstract,1,Chronic kidney disease (CKD) is common in patients with heart failure (HF) and is associated with high morbidity and mortality.,0,127
med:pmid:39076544:sec:abstract:sent:2,med:pmid:39076544,abstract,2,"There has been remarkable progress in the treatment of HF over recent years with the establishment of guideline-directed medical therapies including: (1) Beta-blockers, (2) renal angiotensin aldosterone system (RAAS) inhibition (i.e., angiotensin-converting enzyme inhibitor [ACEi], aldosterone receptor blocker [ARB] or angiotensin receptor-neprilysin inhibitor [ARNI]); (3) mineralocorticoid receptor antagonists (MRA), and (4) sodium-glucose cotransporter-2 inhibitors (SGLT2i).",128,609
med:pmid:39076544:sec:abstract:sent:3,med:pmid:39076544,abstract,3,"However, there are challenges to the implementation of these medications in patients with concomitant CKD due to increased vulnerability to common side-effects (including worsening renal function, hyperkalaemia, hypotension), and most of the pivotal trials which provide evidence of the efficacy of these medications excluded patients with severe CKD.",610,961
med:pmid:39076544:sec:abstract:sent:4,med:pmid:39076544,abstract,4,Patients with CKD and HF often have regular healthcare encounters with multiple professionals and can receive conflicting guidance regarding their medication.,962,1120
med:pmid:39076544:sec:abstract:sent:5,med:pmid:39076544,abstract,5,"Thus, despite being at higher risk of adverse cardiovascular events, patients who have both HF and CKD are more likely to be under-optimised on evidence-based therapies.",1121,1290
med:pmid:39076544:sec:abstract:sent:6,med:pmid:39076544,abstract,6,"This review is an updated summary of the evidence available for the management of HF (including reduced, mildly reduced and preserved left ventricular ejection fraction) in patients with various stages of CKD.",1291,1500
med:pmid:39076544:sec:abstract:sent:7,med:pmid:39076544,abstract,7,"The review covers the evidence for recommended medications, devices such as implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy (CRT), intravenous (IV) iron, and discusses how frailty affects the management of these patients.",1501,1754
med:pmid:39076544:sec:abstract:sent:8,med:pmid:39076544,abstract,8,It also considers emerging evidence for the prevention of HF in the cohort of patients with CKD.,1755,1851
med:pmid:39076544:sec:abstract:sent:9,med:pmid:39076544,abstract,9,"It synthesises the available evidence regarding when to temporarily stop, continue or rechallenge medications in this cohort.",1852,1977
med:pmid:39076544:sec:abstract:sent:10,med:pmid:39076544,abstract,10,"Chronic HF in context of CKD remains a challenging scenario for clinicians to manage, which is usually complicated by frailty, multimorbidity and polypharmacy.",1978,2137
med:pmid:39076544:sec:abstract:sent:11,med:pmid:39076544,abstract,11,Treatment should be tailored to a patients individual needs and management in specialised cardio-renal clinics with a multi-disciplinary team approach has been recommended.,2138,2310
med:pmid:39076544:sec:abstract:sent:12,med:pmid:39076544,abstract,12,This review offers a concise summary on this expansive topic.,2311,2372
med:pmid:38663899:sec:title:sent:0,med:pmid:38663899,title,0,Bilateral renal artery revascularisation in heart failure.,0,58
med:pmid:38663899:sec:abstract:sent:1,med:pmid:38663899,abstract,1,"Renal artery stenosis can complicate the management of heart failure with reduced ejection fraction, as it is a conventional contraindication to the use of ACE inhibitors.",0,171
med:pmid:38663899:sec:abstract:sent:2,med:pmid:38663899,abstract,2,We report a case in which bilateral renal artery revascularisation allowed the safe reintroduction of enalapril (and subsequently sacubitril valsartan) in a patient with severe left ventricular systolic dysfunction.,172,387
med:pmid:38663899:sec:abstract:sent:3,med:pmid:38663899,abstract,3,There is a role for renal artery angioplasty in selected patients to allow optimal medical therapy for patients with heart failure due to impaired systolic function.,388,553
med:pmid:38644253:sec:discussion:sent:0,med:pmid:38644253,discussion,0,of long-term prognosis and risk factors in patients with dilated cardiomyopathy].,0,91
med:pmid:38644253:sec:abstract:sent:1,med:pmid:38644253,abstract,1,<b>Objective:</b> To investigate the risk factors and long-term prognosis of major adverse cardiovascular events(MACEs) in patients with dilated cardiomyopathy (DCM).,0,166
med:pmid:38644253:sec:abstract:sent:2,med:pmid:38644253,abstract,2,<b>Methods:</b> This study was a single-center retrospective cohort study.,167,241
med:pmid:38644253:sec:abstract:sent:3,med:pmid:38644253,abstract,3,Clinical information from 300 patients with DCM hospitalized in Peking Union Medical College Hospital from April 2013 to April 2023 was collected.,242,388
med:pmid:38644253:sec:abstract:sent:4,med:pmid:38644253,abstract,4,"Based on echocardiography results, the patients were divided into two groups: isolated DCM and DCM with left ventricular non-compaction cardiomyopathy (LVNC).",389,547
med:pmid:38644253:sec:abstract:sent:5,med:pmid:38644253,abstract,5,"The MACEs, including major heart failure events, severe ventricular arrhythmias, and cardiovascular death, were recorded by outpatient or telephone follow-up.",548,706
med:pmid:38644253:sec:abstract:sent:6,med:pmid:38644253,abstract,6,Univariate and multivariate Cox proportional hazard regression models were used to analyze the risk factors affecting the prognosis of patients with DCM.,707,860
med:pmid:38644253:sec:abstract:sent:7,med:pmid:38644253,abstract,7,Kaplan-Meier curve and log-rank were used for survival analysis to compare the difference in the incidence of cardiovascular events between the two groups.,861,1016
med:pmid:38644253:sec:abstract:sent:8,med:pmid:38644253,abstract,8,"<b>Results:</b> The included 300 DCM patients were (47.8±16.8) years old, with 197 males (65.7%), of which 237 (79.0%) were isolated DCM and 63 (21.0%) were DCM with LVNC.",1017,1188
med:pmid:38644253:sec:abstract:sent:9,med:pmid:38644253,abstract,9,"The follow-up time was 4.0 (1.9, 6.2) years.",1189,1233
med:pmid:38644253:sec:abstract:sent:10,med:pmid:38644253,abstract,10,"A total of 142 (47.3%) MACEs occurred, including 117 (39.0%) major heart failure events, 20 (6.7%) severe ventricular arrhythmia events, and 53 (17.7%) cardiovascular death events.",1234,1414
med:pmid:38644253:sec:abstract:sent:11,med:pmid:38644253,abstract,11,"Multivariate Cox proportional hazard regression analysis showed that increased left ventricular end-diastolic diameter (<i>HR</i>=1.21, 95%<i>CI</i>: 1.01-1.44, <i>P</i>=0.042), moderate or severe mitral regurgitation (<i>HR</i>=1.71, 95%<i>CI</i>: 1.19-2.47, <i>P</i>=0.004), increased ln (N-terminal pro-B-type natriuretic peptide) (<i>HR</i>=1.30, 95%<i>CI</i>: 1.10-1.54, <i>P</i>=0.002) were independent risk factors for dverse cardiovascular events in DCM patients, and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI) treatment (<i>HR</i>=0.45, 95%<i>CI</i>: 0.26-0.78, <i>P</i>=0.004) was independent protective factor.",1415,2124
med:pmid:38644253:sec:abstract:sent:12,med:pmid:38644253,abstract,12,Kaplan-Meier survival analysis found no significant difference in the risk of MACEs between isolated DCM and DCM with LVNC (<i>P</i>=0.22).,2125,2264
med:pmid:38644253:sec:abstract:sent:13,med:pmid:38644253,abstract,13,"Similarly, there were no significant differences in the incidence of major heart failure, severe ventricular arrhythmia, and cardiovascular death between the two groups (all <i>P</i>>0.05).",2265,2454
med:pmid:38644253:sec:abstract:sent:14,med:pmid:38644253,abstract,14,"<b>Conclusion:</b> An increase in left ventricular end-diastolic diameter, moderate or severe mitral regurgitation, elevated N-terminal pro-B-type natriuretic peptide, and non use of ACEI/ARB/ARNI are independent predictors of cardiovascular events in DCM patients.",2455,2720
med:pmid:38644253:sec:abstract:sent:15,med:pmid:38644253,abstract,15,"There was no significant risk of MACEs in patients with isolated DCM and DCM with LVNC, and suggested that LVNC may be a unique phenotype and should be accurately managed in combination with genetic background.",2721,2931
med:pmid:38279516:sec:title:sent:0,med:pmid:38279516,title,0,Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF.,0,141
med:pmid:38279516:sec:introduction:sent:1,med:pmid:38279516,introduction,1,Recent updates of international treatment guidelines for heart failure with reduced ejection fraction (HFrEF) differ regarding the use of angiotensin receptor neprilysin inhibitor (ARNI) as first-line treatment.,0,225
med:pmid:38279516:sec:introduction:sent:2,med:pmid:38279516,introduction,2,The American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) 2022 guidelines gives ARNI a Class IA recommendation for HFrEF patients while the European Society of Cardiology's guidelines are less clear when ARNI could be considered as first line treatment option in de novo patients.,226,558
med:pmid:38279516:sec:introduction:sent:3,med:pmid:38279516,introduction,3,"This study aimed to model the clinical and budgetary outcomes of implementing these guidelines, comparing conservative ARNI prescription patterns with less conservative in Sweden and in the United Kingdom.",559,764
med:pmid:38279516:sec:results:sent:4,med:pmid:38279516,results,4,A health economic model was developed to compare different treatment patterns for HFrEF.,765,882
med:pmid:38279516:sec:results:sent:5,med:pmid:38279516,results,5,Incident cohorts were included on an annual basis and followed over 10 years.,883,960
med:pmid:38279516:sec:results:sent:6,med:pmid:38279516,results,6,"The model included treatment specific all-cause mortality and hospitalization rates, as well as drug acquisition, monitoring, and hospitalization costs.",961,1113
med:pmid:38279516:sec:results:sent:7,med:pmid:38279516,results,7,Increasing the use of ARNI could lead to about 7000-12 300 life years gained and 2600-4600 hospitalizations prevented in Sweden.,1114,1242
med:pmid:38279516:sec:results:sent:8,med:pmid:38279516,results,8,These health benefits come with an additional cost of 112-195 million euros.,1243,1319
med:pmid:38279516:sec:results:sent:9,med:pmid:38279516,results,9,"Similar results were estimated for the United Kingdom, albeit on a larger population.",1320,1405
med:pmid:38279516:sec:conclusion:sent:10,med:pmid:38279516,conclusion,10,Increasing the proportion of patients receiving ARNI instead of angiotensin converting enzyme inhibitors as first-line treatment of HFrEF will lead to a considerable number of additional life years gained and prevented hospitalizations but with additional cost in terms of health care expenditure in Sweden and in the United Kingdom.,1406,1760
med:pmid:37917889:sec:title:sent:0,med:pmid:37917889,title,0,Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.,0,138
med:pmid:37917889:sec:introduction:sent:1,med:pmid:37917889,introduction,1,Heart failure with preserved ejection fraction (HFpEF) is a prevalent and clinically significant condition characterized by limited treatment options.,0,169
med:pmid:37917889:sec:introduction:sent:2,med:pmid:37917889,introduction,2,"In this context, the objective of this meta-analysis is to evaluate the effectiveness of sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in managing HFpEF.",170,400
med:pmid:37917889:sec:methods:sent:3,med:pmid:37917889,methods,3,"A systematic search of relevant studies was conducted in PubMed, Embase, Web of Science, and Cochrane Library.",401,528
med:pmid:37917889:sec:methods:sent:4,med:pmid:37917889,methods,4,Randomized controlled trials comparing sacubitril/valsartan to ACEIs or ARBs in HFpEF patients were included.,529,638
med:pmid:37917889:sec:methods:sent:5,med:pmid:37917889,methods,5,"Inclusion criteria: LVEF>45%, NYHA II-IV, Sac/Val vs ACEI/ARB, RCTs, treatment duration >3 months, sample size ≥25 per group.",639,764
med:pmid:37917889:sec:methods:sent:6,med:pmid:37917889,methods,6,"Exclusion criteria: Animal studies, unclear/missing data, poor quality, case studies/expert opinions.",765,866
med:pmid:37917889:sec:methods:sent:7,med:pmid:37917889,methods,7,"Hospitalization for heart failure and cardiovascular mortality were the primary outcomes, while the additional results included mortality from all causes, improvement of NYHA class, modifications in NT-proBNP, and with LVEF.",866,1090
med:pmid:37917889:sec:results:sent:8,med:pmid:37917889,results,8,"Sacubitril/valsartan substantially reduced heart failure hospitalization rates compared to ACEIs and ARBs, according to a total of six studies involving 5,201 participants (Relative Risk, 0.78; 95% CI, 0.65 to 0.85; P = .001).",1091,1334
med:pmid:37917889:sec:results:sent:9,med:pmid:37917889,results,9,"Nonetheless, there were no significant improvements in mortality due to cardiovascular disease (Relative Risk, 0.94; 95% CI, 0.79-1.12; P = .563).",1335,1481
med:pmid:37917889:sec:results:sent:10,med:pmid:37917889,results,10,"Sacubitril/valsartan did not affect total mortality from all causes significantly (Relative Risk, 0.95; 95% CI, 0.84-1.09; P = .453), but it did enhance NYHA classification (Relative Risk, 1.25; 95% CI, 1.10-1.43; P = .001).",1482,1706
med:pmid:37917889:sec:results:sent:11,med:pmid:37917889,results,11,"NT-proBNP levels decreased substantially (Weighted Mean Difference, -266.67; 95% CI, -525.86 to -7.47), whereas there had been little major shift in LVEF (Weighted Mean Difference, 1.49; 95% CI, -1.33 to 4.21; P = .342).",1707,1927
med:pmid:37917889:sec:conclusion:sent:12,med:pmid:37917889,conclusion,12,"Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs.",1928,2151
med:pmid:37917889:sec:conclusion:sent:13,med:pmid:37917889,conclusion,13,Sacubitril/valsartan might be considered as a preferred treatment option for HFpEF patients due to its benefits in reducing heart failure hospitalization rates and improving symptom severity.,2152,2343
med:pmid:38555468:sec:title:sent:0,med:pmid:38555468,title,0,Development and validation of a prognostic model for predicting post-discharge mortality risk in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).,0,223
med:pmid:38555468:sec:introduction:sent:1,med:pmid:38555468,introduction,1,Accurately predicting post-discharge mortality risk in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) remains a complex and critical challenge.,0,242
med:pmid:38555468:sec:introduction:sent:2,med:pmid:38555468,introduction,2,The primary objective of this study was to develop and validate a robust risk prediction model to assess the 12-month and 24-month mortality risk in STEMI patients after hospital discharge.,243,432
med:pmid:38555468:sec:methods:sent:3,med:pmid:38555468,methods,3,A retrospective study was conducted on 664 STEMI patients who underwent PPCI at Xiangtan Central Hospital Chest Pain Center between 2020 and 2022.,433,596
med:pmid:38555468:sec:methods:sent:4,med:pmid:38555468,methods,4,The dataset was randomly divided into a training cohort (n = 464) and a validation cohort (n = 200) using a 7:3 ratio.,597,715
med:pmid:38555468:sec:methods:sent:5,med:pmid:38555468,methods,5,The primary outcome was all-cause mortality following hospital discharge.,716,789
med:pmid:38555468:sec:methods:sent:6,med:pmid:38555468,methods,6,The least absolute shrinkage and selection operator (LASSO) regression model was employed to identify the optimal predictive variables.,790,925
med:pmid:38555468:sec:methods:sent:7,med:pmid:38555468,methods,7,"Based on these variables, a regression model was constructed to determine the significant predictors of mortality.",926,1040
med:pmid:38555468:sec:methods:sent:8,med:pmid:38555468,methods,8,The performance of the model was evaluated using receiver operating characteristic (ROC) curve analysis and decision curve analysis (DCA).,1041,1179
med:pmid:38555468:sec:results:sent:9,med:pmid:38555468,results,9,The prognostic model was developed based on the LASSO regression results and further validated using the independent validation cohort.,1180,1332
med:pmid:38555468:sec:results:sent:10,med:pmid:38555468,results,10,"LASSO regression identified five important predictors: age, Killip classification, B-type natriuretic peptide precursor (NTpro-BNP), left ventricular ejection fraction (LVEF), and the usage of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ACEI/ARB/ARNI).",1333,1656
med:pmid:38555468:sec:results:sent:11,med:pmid:38555468,results,11,"The Harrell's concordance index (C-index) for the training and validation cohorts were 0.863 (95% CI: 0.792-0.934) and 0.888 (95% CI: 0.821-0.955), respectively.",1657,1818
med:pmid:38555468:sec:results:sent:12,med:pmid:38555468,results,12,"The area under the curve (AUC) for the training cohort at 12 months and 24 months was 0.785 (95% CI: 0.771-0.948) and 0.812 (95% CI: 0.772-0.940), respectively, while the corresponding values for the validation cohort were 0.864 (95% CI: 0.604-0.965) and 0.845 (95% CI: 0.705-0.951).",1819,2102
med:pmid:38555468:sec:results:sent:13,med:pmid:38555468,results,13,"These results confirm the stability and predictive accuracy of our model, demonstrating its reliable discriminative ability for post-discharge all-cause mortality risk.",2103,2271
med:pmid:38555468:sec:results:sent:14,med:pmid:38555468,results,14,DCA analysis exhibited favorable net benefit of the nomogram.,2272,2333
med:pmid:38555468:sec:conclusion:sent:15,med:pmid:38555468,conclusion,15,The developed nomogram shows potential as a tool for predicting post-discharge mortality in STEMI patients undergoing PPCI.,2334,2477
med:pmid:38555468:sec:conclusion:sent:16,med:pmid:38555468,conclusion,16,"However, its full utility awaits confirmation through broader external and temporal validation.",2478,2573
med:pmid:38508844:sec:title:sent:0,med:pmid:38508844,title,0,Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.,0,79
med:pmid:38508844:sec:introduction:sent:1,med:pmid:38508844,introduction,1,The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been described.,0,203
med:pmid:38508844:sec:introduction:sent:2,med:pmid:38508844,introduction,2,Data from randomized trials of sacubitril/valsartan in HF patients with EF ≤40% (PIONEER-HF [Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode] trial) and >40% (PARAGLIDE-HF [Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF] trial) following recent worsening heart failure (WHF) were pooled to examine treatment effect across the EF spectrum.,204,694
med:pmid:38508844:sec:methods:sent:3,med:pmid:38508844,methods,3,"The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively).",695,870
med:pmid:38508844:sec:methods:sent:4,med:pmid:38508844,methods,4,All participants in the PIONEER-HF trial and 69.5% in the PARAGLIDE-HF trial were enrolled during hospitalization for HF after stabilization.,871,1012
med:pmid:38508844:sec:methods:sent:5,med:pmid:38508844,methods,5,The remainder in the PARAGLIDE-HF trial were enrolled ≤30 days after a WHF event.,1013,1094
med:pmid:38508844:sec:methods:sent:6,med:pmid:38508844,methods,6,The primary endpoint of both trials was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8.,1095,1262
med:pmid:38508844:sec:methods:sent:7,med:pmid:38508844,methods,7,"Adjudicated clinical endpoints were analyzed through the end of follow-up, adjusting for trial.",1263,1358
med:pmid:38508844:sec:results:sent:8,med:pmid:38508844,results,8,"The pooled analysis included 1,347 patients (881 from PIONEER-HF, 466 from PARAGLIDE-HF).",1359,1465
med:pmid:38508844:sec:results:sent:9,med:pmid:38508844,results,9,"Baseline characteristics included median age 66 years, 36% women, 31% Black, 34% de novo HF, and median EF 30%.",1466,1577
med:pmid:38508844:sec:results:sent:10,med:pmid:38508844,results,10,"The reduction in NT-proBNP was 24% greater with sacubitril/valsartan vs control therapy (n = 1,130; ratio of change = 0.76; 95% CI: 0.69-0.83; P < 0.0001).",1578,1733
med:pmid:38508844:sec:results:sent:11,med:pmid:38508844,results,11,Cardiovascular death or hospitalization for HF was reduced by 30% with sacubitril/valsartan vs control therapy (HR: 0.70; 95% CI: 0.54-0.91; P = 0.0077).,1734,1887
med:pmid:38508844:sec:results:sent:12,med:pmid:38508844,results,12,This effect was consistent across the spectrum of EF ≤60%.,1888,1946
med:pmid:38508844:sec:results:sent:13,med:pmid:38508844,results,13,Sacubitril/valsartan increased symptomatic hypotension (risk ratio: 1.35; 95% CI: 1.05-1.72).,1947,2040
med:pmid:38508844:sec:conclusion:sent:14,med:pmid:38508844,conclusion,14,"In patients stabilized after WHF, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP and improved clinical outcome compared with control therapy, in particular across the spectrum of EF ≤60%. (",2041,2272
med:pmid:38508844:sec:conclusion:sent:15,med:pmid:38508844,conclusion,15,"Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890; Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event [HFpEF Decompensation] Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation [PARAGLIDE-HF]; NCT03988634).",2272,2659
med:pmid:38418004:sec:title:sent:0,med:pmid:38418004,title,0,Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.,0,76
med:pmid:38418004:sec:introduction:sent:1,med:pmid:38418004,introduction,1,"Patients who sustain an acute myocardial infarction (AMI), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), remain at high risk for heart failure (HF), coronary events, and death.",0,272
med:pmid:38418004:sec:introduction:sent:2,med:pmid:38418004,introduction,2,Angiotensin-converting enzyme inhibitors have been shown to significantly decrease the risk for cardiovascular events in both STEMI and NSTEMI patients.,273,425
med:pmid:38418004:sec:introduction:sent:3,med:pmid:38418004,introduction,3,"The objectives were to determine whether angiotensin-receptor blockade and neprilysin inhibition with sacubitril/valsartan, compared with ramipril, has impact on reducing cardiovascular events according to the type of AMI.",426,668
med:pmid:38418004:sec:methods:sent:4,med:pmid:38418004,methods,4,The PARADISE-MI (Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction) trial enrolled patients with AMI complicated by left ventricular dysfunction and/or pulmonary congestion and at least 1 risk-enhancing factor.,669,976
med:pmid:38418004:sec:methods:sent:5,med:pmid:38418004,methods,5,Patients were randomized to either sacubitril/valsartan or ramipril.,977,1045
med:pmid:38418004:sec:methods:sent:6,med:pmid:38418004,methods,6,The primary endpoint was death from cardiovascular causes or incident HF.,1046,1119
med:pmid:38418004:sec:methods:sent:7,med:pmid:38418004,methods,7,"In this prespecified analysis, we stratified patients according to AMI type.",1120,1196
med:pmid:38418004:sec:results:sent:8,med:pmid:38418004,results,8,"Of 5,661 enrolled patients, 4,291 (75.8%) had STEMI.",1197,1266
med:pmid:38418004:sec:results:sent:9,med:pmid:38418004,results,9,These patients were younger and had fewer comorbidities and cardiovascular risk factors than NSTEMI patients.,1267,1376
med:pmid:38418004:sec:results:sent:10,med:pmid:38418004,results,10,"After adjustment for potential confounders, the risk for the primary outcome was marginally higher in NSTEMI vs STEMI patients (adjusted HR: 1.19; 95% CI: 1.00-1.41), with borderline statistical significance (P = 0.05).",1377,1596
med:pmid:38418004:sec:results:sent:11,med:pmid:38418004,results,11,The primary composite outcome occurred at similar rates in patients randomized to sacubitril/valsartan vs ramipril in STEMI (10% vs 12%; HR: 0.87; 95% CI: 0.73-1.04; P = 0.13) and NSTEMI patients (17% vs 17%; HR: 0.97; 95% CI: 0.75-1.25; P = 0.80; P interaction = 0.53).,1597,1867
med:pmid:38418004:sec:conclusion:sent:12,med:pmid:38418004,conclusion,12,"Compared with ramipril, sacubitril/valsartan did not significantly decrease the risk for cardiovascular death and HF in patients with AMI complicated by left ventricular dysfunction, irrespective of the type of AMI. (",1868,2106
med:pmid:38418004:sec:conclusion:sent:13,med:pmid:38418004,conclusion,13,Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI; NCT02924727).,2106,2227
med:pmid:38516430:sec:title:sent:0,med:pmid:38516430,title,0,Efficacy of Angiotensin Receptor-Neprilysin Inhibitor and Its Renal Outcome in Heart Failure Patients: A Systematic Review of Randomized Clinical Trials.,0,153
med:pmid:38516430:sec:abstract:sent:1,med:pmid:38516430,abstract,1,Heart failure (HF) is a major cause of morbidity and mortality and imposes a significant financial burden on healthcare systems globally.,0,137
med:pmid:38516430:sec:abstract:sent:2,med:pmid:38516430,abstract,2,"Angiotensin receptor-neprilysin inhibitor (ARNI), a novel neuroendocrine inhibitor, is frequently used in treating HF.",138,256
med:pmid:38516430:sec:abstract:sent:3,med:pmid:38516430,abstract,3,"However, there is still limited understanding regarding how it compares to other neuroendocrine inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs).",257,463
med:pmid:38516430:sec:abstract:sent:4,med:pmid:38516430,abstract,4,The purpose of this research is to present the most recent data regarding the efficacy and renal impact of ARNIs in the treatment of HF in comparison to ACE inhibitors and ARBs.,464,641
med:pmid:38516430:sec:abstract:sent:5,med:pmid:38516430,abstract,5,"Several large-scale randomized controlled trials (RCTs) have recently been conducted to evaluate the benefits of this drug in patients with different types of HF, regardless of their renal status.",642,838
med:pmid:38516430:sec:abstract:sent:6,med:pmid:38516430,abstract,6,"We searched multiple databases, including PubMed, PubMed Central (PMC), and Google Scholar, to find relevant RCTs.",839,953
med:pmid:38516430:sec:abstract:sent:7,med:pmid:38516430,abstract,7,"The efficacy outcome was a composite of the rate of death from cardiovascular causes, the frequency of HF hospitalizations (HFH), and alterations in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.",954,1163
med:pmid:38516430:sec:abstract:sent:8,med:pmid:38516430,abstract,8,The renal outcome was impairment of renal function.,1164,1215
med:pmid:38516430:sec:abstract:sent:9,med:pmid:38516430,abstract,9,"This systematic review analyzed large-scale RCTs involving 17,327 participants, with an average follow-up time of approximately 2.9 years.",1216,1354
med:pmid:38516430:sec:abstract:sent:10,med:pmid:38516430,abstract,10,"sacubitril/valsartan showed notable improvements compared to ACEis and ARBs in the following areas: reduction in NT-proBNP levels, prevention of further deterioration in renal function, and decreased hospitalizations for HF.",1355,1579
med:pmid:38516430:sec:abstract:sent:11,med:pmid:38516430,abstract,11,"Interestingly, there is no increased risk of mortality from cardiovascular causes with sacubitril or valsartan.",1580,1691
med:pmid:38465175:sec:title:sent:0,med:pmid:38465175,title,0,The Safety and Efficacy of the Early Use of Sacubitril/Valsartan After Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.,0,148
med:pmid:38465175:sec:abstract:sent:1,med:pmid:38465175,abstract,1,"Acute myocardial infarction (AMI) is a significant global cause of mortality, necessitating the exploration of innovative treatments against the condition.",0,155
med:pmid:38465175:sec:abstract:sent:2,med:pmid:38465175,abstract,2,"Angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor-neprilysin inhibitors (ARNIs) such as sacubitril/valsartan have demonstrated promise in managing acute heart failure (HF).",156,391
med:pmid:38465175:sec:abstract:sent:3,med:pmid:38465175,abstract,3,"However, despite favorable evidence from clinical trials for the use of sacubitril/valsartan in AMI, its overall efficacy remains a subject of debate.",392,542
med:pmid:38465175:sec:abstract:sent:4,med:pmid:38465175,abstract,4,"Hence, we conducted this review and meta-analysis, by adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and aligned with European Society of Cardiology recommendations, to compare sacubitril/valsartan with traditional ACEI/ARB treatments for AMI.",543,842
med:pmid:38465175:sec:abstract:sent:5,med:pmid:38465175,abstract,5,"We employed Review Manager 5.4 for statistical analysis, the Risk of Bias Tool 2.0 was utilized for quality assessment, and publication bias was assessed using a funnel plot.",843,1017
med:pmid:38465175:sec:abstract:sent:6,med:pmid:38465175,abstract,6,A p-value <0.05 was considered statistically significant.,1018,1075
med:pmid:38465175:sec:abstract:sent:7,med:pmid:38465175,abstract,7,Eight randomized controlled trials (RCTs) were included in this meta-analysis.,1076,1154
med:pmid:38465175:sec:abstract:sent:8,med:pmid:38465175,abstract,8,"Our findings revealed that participants treated with sacubitril experienced significantly improved outcomes in terms of HF (OR=0.79; 95% CI: 0.66-0.95; p=0.01; I<sup>2</sup>=23%), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (MD = -1.58; 95% CI: -1.78 to -1.37, p<0.00001; I<sup>2</sup>=97%), and major adverse cardiovascular events (MACE) (OR=0.84; 95% CI: 0.72-0.99; p=0.03; I<sup>2</sup>=44%).",1155,1567
med:pmid:38465175:sec:abstract:sent:9,med:pmid:38465175,abstract,9,"However, left ventricular ejection fraction (LVEF) (MD=3.68; 95% CI: 3.35-4.01, p<0.00001; I<sup>2</sup>=71%) showed greater improvement in the control group compared to the experimental group.",1568,1761
med:pmid:38465175:sec:abstract:sent:10,med:pmid:38465175,abstract,10,Our meta-analysis suggests that sacubitril offers a favorable balance between safety and effectiveness.,1762,1865
med:pmid:38465175:sec:abstract:sent:11,med:pmid:38465175,abstract,11,"Sacubitril significantly improved outcomes in terms of HF, MACE, and NT-proBNP levels when compared to the control group.",1866,1987
med:pmid:38465175:sec:abstract:sent:12,med:pmid:38465175,abstract,12,"However, improvement in LVEF was notably higher in the control group over the sacubitril/valsartan group.",1988,2093
med:pmid:38402552:sec:title:sent:0,med:pmid:38402552,title,0,The effect of kidney function on guideline-directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction.,0,145
med:pmid:38402552:sec:introduction:sent:1,med:pmid:38402552,introduction,1,Kidney dysfunction (KD) is a main limiting factor of applying guideline-directed medical therapy (GDMT) and reaching the recommended target doses (TD) in heart failure (HF) with reduced ejection fraction (HFrEF).,0,232
med:pmid:38402552:sec:introduction:sent:2,med:pmid:38402552,introduction,2,"<h4>Hypothesis</h4> We aimed to assess the success of optimization, long-term applicability, and adherence of neurohormonal antagonist triple therapy (TT:RASi [ACEi/ARB/ARNI] + βB + MRA) according to the KD after a HF hospitalization and to investigate its impact on prognosis.",233,510
med:pmid:38402552:sec:methods:sent:3,med:pmid:38402552,methods,3,"The data of 247 real-world, consecutive patients were analyzed who were hospitalized in 2019-2021 for HFrEF and then were followed-up for 1 year.",511,673
med:pmid:38402552:sec:methods:sent:4,med:pmid:38402552,methods,4,"The application and the ratio of reached TD of TT at hospital discharge and at 1 year were assessed comparing KD categories (eGFR: ≥90, 60-89, 45-59, 30-44, <30 mL/min/1.73 m<sup>2</sup> ).",674,863
med:pmid:38402552:sec:methods:sent:5,med:pmid:38402552,methods,5,"Moreover, 1-year all-cause mortality and rehospitalization rates in KD subgroups were investigated.",864,963
med:pmid:38402552:sec:results:sent:6,med:pmid:38402552,results,6,Majority of the patients received TT at hospital discharge (77%) and at 1 year (73%).,964,1066
med:pmid:38402552:sec:results:sent:7,med:pmid:38402552,results,7,"More severe KD led to a lower application ratio (p < .05) of TT (92%, 88%, 80%, 73%, 31%) at discharge and at 1 year (81%, 76%, 76%, 68%, 40%).",1067,1210
med:pmid:38402552:sec:results:sent:8,med:pmid:38402552,results,8,"Patients with more severe KD were less likely (p < .05) to receive TD of MRA (81%, 68%, 78%, 61%, 52%) at discharge and a RASi (53%, 49%, 45%, 21%, 27%) at 1 year.",1211,1374
med:pmid:38402552:sec:results:sent:9,med:pmid:38402552,results,9,"One-year all-cause mortality (14%, 15%, 16%, 33%, 48%, p < .001), the ratio of all-cause rehospitalizations (30%, 35%, 40%, 43%, 52%, p = .028), and rehospitalizations for HF (8%, 13%, 18%, 20%, 38%, p = .001) were significantly higher in more severe KD categories.",1375,1640
med:pmid:38402552:sec:conclusion:sent:10,med:pmid:38402552,conclusion,10,"KD unfavorably affects the application of TT in HFrEF, however poorer mortality and rehospitalization rates among them highlight the role of the conscious implementation and up-titration of GDMT.",1641,1857
med:pmid:38032698:sec:title:sent:0,med:pmid:38032698,title,0,American Registry of Ambulatory or acutely decompensated heart failure (AMERICCAASS Registry): First 1000 patients.,0,115
med:pmid:38032698:sec:introduction:sent:1,med:pmid:38032698,introduction,1,About 80% of cardiovascular diseases (including heart failure [HF]) occur in low-income and developing countries.,0,133
med:pmid:38032698:sec:introduction:sent:2,med:pmid:38032698,introduction,2,"However, most clinical trials are conducted in developed countries.",134,201
med:pmid:38032698:sec:introduction:sent:3,med:pmid:38032698,introduction,3,"<h4>Hypothesis</h4> The American Registry of Ambulatory or Acutely Decompensated Heart Failure (AMERICCAASS) aims to describe the sociodemographic characteristics of HF, comorbidities, clinical presentation, and pharmacological management of patients with ambulatory or acutely decompensated HF in America.",202,508
med:pmid:38032698:sec:methods:sent:4,med:pmid:38032698,methods,4,"Descriptive, observational, prospective, and multicenter registry, which includes patients >18 years with HF in an outpatient or hospital setting.",509,676
med:pmid:38032698:sec:methods:sent:5,med:pmid:38032698,methods,5,Collected information is stored in the REDCap electronic platform.,677,743
med:pmid:38032698:sec:methods:sent:6,med:pmid:38032698,methods,6,Quantitative variables are defined according to the normality of the variable using the Shapiro-Wilk test.,744,850
med:pmid:38032698:sec:results:sent:7,med:pmid:38032698,results,7,This analysis includes data from the first 1000 patients recruited.,851,935
med:pmid:38032698:sec:results:sent:8,med:pmid:38032698,results,8,"63.5% were men, the median age of 66 years (interquartile range 56.7-75.4), and 77.6% of the patients were older than 55 years old.",936,1067
med:pmid:38032698:sec:results:sent:9,med:pmid:38032698,results,9,"The percentage of use of the four pharmacological pillars at the time of recruitment was 70.7% for beta-blockers (BB), 77.4% for angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB II)/angiotensin receptor-neprilysin inhibitor (ARNI), 56.8% for mineralocorticoid receptor antagonists (MRA), and 30.7% for sodium-glucose cotransporter type-2 inhibitors (SGLT2i).",1068,1461
med:pmid:38032698:sec:results:sent:10,med:pmid:38032698,results,10,"The main cause of decompensation in hospitalized patients was HF progression (64.4%), and the predominant hemodynamic profile was wet-warm (68.3%).",1462,1609
med:pmid:38032698:sec:conclusion:sent:11,med:pmid:38032698,conclusion,11,AMERICCAASS is the first continental registry to include hospitalized or outpatient patients with HF.,1610,1732
med:pmid:38032698:sec:conclusion:sent:12,med:pmid:38032698,conclusion,12,"Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two-thirds do not receive SGLT2i.",1733,1934
med:pmid:37933210:sec:title:sent:0,med:pmid:37933210,title,0,Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.,0,129
med:pmid:37933210:sec:introduction:sent:1,med:pmid:37933210,introduction,1,Persistent symptoms despite guideline-directed medical therapy (GDMT) and poor tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced ejection fraction (HFrEF).,0,208
med:pmid:37933210:sec:introduction:sent:2,med:pmid:37933210,introduction,2,"However, real-world data on GDMT use, dose, and prognostic implications are lacking.",209,293
med:pmid:37933210:sec:results:sent:3,med:pmid:37933210,results,3,We included 699 consecutive patients with HFrEF and at least one 'I NEED HELP' marker for advanced HF enrolled in a multicentre registry.,294,460
med:pmid:37933210:sec:results:sent:4,med:pmid:37933210,results,4,"Beta-blockers (BB) were administered to 574 (82%) patients, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or angiotensin receptor-neprilysin inhibitors (ACEi/ARB/ARNI) were administered to 381 (55%) patients and 416 (60%) received mineralocorticoid receptor antagonists (MRA).",461,763
med:pmid:37933210:sec:results:sent:5,med:pmid:37933210,results,5,"Overall, ≥50% of target doses were reached in 41%, 22%, and 56% of the patients on BB, ACEi/ARB/ARNI and MRA, respectively.",764,887
med:pmid:37933210:sec:results:sent:6,med:pmid:37933210,results,6,"Hypotension, bradycardia, kidney dysfunction and hyperkalaemia were the main causes of underprescription and/or underdosing, but up to a half of the patients did not receive target doses for unknown causes (51%, 41%, and 55% for BB, ACEi/ARB/ARNI and MRA, respectively).",888,1158
med:pmid:37933210:sec:results:sent:7,med:pmid:37933210,results,7,The proportions of patients receiving BB and ACEi/ARB/ARNI were lower among those fulfilling the 2018 HFA-ESC criteria for advanced HF.,1159,1294
med:pmid:37933210:sec:results:sent:8,med:pmid:37933210,results,8,"Treatment with BB and ACEi/ARB/ARNI were associated with a lower risk of death or HF hospitalizations (adjusted hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.48-0.84, and HR 0.74, 95% CI 0.58-0.95, respectively).",1295,1516
med:pmid:37933210:sec:conclusion:sent:9,med:pmid:37933210,conclusion,9,"In a large, real-world, contemporary cohort of patients with severe HFrEF, with at least one marker for advanced HF, prescription and uptitration of GDMT remained limited.",1517,1709
med:pmid:37933210:sec:conclusion:sent:10,med:pmid:37933210,conclusion,10,A significant proportion of patients were undertreated due to unknown reasons suggesting a potential role of clinical inertia either by the prescribing healthcare professional or by the patient.,1710,1904
med:pmid:37933210:sec:conclusion:sent:11,med:pmid:37933210,conclusion,11,Treatment with BB and ACEi/ARB/ARNI was associated with lower mortality/morbidity.,1905,1987
med:pmid:37757995:sec:title:sent:0,med:pmid:37757995,title,0,"Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry.",0,165
med:pmid:37757995:sec:introduction:sent:1,med:pmid:37757995,introduction,1,Patients hospitalized with heart failure (HF) and diabetes mellitus (DM) are at risk for worsening clinical status.,0,135
med:pmid:37757995:sec:introduction:sent:2,med:pmid:37757995,introduction,2,Little is known about the frequency of therapeutic changes during hospitalization.,136,218
med:pmid:37757995:sec:introduction:sent:3,med:pmid:37757995,introduction,3,"We characterized the use of medical therapies before, during and after hospitalization in patients with HF and DM.",219,333
med:pmid:37757995:sec:methods:sent:4,med:pmid:37757995,methods,4,We identified Medicare beneficiaries in Get With The Guidelines-Heart Failure (GWTG-HF) hospitalized between July 2014 and September 2019 with Part D prescription coverage.,334,523
med:pmid:37757995:sec:methods:sent:5,med:pmid:37757995,methods,5,"We evaluated trends in the use of 7 classes of antihyperglycemic therapies (metformin, sulfonylureas, GLP-1RA, SGLT2-inhibitors, DPP-4 inhibitors, thiazolidinediones, and insulins) and 4 classes of HF therapies (evidence-based β-blockers, ACEi or ARB, MRA, and ARNI).",524,791
med:pmid:37757995:sec:methods:sent:6,med:pmid:37757995,methods,6,"Medication fills were assessed at 6 and 3 months before hospitalization, at hospital discharge and at 3 months post-discharge.",792,918
med:pmid:37757995:sec:results:sent:7,med:pmid:37757995,results,7,"Among 35,165 Medicare beneficiaries, the median age was 77 years, 54% were women, and 76% were white; 11,660 (33%) had HFrEF (LVEF ≤ 40%), 3700 (11%) had HFmrEF (LVEF 41%-49%), and 19,805 (56%) had HFpEF (LVEF ≥ 50%).",919,1153
med:pmid:37757995:sec:results:sent:8,med:pmid:37757995,results,8,"Overall, insulin was the most commonly prescribed antihyperglycemic after HF hospitalization (n = 12,919, 37%), followed by metformin (n = 7460, 21%) and sulfonylureas (n = 7030, 20%).",1154,1338
med:pmid:37757995:sec:results:sent:9,med:pmid:37757995,results,9,"GLP-1RA (n = 700, 2.0%) and SGLT2i (n = 287, 1.0%) use was low and did not improve over time.",1339,1432
med:pmid:37757995:sec:results:sent:10,med:pmid:37757995,results,10,"In patients with HFrEF, evidence-based beta-blocker, RASi, MRA, and ARNI fills during the 6 months preceding HF hospitalization were 63%, 62%, 19%, and 4%, respectively.",1433,1602
med:pmid:37757995:sec:results:sent:11,med:pmid:37757995,results,11,"Fills initially declined prior to hospitalization, but then rose from 3 months before hospitalization to discharge (beta-blocker: 56%-82%; RASi: 51%-57%, MRA: 15%-28%, ARNI: 3%-6%, triple therapy: 8%-20%; P < 0.01 for all).",1603,1826
med:pmid:37757995:sec:results:sent:12,med:pmid:37757995,results,12,Prescription rates 3 months after hospitalization were similar to those at hospital discharge.,1827,1921
med:pmid:37757995:sec:conclusion:sent:13,med:pmid:37757995,conclusion,13,In-hospital optimization of medical therapy in patients with HF and DM is common in participating hospitals of a large US quality improvement registry.,1922,2094
med:pmid:39544776:sec:title:sent:0,med:pmid:39544776,title,0,Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan.,0,116
med:pmid:39544776:sec:introduction:sent:1,med:pmid:39544776,introduction,1,To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI).,0,178
med:pmid:39544776:sec:methods:sent:2,med:pmid:39544776,methods,2,"From January 2018 to December 2021, 63 hospitalized patients diagnosed with HF following acute myocardial infarction (AMI) were enrolled in this prospective clinical trial.",179,368
med:pmid:39544776:sec:methods:sent:3,med:pmid:39544776,methods,3,"The observation group was comprised of 31 patients treated with sacubitril/valsartan (LCZ696) sodium tablets, while the control group, including 32 patients, received enalapril maleate tablets.",369,562
med:pmid:39544776:sec:methods:sent:4,med:pmid:39544776,methods,4,"All patients received standard HF therapy, including water-soluble aspirin, hydroclopidogrel sulfate, once-daily bivalirudin calcium, twice-daily metoprolol tartrate (dose titrated based on heart rate), once-daily spironolactone (dose adjusted for electrolytes), and once-daily dehydroimidazole (dose adjusted for electrolytes).",563,891
med:pmid:39544776:sec:methods:sent:5,med:pmid:39544776,methods,5,"HF symptom control, N-terminal B-type natriuretic peptide precursor (NT-proBNP) levels, cardiac anatomical parameters, heart rate, blood pressure, and 6-minute walking distance over a 90-day follow-up were assessed.",892,1107
med:pmid:39544776:sec:methods:sent:6,med:pmid:39544776,methods,6,The study is registered under ClinicalTrials.gov [ChiCTR2100042944].,1108,1176
med:pmid:39544776:sec:results:sent:7,med:pmid:39544776,results,7,"On the 30th day post-discharge, the observation group exhibited a marked decrease in NT-proBNP levels and an improvement in left ventricular end-diastolic diameter, in contrast to the control group (both P<0.05).",1177,1406
med:pmid:39544776:sec:results:sent:8,med:pmid:39544776,results,8,"By the 90th day, the observation group showed significant improvements in left ventricular ejection fraction and left ventricular end-systolic diameter index, along with reduced blood pressure and serum creatinine levels (all P<0.05).",1407,1641
med:pmid:39544776:sec:results:sent:9,med:pmid:39544776,results,9,"Furthermore, the observation group displayed a more favorable New York Heart Association class distribution and enhanced performance in the 6-minute walk test (both P<0.05).",1642,1815
med:pmid:39544776:sec:results:sent:10,med:pmid:39544776,results,10,No significant difference in the incidence of major adverse cardiovascular events was observed between the two groups during the 90-day follow-up period (P>0.05).,1816,1978
med:pmid:39544776:sec:conclusion:sent:11,med:pmid:39544776,conclusion,11,"Our findings indicate that sacubitril/valsartan (LCZ696) Sodium Tablets effectively enhance ventricular remodeling and cardiac function in patients with HF post-AMI, following a short-term treatment regimen.",1979,2206
med:pmid:39544776:sec:conclusion:sent:12,med:pmid:39544776,conclusion,12,This therapeutic approach holds promise for improving clinical outcomes in this patient population.,2207,2306
med:pmid:39156077:sec:title:sent:0,med:pmid:39156077,title,0,Web-Based Dynamic Nomogram for Predicting Risk of Mortality in Heart Failure with Mildly Reduced Ejection Fraction.,0,115
med:pmid:39156077:sec:introduction:sent:1,med:pmid:39156077,introduction,1,"This study aimed to develop an integrative dynamic nomogram, including N-terminal pro-B type natural peptide (NT-proBNP) and estimated glomerular filtration rate (eGFR), for predicting the risk of all-cause mortality in HFmrEF patients.",0,253
med:pmid:39156077:sec:methods:sent:2,med:pmid:39156077,methods,2,790 HFmrEF patients were prospectively enrolled in the development cohort for the model.,254,372
med:pmid:39156077:sec:methods:sent:3,med:pmid:39156077,methods,3,The least absolute shrinkage and selection operator (LASSO) regression and Random Survival Forest (RSF) were employed to select predictors for all-cause mortality.,373,536
med:pmid:39156077:sec:methods:sent:4,med:pmid:39156077,methods,4,"Develop a nomogram based on the Cox proportional hazard model for predicting long-term mortality (1-, 3-, and 5-year) in HFmrEF.",537,665
med:pmid:39156077:sec:methods:sent:5,med:pmid:39156077,methods,5,"Internal validation was conducted using Bootstrap, and the final model was validated in an external cohort of 338 consecutive adult patients.",666,807
med:pmid:39156077:sec:methods:sent:6,med:pmid:39156077,methods,6,"Discrimination and predictive performance were evaluated by calculating the time-dependent concordance index (C-index), area under the ROC curve (AUC), and calibration curve, with clinical value assessed via decision curve analysis (DCA).",808,1046
med:pmid:39156077:sec:methods:sent:7,med:pmid:39156077,methods,7,Integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were used to assess the contributions of NT-proBNP and eGFR to the nomogram.,1047,1210
med:pmid:39156077:sec:methods:sent:8,med:pmid:39156077,methods,8,"Finally, develop a dynamic nomogram using the ""Dynnom"" package.",1211,1274
med:pmid:39156077:sec:results:sent:9,med:pmid:39156077,results,9,"The optimal independent predictors for all-cause mortality (<i>APSELNH: A: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI), P: percutaneous coronary intervention/coronary artery bypass graft (PCI/CABG), S: stroke, E: eGFR, L: lg of NT-proBNP</i>, <i>N: NYHA, H: healthcare</i>) were incorporated into the dynamic nomogram.",1275,1695
med:pmid:39156077:sec:results:sent:10,med:pmid:39156077,results,10,"The C-index in the development cohort and validation cohort were 0.858 and 0.826, respectively, with AUCs exceeding 0.8, indicating good discrimination and predictive ability.",1696,1871
med:pmid:39156077:sec:results:sent:11,med:pmid:39156077,results,11,DCA curves and calibration curves demonstrated clinical applicability and good consistency of the nomogram.,1872,1979
med:pmid:39156077:sec:results:sent:12,med:pmid:39156077,results,12,NT-proBNP and eGFR provided significant net benefits to the nomogram.,1980,2049
med:pmid:39156077:sec:conclusion:sent:13,med:pmid:39156077,conclusion,13,"In this study, the dynamic APSELNH nomogram developed serves as an accessible, functional, and effective clinical decision support calculator, offering accurate prognostic assessment for patients with HFmrEF.",2050,2278
med:pmid:39105079:sec:title:sent:0,med:pmid:39105079,title,0,Real-world experience of angiotensin receptor-neprilysin inhibitors in patients with heart failure and dialysis.,0,112
med:pmid:39105079:sec:introduction:sent:1,med:pmid:39105079,introduction,1,"Although angiotensin receptor-neprilysin inhibitor (ARNI) has shown promise in patients with heart failure and reduced ejection fraction (HFrEF), the treatment effect in HFrEF patients with end-stage renal disease (ESRD) undergoing dialysis is uncertain.",0,276
med:pmid:39105079:sec:introduction:sent:2,med:pmid:39105079,introduction,2,This study aimed to examine the real-world effects of ARNI vs. angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) in this subpopulation.,277,444
med:pmid:39105079:sec:methods:sent:3,med:pmid:39105079,methods,3,"This multi-institutional, retrospective study identified 349 HFrEF patients with ESRD on dialysis, who initiated either ARNI or ACEI/ARB therapy.",445,607
med:pmid:39105079:sec:methods:sent:4,med:pmid:39105079,methods,4,"Efficacy outcomes included rates of hospitalization for heart failure (HHF) and mortality, as well as changes in echocardiographic parameters.",608,750
med:pmid:39105079:sec:methods:sent:5,med:pmid:39105079,methods,5,Safety outcomes encompassed hypotension and hyperkalemia.,751,808
med:pmid:39105079:sec:methods:sent:6,med:pmid:39105079,methods,6,"Treatment effects were assessed using Cox proportional hazards models, with additional sensitivity analyses for robustness.",809,932
med:pmid:39105079:sec:results:sent:7,med:pmid:39105079,results,7,"Out of 349 patients screened, 89 were included in the final analysis (42 in the ARNI group and 47 in the ACEI/ARB group).",933,1071
med:pmid:39105079:sec:results:sent:8,med:pmid:39105079,results,8,"After 1 year of treatment, echocardiographic measures between the two groups were comparable.",1072,1165
med:pmid:39105079:sec:results:sent:9,med:pmid:39105079,results,9,"The primary composite rate of HHF or mortality was 20.6 events per 100 patient-years in the ARNI group and 26.1 in the ACEI/ARB group; the adjusted hazard ratio was 0.98 (95% CI: 0.28-3.43, <i>P</i> = 0.97).",1166,1373
med:pmid:39105079:sec:results:sent:10,med:pmid:39105079,results,10,Their safety outcomes did not differ significantly.,1374,1425
med:pmid:39105079:sec:results:sent:11,med:pmid:39105079,results,11,"Sensitivity analyses, including repetitive sampling, propensity score matching, and extended follow-up, corroborated these findings.",1426,1558
med:pmid:39105079:sec:conclusion:sent:12,med:pmid:39105079,conclusion,12,"ARNI has proven effective in treating HFrEF patients; however, significant benefits were not observed in these patients with ESRD undergoing dialysis compared with ACEI/ARB in this real-world cohort.",1559,1778
med:pmid:39105079:sec:conclusion:sent:13,med:pmid:39105079,conclusion,13,"Future research employing a more extended follow-up period, larger sample size, or randomized design is warranted to investigate the treatment effects in this subpopulation.",1779,1952
med:pmid:39033432:sec:title:sent:0,med:pmid:39033432,title,0,Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease.,0,236
med:pmid:39033432:sec:abstract:sent:1,med:pmid:39033432,abstract,1,<b>Background and Objectives:</b> The efficacy and safety of a lower target dose of sacubitril/valsartan (angiotensin receptor neprilysin inhibitor [ARNI]) for treating heart failure with reduced ejection fraction (HFrEF) in Chinese patients with moderate-to-severe chronic kidney disease (CKD) remain unknown.,0,310
med:pmid:39033432:sec:abstract:sent:2,med:pmid:39033432,abstract,2,We performed a retrospective study to compare the efficacy of ARNI with that of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in patients with HFrEF and moderate-to-severe CKD.,311,527
med:pmid:39033432:sec:abstract:sent:3,med:pmid:39033432,abstract,3,<b>Methods:</b> This retrospective study included 129 patients.,528,591
med:pmid:39033432:sec:abstract:sent:4,med:pmid:39033432,abstract,4,An inverse probability of treatment weighting (IPTW) analysis was performed to compare the baseline characteristics and outcomes between the 2 groups.,592,742
med:pmid:39033432:sec:abstract:sent:5,med:pmid:39033432,abstract,5,"The incidence of death due to cardiovascular disease, rehospitalization due to heart failure after treatment, and improvement in cardiac function symptoms (New York Heart Association [NYHA]) were assessed after 12 months.",743,964
med:pmid:39033432:sec:abstract:sent:6,med:pmid:39033432,abstract,6,"Improvements of ejection fraction (EF), N-terminal pro-brain natriuretic peptide (NT-proBNP) level, left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD) were compared.",965,1179
med:pmid:39033432:sec:abstract:sent:7,med:pmid:39033432,abstract,7,"<b>Results:</b> Compared with the ACEI/ARB group, the ARNI group, with 90.77% (59/65) in the lower target dose group, showed a lower rate of death due to cardiovascular disease (6.6% vs 0.9% after IPTW) and a lower incidence of rehospitalization (46.5% vs 30.4% after IPTW).",1180,1454
med:pmid:39033432:sec:abstract:sent:8,med:pmid:39033432,abstract,8,"NYHA class, estimated glomerular filtration rate, EF, NT-ProBNP levels, LVEDD, and LVESD improved in the ARNI group.",1455,1571
med:pmid:39033432:sec:abstract:sent:9,med:pmid:39033432,abstract,9,None of the patients withdrew from treatment because of adverse drug reactions.,1572,1651
med:pmid:39033432:sec:abstract:sent:10,med:pmid:39033432,abstract,10,<b>Conclusion:</b> Our study showed that ARNI resulted in a greater improvement in heart failure than ACEIs/ARBs in patients with HFrEF and moderate-to-severe CKD.,1652,1815
med:pmid:38359813:sec:title:sent:0,med:pmid:38359813,title,0,Adherence to Treatment Guidelines in Ambulatory Heart Failure Patients with Reduced Ejection Fraction in a Latin-American Country: Observational Study of the Colombian Heart Failure Registry (RECOLFACA).,0,203
med:pmid:38359813:sec:introduction:sent:1,med:pmid:38359813,introduction,1,"Although several guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) be treated with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) or angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitor (SGLT2i), there are still several gaps in their prescription and dosage in Colombia.",0,481
med:pmid:38359813:sec:introduction:sent:2,med:pmid:38359813,introduction,2,This study aimed to describe the use patterns of HFrEF treatments in the Colombian Heart Failure Registry (RECOLFACA).,482,600
med:pmid:38359813:sec:methods:sent:3,med:pmid:38359813,methods,3,Patients with HFrEF enrolled in RECOLFACA during 2017-2019 were included.,601,691
med:pmid:38359813:sec:methods:sent:4,med:pmid:38359813,methods,4,Heart failure (HF) medication prescription and daily dose were assessed using absolute numbers and proportions.,692,803
med:pmid:38359813:sec:methods:sent:5,med:pmid:38359813,methods,5,Therapeutic schemes of patients treated by internal medicine specialists were compared with those treated by cardiologists.,804,927
med:pmid:38359813:sec:results:sent:6,med:pmid:38359813,results,6,"Out of 2,528 patients in the registry, 1,384 (54.7%) had HFrEF.",928,1008
med:pmid:38359813:sec:results:sent:7,med:pmid:38359813,results,7,"Among those individuals, 88.9% were prescribed beta-blockers, 72.3% with ACEI/ARBs, 67.9% with MRAs, and 13.1% with ARNIs.",1009,1131
med:pmid:38359813:sec:results:sent:8,med:pmid:38359813,results,8,"Moreover, less than a third of the total patients reached the target doses recommended by the European HF guidelines.",1132,1249
med:pmid:38359813:sec:results:sent:9,med:pmid:38359813,results,9,No significant differences in the therapeutic schemes or target doses were observed between patients treated by internal medicine specialists or cardiologists.,1250,1409
med:pmid:38359813:sec:conclusion:sent:10,med:pmid:38359813,conclusion,10,Prescription rates and target dose achievement are suboptimal in Colombia.,1410,1504
med:pmid:38359813:sec:conclusion:sent:11,med:pmid:38359813,conclusion,11,"Nevertheless, RECOLFACA had one of the highest prescription rates of beta-blockers and MRAs compared to some of the most recent HF registries.",1505,1647
med:pmid:38359813:sec:conclusion:sent:12,med:pmid:38359813,conclusion,12,"However, ARNIs remain underprescribed.",1648,1686
med:pmid:38359813:sec:conclusion:sent:13,med:pmid:38359813,conclusion,13,Continuous registry updates can improve the identification of patients suitable for ARNI and SGLT2i therapy to promote their use in clinical practice.,1687,1837
med:pmid:38356826:sec:title:sent:0,med:pmid:38356826,title,0,Comparison of the efficacy of combining left bundle branch pacing with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure: A retrospective observational analysis.,0,194
med:pmid:38356826:sec:introduction:sent:1,med:pmid:38356826,introduction,1,To assess the efficacy of left bundle branch pacing (LBBP) combined with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure (CHF).,0,181
med:pmid:38356826:sec:methods:sent:2,med:pmid:38356826,methods,2,We retrospectively reviewed the records of 138 patients with CHF admitted to Dazhou Central Hospital between June 2020 and June 2022 to extract clinical data.,182,357
med:pmid:38356826:sec:methods:sent:3,med:pmid:38356826,methods,3,"We divided the data into two treatment groups for the analysis: 71 patients received LBBP combined with sacubitril/valsartan treatment (sacubitril/valsartan group), and 67 received LBBP combined with enalapril treatment (enalapril group).",358,596
med:pmid:38356826:sec:methods:sent:4,med:pmid:38356826,methods,4,"The levels of cardiac and cardiopulmonary function indicators, levels of myocardial injury markers, and the scores of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) before and after the treatment were compared between the two groups.",597,845
med:pmid:38356826:sec:results:sent:5,med:pmid:38356826,results,5,"After six months of treatment, patients in the sacubitril/valsartan group had lower myocardial injury markers, higher cardiopulmonary function indicators, and lower MLHFQ scores (<i>P</i><0.05).",846,1057
med:pmid:38356826:sec:conclusion:sent:6,med:pmid:38356826,conclusion,6,"In CHF patients, the combination of LBBP with sacubitril/valsartan had a better therapeutic effect compared to LBBP with enalapril, with more effective improvement of the cardiopulmonary function, reduction of myocardial injury, and improvement in quality of life.",1058,1343
med:pmid:37933184:sec:title:sent:0,med:pmid:37933184,title,0,Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.,0,197
med:pmid:37933184:sec:introduction:sent:1,med:pmid:37933184,introduction,1,It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high-risk myocardial infarction (MI) patients.,0,260
med:pmid:37933184:sec:introduction:sent:2,med:pmid:37933184,introduction,2,The aim of this study was to examine whether MRA modifies safety and clinical endpoints by use of sacubitril/valsartan in patients with a MI and left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion.,261,479
med:pmid:37933184:sec:results:sent:3,med:pmid:37933184,results,3,Patients (n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA.,480,706
med:pmid:37933184:sec:results:sent:4,med:pmid:37933184,results,4,Primary outcomes in this substudy were worsening heart failure or cardiovascular death.,707,794
med:pmid:37933184:sec:results:sent:5,med:pmid:37933184,results,5,"Safety was defined as symptomatic hypotension, hyperkalaemia >5.5 mmol/L, or permanent drug discontinuation.",795,903
med:pmid:37933184:sec:results:sent:6,med:pmid:37933184,results,6,A total of 2338 patients (41%) were treated with MRA.,904,957
med:pmid:37933184:sec:results:sent:7,med:pmid:37933184,results,7,"Safety of ARNI compared to ramipril was not altered significantly by ± MRA, and both groups had similar increase in symptomatic hypotension with ARNI.",958,1108
med:pmid:37933184:sec:results:sent:8,med:pmid:37933184,results,8,"In patients taking MRA, the risk of hyperkalaemia or permanent drug discontinuation was not significantly altered by ARNI (p > 0.05 for all comparisons).",1109,1262
med:pmid:37933184:sec:results:sent:9,med:pmid:37933184,results,9,"The effect of ARNI compared with ramipril was similar in those who were and were not taking MRA (hazard ratio [HR]<sub>MRA</sub> 0.96, 95% confidence interval [CI] 0.77-1.19 and HR<sub>MRA-</sub> 0.87, 95% CI 0.71-1.05, for the primary endpoint; p = 0.51 for interaction [Clinical Endpoint Committee adjudicated]); similar findings were observed if investigator-reported endpoints were evaluated (p = 0.61 for interaction).",1263,1686
med:pmid:37933184:sec:conclusion:sent:10,med:pmid:37933184,conclusion,10,Use of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post-MI setting in patients with LVSD and/or congestion.,1687,1879
med:pmid:37640175:sec:title:sent:0,med:pmid:37640175,title,0,Use of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation.,0,105
med:pmid:37640175:sec:abstract:sent:1,med:pmid:37640175,abstract,1,Optimal medical therapy (OMT) in patients with coronary artery disease (CAD) and/or heart failure (HF) is underused despite the established benefits of these medications.,0,170
med:pmid:37640175:sec:abstract:sent:2,med:pmid:37640175,abstract,2,Cardiac rehabilitation (CR) may be one place where OMT could be promoted.,171,244
med:pmid:37640175:sec:abstract:sent:3,med:pmid:37640175,abstract,3,We sought to describe the prevalence and characteristics of OMT use in patients with CAD or HF undergoing CR.,245,354
med:pmid:37640175:sec:abstract:sent:4,med:pmid:37640175,abstract,4,"We included patients with CAD (myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, angina) and HF enrolled in our CR program.",355,520
med:pmid:37640175:sec:abstract:sent:5,med:pmid:37640175,abstract,5,"For patients with CAD, we defined OMT to consist of aspirin or other antiplatelets, statins, and beta-blockers (BB).",521,637
med:pmid:37640175:sec:abstract:sent:6,med:pmid:37640175,abstract,6,"For patients with HF or EF ≤ 40%, OMT included BB, spironolactone, and either Angiotensin Converting Enzyme inhibitors (ACEi)/angiotensin receptor blockers or angiotensin receptor neprilysin inhibitor (ARNI).",638,846
med:pmid:37640175:sec:abstract:sent:7,med:pmid:37640175,abstract,7,"For CAD patients with normal EF, OMT also included ACEi/ARB/ARNI if they also had diabetes type 2.",847,945
med:pmid:37640175:sec:abstract:sent:8,med:pmid:37640175,abstract,8,"From January 2015 to December 2019, 828 patients were referred to CR and 743 attended.",946,1032
med:pmid:37640175:sec:abstract:sent:9,med:pmid:37640175,abstract,9,"Among 612 patients (mean age: 65, 23% female) with CAD, 483 (79%) patients were on OMT.",1033,1120
med:pmid:37640175:sec:abstract:sent:10,med:pmid:37640175,abstract,10,"Of the 131 HF patients (mean age: 64, 21% female) enrolled in CR, only 23 (18%) met all 3 OMT criteria, whereas most patients were on only 1 (93 %) or 2 (76%) HF specific medications.",1121,1304
med:pmid:37640175:sec:abstract:sent:11,med:pmid:37640175,abstract,11,Spironolactone was the least prescribed (22%) medication.,1305,1362
med:pmid:37640175:sec:abstract:sent:12,med:pmid:37640175,abstract,12,"Over the study period, we observed a steady increase in the use of ARNI (2015: 0% vs 2019: 27%, p < 0.01).",1363,1469
med:pmid:37640175:sec:abstract:sent:13,med:pmid:37640175,abstract,13,"Among the individuals, 69 patients experienced both CAD and HF, while only 7 patients were under OMT for both CAD and HF.",1470,1591
med:pmid:37640175:sec:abstract:sent:14,med:pmid:37640175,abstract,14,"Most patients attending CR with CAD are receiving OMT, but most patients with HF are not.",1592,1681
med:pmid:37640175:sec:abstract:sent:15,med:pmid:37640175,abstract,15,"Although OMT has improved over time, there remains room for improvement, particularly among patients with HF.",1682,1791
med:pmid:37217135:sec:title:sent:0,med:pmid:37217135,title,0,Prevalence and clinical profile of kidney disease in patients with chronic heart failure.,0,89
med:pmid:37217135:sec:title:sent:1,med:pmid:37217135,title,1,Insights from the Spanish cardiorenal registry.,90,137
med:pmid:37217135:sec:abstract:sent:2,med:pmid:37217135,abstract,2,<h4>Introduction and objectives</h4> Patients with combined heart failure (HF) and chronic kidney disease (CKD) have been underrepresented in clinical trials.,0,158
med:pmid:37217135:sec:abstract:sent:3,med:pmid:37217135,abstract,3,The prevalence of CKD in these patients and their clinical profile require constant evaluation.,159,254
med:pmid:37217135:sec:abstract:sent:4,med:pmid:37217135,abstract,4,"This study aimed to analyze the prevalence of CKD, its clinical profile, and patterns of use of evidence-based medical therapies in HF across CKD stages in a contemporary cohort of ambulatory patients with HF.",255,464
med:pmid:37217135:sec:methods:sent:5,med:pmid:37217135,methods,5,"From October 2021 to February 2022, the CARDIOREN registry included 1107 ambulatory HF patients from 13 HF clinics in Spain.",465,606
med:pmid:37217135:sec:results:sent:6,med:pmid:37217135,results,6,"The median age was 75 years, 63% were male, and 48% had heart failure with reduced left ventricular ejection fraction (HFrEF).",607,750
med:pmid:37217135:sec:results:sent:7,med:pmid:37217135,results,7,"A total of 654 (59.1%) had an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m<sup>2</sup>, and 122 (11%) patients with eGFR ≥ 60 mL/min/1.73 m<sup>2</sup> had a urine albumin-creatinin ratio ≥ 30 mg/g. The most important variables associated with lower eGFR were age (R2=61%) and furosemide dose (R2=21%).",751,1070
med:pmid:37217135:sec:results:sent:8,med:pmid:37217135,results,8,"The proportion of patients receiving an angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin II receptor blockers (ARB), an angiotensin receptor-neprilysin inhibitor (ARNi), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), or a mineralocorticoid receptor antagonist (MRA) progressively decreased with lower eGFR categories.",1071,1405
med:pmid:37217135:sec:results:sent:9,med:pmid:37217135,results,9,"Notably, 32% of the patients with HFrEF and an eGFR <30 mL/min/1.73 m<sup>2</sup> received the combination of ACEI/ARB/ARNi+beta-blockers+MRA+SGLT2i.",1406,1555
med:pmid:37217135:sec:conclusion:sent:10,med:pmid:37217135,conclusion,10,"In this contemporary HF registry, 70% of patients had kidney disease.",1556,1646
med:pmid:37217135:sec:conclusion:sent:11,med:pmid:37217135,conclusion,11,"Although this population is less likely to receive evidence-based therapies, structured and specialized follow-up approaches within HF clinics may facilitate the adoption of these life-saving drugs.",1647,1845
med:pmid:37195574:sec:title:sent:0,med:pmid:37195574,title,0,The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.,0,113
med:pmid:37195574:sec:introduction:sent:1,med:pmid:37195574,introduction,1,"Sacubitril/valsartan, a new pharmacological class of angiotensin receptor neprilysin inhibitor, is beneficial to heart failure through blocking the degradation of natriuretic peptides and inhibiting renin-angiotensin-aldosterone system (RAAS) activation which also relate to the pathophysiologic mechanisms of chronic kidney disease (CKD).",0,359
med:pmid:37195574:sec:introduction:sent:2,med:pmid:37195574,introduction,2,"However, its effects on CKD remain unclear.",360,403
med:pmid:37195574:sec:introduction:sent:3,med:pmid:37195574,introduction,3,"To assess the efficacy and safety of sacubitril/valsartan for patients with CKD, we performed this meta-analysis.",404,517
med:pmid:37195574:sec:methods:sent:4,med:pmid:37195574,methods,4,"The Embase, PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) that compared sacubitril/valsartan with ACEI/ARBs in patients with CKD whose estimated glomerular filtration rate (eGFR) was below 60 mL/min/1.73 m<sup>2</sup>.",518,793
med:pmid:37195574:sec:methods:sent:5,med:pmid:37195574,methods,5,We adopted the Cochrane Collaboration tool for assessing the risk of bias.,794,868
med:pmid:37195574:sec:methods:sent:6,med:pmid:37195574,methods,6,The effect size was estimated using the odds ratio (OR) with 95% confidence interval (CI).,869,959
med:pmid:37195574:sec:results:sent:7,med:pmid:37195574,results,7,Six trials with a total of 6217 patients with CKD were included.,960,1041
med:pmid:37195574:sec:results:sent:8,med:pmid:37195574,results,8,"In terms of cardiovascular events, sacubitril/valsartan attenuated the risk of cardiovascular death or heart failure hospitalization (OR: 0.68, 95% CI 0.61-0.76, P < 0.00001, I<sup>2</sup> = 43%).",1042,1238
med:pmid:37195574:sec:results:sent:9,med:pmid:37195574,results,9,"With respect to renal function, sacubitril/valsartan prevented the incidence of serum creatinine (Scr) elevation among patients with CKD (OR: 0.79, 95% CI 0.67-0.95, P = 0.01, I<sup>2</sup> = 0%).",1239,1435
med:pmid:37195574:sec:results:sent:10,med:pmid:37195574,results,10,"Subgroup analysis about eGFR demonstrated that with long follow-up, sacubitril/valsartan significantly decreased the number of patients with more than 50% reduction in eGFR compared with ACEI/ARBs (OR: 0.52, 95% CI 0.32-0.84, P = 0.008, I<sup>2</sup> = 9%).",1436,1693
med:pmid:37195574:sec:results:sent:11,med:pmid:37195574,results,11,"In patients with CKD, the incidence of end-stage renal disease (ESRD) was reduced with sacubitril/valsartan treatment, despite no statistically significant difference between the two groups (OR: 0.59, 95% CI 0.29-1.20, P = 0.14, I<sup>2</sup> = 0%).",1694,1943
med:pmid:37195574:sec:results:sent:12,med:pmid:37195574,results,12,"As for the safety, we found that sacubitril/valsartan was associated with the occurrence of hypotension (OR: 1.71, 95% CI 1.15-2.56, P = 0.008, I<sup>2</sup> = 51%).",1944,2109
med:pmid:37195574:sec:results:sent:13,med:pmid:37195574,results,13,"However, there was no trend towards increasing the risk of hyperkalemia in patients who received sacubitril/valsartan (OR: 1.09, 95% CI 0.75-1.60, P = 0.64, I<sup>2</sup> = 64%).",2110,2288
med:pmid:37195574:sec:conclusion:sent:14,med:pmid:37195574,conclusion,14,"This meta-analysis indicated that sacubitril/valsartan improved renal function and conferred effective cardiovascular benefits in patients with CKD, without serious safety issues being observed.",2289,2503
med:pmid:37195574:sec:conclusion:sent:15,med:pmid:37195574,conclusion,15,"Thus, sacubitril/valsartan may be a promising option for patients with CKD.",2504,2579
med:pmid:37195574:sec:conclusion:sent:16,med:pmid:37195574,conclusion,16,"Certainly, further large-scale randomized controlled trials are needed to confirm these conclusions.",2580,2680
med:pmid:37195574:sec:conclusion:sent:17,med:pmid:37195574,conclusion,17,"<h4>Systematic review registration</h4>[ https://inplasy.com/inplasy-2022-4-0045/ ], identifier [INPLASY202240045].",2681,2796
med:pmid:38040431:sec:title:sent:0,med:pmid:38040431,title,0,Cohort profile: a large EHR-based cohort with linked pharmacy refill and neighbourhood social determinants of health data to assess heart failure medication adherence.,0,167
med:pmid:38040431:sec:introduction:sent:1,med:pmid:38040431,introduction,1,Clinic-based or community-based interventions can improve adherence to guideline-directed medication therapies (GDMTs) among patients with heart failure (HF).,0,175
med:pmid:38040431:sec:introduction:sent:2,med:pmid:38040431,introduction,2,"However, opportunities for such interventions are frequently missed, as providers may be unable to recognise risk patterns for medication non-adherence.",176,328
med:pmid:38040431:sec:introduction:sent:3,med:pmid:38040431,introduction,3,Machine learning algorithms can help in identifying patients with high likelihood of non-adherence.,329,428
med:pmid:38040431:sec:introduction:sent:4,med:pmid:38040431,introduction,4,"While a number of multilevel factors influence adherence, prior models predicting non-adherence have been limited by data availability.",429,564
med:pmid:38040431:sec:introduction:sent:5,med:pmid:38040431,introduction,5,We have established an electronic health record (EHR)-based cohort with comprehensive data elements from multiple sources to improve on existing models.,565,717
med:pmid:38040431:sec:introduction:sent:6,med:pmid:38040431,introduction,6,We linked EHR data with pharmacy refill data for real-time incorporation of prescription fills and with social determinants data to incorporate neighbourhood factors.,718,884
med:pmid:38040431:sec:introduction:sent:7,med:pmid:38040431,introduction,7,"<h4>Participants</h4> Patients seen at a large health system in New York City (NYC), who were >18 years old with diagnosis of HF or reduced ejection fraction (<40%) since 2017, had at least one clinical encounter between 1 April 2021 and 31 October 2022 and active prescriptions for any of the four GDMTs (beta-blocker, ACEi/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonist (MRA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i)) during the study period.",885,1418
med:pmid:38040431:sec:introduction:sent:8,med:pmid:38040431,introduction,8,Patients with non-geocodable address or outside the continental USA were excluded.,1419,1501
med:pmid:38040431:sec:introduction:sent:9,med:pmid:38040431,introduction,9,"<h4>Findings to date</h4> Among 39 963 patients in the cohort, the average age was 73±14 years old, 44% were female and 48% were current/former smokers.",1502,1654
med:pmid:38040431:sec:introduction:sent:10,med:pmid:38040431,introduction,10,"The common comorbid conditions were hypertension (77%), cardiac arrhythmias (56%), obesity (33%) and valvular disease (33%).",1655,1779
med:pmid:38040431:sec:introduction:sent:11,med:pmid:38040431,introduction,11,"During the study period, 33 606 (84%) patients had an active prescription of beta blocker, 32 626 (82%) had ACEi/ARB/ARNI, 11 611 (29%) MRA and 7472 (19%) SGLT2i.",1780,1942
med:pmid:38040431:sec:introduction:sent:12,med:pmid:38040431,introduction,12,Ninety-nine per cent were from urban metropolitan areas.,1943,1999
med:pmid:38040431:sec:introduction:sent:13,med:pmid:38040431,introduction,13,"<h4>Future plans</h4> We will use the established cohort to develop a machine learning model to predict medication adherence, and to support ancillary studies assessing associates of adherence.",2000,2193
med:pmid:38040431:sec:introduction:sent:14,med:pmid:38040431,introduction,14,"For external validation, we will include data from an additional hospital system in NYC.",2194,2282
med:pmid:37989299:sec:title:sent:0,med:pmid:37989299,title,0,Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Heart Failure According to Baseline Systolic Blood Pressure　- Results From a Subgroup Analysis of the PARALLEL-HF Study.,0,190
med:pmid:37989299:sec:introduction:sent:1,med:pmid:37989299,introduction,1,Lower systolic blood pressure (SBP) is known to be associated with poor prognosis in heart failure (HF).,0,124
med:pmid:37989299:sec:introduction:sent:2,med:pmid:37989299,introduction,2,We evaluated the efficacy and safety of sacubitril/valsartan according to baseline SBP tertiles in Japanese patients from the PARALLEL-HF study.,125,269
med:pmid:37989299:sec:results:sent:3,med:pmid:37989299,results,3,"In all, 223 patients were stratified into tertiles according to baseline SBP (≤114 mmHg: n=75; >114 and ≤130 mmHg: n=76; and >130 mmHg: n=72).",270,441
med:pmid:37989299:sec:results:sent:4,med:pmid:37989299,results,4,Patients with lower SBP (≤114 mmHg) had the highest median N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations at baseline (P=0.0184).,442,593
med:pmid:37989299:sec:results:sent:5,med:pmid:37989299,results,5,No significant difference was observed between sacubitril/valsartan and enalapril for the composite outcome of cardiovascular death and HF hospitalization across SBP tertiles (P-interaction=0.2682).,594,792
med:pmid:37989299:sec:results:sent:6,med:pmid:37989299,results,6,"Although the P-interaction value was not significant (0.2106), a greater reduction in NT-proBNP with sacubitril/valsartan compared with enalapril was observed in patients with SBP >130 mmHg (P=0.0076).",793,994
med:pmid:37989299:sec:results:sent:7,med:pmid:37989299,results,7,"The incidence of hypotension-related events and reduction or discontinuation of treatment due to hypotension-related events was higher in the lower SBP subgroup, and these events were more frequent in the sacubitril/valsartan than enalapril group.",995,1242
med:pmid:37989299:sec:conclusion:sent:8,med:pmid:37989299,conclusion,8,The efficacy of sacubitril/valsartan compared with enalapril was consistent across baseline SBP tertiles in Japanese patients from the PARALLEL-HF study.,1243,1417
med:pmid:37989299:sec:conclusion:sent:9,med:pmid:37989299,conclusion,9,Hypotension-related events were more common in patients treated with sacubitril/valsartan with lower SBP.,1418,1523
med:pmid:37705397:sec:title:sent:0,med:pmid:37705397,title,0,Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.,0,118
med:pmid:37705397:sec:introduction:sent:1,med:pmid:37705397,introduction,1,The long-term effect of angiotensin receptor-neprilysin inhibitor (ARNI) remains uncertain in patients who have experienced improvements in left ventricular (LV) systolic function or significant LV reverse remodelling following a certain period of treatment.,0,272
med:pmid:37705397:sec:introduction:sent:2,med:pmid:37705397,introduction,2,It is also unclear how ARNI performs in patients who have not shown these improvements.,273,360
med:pmid:37705397:sec:introduction:sent:3,med:pmid:37705397,introduction,3,This study aimed to assess the impact of prolonged ARNI use compared with angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in patients with and without significant treatment response after 1 year of heart failure (HF) treatment.,361,626
med:pmid:37705397:sec:results:sent:4,med:pmid:37705397,results,4,The present study enrolled patients with HF with reduced ejection fraction (HFrEF) who were treated with either ARNI or ACEIs/ARBs within 1 year of undergoing index echocardiography.,627,838
med:pmid:37705397:sec:results:sent:5,med:pmid:37705397,results,5,"After 1 year of treatment, patients were reclassified into the following groups: (i) patients with HF with improved ejection fraction and persistent HFrEF and (ii) patients with and without LV reverse remodelling based on the follow-up echocardiography.",839,1092
med:pmid:37705397:sec:results:sent:6,med:pmid:37705397,results,6,The effect of ARNI versus that of ACEIs/ARBs in each group was assessed from the time of categorizing into new groups using the composite event of all-cause mortality and HF hospitalization.,1093,1283
med:pmid:37705397:sec:results:sent:7,med:pmid:37705397,results,7,"A total of 671 patients with HFrEF (age, 66.4 ± 14.1 years; males, 66.8%) were included, and 133 (19.8%) composite events of death and rehospitalization for HF were observed during the follow-up (median follow-up, 44 [interquartile range, 34-51] months).",1284,1538
med:pmid:37705397:sec:results:sent:8,med:pmid:37705397,results,8,"ARNI had a significantly lower event rate than ACEIs/ARBs in patients with HF with improved ejection fraction (7.0% vs. 30.4%, P = 0.020) and those with persistent HFrEF (17.6% vs. 49.7%, P < 0.001).",1539,1738
med:pmid:37705397:sec:results:sent:9,med:pmid:37705397,results,9,"Irrespective of whether patients exhibited LV reverse remodelling (15.8% vs. 31.1%, P = 0.001) or not (15.0% vs. 54.9%, P < 0.001), ARNIs were associated with a significantly lower event rate than ACEIs/ARBs.",1739,1947
med:pmid:37705397:sec:conclusion:sent:10,med:pmid:37705397,conclusion,10,"Regardless of significant treatment response measured by either LVEF or LV reverse remodelling after 1 year of treatment, the extended utilization of ARNI demonstrated a more favourable prognosis than that of ACEIs/ARBs in patients with HFrEF.",1948,2212
med:pmid:37635080:sec:title:sent:0,med:pmid:37635080,title,0,Long-Term Treatment With Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Open-Label Extension of the PARALLEL-HF Study.,0,172
med:pmid:37635080:sec:introduction:sent:1,med:pmid:37635080,introduction,1,The PARALLEL-HF study assessed the efficacy and safety of sacubitril/valsartan vs. enalapril in Japanese patients with chronic heart failure with reduced ejection fraction (HFrEF).,0,200
med:pmid:37635080:sec:introduction:sent:2,med:pmid:37635080,introduction,2,This open-label extension (OLE) assessed long-term safety with sacubitril/valsartan.,201,285
med:pmid:37635080:sec:results:sent:3,med:pmid:37635080,results,3,"This study enrolled 150 patients who received sacubitril/valsartan 50 or 100 mg, b.i.d.,",286,403
med:pmid:37635080:sec:results:sent:4,med:pmid:37635080,results,4,in addition to optimal background heart failure (HF) therapy.,404,465
med:pmid:37635080:sec:results:sent:5,med:pmid:37635080,results,5,"A dose level of sacubitril/valsartan 200 mg, b.i.d.,",466,518
med:pmid:37635080:sec:results:sent:6,med:pmid:37635080,results,6,was targeted by Week 8.,519,542
med:pmid:37635080:sec:results:sent:7,med:pmid:37635080,results,7,"At OLE baseline, higher concentrations of B-type natriuretic peptide (BNP) and urine cGMP, and lower concentrations of N-terminal pro B-type natriuretic peptide (NT-proBNP), were observed in the sacubitril/valsartan core group (patients who received sacubitril/valsartan in both the core and extension study) than in the enalapril core group (patients who received enalapril in the core study and were then transitioned to sacubitril/valsartan).",543,988
med:pmid:37635080:sec:results:sent:8,med:pmid:37635080,results,8,The mean exposure to study drug was 98.9%.,989,1031
med:pmid:37635080:sec:results:sent:9,med:pmid:37635080,results,9,There was no trend of worsening of HF at Month 12.,1032,1082
med:pmid:37635080:sec:results:sent:10,med:pmid:37635080,results,10,"No obvious changes in cardiac biomarkers were observed, whereas BNP and urine cGMP increased and NT-proBNP decreased in the enalapril core group, which was evident at Weeks 2-4 and sustained to Month 12.",1083,1286
med:pmid:37635080:sec:conclusion:sent:11,med:pmid:37635080,conclusion,11,"Long-term sacubitril/valsartan at doses up to 200 mg, b.i.d.,",1287,1369
med:pmid:37635080:sec:conclusion:sent:12,med:pmid:37635080,conclusion,12,has a positive risk-benefit profile; it was safe and well tolerated in Japanese patients with chronic HFrEF.,1370,1478
med:pmid:38084196:sec:title:sent:0,med:pmid:38084196,title,0,Comparison of Outcomes Between Sacubitril/Valsartan and Enalapril in Patients With Heart Failure: A Systematic Review and Meta-Analysis.,0,136
med:pmid:38084196:sec:abstract:sent:1,med:pmid:38084196,abstract,1,The objective of this meta-analysis was to compare outcomes between sacubitril/valsartan and enalapril in patients with heart failure.,0,134
med:pmid:38084196:sec:abstract:sent:2,med:pmid:38084196,abstract,2,We performed this meta-analysis according to the guidelines reported in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.,135,297
med:pmid:38084196:sec:abstract:sent:3,med:pmid:38084196,abstract,3,"Two independent authors systematically searched online databases including PubMed, Cochrane Library, and Web of Science from inception till September 15, 2023.",298,457
med:pmid:38084196:sec:results:sent:4,med:pmid:38084196,results,4,"assessed in this meta-analysis included all-cause mortality, cardiovascular mortality, and cardiovascular-related hospitalization.",458,597
med:pmid:38084196:sec:results:sent:5,med:pmid:38084196,results,5,A total of nine studies were included in this meta-analysis.,598,658
med:pmid:38084196:sec:results:sent:6,med:pmid:38084196,results,6,Pooled analysis showed that the risk of all-cause mortality was higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan (risk ratio [RR]: 0.57; 95% CI: 0.31 to 1.04).,659,860
med:pmid:38084196:sec:results:sent:7,med:pmid:38084196,results,7,Risk of cardiovascular mortality was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.75; 95% CI: 0.62 to 0.91).,861,1018
med:pmid:38084196:sec:results:sent:8,med:pmid:38084196,results,8,The risk of cardiovascular hospitalization was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.76; 95% CI: 0.66 to 0.86).,1019,1186
med:pmid:38084196:sec:results:sent:9,med:pmid:38084196,results,9,"In conclusion, our meta-analysis of nine studies underscores the superior clinical performance of sacubitril/valsartan compared to enalapril in managing patients with heart failure.",1187,1368
med:pmid:37940331:sec:title:sent:0,med:pmid:37940331,title,0,Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials.,0,211
med:pmid:37940331:sec:introduction:sent:1,med:pmid:37940331,introduction,1,"Currently, there is no head-to-head comparison of novel pharmacological treatments for heart failure with reduced ejection fraction (HFrEF).",0,160
med:pmid:37940331:sec:introduction:sent:2,med:pmid:37940331,introduction,2,A network meta-analysis aimed to compare effects of both conventional and alternative drug combinations on time to develop primary composite outcome of cardiovascular death or heart failure hospitalisation (PCO).,161,373
med:pmid:37940331:sec:methods:sent:3,med:pmid:37940331,methods,3,"Randomised controlled trials (RCTs) were identified from Medline, Scopus up to June 2021.",374,480
med:pmid:37940331:sec:methods:sent:4,med:pmid:37940331,methods,4,"The RCTs were included if comparing any single or combination of drugs, that is, ACE inhibitors (ACEI), angiotensin receptor blockers, beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), ivabradine (IVA), angiotensin receptor blocker/neprilysin inhibitors (ARNI) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), soluble guanylyl cyclase and omecamtiv mecarbil and reporting PCO.",481,880
med:pmid:37940331:sec:results:sent:5,med:pmid:37940331,results,5,"were extracted from Kaplan-Meier curves, individual patient data were generated.",881,966
med:pmid:37940331:sec:results:sent:6,med:pmid:37940331,results,6,A mixed-effect Weibull regression was applied.,967,1013
med:pmid:37940331:sec:results:sent:7,med:pmid:37940331,results,7,"Median time to PCO, HRs with 95% CI were estimated accordingly.",1014,1077
med:pmid:37940331:sec:results:sent:8,med:pmid:37940331,results,8,"Our findings suggested that ACEI+BB+MRA+SGLT2i, BB+MRA+ARNI, and ACEI+BB+MRA+IVA had lower probability of PCOs than the conventional triple therapy (ACEI+BB+MRA).",1078,1240
med:pmid:37940331:sec:results:sent:9,med:pmid:37940331,results,9,Median time to PCOs of ACEI+BB+MRA was 57.7 months whereas median times to those new combinations were longer than 57.7 months.,1241,1385
med:pmid:37940331:sec:results:sent:10,med:pmid:37940331,results,10,"In addition, the three new regimens had a significantly lower PCO risks than ACEI+BB+MRA, with the HRs (95% CI) of 0.51 (0.43 to 0.61), 0.55 (0.46 to 0.65) and 0.56 (0.47 to 0.67), accordingly.",1386,1579
med:pmid:37940331:sec:conclusion:sent:11,med:pmid:37940331,conclusion,11,"This study suggested that SGLT2i, ARNI and IVA in addition to ACEI+BB+MRA may be better in prolonging time to develop PCO in HFrEF patients.",1580,1740
med:pmid:37755814:sec:title:sent:0,med:pmid:37755814,title,0,Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.,0,84
med:pmid:37755814:sec:abstract:sent:1,med:pmid:37755814,abstract,1,"<h4>Importance</h4> The US Food and Drug Administration expanded labeling of sacubitril-valsartan from the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (EF) to all patients with HF, noting the greatest benefits in those with below-normal EF.",0,281
med:pmid:37755814:sec:abstract:sent:2,med:pmid:37755814,abstract,2,"However, the upper bound of below normal is not clearly defined, and value determinations across a broader EF range are unknown.",282,410
med:pmid:37755814:sec:introduction:sent:3,med:pmid:37755814,introduction,3,To estimate the cost-effectiveness of sacubitril-valsartan vs renin-angiotensin system inhibitors (RASis) across various upper-level cutoffs of EF.,411,577
med:pmid:37755814:sec:introduction:sent:4,med:pmid:37755814,introduction,4,"<h4>Design, setting, and participants</h4> This economic evaluation included participant-level data from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and the PARAGON-HF (Prospective Comparison of ARNi with ARB Global Outcomes in HF With Preserved Ejection Fraction) trials.",578,936
med:pmid:37755814:sec:introduction:sent:5,med:pmid:37755814,introduction,5,"PARADIGM-HF was conducted between 2009 and 2014, PARAGON-HF was conducted between 2014 and 2019, and this analysis was conducted between 2021 and 2023.",937,1088
med:pmid:37755814:sec:introduction:sent:6,med:pmid:37755814,introduction,6,<h4>Main outcomes and measures</h4> A 5-state Markov model used risk reductions for all-cause mortality and HF hospitalization from PARADIGM-HF and PARAGON-HF.,1089,1248
med:pmid:37755814:sec:introduction:sent:7,med:pmid:37755814,introduction,7,Quality-of-life differences were estimated from EuroQol-5D scores.,1249,1315
med:pmid:37755814:sec:introduction:sent:8,med:pmid:37755814,introduction,8,Hospitalization and medication costs were obtained from published national sources; the wholesale acquisition cost of sacubitril-valsartan was $7092 per year.,1316,1474
med:pmid:37755814:sec:introduction:sent:9,med:pmid:37755814,introduction,9,Risk estimates and treatment effects were generated in consecutive 5% EF increments up to 60% and applied to an EF distribution of US patients with HF from the Get With the Guidelines-Heart Failure registry.,1475,1682
med:pmid:37755814:sec:introduction:sent:10,med:pmid:37755814,introduction,10,The base case included a lifetime horizon from a health care sector perspective.,1683,1763
med:pmid:37755814:sec:introduction:sent:11,med:pmid:37755814,introduction,11,Incremental cost-effectiveness ratios (ICERs) were estimated at EFs of 60% or less (base case) and at various upper-level EF cutoffs.,1764,1897
med:pmid:37755814:sec:results:sent:12,med:pmid:37755814,results,12,"Among 13 264 total patients whose data were analyzed, for those with EFs of 60% or less, sacubitril-valsartan was projected to add 0.53 quality-adjusted life-years (QALYs) at an incremental lifetime cost of $40 892 compared with RASi, yielding an ICER of $76 852 per QALY.",1898,2187
med:pmid:37755814:sec:results:sent:13,med:pmid:37755814,results,13,"In a probabilistic sensitivity analysis, 95% of the values of the ICER occurred between $71 516 and $82 970 per QALY.",2188,2305
med:pmid:37755814:sec:results:sent:14,med:pmid:37755814,results,14,"Among patients with chronic HF and an EF of 60% or less, treatment with sacubitril-valsartan vs RASis would be at least of economic intermediate value (ICER <$180 000 per QALY) at a sacubitril-valsartan cost of $10 242 or less per year, of high economic value (ICER <$60 000 per QALY) at a cost of $3673 or less per year, and cost-saving at a cost of $338 or less per year.",2306,2679
med:pmid:37755814:sec:results:sent:15,med:pmid:37755814,results,15,"The ICERs were $67 331 per QALY, $59 614 per QALY, and $56 786 per QALY at EFs of 55% or less, 50% or less, and 45% or less, respectively.",2680,2818
med:pmid:37755814:sec:results:sent:16,med:pmid:37755814,results,16,Treatment with sacubitril-valsartan in only those with EFs of 45% or greater (up to ≤60%) yielded an ICER of $127 172 per QALY gained; treatment was more cost-effective in those at the lower end of this range (ICER of $100 388 per QALY gained for those with EFs of 45%-55%; ICER of $84 291 per QALY gained for those with EFs of 45%-50%).,2819,3156
med:pmid:37755814:sec:conclusion:sent:17,med:pmid:37755814,conclusion,17,Cost-effectiveness modeling provided an ICER for treatment with sacubitril-valsartan vs RASis consistent with high economic value for patients with reduced and mildly reduced EFs (≤50%) and at least intermediate value at the current undiscounted wholesale acquisition cost price at an EF of 60% or less.,3157,3495
med:pmid:37755814:sec:conclusion:sent:18,med:pmid:37755814,conclusion,18,Treatment was more cost-effective at lower EF ranges.,3496,3549
med:pmid:37755814:sec:conclusion:sent:19,med:pmid:37755814,conclusion,19,These findings may have implications for coverage decisions and value assessments in contemporary clinical practice guidelines.,3550,3677
med:pmid:37558137:sec:title:sent:0,med:pmid:37558137,title,0,Prognostic value of cardiopulmonary exercise testing repetition during follow-up of clinically stable patients with severe dilated cardiomyopathy.,0,146
med:pmid:37558137:sec:title:sent:1,med:pmid:37558137,title,1,A preliminary study.,147,167
med:pmid:37558137:sec:introduction:sent:2,med:pmid:37558137,introduction,2,Cardiopulmonary exercise testing (CPET) is a recognized tool for prognostic stratification in patients with dilated cardiomyopathy (DCM).,0,157
med:pmid:37558137:sec:introduction:sent:3,med:pmid:37558137,introduction,3,"Given the lack of data currently available, the aim of this study was to test the prognostic value of repeating CPET during the follow-up of patients with DCM.",158,317
med:pmid:37558137:sec:methods:sent:4,med:pmid:37558137,methods,4,"This multicenter, retrospective study, analyzed DCM patients who consecutively performed two echocardiographies and CPETs during clinical stability.",318,483
med:pmid:37558137:sec:methods:sent:5,med:pmid:37558137,methods,5,"The study end-point was a composite of death from all causes, heart transplantation, left ventricular assist device implantation, life-threatening ventricular arrhythmias or hospitalization for heart failure.",484,692
med:pmid:37558137:sec:results:sent:6,med:pmid:37558137,results,6,"216 DCM patients were enrolled (52 years, 78% male, NYHA I-II 82%, LVEF 32%, 94% on ACE inhibitors/ARNI, 95% on beta-blockers).",693,837
med:pmid:37558137:sec:results:sent:7,med:pmid:37558137,results,7,The interval between CPETs was 15 months.,838,879
med:pmid:37558137:sec:results:sent:8,med:pmid:37558137,results,8,"During a median follow-up of 38 months from the second CPET, 102 (47%) patients experienced the study end-point.",880,992
med:pmid:37558137:sec:results:sent:9,med:pmid:37558137,results,9,"Among them, there was stability of echocardiographic values but a significant worsening of functional capacity.",993,1104
med:pmid:37558137:sec:results:sent:10,med:pmid:37558137,results,10,"Among the 173 patients (80%) who did not show echocardiographic left ventricular reverse remodeling (LVRR), the 1-year prevalence of the study-end point was higher in patients who worsened vs patients who maintained stable their functional capacity at CPET (38 vs. 15% respectively, p-value: 0.001).",1105,1404
med:pmid:37558137:sec:results:sent:11,med:pmid:37558137,results,11,These results were consistent also when excluding life-threatening ventricular arrhythmias from the composite end-point.,1405,1525
med:pmid:37558137:sec:conclusion:sent:12,med:pmid:37558137,conclusion,12,"In clinically stable DCM patients with important depression of LVEF, the repetition of combined echocardiography and CPET might be recommended.",1526,1689
med:pmid:37558137:sec:conclusion:sent:13,med:pmid:37558137,conclusion,13,"When LVRR fails, 1-year repetition of CPET could identify higher-risk patients.",1690,1769
med:pmid:37941691:sec:title:sent:0,med:pmid:37941691,title,0,Real-world Practical Experience of Angiotensin Receptor-neprilysin Inhibitor in Older Japanese Patients with Chronic Heart Failure.,0,131
med:pmid:37941691:sec:introduction:sent:1,med:pmid:37941691,introduction,1,"Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is superior to enalapril for chronic heart failure (CHF) with reduced ejection fraction (EF).",0,190
med:pmid:37941691:sec:introduction:sent:2,med:pmid:37941691,introduction,2,"However, its efficacy and safety in older Japanese patients in clinical practice are poorly understood.",191,294
med:pmid:37941691:sec:introduction:sent:3,med:pmid:37941691,introduction,3,We aimed to investigate the efficacy and safety of ARNI compared with angiotensin receptor blocker (ARB) in older patients with CHF in real-world clinical practice.,295,459
med:pmid:37941691:sec:introduction:sent:4,med:pmid:37941691,introduction,4,"In addition, nutritional status and body composition were investigated as essential indicators of efficacy.",460,567
med:pmid:37941691:sec:methods:sent:5,med:pmid:37941691,methods,5,This retrospective single-center observational study enrolled 55 consecutive older patients (aged ≥75 years) with CHF who received ARNI (n = 27) or ARB (n = 28) therapy between October 2020 and March 2021.,568,790
med:pmid:37941691:sec:methods:sent:6,med:pmid:37941691,methods,6,"Blood samples were collected before (baseline) and 4, 12, and 24 weeks after ARNI or ARB therapy initiation.",791,899
med:pmid:37941691:sec:methods:sent:7,med:pmid:37941691,methods,7,"Furthermore, echocardiography was performed before (baseline) and 24 weeks after ARNI or ARB therapy initiation.",900,1012
med:pmid:37941691:sec:methods:sent:8,med:pmid:37941691,methods,8,"The efficacy endpoints were changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, left ventricular EF, nutritional status, and body composition changes.",1013,1184
med:pmid:37941691:sec:methods:sent:9,med:pmid:37941691,methods,9,The controlling nutritional status (CONUT) score and geriatric nutritional risk index were investigated as nutritional status indices.,1185,1319
med:pmid:37941691:sec:methods:sent:10,med:pmid:37941691,methods,10,"The safety endpoints were symptomatic hypotension, renal function exacerbation, and hyperkalemia in patients who continued ARNI or ARB therapy for >24 weeks without additional nonpharmacological treatment.",1320,1525
med:pmid:37941691:sec:results:sent:11,med:pmid:37941691,results,11,"There were no significant changes in NT-proBNP levels and estimated glomerular filtration rates; however, there was a significant CONUT score improvement in the ARNI group (least-squares mean difference, -1.0; 95% confidence interval, -1.4 to -0.3; <i>p</i> = 0.04).",1526,1809
med:pmid:37941691:sec:results:sent:12,med:pmid:37941691,results,12,The initial ARNI dose could not be uptitrated in five patients (19%) due to hypotension.,1810,1898
med:pmid:37941691:sec:conclusion:sent:13,med:pmid:37941691,conclusion,13,ARNI exhibited significant improvement in the nutritional status in older patients with CHF compared with ARB.,1899,2030
med:pmid:37941691:sec:conclusion:sent:14,med:pmid:37941691,conclusion,14,"However, the ARNI dose should be adjusted according to the patient's blood pressure.",2031,2115
med:pmid:37933369:sec:title:sent:0,med:pmid:37933369,title,0,The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis.,0,181
med:pmid:37933369:sec:abstract:sent:1,med:pmid:37933369,abstract,1,"Acute myocardial infarction (MI) is one of the leading global healthcare emergencies, contributing to over three million global deaths.",0,135
med:pmid:37933369:sec:abstract:sent:2,med:pmid:37933369,abstract,2,The purpose of this study is to investigate further the efficacy of sacubitril/valsartan over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in reducing the risk of heart failure (HF) in post-MI patients and providing a clear evidence-based medicine guideline for future use.,136,453
med:pmid:37933369:sec:abstract:sent:3,med:pmid:37933369,abstract,3,An electronic database search was conducted on English databases.,454,519
med:pmid:37933369:sec:abstract:sent:4,med:pmid:37933369,abstract,4,"Eight articles were included, fulfilling our inclusion criteria, i.e., adult patients of ≥18 years with a recent diagnosis of acute MI.",520,655
med:pmid:37933369:sec:abstract:sent:5,med:pmid:37933369,abstract,5,"Pooled analysis was done using Review Manager version 5.4.1 (Cochrane Collaboration, London, England), and the data for each outcome were analyzed as dichotomous variables.",656,828
med:pmid:37933369:sec:abstract:sent:6,med:pmid:37933369,abstract,6,A total of eight clinical trials were included in the meta-analysis.,829,897
med:pmid:37933369:sec:abstract:sent:7,med:pmid:37933369,abstract,7,Six studies analyzed the sacubitril/valsartan and ACEI combination.,898,965
med:pmid:37933369:sec:abstract:sent:8,med:pmid:37933369,abstract,8,"The pooled analysis reported a significant increase in the risk of hypotension (relative risk {RR}: 1.29 {1.18, 1.41}) in the sacubitril/valsartan compared to the ACEI alone group.",966,1146
med:pmid:37933369:sec:abstract:sent:9,med:pmid:37933369,abstract,9,"In addition, a significant increase was observed in the left ventricle ejection fraction (LVEF) after using the sacubitril/valsartan combination compared to using ACEI alone (RR: 3.08 {2.68, 4.48}).",1147,1345
med:pmid:37933369:sec:abstract:sent:10,med:pmid:37933369,abstract,10,"Furthermore, no significant difference was observed between the groups in terms of mortality rate (RR: 0.86 {0.73, 1.02}), the risk of heart failure (RR: 0.62 {0.39, 1.00}), the frequency of recurrent MI (RR: 0.86 {0.27, 2.76}), and the mean difference of N-terminal pro-B-type natriuretic peptide (NT-proBNP) (weighted mean difference {WMD}: -174.36 {-414.18, 65.46}) between both the groups.",1346,1739
med:pmid:37933369:sec:abstract:sent:11,med:pmid:37933369,abstract,11,"However, the sacubitril/valsartan combination proved to be beneficial in significantly reducing the risk of major adverse cardiac events (MACE) (RR: 0.64 {0.48, 0.84}) and rehospitalizations (RR: 0.53 {0.39, 0.71}) as compared to ACEI post MI.",1740,1983
med:pmid:37933369:sec:abstract:sent:12,med:pmid:37933369,abstract,12,"Additionally, sacubitril/valsartan and ARB's combination was reported in two studies.",1984,2069
med:pmid:37933369:sec:abstract:sent:13,med:pmid:37933369,abstract,13,"This led to a significant decrease in NT-proBNP concentration (WMD: -71.91 {-138.43, -5.39}) post MI in the sacubitril/valsartan combination group compared to the ARB usage alone.",2070,2249
med:pmid:37933369:sec:abstract:sent:14,med:pmid:37933369,abstract,14,"However, no significant difference was observed in the improvement of LVEF (WMD: 0.88 {-5.11, 6.87}) between both groups.",2250,2371
med:pmid:37933369:sec:abstract:sent:15,med:pmid:37933369,abstract,15,"Although the sacubitril/valsartan combination has no difference in mortality and outcomes compared to ACEI, there is evidence that using it proves to be more beneficial post MI compared to ACEI and ARB usage alone.",2372,2586
med:pmid:37646297:sec:title:sent:0,med:pmid:37646297,title,0,Pharmaco-disparities in heart failure: a survey of the affordability of guideline recommended therapy in 10 countries.,0,118
med:pmid:37646297:sec:introduction:sent:1,med:pmid:37646297,introduction,1,Heart failure with reduced ejection fraction (HFrEF) is treatable but guideline-directed medical therapy (GDMT) may not be affordable or accessible to people living with the disease.,0,196
med:pmid:37646297:sec:results:sent:2,med:pmid:37646297,results,2,"In this cross-sectional survey, we investigated the price, affordability, and accessibility of four pivotal classes of HFrEF GDMT: angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or angiotensin-neprilysin inhibitors (ARNI); beta-blockers; mineralocorticoid receptor antagonists (MRA); and sodium glucose co-transporter 2 inhibitors (SGLT2i).",197,604
med:pmid:37646297:sec:results:sent:3,med:pmid:37646297,results,3,"We sampled online or community pharmacies in 10 countries across a range of World Bank income groups, assessing mean 30 day retail prescription prices, affordability relative to gross national income per capita per month, and accessibility.",605,845
med:pmid:37646297:sec:results:sent:4,med:pmid:37646297,results,4,We reported median price ratios relative to the International Reference Standard.,846,927
med:pmid:37646297:sec:results:sent:5,med:pmid:37646297,results,5,We performed a literature review to evaluate accessibility to GDMT classes through publicly funded drug programmes in each country.,928,1059
med:pmid:37646297:sec:results:sent:6,med:pmid:37646297,results,6,"HFrEF GDMT prices, both absolute and relative to the international reference, were highest in the United States and lowest in Pakistan and Bangladesh.",1060,1210
med:pmid:37646297:sec:results:sent:7,med:pmid:37646297,results,7,"The most expensive drug was the ARNI, sacubitril/valsartan, with a mean (standard deviation, SD) 30 day price ranging from $11.06 (0.81) in Pakistan to $611.50 (3.54) in United States.",1211,1395
med:pmid:37646297:sec:results:sent:8,med:pmid:37646297,results,8,"The least expensive drug was the MRA, spironolactone, with a mean (SD) 30 day price ranging from $0.18 (0.00) in Pakistan to $12.32 (0.00) in England.",1396,1546
med:pmid:37646297:sec:results:sent:9,med:pmid:37646297,results,9,"Affordability (SD) of quadruple therapy-ARNI, beta-blockers, MRA, and SGLT2i-was best in high-income and worst in low-income countries, ranging from 1.49 (0.00)% of gross national income per capita per month in England to 232.47 (31.47)% in Uganda.",1547,1795
med:pmid:37646297:sec:results:sent:10,med:pmid:37646297,results,10,"Publicly funded drug programmes offset costs for eligible patients, but ARNI and SGLT2i were inaccessible through these programmes in low- and middle-income countries.",1796,1963
med:pmid:37646297:sec:results:sent:11,med:pmid:37646297,results,11,"Price, affordability, and access were substantially improved in all countries by substituting ARNI for ACEi/ARB.",1964,2076
med:pmid:37646297:sec:conclusion:sent:12,med:pmid:37646297,conclusion,12,There was marked variation between countries in the retail price of HFrEF GDMT.,2077,2177
med:pmid:37646297:sec:conclusion:sent:13,med:pmid:37646297,conclusion,13,"Despite higher prices in high-income countries, GDMT was more accessible and affordable than in low- and middle-income countries.",2178,2307
med:pmid:37646297:sec:conclusion:sent:14,med:pmid:37646297,conclusion,14,Publicly funded drug programmes in lower income countries increased affordability but limited access to newer HFrEF GDMT classes.,2308,2437
med:pmid:37646297:sec:conclusion:sent:15,med:pmid:37646297,conclusion,15,Pharmaco-disparities must be addressed to improve HFrEF outcomes globally.,2438,2512
med:pmid:37619492:sec:title:sent:0,med:pmid:37619492,title,0,Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials.,0,148
med:pmid:37619492:sec:abstract:sent:1,med:pmid:37619492,abstract,1,Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) associated with a decreased risk of death and hospitalization for selected patients with heart failure (HF).,0,184
med:pmid:37619492:sec:abstract:sent:2,med:pmid:37619492,abstract,2,"However, its association with improved atherosclerotic cardiovascular disease (ASCVD) events remains unclear.",185,294
med:pmid:37619492:sec:abstract:sent:3,med:pmid:37619492,abstract,3,We performed a meta-analysis to evaluate the association of ARNI with ASCVD events in patients with HF.,295,398
med:pmid:37619492:sec:abstract:sent:4,med:pmid:37619492,abstract,4,"We systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for studies comparing ARNIs with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in terms of myocardial infarction, stroke, angina pectoris, peripheral artery disease, and the composite end point in patients with HF.",399,732
med:pmid:37619492:sec:abstract:sent:5,med:pmid:37619492,abstract,5,"A total of 8 randomized controlled trials were included, with 17,541 patients assigned to either the ARNI (8,764 patients) or ACEi/ARB (8,777 patients) groups.",733,892
med:pmid:37619492:sec:abstract:sent:6,med:pmid:37619492,abstract,6,"The incidence of composite end point (risk ratio [RR] 1.03, 95% confidence interval [CI] 0.93 to 1.13, p = 0.63), myocardial infarction (RR 1.02, 95% CI 0.81 to 1.30, p = 0.85), angina pectoris (RR 0.96, 95% CI 0.80 to 1.17, p = 0.70), and stroke (RR 0.99, 95% CI 0.85 to 1.16, p = 0.93) were not statistically different between the ARNI and ACEi/ARB groups.",893,1251
med:pmid:37619492:sec:abstract:sent:7,med:pmid:37619492,abstract,7,"However, ARNI was associated with a higher incidence of peripheral artery disease (RR 1.63, 95% CI 1.05 to 2.52, p = 0.03).",1252,1375
med:pmid:37619492:sec:abstract:sent:8,med:pmid:37619492,abstract,8,"In conclusion, this meta-analysis found no association between ARNI therapy and improved ASCVD events in patients with HF.",1375,1498
med:pmid:37573615:sec:title:sent:0,med:pmid:37573615,title,0,Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.,0,114
med:pmid:37573615:sec:abstract:sent:1,med:pmid:37573615,abstract,1,"Randomized controlled trials have demonstrated mortality benefits for several medication classes in patients with heart failure (HF), especially with reduced ejection fraction (EF).",0,181
med:pmid:37573615:sec:abstract:sent:2,med:pmid:37573615,abstract,2,"However, the benefit of these traditional HF therapies in patients with HF from cardiac amyloidosis is unclear.",182,293
med:pmid:37573615:sec:abstract:sent:3,med:pmid:37573615,abstract,3,our study aimed to evaluate the safety and efficacy of traditional HF therapies in patients with cardiac amyloidosis and HF with reduced EF or HF with mid-range EF (HFmrEF).,294,467
med:pmid:37573615:sec:abstract:sent:4,med:pmid:37573615,abstract,4,We conducted a single-center retrospective study.,468,517
med:pmid:37573615:sec:abstract:sent:5,med:pmid:37573615,abstract,5,Patients were included if they were diagnosed with cardiac amyloidosis and HF with reduced EF or HF with mid-range EF between January 2012 and 2022.,518,666
med:pmid:37573615:sec:abstract:sent:6,med:pmid:37573615,abstract,6,"The primary outcomes of interest were medication use patterns (for β blockers [BB], angiotensin-converting enzyme inhibitors [ACEI], angiotensin receptor blockers [ARBs], angiotensin receptor neprilysin inhibitors [ARNI], and mineralocorticoid receptor antagonists [MRAs]); potential medication side effects (symptomatic bradycardia, fatigue, hypotension, lightheadedness, and syncope); hospitalization; and death.",667,1081
med:pmid:37573615:sec:abstract:sent:7,med:pmid:37573615,abstract,7,"The associations of BB, ACEI/ARB/ARNI, and MRA use with clinical outcomes were evaluated using Kaplan-Meier and Cox proportional hazards regression.",1082,1230
med:pmid:37573615:sec:abstract:sent:8,med:pmid:37573615,abstract,8,A total of 82 patients met study criteria.,1231,1273
med:pmid:37573615:sec:abstract:sent:9,med:pmid:37573615,abstract,9,"At time of cardiac amyloidosis diagnosis, 63.4% were on a BB, 51.2% were on an ACEI/ARB/ARNI, and 43.9% were on an MRA.",1274,1393
med:pmid:37573615:sec:abstract:sent:10,med:pmid:37573615,abstract,10,"At last follow-up, 51.2% were on a BB, 35.4% were on an ACEI/ARB/ARNI, and 43.9% were on an MRA.",1394,1490
med:pmid:37573615:sec:abstract:sent:11,med:pmid:37573615,abstract,11,There were no statistically significant differences in rates of potential medication side effects in patients on the medication class compared with those who were not.,1491,1658
med:pmid:37573615:sec:abstract:sent:12,med:pmid:37573615,abstract,12,"There was no association with hospitalization or mortality for baseline or follow-up BB, ACEI/ARB/ARNI, or MRA use.",1659,1774
med:pmid:37573615:sec:abstract:sent:13,med:pmid:37573615,abstract,13,"In conclusion, BBs, ACEI/ARB/ARNIs, and MRAs may be safely used in this population.",1775,1858
med:pmid:37573615:sec:abstract:sent:14,med:pmid:37573615,abstract,14,"However, their use does not appear to improve mortality or hospitalization.",1859,1934
med:pmid:37544137:sec:title:sent:0,med:pmid:37544137,title,0,Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Naïve to Renin-Angiotensin System Inhibitors.,0,163
med:pmid:37544137:sec:abstract:sent:1,med:pmid:37544137,abstract,1,Sacubitril/valsartan improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) compared with angiotensin-converting enzyme inhibitors (ACEis).,0,172
med:pmid:37544137:sec:abstract:sent:2,med:pmid:37544137,abstract,2,"However, data on postdischarge outcomes in renin-angiotensin system inhibitor (RASi)-naïve patients are limited.",173,285
med:pmid:37544137:sec:abstract:sent:3,med:pmid:37544137,abstract,3,"We included Medicare beneficiaries aged ≥65 years who were hospitalized for HFrEF in the Get With The Guidelines-Heart Failure registry between October 2015 and June 2019, had part D prescription coverage, and were not on RASi therapy during the 6 months before hospital admission.",286,567
med:pmid:37544137:sec:abstract:sent:4,med:pmid:37544137,abstract,4,We examined the associations between sacubitril/valsartan prescription at hospital discharge and outcomes at 30 days and 1 year after discharge using overlap-weighted median regression and Cox proportional hazards models.,568,789
med:pmid:37544137:sec:abstract:sent:5,med:pmid:37544137,abstract,5,"The end points included ""home time"" (defined as days alive and out of any health care institution), mortality, and rehospitalization.",790,923
med:pmid:37544137:sec:abstract:sent:6,med:pmid:37544137,abstract,6,"Among 3,572 patients with HFrEF and who are naïve to RASi therapy, at discharge, 290 (8.1%) were prescribed sacubitril/valsartan and 1,390 (38.9%) were prescribed ACEis and angiotensin receptor blockers.",924,1127
med:pmid:37544137:sec:abstract:sent:7,med:pmid:37544137,abstract,7,"After adjusting for baseline characteristics, patients prescribed sacubitril/valsartan had a longer median home time (parameter estimate 27.0 days, 95% confidence interval [CI] 12.40 to 41.6, p <0.001) and lower all-cause mortality (hazard ratio [HR] 0.74, 95% CI 0.61 to 0.91, p = 0.004) at 1 year than patients not prescribed sacubitril/valsartan.",1128,1477
med:pmid:37544137:sec:abstract:sent:8,med:pmid:37544137,abstract,8,"The prescription of sacubitril/valsartan was not significantly associated with all-cause rehospitalization (HR 0.87, 95% CI 0.74 to 1.03, p = 0.10) or heart failure rehospitalization (HR 0.87, 95% CI 0.70 to 1.07, p = 0.19).",1478,1702
med:pmid:37544137:sec:abstract:sent:9,med:pmid:37544137,abstract,9,"In a restricted comparison of patients discharged on sacubitril/valsartan versus ACEis and angiotensin receptor blockers, there were no significant differences in the outcomes.",1703,1879
med:pmid:37544137:sec:abstract:sent:10,med:pmid:37544137,abstract,10,"In conclusion, in this contemporary population of RASi-naïve patients with HFrEF from routine clinical practice, compared with not initiating, the initiation of sacubitril/valsartan at discharge was associated with longer home time and improvements in overall survival.",1880,2149
med:pmid:37435776:sec:title:sent:0,med:pmid:37435776,title,0,Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.,0,134
med:pmid:37435776:sec:introduction:sent:1,med:pmid:37435776,introduction,1,"To explore whether the beneficial cardiovascular (CV) effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors is consistent with or without concurrent use of CV medications in patients with type 2 diabetes, heart failure (HF) or chronic kidney disease.",0,271
med:pmid:37435776:sec:methods:sent:2,med:pmid:37435776,methods,2,We searched Medline and Embase up to September 2022 for CV outcomes trials.,272,364
med:pmid:37435776:sec:methods:sent:3,med:pmid:37435776,methods,3,The primary endpoint was the composite of cardiovascular (CV) death or hospitalization for HF.,365,459
med:pmid:37435776:sec:methods:sent:4,med:pmid:37435776,methods,4,"Secondary outcomes included the individual components of CV death, hospitalization for HF, death from any cause, major adverse CV events or renal events, volume depletion and hyperkalaemia.",460,649
med:pmid:37435776:sec:methods:sent:5,med:pmid:37435776,methods,5,We pooled hazard ratios (HRs) and risk ratios alongside 95% confidence intervals (CIs).,650,737
med:pmid:37435776:sec:results:sent:6,med:pmid:37435776,results,6,We included 12 trials comprising 83 804 patients.,738,804
med:pmid:37435776:sec:results:sent:7,med:pmid:37435776,results,7,"SGLT-2 inhibitors reduced the risk of CV death or hospitalization for HF regardless of background use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), b-blockers, diuretics, mineralocorticoid receptor antagonists (MRAs), or triple combination therapy of either an ACEI/ARB plus b-blocker plus MRA, or an ARNI plus b-blocker plus MRA (HRs ranged from 0.61 to 0.83; P > .1 for each subgroup interaction).",805,1298
med:pmid:37435776:sec:results:sent:8,med:pmid:37435776,results,8,"Similarly, no subgroup differences were evident for most analyses for the secondary outcomes of CV death, hospitalization for HF, all-cause mortality, major adverse CV or renal events, hyperkalaemia and volume depletion rate.",1299,1524
med:pmid:37435776:sec:conclusion:sent:9,med:pmid:37435776,conclusion,9,The benefit of SGLT-2 inhibitors seems to be additive to background use of CV medications in a broad population of patients.,1525,1670
med:pmid:37435776:sec:conclusion:sent:10,med:pmid:37435776,conclusion,10,These findings should be interpreted as hypothesis generating because most of the subgroups analysed were not prespecified.,1671,1794
med:pmid:35392695:sec:title:sent:0,med:pmid:35392695,title,0,A Retrospective Cohort Evaluation of a Pharmacist-Led Approach for Transitioning Patients to an Angiotensin Receptor-Neprilysin Inhibitor.,0,138
med:pmid:35392695:sec:abstract:sent:1,med:pmid:35392695,abstract,1,<b>Background:</b> Heart failure guidelines recommend replacing an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) with an angiotensin receptor neprilysin inhibitor (ARNI) to reduce morbidity and mortality in NYHA Class II-III patients with reduced ejection fraction (HFrEF).,0,312
med:pmid:35392695:sec:abstract:sent:2,med:pmid:35392695,abstract,2,<b>Objective:</b> This study aims to determine if a pharmacist-led outpatient ARNI replacement and titration program led to more patients achieving target doses of ARNI compared to usual care.,313,505
med:pmid:35392695:sec:abstract:sent:3,med:pmid:35392695,abstract,3,"<b>Methods:</b> A single health system, retrospective electronic medical record review identified 791 patients with active ARNI prescriptions and at least two outpatient cardiology visits with a pharmacist or usual care provider between January 2015 through September 2018.",506,779
med:pmid:35392695:sec:abstract:sent:4,med:pmid:35392695,abstract,4,The primary outcome was the percentage of patients who achieved a target ARNI dose of 97/103 mg twice daily.,780,888
med:pmid:35392695:sec:abstract:sent:5,med:pmid:35392695,abstract,5,"The secondary outcomes were the median dose achieved, number of visits required to achieve target dose, hospitalizations, and all-cause death.",889,1031
med:pmid:35392695:sec:abstract:sent:6,med:pmid:35392695,abstract,6,<b>Results:</b> ARNI was initiated and continued by a pharmacist in 64 patients and 727 by usual care.,1032,1134
med:pmid:35392695:sec:abstract:sent:7,med:pmid:35392695,abstract,7,"More patients in the pharmacist group, 60.9% (n = 39), achieved target dose vs. 18.0% (n = 131) of patients managed by usual care (95% CI, 0.31-0.55, p < 0.0001).",1135,1297
med:pmid:35392695:sec:abstract:sent:8,med:pmid:35392695,abstract,8,"The pharmacist group also had higher median total daily dose of ARNI (200 mg (IQR = 300) vs 100 mg (IQR = 100), p < 0.0001) and more likely to achieve a higher total daily dose in fewer visits.",1298,1491
med:pmid:35392695:sec:abstract:sent:9,med:pmid:35392695,abstract,9,<b>Conclusions:</b> An advanced practice provider pharmacist-led outpatient ARNI replacement and titration program was more effective in achieving target doses of ARNI in HFrEF patients as compared to usual care.,1492,1704
med:pmid:37759279:sec:title:sent:0,med:pmid:37759279,title,0,How do we define high and low dose intensity of heart failure medications: a scoping review.,0,92
med:pmid:37759279:sec:introduction:sent:1,med:pmid:37759279,introduction,1,Older adults with heart failure often experience adverse drug events with high doses of heart failure medications.,0,134
med:pmid:37759279:sec:introduction:sent:2,med:pmid:37759279,introduction,2,"Recognizing whether a patient is on a high or low dose intensity heart failure medication can be helpful for daily practice, since it could potentially guide the physician on which symptoms to look for, whether from overdosing or underdosing.",135,377
med:pmid:37759279:sec:introduction:sent:3,med:pmid:37759279,introduction,3,"However, the current guideline does not provide sufficient information about the dose intensity below the target dose.",378,496
med:pmid:37759279:sec:introduction:sent:4,med:pmid:37759279,introduction,4,"Furthermore, the definition of high or low-intensity heart failure medication is unclear, and there is no consensus.",497,613
med:pmid:37759279:sec:methods:sent:5,med:pmid:37759279,methods,5,"To close the knowledge gap, we conducted a scoping review of the current literature to identify the most frequently used definition of high versus low doses of heart failure medications.",614,817
med:pmid:37759279:sec:methods:sent:6,med:pmid:37759279,methods,6,"We searched Pubmed, Embase, CINAHL, and Cochrane Library using comprehensive search terms that can capture the intensity of heart failure medications.",818,968
med:pmid:37759279:sec:results:sent:7,med:pmid:37759279,results,7,"We reviewed 464 articles, including 144 articles that had information about beta-blockers (BB), 179 articles about angiotensin-converting enzyme inhibitors (ACEi), 75 articles about angiotensin receptor blockers (ARB), 80 articles about diuretics, 37 articles about mineralocorticoid receptor antagonists (MRA), and 33 articles about angiotensin receptor-neprilysin inhibitor (ARNI).",969,1369
med:pmid:37759279:sec:results:sent:8,med:pmid:37759279,results,8,"For hydralazine with isosorbide dinitrate or ivabradine, we could not identify any eligible articles.",1370,1471
med:pmid:37759279:sec:results:sent:9,med:pmid:37759279,results,9,We identified 40 medications with most frequently used definitions of dose intensity.,1472,1557
med:pmid:37759279:sec:results:sent:10,med:pmid:37759279,results,10,"Four medications (nadolol, pindolol, cilazapril, and torsemide) did not reach consensus in definitions.",1558,1661
med:pmid:37759279:sec:results:sent:11,med:pmid:37759279,results,11,"Most of the BBs, ACEis, or ARBs used the definition of low being < 50% of the target dose and high being ≥ 50% of the target dose from the guideline.",1662,1811
med:pmid:37759279:sec:results:sent:12,med:pmid:37759279,results,12,"However, for lisinopril and losartan, the most commonly used definitions of high or low were from pivotal clinical trials with a pre-defined definition of high or low.",1812,1979
med:pmid:37759279:sec:conclusion:sent:13,med:pmid:37759279,conclusion,13,Our comprehensive scoping review studies identified the most frequently used definition of dose intensity for 40 medications but could not identify the definitions for 4 medications.,1980,2182
med:pmid:37759279:sec:conclusion:sent:14,med:pmid:37759279,conclusion,14,"The results of the current scoping review will be helpful for clinicians to have awareness whether the currently prescribed dose is considered high - requiring close monitoring of side effects, or low - requiring more aggressive up-titration.",2183,2425
med:pmid:37660348:sec:title:sent:0,med:pmid:37660348,title,0,[The effect of kidney function on the optimization of medical therapy and on mortality in heart failure with reduced ejection fraction].,0,136
med:pmid:37660348:sec:introduction:sent:1,med:pmid:37660348,introduction,1,Renal dysfunction is a main limiting factor of applying and up-titrating guideline-directed medical therapy (GDMT) among patients with heart failure with reduced ejection fraction (HFrEF).,0,210
med:pmid:37660348:sec:introduction:sent:2,med:pmid:37660348,introduction,2,Our retrospective monocentric observational study aimed to analyse the application ratio of combined neurohormonal antagonist therapy (RASi: ACEI/ARB/ARNI + βB + MRA) and 12-month all-cause mortality differences in terms of renal dysfunction among HFrEF patients hospitalized for heart failure.,211,524
med:pmid:37660348:sec:introduction:sent:3,med:pmid:37660348,introduction,3,"<h4>Method</h4> We retrospectively analysed the cohort of consecutive HFrEF patients, hospitalized at the Heart Failure Unit of our tertiary cardiological centre in 2019-2021.",525,700
med:pmid:37660348:sec:introduction:sent:4,med:pmid:37660348,introduction,4,"The application ratio of discharge triple therapy (TT) in five groups established on admission eGFR parameters, representing severity of renal dysfunction (eGFR≥90, eGFR = 60-89, eGFR = 45-59, eGFR = 30-44, eGFR<30 ml/min/1.73 m2) was investigated with chi-square test, while 12-month mortality differences were analysed with Kaplan-Meier method and log-rank test.",701,1065
med:pmid:37660348:sec:results:sent:5,med:pmid:37660348,results,5,257 patients were included.,1066,1110
med:pmid:37660348:sec:results:sent:6,med:pmid:37660348,results,6,"Median eGFR was 57 (39-75) ml/min/1.73 m2, 54% of patients had eGFR<60 ml/min/1.73 m2.",1111,1197
med:pmid:37660348:sec:results:sent:7,med:pmid:37660348,results,7,"The proportion of patients in eGFR≥90, 60-89, 45-59, 30-44, <30 ml/min/1.73 m2 subgroups was 12%, 34%, 18%, 21%, 15%, respectively.",1198,1329
med:pmid:37660348:sec:results:sent:8,med:pmid:37660348,results,8,2% of patients were on dialysis.,1330,1362
med:pmid:37660348:sec:results:sent:9,med:pmid:37660348,results,9,"Even though the application rate of TT was notably high (77%) in the total cohort, more severe renal dysfunction led to a significantly lower implementation rate of TT (94%, 86%, 91%, 70%, 34%; p<0.0001): the application rate of RASi (100%, 98%, 96%, 89%, 50%, p<0.0001), βB (94%, 88%, 96%, 79%, 68%; p = 0.003) and MRA therapy (97%, 99%, 98%, 94%, 82%; p = 0.001) differed significantly.",1363,1751
med:pmid:37660348:sec:results:sent:10,med:pmid:37660348,results,10,12-month all-cause mortality was 23% in the whole cohort.,1752,1809
med:pmid:37660348:sec:results:sent:11,med:pmid:37660348,results,11,"Mortality rates were higher in more severe renal dysfunction (3%, 15%, 22%, 31%, 46%; p<0.0001).",1810,1906
med:pmid:37660348:sec:conclusion:sent:12,med:pmid:37660348,conclusion,12,"Even though the proportion of patients on TT in the whole cohort was remarkably high, renal dysfunction led to a significantly lower application ratio of TT, associating with worse survival.",1907,2117
med:pmid:37660348:sec:conclusion:sent:13,med:pmid:37660348,conclusion,13,Our results highlight that despite renal dysfunction the application of HFrEF cornerstone pharmacotherapy is essential.,2118,2237
med:pmid:37660348:sec:conclusion:sent:14,med:pmid:37660348,conclusion,14,Orv Hetil.,2238,2248
med:pmid:37660348:sec:conclusion:sent:15,med:pmid:37660348,conclusion,15,2023; 164(35): 1387-1396.,2249,2274
med:pmid:37429446:sec:title:sent:0,med:pmid:37429446,title,0,Clinical benefits of angiotensin receptor-Neprilysin inhibitor in adults with congenital heart disease.,0,103
med:pmid:37429446:sec:introduction:sent:1,med:pmid:37429446,introduction,1,There are limited data about the clinical benefits of angiotensin receptor-neprilysin inhibitor (ARNI) in adults with congenital heart disease (CHD).,0,169
med:pmid:37429446:sec:introduction:sent:2,med:pmid:37429446,introduction,2,The purpose of the study was to assess the clinical benefits (chamber function and heart failure indices) of ARNI in adults with CHD.,170,303
med:pmid:37429446:sec:introduction:sent:3,med:pmid:37429446,introduction,3,"<h4>Method</h4> In this retrospective cohort study, we compared the temporal change in chamber function and heart failure indices between 35 patients that received ARNI for >6 months, and a propensity matched control group (n = 70) of patients that received angiotensin converting enzyme inhibitor or angiotensin-II receptor blocker (ACEI/ARB) within the same period.",304,671
med:pmid:37429446:sec:results:sent:4,med:pmid:37429446,results,4,"Of the 35 patients in the ARNI group, 21 (60%) had systemic left ventricle (LV) while 14 (40%) had systemic right ventricle (RV).",672,818
med:pmid:37429446:sec:results:sent:5,med:pmid:37429446,results,5,"Compared to the ACEI/ARB group, the ARNI group had greater relative improvement in LV global longitudinal strain (GLS) (28% versus 11% increase from baseline, p < 0.001) and RV-GLS (11% versus 4% increase from baseline, p < 0.001), and greater relative improvement in New York Heart Association functional class (-14 versus -2% change from baseline, p = 0.006) and N-terminal pro-brain natriuretic peptide levels (-29% versus -13% change from baseline, p < 0.001).",819,1283
med:pmid:37429446:sec:results:sent:6,med:pmid:37429446,results,6,These results were consistent across different systemic ventricular morphologies.,1284,1365
med:pmid:37429446:sec:conclusion:sent:7,med:pmid:37429446,conclusion,7,"ARNI was associated with improvement in biventricular systolic function, functional status, and neurohormonal activation, suggesting prognostic benefit.",1366,1539
med:pmid:37429446:sec:conclusion:sent:8,med:pmid:37429446,conclusion,8,"These results provide a foundation for a randomized clinical trial to empirically test the prognostic benefits of ARNI in adults with CHD, as the next step towards evidence-based recommendations for heart failure management in this population.",1540,1783
med:pmid:37311917:sec:title:sent:0,med:pmid:37311917,title,0,Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.,0,110
med:pmid:37311917:sec:abstract:sent:1,med:pmid:37311917,abstract,1,Multiple landmark trials have helped to advance the treatment of heart failure with reduced ejection fraction (HFrEF) significantly over the past decade.,0,153
med:pmid:37311917:sec:abstract:sent:2,med:pmid:37311917,abstract,2,"These trials have led to the introduction of four main drug classes into the 2021 ESC guideline, namely angiotensin-receptor neprilysin inhibitors/angiotensin-converting-enzyme inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors.",154,444
med:pmid:37311917:sec:abstract:sent:3,med:pmid:37311917,abstract,3,"The life-saving effect of these therapies has been shown to be additive and becomes apparent within weeks, which is why maximally tolerated or target doses of all drug classes should be strived for as quickly as possible.",445,666
med:pmid:37311917:sec:abstract:sent:4,med:pmid:37311917,abstract,4,"Recent evidence, such as the STRONG-HF trial, demonstrated that rapid drug implementation and up-titration is superior to the traditional and more gradual step-by-step approach where valuable time is lost to up-titration.",667,888
med:pmid:37311917:sec:abstract:sent:5,med:pmid:37311917,abstract,5,"Accordingly, multiple rapid drug implementation and sequencing strategies have been proposed to significantly reduce the time needed for the titration process.",889,1048
med:pmid:37311917:sec:abstract:sent:6,med:pmid:37311917,abstract,6,Such strategies are urgently needed since previous large-scale registries have shown that guideline-directed medical therapy (GDMT) implementation is a challenge.,1049,1211
med:pmid:37311917:sec:abstract:sent:7,med:pmid:37311917,abstract,7,"This challenge is reflected by generally low adherence rates, which can be attributed to factors considering the patient, health care system, and local hospital/health care provider.",1212,1394
med:pmid:37311917:sec:abstract:sent:8,med:pmid:37311917,abstract,8,"This review of the four medication classes used to treat HFrEF seeks to present a thorough overview of the data supporting current GDMT, discuss the obstacles to GDMT implementation and up-titration, and identify multiple sequencing strategies that could improve GDMT adherence.",1395,1673
med:pmid:37311917:sec:abstract:sent:9,med:pmid:37311917,abstract,9,Sequencing strategies for GDMT implementation.,1674,1720
med:pmid:37311917:sec:abstract:sent:10,med:pmid:37311917,abstract,10,GDMT: guideline-directed medical therapy; ACEi: angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; ARNi: angiotensin receptor-neprilysin inhibitor; BB: beta-blocker; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium-glucose co-transporter 2 inhibitor.,1721,2009
med:pmid:37164146:sec:title:sent:0,med:pmid:37164146,title,0,Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes.,0,80
med:pmid:37164146:sec:title:sent:1,med:pmid:37164146,title,1,Insights from the diabetes collaborative registry.,81,131
med:pmid:37164146:sec:introduction:sent:2,med:pmid:37164146,introduction,2,Cardiovascular disease remains the primary source of morbidity and mortality in type 2 diabetes (T2D).,0,122
med:pmid:37164146:sec:methods:sent:3,med:pmid:37164146,methods,3,"We characterized the change over time in the use of evidence-based therapies to reduce cardiovascular risk in US patients with T2D.   Data from a longitudinal outpatient diabetes registry were used to calculate the prescription of SGLT2i or GLP-1RA over time and among those with high-risk comorbidities (atherosclerotic cardiovascular disease [ASCVD], heart failure [HF], chronic kidney disease [CKD]) and a diabetes cardiovascular composite score (DCCS; calculated as: #eligible medications prescribed/#eligible medications x 100 for SGLT2i, GLP-1RA, statin, antiplatelet/anticoagulant therapy, ACEi/ARB/ARNI).",123,750
med:pmid:37164146:sec:methods:sent:4,med:pmid:37164146,methods,4,Scores ranged from 0% to 100% (higher=more optimal care).,751,808
med:pmid:37164146:sec:results:sent:5,med:pmid:37164146,results,5,"Among 1,001,542 outpatients from 391 US sites, 51.7% patients had ASVCD, 17.7% HF, and 23.0% CKD.",809,923
med:pmid:37164146:sec:results:sent:6,med:pmid:37164146,results,6,"The percentage of patients prescribed an SGLT2i or GLP-1RA increased over time (7.3% in 2013 to 28.8% in 2019), and 18.3% of patients with ASCVD, HF, or CKD were on at least one of these medications at last follow-up vs 25.5% of patients without any of these comorbidities.",924,1197
med:pmid:37164146:sec:results:sent:7,med:pmid:37164146,results,7,"Mean DCCS was 54±36%; 54±25% in patients with ASCVD, HF, or CKD vs 52±50% in patients without any of these comorbidities (P<0.001 for both).",1198,1338
med:pmid:37164146:sec:results:sent:8,med:pmid:37164146,results,8,"In a hierarchical linear model, male sex, and a diagnosis of CKD were independently associated with higher DCCS whereas a diagnosis of HF or ASCVD was associated with a lower DCCS.",1339,1519
med:pmid:37164146:sec:conclusion:sent:9,med:pmid:37164146,conclusion,9,"In a large, contemporary cohort of patients with T2D, we found improvement in the use of SGLT2i and GLP-1RA but unexpectedly lower use in patients with ASCVD, heart failure, and CKD, highlighting a treatment-risk paradox.",1520,1762
med:pmid:37164146:sec:conclusion:sent:10,med:pmid:37164146,conclusion,10,Further education is needed to shift the understanding of these medications as tools for glucose-lowering to cardiovascular risk reduction and to improve their implementation in clinical practice.,1763,1959
med:pmid:36475871:sec:title:sent:0,med:pmid:36475871,title,0,Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.,0,144
med:pmid:36475871:sec:introduction:sent:1,med:pmid:36475871,introduction,1,Data on the effects of sacubitril/valsartan compared with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) on health-related quality of life (HRQoL) are limited.,0,214
med:pmid:36475871:sec:introduction:sent:2,med:pmid:36475871,introduction,2,"To evaluate the comparative effects between sacubitril/valsartan and ACEI/ARB on HRQoL, a systematic review and meta-analysis were performed.",215,375
med:pmid:36475871:sec:methods:sent:3,med:pmid:36475871,methods,3,"PubMed, EMBASE, Web of Science, and ClinicalTrials.gov were searched from inception to March 2, 2022 for randomized controlled trials that compared the HRQoL scores, including Kansas City Cardiomyopathy Questionnaire (KCCQ), Minnesota Living with Heart Failure Questionnaire (MLHFQ), or Medical Outcomes Study Short-Form Health Survey 12 or 36 (SF-12/36), between sacubitril/valsartan and ACEI/ARB.",376,791
med:pmid:36475871:sec:methods:sent:4,med:pmid:36475871,methods,4,"After screening, studies that met the inclusion criteria were eventually included and analyzed.",792,887
med:pmid:36475871:sec:results:sent:5,med:pmid:36475871,results,5,"A total of 8 studies with 17 390 patients (8693 patients used sacubitril/valsartan, and 8697 patients used ACEI/ARB) were included in this study.",888,1050
med:pmid:36475871:sec:results:sent:6,med:pmid:36475871,results,6,"Five of these studies used KCCQ, 1 used SF-12/36, 1 used MLHFQ, and 1 used both KCCQ and SF-12/36.",1051,1149
med:pmid:36475871:sec:results:sent:7,med:pmid:36475871,results,7,"The KCCQ overall summary score and its subscales were significantly higher in sacubitril/valsartan compared with ACEI/ARB in heart failure patients with reduced ejection fraction, but were similar in heart failure patients with preserved ejection fraction.",1150,1406
med:pmid:36475871:sec:results:sent:8,med:pmid:36475871,results,8,Sacubitril/valsartan conferred similar HRQoL scores in MLHFQ and SF-12/36 to ACEI/ARB.,1407,1493
med:pmid:36475871:sec:results:sent:9,med:pmid:36475871,results,9,The most frequently reported adverse event for sacubitril/valsartan is hypotension and the risk is higher than for ACEI/ARB.,1494,1618
med:pmid:36475871:sec:conclusion:sent:10,med:pmid:36475871,conclusion,10,Sacubitril/valsartan may have the potential to improve HRQoL in heart failure patients with reduced ejection fraction compared with ACEI/ARB.,1619,1781
med:pmid:36475871:sec:conclusion:sent:11,med:pmid:36475871,conclusion,11,Hypotension is the most common adverse event with sacubitril/valsartan compared with ACEI/ARB.,1782,1876
med:pmid:36475871:sec:conclusion:sent:12,med:pmid:36475871,conclusion,12,The results of this study may contribute to the rational use of sacubitril/valsartan.,1877,1962
med:pmid:35418252:sec:title:sent:0,med:pmid:35418252,title,0,Cost-Effectiveness of Sacubitril-Valsartan Compared to Angiotensin-Converting Enzyme Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction.,0,158
med:pmid:35418252:sec:abstract:sent:1,med:pmid:35418252,abstract,1,<b>Objectives:</b> The goal of this study was to compare cost-effectiveness of sacubitril/valsartan with angiotensin-converting enzyme (ACE) inhibitors for treating chronic heart failure patients with reduced ejection fraction (HFrEF) from the published articles and explore the methodology applied in the studies.,0,314
med:pmid:35418252:sec:abstract:sent:2,med:pmid:35418252,abstract,2,"<b>Methods:</b> Systematic research was conducted in February 2021 using PubMed, Cochrane, and EBSCO.",315,416
med:pmid:35418252:sec:abstract:sent:3,med:pmid:35418252,abstract,3,"A combination of MeSH terms of ""cost-effectiveness analysis,"" ""heart failure with reduced ejection fraction,"" ""sacubitril valsartan,"" and ""angiotensin converting enzyme inhibitor"" was employed.",417,610
med:pmid:35418252:sec:abstract:sent:4,med:pmid:35418252,abstract,4,The review selected for articles published in the last five years in English.,611,688
med:pmid:35418252:sec:abstract:sent:5,med:pmid:35418252,abstract,5,<b>Results:</b> A total of 15 studies were included in this review.,689,756
med:pmid:35418252:sec:abstract:sent:6,med:pmid:35418252,abstract,6,We found that these studies had been conducted in 12 different countries.,757,830
med:pmid:35418252:sec:abstract:sent:7,med:pmid:35418252,abstract,7,"The United States had the greatest number of publications (5), followed by the Netherlands (2).",831,926
med:pmid:35418252:sec:abstract:sent:8,med:pmid:35418252,abstract,8,The study method most used was the Markov decision model (73%).,927,990
med:pmid:35418252:sec:abstract:sent:9,med:pmid:35418252,abstract,9,Almost all studies produced ICERs and QALYs that were numerically high.,991,1062
med:pmid:35418252:sec:abstract:sent:10,med:pmid:35418252,abstract,10,<b>Conclusions:</b> The use of sacubitril/valsartan associates with longer life expectancy and incremental cost-effectiveness ratio than angiotensin-converting enzyme inhibitors.,1063,1241
med:pmid:37407154:sec:title:sent:0,med:pmid:37407154,title,0,Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.,0,84
med:pmid:37407154:sec:introduction:sent:1,med:pmid:37407154,introduction,1,Anemia is common in patients with heart failure with reduced ejection fraction and is associated with poor clinical outcomes.,0,145
med:pmid:37407154:sec:introduction:sent:2,med:pmid:37407154,introduction,2,Renin-angiotensin system blockers lower hemoglobin and may induce anemia.,146,219
med:pmid:37407154:sec:introduction:sent:3,med:pmid:37407154,introduction,3,The authors investigated whether concomitant neprilysin inhibition might ameliorate this effect of renin-angiotensin system blockers in PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure).,220,502
med:pmid:37407154:sec:methods:sent:4,med:pmid:37407154,methods,4,Anemia was defined as hemoglobin <120 g/L in women and <130 g/L in men at screening.,503,604
med:pmid:37407154:sec:methods:sent:5,med:pmid:37407154,methods,5,"The authors investigated the effect of randomized treatment on clinical outcomes according to anemia status, change in hemoglobin from baseline, and the incidence of anemia.",605,778
med:pmid:37407154:sec:results:sent:6,med:pmid:37407154,results,6,"Of 8,239 participants with a baseline hemoglobin measurement, 1,677 (20.4%) were anemic.",779,884
med:pmid:37407154:sec:results:sent:7,med:pmid:37407154,results,7,"Patients with anemia had a more severe heart failure profile, worse kidney function, greater neurohormonal derangement, and worse clinical outcomes.",885,1033
med:pmid:37407154:sec:results:sent:8,med:pmid:37407154,results,8,"Sacubitril/valsartan, compared with enalapril, decreased the risk of cardiovascular death or heart failure hospitalization similarly in patients with (HR: 0.84; 95% CI: 0.71-1.00) and without anemia (HR: 0.78 [95% CI: 0.71-0.87]; P value for interaction = 0.478).",1034,1297
med:pmid:37407154:sec:results:sent:9,med:pmid:37407154,results,9,"Between baseline and 12 months, hemoglobin decreased by 1.5 g/L (95% CI: 1.2-1.7 g/L) with sacubitril/valsartan compared with 2.3 g/L (95% CI: 2.0-2.6 g/L) with enalapril: mean difference 0.8 g/L (95% CI: 0.5-1.2 g/L; P < 0.001).",1298,1527
med:pmid:37407154:sec:results:sent:10,med:pmid:37407154,results,10,"Patients assigned to sacubitril/valsartan were less likely to develop anemia at 12 months (321 of 2,806 [11.4%]) compared with patients randomized to enalapril (440 of 2,824 [15.6%]) (OR: 0.70 [95% CI: 0.60-0.81]; P < 0.001).",1528,1753
med:pmid:37407154:sec:results:sent:11,med:pmid:37407154,results,11,These findings were similar in PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) (sacubitril/valsartan vs valsartan).,1754,1929
med:pmid:37407154:sec:results:sent:12,med:pmid:37407154,results,12,There was biomarker evidence of increased iron utilization with sacubitril/valsartan.,1930,2015
med:pmid:37407154:sec:conclusion:sent:13,med:pmid:37407154,conclusion,13,"Irrespective of anemia status, sacubitril/valsartan compared with enalapril, decreased mortality and hospitalization.",2016,2154
med:pmid:37407154:sec:conclusion:sent:14,med:pmid:37407154,conclusion,14,Hemoglobin decreased less with sacubitril/valsartan and the incidence of new anemia was lower with sacubitril/valsartan. (,2155,2277
med:pmid:37407154:sec:conclusion:sent:15,med:pmid:37407154,conclusion,15,Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure [PARADIGM-HF] trial; NCT01035255).,2277,2423
med:pmid:37115135:sec:title:sent:0,med:pmid:37115135,title,0,Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial.,0,121
med:pmid:37115135:sec:introduction:sent:1,med:pmid:37115135,introduction,1,"In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) trial, a central committee of heart failure (HF) specialists optimized guideline-directed medical therapies (GDMT) and documented medication and goal dose intolerances before patient enrollment.",0,366
med:pmid:37115135:sec:introduction:sent:2,med:pmid:37115135,introduction,2,"The authors sought to assess the rates, reasons, and predictors of GDMT intolerance in the COAPT trial.",367,490
med:pmid:37115135:sec:methods:sent:3,med:pmid:37115135,methods,3,"Baseline use, dose, and intolerances of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), angiotensin receptor neprilysin inhibitors (ARNIs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) were analyzed in patients with left ventricular ejection fraction (LVEF) ≤40%, in whom maximally tolerated doses of these agents as assessed by an independent HF specialist were required before enrollment.",491,961
med:pmid:37115135:sec:results:sent:4,med:pmid:37115135,results,4,A total of 464 patients had LVEF ≤40% and complete medication information.,962,1053
med:pmid:37115135:sec:results:sent:5,med:pmid:37115135,results,5,"At baseline, 38.8%, 39.4%, and 19.8% of patients tolerated 3, 2, and 1 GDMT classes, respectively (any dose); only 1.9% could not tolerate any GDMT.",1054,1202
med:pmid:37115135:sec:results:sent:6,med:pmid:37115135,results,6,"Beta-blockers were the most frequently tolerated GDMT (93.1%), followed by ACEIs/ARBs/ARNIs (68.5%), and then MRAs (55.0%).",1203,1326
med:pmid:37115135:sec:results:sent:7,med:pmid:37115135,results,7,"Intolerances differed by GDMT class, but hypotension and kidney dysfunction were most common.",1327,1420
med:pmid:37115135:sec:results:sent:8,med:pmid:37115135,results,8,Goal doses were uncommonly achieved for beta-blockers (32.3%) and ACEIs/ARBs/ARNIs (10.2%) due to intolerances limiting titration.,1421,1551
med:pmid:37115135:sec:results:sent:9,med:pmid:37115135,results,9,Only 2.2% of patients tolerated goal doses of all 3 GDMT classes.,1552,1617
med:pmid:37115135:sec:conclusion:sent:10,med:pmid:37115135,conclusion,10,"In a contemporary trial population with HF, severe mitral regurgitation, and systematic HF specialist-directed GDMT optimization, most patients had medical intolerances prohibiting 1 or more GDMT classes and achieving goal doses.",1618,1868
med:pmid:37115135:sec:conclusion:sent:11,med:pmid:37115135,conclusion,11,The specific intolerances noted and methods used for GDMT optimization provide important lessons for the implementation of GDMT optimization in future clinical trials. (,1869,2038
med:pmid:37115135:sec:conclusion:sent:12,med:pmid:37115135,conclusion,12,Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).,2038,2215
med:pmid:37104912:sec:title:sent:0,med:pmid:37104912,title,0,Budget Impact Analysis of Utilization of Sacubitril/Valsartan for the Treatment of Heart Failure With Reduced Ejection Fraction in the Philippines.,0,147
med:pmid:37104912:sec:introduction:sent:1,med:pmid:37104912,introduction,1,This study aimed to estimate the financial and economic impact of sacubitril/valsartan compared with enalapril for the treatment and prevention of hospitalization/rehospitalization because of heart failure with reduced ejection fraction (HFrEF).,0,265
med:pmid:37104912:sec:methods:sent:2,med:pmid:37104912,methods,2,The budget impact analysis was guided by the Philippine Reference Case and ISPOR's Principles of Good Practice for Budget Impact Analysis.,266,421
med:pmid:37104912:sec:methods:sent:3,med:pmid:37104912,methods,3,A government-funded healthcare payer perspective and a societal perspective were considered.,422,514
med:pmid:37104912:sec:results:sent:4,med:pmid:37104912,results,4,collection was guided by the pathways of disease progression and care.,515,590
med:pmid:37104912:sec:results:sent:5,med:pmid:37104912,results,5,Collection of costing data followed a bottom-up approach.,591,648
med:pmid:37104912:sec:results:sent:6,med:pmid:37104912,results,6,The model was based on a Markov model used in a study in Thailand.,649,715
med:pmid:37104912:sec:results:sent:7,med:pmid:37104912,results,7,"Over the next 5 years, there will be 17 625 less hospitalizations (∼5.1% less than enalapril arm) and 7968 less cardiovascular-related deaths (∼7.0% less than enalapril arm).",716,907
med:pmid:37104912:sec:results:sent:8,med:pmid:37104912,results,8,"In 5 years, the total cost of treating patients with HFrEF with sacubitril/valsartan at current market coverage and annual growth conditions is ₱15.430 billion, which is ₱11.077 billion higher than fully treating with enalapril only.",908,1141
med:pmid:37104912:sec:results:sent:9,med:pmid:37104912,results,9,"The total required additional investment with treatment of sacubitril/valsartan compared with the full enalapril arm are ₱407 million (at 30-day coverage), ₱800 million (at 60-day coverage), and ₱1.181 billion (at 90-day coverage).",1142,1373
med:pmid:37104912:sec:results:sent:10,med:pmid:37104912,results,10,"If hospitalizations costs alone are considered, only the 30-day coverage is cost-saving.",1374,1462
med:pmid:37104912:sec:results:sent:11,med:pmid:37104912,results,11,"If a societal perspective is considered, all options are cost-saving where at least ₱4.003 billion is saved by the economy.",1463,1586
med:pmid:37104912:sec:conclusion:sent:12,med:pmid:37104912,conclusion,12,"The initial investment required to treat patients with HFrEF with sacubitril/valsartan is high; nevertheless, the year-on-year cost deficit shrinks in favor of investing in sacubitril/valsartan treatment.",1587,1811
med:pmid:38938237:sec:title:sent:0,med:pmid:38938237,title,0,Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection Fraction.,0,92
med:pmid:38938237:sec:introduction:sent:1,med:pmid:38938237,introduction,1,Recent trial data refute concerns about neurocognitive off-target effects of neprilysin inhibition with sacubitril and suggest benefit in patients with heart failure and ejection fraction >40%.,0,213
med:pmid:38938237:sec:introduction:sent:2,med:pmid:38938237,introduction,2,We hypothesized that sacubitril/valsartan is associated with improved cognitive outcomes in patients with heart failure and reduced ejection fraction (HFrEF).,214,372
med:pmid:38938237:sec:introduction:sent:3,med:pmid:38938237,introduction,3,The purpose of this study was to compare 3-year cognitive outcomes in patients with HFrEF who receive sacubitril/valsartan vs angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).,373,608
med:pmid:38938237:sec:methods:sent:4,med:pmid:38938237,methods,4,"Retrospective cohort study of: 1) 11,313 adults with HFrEF (International Classification of Diseases-10th Revision-Clinical Modification [ICD-10-CM] codes: I50.2 or I50.4) started on sacubitril/valsartan between 1/1/2015 and 12/31/2019; and 2) 11,313 propensity matched patients receiving ACEI/ARB during that time.",609,941
med:pmid:38938237:sec:results:sent:5,med:pmid:38938237,results,5,"were obtained from the TriNetX Research Network, encompassing 41 health care organizations in the United States.",942,1059
med:pmid:38938237:sec:results:sent:6,med:pmid:38938237,results,6,"Primary endpoint was the composite of cognitive decline (ICD-10-CM: R41.8), dementia (ICD-10-CM: F01-F03), and Alzheimer's disease (ICD-10-CM: G30).",1060,1208
med:pmid:38938237:sec:results:sent:7,med:pmid:38938237,results,7,"At 3 years, 858 patients on sacubitril/valsartan met the primary endpoint vs 1,209 on ACEI/ARB (3-year incidence: 10.7% vs 15.0%; HR: 0.69; 95% CI: 0.63-0.75; <i>P</i> < 0.001), with consistently lower rates of cognitive decline (9.5% vs 13.3%; HR: 0.69; 95% CI: 0.63-0.76; <i>P</i> < 0.001), dementia (3.4% vs 5.0%; HR: 0.65; 95% CI: 0.57-0.77; <i>P</i> < 0.001), and Alzheimer's disease (0.6% vs 1.3%; HR: 0.48; 95% CI: 0.35-0.66; <i>P</i> < 0.001) in the sacubitril/valsartan cohort.",1209,1712
med:pmid:38938237:sec:results:sent:8,med:pmid:38938237,results,8,were consistent in matched sex and race subgroups.,1713,1771
med:pmid:38938237:sec:results:sent:9,med:pmid:38938237,results,9,Three-year mortality was 22.0% on sacubitril/valsartan vs 24.6% on ACEI/ARB (HR: 0.89; 95% CI: 0.84-0.94; <i>P</i> < 0.001).,1772,1896
med:pmid:38938237:sec:conclusion:sent:10,med:pmid:38938237,conclusion,10,Sacubitril/valsartan was associated with lower 3-year rates of neurocognitive disorders when compared to ACEI/ARBs in patients with HFrEF.,1897,2056
med:pmid:37374004:sec:title:sent:0,med:pmid:37374004,title,0,Heart Failure Therapies following Acute Coronary Syndromes with Reduced Ejection Fraction: Data from the ACSIS Survey.,0,118
med:pmid:37374004:sec:introduction:sent:1,med:pmid:37374004,introduction,1,Guideline-directed medical therapies for heart failure (HF) may benefit patients with reduced left ventricular ejection fraction (LVEF) following acute coronary syndromes (ACS).,0,197
med:pmid:37374004:sec:introduction:sent:2,med:pmid:37374004,introduction,2,Few real-world data are available regarding the early implementation of HF therapies in patients with ACS and reduced LVEF.,198,321
med:pmid:37374004:sec:methods:sent:3,med:pmid:37374004,methods,3,"Data collected from the 2021 nationwide, prospective ACS Israeli Survey (ACSIS).",322,419
med:pmid:37374004:sec:methods:sent:4,med:pmid:37374004,methods,4,"Drug classes included: (a) angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) or angiotensin receptor-neprilysin inhibitors (ARNI); (b) beta-blockers; (c) mineralocorticoid receptor antagonist (MRA) and (d) sodium-glucose cotransporter-2 inhibitors (SGLT2I).",420,712
med:pmid:37374004:sec:methods:sent:5,med:pmid:37374004,methods,5,The utilization of HF therapies at discharge or 90 days following ACS was analyzed in relation to LVEF [reduced ≤40% (<i>n</i> = 406) or mildly-reduced 41-49% (<i>n</i> = 255)] and short-term adverse outcomes.,713,922
med:pmid:37374004:sec:results:sent:6,med:pmid:37374004,results,6,"History of HF, anterior wall myocardial infarction and Killip class II-IV (32% vs. 14% <i>p</i> < 0.001) were more prevalent in those with reduced compared to mildly-reduced LVEF.",923,1119
med:pmid:37374004:sec:results:sent:7,med:pmid:37374004,results,7,"ACEI/ARB/ARNI and beta-blockers were used by the majority of patients in both LVEF groups, though ARNI was prescribed to only 3.9% (LVEF ≤ 40%).",1120,1264
med:pmid:37374004:sec:results:sent:8,med:pmid:37374004,results,8,"MRA was used by 42.9% and 12.2% of patients with LVEF ≤40% and 41-49%, respectively, and SGLT2I in about a quarter of both LVEF groups.",1265,1400
med:pmid:37374004:sec:results:sent:9,med:pmid:37374004,results,9,"Overall, ≥3 HF drug classes were documented in 44% of the patients.",1401,1468
med:pmid:37374004:sec:results:sent:10,med:pmid:37374004,results,10,"A trend towards higher rates of 90-day HF rehospitalizations, recurrent ACS or all-cause death was noted in those with reduced (7.6%) vs. mildly-reduced (3.7%) LVEF, <i>p</i> = 0.084.",1469,1652
med:pmid:37374004:sec:results:sent:11,med:pmid:37374004,results,11,No association was observed between the number of HF drug classes or the use of ARNI and/or SGLT2I with adverse clinical outcomes.,1653,1783
med:pmid:37374004:sec:conclusion:sent:12,med:pmid:37374004,conclusion,12,"In current clinical practice, the majority of patients with reduced and mildly-reduced LVEF are treated by ACEI/ARB and beta-blockers early following ACS, whereas MRA is underutilized and the adoption of SGLT2I and ARNI is low.",1784,2032
med:pmid:37374004:sec:conclusion:sent:13,med:pmid:37374004,conclusion,13,A greater number of therapeutic classes was not associated with reduced short-term rehospitalizations or mortality.,2033,2148
med:pmid:37278232:sec:title:sent:0,med:pmid:37278232,title,0,Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.,0,123
med:pmid:37278232:sec:introduction:sent:1,med:pmid:37278232,introduction,1,The 2022 clinical guidelines for management of heart failure with reduced ejection fraction call for quadruple therapy.,0,139
med:pmid:37278232:sec:introduction:sent:2,med:pmid:37278232,introduction,2,"Quadruple therapy consists of an angiotensin receptor-neprilysin inhibitor (ARNi), sodium-glucose cotransporter-2 inhibitor (SGLT2i), mineralocorticoid receptor antagonist, and beta blocker.",140,330
med:pmid:37278232:sec:introduction:sent:3,med:pmid:37278232,introduction,3,The ARNi and sodium-glucose cotransporter-2 inhibitor are newer additions to standard of care with the ARNi replacing ACE (angiotensin-converting enzyme) inhibitors and angiotensin II receptor blockers.,331,533
med:pmid:37278232:sec:methods:sent:4,med:pmid:37278232,methods,4,We investigate the cost-effectiveness of sequentially adding the SGLT2i and ARNi to form quadruple therapy as compared with the previous standard of care with ACE inhibitor/mineralocorticoid receptor antagonist/beta blocker.,534,775
med:pmid:37278232:sec:methods:sent:5,med:pmid:37278232,methods,5,"Using a 2-stage Markov model, we projected the expected lifetime discounted costs and quality-adjusted life years (QALYs) of a simulated cohort of US patients who underwent each treatment option and calculated incremental cost-effectiveness ratios.",776,1024
med:pmid:37278232:sec:methods:sent:6,med:pmid:37278232,methods,6,"We assessed incremental cost-effectiveness ratios using criteria for health care value (<$50 000/quality-adjusted life year [QALY] indicating high-value, $50 000-150 000/QALY indicating intermediate value, and >$150 000/QALY indicating low-value) and a standard $100 000/QALY cost-effectiveness threshold.",1025,1330
med:pmid:37278232:sec:results:sent:7,med:pmid:37278232,results,7,"Compared with the previous standard of care, the SGLT2i addition had an incremental cost-effectiveness ratio of $73 000/QALY and weakly dominated the ARNi addition.",1331,1512
med:pmid:37278232:sec:results:sent:8,med:pmid:37278232,results,8,"The addition of both the ARNi and SGLT2i for quadruple therapy offered 0.68 additional discounted QALYs over the SGLT2i addition alone at a lifetime discounted cost of $66 700, resulting in an incremental cost-effectiveness ratio of $98 500/QALY.",1513,1759
med:pmid:37278232:sec:results:sent:9,med:pmid:37278232,results,9,"In sensitivity analysis varying drug prices, the incremental cost-effectiveness ratio for quadruple therapy ranged from $73 500/QALY using prices available to the US Department of Veterans Affairs to $110 000/QALY using drug list prices.",1760,1997
med:pmid:37278232:sec:conclusion:sent:10,med:pmid:37278232,conclusion,10,"While quadruple therapy offers intermediate value, it is borderline cost effective compared with adding the SGLT2i alone to previous standard of care.",1998,2169
med:pmid:37278232:sec:conclusion:sent:11,med:pmid:37278232,conclusion,11,"Thus, its cost-effectiveness is sensitive to a payer's ability to negotiate discounts off the increasing list prices for ARNI and SGLT2is.",2170,2308
med:pmid:37278232:sec:conclusion:sent:12,med:pmid:37278232,conclusion,12,The demonstrated benefits of ARNi and SGLT2is should be weighed against their high prices in payer and policy considerations.,2309,2434
med:pmid:37051752:sec:title:sent:0,med:pmid:37051752,title,0,Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.,0,89
med:pmid:37051752:sec:introduction:sent:1,med:pmid:37051752,introduction,1,The 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation combining creatinine and cystatin C provides a better estimation of glomerular filtration rate (GFR) compared to the creatinine-only equation.,0,234
med:pmid:37051752:sec:results:sent:2,med:pmid:37051752,results,2,CKD-EPI creatinine-cystatin C equation (creatinine-cystatin) was compared to creatinine-only (creatinine) equation in a subpopulation of Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF).,235,527
med:pmid:37051752:sec:results:sent:3,med:pmid:37051752,results,3,"Patients were categorized according to difference in eGFR using the two equations: Group 1 (<-10 mL/min/1.73 m2, i.e. creatinine-cystatin more than 10 mL/min lower than creatinine), Group 2 (>-10 and <10 mL/min/1.73 m2), and Group 3 (>10 mL/min/1.73 m2, i.e. creatinine-cystatin more than 10 mL/min higher than creatinine).",528,851
med:pmid:37051752:sec:results:sent:4,med:pmid:37051752,results,4,Cystatin C and creatinine were available in 1966 patients at randomization.,852,927
med:pmid:37051752:sec:results:sent:5,med:pmid:37051752,results,5,Median (interquartile range) eGFR difference was -0.7 (-6.4-4.8) mL/min/1.73 m2.,928,1008
med:pmid:37051752:sec:results:sent:6,med:pmid:37051752,results,6,"Compared to creatinine, creatinine-cystatin led to a substantial reclassification of chronic kidney disease stages.",1009,1124
med:pmid:37051752:sec:results:sent:7,med:pmid:37051752,results,7,"Overall, 212 (11%) and 355 (18%) patients were reallocated to a better and worse eGFR category, respectively.",1125,1234
med:pmid:37051752:sec:results:sent:8,med:pmid:37051752,results,8,"Compared to patients in Group 2, those in Group 1 (lower eGFR with creatinine-cystatin) had higher mortality and those in Group 3 (higher eGFR with creatinine-cystatin) had lower mortality.",1235,1424
med:pmid:37051752:sec:results:sent:9,med:pmid:37051752,results,9,Increasing difference in eGFR (due to lower eGFR with creatinine-cystatin compared to creatinine) was associated with increasing elevation of biomarkers (including N-terminal pro-B-type natriuretic peptide and troponin) and worsening Kansas City Cardiomyopathy Questionnaire clinical summary score.,1425,1723
med:pmid:37051752:sec:conclusion:sent:10,med:pmid:37051752,conclusion,10,The reason why the equations diverged with increasing severity of heart failure was that creatinine did not rise as steeply as cystatin C.   The CKD-EPI creatinine-only equation may overestimate GFR in sicker patients.,1724,1960
med:pmid:37051752:sec:conclusion:sent:11,med:pmid:37051752,conclusion,11,<h4>Clinical trial registration</h4> URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01035255.,1961,2066
med:pmid:36942494:sec:title:sent:0,med:pmid:36942494,title,0,Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure.,0,106
med:pmid:36942494:sec:introduction:sent:1,med:pmid:36942494,introduction,1,"Although the haemodynamic effects of angiotensin receptor-neprilysin inhibitor (ARNI) on patients with heart failure have been demonstrated, the effect on glucose metabolism has not been fully elucidated.",0,218
med:pmid:36942494:sec:introduction:sent:2,med:pmid:36942494,introduction,2,We retrospectively investigated the effect of ARNI on abnormal glucose metabolism in patients with stable chronic heart failure using an additional structural equation model (SEM) analysis.,219,408
med:pmid:36942494:sec:methods:sent:3,med:pmid:36942494,methods,3,We analysed 34 patients who regularly visited to the outpatient department of our institute with heart failure from October 2021 and July 2022 and who were taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).,409,676
med:pmid:36942494:sec:methods:sent:4,med:pmid:36942494,methods,4,"Seventeen patients switched from ACE inhibitors or ARBs to an ARNI (ARNI group), and the other 17 patients continued treatment with ACE inhibitors or ARBs (control group).",677,848
med:pmid:36942494:sec:results:sent:5,med:pmid:36942494,results,5,"At baseline, although the ARNI group included fewer patients with heart failure with preserved ejection fraction in comparison with the control group (P = 0.004), patients with heart failure with mildly reduced ejection fraction, and heart failure with reduced ejection fraction were mostly biased towards the ARNI group (although not statistically significant).",849,1228
med:pmid:36942494:sec:results:sent:6,med:pmid:36942494,results,6,"The baseline insulin resistance in the ARNI group was already significantly higher in comparison with the control group [fasting blood insulin, 9.7 (7.4, 11.6) vs. 7.8 (5.2, 9.2) μU/mL, P = 0.033; homoeostasis model assessment of insulin resistance (HOMA-IR), 3.10 (1.95, 4.19) vs. 2.02 (1.56, 2.42), P = 0.014].",1229,1541
med:pmid:36942494:sec:results:sent:7,med:pmid:36942494,results,7,"Three months later, the fasting blood insulin and the HOMA-IR levels were both found to have decreased in comparison with the baseline values [baseline to 3 months: insulin, 9.7 (7.4, 11.6) to 7.3 (4.6, 9.4) μU/mL, P < 0.001; HOMA-IR, 3.10 (1.95, 4.19) to 1.96 (1.23, 3.09), P < 0.001].",1542,1828
med:pmid:36942494:sec:results:sent:8,med:pmid:36942494,results,8,"An additional SEM analysis demonstrated that the initiation of ARNI had caused a reduction in the fasting blood insulin and the HOMA-IR levels at 3 months independently of the baseline fasting blood insulin and HOMA-IR levels, respectively.",1829,2069
med:pmid:36942494:sec:results:sent:9,med:pmid:36942494,results,9,"Similarly, the initiation of ARNI resulted in a significant reduction in serum uric acid levels (6.28 ± 0.35 to 5.80 ± 0.30 mg/dL, P = 0.008).",2070,2212
med:pmid:36942494:sec:conclusion:sent:10,med:pmid:36942494,conclusion,10,"In conclusion, even in a short period of only 3 months, the administration of ARNI improved insulin resistance and consequently reduced the serum uric acid levels in patients with stable chronic heart failure.",2213,2443
med:pmid:36942494:sec:conclusion:sent:11,med:pmid:36942494,conclusion,11,"Although the ARNI group already had high insulin resistance at baseline, an additional SEM analysis revealed that the decreased insulin resistance was truly due to the effect of ARNI.",2444,2627
med:pmid:36896801:sec:title:sent:0,med:pmid:36896801,title,0,The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.,0,111
med:pmid:36896801:sec:introduction:sent:1,med:pmid:36896801,introduction,1,Recent heart failure (HF) guidelines have re-classified HF patients with left ventricular ejection fraction (LVEF) between 41% and 49% as HF with mildly reduced ejection fraction (HFmrEF).,0,208
med:pmid:36896801:sec:introduction:sent:2,med:pmid:36896801,introduction,2,HFmrEF treatment is often considered a grey zone as no randomized controlled trials (RCTs) were conducted exclusively on these patients.,209,345
med:pmid:36896801:sec:introduction:sent:3,med:pmid:36896801,introduction,3,"A network meta-analysis (NMA) was performed to compare treatment effect of mineralocorticoid receptor antagonists (MRA), angiotensin receptor neprilysin inhibitor (ARNi), angiotensin receptor blockers (ARB), angiotensin-converting-enzyme inhibitors (ACEi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and beta-blockers (BB) in HFmrEF cardiovascular (CV) outcomes.",346,731
med:pmid:36896801:sec:results:sent:4,med:pmid:36896801,results,4,RCTs sub-analyses evaluating the efficacy of pharmacological treatment in HFmrEF patients were searched.,732,865
med:pmid:36896801:sec:results:sent:5,med:pmid:36896801,results,5,"Hazard ratios (HRs) and their variance were extracted from each RCT for (i) composite of CV death or HF hospitalizations, (ii) CV death, and (iii) HF hospitalizations.",866,1033
med:pmid:36896801:sec:results:sent:6,med:pmid:36896801,results,6,A random-effects NMA was performed to compare and assess the treatment efficiency.,1034,1116
med:pmid:36896801:sec:results:sent:7,med:pmid:36896801,results,7,"Six RCTs with subgroup analysis according to participants' ejection fraction, a patient-level pooled meta-analysis of two RCTs, and an individual patient-level analysis of eleven BB RCTs were included, totalling 7966 patients.",1117,1343
med:pmid:36896801:sec:results:sent:8,med:pmid:36896801,results,8,"To our primary endpoint, SGLT2i vs. placebo was the only comparison with significant results, with a 19% risk reduction in the composite of CV death or HF hospitalizations [HR 0.81, 95% confidence interval (CI) 0.67-0.98].",1344,1566
med:pmid:36896801:sec:results:sent:9,med:pmid:36896801,results,9,"In HF hospitalizations, the impact of the pharmacological therapies was more notorious, and ARNi reduced in 40% the risk of HF hospitalizations (HR 0.60, 95% CI 0.39-0.92), SGLT2i in 26% (HR 0.74, 95% CI 0.59-0.93) and renin-angiotensin system inhibition (RASi) with ARB and ACEi in 28% (HR 0.72, 95% CI 0.53-0.98).",1567,1882
med:pmid:36896801:sec:results:sent:10,med:pmid:36896801,results,10,"Although BBs were globally less beneficial, they were the only class that supported a reduced risk of CV death (HR vs. placebo: 0.48, 95% CI 0.24-0.95).",1883,2035
med:pmid:36896801:sec:results:sent:11,med:pmid:36896801,results,11,We did not observe a statistically significant difference in any comparison between active treatments.,2036,2138
med:pmid:36896801:sec:results:sent:12,med:pmid:36896801,results,12,"There was a sound reduction with ARNi on the primary endpoint (HR vs. BB: 0.81, 95% CI 0.47-1.41; HR vs. MRA 0.94, 95% CI 0.53-1.66) and on HF hospitalizations (HR vs. RASi 0.83, 95% CI 0.62-1.11; HR vs. SGLT2i 0.80, 95% CI 0.50-1.30).",2139,2374
med:pmid:36896801:sec:conclusion:sent:13,med:pmid:36896801,conclusion,13,"In addition to SGLT2i, pharmacological treatment recommended for HF with reduced LVEF, namely, ARNi, MRA, and BB, can also be effective in HFmrEF.",2375,2542
med:pmid:36896801:sec:conclusion:sent:14,med:pmid:36896801,conclusion,14,This NMA did not show significant superiority over any pharmacological class.,2543,2620
med:pmid:36852608:sec:title:sent:0,med:pmid:36852608,title,0,Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study.,0,117
med:pmid:36852608:sec:introduction:sent:1,med:pmid:36852608,introduction,1,Heart failure (HF) is an increasing concern worldwide.,0,68
med:pmid:36852608:sec:introduction:sent:2,med:pmid:36852608,introduction,2,A rising HF burden is expected due to the prospected future demographic changes with aging populations.,69,172
med:pmid:36852608:sec:introduction:sent:3,med:pmid:36852608,introduction,3,"Consequently, the long-term follow-up and treatment will be performed increasingly by primary care physicians in the future.",173,297
med:pmid:36852608:sec:introduction:sent:4,med:pmid:36852608,introduction,4,Contemporary data on HF patients in primary care are needed to plan and ensure an effective and safe follow-up of future patients.,298,428
med:pmid:36852608:sec:results:sent:5,med:pmid:36852608,results,5,"The electronic patient journals of 148 primary care clinics in Denmark were searched in a standardized manner to identify patients with HF [code K77 of the International Classification of Primary Care, Second Edition].",429,676
med:pmid:36852608:sec:results:sent:6,med:pmid:36852608,results,6,"Prespecified variables including demographic information, clinical variables, co-morbidities, prescribed medications, and setting of follow-up were recorded.",677,834
med:pmid:36852608:sec:results:sent:7,med:pmid:36852608,results,7,"In total, 1111 patients were included in the study.",835,886
med:pmid:36852608:sec:results:sent:8,med:pmid:36852608,results,8,The mean timepoint for the HF diagnosis was August 2018.,887,943
med:pmid:36852608:sec:results:sent:9,med:pmid:36852608,results,9,"In 95% of cases, the diagnosis of HF was made in a specialized setting.",944,1015
med:pmid:36852608:sec:results:sent:10,med:pmid:36852608,results,10,The echocardiogram data used for phenotyping were available in 1042 (94%) of the 1111 patients.,1016,1111
med:pmid:36852608:sec:results:sent:11,med:pmid:36852608,results,11,"HF with reduced ejection fraction (HFrEF) was present in 43%, recovered HFrEF in 31%, and HF with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) in 26%.",1112,1280
med:pmid:36852608:sec:results:sent:12,med:pmid:36852608,results,12,"In patients with HFrEF or recovered HFrEF, fundamental treatments were prescribed in 86% for angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or angiotensin receptor neprilysin inhibitor (ARNI), in 82% for beta-blocker, in 38% for mineralocorticoid receptor antagonist (MRA), and in 12% for sodium-glucose co-transporter-2 inhibitor (SGLT2i).",1281,1658
med:pmid:36852608:sec:results:sent:13,med:pmid:36852608,results,13,"Older patients were treated to a significantly lesser extent than young patients for all drug classes [odds ratio (OR) point estimates 0.50 to 0.69, all P-values < 0.05].",1659,1829
med:pmid:36852608:sec:results:sent:14,med:pmid:36852608,results,14,"In patients with HFmrEF or HFpEF, an ACEI, ARB, or ARNI was prescribed in 67%, beta-blocker in 67%, MRA in 22%, and SGLT2i in 7.4% with significantly lower probability of treatment compared to patients with HFrEF or recovered HFrEF [OR point estimates 0.33 to 0.57, all P-values < 0.05].",1830,2117
med:pmid:36852608:sec:results:sent:15,med:pmid:36852608,results,15,The setting of follow-up was available in 96% of patients.,2118,2176
med:pmid:36852608:sec:results:sent:16,med:pmid:36852608,results,16,"Irrespective of HF phenotype, follow-up was performed solely in primary care in 64%.",2177,2261
med:pmid:36852608:sec:results:sent:17,med:pmid:36852608,results,17,"These patients were generally treated to a lesser extent with HF therapies compared with patients where follow-up included specialized care, yet differences were generally small.",2262,2440
med:pmid:36852608:sec:conclusion:sent:18,med:pmid:36852608,conclusion,18,HFrEF is the most common phenotype of HF in primary care followed by recovered HFrEF and fundamental therapies are markedly underutilized.,2441,2600
med:pmid:36852608:sec:conclusion:sent:19,med:pmid:36852608,conclusion,19,Initiatives to increase the use of recommended therapies are needed to improve the future care of patients with HF.,2601,2716
med:pmid:37240819:sec:title:sent:0,med:pmid:37240819,title,0,Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients.,0,89
med:pmid:37240819:sec:abstract:sent:1,med:pmid:37240819,abstract,1,Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril.,0,141
med:pmid:37240819:sec:abstract:sent:2,med:pmid:37240819,abstract,2,"However, its effects on functional capacity remain uncertain; consequently, we sought to compare Sac/Val vs. standard medical therapy, in terms of effects on prognostically significant CPET parameters, in HFrEF patients during a long follow-up period.",142,393
med:pmid:37240819:sec:abstract:sent:3,med:pmid:37240819,abstract,3,"We conducted a single-center, observational study in an HF clinic; specifically, we retrospectively identified that 12 patients switched to Sac/Val and 13 patients that managed with standard, optimal medical therapy (control group).",394,626
med:pmid:37240819:sec:abstract:sent:4,med:pmid:37240819,abstract,4,"At each visit, baseline, and follow-up (median time: 16 months; IQ range: 11.5-22), we collected demographic information, medical history, vital signs, cardiopulmonary exercise testing, standard laboratory data, pharmacological treatment information, and echocardiographic parameters.",627,911
med:pmid:37240819:sec:abstract:sent:5,med:pmid:37240819,abstract,5,The study's primary end-point was the change from baseline in peak VO<sub>2</sub> (adjusted to body weight).,912,1020
med:pmid:37240819:sec:abstract:sent:6,med:pmid:37240819,abstract,6,We did not observe significant differences between the two study groups at baseline.,1021,1105
med:pmid:37240819:sec:abstract:sent:7,med:pmid:37240819,abstract,7,"Similarly, we did not observe any significant differences during the follow-up in mean values of peak VO<sub>2</sub> corrected for body weight: Sac/Val baseline: 12.2 ± 4.6 and FU: 12.7 ± 3.3 vs. control group: 13.1 ± 4.2 and 13.0 ± 4.2 mL/kg/min; <i>p</i> = 0.49.",1106,1370
med:pmid:37240819:sec:abstract:sent:8,med:pmid:37240819,abstract,8,No significant treatment differences were observed for changes in VE/VCO<sub>2</sub> slope: Sac/Val baseline: 35.4 ± 7.4 and FU: 37.2 ± 13.1 vs. control group: 34.6 ± 9.1 and 34.0 ± 7.3; <i>p</i> = 0.49.,1371,1574
med:pmid:37240819:sec:abstract:sent:9,med:pmid:37240819,abstract,9,"In conclusion, after a median follow-up period of 16 months, there was no significant benefit of Sac/Val on peak VO<sub>2</sub> and other measures of CPET compared with standard optimal therapy in patients with HFrEF.",1575,1792
med:pmid:37137558:sec:results:sent:0,med:pmid:37137558,results,0,of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis.,0,131
med:pmid:37137558:sec:introduction:sent:1,med:pmid:37137558,introduction,1,Renin-angiotensin system (RAS) plays a key role in various types of cardiovascular disease and many kinds of RAS inhibitors have been developed.,0,166
med:pmid:37137558:sec:introduction:sent:2,med:pmid:37137558,introduction,2,The effect of discontinuation of RAS inhibitors on clinical outcomes is still controversial.,167,259
med:pmid:37137558:sec:introduction:sent:3,med:pmid:37137558,introduction,3,This study aims to evaluate the effects of discontinuing RAS inhibitor medication on the clinical outcomes of patients continuously taking these agents.,260,412
med:pmid:37137558:sec:introduction:sent:4,med:pmid:37137558,introduction,4,<h4>Methods and analysis</h4> This article presents a systematic review protocol described in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines.,413,610
med:pmid:37137558:sec:introduction:sent:5,med:pmid:37137558,introduction,5,We will include randomised controlled trials in which the effects of RAS inhibitor withdrawal were evaluated.,611,720
med:pmid:37137558:sec:introduction:sent:6,med:pmid:37137558,introduction,6,"Initially, four authors will search for eligible studies in MEDLINE, EMBASE, the Cochrane Database Trial Register, European trial registry and ClinicalTrials.gov.",721,883
med:pmid:37137558:sec:introduction:sent:7,med:pmid:37137558,introduction,7,Abstracts and full-text screenings will be performed by the four authors with data extraction performed by each author independently.,884,1017
med:pmid:37137558:sec:introduction:sent:8,med:pmid:37137558,introduction,8,"We will include patients taking RAS inhibitors-including ACE inhibitor, angiotensin receptor blocker and angiotensin receptor neprilysin inhibitor and exclude the patients undergoing renal replacement therapy (RRT), adolescents (under 18 years of age) and patients with acute infectious diseases.",1018,1314
med:pmid:37137558:sec:introduction:sent:9,med:pmid:37137558,introduction,9,Our search will be performed on 1 May 2023.,1315,1358
med:pmid:37137558:sec:introduction:sent:10,med:pmid:37137558,introduction,10,Studies in which the patients discontinued RAS inhibitors due to any reason will be included.,1359,1452
med:pmid:37137558:sec:introduction:sent:11,med:pmid:37137558,introduction,11,Patients who continuously took RAS inhibitors under conditions in which the intervention group discontinued these agents will be considered eligible as the comparison group.,1453,1626
med:pmid:37137558:sec:introduction:sent:12,med:pmid:37137558,introduction,12,"Death (any cause), Death (cardiovascular disease (CVD)) and CVD events will be set as primary outcomes.",1627,1730
med:pmid:37137558:sec:introduction:sent:13,med:pmid:37137558,introduction,13,"Secondary outcomes will be set as RRT, acute kidney injury, renal function (analysis of the change in estimated glomerular filtration rate), hyperkalaemia, proteinuria and blood pressure.",1731,1918
med:pmid:37137558:sec:introduction:sent:14,med:pmid:37137558,introduction,14,"<h4>Ethics and dissemination</h4> Research ethics approval was not required in this study due to it being a systematic review, and any data belonging to individuals cannot be identified.",1919,2105
med:pmid:37137558:sec:introduction:sent:15,med:pmid:37137558,introduction,15,The results of this study will be disseminated through peer-reviewed journals and conferences.,2106,2200
med:pmid:37137558:sec:introduction:sent:16,med:pmid:37137558,introduction,16,<h4>Trial registration number</h4> PROSPERO CRD42022300777.,2201,2260
med:pmid:37125529:sec:title:sent:0,med:pmid:37125529,title,0,Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.,0,146
med:pmid:37125529:sec:introduction:sent:1,med:pmid:37125529,introduction,1,NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a potent predictor of death and heart failure (HF) across multiple populations.,0,156
med:pmid:37125529:sec:introduction:sent:2,med:pmid:37125529,introduction,2,"We evaluated the prognostic importance of NT-proBNP in patients with acute myocardial infarction (MI) complicated by left ventricular systolic dysfunction, pulmonary congestion, or both and ≥1 of 8 risk-augmenting factors enrolled in the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction).",157,541
med:pmid:37125529:sec:methods:sent:3,med:pmid:37125529,methods,3,Patients were randomized to sacubitril/valsartan 200 mg or ramipril 5 mg twice daily within 0.5 to 7 days of a MI.,542,673
med:pmid:37125529:sec:methods:sent:4,med:pmid:37125529,methods,4,Patients with prior HF were excluded.,674,711
med:pmid:37125529:sec:methods:sent:5,med:pmid:37125529,methods,5,NT-proBNP and hs-cTnT (high-sensitivity troponin T) were collected at randomization in a prespecified substudy of 1129 patients.,712,840
med:pmid:37125529:sec:methods:sent:6,med:pmid:37125529,methods,6,"The primary end point of PARADISE-MI was a composite of cardiovascular death or incident HF (hospitalization or outpatient symptomatic HF), analyzed as time-to-first event; additional end points included all-cause death and the composite of fatal or nonfatal MI or stroke.",841,1113
med:pmid:37125529:sec:results:sent:7,med:pmid:37125529,results,7,"Median NT-proBNP was 1757 ng/L (25th-75th percentiles, 896-3462 ng/L) at randomization (4.0±1.8 days after the index MI).",1114,1252
med:pmid:37125529:sec:results:sent:8,med:pmid:37125529,results,8,"Patients in the highest quartile of NT-proBNP were older, more commonly women and had more hypertension, atrial fibrillation, renal dysfunction, and pulmonary congestion on presentation (all <i>P</i><0.001).",1253,1460
med:pmid:37125529:sec:results:sent:9,med:pmid:37125529,results,9,"NT-proBNP was strongly associated with the primary end point (adjusted hazard ratio, 1.45 per doubling of NT-proBNP; [95% CI, 1.23-1.70]), adjusted for clinical variables and baseline hs-cTnT. NT-proBNP was also independently associated with all-cause death (adjusted hazard ratio, 1.74 [95% CI, 1.38-2.21]) and fatal or nonfatal MI or stroke (adjusted hazard ratio, 1.24 [95% CI, 1.05-1.45]).",1461,1854
med:pmid:37125529:sec:results:sent:10,med:pmid:37125529,results,10,NT-proBNP did not significantly modify the neutral treatment effect of sacubitril/valsartan relative to ramipril (<i>P</i> interaction=0.46).,1855,1996
med:pmid:37125529:sec:conclusion:sent:11,med:pmid:37125529,conclusion,11,"Within the first week of a high-risk MI NT-proBNP is associated with incident HF, death and atherosclerotic events.",1997,2133
med:pmid:37125529:sec:conclusion:sent:12,med:pmid:37125529,conclusion,12,This prognostic information is independent of hs-cTnT. <h4>Registration</h4> URL: https://www.,2134,2228
med:pmid:37125529:sec:conclusion:sent:13,med:pmid:37125529,conclusion,13,<h4>Clinicaltrials</h4> gov; Unique identifier: NCT02924727.,2229,2289
med:pmid:37062869:sec:title:sent:0,med:pmid:37062869,title,0,Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most?,0,119
med:pmid:37062869:sec:title:sent:1,med:pmid:37062869,title,1,An analysis of PARADIGM-HF and ATMOSPHERE.,120,162
med:pmid:37062869:sec:introduction:sent:2,med:pmid:37062869,introduction,2,"Multimorbidity, the coexistence of two or more chronic conditions, is synonymous with heart failure (HF).",0,119
med:pmid:37062869:sec:introduction:sent:3,med:pmid:37062869,introduction,3,How risk related to comorbidities compares at individual and population levels is unknown.,120,210
med:pmid:37062869:sec:introduction:sent:4,med:pmid:37062869,introduction,4,"The aim of this study is to examine the risk related to comorbidities, alone and in combination, both at individual and population levels.",211,349
med:pmid:37062869:sec:results:sent:5,med:pmid:37062869,results,5,Using two clinical trials in HF - the Prospective comparison of ARNI (Angiotensin Receptor-Neprilysin Inhibitor) with ACEI (Angiotensin-Converting Enzyme Inhibitor) to Determine Impact on Global Mortality and morbidity in HF trial (PARADIGM-HF) and the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure trials (ATMOSPHERE) - we identified the 10 most common comorbidities and examined 45 possible pairs.,350,800
med:pmid:37062869:sec:results:sent:6,med:pmid:37062869,results,6,We calculated population attributable fractions (PAF) for all-cause death and relative excess risk due to interaction with Cox proportional hazard models.,801,955
med:pmid:37062869:sec:results:sent:7,med:pmid:37062869,results,7,"Of 15 066 patients in the study, 14 133 (93.7%) had at least one and 11 867 (78.8%) had at least two of the 10 most prevalent comorbidities.",956,1096
med:pmid:37062869:sec:results:sent:8,med:pmid:37062869,results,8,The greatest individual risk among pairs was associated with peripheral artery disease (PAD) in combination with stroke (hazard ratio [HR] 1.73; 95% confidence interval [CI] 1.28-2.33) and anaemia (HR 1.71; 95% CI 1.39-2.11).,1097,1322
med:pmid:37062869:sec:results:sent:9,med:pmid:37062869,results,9,The combination of chronic kidney disease (CKD) and hypertension had the highest PAF (5.65%; 95% CI 3.66-7.61).,1323,1434
med:pmid:37062869:sec:results:sent:10,med:pmid:37062869,results,10,"Two pairs demonstrated significant synergistic interaction (atrial fibrillation with CKD and coronary artery disease, respectively) and one an antagonistic interaction (anaemia and obesity).",1435,1625
med:pmid:37062869:sec:conclusion:sent:11,med:pmid:37062869,conclusion,11,"In HF, the impact of multimorbidity differed at the individual patient and population level, depending on the prevalence of and the risk related to each comorbidity, and the interaction between individual comorbidities.",1626,1866
med:pmid:37062869:sec:conclusion:sent:12,med:pmid:37062869,conclusion,12,"Patients with coexistent PAD and stroke were at greatest individual risk whereas, from a population perspective, coexistent CKD and hypertension mattered most.",1867,2026
med:pmid:36892492:sec:title:sent:0,med:pmid:36892492,title,0,Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction.,0,103
med:pmid:36892492:sec:introduction:sent:1,med:pmid:36892492,introduction,1,Heart failure with reduced ejection fraction (HFrEF) is one of the most costly and deadly chronic disease states.,0,133
med:pmid:36892492:sec:introduction:sent:2,med:pmid:36892492,introduction,2,The cost effectiveness of a comprehensive quadruple therapy regimen for HFrEF has not been studied.,134,233
med:pmid:36892492:sec:introduction:sent:3,med:pmid:36892492,introduction,3,"The authors sought to determine the cost-effectiveness of quadruple therapy comprised of beta-blockers, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors, and sodium glucose cotransporter-2 inhibitors vs regimens composed of only beta-blockers, angiotensin-converting enzyme inhibitors, and mineralocorticoid receptor antagonists (triple therapy), and angiotensin-converting enzyme inhibitors and beta-blockers (double therapy).",234,715
med:pmid:36892492:sec:methods:sent:4,med:pmid:36892492,methods,4,"Using a 2-state Markov model, the authors performed a cost-effectiveness study using simulated populations of 1,000 patients with HFrEF based on the participants in the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial and compared them by treatment strategy (quadruple therapy vs triple and double therapy) from a United States health care system perspective.",716,1175
med:pmid:36892492:sec:methods:sent:5,med:pmid:36892492,methods,5,"The authors also performed 10,000 probabilistic simulations.",1176,1236
med:pmid:36892492:sec:results:sent:6,med:pmid:36892492,results,6,"Treatment with quadruple therapy resulted in an increase of 1.73 and 2.87 life-years compared with triple therapy and double therapy, respectively, and an increase in quality-adjusted life-years of 1.12 and 1.85 years, respectively.",1237,1486
med:pmid:36892492:sec:results:sent:7,med:pmid:36892492,results,7,"The incremental cost-effectiveness ratios of quadruple therapy vs triple therapy and double therapy were $81,000 and $51,081, respectively.",1487,1626
med:pmid:36892492:sec:results:sent:8,med:pmid:36892492,results,8,"In 91.7% and 99.9% of probabilistic simulations quadruple therapy had an incremental cost-effectiveness ratio of <$150,000 compared with triple therapy and double therapy, respectively.",1627,1812
med:pmid:36892492:sec:conclusion:sent:9,med:pmid:36892492,conclusion,9,"At current pricing, the use of quadruple therapy in patients with HFrEF was cost effective compared with triple therapy and double therapy.",1813,1973
med:pmid:36892492:sec:conclusion:sent:10,med:pmid:36892492,conclusion,10,These findings highlight the need for improved access and optimal implementation of comprehensive quadruple therapy in eligible patients with HFrEF.,1974,2122
med:pmid:37066800:sec:title:sent:0,med:pmid:37066800,title,0,Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.,0,148
med:pmid:37066800:sec:abstract:sent:1,med:pmid:37066800,abstract,1,"The incidence of heart failure and chronic kidney disease is increasing, and many patients develop both diseases.",0,113
med:pmid:37066800:sec:abstract:sent:2,med:pmid:37066800,abstract,2,Angiotensin receptor-neprilysin inhibitor (ARNI) is a promising therapeutic candidate for both diseases.,114,218
med:pmid:37066800:sec:abstract:sent:3,med:pmid:37066800,abstract,3,ARNI has demonstrated superior cardioprotective effects compared with renin-angiotensin system inhibitors (RAS-Is) in large clinical trials such as the PARADIGM-HF (Prospective Comparison of ARNI With ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial.,219,545
med:pmid:37066800:sec:abstract:sent:4,med:pmid:37066800,abstract,4,It has also been suggested that ARNI can provide renoprotective effects beyond those of RAS-Is in patients with HF.,546,661
med:pmid:37066800:sec:abstract:sent:5,med:pmid:37066800,abstract,5,ARNI might have beneficial effects on the kidneys because of its ability to improve cardiac function in patients with heart failure and affect renal hemodynamics by enhancing the effects of hormones such as natriuretic peptide.,662,889
med:pmid:37066800:sec:abstract:sent:6,med:pmid:37066800,abstract,6,"In contrast, in the PARADIGM-HF trial, ARNI was associated with more albuminuria compared with RAS-I; thus, it is unclear whether long-term ARNI therapy has renoprotective effects.",890,1070
med:pmid:37066800:sec:abstract:sent:7,med:pmid:37066800,abstract,7,"Additionally, ARNI did not provide renoprotective effects beyond RAS-I in patients with chronic kidney disease in the UK HARP-III (United Kingdom Heart and Renal Protection-III) trial.",1071,1255
med:pmid:37066800:sec:abstract:sent:8,med:pmid:37066800,abstract,8,"In other words, the patient population in which ARNI is more renoprotective than RAS-I might be limited.",1256,1360
med:pmid:37066800:sec:abstract:sent:9,med:pmid:37066800,abstract,9,"Collectively, ARNI may have renoprotective effects in addition to cardioprotective effects, but the evidence to date is applicable only to heart failure.",1361,1514
med:pmid:37066800:sec:abstract:sent:10,med:pmid:37066800,abstract,10,"Theoretically, given the molecular mechanism of ARNI, it could also be renoprotective in conditions such as nephrosclerosis, which has low risks of albuminuria and reduced kidney perfusion, but the evidence for such effects is lacking.",1515,1750
med:pmid:37066800:sec:abstract:sent:11,med:pmid:37066800,abstract,11,Further research is needed to clarify whether ARNI therapy is an acceptable treatment strategy for renal protection.,1751,1867
med:pmid:36944496:sec:title:sent:0,med:pmid:36944496,title,0,Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox.,0,125
med:pmid:36944496:sec:introduction:sent:1,med:pmid:36944496,introduction,1,"Although body mass index (BMI) is the most commonly used anthropometric measure, newer indices such as the waist-to-height ratio, better reflect the location and amount of ectopic fat, as well as the weight of the skeleton, and may be more useful.",0,261
med:pmid:36944496:sec:results:sent:2,med:pmid:36944496,results,2,The prognostic value of several newer anthropometric indices was compared with that of BMI in patients with heart failure (HF) and reduced ejection fraction (HFrEF) enrolled in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure.,262,580
med:pmid:36944496:sec:results:sent:3,med:pmid:36944496,results,3,The primary outcome was HF hospitalization or cardiovascular death.,581,648
med:pmid:36944496:sec:results:sent:4,med:pmid:36944496,results,4,"The association between anthropometric indices and outcomes were comprehensively adjusted for other prognostic variables, including natriuretic peptides.",649,802
med:pmid:36944496:sec:results:sent:5,med:pmid:36944496,results,5,An 'obesity-survival paradox' related to lower mortality risk in those with BMI ≥25 kg/m2 (compared with normal weight) was identified but this was eliminated by adjustment for other prognostic variables.,803,1007
med:pmid:36944496:sec:results:sent:6,med:pmid:36944496,results,6,"This paradox was less evident for waist-to-height ratio (as an exemplar of indices not incorporating weight) and eliminated by adjustment: the adjusted hazard ratio (aHR) for all-cause mortality, for quintile 5 vs. quintile 1, was 1.10 [95% confidence interval (CI) 0.87-1.39].",1008,1285
med:pmid:36944496:sec:results:sent:7,med:pmid:36944496,results,7,"However, both BMI and waist-to-height ratio showed that greater adiposity was associated with a higher risk of the primary outcome and HF hospitalization; this was more evident for waist-to-height ratio and persisted after adjustment e.g. the aHR for HF hospitalization for quintile 5 vs. quintile 1 of waist-to-height ratio was 1.39 (95% CI 1.06-1.81).",1286,1639
med:pmid:36944496:sec:conclusion:sent:8,med:pmid:36944496,conclusion,8,"In patients with HFrEF, alternative anthropometric measurements showed no evidence for an 'obesity-survival paradox'.",1640,1777
med:pmid:36944496:sec:conclusion:sent:9,med:pmid:36944496,conclusion,9,Newer indices that do not incorporate weight showed that greater adiposity was clearly associated with a higher risk of HF hospitalization.,1778,1917
med:pmid:36871177:sec:title:sent:0,med:pmid:36871177,title,0,Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis.,0,88
med:pmid:36871177:sec:introduction:sent:1,med:pmid:36871177,introduction,1,Sacubitril/valsartan reduces all-cause mortality in heart failure (HF) patients compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).,0,204
med:pmid:36871177:sec:introduction:sent:2,med:pmid:36871177,introduction,2,ACEIs/ARBs have been shown to decrease the incidence of atrial fibrillation (AF).,205,286
med:pmid:36871177:sec:introduction:sent:3,med:pmid:36871177,introduction,3,We hypothesized sacubitril-valsartan decreases the incidence of AF compared to ACEis/ARBs.,287,377
med:pmid:36871177:sec:methods:sent:4,med:pmid:36871177,methods,4,"Clinicaltrials.gov was searched for trials by terms sacubitril/valsartan, entresto, sacubitril, valsartan.",378,501
med:pmid:36871177:sec:methods:sent:5,med:pmid:36871177,methods,5,Randomized controlled human trials of sacubitril/valsartan reporting AF were included.,502,588
med:pmid:36871177:sec:results:sent:6,med:pmid:36871177,results,6,were extracted independently by two reviewers.,589,640
med:pmid:36871177:sec:results:sent:7,med:pmid:36871177,results,7,was pooled using a random effect model.,641,685
med:pmid:36871177:sec:results:sent:8,med:pmid:36871177,results,8,Publication bias was evaluated by funnel plots.,686,733
med:pmid:36871177:sec:results:sent:9,med:pmid:36871177,results,9,"A total of 11 trials including 11,458 patients on sacubitril/valsartan and 10,128 patients on ACEI/ARBs were identified.",734,871
med:pmid:36871177:sec:results:sent:10,med:pmid:36871177,results,10,A total of 284 AF events were reported in the sacubitril/valsartan group compared to 256 AF events in ACEIs/ARBs.,872,985
med:pmid:36871177:sec:results:sent:11,med:pmid:36871177,results,11,"Patients on sacubitril/valsartan were as likely as patients on ACEIs/ARBs to develop AF (pooled odds ratio [OR] = 1.091, 95% confidence interval [CI] = 0.917-1.298, p = .324).",986,1161
med:pmid:36871177:sec:results:sent:12,med:pmid:36871177,results,12,Six atrial flutter (AFl) events were reported in six trials; 48 out of 9165 patients in the sacubitril/valsartan group developed AFl compared to 46 out of 8759 in ACEi/ARBs group.,1162,1341
med:pmid:36871177:sec:results:sent:13,med:pmid:36871177,results,13,"There was no difference in AFl risk between the two groups (pooled OR = 1.028, 95% CI = 0.681-1.553, p = .894).",1342,1453
med:pmid:36871177:sec:results:sent:14,med:pmid:36871177,results,14,"Finally, sacubitril/valsartan did not reduce the risk of atrial arrhythmias (AF + AFl) compared to ACEi/ARBs (pooled OR = 1.081, 95% CI = 0.922-1.269, p = .337).",1454,1615
med:pmid:36871177:sec:conclusion:sent:15,med:pmid:36871177,conclusion,15,"Although sacubitril/valsartan reduces mortality compared to ACEIs/ARBs in HF patients, they do not reduce AF risk compared to these drugs.",1616,1774
med:pmid:36812948:sec:title:sent:0,med:pmid:36812948,title,0,Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.,0,104
med:pmid:36812948:sec:introduction:sent:1,med:pmid:36812948,introduction,1,Some patients with heart failure may experience transient changes in kidney function upon transition to sacubitril/valsartan.,0,145
med:pmid:36812948:sec:introduction:sent:2,med:pmid:36812948,introduction,2,Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan continuation is unknown.,146,284
med:pmid:36812948:sec:introduction:sent:3,med:pmid:36812948,introduction,3,This investigation aimed to evaluate the association between the occurrence of moderate estimated glomerular filtration rate (eGFR) decline (>15%) after initial exposure to sacubitril/valsartan and subsequent cardiovascular outcomes and its treatment benefits in PARADIGM-HF and PARAGON-HF.,285,595
med:pmid:36812948:sec:methods:sent:4,med:pmid:36812948,methods,4,"In sequential run-in phases, patients were titrated to enalapril 10 mg twice daily and then sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF) or valsartan 80 mg twice daily and then sacubitril/valsartan 49 mg/51 mg twice daily (in PARAGON-HF).",596,869
med:pmid:36812948:sec:results:sent:5,med:pmid:36812948,results,5,"Among randomized participants, 11% in PARADIGM-HF and 10% in PARAGON-HF experienced eGFR decline (>15%) during sacubitril/valsartan run-in.",870,1026
med:pmid:36812948:sec:results:sent:6,med:pmid:36812948,results,6,eGFR partially recovered (from nadir to postrandomization week 16) regardless of sacubitril/valsartan continuation or switch to renin-angiotensin system inhibitor (RASi) postrandomization.,1027,1215
med:pmid:36812948:sec:results:sent:7,med:pmid:36812948,results,7,Initial eGFR decline was not consistently associated with clinical outcomes in either trial.,1216,1308
med:pmid:36812948:sec:results:sent:8,med:pmid:36812948,results,8,"Treatment benefits of sacubitril/valsartan vs RASi on primary outcomes were similar irrespective of run-in eGFR decline in PARADIGM-HF (eGFR decline, HR: 0.69; 95% CI: 0.53-0.90; and no eGFR decline, HR: 0.80; 95% CI: 0.73-0.88; P<sub>interaction</sub> = 0.32) and PARAGON-HF (eGFR decline, rate ratio [RR]: 0.84; 95% CI: 0.52-1.36 and no eGFR decline, RR: 0.87; 95% CI: 0.75-1.02, P<sub>interaction</sub> = 0.92).",1309,1723
med:pmid:36812948:sec:results:sent:9,med:pmid:36812948,results,9,The treatment effect of sacubitril/valsartan remained consistent across a range of eGFR declines.,1724,1821
med:pmid:36812948:sec:conclusion:sent:10,med:pmid:36812948,conclusion,10,"Moderate eGFR decline when transitioning from RASi to sacubitril/valsartan is not consistently associated with adverse outcomes, and its long-term benefits are retained in heart failure across a broad range of eGFR declines.",1822,2067
med:pmid:36812948:sec:conclusion:sent:11,med:pmid:36812948,conclusion,11,Early eGFR changes should not deter continuation of sacubitril/valsartan or stall uptitration. (,2068,2164
med:pmid:36812948:sec:conclusion:sent:12,med:pmid:36812948,conclusion,12,"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711; Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitors with Angiotensin-Converting Enzyme Inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255).",2164,2544
med:pmid:36604473:sec:title:sent:0,med:pmid:36604473,title,0,Blood pressure in heart failure management and prevention.,0,58
med:pmid:36604473:sec:abstract:sent:1,med:pmid:36604473,abstract,1,Hypertension is a leading cause of heart failure and other cardiovascular diseases.,0,83
med:pmid:36604473:sec:abstract:sent:2,med:pmid:36604473,abstract,2,Its role in the pathogenesis of heart failure with reduced ejection fraction (HFrEF) differs from that in heart failure with preserved ejection fraction (HFpEF).,84,245
med:pmid:36604473:sec:abstract:sent:3,med:pmid:36604473,abstract,3,"Moreover, rigorous blood pressure control may reduce the incidence of heart failure.",246,330
med:pmid:36604473:sec:abstract:sent:4,med:pmid:36604473,abstract,4,"However, once heart failure develops, prognosis is affected by blood pressure, which may differ between patients with and without heart failure.",331,475
med:pmid:36604473:sec:abstract:sent:5,med:pmid:36604473,abstract,5,"Therefore, the association between guideline-directed medical therapy (GDMT) for heart failure and its uptitration must be considered for blood pressure management and should not be overlooked.",476,669
med:pmid:36604473:sec:abstract:sent:6,med:pmid:36604473,abstract,6,Heart failure medications affect the blood pressure and efficacy per baseline blood pressure value.,670,769
med:pmid:36604473:sec:abstract:sent:7,med:pmid:36604473,abstract,7,"This review discusses the potential mechanisms by which hypertension leads to HFrEF or HFpEF, the impact of hypertension on incident heart failure, and the recommended approaches for blood pressure management in patients with heart failure.",770,1010
med:pmid:36604473:sec:abstract:sent:8,med:pmid:36604473,abstract,8,"Comparison between patients with and without heart failure regarding blood pressure The association between CV events and SBP is linear in patients without heart failure; however, it becomes J-shaped or inverse linear in those with heart failure.",1011,1257
med:pmid:36604473:sec:abstract:sent:9,med:pmid:36604473,abstract,9,"The management of BP, including optimal BP or pharmacotherapy, differs between the two populations.",1258,1357
med:pmid:36604473:sec:abstract:sent:10,med:pmid:36604473,abstract,10,"ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers; ARNi angiotensin receptor-neprilysin inhibitors, BB beta-blockers, BP blood pressure, CV cardiovascular, DASH Dietary Approaches to Stop Hypertension, GDMT guideline-directed medical therapy, HF heart failure, HFrEF heart failure with reduced ejection fraction, MRA mineralocorticoid receptor antagonists, SBP systolic blood pressure, SGLT2i sodium-glucose cotransporter 2 inhibitors.",1358,1827
med:pmid:36519802:sec:title:sent:0,med:pmid:36519802,title,0,Efficacy of guideline-directed medical treatment in heart failure with mildly reduced ejection fraction.,0,104
med:pmid:36519802:sec:introduction:sent:1,med:pmid:36519802,introduction,1,Heart failure with mildly reduced ejection fraction (HFmrEF) has received increasing attention following the publication of the latest ESC guidelines in 2021.,0,172
med:pmid:36519802:sec:introduction:sent:2,med:pmid:36519802,introduction,2,"However, it remains unclear whether patients with HFmrEF could benefit from guideline-directed medical treatment (GDMT), referring the combination of ACEI/ARB/ARNI, β-blockers, and MRAs, which are recommended for those with reduced ejection fraction.",173,423
med:pmid:36519802:sec:introduction:sent:3,med:pmid:36519802,introduction,3,This study explored the efficacy of GDMT in HFmrEF patients.,424,484
med:pmid:36519802:sec:methods:sent:4,med:pmid:36519802,methods,4,This was a retrospective cohort study of HFmrEF patients admitted to The First Affiliated Hospital of Dalian Medical University between 1 September 2015 and 30 November 2019.,485,676
med:pmid:36519802:sec:methods:sent:5,med:pmid:36519802,methods,5,Propensity score matching (1:2) between patients receiving triple-drug therapy (TT) and non-triple therapy (NTT) based on age and sex was performed.,677,825
med:pmid:36519802:sec:methods:sent:6,med:pmid:36519802,methods,6,"The primary outcome was all cause death, cardiac death, rehospitalization from any cause, and rehospitalization due to worsening heart failure.",826,969
med:pmid:36519802:sec:results:sent:7,med:pmid:36519802,results,7,"Of the 906 patients enrolled in the matched cohort (TT group, n = 302; NTT group, N = 604), 653 (72.08%) were male, and mean age was 61.1 ± 11.92.",970,1133
med:pmid:36519802:sec:results:sent:8,med:pmid:36519802,results,8,Survival analysis suggested that TT group experienced a significantly lower incidence of prespecified primary endpoints than NTT group.,1134,1269
med:pmid:36519802:sec:results:sent:9,med:pmid:36519802,results,9,"Multivariable Cox regression showed that TT group had a lower risk of all-cause mortality (HR 0.656, 95% CI 0.447-0.961, P = 0.030), cardiac death (HR 0.599, 95% CI 0.380-0.946, P = 0.028), any-cause rehospitalization (HR 0.687, 95% CI 0.541-0.872, P = 0.002), and heart failure rehospitalization (HR 0.732, 95% CI 0.565-0.948, P = 0.018).",1270,1609
med:pmid:36519802:sec:conclusion:sent:10,med:pmid:36519802,conclusion,10,"In patients with HFmrEF, combined use of neurohormonal antagonists produces remarkable effects in reducing the occurrence of the primary outcome of rehospitalization and death.",1610,1807
med:pmid:36519802:sec:conclusion:sent:11,med:pmid:36519802,conclusion,11,"Thus, the treatment of HFmrEF should be categorized as HFrEF due to the similar benefit of neurohormonal blocking therapy in HFrEF and HFmrEF.",1808,1950
med:pmid:37090394:sec:title:sent:0,med:pmid:37090394,title,0,Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis.,0,159
med:pmid:37090394:sec:abstract:sent:1,med:pmid:37090394,abstract,1,The present meta-analysis was conducted to compare the safety and efficacy of angiontensin receptor neprilysin inhibitor (ARNI) with angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme inhibitors (ACEi) in patients with heart failure with reduced ejection fraction (HFrEF).,0,292
med:pmid:37090394:sec:abstract:sent:2,med:pmid:37090394,abstract,2,This meta-analysis was conducted and reported in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement.,292,466
med:pmid:37090394:sec:abstract:sent:3,med:pmid:37090394,abstract,3,"Two authors carried out a scientific literature search on online databases, including EMBASE, PubMed, and the Cochrane Library.",466,594
med:pmid:37090394:sec:abstract:sent:4,med:pmid:37090394,abstract,4,"The following keywords or corresponding Medical Subject Headings (MeSH) were used for the search of relevant articles: ""heart failure with reduced ejection fraction,"" ""angiotensin receptor-neprilysin inhibitor,"" ""Angiotensin receptor blockers,"" and ""clinical outcomes.""",595,864
med:pmid:37090394:sec:results:sent:5,med:pmid:37090394,results,5,assessed in the present meta-analysis included changes in ejection fraction (EF) from baseline in percentage.,864,983
med:pmid:37090394:sec:results:sent:6,med:pmid:37090394,results,6,"Other outcomes assessed in the present meta-analysis included all-cause mortality, cardiovascular death, and hospitalization due to heart failure.",984,1130
med:pmid:37090394:sec:results:sent:7,med:pmid:37090394,results,7,"Adverse events assessed in the present meta-analysis included hypokalemia, acute kidney injury, and hypotension.",1131,1243
med:pmid:37090394:sec:results:sent:8,med:pmid:37090394,results,8,Total 10 studies were included.,1244,1275
med:pmid:37090394:sec:results:sent:9,med:pmid:37090394,results,9,This meta-analysis showed that treatment with ARNI was associated with a significantly lower risk of all-cause mortality and cardiovascular death compared to control groups.,1276,1449
med:pmid:37090394:sec:results:sent:10,med:pmid:37090394,results,10,There was no significant difference between the two groups in terms of change of EF from baseline or hospitalization related to heart failure.,1450,1592
med:pmid:37090394:sec:results:sent:11,med:pmid:37090394,results,11,"However, the risk of hypotension was significantly higher in patients receiving ARNI.",1593,1678
med:pmid:37090394:sec:results:sent:12,med:pmid:37090394,results,12,The study findings support the use of ARNI as first-line therapy for heart failure with reduced ejection fraction.,1679,1793
med:pmid:37090394:sec:results:sent:13,med:pmid:37090394,results,13,Further studies are required to determine the optimal use of ARNI in heart failure management and to investigate the mechanisms underlying the increased risk of hypotension.,1794,1967
med:pmid:36972959:sec:title:sent:0,med:pmid:36972959,title,0,"<i>P</i>rimary care <i>A</i>dherence <i>T</i>o <i>H</i>eart <i>F</i>ailure guidelines <i>IN D</i>iagnosis, <i>E</i>valuation and <i>R</i>outine management (PATHFINDER): a randomised controlled trial protocol.",0,208
med:pmid:36972959:sec:introduction:sent:1,med:pmid:36972959,introduction,1,"General practitioners (GPs) routinely provide care for patients with heart failure (HF); however, adherence to management guidelines, including titrating medication to optimal dose, can be challenging in this setting.",0,239
med:pmid:36972959:sec:introduction:sent:2,med:pmid:36972959,introduction,2,This study will evaluate the effectiveness of a multifaceted intervention to support adherence to HF management guidelines in primary care.,240,379
med:pmid:36972959:sec:introduction:sent:3,med:pmid:36972959,introduction,3,"<h4>Methods and analysis</h4> We will undertake a multicentre, parallel-group, randomised controlled trial of 200 participants with HF with reduced ejection fraction.",380,546
med:pmid:36972959:sec:introduction:sent:4,med:pmid:36972959,introduction,4,Participants will be recruited during a hospital admission due to HF.,547,616
med:pmid:36972959:sec:introduction:sent:5,med:pmid:36972959,introduction,5,"Following hospital discharge, the intervention group will have follow-up with their GP scheduled at 1 week, 4 weeks and 3 months with the provision of a medication titration plan approved by a specialist HF cardiologist.",617,837
med:pmid:36972959:sec:introduction:sent:6,med:pmid:36972959,introduction,6,The control group will receive usual care.,838,880
med:pmid:36972959:sec:introduction:sent:7,med:pmid:36972959,introduction,7,"The primary endpoint, assessed at 6 months, will be the difference between groups in the proportion of participants being prescribed five guideline-recommended treatments; (1) ACE inhibitor/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitor at least 50% of target dose, (2) beta-blocker at least 50% of target dose, (3) mineralocorticoid receptor antagonist at any dose, (4) anticoagulation for patients diagnosed with atrial fibrillation, (5) referral to cardiac rehabilitation.",881,1380
med:pmid:36972959:sec:introduction:sent:8,med:pmid:36972959,introduction,8,Secondary outcomes will include functional capacity (6-minute walk test); quality of life (Kansas City Cardiomyopathy Questionnaire); depressive symptoms (Patient Health Questionnaire-2); self-care behaviour (Self-Care of Heart Failure Index).,1381,1624
med:pmid:36972959:sec:introduction:sent:9,med:pmid:36972959,introduction,9,Resource utilisation will also be assessed.,1625,1668
med:pmid:36972959:sec:introduction:sent:10,med:pmid:36972959,introduction,10,"<h4>Ethics and dissemination</h4> Ethical approval was granted by the South Metropolitan Health Service Ethics Committee (RGS3531), with reciprocal approval at Curtin University (HRE2020-0322).",1669,1862
med:pmid:36972959:sec:results:sent:11,med:pmid:36972959,results,11,will be disseminated via peer-reviewed publications and conferences.,1863,1939
med:pmid:36972959:sec:results:sent:12,med:pmid:36972959,results,12,<h4>Trial registration number</h4> ACTRN12620001069943.,1940,1995
med:pmid:36943907:sec:title:sent:0,med:pmid:36943907,title,0,"Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.",0,207
med:pmid:36943907:sec:introduction:sent:1,med:pmid:36943907,introduction,1,The ratio of ucGMP (urinary cyclic guanosine monophosphate) to BNP (B-type natriuretic peptide) is thought to reflect the responsiveness of tissues to natriuretic peptides.,0,192
med:pmid:36943907:sec:methods:sent:2,med:pmid:36943907,methods,2,"We examined the relationship between ucGMP/BNP ratio and clinical outcomes, the effect of sacubitril/valsartan, compared with enalapril, on the ucGMP/BNP ratio, and the efficacy of sacubitril/valsartan on clinical outcomes according to baseline ucGMP/BNP ratio in PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).",193,606
med:pmid:36943907:sec:methods:sent:3,med:pmid:36943907,methods,3,"ucGMP/BNP ratio was available at baseline (N=2031), 1 month (N=1959), and 8 months after randomization (N=1746).",607,719
med:pmid:36943907:sec:methods:sent:4,med:pmid:36943907,methods,4,The primary outcome was a composite of heart failure hospitalization or cardiovascular death.,720,813
med:pmid:36943907:sec:results:sent:5,med:pmid:36943907,results,5,"Compared with the lowest tertile of baseline ucGMP/BNP ratio, patients in the higher tertiles had a lower risk of the primary outcome (tertile 1, reference; tertile 2, hazard ratio 0.57 [95% CI, 0.45-0.71]; tertile 3, hazard ratio, 0.54 [0.43-0.67]).",814,1081
med:pmid:36943907:sec:results:sent:6,med:pmid:36943907,results,6,"Compared with baseline, the ucGMP/BNP ratio at 1 month and 8 months after randomization was higher with sacubitril/valsartan than with enalapril: ratio of geometric mean ratios at 1 month, 1.38 (95% CI, 1.27-1.51) and 8 months, 1.32 (95% CI, 1.20-1.45), and this difference was consistent across tertiles of ucGMP/BNP ratio at baseline (<i>P</i><sub>interaction</sub>=0.19 and 0.91, respectively).",1082,1479
med:pmid:36943907:sec:results:sent:7,med:pmid:36943907,results,7,"The effect of sacubitril/valsartan, compared with enalapril, was consistent across tertiles of ucGMP/BNP ratio at baseline for all outcomes (<i>P</i><sub>interaction</sub> ≥0.31).",1480,1659
med:pmid:36943907:sec:conclusion:sent:8,med:pmid:36943907,conclusion,8,"In patients with heart failure and reduced ejection fraction, higher ucGMP/BNP ratio was associated with better outcomes.",1660,1802
med:pmid:36943907:sec:conclusion:sent:9,med:pmid:36943907,conclusion,9,"Sacubitril/valsartan increased the ucGMP/BNP ratio, compared with enalapril, and the effect of sacubitril/valsartan on clinical outcomes was not modified by baseline ucGMP/BNP ratio.",1803,1985
med:pmid:36943907:sec:conclusion:sent:10,med:pmid:36943907,conclusion,10,<h4>Registration</h4> URL: https://www.,1986,2025
med:pmid:36943907:sec:conclusion:sent:11,med:pmid:36943907,conclusion,11,<h4>Clinicaltrials</h4> gov; Unique Identifier: NCT01035255.,2026,2086
med:pmid:36601956:sec:title:sent:0,med:pmid:36601956,title,0,Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial.,0,145
med:pmid:36601956:sec:introduction:sent:1,med:pmid:36601956,introduction,1,Sacubitril/valsartan has been approved for the management of heart failure (HF) with reduced ejection fraction in adults.,0,141
med:pmid:36601956:sec:introduction:sent:2,med:pmid:36601956,introduction,2,PANORAMA-HF trial (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) investigated its effects on clinical outcomes in pediatric patients with HF.,142,416
med:pmid:36601956:sec:methods:sent:3,med:pmid:36601956,methods,3,"PANORAMA-HF is a multicenter, Phase II/III study using an adaptive, seamless, 2-part design.",417,526
med:pmid:36601956:sec:methods:sent:4,med:pmid:36601956,methods,4,"The study aimed to evaluate the pharmacokinetics and pharmacodynamics of single doses of sacubitril/valsartan (Part 1), and the efficacy and safety of sacubitril/valsartan versus enalapril administered twice daily for 52 weeks (Part 2) in pediatric patients with HF due to left ventricular systolic dysfunction with biventricular heart physiology.",527,874
med:pmid:36601956:sec:methods:sent:5,med:pmid:36601956,methods,5,An innovative trial design using a novel global rank assessment of severity was employed.,875,964
med:pmid:36601956:sec:methods:sent:6,med:pmid:36601956,methods,6,"For analysis, eligible patients were stratified into 3 age groups (Group 1, 6 to <18 years; Group 2a, 2 to <6 years; and Group 3a, 1 month to <2 years) and functional classification (New York Heart Association/Ross class I/II and III/IV).",965,1203
med:pmid:36601956:sec:results:sent:7,med:pmid:36601956,results,7,"We report the key demographic, baseline, and clinical characteristics of 375 pediatric patients randomized to receive the study medication.",1204,1360
med:pmid:36601956:sec:results:sent:8,med:pmid:36601956,results,8,"The mean age for patients in Groups 1, 2a, and 3a was 12.2, 3.2, and 1.3 years, respectively.",1361,1454
med:pmid:36601956:sec:results:sent:9,med:pmid:36601956,results,9,"About 70% of patients had a prior HF hospitalization, 85% had New York Heart Association/Ross class I/II HF, and ≈8% were angiotensin-converting enzyme inhibitor/angiotensin receptor blocker naïve.",1455,1652
med:pmid:36601956:sec:conclusion:sent:10,med:pmid:36601956,conclusion,10,"Compared to other pediatric HF studies, PANORAMA-HF recruited a relatively homogeneous pediatric HF population across 3 age groups, enabling a more robust evaluation of pharmacokinetics/pharmacodynamics and efficacy/safety of sacubitril/valsartan.",1653,1921
med:pmid:36601956:sec:conclusion:sent:11,med:pmid:36601956,conclusion,11,Most patients had mildly symptomatic HF at baseline.,1922,1974
med:pmid:36601956:sec:conclusion:sent:12,med:pmid:36601956,conclusion,12,<h4>Registration</h4> URL: https://www.,1975,2014
med:pmid:36601956:sec:conclusion:sent:13,med:pmid:36601956,conclusion,13,<h4>Clinicaltrials</h4> gov; Unique identifier: NCT02678312.,2015,2075
med:pmid:36516938:sec:title:sent:0,med:pmid:36516938,title,0,Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.,0,233
med:pmid:36516938:sec:introduction:sent:1,med:pmid:36516938,introduction,1,A substantial proportion of patients with heart failure and kidney disease have poorly controlled blood pressures.,0,134
med:pmid:36516938:sec:introduction:sent:2,med:pmid:36516938,introduction,2,This study aimed to evaluate patterns of blood pressure after initiation of an angiotensin receptor neprilysin inhibitor (ARNI) or an angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) across the spectrum of kidney function.,135,390
med:pmid:36516938:sec:methods:sent:3,med:pmid:36516938,methods,3,"Between 2016 and 2020, we evaluated 26,091 patients admitted to a Veterans Affairs hospital for an acute heart failure exacerbation with reduced ejection fraction.",391,571
med:pmid:36516938:sec:methods:sent:4,med:pmid:36516938,methods,4,"We assessed patterns of systolic and diastolic blood pressure among those started on ARNI or ACEI/ARB over 6 months, overall and across estimated glomerular filtration rate (eGFR).",572,752
med:pmid:36516938:sec:methods:sent:5,med:pmid:36516938,methods,5,"To account for differential treatment factors, we applied 1:1 propensity score matching using 15 known baseline covariates.",753,876
med:pmid:36516938:sec:results:sent:6,med:pmid:36516938,results,6,"There were 13,781 individuals treated with an ACEI or ARB and 2589 individuals treated with an ARNI prescription.",877,1007
med:pmid:36516938:sec:results:sent:7,med:pmid:36516938,results,7,"After propensity score matching, 839 patients were matched in each of the ARNI and ACEI/ARB groups.",1008,1107
med:pmid:36516938:sec:results:sent:8,med:pmid:36516938,results,8,"Mean baseline estimated glomerular filtration rate (eGFR) was 63.8 (standard deviation 21.6), and 10% had stage 4 or 5 chronic kidney disease.",1108,1250
med:pmid:36516938:sec:results:sent:9,med:pmid:36516938,results,9,"Patients in the ARNI group experienced greater systolic blood pressure reduction at month 3 (-5.2 mmHg vs -2.2 mmHg, ARNI vs ACEI/ARB; P < 0.001), and month 6 (-4.7 mmHg vs -1.85 mmHg, ARNI vs ACEI/ARB; P < 0.001).",1251,1465
med:pmid:36516938:sec:results:sent:10,med:pmid:36516938,results,10,These differences in systolic blood pressure by 6 months did not vary by eGFR above and below 60 mL/min/1.73m<sup>2</sup> or continuously across a wide range of eGFR (P<sub>interaction</sub> > 0.10 for both).,1466,1674
med:pmid:36516938:sec:conclusion:sent:11,med:pmid:36516938,conclusion,11,"The use of ARNI was associated with significant reduction in blood pressure as compared to the ACEI/ARB group overall and across the eGFR spectrum, including in advanced chronic kidney disease.",1675,1888
med:pmid:38510191:sec:title:sent:0,med:pmid:38510191,title,0,Trends in pharmacotherapy utilization among patients with heart failure with preserved ejection fraction.,0,105
med:pmid:38510191:sec:abstract:sent:1,med:pmid:38510191,abstract,1,<h4>Study objective</h4> Half of patients with heart failure have preserved ejection fraction (HFpEF).,0,102
med:pmid:38510191:sec:abstract:sent:2,med:pmid:38510191,abstract,2,"Over the years, guidelines have recommended or advised against various therapies for HFpEF management.",103,205
med:pmid:38510191:sec:abstract:sent:3,med:pmid:38510191,abstract,3,"However, there is limited evidence on the trends in utilization of the various medications.",206,297
med:pmid:38510191:sec:abstract:sent:4,med:pmid:38510191,abstract,4,The aim of this study was to examine the trends in the use of pharmacotherapies among patients with HFpEF from 2008 through 2020.,298,427
med:pmid:38510191:sec:abstract:sent:5,med:pmid:38510191,abstract,5,<h4>Design</h4> Retrospective cohort study of patients with HFpEF used MarketScan® Commercial and Medicare Supplemental Databases (2007-2020).,428,570
med:pmid:38510191:sec:abstract:sent:6,med:pmid:38510191,abstract,6,<h4>Participants</h4> Patients with HFpEF.,571,613
med:pmid:38510191:sec:abstract:sent:7,med:pmid:38510191,abstract,7,"<h4>Outcome measures</h4> Utilization rates for angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), aldosterone receptor antagonists (ARAs), diuretics, β-blockers, calcium channel blockers (CCBs), phosphodiesterase 5 inhibitors (PDE5Is), nitrates, digoxin, and sodium glucose cotransporter-2 inhibitors (SGLT2i) within 90 days of the first HFpEF diagnosis.",614,1058
med:pmid:38510191:sec:results:sent:8,med:pmid:38510191,results,8,"We identified 156,730 patients with HFpEF (mean [SD] age, 73 [13.4] years; 57 % females).",1059,1165
med:pmid:38510191:sec:results:sent:9,med:pmid:38510191,results,9,"From 2008 to 2020, we found increased utilization rates for ARNIs (0.02 % vs. 0.17 % of all patients, <i>p</i> < 0.01), ARBs (14.3 % vs. 18.6 %, <i>p</i> < 0.01), ARAs (7.0 % vs. 8.4 %, p < 0.01), CCBs (30.6 % vs. 33.4 %, p < 0.01), and SGLT2i (0.001 % vs. 0.021 %, p < 0.01).",1166,1442
med:pmid:38510191:sec:results:sent:10,med:pmid:38510191,results,10,"By contrast, the utilization of ACEIs (30.4 % vs. 20.5 %, p < 0.01), digoxin (9.5 % vs. 2.4 %, p < 0.01), nitrates (10.7 % vs. 4.9 %, p < 0.01), diuretics (54.1 % vs. 50.4 %, <i>p</i> = 0.20), and β-blockers (52.6 % vs. 51.7 %, p < 0.01) decreased, while utilization rates of PDE5Is remained stable (1.5 % vs. 1.1 %, <i>p</i> = 0.90) .",1443,1778
med:pmid:38510191:sec:conclusion:sent:11,med:pmid:38510191,conclusion,11,"During the 13-year study period, the utilization of ARNIs, ARBs, ARAs, CCBs, and SGLT2i increased while the utilization of digoxin, nitrates, diuretics, and β-blockers decreased among patients with HFpEF.",1779,2004
med:pmid:36808581:sec:title:sent:0,med:pmid:36808581,title,0,Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina.,0,136
med:pmid:36808581:sec:introduction:sent:1,med:pmid:36808581,introduction,1,Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor-ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compared with enalapril.,0,317
med:pmid:36808581:sec:introduction:sent:2,med:pmid:36808581,introduction,2,It proved to be a cost-effective treatment in many countries with stable economies.,318,401
med:pmid:36808581:sec:introduction:sent:3,med:pmid:36808581,introduction,3,"In Argentina, a country with chronic financial instability and a fragmented health care system, the estimation of its cost-effectiveness requires to consider local financial data.",402,581
med:pmid:36808581:sec:introduction:sent:4,med:pmid:36808581,introduction,4,To estimate the cost-effectiveness of sacubitril/valsartan in HFrEF in Argentina.,582,683
med:pmid:36808581:sec:methods:sent:5,med:pmid:36808581,methods,5,"We populated an Excel-based cost-effectiveness model, previously validated, using inputs from the pivotal phase-3 PARADIGM-HF trial and from local sources.",684,856
med:pmid:36808581:sec:methods:sent:6,med:pmid:36808581,methods,6,"As the main problem to consider was the financial instability, we adopted a differential approach to cost discounting based on the opportunity cost of capital.",857,1016
med:pmid:36808581:sec:methods:sent:7,med:pmid:36808581,methods,7,"Thus, a discount rate for costs were set at 31.6%, using the BADLAR rate published by the Central Bank of Argentina.",1017,1133
med:pmid:36808581:sec:methods:sent:8,med:pmid:36808581,methods,8,Discount for effects were set at 5% as is the current practice.,1134,1197
med:pmid:36808581:sec:methods:sent:9,med:pmid:36808581,methods,9,Costs were expressed in Argentinian pesos (ARS).,1198,1246
med:pmid:36808581:sec:methods:sent:10,med:pmid:36808581,methods,10,We used the perspective for both the social security and private payers at a 30-year horizon.,1247,1340
med:pmid:36808581:sec:methods:sent:11,med:pmid:36808581,methods,11,"The primary analysis was the incremental cost-effectiveness ratio (ICER) versus enalapril, the previous standard of care.",1341,1462
med:pmid:36808581:sec:methods:sent:12,med:pmid:36808581,methods,12,Alternative scenarios performed included a 5% cost discount rate and 3 a 5-year horizon (as is usually used).,1463,1572
med:pmid:36808581:sec:results:sent:13,med:pmid:36808581,results,13,"In Argentina the cost-per quality adjusted life-year (QALY) gained for sacubitril/valsartan versus enalapril was 391,158 ARS and 376,665 ARS for a social security and a private payer, respectively, at a 30- year horizon.",1573,1810
med:pmid:36808581:sec:results:sent:14,med:pmid:36808581,results,14,"These ICERs were under the cost- effectiveness threshold of 520,405.79 ARS (1 Gross domestic product (GDP) per capita) suggested by Argentinian health technology assessment bodies.",1811,1991
med:pmid:36808581:sec:results:sent:15,med:pmid:36808581,results,15,"Probabilistic sensitivity analysis showed an acceptability of sacubitril/valsartan as a cost-effective alternative of 86.40% and 88.25% for social security and private payers, respectively.",1992,2181
med:pmid:36808581:sec:conclusion:sent:16,med:pmid:36808581,conclusion,16,Sacubitril/valsartan is a cost-effective treatment in HFrEF using local inputs that considered the financial instability.,2182,2323
med:pmid:36808581:sec:conclusion:sent:17,med:pmid:36808581,conclusion,17,For both payers considered the cost per QALY gained are under the cost-effectiveness threshold considered.,2324,2430
med:pmid:36266969:sec:title:sent:0,med:pmid:36266969,title,0,"Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020.",0,114
med:pmid:36266969:sec:introduction:sent:1,med:pmid:36266969,introduction,1,"We aimed to study initiation, adherence, and long-term persistence to beta-blockers (BB), renin-angiotensin system inhibitors (RASi), and mineralocorticoid receptor antagonists (MRA) in a nationwide cohort of patients with heart failure (HF).",0,256
med:pmid:36266969:sec:methods:sent:2,med:pmid:36266969,methods,2,Patients aged 18-80 years in Norway with a first diagnosis of HF from 2014 until 2020 that survived ≥30 days were identified from the Norwegian Patient Registry and linked to the Norwegian Prescription Database.,257,485
med:pmid:36266969:sec:methods:sent:3,med:pmid:36266969,methods,3,"We collected information about BB, RASi [angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), and angiotensin receptor-neprilysin inhibitors (ARNI)], and MRA.",486,679
med:pmid:36266969:sec:methods:sent:4,med:pmid:36266969,methods,4,"Dual HF therapy was defined as taking at least two out of three drug classes, whereas triple HF therapy was defined as taking all three.",680,816
med:pmid:36266969:sec:methods:sent:5,med:pmid:36266969,methods,5,"Initiation (time to initiation) and persistence (time to discontinuation using a grace period of 30 days) of HF drugs was calculated by the Kaplan-Meier method, followed to outcome of interest, death, or December 2020.",817,1035
med:pmid:36266969:sec:methods:sent:6,med:pmid:36266969,methods,6,One-year adherence was measured as proportion of days covered (PDC) using a cut-off at 80%.,1036,1127
med:pmid:36266969:sec:methods:sent:7,med:pmid:36266969,methods,7,"For adherence and persistence measurements, we allowed for maximum 60 days of stockpiling and switching within drug groups.",1128,1251
med:pmid:36266969:sec:methods:sent:8,med:pmid:36266969,methods,8,We performed sensitivity analyses to test the robustness of our findings.,1252,1325
med:pmid:36266969:sec:results:sent:9,med:pmid:36266969,results,9,"Out of 54 899 patients included in the cohort, 75%, 69%, and 21% initiated a BB, RASi, and MRA, respectively, whereas 13% did not receive any.",1326,1485
med:pmid:36266969:sec:results:sent:10,med:pmid:36266969,results,10,"Dual and triple HF therapy was prescribed to 61% and 16%, respectively.",1486,1557
med:pmid:36266969:sec:results:sent:11,med:pmid:36266969,results,11,"The proportion of adherent patients during the first year following initiation was 83%, 81%, 84%, and 61% for BB, RASi, ARNI, and MRA, whereas 42% and 5% were adherent to dual and triple HF therapy, respectively.",1558,1770
med:pmid:36266969:sec:results:sent:12,med:pmid:36266969,results,12,"From 2 to 5 years following initiation, persistence decreased from 58% to 38%, 57% to 37%, and 31% to 15% for BB, RASi, and MRA, respectively.",1771,1913
med:pmid:36266969:sec:results:sent:13,med:pmid:36266969,results,13,"Within the RASi group, persistence was higher for ARNI than for ACEI and ARB.",1914,1991
med:pmid:36266969:sec:results:sent:14,med:pmid:36266969,results,14,"There were no major changes in either initiation or adherence of the drug classes from 2014 to 2019, except for an increase in initiation and adherence of MRA.",1992,2151
med:pmid:36266969:sec:conclusion:sent:15,med:pmid:36266969,conclusion,15,We found low adherence to dual and triple HF therapies in this nationwide cohort study of newly diagnosed HF patients.,2152,2291
med:pmid:36266969:sec:conclusion:sent:16,med:pmid:36266969,conclusion,16,"Efforts are needed to increase adherence and persistence to HF therapies into clinical practice, emphasizing maintenance of multiple drug therapies in patients with such an indication.",2292,2476
med:pmid:38047039:sec:title:sent:0,med:pmid:38047039,title,0,"Effectiveness of Heart Failure Checklist Management in Patients with Chronic Heart Failure: An Open-Label, Single-Center Controlled Study During 18 Months of Follow-Up.",0,168
med:pmid:38047039:sec:introduction:sent:1,med:pmid:38047039,introduction,1,The efficacy of chronic heart failure (CHF) checklist management in reducing adverse outcomes of heart failure patients is still uncertain.,0,159
med:pmid:38047039:sec:introduction:sent:2,med:pmid:38047039,introduction,2,This study explores whether CHF checklist management is more useful than usual care in reducing adverse health outcomes in the medium- and long-term among CHF patients.,160,328
med:pmid:38047039:sec:methods:sent:3,med:pmid:38047039,methods,3,"In our prospective study, 132 patients with CHF were randomly assigned to CHF management group and usual care group by random number method.",329,486
med:pmid:38047039:sec:methods:sent:4,med:pmid:38047039,methods,4,Patients in CHF management group were conducted through CHF checklist by cardiologists and general practitioner.,487,599
med:pmid:38047039:sec:methods:sent:5,med:pmid:38047039,methods,5,Patients assigned to usual care were treated by non-stationary medical group without checklist.,600,695
med:pmid:38047039:sec:methods:sent:6,med:pmid:38047039,methods,6,All groups were followed up for 18 months.,696,738
med:pmid:38047039:sec:results:sent:7,med:pmid:38047039,results,7,"There was no significant difference in overall mortality rate between management group and control group during 18 months (12.3% [8/65] vs. 11.7% [7/60], P = 0.",739,916
med:pmid:38047039:sec:results:sent:8,med:pmid:38047039,results,8,912]).,917,923
med:pmid:38047039:sec:results:sent:9,med:pmid:38047039,results,9,The re-hospitalization rate of heart failure in management group (18.5% [12/65]) was significantly lower than that in usual care group (38.3% [23/60]) after 18 months of follow-up (P = 0.013).,924,1116
med:pmid:38047039:sec:results:sent:10,med:pmid:38047039,results,10,"Median NT-proBNP level (632.3 ng/l vs. 1678 ng/l, p = 0.004) was lower in management group than that in usual care group.",1117,1238
med:pmid:38047039:sec:results:sent:11,med:pmid:38047039,results,11,Cardiac ultrasonography was performed at 18 months between the management and usual care group.,1239,1334
med:pmid:38047039:sec:results:sent:12,med:pmid:38047039,results,12,LVEDD (55.88±7.11 mm vs. 60.92±8.06 mm) and LVESD (43.25±8.42mm vs. 48.41± 9.02mm) were decreased (P<0.01).,1335,1442
med:pmid:38047039:sec:results:sent:13,med:pmid:38047039,results,13,"LVEF was increased (45.36±10.64% vs. 39.96 ±10.15%, P<0.01).",1443,1503
med:pmid:38047039:sec:results:sent:14,med:pmid:38047039,results,14,"The utilization rate of ACEI/ARB/ARNI, β-blocker were high in management group.",1504,1583
med:pmid:38047039:sec:conclusion:sent:15,med:pmid:38047039,conclusion,15,CHF checklist management by cardiologists and general practitioners can significantly reduce the re-hospitalization and improve cardiac function.,1584,1749
med:pmid:38047039:sec:conclusion:sent:16,med:pmid:38047039,conclusion,16,CHF management through heart failure checklist may improve prognosis in patients with CHF in the medium- and long-term.,1750,1869
med:pmid:37601056:sec:title:sent:0,med:pmid:37601056,title,0,The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.,0,214
med:pmid:37601056:sec:abstract:sent:1,med:pmid:37601056,abstract,1,<b>Purpose:</b> To systematically assess the efficacy and safety of sacubitril/valsartan (SV) by comparison with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for the treatment of heart failure caused by acute myocardial infarction (HF-AMI) based on current randomized controlled trials (RCTs).,0,337
med:pmid:37601056:sec:abstract:sent:2,med:pmid:37601056,abstract,2,<b>Methods:</b> Several electronic databases were searched up to 27 May 2023.,338,415
med:pmid:37601056:sec:abstract:sent:3,med:pmid:37601056,abstract,3,"Primary endpoints were the efficacy including the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), N-terminal pro-B type natriuretic peptide (NT-proBNP) and 6-min walk test (6MWT) and secondary endpoints were the safety including the major adverse cardiovascular event (MACE) and adverse reaction (AE).",416,761
med:pmid:37601056:sec:abstract:sent:4,med:pmid:37601056,abstract,4,<b>Results:</b> A total of 14 RCTs were included and all patients were from China.,762,844
med:pmid:37601056:sec:abstract:sent:5,med:pmid:37601056,abstract,5,"Among included 1,991 patients, 997 patients received SVs and 994 patients received ACEIs/ARBs.",845,939
med:pmid:37601056:sec:abstract:sent:6,med:pmid:37601056,abstract,6,"The pooled results demonstrated that patients in the SV group showed significantly better efficacy representing as increased LVEF [weighted mean difference (WMD): 4.43%, 95% confidence interval (CI): 2.84%-6.02%, <i>p</i> < 0.001] and 6MWT (WMD: 30.84 m, 95% CI: 25.65 m-36.03 m, <i>p</i> < 0.001) and decreased LVEDD (WMD: -3.24 mm, 95% CI: -4.96 mm ∼ -1.52 mm, <i>p</i> < 0.001) and NT-proBNP (WMD: -188.12 pg/mL, 95% CI: -246.75 pg/mL ∼ 129.49 pg/mL, <i>p</i> < 0.001), which was also verified by subgroup analysis based on the history of percutaneous coronary intervention (PCI).",940,1523
med:pmid:37601056:sec:abstract:sent:7,med:pmid:37601056,abstract,7,"Besides, the SV group showed significantly lower incidence rate of MACE [relative risk (RR): 0.60, 95% CI: 0.47-0.75, <i>p</i> < 0.001] and patients receiving SVs in the non-PCI group also showed lower incidence of AE (RR: 0.38, 95% CI: 0.20-0.71, <i>p</i> = 0.002).",1524,1790
med:pmid:37601056:sec:abstract:sent:8,med:pmid:37601056,abstract,8,"<b>Conclusion:</b> For the treatment of HF-AMI, SV is more effective and safer than ACEI/ARB based on current evidence, but more high-quality RCTs are still needed to verify above findings.",1791,1980
med:pmid:37416920:sec:title:sent:0,med:pmid:37416920,title,0,A machine learning evaluation of patient characteristics associated with prescribing of guideline-directed medical therapy for heart failure.,0,141
med:pmid:37416920:sec:introduction:sent:1,med:pmid:37416920,introduction,1,Patients with heart failure and reduced ejection fraction (HFrEF) are consistently underprescribed guideline-directed medications.,0,163
med:pmid:37416920:sec:introduction:sent:2,med:pmid:37416920,introduction,2,"Although many barriers to prescribing are known, identification of these barriers has relied on traditional <i>a priori</i> hypotheses or qualitative methods.",164,322
med:pmid:37416920:sec:introduction:sent:3,med:pmid:37416920,introduction,3,Machine learning can overcome many limitations of traditional methods to capture complex relationships in data and lead to a more comprehensive understanding of the underpinnings driving underprescribing.,323,527
med:pmid:37416920:sec:introduction:sent:4,med:pmid:37416920,introduction,4,"Here, we used machine learning methods and routinely available electronic health record data to identify predictors of prescribing.",528,659
med:pmid:37416920:sec:methods:sent:5,med:pmid:37416920,methods,5,"We evaluated the predictive performance of machine learning algorithms to predict prescription of four types of medications for adults with HFrEF: angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACE/ARB), angiotensin receptor-neprilysin inhibitor (ARNI), evidence-based beta blocker (BB), or mineralocorticoid receptor antagonist (MRA).",660,1035
med:pmid:37416920:sec:methods:sent:6,med:pmid:37416920,methods,6,The models with the best predictive performance were used to identify the top 20 characteristics associated with prescribing each medication type.,1036,1182
med:pmid:37416920:sec:methods:sent:7,med:pmid:37416920,methods,7,Shapley values were used to provide insight into the importance and direction of the predictor relationships with medication prescribing.,1183,1320
med:pmid:37416920:sec:results:sent:8,med:pmid:37416920,results,8,"For 3,832 patients meeting the inclusion criteria, 70% were prescribed an ACE/ARB, 8% an ARNI, 75% a BB, and 40% an MRA.",1321,1458
med:pmid:37416920:sec:results:sent:9,med:pmid:37416920,results,9,The best-predicting model for each medication type was a random forest (area under the curve: 0.788-0.821; Brier score: 0.063-0.185).,1459,1592
med:pmid:37416920:sec:results:sent:10,med:pmid:37416920,results,10,"Across all medications, top predictors of prescribing included prescription of other evidence-based medications and younger age.",1593,1721
med:pmid:37416920:sec:results:sent:11,med:pmid:37416920,results,11,"Unique to prescribing an ARNI, the top predictors included lack of diagnoses of chronic kidney disease, chronic obstructive pulmonary disease, or hypotension, as well as being in a relationship, nontobacco use, and alcohol use.",1722,1949
med:pmid:37416920:sec:discussion:sent:12,med:pmid:37416920,discussion,12,We identified multiple predictors of prescribing for HFrEF medications that are being used to strategically design interventions to address barriers to prescribing and to inform further investigations.,1950,2183
med:pmid:37416920:sec:discussion:sent:13,med:pmid:37416920,discussion,13,The machine learning approach used in this study to identify predictors of suboptimal prescribing can also be used by other health systems to identify and address locally relevant gaps and solutions to prescribing.,2184,2398
med:pmid:37313196:sec:title:sent:0,med:pmid:37313196,title,0,Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials.,0,192
med:pmid:37313196:sec:introduction:sent:1,med:pmid:37313196,introduction,1,Heart failure (HF) is still a major cause of morbidity and mortality all over the world.,0,110
med:pmid:37313196:sec:introduction:sent:2,med:pmid:37313196,introduction,2,of the study was to assess the benefits and harms of sacubitril/valsartan (S/V) compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in patients with HF.,111,314
med:pmid:37313196:sec:introduction:sent:3,med:pmid:37313196,introduction,3,<h4>Material and methods</h4> We systematically searched for randomised controlled trials (RCTs) evaluating S/V vs. ACEI or ARB in acute or chronic HF in August 2021.,315,481
med:pmid:37313196:sec:introduction:sent:4,med:pmid:37313196,introduction,4,"Primary outcomes were HF hospitalisations and cardiovascular (CV) mortality; secondary outcomes included all-cause mortality, biomarkers, and renal function.",482,639
med:pmid:37313196:sec:results:sent:5,med:pmid:37313196,results,5,We selected 11 RCTs (<i>n</i> = 18766) with 2-48 months follow-up.,640,723
med:pmid:37313196:sec:results:sent:6,med:pmid:37313196,results,6,"Five RCTs had ACEIs as control, 5 RCTs had ARBs as control, and one RCT had both ACEI and ARB as control.",724,829
med:pmid:37313196:sec:results:sent:7,med:pmid:37313196,results,7,"Compared to ACEI or ARB, S/V reduced HF hospitalisations by 20% (HR = 0.80, 95% CI: 0.68-0.94; 3 RCTs; <i>I<sup>2</sup></i> = 65%; high CoE), CV mortality by 14% (HR = 0.86, 95% CI: 0.73-1.01; 2 RCTs; <i>I<sup>2</sup></i> = 57%; high CoE), and all-cause mortality by 11% (HR = 0.89, 95% CI: 0.78-1.00; 3 RCTs; <i>I<sup>2</sup></i> = 36%; high CoE).",830,1178
med:pmid:37313196:sec:results:sent:8,med:pmid:37313196,results,8,"S/V reduced NTproBNP (SMD = -0.34, 95% CI: -0.52 to -0.16; 3 RCTs; <i>I<sup>2</sup></i> = 62%) and hs-TNT (ratio of differences = 0.84, 95% CI: 0.79-0.88; 2 RCTs; <i>I<sup>2</sup></i> = 0%), and caused a decline in renal function by 33% (HR = 0.67, 95% CI: 0.39-1.14; 2 RCTs; <i>I<sup>2</sup></i> = 78%; high CoE).",1179,1493
med:pmid:37313196:sec:results:sent:9,med:pmid:37313196,results,9,"S/V increased hypotension (RR = 1.69, 95% CI: 1.33-2.15; 9 RCTs; <i>I<sup>2</sup></i> = 65%; high CoE).",1494,1597
med:pmid:37313196:sec:results:sent:10,med:pmid:37313196,results,10,Hyperkalaemia and angioedema events were similar.,1598,1647
med:pmid:37313196:sec:results:sent:11,med:pmid:37313196,results,11,Effects were in the same direction when stratified by type of control (ACEI vs. ARB).,1648,1733
med:pmid:37313196:sec:conclusion:sent:12,med:pmid:37313196,conclusion,12,"Sacubitril/valsartan had better clinical, intermediate, and renal outcomes in HF in comparison to ACEI or ARB.",1734,1865
med:pmid:37313196:sec:conclusion:sent:13,med:pmid:37313196,conclusion,13,"There was no difference in angioedema and hyperkalaemia events, but there were more hypotension events.",1866,1969
med:pmid:37146072:sec:title:sent:0,med:pmid:37146072,title,0,Clinical effect of Danshen decoction in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.,0,139
med:pmid:37146072:sec:introduction:sent:1,med:pmid:37146072,introduction,1,"The incidence of heart failure (HF) is increasing year by year, posing a great threat to human health.",0,122
med:pmid:37146072:sec:introduction:sent:2,med:pmid:37146072,introduction,2,"Although pharmacotherapy has been able to significantly prolong patient survival, pharmacotherapy for HF still has limitations due to its complex pathogenesis and considerable individual variability, there is a great need to explore complementary and alternative therapies to slow down the progression of HF.",123,431
med:pmid:37146072:sec:introduction:sent:3,med:pmid:37146072,introduction,3,"Danshen decoction is used to treat several cardiovascular diseases including HF, but the efficacy of stabilization is uncertain.",432,560
med:pmid:37146072:sec:introduction:sent:4,med:pmid:37146072,introduction,4,This meta-analysis evaluated the clinical efficacy of Danshen Decoction for the treatment of HF.,561,657
med:pmid:37146072:sec:methods:sent:5,med:pmid:37146072,methods,5,The registration number assigned to this meta-analysis on the PROSPERO platform is CRD42022351918.,658,773
med:pmid:37146072:sec:methods:sent:6,med:pmid:37146072,methods,6,"Four databases were searched, and randomized controlled trials (RCTs) of Danshen decoction combined with conventional treatment (CT) of HF were screened, CT included medical treatments other than Danshen Decoction to which the patient was treated (including but not limited to angiotensin converting enzyme inhibitor, angiotensin receptor blocker, angiotensin receptor neprilysin inhibitors, β-blockers, diuretics, mineralcorticoid recept antagonist etc.).",774,1230
med:pmid:37146072:sec:methods:sent:7,med:pmid:37146072,methods,7,"The clinical efficacy rate (CER), left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic diameter (LVESD), brain natriuretic peptide (BNP), N-terminal pro-B type natriuretic peptide (NT-proBNP) and hypersensitive C-reactive protein (hs-CRP) were included as outcome indicators.",1231,1576
med:pmid:37146072:sec:methods:sent:8,med:pmid:37146072,methods,8,The GRADE grading scale was used to grade the above indicators.,1577,1640
med:pmid:37146072:sec:methods:sent:9,med:pmid:37146072,methods,9,The Cochrane risk-of-bias tool and the Jadad quality scale were used to assess the methodological quality of RCTs.,1641,1755
med:pmid:37146072:sec:methods:sent:10,med:pmid:37146072,methods,10,"Finally, RevMan V.4.5 software was used for data synthesis, 95% confidence intervals (CI) for dichotomous data, risk ratios (RR), and mean differences (MD) for continuous variables were calculated, Chi-square and I2 were used for heterogeneity assessment.",1756,2011
med:pmid:37146072:sec:results:sent:11,med:pmid:37146072,results,11,"Nine RCTs with a total of 855 patients were included in this study, and all included RCTs had a low overall quality risk of bias and high quality of reported information.",2012,2199
med:pmid:37146072:sec:results:sent:12,med:pmid:37146072,results,12,"The results of the meta-analysis showed that compared with the use of CT, CER (%) was significantly improved due to Danshen decoction combined with CT (MD = 3.95, 95% CI [2.58, 6.04], P < 0.00001), LVEF (%) was significantly improved (MD = 5.46, 95% CI [5.32, 5.60], P < 0.00001), LVEDD (mm) was significantly reduced (MD = -5.27, 95% CI [-6.21, -4.32], P < 0.00001), LVESD (mm) was significantly reduced (MD = -4.60, 95% CI [-5.87, -3.32], P < 0.00001), BNP (pg/mL) was significantly reduced (MD = -88.61, 95% CI [-121.98, -55.24], P < 0.00001), NT-proBNP (pg/mL) was significantly decreased (SMD = -3.33, 95% CI [-5.92, -0.73], P = 0.01), hs-CRP (mg/L) was significantly decreased (MD = -2.73, 95% CI [-4.11, -1.34], P = 0.0001).",2200,2931
med:pmid:37146072:sec:results:sent:13,med:pmid:37146072,results,13,The quality of the GRADE evidence for all outcomes was moderate to low and no RCTs reported adverse events.,2932,3039
med:pmid:37146072:sec:conclusion:sent:14,med:pmid:37146072,conclusion,14,Our research demonstrates that Danshen decoction is an effective and safe treatment option for HF.,3040,3158
med:pmid:37146072:sec:conclusion:sent:15,med:pmid:37146072,conclusion,15,"Nevertheless, considering the limitations of methodological and the quality of RCTs, more rigorous, large-scale, multicenter randomized clinical trials are needed to further evaluate the efficacy and safety of Danshen decoction in the treatment of HF patients.",3159,3419
med:pmid:37077749:sec:title:sent:0,med:pmid:37077749,title,0,Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone.,0,198
med:pmid:37077749:sec:abstract:sent:1,med:pmid:37077749,abstract,1,We aimed to compare therapies of sacubitril/valsartan + spironolactone (S/V + S) with angiotensin-converting enzyme inhibitors + spironolactone (ACEI + S) on the left-sided cardiac reverse remodeling (L-CRR).,0,208
med:pmid:37077749:sec:abstract:sent:2,med:pmid:37077749,abstract,2,The second objective was to analyze the usefulness of GLS and LVEF in response to therapy.,209,299
med:pmid:37077749:sec:methods:sent:3,med:pmid:37077749,methods,3,"78 patients (mean age 63.4 years, 20 females) with symptomatic heart failure with reduced ejection fraction were randomized to groups of equal numbers, i.e., 39 patients, and started on therapy of S/V + S or ACEI + S. Second evaluations were made after 6-8 weeks of therapy.",300,591
med:pmid:37077749:sec:results:sent:4,med:pmid:37077749,results,4,GLS changed from -7.4% to -9.4% (18% improvement) in both arms equally.,592,680
med:pmid:37077749:sec:results:sent:5,med:pmid:37077749,results,5,"More than 50% of patients, initially with very severe systolic dysfunction (GLS > -8%), were reclassified to severe (GLS -8% to -12%).",681,815
med:pmid:37077749:sec:results:sent:6,med:pmid:37077749,results,6,LVEF did not improve in any of the groups.,816,858
med:pmid:37077749:sec:results:sent:7,med:pmid:37077749,results,7,The quality of life measured by MLHFQ and walking distance by 6-MWT increased.,859,937
med:pmid:37077749:sec:results:sent:8,med:pmid:37077749,results,8,"Positive correlations between GLS and 6MWT (<i>r</i> = 0.41, <i>p</i> = 0.02) and GLS and MHFLQ (<i>r</i> = 0.42, <i>p</i> = 0.03) were found.",938,1080
med:pmid:37077749:sec:conclusion:sent:9,med:pmid:37077749,conclusion,9,"The S/V + S subgroup demonstrated improvements in LVEDV (Δ16.7 vs. 4.5 ml), E/e ratio (Δ 2.8 vs. 1.4), and LAVI (Δ 9.4 vs. 8.4 ml/m<sup>2</sup>) as compared to ACEI + S.   GLS, unlike LVEF, detects early changes in LV systolic function after 6-8 weeks of combined therapy, i.e., SV + S and ACE + S. GLS is more useful than LVEF in assessing early response to treatment.",1081,1468
med:pmid:37077749:sec:conclusion:sent:10,med:pmid:37077749,conclusion,10,"The effect of S/V + S and ACEI + S on LV systolic function was comparable, but the improvement in diastolic function as expressed by E/e', LAVI, and LVEDV was more pronounced with S/V + S.",1469,1657
med:pmid:37042870:sec:title:sent:0,med:pmid:37042870,title,0,Angiotensin receptor-neprilysin inhibitors and cardiac remodeling.,0,66
med:pmid:37042870:sec:abstract:sent:1,med:pmid:37042870,abstract,1,The aim of this study was to determine how sacubitril/valsartan compared with valsartan in an outpatient setting affects left ventricular remodeling in heart failure with reduced ejection fraction and functional (or secondary) mitral regurgitation (SMR) due to the effect of dual inhibition of the renin-angiotensin system and neprilysin.,0,338
med:pmid:37042870:sec:abstract:sent:2,med:pmid:37042870,abstract,2,The outpatient study included 90 patients with chronic SMR who were followed up for 12 months.,339,433
med:pmid:37042870:sec:abstract:sent:3,med:pmid:37042870,abstract,3,"They received sacubitril/valsartan or valsartan instead of the more commonly used angiotensin-converting enzyme inhibitor enalapril for heart failure, in addition to standard medical therapy for heart failure.",434,643
med:pmid:37042870:sec:abstract:sent:4,med:pmid:37042870,abstract,4,The difference in NT-proBNP change between groups was the primary endpoint.,644,719
med:pmid:37042870:sec:abstract:sent:5,med:pmid:37042870,abstract,5,"Changes in effective regurgitation orifice area, left ventricular ejection fraction, left ventricular end-systolic and end-diastolic volume indices, left atrial volume index, E/e' index, and exercise tolerance on the 6-minute walk test were secondary endpoints.",720,981
med:pmid:37042870:sec:abstract:sent:6,med:pmid:37042870,abstract,6,"In the treatment efficacy analysis, NT-proBNP levels decreased significantly by 37% in the sacubitril/valsartan group and by 11% in the valsartan group (P<0.001).",982,1144
med:pmid:37042870:sec:abstract:sent:7,med:pmid:37042870,abstract,7,Ejection fraction and exercise tolerance (increase in walking distance in the 6-min test) increased in the sacubitril/valsartan group (P<0.05).,1145,1288
med:pmid:37042870:sec:abstract:sent:8,med:pmid:37042870,abstract,8,"Also, in this group, the effective area of the regurgitation orifice, the left atrial volume index, the E/e' index, and the indices of the end-systolic and end-diastolic volume of the left ventricle (P<0.05) decreased more pronouncedly.",1289,1525
med:pmid:37042870:sec:abstract:sent:9,med:pmid:37042870,abstract,9,"Compared with valsartan, treatment with sacubitril/valsartan led to a significant improvement in cardiac remodeling in patients with SMR and heart failure with reduced ejection fraction.",1526,1712
med:pmid:36927423:sec:title:sent:0,med:pmid:36927423,title,0,"Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review",0,169
med:pmid:36927423:sec:abstract:sent:1,med:pmid:36927423,abstract,1,"Heart failure with reduced ejection fraction (HFrEF) has been associated with poor prognosis, reduced quality of life, and increased healthcare expenditure.",0,156
med:pmid:36927423:sec:abstract:sent:2,med:pmid:36927423,abstract,2,"Despite tremendous advances in HFrEF management, reduced survival and a high rate of hospitalization remain unsolved issues.",157,281
med:pmid:36927423:sec:abstract:sent:3,med:pmid:36927423,abstract,3,"Furthermore, HFrEF morbidity and economic burden are estimated to increase in the following years; hence, new therapies are constantly emerging.",282,426
med:pmid:36927423:sec:abstract:sent:4,med:pmid:36927423,abstract,4,"In the last few years, a series of landmark clinical trials have expanded our therapeutic armamentarium with a ground-breaking change in HFrEF-related outcomes.",427,587
med:pmid:36927423:sec:abstract:sent:5,med:pmid:36927423,abstract,5,Sodium-glucose co-transporter 2 inhibitors (mainly dapagliflozin and empagliflozin) have already revolutionized the management of HFrEF patients via a significant reduction in cardiovascular mortality and heart failure hospitalizations.,588,824
med:pmid:36927423:sec:abstract:sent:6,med:pmid:36927423,abstract,6,"Furthermore, vericiguat and omecamtiv mecarbil have emerged as promising and novel disease-modifying therapies.",825,936
med:pmid:36927423:sec:abstract:sent:7,med:pmid:36927423,abstract,7,"The former restores the impaired cyclic guanosine monophosphate pathway, and the latter stimulates cardiac myosin without marked arrhythmogenesis.",937,1083
med:pmid:36927423:sec:abstract:sent:8,med:pmid:36927423,abstract,8,Both vericiguat and omecamtiv mecarbil have been shown to reduce heart failure admissions.,1084,1174
med:pmid:36927423:sec:abstract:sent:9,med:pmid:36927423,abstract,9,Sacubitril/valsartan is an established and effective therapy in HFrEF patients and should be considered as a replacement for angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs).,1175,1391
med:pmid:36927423:sec:abstract:sent:10,med:pmid:36927423,abstract,10,"Lastly, inflammasome activity is implicated in HFrEF pathophysiology, and the role of anti-inflammatory agents in HFrEF trajectories is readily scrutinized, yet available therapies are ineffective.",1392,1589
med:pmid:36927423:sec:abstract:sent:11,med:pmid:36927423,abstract,11,"This mini-review summarizes the major and most recent studies in this field, thus covering the current advances in HFrEF therapeutics.",1590,1724
med:pmid:36918781:sec:title:sent:0,med:pmid:36918781,title,0,"""Renalism"" with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review.",0,204
med:pmid:36918781:sec:introduction:sent:1,med:pmid:36918781,introduction,1,"Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRA) reduce mortality and hospitalizations in heart failure with reduced ejection fraction (HFrEF) but their use is limited in advanced chronic kidney disease (CKD).",0,367
med:pmid:36918781:sec:methods:sent:2,med:pmid:36918781,methods,2,We carried out a systematic review of studies on HFrEF and CKD patients.,368,457
med:pmid:36918781:sec:methods:sent:3,med:pmid:36918781,methods,3,"The mean overall percentage of reported ACEI, ARB, MRA, and ARNI use, and the proportion of trials that included patients with advanced CKD grades 4-5 (estimated glomerular filtration rate (eGFR) <15-30 ml/min/1.73m<sup>2</sup>) were recorded per year.",458,710
med:pmid:36918781:sec:methods:sent:4,med:pmid:36918781,methods,4,"The proportion of trials with advanced CKD was logtransformed, and then fitted into a time regression model.",711,819
med:pmid:36918781:sec:methods:sent:5,med:pmid:36918781,methods,5,"The interactions between the proportion of trials that included CKD grades 4-5 and the proportion of reported use of ACEI, ARB, and MRAs per year were explored using Pearson's correlation and univariate linear regression.",820,1041
med:pmid:36918781:sec:results:sent:6,med:pmid:36918781,results,6,"A total of 706 articles were included; 76% reported background ACEI/ARB use, while 51% reported MRA use.",1042,1163
med:pmid:36918781:sec:results:sent:7,med:pmid:36918781,results,7,ACEI/ARB use averaged 83% and MRA 50%.,1164,1202
med:pmid:36918781:sec:results:sent:8,med:pmid:36918781,results,8,"Of the trials, 57% included CKD grades 4-5.",1203,1246
med:pmid:36918781:sec:results:sent:9,med:pmid:36918781,results,9,"Over 10 years, the proportion of trials with CKD grades 4-5 increased while ACEI/ARB use decreased.",1247,1346
med:pmid:36918781:sec:results:sent:10,med:pmid:36918781,results,10,MRA use rates remained about the same.,1347,1385
med:pmid:36918781:sec:results:sent:11,med:pmid:36918781,results,11,There was an inverse association found between the proportion of trials with CKD grades 4-5 and ACEI/ARB use per year.,1386,1504
med:pmid:36918781:sec:conclusion:sent:12,med:pmid:36918781,conclusion,12,"In the past 10 years, CKD grades 4-5 patients have been increasingly included in HFrEF clinical trials.",1505,1628
med:pmid:36918781:sec:conclusion:sent:13,med:pmid:36918781,conclusion,13,"Concurrently, ACEI/ARB use has reportedly decreased.",1629,1681
med:pmid:36769667:sec:title:sent:0,med:pmid:36769667,title,0,Heart Failure Pharmacological Management: Gaps and Current Perspectives.,0,72
med:pmid:36769667:sec:abstract:sent:1,med:pmid:36769667,abstract,1,Proper therapeutic management of patients with heart failure (HF) is a major challenge for cardiologists.,0,105
med:pmid:36769667:sec:abstract:sent:2,med:pmid:36769667,abstract,2,"Current guidelines indicate to start therapy with angiotensin converting enzyme inhibitors/angiotensin receptor neprilysin inhibitors (ACEi/ARNI), beta blockers (BB), mineralocorticoid receptor antagonists (MRAs) and sodium glucose cotransporter 2 inhibitors (SGLT2i) to reduce the risk of death and hospitalization due to HF.",106,432
med:pmid:36769667:sec:abstract:sent:3,med:pmid:36769667,abstract,3,"However, certain aspects still need to be defined.",433,483
med:pmid:36769667:sec:abstract:sent:4,med:pmid:36769667,abstract,4,Current guidelines propose therapeutic algorithms based on left ventricular ejection fraction values and clinical presentations.,484,612
med:pmid:36769667:sec:abstract:sent:5,med:pmid:36769667,abstract,5,"However, these last do not always reflect the precise hemodynamic status of patients and pathophysiological mechanisms involved, particularly in the acute setting.",613,776
med:pmid:36769667:sec:abstract:sent:6,med:pmid:36769667,abstract,6,Even in the field of chronic management there are still some critical points to discuss.,777,865
med:pmid:36769667:sec:abstract:sent:7,med:pmid:36769667,abstract,7,"The guidelines do not specify which of the four pillar drugs to start first, nor at what dosage.",866,962
med:pmid:36769667:sec:abstract:sent:8,med:pmid:36769667,abstract,8,"Some authors suggest starting with SGLT2i and BB, others with ACEi or ARNI, while one of the most recent approach proposes to start with all four drugs together at low doses.",963,1137
med:pmid:36769667:sec:abstract:sent:9,med:pmid:36769667,abstract,9,"The aim of this review is to revise current gaps and perspectives regarding pharmacological therapy management in HF patients, in both the acute and chronic phase.",1138,1301
med:pmid:36685156:sec:title:sent:0,med:pmid:36685156,title,0,Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events.,0,106
med:pmid:36685156:sec:introduction:sent:1,med:pmid:36685156,introduction,1,Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH).,0,180
med:pmid:36685156:sec:introduction:sent:2,med:pmid:36685156,introduction,2,"However, whether prescription pattern is associated with heart failure outcome is unknown.",181,271
med:pmid:36685156:sec:methods:sent:3,med:pmid:36685156,methods,3,This is a retrospective study of 153 patients who received ARNI in a tertiary medical center in Taiwan.,272,392
med:pmid:36685156:sec:methods:sent:4,med:pmid:36685156,methods,4,"We analyzed the impact of dose up-titration and prescription timing including during initial admission, within 3 months after initial HFH discharge, and at outpatient clinics without prior HFH.",393,586
med:pmid:36685156:sec:methods:sent:5,med:pmid:36685156,methods,5,The primary endpoint was the composite of cardiovascular death and HFH.,587,658
med:pmid:36685156:sec:results:sent:6,med:pmid:36685156,results,6,"After a mean follow-up period of 287 ± 197 days, the primary endpoint occurred in 43 (28.1%) subjects.",659,778
med:pmid:36685156:sec:results:sent:7,med:pmid:36685156,results,7,"Patients without and with a primary endpoint significantly differed in terms of history of valvular heart disease (VHD, p = 0.006), ventricular tachyarrhythmia (VT, p = 0.043), percutaneous coronary intervention (p = 0.007), coronary artery bypass grafting (p = 0.002), chronic kidney disease (p = 0.002), age (p = 0.002), diastolic blood pressure (p = 0.025), and prescription timing (p = 0.002).",779,1176
med:pmid:36685156:sec:results:sent:8,med:pmid:36685156,results,8,"Kaplan-Meier analysis showed ARNI up-titration and prescription timing had a significant association with primary endpoint-free survival (Breslow test; p = 0.032, and log-rank test; p = 0.001, respectively).",1177,1384
med:pmid:36685156:sec:results:sent:9,med:pmid:36685156,results,9,"Cox regression analysis showed that independent predictors for the primary endpoint were ARNI up-titration [hazard ratio (HR): 0.41, p = 0.024], non-hospital ARNI versus hospital ARNI (HR: 0.41, p = 0.009), VHD (HR: 2.71, p = 0.013), VT (HR: 3.09, p = 0.02), and age (HR: 1.03, p = 0.033).",1385,1674
med:pmid:36685156:sec:conclusion:sent:10,med:pmid:36685156,conclusion,10,The prescription pattern of ARNI could be associated with heart failure events.,1675,1775
med:pmid:36660017:sec:title:sent:0,med:pmid:36660017,title,0,Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction.,0,162
med:pmid:36660017:sec:abstract:sent:1,med:pmid:36660017,abstract,1,One of the most relevant and differentiating aspects provided by the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure is the retraction of the historical stepped and vertical pharmacological treatment scheme for heart failure with reduced ejection fraction (HFrEF).,0,330
med:pmid:36660017:sec:abstract:sent:2,med:pmid:36660017,abstract,2,"Subsequently, it was replaced by an updated algorithm that places four therapeutic families in the same initial horizontal step with an equally high degree of recommendation (class I).",331,515
med:pmid:36660017:sec:abstract:sent:3,med:pmid:36660017,abstract,3,"In this context, these four pillars, which have demonstrated a significant reduction in mortality and hospitalizations in patients with HFrEF, include (1) angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB)/angiotensin II receptor-neprilysin inhibitors (ARNi), (2) beta blockers, (3) mineralocorticoid receptor antagonists (MRA) and (4) sodium-glucose cotransporter 2 inhibitors (SGLT2is) as the main novelty.",516,957
med:pmid:36660017:sec:abstract:sent:4,med:pmid:36660017,abstract,4,"This manuscript reviews the current therapeutic algorithm with a special focus on the therapeutic value of adding an MRA (still underused in both clinical trials and real world), changing an ACEi/ARB for an ARNi and incorporating an SGLT2i in patients with HFrEF.",958,1221
med:pmid:36660017:sec:abstract:sent:5,med:pmid:36660017,abstract,5,This article is part of the <i>Emerging concepts in heart failure management and treatment</i> Special Issue: https://www.drugsincontext.com/special_issues/emerging-concepts-in-heart-failure-management-and-treatment.,1222,1438
med:pmid:36470212:sec:title:sent:0,med:pmid:36470212,title,0,The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice.,0,170
med:pmid:36470212:sec:introduction:sent:1,med:pmid:36470212,introduction,1,Hospitalization due to heart failure (HF) progression is associated with poor prognosis.,0,110
med:pmid:36470212:sec:introduction:sent:2,med:pmid:36470212,introduction,2,This highlights the role of the implementation of guideline-directed medical therapy (GDMT) in improving the morbidity and mortality of patients with heart failure with reduced ejection fraction (HFrEF).,111,314
med:pmid:36470212:sec:introduction:sent:3,med:pmid:36470212,introduction,3,There are limited data about the intrahospital applicability of GDMT in real-world circumstances.,315,412
med:pmid:36470212:sec:introduction:sent:4,med:pmid:36470212,introduction,4,"We aimed to assess retrospectively the use of cornerstone GDMT including RASi (ACEI/ARB/ARNI), βB, MRA, and SGLT2i treatment in a consecutive real-world HFrEF patient population admitted with signs and symptoms of HF to the HF Unit of a Hungarian tertiary cardiac center between 2019 and 2021.",413,706
med:pmid:36470212:sec:introduction:sent:5,med:pmid:36470212,introduction,5,"The independent predictors of therapy optimization and the applicability of new HFrEF medication (ARNI, SGLT2i, vericiguat) were also investigated.",707,854
med:pmid:36470212:sec:methods:sent:6,med:pmid:36470212,methods,6,Statistical comparison of admission and discharge medication was accomplished with Fisher's exact test.,855,975
med:pmid:36470212:sec:methods:sent:7,med:pmid:36470212,methods,7,The independent predictors of the introduction of triple therapy (RASi + βB + MRA) were analyzed using univariate and multivariate logistic regression.,976,1127
med:pmid:36470212:sec:methods:sent:8,med:pmid:36470212,methods,8,"The proportion of patients eligible for vericiguat based on the inclusion and exclusion criteria of the VICTORIA trial was also investigated, as well as the number of patients suitable for ARNI and SGLT2i, taking into account the contraindications of application contained in the ESC 2021 HF Guidelines.",1128,1431
med:pmid:36470212:sec:results:sent:9,med:pmid:36470212,results,9,238 patients were included.,1432,1476
med:pmid:36470212:sec:results:sent:10,med:pmid:36470212,results,10,"During hospitalization, the use of RASi (69% vs. 89%) (ACEI/ARBs [58% vs. 70%], ARNI [10% vs. 19%]), βBs (69% vs. 85%), and MRAs (61% vs. 95%) increased significantly (p < 0.05) compared to at admission, and the use of SGLT2i (3% vs. 11%) also rose (p = 0.0005).",1477,1739
med:pmid:36470212:sec:results:sent:11,med:pmid:36470212,results,11,The application ratio of triple (RASi + βB + MRA; 43% vs. 77%) and quadruple (RASi + βB + MRA + SGLT2i; 2% vs. 11%) therapy increased as well (p < 0.0001).,1740,1895
med:pmid:36470212:sec:results:sent:12,med:pmid:36470212,results,12,"The independent predictors of discharge application of triple therapy revealed through multivariate logistic regression analysis were age, duration of hospitalization, eGFR, NTproBNP, and presence of diabetes mellitus.",1896,2114
med:pmid:36470212:sec:results:sent:13,med:pmid:36470212,results,13,"Sixty-eight percent of the cohort would have been suitable for vericiguat, 83% for ARNI, and 84% for SGLT2i.",2115,2223
med:pmid:36470212:sec:conclusion:sent:14,med:pmid:36470212,conclusion,14,"High rates of application of disease-modifying drugs are achievable among hospitalized HFrEF patients in severe clinical condition; thus, awareness of the need for their initiation must be raised.",2224,2440
med:pmid:36443599:sec:title:sent:0,med:pmid:36443599,title,0,Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.,0,116
med:pmid:36443599:sec:introduction:sent:1,med:pmid:36443599,introduction,1,Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) with a class-1 guideline recommendation.,0,144
med:pmid:36443599:sec:introduction:sent:2,med:pmid:36443599,introduction,2,We assessed the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) on all-cause and cardiovascular (CV)-related mortality and hospitalizations in heart failure (HF) with reduced or mildly reduced ejection fraction (EF).,145,433
med:pmid:36443599:sec:methods:sent:3,med:pmid:36443599,methods,3,"Patient-level clinical, laboratory, drug dispensation, hospitalization, and mortality data were derived from the Swedish Heart Failure Registry (SwedeHF) and interlinked databases (1 April 2016-31 December 2020).",434,663
med:pmid:36443599:sec:methods:sent:4,med:pmid:36443599,methods,4,"Eligible ARNI:ACEi/ARB patients (n = 7275:24,604) had a left ventricular EF < 50%.",664,746
med:pmid:36443599:sec:methods:sent:5,med:pmid:36443599,methods,5,"Mortality and hospitalizations with ARNI (≤ 3 months pre-/post-1 April 2016 index [SwedeHF]; n = 1506) versus ACEi/ARB (≤ 3 months post-index; n = 17,108) were assessed using propensity score matching (1:1 ratio) with clinical variables, and sensitivity analysis (1:2/1:3 with, and 1:2 without clinical variables).",747,1061
med:pmid:36443599:sec:results:sent:6,med:pmid:36443599,results,6,"ARNI induced a 23% reduction in all-cause mortality versus ACEi/ARB (1:1 hazard ratio [HR; 95% confidence interval (CI)]: 0.77 [0.63-0.95], p = 0.013), and a non-significant 23% relative risk reduction in CV-related mortality (0.77 [0.54-1.09], p = 0.13), but no difference in all-cause or CV-related hospitalization (1.02 [0.91-1.13]; p = 0.76; 1.01 [0.91-1.15]; p = 0.84, respectively).",1062,1467
med:pmid:36443599:sec:results:sent:7,med:pmid:36443599,results,7,"Sensitivity analyses confirmed all-cause mortality was reduced for ARNI versus ACEi/ARB (HR 0.90 [95% CI 0.82-0.99], p = 0.026), but not CV-related mortality (HR 1.04 [95% CI 0.89-1.22], p = 0.63).",1468,1665
med:pmid:36443599:sec:conclusion:sent:8,med:pmid:36443599,conclusion,8,"In this nationwide real-world study including a population of patients with HF with reduced or mildly reduced EF, ARNI as part of guideline-led Swedish clinical practice was associated with a statistically significant relative risk reduction in all-cause mortality compared with ACEi/ARB.",1666,1975
med:pmid:36202739:sec:title:sent:0,med:pmid:36202739,title,0,"Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF).",0,121
med:pmid:36202739:sec:introduction:sent:1,med:pmid:36202739,introduction,1,Guidelines recommend early initiation of multiple guideline-directed medical therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and reduced ejection fraction.,0,214
med:pmid:36202739:sec:introduction:sent:2,med:pmid:36202739,introduction,2,Understanding GDMT use is critical to improving clinical practice.,215,281
med:pmid:36202739:sec:introduction:sent:3,med:pmid:36202739,introduction,3,"This study sought to describe GDMT use in Japan, Sweden, and the United States in contemporary real-world settings.",282,417
med:pmid:36202739:sec:methods:sent:4,med:pmid:36202739,methods,4,EVOLUTION HF (Utilization of Dapagliflozin and Other Guideline Directed Medical Therapies in Heart Failure Patients: A Multinational Observational Study Based on Secondary Data) is an observational cohort study using routine-care databases.,418,675
med:pmid:36202739:sec:methods:sent:5,med:pmid:36202739,methods,5,Patients initiating any GDMT within 12 months of a hospitalization for heart failure (hHF) discharge were included.,676,791
med:pmid:36202739:sec:methods:sent:6,med:pmid:36202739,methods,6,"Dapagliflozin (the only sodium-glucose cotransporter-2 inhibitor approved at study onset), sacubitril/valsartan, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) were considered separately.",792,1083
med:pmid:36202739:sec:methods:sent:7,med:pmid:36202739,methods,7,Doses and discontinuation were assessed in the 12 months following initiation.,1084,1162
med:pmid:36202739:sec:methods:sent:8,med:pmid:36202739,methods,8,Target dose was defined as ≥100% of the guideline-recommended dose.,1163,1230
med:pmid:36202739:sec:results:sent:9,med:pmid:36202739,results,9,"Overall, 266,589 patients were included.",1231,1288
med:pmid:36202739:sec:results:sent:10,med:pmid:36202739,results,10,"Mean times from hHF to GDMT initiation were longer for novel GDMTs (dapagliflozin or sacubitril/valsartan) than for other GDMTs: 39 and 44 vs 12 to 13 days (Japan), 44 and 33 vs 22 to 31 days (Sweden), and 33 and 19 vs 18 to 24 days (United States).",1289,1538
med:pmid:36202739:sec:results:sent:11,med:pmid:36202739,results,11,"Pooled across countries, proportions of patients who discontinued therapy (not including switches from ACE inhibitor or ARB to sacubitril/valsartan) within 12 months were 23.5% (dapagliflozin), 26.4% (sacubitril/valsartan), 38.4% (ACE inhibitors), 33.4% (ARBs), 25.2% (beta-blockers), and 42.2% (MRAs).",1539,1841
med:pmid:36202739:sec:results:sent:12,med:pmid:36202739,results,12,"Corresponding target dose achievements were 75.7%, 28.2%, 20.1%, 6.7%, 7.2%, and 5.1%, respectively.",1842,1942
med:pmid:36202739:sec:conclusion:sent:13,med:pmid:36202739,conclusion,13,Initiation of novel GDMTs is delayed compared with other GDMTs.,1943,2027
med:pmid:36202739:sec:conclusion:sent:14,med:pmid:36202739,conclusion,14,Few patients received target doses of GDMTs requiring uptitration.,2028,2094
med:pmid:36202739:sec:conclusion:sent:15,med:pmid:36202739,conclusion,15,Persistence was higher for dapagliflozin than other GDMTs.,2095,2153
med:pmid:36614899:sec:title:sent:0,med:pmid:36614899,title,0,"The Prescription Pattern of Heart Failure Medications in Reduced, Mildly Reduced, and Preserved Ejection Fractions.",0,115
med:pmid:36614899:sec:abstract:sent:1,med:pmid:36614899,abstract,1,A substantial proportion of patients with heart failure (HF) receive suboptimal guideline-recommended therapy.,0,110
med:pmid:36614899:sec:abstract:sent:2,med:pmid:36614899,abstract,2,We aimed to identify the factors leading to suboptimal drug prescription in HF and according to HF phenotypes.,111,221
med:pmid:36614899:sec:abstract:sent:3,med:pmid:36614899,abstract,3,"This retrospective, single-centre observational cohort study included 702 patients admitted for worsening HF (HF with a reduced ejection fraction [HFrEF], n = 198; HF with a mildly reduced EF [HFmrEF], n = 122; and HF with a preserved EF [HFpEF], n = 382).",222,478
med:pmid:36614899:sec:abstract:sent:4,med:pmid:36614899,abstract,4,"A score based on the prescription and dose percentage of ACEi/ARBs, β-blockers, and MRAs at discharge was calculated (a total score ranging from zero to six).",479,637
med:pmid:36614899:sec:abstract:sent:5,med:pmid:36614899,abstract,5,"Approximately 70% of patients received ACEi/ARBs/ARNi, 80% of patients received β-blockers, and 20% received MRAs.",638,752
med:pmid:36614899:sec:abstract:sent:6,med:pmid:36614899,abstract,6,"The mean HF drug dose was approximately 50% of the recommended dose, irrespective of the HF phenotype.",753,855
med:pmid:36614899:sec:abstract:sent:7,med:pmid:36614899,abstract,7,"Ischaemic heart disease was associated with a higher prescription score (ranging from 0.4 to 1) compared to no history of ischaemic heart disease, irrespective of the left ventricular EF (LVEF) level.",856,1056
med:pmid:36614899:sec:abstract:sent:8,med:pmid:36614899,abstract,8,A lower prescription score was associated with older age and male sex in HFrEF and diabetes in HFmrEF.,1057,1159
med:pmid:36614899:sec:abstract:sent:9,med:pmid:36614899,abstract,9,"The overall ability of the models to predict the optimal drug dose, including key HF variables (including natriuretic peptides at admission), was poor (R2 < 0.25).",1160,1323
med:pmid:36614899:sec:abstract:sent:10,med:pmid:36614899,abstract,10,"A higher prescription score was associated with a lower risk of re-hospitalization and death (HR: 0.75 (0.57−0.97), p = 0.03), irrespective of phenotype (p-interaction = 0.41).",1324,1500
med:pmid:36614899:sec:abstract:sent:11,med:pmid:36614899,abstract,11,"Despite very different HF management guidelines according to LVEF, the prescription pattern of HF drugs is poorly related to LVEF and clinical characteristics, thus suggesting that physician-driven factors may be involved in the setting of therapeutic inertia.",1501,1761
med:pmid:36614899:sec:abstract:sent:12,med:pmid:36614899,abstract,12,It may also be related to drug intolerance or clinical stability that is not predicted by the patients’ profiles.,1762,1875
med:pmid:36530836:sec:title:sent:0,med:pmid:36530836,title,0,Effects of Sacubitril/Valsartan on Glycemic Control in Japanese Patients With Heart Failure and/or Hypertension.,0,112
med:pmid:36530836:sec:abstract:sent:1,med:pmid:36530836,abstract,1,<b><i>Background:</i></b> Post hoc analysis of the PARADIGM-HF trial showed that sacubitril/valsartan (S/V) was more effective than enalapril in lowering HbA1c in patients with heart failure and diabetes.,0,204
med:pmid:36530836:sec:abstract:sent:2,med:pmid:36530836,abstract,2,"<b><i>Methods and Results:</i></b> In the present study, the effect of S/V on glycemic control was retrospectively analyzed in 150 patients (median age 74 years) who were prescribed S/V for the treatment of heart failure and/or hypertension.",205,446
med:pmid:36530836:sec:abstract:sent:3,med:pmid:36530836,abstract,3,"After a median period of 13 weeks treatment, mean (±SD) HbA1c levels decreased significantly from 6.56±0.68% to 6.49±0.63%.",447,570
med:pmid:36530836:sec:abstract:sent:4,med:pmid:36530836,abstract,4,"The decrease in HbA1c was evident in patients with (n=111), but not in those without, diabetes.",571,666
med:pmid:36530836:sec:abstract:sent:5,med:pmid:36530836,abstract,5,"There were no significant changes in renal function after S/V treatment, but systolic blood pressure was significantly reduced from 141±21 to 134±19 mmHg.",667,821
med:pmid:36530836:sec:abstract:sent:6,med:pmid:36530836,abstract,6,"Ninety patients had N-terminal pro B-type natriuretic peptide (NT-proBNP) tested, and S/V significantly decreased median NT-proBNP concentrations from 1,026 to 618 pg/mL; however, there was no correlation between the degree of decrease in HbA1c and that in NT-proBNP.",822,1089
med:pmid:36530836:sec:abstract:sent:7,med:pmid:36530836,abstract,7,"Multiple regression analysis revealed that being diabetic, rather than having heart failure, was a significant independent variable for a reduction in HbA1c.",1090,1247
med:pmid:36530836:sec:abstract:sent:8,med:pmid:36530836,abstract,8,"<b><i>Conclusions:</i></b> Treatment with S/V improved glycemic control in patients with heart failure and/or hypertension, especially in those with concomitant diabetes.",1248,1418
med:pmid:36530836:sec:abstract:sent:9,med:pmid:36530836,abstract,9,This favorable effect on glucose metabolism may be mediated by neprilysin inhibition and is desirable in the treatment of heart failure and hypertension in diabetic patients.,1419,1593
med:pmid:36527023:sec:title:sent:0,med:pmid:36527023,title,0,Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.,0,160
med:pmid:36527023:sec:introduction:sent:1,med:pmid:36527023,introduction,1,"Sacubitril/valsartan and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) therapies were reported to affect glycaemic control and the development of diabetes mellitus (DM), but the findings are inconsistent.",0,260
med:pmid:36527023:sec:introduction:sent:2,med:pmid:36527023,introduction,2,We examined the evidence for the effects of sacubitril/valsartan and ACEI/ARB in DM by conducting a meta-analysis.,261,375
med:pmid:36527023:sec:methods:sent:3,med:pmid:36527023,methods,3,"The Cochrane Central Register of Controlled Trials (The Cochrane Library), Embase, PubMed, and ClinicalTrials.gov were searched for data from randomised clinical trials (RCTs) that evaluated the efficacy of sacubitril/valsartan and ACEI/ARB in patients, as of May 25, 2022.",376,666
med:pmid:36527023:sec:methods:sent:4,med:pmid:36527023,methods,4,Patients were grouped by their disease background at baseline.,667,729
med:pmid:36527023:sec:methods:sent:5,med:pmid:36527023,methods,5,"The main outcomes were the number of new-onset DM and hypoglycaemia, elevated glycaemia, inadequate DM control, diabetes treatment, and diabetic complications, from baseline to the end of the trials.",730,929
med:pmid:36527023:sec:methods:sent:6,med:pmid:36527023,methods,6,The risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (ROB 2).,930,1035
med:pmid:36527023:sec:methods:sent:7,med:pmid:36527023,methods,7,"The quality of the evidence was evaluated according to the Recommendations for Assessment, Development, and Evaluation guidelines.",1036,1166
med:pmid:36527023:sec:methods:sent:8,med:pmid:36527023,methods,8,The meta-analysis of the incidence of various outcomes was conducted using fixed or random effects models.,1167,1273
med:pmid:36527023:sec:methods:sent:9,med:pmid:36527023,methods,9,"The results are expressed as binary risk, 95% confidence interval (CI), and relative risk (RR).",1274,1369
med:pmid:36527023:sec:methods:sent:10,med:pmid:36527023,methods,10,The Mantel-Haenszel method and Z test were used to determine the overall results and determine the significance of the RR.,1370,1492
med:pmid:36527023:sec:results:sent:11,med:pmid:36527023,results,11,"This study included 31 RCTs and 86,809 subjects.",1493,1558
med:pmid:36527023:sec:results:sent:12,med:pmid:36527023,results,12,"Compared with placebo, sacubitril/valsartan treatment significantly reduced the risk of new-onset DM among all patients (RR = 0.78, 95% CI: 0.64-0.95), patients with heart failure (HF) (RR = 0.24, 95% CI: 0.12-0.48), HF with reduced ejection fraction (HFrEF) (RR = 0.24, 95% CI: 0.12-0.50), and HF with preserved ejection fraction (HFpEF) (RR = 0.54, 95% CI 0.34-0.85).",1559,1928
med:pmid:36527023:sec:results:sent:13,med:pmid:36527023,results,13,"In contrast, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among all patients (RR = 1.91, 95% CI: 1.05-3.47), patients with not all-DM (defined as part of the study population having DM at baseline) (RR = 5.71, 95% CI: 2.02-16.21), and patients with HFpEF (RR = 7.06, 95% CI: 2.10-23.76).",1929,2252
med:pmid:36527023:sec:results:sent:14,med:pmid:36527023,results,14,"Compared with ACEI/ARB, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among patients with HF (RR 1.85, 95% CI 1.12-3.06, p = 0.02) and HFpEF (RR 3.59, 95% CI 1.51-8.55, p = 0.004).",2253,2468
med:pmid:36527023:sec:results:sent:15,med:pmid:36527023,results,15,"Compared with placebo, ACEI/ARB treatment did significantly reduce the risk of new-onset DM among all patients (RR 0.85, 95% CI 0.77-0.93, p = 0.0007) and patients with not all-HF (defined as part of the study population having HF at baseline) (RR 0.87, 95% CI 0.82-0.93, p<0.0001) and HFpEF (RR 0.60, 95% CI 0.44-0.83, p = 0.002), diabetes complications among patients with non-HF (/not all-DM) (RR 0.87, 95% CI 0.76-0.99, p = 0.04), and subsequent diabetes treatment among patients with new-onset DM (RR 0.70, 95% CI 0.58-0.84, p = 0.0002) and significantly increased the risk of hypoglycaemia among patients with not all-DM (RR 2.06, 95% CI 1.172-3.61, p = 0.01).",2469,3135
med:pmid:36527023:sec:conclusion:sent:16,med:pmid:36527023,conclusion,16,"The results of our study, especially in reducing glycaemia and new-onset DM, revealed that sacubitril/valsartan had a positive effect on the control of glycaemia and the development of DM.",3136,3345
med:pmid:36527023:sec:conclusion:sent:17,med:pmid:36527023,conclusion,17,ACEI/ARB also had a beneficial effect but the effect was weaker than that of sacubitril/valsartan.,3346,3444
med:pmid:36527023:sec:conclusion:sent:18,med:pmid:36527023,conclusion,18,The above effects varied across diseases but the evidence was strongest in patients with HF.,3445,3537
med:pmid:36527023:sec:conclusion:sent:19,med:pmid:36527023,conclusion,19,<h4>Trial registration</h4> CRD42022336311.,3538,3581
med:pmid:36321459:sec:title:sent:0,med:pmid:36321459,title,0,The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.,0,165
med:pmid:36321459:sec:introduction:sent:1,med:pmid:36321459,introduction,1,"In patients who survive an acute myocardial infarction (AMI), angiotensin-converting enzyme inhibitors decrease the risk of subsequent major cardiovascular events.",0,183
med:pmid:36321459:sec:introduction:sent:2,med:pmid:36321459,introduction,2,Whether angiotensin-receptor blockade and neprilysin inhibition with sacubitril/valsartan reduce major coronary events more effectively than angiotensin-converting enzyme inhibitors in high-risk patients with recent AMI remains unknown.,184,420
med:pmid:36321459:sec:introduction:sent:3,med:pmid:36321459,introduction,3,We aimed to compare the effects of sacubitril/valsartan on coronary outcomes in patients with AMI.,421,519
med:pmid:36321459:sec:methods:sent:4,med:pmid:36321459,methods,4,"We conducted a prespecified analysis of the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitors Trial to Determine Superiority in Reducing Heart Failure Events After MI), which compared sacubitril/valsartan (97/103 mg twice daily) with ramipril (5 mg twice daily) for reducing heart failure events after myocardial infarction in 5661 patients with AMI complicated by left ventricular systolic dysfunction, pulmonary congestion, or both.",520,975
med:pmid:36321459:sec:methods:sent:5,med:pmid:36321459,methods,5,"In the present analysis, the prespecified composite coronary outcome was the first occurrence of death from coronary heart disease, nonfatal myocardial infarction, hospitalization for angina, or postrandomization coronary revascularization.",976,1216
med:pmid:36321459:sec:results:sent:6,med:pmid:36321459,results,6,"Patients were randomly assigned at a median of 4.4 [3.0-5.8] days after index AMI (ST-segment-elevation myocardial infarction 76%, non-ST-segment-elevation myocardial infarction 24%), by which time 89% of patients had undergone coronary reperfusion.",1217,1483
med:pmid:36321459:sec:results:sent:7,med:pmid:36321459,results,7,"Compared with ramipril, sacubitril/valsartan decreased the risk of coronary outcomes (hazard ratio, 0.86 [95% CI, 0.74-0.99], <i>P</i>=0.04) over a median follow-up of 22 months.",1484,1662
med:pmid:36321459:sec:results:sent:8,med:pmid:36321459,results,8,Rates of the components of the composite outcomes were lower in patients on sacubitril/valsartan but were not individually significantly different.,1663,1810
med:pmid:36321459:sec:conclusion:sent:9,med:pmid:36321459,conclusion,9,"In survivors of an AMI with left ventricular systolic dysfunction and pulmonary congestion, sacubitril/valsartan-compared with ramipril-reduced the risk of a prespecified major coronary composite outcome.",1811,2036
med:pmid:36321459:sec:conclusion:sent:10,med:pmid:36321459,conclusion,10,Dedicated studies are necessary to confirm this finding and elucidate its mechanism.,2037,2121
med:pmid:36321459:sec:conclusion:sent:11,med:pmid:36321459,conclusion,11,<h4>Registration</h4> URL: https://www.,2122,2161
med:pmid:36321459:sec:conclusion:sent:12,med:pmid:36321459,conclusion,12,<h4>Clinicaltrials</h4> gov; Unique identifier: NCT02924727.,2162,2222
med:pmid:35921043:sec:title:sent:0,med:pmid:35921043,title,0,Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials.,0,90
med:pmid:35921043:sec:abstract:sent:1,med:pmid:35921043,abstract,1,"Heart failure (HF) treatment has changed substantially over the last 30 years, leading to significant reductions in mortality and hospital admissions in patients with HF with reduced ejection fraction (HFrEF).",0,209
med:pmid:35921043:sec:abstract:sent:2,med:pmid:35921043,abstract,2,"Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve quality of life, mortality, and HF hospitalizations for patients with HFrEF.",210,395
med:pmid:35921043:sec:abstract:sent:3,med:pmid:35921043,abstract,3,The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (S/V) has an important role in the treatment of patients with HFrEF.,396,531
med:pmid:35921043:sec:abstract:sent:4,med:pmid:35921043,abstract,4,The PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) randomized controlled trial has established solid evidence for the treatment of HFrEF in various subgroups.,532,769
med:pmid:35921043:sec:abstract:sent:5,med:pmid:35921043,abstract,5,"Apart from HFrEF, several studies have been conducted using S/V in various indications: patients hospitalized with acute decompensated HF, HF with preserved ejection fraction, acute myocardial infarction with reduced ejection fraction, uncontrolled and resistant hypertension, and chronic kidney disease.",770,1074
med:pmid:35921043:sec:results:sent:6,med:pmid:35921043,results,6,"from the German Institute for Drug Use Evaluation reveal that implementation of S/V has increased steadily over time and, by the end of 2021, an estimated 266 000 patients were treated with S/V in Germany.",1075,1285
med:pmid:35921043:sec:results:sent:7,med:pmid:35921043,results,7,The estimated cumulative real-world patient exposure is >5.5 million patient-treatment years worldwide.,1286,1389
med:pmid:35921043:sec:results:sent:8,med:pmid:35921043,results,8,"The number of patients treated with S/V largely exceeds the number of patients treated in clinical trials, and the current indication for S/V is larger than the strict inclusion/exclusion criteria of the randomized trials.",1390,1612
med:pmid:35921043:sec:results:sent:9,med:pmid:35921043,results,9,"Especially elderly patients, women, and patients with more and more severe comorbidities are underrepresented in the clinical trials.",1613,1746
med:pmid:35921043:sec:results:sent:10,med:pmid:35921043,results,10,We therefore aimed to summarize the importance of S/V in HF in terms of efficacy and safety in clinical trials and daily clinical practice.,1747,1886
med:pmid:35501544:sec:title:sent:0,med:pmid:35501544,title,0,Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF).,0,111
med:pmid:35501544:sec:abstract:sent:1,med:pmid:35501544,abstract,1,This prospective study included patients with heart failure (HF) with reduced ejection fraction (HFrEF) with LVEF < = 40% to evaluate the impact of pharmacist on guideline directed medical therapy (GDMT).,0,204
med:pmid:35501544:sec:abstract:sent:2,med:pmid:35501544,abstract,2,"The primary outcome was to compare proportion of triple GDMT achieved for Angiotensin-Converting-Enzyme-Inhibitors (ACEI)/Angiotensin-Receptor-Blockers (ARB)/Angiotensin-Receptor-Neprilysin-Inhibitors (ARNI), beta-blockers, aldosterone antagonists (AA), and quadruple GDMT which in additional to triple therapy, included Sodium glucose co-transporter 2 inhibitor (SGLT2i) at 90-day post-enrollment compared to baseline.",205,624
med:pmid:35501544:sec:abstract:sent:3,med:pmid:35501544,abstract,3,Secondary endpoints included achieving target and/or maximally tolerated ACEI/ARB/ARNI and beta-blockers combined and individually as well as SGLT2i and AA GDMT at 90-day post-enrollment compared to baseline.,625,833
med:pmid:35501544:sec:abstract:sent:4,med:pmid:35501544,abstract,4,We also compared combined and individual HF-related hospitalization/emergency room (ER) visits 90 days pre-/post-enrollment.,834,958
med:pmid:35501544:sec:abstract:sent:5,med:pmid:35501544,abstract,5,"Of the total 974 patients screened, 80 patients seen at least once in the heart failure medication titration clinic (HMTC) were included in the analysis.",959,1112
med:pmid:35501544:sec:abstract:sent:6,med:pmid:35501544,abstract,6,Median (IQR) age was 71 (57-69) years with majority white male.,1113,1176
med:pmid:35501544:sec:abstract:sent:7,med:pmid:35501544,abstract,7,There was a significant improvement in the proportion of patients who achieved quadruple GDMT (p = 0.001) and triple GDMT (p-value = 0.020) at 90-day post-enrollment compared to baseline.,1177,1364
med:pmid:35501544:sec:abstract:sent:8,med:pmid:35501544,abstract,8,The secondary GDMT outcomes were also significantly increased at 90 days post-enrollment compared to baseline.,1365,1475
med:pmid:35501544:sec:abstract:sent:9,med:pmid:35501544,abstract,9,Significant difference in mean as well as proportion of combined HF-related hospitalization/ER-visits was found 90 days pre-/post-enrollment (p = 0.047).,1476,1629
med:pmid:35501544:sec:abstract:sent:10,med:pmid:35501544,abstract,10,Our study found that pharmacist's intervention increased the proportion of patients who achieved GDMT at 90 days.,1630,1743
med:pmid:36633029:sec:title:sent:0,med:pmid:36633029,title,0,[New therapeutic options in heart failure: the importance of the left ventricular ejection fraction].,0,101
med:pmid:36633029:sec:abstract:sent:1,med:pmid:36633029,abstract,1,Heart failure is a chronic illness with a high prevalence and mortality rate.,0,77
med:pmid:36633029:sec:abstract:sent:2,med:pmid:36633029,abstract,2,The aim of this article is to give an update on new treatment options for heart failure and the value of the left ventricular ejection fraction (LVEF) in the diagnosis and treatment of heart failure.,78,277
med:pmid:36633029:sec:abstract:sent:3,med:pmid:36633029,abstract,3,"Based on LVEF, three groups of heart failure can be distinguished: (1) heart failure with reduced ejection fraction (HFrEF; LVEF ≤ 40%), (2) heart failure with mildly reduced ejection fraction (HFmrEF; LVEF 41-49%) and (3) heart failure with preserved ejection fraction (HFpEF; LVEF ≥ 50%).",278,568
med:pmid:36633029:sec:abstract:sent:4,med:pmid:36633029,abstract,4,"The treatment of HFrEF consists of four pillars, the application of which leads to symptom reduction and better survival: (1) angiotensin converting enzyme inhibitor (ACE-i) or angiotensin receptor-neprilysin inhibitor (ARNI), (2) β-blocker, (3) mineralocorticoid receptor antagonist (MRA) and (4) sodium-glucose co-transporter 2 (SGLT2) inhibitor.",569,917
med:pmid:36633029:sec:abstract:sent:5,med:pmid:36633029,abstract,5,"ACE-I, β-blocker and MRA can be considered as treatment of HFmrEF.",918,984
med:pmid:36633029:sec:abstract:sent:6,med:pmid:36633029,abstract,6,The treatment of HFpEF mainly focuses on symptom reduction.,985,1044
med:pmid:36348348:sec:title:sent:0,med:pmid:36348348,title,0,Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials.,0,186
med:pmid:36348348:sec:introduction:sent:1,med:pmid:36348348,introduction,1,Optimal treatment strategies for patients with heart failure with preserved ejection fraction (HFpEF) remain uncertain.,0,139
med:pmid:36348348:sec:introduction:sent:2,med:pmid:36348348,introduction,2,The goal of this study was to compare the treatment effects of different therapeutic agents for patients with HFpEF.,140,256
med:pmid:36348348:sec:methods:sent:3,med:pmid:36348348,methods,3,"Randomized controlled trials (RCTs) published before June 2022 were searched from PubMed, Clinical Trials gov, and the Cochrane Central Register databases.",257,429
med:pmid:36348348:sec:methods:sent:4,med:pmid:36348348,methods,4,Combined odds ratios (ORs) with 95% confidence intervals (CI) were calculated for the primary and secondary outcomes.,430,547
med:pmid:36348348:sec:methods:sent:5,med:pmid:36348348,methods,5,"All-cause death was the primary endpoint and cardiac death, hospitalization for HF, and worsening HF (WHF) events were secondary endpoints in this meta-analysis.",548,709
med:pmid:36348348:sec:results:sent:6,med:pmid:36348348,results,6,"Fifteen RCTs including 31,608 patients were included in this meta-analysis.",710,802
med:pmid:36348348:sec:results:sent:7,med:pmid:36348348,results,7,All-cause and cardiac death were not significantly correlated between drug treatments and placebo.,803,901
med:pmid:36348348:sec:results:sent:8,med:pmid:36348348,results,8,"Compared with placebo, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitors (ARNIs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors significantly reduced HF hospitalizations [odds ratio (OR) = 0.64, (95% confidence interval (95%CI 0.43 - 0.96), OR = 0.73, (95%CI 0.61 - 0.86), and OR = 0.74, (95%CI 0.66 - 0.83), respectively] without heterogeneity among studies.",902,1312
med:pmid:36348348:sec:results:sent:9,med:pmid:36348348,results,9,"Only SGLT2 inhibitors significantly reduced WHF events [OR = 0.75, (95%CI 0.67 - 0.83)].",1313,1401
med:pmid:36348348:sec:conclusion:sent:10,med:pmid:36348348,conclusion,10,"No treatments were effective in reducing mortality, but ARNIs, ACEIs or SGLT2 inhibitors reduced HF hospitalizations and only SGLT2 inhibitors reduced WHF events for patients with HFpEF.",1402,1609
med:pmid:36333668:sec:title:sent:0,med:pmid:36333668,title,0,Short-term efficacy of angiotensin receptor-neprilysin inhibitor treatment in patients with ST-segment elevation myocardial infarction with reduced ejection fraction after primary percutaneous coronary intervention: a propensity score matching study.,0,250
med:pmid:36333668:sec:introduction:sent:1,med:pmid:36333668,introduction,1,"Acute myocardial infarction (AMI) causes a series of pathophysiological changes, including myocardial necrosis, myocardial edema, and microvascular damage.",0,175
med:pmid:36333668:sec:introduction:sent:2,med:pmid:36333668,introduction,2,"These changes eventually lead to severe cardiovascular events, such as ventricular remodeling, heart failure, and papillary dysfunction.",176,312
med:pmid:36333668:sec:introduction:sent:3,med:pmid:36333668,introduction,3,Impaired cardiac function after ST-segment elevation myocardial infarction (STEMI) often manifests as a decrease in left ventricular ejection fraction (LVEF).,313,471
med:pmid:36333668:sec:introduction:sent:4,med:pmid:36333668,introduction,4,Clinical trials have shown that angiotensin receptor-neprilysin inhibitor (ARNI) treatment has the potential to improve LVEF in patients with STEMI after primary percutaneous coronary intervention (PPCI).,472,676
med:pmid:36333668:sec:introduction:sent:5,med:pmid:36333668,introduction,5,The purpose of this study was to evaluate the short-term efficacy of ARNI versus angiotensin-converting enzyme inhibitor (ACEI) treatment in patients with STEMI who exhibit reduced LVEF after PPCI.,677,893
med:pmid:36333668:sec:methods:sent:6,med:pmid:36333668,methods,6,A total of 169 patients with STEMI exhibiting post-PPCI LVEF below 50% who were orally treated with ARNI between December 2017 and August 2020 were selected as the experimental group.,894,1094
med:pmid:36333668:sec:methods:sent:7,med:pmid:36333668,methods,7,A total of 136 patients with STEMI exhibiting post-PPCI LVEF below 50% who were orally treated with an ACEI between January 2016 and August 2020 were selected as the control group.,1095,1275
med:pmid:36333668:sec:methods:sent:8,med:pmid:36333668,methods,8,LVEF was measured using cardiac ultrasonography during hospitalization and 3 months after discharge.,1276,1376
med:pmid:36333668:sec:methods:sent:9,med:pmid:36333668,methods,9,Linear and logistic regression analyses were performed to compare patient demographics and hospitalization variables to evaluate the risk factors for change and rate of improvement in LVEF.,1377,1566
med:pmid:36333668:sec:methods:sent:10,med:pmid:36333668,methods,10,Propensity score matching (PSM) was used to account for confounding factors.,1567,1643
med:pmid:36333668:sec:results:sent:11,med:pmid:36333668,results,11,"After PSM, the study cohort consisted of 81 patients in the ARNI group and 123 in the ACEI group.",1644,1758
med:pmid:36333668:sec:results:sent:12,med:pmid:36333668,results,12,"After an average follow-up period of 3 months, no significant difference was noted in the LVEF improvement rate between the experimental and control groups (P = 0.475, 95% CI: -0.062 to 0.134).",1759,1952
med:pmid:36333668:sec:results:sent:13,med:pmid:36333668,results,13,Multivariate logistic regression analysis also indicated no significant correlation between the change in LVEF and oral ARNI treatment in patients with STEMI exhibiting reduced LVEF after PPCI (P &gt; 0.05).,1953,2160
med:pmid:36333668:sec:conclusion:sent:14,med:pmid:36333668,conclusion,14,The short-term effect of ARNI treatment on the cardiac function of patients with STEMI and reduced LVEF after PPCI is not superior to that of ACEI treatment.,2161,2338
med:pmid:36125514:sec:title:sent:0,med:pmid:36125514,title,0,[Management of chronic heart failure: state of the art according to the 2021 guideline].,0,88
med:pmid:36125514:sec:abstract:sent:1,med:pmid:36125514,abstract,1,Treatment of heart failure with reduced ejection fraction (HFrEF) requires four drug classes that should be initiated simultaneously and up-titrated rapidly.,0,157
med:pmid:36125514:sec:abstract:sent:2,med:pmid:36125514,abstract,2,All four have received class I recommendations.,158,205
med:pmid:36125514:sec:abstract:sent:3,med:pmid:36125514,abstract,3,"Sacubitril/valsartan can be considered in initial treatment, even for patients in whom no previous treatment with an angiotensin converting enzyme inhibitor has been given.",206,378
med:pmid:36125514:sec:abstract:sent:4,med:pmid:36125514,abstract,4,Treatment with dapagliflozin and empagliflozin is started irrespective of diabetes mellitus to reduce mortality and hospitalization rates for heart failure.,379,535
med:pmid:36125514:sec:abstract:sent:5,med:pmid:36125514,abstract,5,"Most drug treatment recommendations for HFrEF can be extrapolated to heart failure with mildly-reduced ejection fraction, even though the evidence base is not as robust as in HFrEF.",536,717
med:pmid:36125514:sec:abstract:sent:6,med:pmid:36125514,abstract,6,"Treatment individualization considers co-morbidities such as atrial fibrillation, valvular disease and iron deficiency as well as advanced heart failure.",718,871
med:pmid:36125514:sec:abstract:sent:7,med:pmid:36125514,abstract,7,"Following cardiac decompensation, verciguat is now available as an additional treatment option.",872,967
med:pmid:35999128:sec:title:sent:0,med:pmid:35999128,title,0,Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66).,0,153
med:pmid:35999128:sec:introduction:sent:1,med:pmid:35999128,introduction,1,Guidelines recommend angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB)/angiotensin receptor neprilysin inhibitors (ARNI); beta blockers; and mineralocorticoid receptor antagonists (MRA) in patients with symptomatic heart failure and reduced left ventricular ejection fraction before consideration of primary prevention implantable cardioverter defibrillator (ICD).,0,420
med:pmid:35999128:sec:introduction:sent:2,med:pmid:35999128,introduction,2,This study aims to investigate dispensing rates of guideline-directed medical therapy (GDMT) before and after primary prevention ICD implantation in New Zealand.,421,582
med:pmid:35999128:sec:methods:sent:3,med:pmid:35999128,methods,3,All patients receiving a primary prevention ICD between 2009 and 2018 were identified using nationally collected data on all public hospital admissions in New Zealand.,583,767
med:pmid:35999128:sec:methods:sent:4,med:pmid:35999128,methods,4,This was anonymously linked to national pharmaceutical data to obtain medication dispensing.,768,860
med:pmid:35999128:sec:methods:sent:5,med:pmid:35999128,methods,5,"Medications were categorised as low dose (<50% of target dose), 50-99% of target dose or target dose based on international guidelines.",861,996
med:pmid:35999128:sec:results:sent:6,med:pmid:35999128,results,6,"Of the 1,698 patients identified, ACEi/ARB/ARNI, beta blockers and MRA were dispensed in 80.2%, 83.6% and 45.4%, respectively, prior to ICD implant.",997,1162
med:pmid:35999128:sec:results:sent:7,med:pmid:35999128,results,7,"However, ≥50% target doses of each medication class were dispensed in only 51.8%, 51.8% and 34.5%, respectively.",1163,1275
med:pmid:35999128:sec:results:sent:8,med:pmid:35999128,results,8,Only 15.8% of patients were receiving ≥50% target doses of all three classes of medications.,1276,1368
med:pmid:35999128:sec:results:sent:9,med:pmid:35999128,results,9,"In the 1,666 patients who survived 1 year after ICD implant, the proportions of patients dispensed each class of medications remained largely unchanged.",1369,1521
med:pmid:35999128:sec:conclusion:sent:10,med:pmid:35999128,conclusion,10,"Dispensing of GDMT was suboptimal in patients before and after primary prevention ICD implantation in New Zealand, and only a minority received ≥50% target doses of all classes of medication.",1522,1733
med:pmid:35999128:sec:methods:sent:11,med:pmid:35999128,methods,11,are needed to optimise use of these standard evidence-based medications to improve clinical outcomes and avoid unnecessary device implantation.,1734,1891
med:pmid:35851740:sec:title:sent:0,med:pmid:35851740,title,0,"Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.",0,200
med:pmid:35851740:sec:introduction:sent:1,med:pmid:35851740,introduction,1,Half of heart failure (HF) patients have chronic kidney disease (CKD) complicating their pharmacological management.,0,129
med:pmid:35851740:sec:introduction:sent:2,med:pmid:35851740,introduction,2,We evaluated physicians' and patients' patterns of use of evidence-based medical therapies in HF across CKD stages.,130,245
med:pmid:35851740:sec:results:sent:3,med:pmid:35851740,results,3,We studied HF patients with reduced (HFrEF) and mildly reduced (HFmrEF) ejection fraction enrolled in the Swedish Heart Failure Registry in 2009-2018.,246,425
med:pmid:35851740:sec:results:sent:4,med:pmid:35851740,results,4,"We investigated the likelihood of physicians to prescribe guideline-recommended therapies to patients with CKD, and of patients to fill the prescriptions within 90 days of incident HF (initiating therapy), to adhere (proportion of days covered ≥80%) and persist (continued use) on these treatments during the first year of therapy.",426,757
med:pmid:35851740:sec:results:sent:5,med:pmid:35851740,results,5,"We identified 31 668 patients with HFrEF (median age 74 years, 46% CKD).",758,830
med:pmid:35851740:sec:results:sent:6,med:pmid:35851740,results,6,"The proportions receiving a prescription for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ACEi/ARB/ARNi) were 96%, 92%, 86%, and 68%, for estimated glomerular filtration rate (eGFR) ≥60, 45-59, 30-44, and <30 ml/min/1.73 m<sup>2</sup> , respectively; for beta-blockers 94%, 93%, 92%, and 92%, for mineralocorticoid receptor antagonists (MRAs) 45%, 44%, 37%, 24%; and for triple therapy (combination of ACEi/ARB/ARNi + beta-blockers + MRA) 38%, 35%, 28%, and 15%.",831,1363
med:pmid:35851740:sec:results:sent:7,med:pmid:35851740,results,7,"Patients with CKD were less likely to initiate these medications, and less likely to adhere to and persist on ACEi/ARB/ARNi, MRA, and triple therapy.",1364,1513
med:pmid:35851740:sec:results:sent:8,med:pmid:35851740,results,8,"Among stoppers, CKD patients were less likely to restart these medications.",1514,1589
med:pmid:35851740:sec:results:sent:9,med:pmid:35851740,results,9,were consistent after multivariable adjustment and in patients with HFmrEF (n = 15 114).,1590,1686
med:pmid:35851740:sec:conclusion:sent:10,med:pmid:35851740,conclusion,10,"Patients with HF and CKD are less likely to be prescribed and to fill prescriptions for evidence-based therapies, showing lower adherence and persistence, even at eGFR categories where these therapies are recommended and have shown efficacy in clinical trials.",1687,1968
med:pmid:35022763:sec:title:sent:0,med:pmid:35022763,title,0,Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis.,0,96
med:pmid:35022763:sec:introduction:sent:1,med:pmid:35022763,introduction,1,"While it is well known that angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) increase the risk of acute renal failure, the role of neprilysin inhibition (NEPi) is unclear and some physicians are reluctant to prescribe sacubitril/valsartan because of safety concerns.",0,322
med:pmid:35022763:sec:introduction:sent:2,med:pmid:35022763,introduction,2,"This meta-analysis aimed to examine the risk for renal events, progression of chronic kidney disease (CKD) or progression to dialysis on combined NEPi and ACEi/ARBs compared with ACEi or ARBs.",323,515
med:pmid:35022763:sec:methods:sent:3,med:pmid:35022763,methods,3,"We performed a systematic meta-analysis including 17 randomized controlled trials (study drug sacubitril/valsartan or omapatrilat), involving a total of 23 569 patients, after searching PubMed, Cochrane, ClinicalTrials.org and Embase for eligible studies.",516,788
med:pmid:35022763:sec:methods:sent:4,med:pmid:35022763,methods,4,"From the included trials, all renal endpoints, including long- and short-term outcomes and hyperkalemia, were extracted.",789,909
med:pmid:35022763:sec:methods:sent:5,med:pmid:35022763,methods,5,Pooled odds ratios (ORs) were calculated using the DerSimonian and Laird method.,910,990
med:pmid:35022763:sec:methods:sent:6,med:pmid:35022763,methods,6,The study was registered at PROSPERO.,991,1028
med:pmid:35022763:sec:results:sent:7,med:pmid:35022763,results,7,"Overall, treatment with sacubitril/valsartan or omapatrilat showed a slightly lower risk of any renal event [OR 0.82 (0.7-0.97)] compared with treatment with an ACEi or ARB alone.",1029,1225
med:pmid:35022763:sec:results:sent:8,med:pmid:35022763,results,8,"Also, there was a decreased risk of severe acute renal events [OR 0.8 (0.69-0.93)] and a decrease in estimated glomerular filtration rate decline [mean difference -0.58 mL/min (-0.83 to -0.33 mL/min)].",1226,1427
med:pmid:35022763:sec:results:sent:9,med:pmid:35022763,results,9,There was no difference in chronic renal events [OR 0.92 (0.8-1.05)] or hyperkalemia [OR 1.02 (0.84-1.23)].,1428,1535
med:pmid:35022763:sec:conclusion:sent:10,med:pmid:35022763,conclusion,10,NEPi + ACEi/ARBs are safe in terms of renal adverse events.,1536,1615
med:pmid:35022763:sec:conclusion:sent:11,med:pmid:35022763,conclusion,11,Longer trials focusing on CKD are needed to evaluate the effect of NEPi on decreasing progression of CKD.,1616,1721
med:pmid:37143752:sec:title:sent:0,med:pmid:37143752,title,0,Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review.,0,150
med:pmid:37143752:sec:introduction:sent:1,med:pmid:37143752,introduction,1,To assess the cost-effectiveness of sacubitril/valsartan compared with enalapril in patients with heart failure with reduced ejection (HFrEF).,0,162
med:pmid:37143752:sec:methods:sent:2,med:pmid:37143752,methods,2,"A systematic literature search was conducted searching in major electronic databases from inception to January 1, 2021.",163,299
med:pmid:37143752:sec:methods:sent:3,med:pmid:37143752,methods,3,All relevant full economic evaluation studies of sacubitril/valsartan versus enalapril for the treatment of patients with HFrEF were identified using ad hoc search strategies.,300,475
med:pmid:37143752:sec:methods:sent:4,med:pmid:37143752,methods,4,"Mortality, hospital admissions, quality-adjusted life years (QALYs), life-years (LYQs), annual drug costs, total lifetime costs, and incremental cost-effectiveness ratio (ICER) were considered as the outcomes.",476,685
med:pmid:37143752:sec:methods:sent:5,med:pmid:37143752,methods,5,The quality of the included studies was assessed using the CHEERS checklist.,686,762
med:pmid:37143752:sec:methods:sent:6,med:pmid:37143752,methods,6,"This study was conducted and reported in accordance with the ""Preferred Reporting Items for Systematic Reviews and Meta-Analyses"" (PRISMA) guidelines.",763,913
med:pmid:37143752:sec:results:sent:7,med:pmid:37143752,results,7,"The initial search yielded a pool of 1026 articles, of which 703 unique articles were screened, 65 full-text articles were assessed for eligibility and 15 studies finally included in the qualitative synthesis.",914,1140
med:pmid:37143752:sec:results:sent:8,med:pmid:37143752,results,8,Studies show that sacubitril/valsartan reduces mortality and hospitalization rate.,1141,1223
med:pmid:37143752:sec:results:sent:9,med:pmid:37143752,results,9,"The mean of death risk ratio and hospitalization were computed at 0.843 and 0.844, respectively.",1224,1320
med:pmid:37143752:sec:results:sent:10,med:pmid:37143752,results,10,Sacubitril/valsartan produced higher annual and total lifetime costs.,1321,1390
med:pmid:37143752:sec:results:sent:11,med:pmid:37143752,results,11,"The lowest and highest lifetime costs for sacubitril/valsartan were found in Thailand ($4,756) and Germany ($118,815), respectively.",1391,1523
med:pmid:37143752:sec:results:sent:12,med:pmid:37143752,results,12,"The lowest ICER was reported in Thailand ($4857/QALY) and the highest in the USA ($143,891/QALY).",1524,1621
med:pmid:37143752:sec:conclusion:sent:13,med:pmid:37143752,conclusion,13,Sacubitril/valsartan is associated with better outcomes and may be cost-effective compared to enalapril for the management of HFrEF.,1622,1774
med:pmid:37143752:sec:conclusion:sent:14,med:pmid:37143752,conclusion,14,"However, in developing countries such as Thailand, sacubitril-valsartan costs must be reduced to yield an ICER below the threshold.",1775,1906
med:pmid:36252108:sec:title:sent:0,med:pmid:36252108,title,0,Inpatient Quality-of-Care Measures for Heart Failure: Treatment Gaps and Opportunities in the Contemporary Era.,0,111
med:pmid:36252108:sec:introduction:sent:1,med:pmid:36252108,introduction,1,Quality of care measures are vital tools to assess processes of care within and between health care systems.,0,128
med:pmid:36252108:sec:introduction:sent:2,med:pmid:36252108,introduction,2,The 2020 American College of Cardiology/AHA performance measures for heart failure provide a new set of such measures.,129,247
med:pmid:36252108:sec:introduction:sent:3,med:pmid:36252108,introduction,3,We evaluated the achievement of these and other performance measures within the Veterans Affairs hospital system in a contemporary cohort of patients hospitalized for heart failure.,248,429
med:pmid:36252108:sec:methods:sent:4,med:pmid:36252108,methods,4,Hospital discharges from January 2010 to February 2021 with a primary diagnosis of heart failure (n=289 810) were evaluated.,430,571
med:pmid:36252108:sec:methods:sent:5,med:pmid:36252108,methods,5,Adherence to each measure was determined using the measure's stated definition and by site.,572,663
med:pmid:36252108:sec:results:sent:6,med:pmid:36252108,results,6,"Among patients with reduced ejection fraction (53.0%), beta blocker use was high (89.0%), ACE (angiotensin-converting enzyme) inhibitor, angiotensin receptor blocker, or angiotensin receptor-neprilysin inhibitor (ARNI) use decreased over time (75.3% in 2010, 55.8% in 2020), and hydralazine/nitrate use in eligible Black patients (19.3%) was low.",664,1027
med:pmid:36252108:sec:results:sent:7,med:pmid:36252108,results,7,"While 68.1% were eligible for ARNI, only 6.0% received them, reaching 17.2% by 2020.",1028,1112
med:pmid:36252108:sec:results:sent:8,med:pmid:36252108,results,8,"Mineralocorticoid receptor antagonists were used in 49.3% of those eligible; laboratory testing 7 days after their initiation was 73.0%, detecting hyperkalemia in 2.2%, although it occurred in 13.7% by 90 days.",1113,1323
med:pmid:36252108:sec:results:sent:9,med:pmid:36252108,results,9,"Achievement of ≥50% target dose was low (beta blocker 45.9%, ACE inhibitor/angiotensin receptor blocker 31.6%, ARNI 19.0%) and for ACE inhibitor/angiotensin receptor blocker/ARNI, decreased over time.",1324,1524
med:pmid:36252108:sec:results:sent:10,med:pmid:36252108,results,10,Discharge appointments were 56.2% at 7 days and 78.8% at 14 days.,1525,1590
med:pmid:36252108:sec:results:sent:11,med:pmid:36252108,results,11,Cardiac rehabilitation referral was low (10.5%) but increased.,1591,1653
med:pmid:36252108:sec:results:sent:12,med:pmid:36252108,results,12,"There were significant site-level differences, particularly for hydralazine, ARNI, devices, and cardiac rehabilitation.",1654,1773
med:pmid:36252108:sec:conclusion:sent:13,med:pmid:36252108,conclusion,13,Important inpatient quality of care measures can be readily measured across the Veterans Administration health care system from electronic health records.,1774,1949
med:pmid:36252108:sec:conclusion:sent:14,med:pmid:36252108,conclusion,14,Treatment gaps and site-level differences persisted into the contemporary era and will likely be exacerbated as newer treatments are added to this complex baseline.,1950,2114
med:pmid:36252108:sec:conclusion:sent:15,med:pmid:36252108,conclusion,15,"These measures and methods also offer the opportunity to target global, local, and individual processes of care for innovative quality improvement initiatives.",2115,2274
med:pmid:36125061:sec:title:sent:0,med:pmid:36125061,title,0,Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system.,0,166
med:pmid:36125061:sec:abstract:sent:1,med:pmid:36125061,abstract,1,<b>BACKGROUND:</b> Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for patients with heart failure with reduced ejection fraction (HFrEF).,0,310
med:pmid:36125061:sec:abstract:sent:2,med:pmid:36125061,abstract,2,"However, it has not been broadly adopted in clinical practice.",311,373
med:pmid:36125061:sec:abstract:sent:3,med:pmid:36125061,abstract,3,<b>OBJECTIVE:</b> To characterize ARNI use within a large diverse real-world population and assess for any racial disparities.,374,500
med:pmid:36125061:sec:abstract:sent:4,med:pmid:36125061,abstract,4,<b>METHODS:</b> We conducted a cross-sectional study within Kaiser Permanente Southern California.,501,599
med:pmid:36125061:sec:abstract:sent:5,med:pmid:36125061,abstract,5,"Adult patients with HFrEF who received ARNIs, ACEIs, or ARBs between January 1, 2014, and November 30, 2020, were identified.",600,725
med:pmid:36125061:sec:abstract:sent:6,med:pmid:36125061,abstract,6,The prevalence of ARNI use among the cohort and patient characteristics by ARNIs vs ACEIs/ARBs use were described.,726,840
med:pmid:36125061:sec:abstract:sent:7,med:pmid:36125061,abstract,7,Multivariable regression was performed to estimate odds ratios and 95% CIs of receiving ARNI by race and ethnicity.,841,956
med:pmid:36125061:sec:abstract:sent:8,med:pmid:36125061,abstract,8,"<b>RESULTS:</b> Among 12,250 patients with HFrEF receiving ACEIs, ARBs, or ARNIs, 556 (4.54%) patients received ARNIs.",957,1075
med:pmid:36125061:sec:abstract:sent:9,med:pmid:36125061,abstract,9,ARNI use among this cohort increased from 0.02% in 2015 to 7.48% in 2020.,1076,1149
med:pmid:36125061:sec:abstract:sent:10,med:pmid:36125061,abstract,10,Patients receiving ARNIs were younger (aged 62 vs 69 years) and had a lower median ejection fraction (27% vs 32%) compared with patients receiving ACEIs/ARBs.,1150,1308
med:pmid:36125061:sec:abstract:sent:11,med:pmid:36125061,abstract,11,They also had higher use of mineralocorticoid antagonists (24.1% vs 19.8%) and automatic implantable cardioverterdefibrillators (17.4% vs 13.3%).,1309,1454
med:pmid:36125061:sec:abstract:sent:12,med:pmid:36125061,abstract,12,There were no significant differences in rate of ARNI use by race and ethnicity.,1455,1535
med:pmid:36125061:sec:abstract:sent:13,med:pmid:36125061,abstract,13,"<b>CONCLUSIONS:</b> Within a large diverse integrated health system in Southern California, the rate of ARNI use has risen over time.",1536,1669
med:pmid:36125061:sec:abstract:sent:14,med:pmid:36125061,abstract,14,"Patients given ARNIs were younger with fewer comorbidities, while having worse ejection fraction.",1670,1767
med:pmid:36125061:sec:abstract:sent:15,med:pmid:36125061,abstract,15,Racial minorities were no less likely to receive ARNIs compared with White patients.,1768,1852
med:pmid:36125061:sec:abstract:sent:16,med:pmid:36125061,abstract,16,<b>DISCLOSURES:</b> Dr Huang had stock ownership in Gilead and Pfizer.,1853,1923
med:pmid:36125061:sec:abstract:sent:17,med:pmid:36125061,abstract,17,Dr Liang received support for article processing and medical writing.,1924,1993
med:pmid:36082663:sec:title:sent:0,med:pmid:36082663,title,0,Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.,0,166
med:pmid:36082663:sec:introduction:sent:1,med:pmid:36082663,introduction,1,Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI).,0,145
med:pmid:36082663:sec:introduction:sent:2,med:pmid:36082663,introduction,2,"Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data are conflicting.",146,277
med:pmid:36082663:sec:introduction:sent:3,med:pmid:36082663,introduction,3,The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) tested the effect of sacubitril/valsartan compared with ramipril on LV function and adverse remodeling after high risk-AMI.,278,560
med:pmid:36082663:sec:methods:sent:4,med:pmid:36082663,methods,4,"In a prespecified substudy, 544 PARADISE-MI participants were enrolled in the Echo Study to undergo protocol echocardiography at randomization and after 8 months.",561,740
med:pmid:36082663:sec:methods:sent:5,med:pmid:36082663,methods,5,Patients were randomized within 0.5 to 7 days of presentation with their index AMI to receive a target dose of sacubitril/valsartan 200 mg or ramipril 5 mg twice daily.,741,909
med:pmid:36082663:sec:methods:sent:6,med:pmid:36082663,methods,6,Echocardiographic measures were performed at a core laboratory by investigators blinded to treatment assignment.,910,1022
med:pmid:36082663:sec:methods:sent:7,med:pmid:36082663,methods,7,The effect of treatment on change in echo measures was assessed with ANCOVA with adjustment for baseline value and enrollment region.,1023,1156
med:pmid:36082663:sec:methods:sent:8,med:pmid:36082663,methods,8,"The primary end points were change in LV ejection fraction (LVEF) and left atrial volume (LAV), and prespecified secondary end points included changes in LV end-diastolic and end-systolic volumes.",1157,1353
med:pmid:36082663:sec:results:sent:9,med:pmid:36082663,results,9,"Mean age was 64±12 years; 26% were women; mean LVEF was 42±12%; and LAV was 49±17 mL. Of 544 enrolled patients, 457 (84%) had a follow-up echo at 8 months (228 taking sacubitril/valsartan, 229 taking ramipril).",1354,1581
med:pmid:36082663:sec:results:sent:10,med:pmid:36082663,results,10,There was no significant difference in change in LVEF (<i>P</i>=0.79) or LAV (<i>P</i> =0.62) by treatment group.,1582,1695
med:pmid:36082663:sec:results:sent:11,med:pmid:36082663,results,11,"Patients randomized to sacubitril/valsartan demonstrated less increase in LV end-diastolic volume (<i>P</i>=0.025) and greater decline in LV mass index (<i>P</i>=0.037), increase in tissue Doppler e'<sub>lat</sub> (<i>P</i>=0.005), decrease in E/e'<sub>lat</sub> (<i>P</i>=0.045), and decrease in tricuspid regurgitation peak velocity (<i>P</i>=0.024) than patients randomized to ramipril.",1696,2085
med:pmid:36082663:sec:results:sent:12,med:pmid:36082663,results,12,These differences remained significant after adjustment for differences in baseline characteristics.,2086,2186
med:pmid:36082663:sec:results:sent:13,med:pmid:36082663,results,13,"Baseline LVEF, LV end-diastolic volume, LV end-systolic volume, LV mass index, LAV, and Doppler-based diastolic indices were associated with risk of cardiovascular death or incident heart failure.",2187,2383
med:pmid:36082663:sec:conclusion:sent:14,med:pmid:36082663,conclusion,14,Treatment with sacubitril/valsartan compared with ramipril after AMI did not result in changes in LVEF or LAV at 8 months.,2384,2527
med:pmid:36082663:sec:conclusion:sent:15,med:pmid:36082663,conclusion,15,Patients randomized to sacubitril/valsartan had less LV enlargement and greater improvement in filling pressure.,2528,2640
med:pmid:36082663:sec:conclusion:sent:16,med:pmid:36082663,conclusion,16,"Measures of LV size, systolic function, and diastolic properties were predictive of cardiovascular death and incident heart failure after AMI in this contemporary, well-treated cohort.",2641,2825
med:pmid:36082663:sec:conclusion:sent:17,med:pmid:36082663,conclusion,17,<h4>Registration</h4> URL: https://www.,2826,2865
med:pmid:36082663:sec:conclusion:sent:18,med:pmid:36082663,conclusion,18,<h4>Clinicaltrials</h4> gov; Unique identifier: NCT02924727.,2866,2926
med:pmid:35902033:sec:title:sent:0,med:pmid:35902033,title,0,Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.,0,116
med:pmid:35902033:sec:introduction:sent:1,med:pmid:35902033,introduction,1,Guideline-directed medical therapy (GDMT) dramatically improves outcomes in heart failure with reduced ejection fraction (HFrEF).,0,149
med:pmid:35902033:sec:introduction:sent:2,med:pmid:35902033,introduction,2,Our goal was to examine GDMT use in community patients with newly diagnosed HFrEF.,150,232
med:pmid:35902033:sec:results:sent:3,med:pmid:35902033,results,3,"We performed a population-based, retrospective cohort study of all Olmsted County, Minnesota, residents with newly diagnosed HFrEF (EF ≤ 40%) 2007-2017.",233,414
med:pmid:35902033:sec:results:sent:4,med:pmid:35902033,results,4,We excluded patients with contraindications to medication initiation.,415,484
med:pmid:35902033:sec:results:sent:5,med:pmid:35902033,results,5,"We examined the use of beta-blockers, HF beta-blockers (metoprolol succinate, carvedilol, bisoprolol), angiotensin converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), angiotensin receptor neprilysin inhibitors (ARNIS), and mineralocorticoid receptor antagonists (MRAs) in the first year after HFrEF diagnosis.",485,818
med:pmid:35902033:sec:results:sent:6,med:pmid:35902033,results,6,We used Cox models to evaluate the association of being seen in an HF clinic with the initiation of GDMT.,819,924
med:pmid:35902033:sec:results:sent:7,med:pmid:35902033,results,7,"From 2007 to 2017, 1160 patients were diagnosed with HFrEF (mean age 69.7 years, 65.6% men).",925,1017
med:pmid:35902033:sec:results:sent:8,med:pmid:35902033,results,8,Most eligible patients received beta-blockers (92.6%) and ACEis/ARBs/ARNIs (87.0%) in the first year.,1018,1119
med:pmid:35902033:sec:results:sent:9,med:pmid:35902033,results,9,"However, only 63.8% of patients were treated with an HF beta-blocker, and few received MRAs (17.6%).",1120,1220
med:pmid:35902033:sec:results:sent:10,med:pmid:35902033,results,10,"In models accounting for the role of an HF clinic in initiation of these medications, being seen in an HF clinic was independently associated with initiation of new GDMT across all medication classes, with a hazard ratio (95% CI) of 1.54 (1.15-2.06) for any beta-blocker, 2.49 (1.95-3.20) for HF beta-blockers, 1.97 (1.46-2.65) for ACEis/ARBs/ARNIs, and 2.14 (1.49-3.08) for MRAs.",1221,1601
med:pmid:35902033:sec:conclusion:sent:11,med:pmid:35902033,conclusion,11,"In this population-based study, most patients with newly diagnosed HFrEF received beta-blockers and ACEis/ARBs/ARNIs.",1602,1740
med:pmid:35902033:sec:conclusion:sent:12,med:pmid:35902033,conclusion,12,"GDMT use was higher in patients seen in an HF clinic, suggesting the potential benefit of referral to an HF clinic for patients with newly diagnosed HFrEF.",1741,1896
med:pmid:35712811:sec:title:sent:0,med:pmid:35712811,title,0,Angiotensin receptor-neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime.,0,116
med:pmid:35712811:sec:introduction:sent:1,med:pmid:35712811,introduction,1,"Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder, characterized by significant long-term cardiac involvement.",0,156
med:pmid:35712811:sec:introduction:sent:2,med:pmid:35712811,introduction,2,"Dilated cardiomyopathy (DCM) is the main cause of death in DMD, and angiotensin-converting enzyme inhibitors (ACEi) and beta-blockers (BB) are first-line treatments in DCM.",157,329
med:pmid:35712811:sec:introduction:sent:3,med:pmid:35712811,introduction,3,It is unknown whether angiotensin receptor-neprilysin inhibitor (ARNi) could provide greater benefits in this setting.,330,448
med:pmid:35712811:sec:introduction:sent:4,med:pmid:35712811,introduction,4,Our aim is to assess whether ARNi use may prevent deterioration in ejection fraction (EF) or is associated with EF improvement compared with ACEi in DMD patients with heart failure and to report the tolerability of ARNi in this group of patients.,449,695
med:pmid:35712811:sec:results:sent:5,med:pmid:35712811,results,5,"We followed 22 DMD patients, 6 of them with an EF < 40% and 16 with an EF > 40%.",696,805
med:pmid:35712811:sec:results:sent:6,med:pmid:35712811,results,6,"The first group received ARNi on top of BB, while the control group started or continued first-line therapy with ACEi ± BB.",806,929
med:pmid:35712811:sec:results:sent:7,med:pmid:35712811,results,7,"From December 2016 to December 2021, we recorded EF values at baseline and at follow-up, comparing EF changes.",930,1040
med:pmid:35712811:sec:results:sent:8,med:pmid:35712811,results,8,Median follow-up was 7 months (interquartile range 4.7-9.1).,1041,1101
med:pmid:35712811:sec:results:sent:9,med:pmid:35712811,results,9,"At baseline, the mean of EF (%) in the ARNi group was 31 ± 2%, while it was 59 ± 9% in the control group.",1102,1207
med:pmid:35712811:sec:results:sent:10,med:pmid:35712811,results,10,"At follow-up, we recorded an EF improvement in the ARNi group (38 ± 6%, P-value < 0.05).",1208,1296
med:pmid:35712811:sec:results:sent:11,med:pmid:35712811,results,11,"Among controls, EF at follow-up was substantially unchanged from baseline.",1297,1371
med:pmid:35712811:sec:conclusion:sent:12,med:pmid:35712811,conclusion,12,Our data suggest that the use of ARNi in DMD patients with DCM and an EF < 40% might be associated with an EF improvement and a safe tolerability profile.,1372,1547
med:pmid:35702942:sec:title:sent:0,med:pmid:35702942,title,0,Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.,0,96
med:pmid:35702942:sec:introduction:sent:1,med:pmid:35702942,introduction,1,"The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all-cause mortality in patients with ambulatory heart failure and reduced ejection fraction (HFrEF), in particular when it is maximally up-titrated.",0,336
med:pmid:35702942:sec:introduction:sent:2,med:pmid:35702942,introduction,2,"Unfortunately, the target dose is achieved in less than 50% of HFrEF patients, thus undermining the beneficial effects on the outcomes.",337,472
med:pmid:35702942:sec:introduction:sent:3,med:pmid:35702942,introduction,3,"In this study, we aimed to evaluate the role of Sac/Val and its titration dose on reverse cardiac remodelling and determine which echocardiographic index best predicts the up-titration success.",473,666
med:pmid:35702942:sec:results:sent:4,med:pmid:35702942,results,4,"From January 2020 to June 2021, we retrospectively identified 95 patients (65.6 [59.1-72.8] years; 15.8% females) with chronic HFrEF who were prescribed Sac/Val from the HF Clinics of 5 Italian University Hospitals and evaluated the tolerability of Sac/Val high dose (the ability of the patient to achieve and stably tolerate the maximum dose) as the primary endpoint in the cohort.",667,1078
med:pmid:35702942:sec:results:sent:5,med:pmid:35702942,results,5,"We used a multivariable logistic regression analysis, with a stepwise backward selection method, to determine the independent predictors of Sac/Val maximum dose tolerability, using, as candidate predictors, only variables with a P-value < 0.1 in the univariate analyses.",1079,1349
med:pmid:35702942:sec:results:sent:6,med:pmid:35702942,results,6,"Candidate predictors identified for the multivariable backward logistic regression analysis were age, sex, body mass index (BMI), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), dyslipidaemia, atrial fibrillation, systolic blood pressure (SBP), baseline tolerability of ACEi/ARBs maximum dose, left ventricle global longitudinal strain (LVgLS), LV ejection fraction (EF), tricuspid annulus plane systolic excursion (TAPSE), right ventricle (RV) fractional area change (FAC), RV global and free wall longitudinal strain (RVgLS and RV-FW-LS).",1350,1918
med:pmid:35702942:sec:results:sent:7,med:pmid:35702942,results,7,"After the multivariable analysis, only one categorical (ACEi/ARBs maximum dose at baseline) and three continuous (younger age, higher SBP, and higher TAPSE), resulted significantly associated with the study outcome variable with a strong discriminatory capacity (area under the curve 0.874, 95% confidence interval (CI) (0.794-0.954) to predict maximum Sac/Val dose tolerability.",1919,2298
med:pmid:35702942:sec:conclusion:sent:8,med:pmid:35702942,conclusion,8,"Our study is the first to analyse the potential role of echocardiography and, in particular, of RV dysfunction, measured by TAPSE, in predicting Sac/Val maximum dose tolerability.",2299,2499
med:pmid:35702942:sec:conclusion:sent:9,med:pmid:35702942,conclusion,9,"Therefore, patients with RV dysfunction (baseline TAPSE <16 mm, in our cohort) might benefit from a different strategy to titrate Sac/Val, such as starting from the lowest dose and/or waiting for a more extended period of observation before attempting with the higher doses.",2500,2774
med:pmid:36196235:sec:title:sent:0,med:pmid:36196235,title,0,The Impact of Angiotensin Receptor-Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis.,0,142
med:pmid:36196235:sec:abstract:sent:1,med:pmid:36196235,abstract,1,Angiotensin receptor-neprilysin inhibitor (ARNI) use has become increasingly popular.,0,85
med:pmid:36196235:sec:abstract:sent:2,med:pmid:36196235,abstract,2,Current guidelines recommend using ARNI therapy for heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF).,86,213
med:pmid:36196235:sec:abstract:sent:3,med:pmid:36196235,abstract,3,"As therapies become more widely available, heart failure-associated burdens such as ventricular arrhythmias and sudden cardiac death (SCD) will become increasingly prevalent.",214,388
med:pmid:36196235:sec:abstract:sent:4,med:pmid:36196235,abstract,4,We conducted a systematic review and meta-analysis to assess the impact of ARNI therapy on HFrEF and HFpEF pertaining to arrhythmogenesis and SCD.,389,535
med:pmid:36196235:sec:abstract:sent:5,med:pmid:36196235,abstract,5,"We performed a search of MEDLINE (PubMed), the Cochrane Library, and ClinicalTrials.gov for relevant studies.",536,645
med:pmid:36196235:sec:abstract:sent:6,med:pmid:36196235,abstract,6,"The odds ratios (ORs) of SCD, ventricular tachycardia (VT), ventricular fibrillation (VF), atrial fibrillation/flutter (AF), supraventricular tachycardia (SVT), and implantable cardioverter-defibrillator (ICD) shocks were calculated.",646,879
med:pmid:36196235:sec:abstract:sent:7,med:pmid:36196235,abstract,7,"A total of 10 studies, including 6 randomized controlled trials and 4 observational studies, were included in the analysis.",880,1003
med:pmid:36196235:sec:abstract:sent:8,med:pmid:36196235,abstract,8,"A total of 18,548 patients from all studies were included, with 9,328 patients in the ARNI arm and 9,220 patients in the angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) arm, with a median follow-up time of 15 months.",1004,1257
med:pmid:36196235:sec:abstract:sent:9,med:pmid:36196235,abstract,9,"There was a significant reduction in the composite outcomes of SCD and ventricular arrhythmias in patients treated with ARNIs compared to those treated with ACEIs/ARBs (OR, 0.71; 95% confidence interval, 0.54-0.93; <i>P</i> = .01; I<sup>2</sup> = 17%; <i>P</i> = .29).",1258,1526
med:pmid:36196235:sec:abstract:sent:10,med:pmid:36196235,abstract,10,ARNI therapy was also associated with a significant reduction in ICD shocks.,1527,1603
med:pmid:36196235:sec:abstract:sent:11,med:pmid:36196235,abstract,11,"There was no significant reduction in the VT, VF, AF, or SVT incidence rate in the ARNI group compared to the ACEI/ARB group.",1604,1729
med:pmid:36196235:sec:abstract:sent:12,med:pmid:36196235,abstract,12,"In conclusion, the use of ARNIs confers a reduction in composite outcomes of SCD and ventricular arrhythmias among patients with heart failure.",1730,1873
med:pmid:36196235:sec:abstract:sent:13,med:pmid:36196235,abstract,13,These outcomes were mainly driven by SCD reduction in patients treated with ARNIs.,1874,1956
med:pmid:36062622:sec:title:sent:0,med:pmid:36062622,title,0,Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease.,0,93
med:pmid:36062622:sec:introduction:sent:1,med:pmid:36062622,introduction,1,Heart failure with reduced ejection fraction (HFrEF) is a chronic disease with substantial mortality.,0,112
med:pmid:36062622:sec:introduction:sent:2,med:pmid:36062622,introduction,2,Management of HFrEF has seen significant breakthrough after the launch of neprilysin inhibitor.,113,208
med:pmid:36062622:sec:introduction:sent:3,med:pmid:36062622,introduction,3,The PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impacton Global Mortality and Morbidity in Heart Failure) trial showed that sacubitril/valsartan significantly reduces HFrEF mortality and the heart failure hospitalization rate.,209,458
med:pmid:36062622:sec:introduction:sent:4,med:pmid:36062622,introduction,4,"However, in patients with advanced kidney disease, who have the highest prevalence of heart failure, the efficacy and safety of sacubitril/valsartan remains uncertain.",459,626
med:pmid:36062622:sec:introduction:sent:5,med:pmid:36062622,introduction,5,We aim to study the efficiency of sacubitril/valsartan in patients with end-stage kidney disease.,627,724
med:pmid:36062622:sec:methods:sent:6,med:pmid:36062622,methods,6,and Results Heart function was screened by echocardiogram among all patients with end-stage kidney disease in 2 hospitals.,725,855
med:pmid:36062622:sec:methods:sent:7,med:pmid:36062622,methods,7,Patients with HFrEF received either sacubitril/valsartan or conventional treatment.,856,939
med:pmid:36062622:sec:methods:sent:8,med:pmid:36062622,methods,8,Fifteen echocardiographic parameters were compared before and after treatment.,940,1018
med:pmid:36062622:sec:methods:sent:9,med:pmid:36062622,methods,9,"After 1-year sacubitril/valsartan treatment, parameters of systolic (left ventricular ejection fraction 31.3% to 45.1%, <i>P</i><0.0001; left ventricular end-systolic volume 95.7 to 70.1 mL, <i>P</i>=0.006; left ventricular internal diameter at end-systole phase 47.2 to 40.1 mm, <i>P</i>=0.005), and diastolic (E/A ratio 1.3 to 0.8, <i>P</i>=0.009; E/Med e' ratio 25.3 to 18.8, <i>P</i>=0.010) function improved in patients with HFrEF and end-stage kidney disease.",1019,1484
med:pmid:36062622:sec:methods:sent:10,med:pmid:36062622,methods,10,These parameters were unchanged in the conventional treatment group.,1485,1553
med:pmid:36062622:sec:methods:sent:11,med:pmid:36062622,methods,11,Serum potassium did not increase in the sacubitril/valsartan group.,1554,1621
med:pmid:36062622:sec:conclusion:sent:12,med:pmid:36062622,conclusion,12,Sacubitril/valsartan improves left ventricular systolic and diastolic function in patients with HFrEF and end-stage kidney disease.,1622,1765
med:pmid:35689603:sec:title:sent:0,med:pmid:35689603,title,0,Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of &gt;25 000 Medicare beneficiaries.,0,163
med:pmid:35689603:sec:introduction:sent:1,med:pmid:35689603,introduction,1,"Sacubitril/valsartan is strongly supported in guidelines for the management of heart failure, but suboptimal adherence and treatment non-persistence may limit the population-level benefit that this therapy might otherwise offer.",0,242
med:pmid:35689603:sec:results:sent:2,med:pmid:35689603,results,2,We identified a cohort of Medicare beneficiaries (2014-2017) initiating sacubitril/valsartan after ≥6 months of continuous enrolment.,243,405
med:pmid:35689603:sec:results:sent:3,med:pmid:35689603,results,3,We assessed adherence as the proportion of days covered (PDC) and proportion of patients non-persistent (having no prescription available) at 180 days after initiation.,406,574
med:pmid:35689603:sec:results:sent:4,med:pmid:35689603,results,4,We fit a multivariable negative binomial model with a count of adherent days to evaluate independent factors associated with of sacubitril/valsartan adherence.,575,734
med:pmid:35689603:sec:results:sent:5,med:pmid:35689603,results,5,"Among 27 063 new sacubitril/valsartan users, most (n = 17 663, 65%) were prescribed low-dose at 24 mg/26 mg and most (n = 19 984, 74%) were switched from prior angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) rather than being RASi treatment naïve.",735,1014
med:pmid:35689603:sec:results:sent:6,med:pmid:35689603,results,6,Median 180-day PDC was 86% (25th-75th percentiles 58-98%).,1015,1073
med:pmid:35689603:sec:results:sent:7,med:pmid:35689603,results,7,"Black patients, those with high comorbid disease burden (≥8 comorbidities), and patients with recent hospitalization within 30 days had fewer adherent days, while those treated with preceding ACEi/ARB had more adherent days.",1074,1298
med:pmid:35689603:sec:results:sent:8,med:pmid:35689603,results,8,Thirty-four percent of patients did not have an active sacubitril/valsartan prescription at day 180.,1299,1399
med:pmid:35689603:sec:results:sent:9,med:pmid:35689603,results,9,"Among these, few had preceding dose down-titrations (6% among patients on 49 mg/51 mg and 9% among patients on 97 mg/103 mg) and 68% did not have a subsequent ACEi/ARB prescription.",1400,1581
med:pmid:35689603:sec:results:sent:10,med:pmid:35689603,results,10,"Among patients who remained persistent, dose up-titrations occurred in 29% of patients who started on 24 mg/26 mg and 27% of patients on 49 mg/51 mg.",1582,1731
med:pmid:35689603:sec:conclusion:sent:11,med:pmid:35689603,conclusion,11,"Overall adherence to sacubitril/valsartan among Medicare beneficiaries is acceptable, but is lower in Black patients, those with higher comorbidities or those who started therapy after recent hospitalization.",1732,1961
med:pmid:35689603:sec:conclusion:sent:12,med:pmid:35689603,conclusion,12,"While broad implementation of guideline-directed medical therapy is a key priority, additional focused efforts to improve adherence early after hospitalization and among at-risk patients are needed in parallel.",1962,2172
med:pmid:34989105:sec:title:sent:0,med:pmid:34989105,title,0,Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.,0,111
med:pmid:34989105:sec:introduction:sent:1,med:pmid:34989105,introduction,1,"Patients with heart failure are at higher risk of progression to end-stage renal disease (ESRD), regardless of ejection fraction (EF).",0,148
med:pmid:34989105:sec:introduction:sent:2,med:pmid:34989105,introduction,2,We assessed the renal effects of angiotensin-neprilysin inhibition in a pooled analysis of 13 195 patients with heart failure with reduced and preserved EF.,149,305
med:pmid:34989105:sec:results:sent:3,med:pmid:34989105,results,3,We combined data from PARADIGM-HF (EF ≤40%; n = 8399) and PARAGON-HF (EF ≥45%; n = 4796) in a pre-specified pooled analysis.,306,459
med:pmid:34989105:sec:results:sent:4,med:pmid:34989105,results,4,"We assessed the effect of treatment (sacubitril/valsartan vs. enalapril or valsartan) on a composite of either ≥50% reduction in estimated glomerular filtration rate (eGFR), ESRD, or death from renal causes, in addition to changes in eGFR slope.",460,705
med:pmid:34989105:sec:results:sent:5,med:pmid:34989105,results,5,We assessed whether baseline renal function or EF modified the effect of therapy on renal outcomes.,706,805
med:pmid:34989105:sec:results:sent:6,med:pmid:34989105,results,6,"At randomization, eGFR was 68 ± 20 ml/min/1.73 m<sup>2</sup> in PARADIGM-HF and 63 ± 19 ml/min/1.73 m<sup>2</sup> in PARAGON-HF.",806,934
med:pmid:34989105:sec:results:sent:7,med:pmid:34989105,results,7,"The composite renal outcome occurred in 70 of 6594 patients (1.1%) in the sacubitril/valsartan group and in 123 of 6601 patients (1.9%) in the valsartan or enalapril group (hazard ratio 0.56, 95% confidence interval [CI] 0.42-0.75; p < 0.001).",935,1178
med:pmid:34989105:sec:results:sent:8,med:pmid:34989105,results,8,"The mean eGFR change was -1.8 (95% CI -1.9 to -1.7) ml/min/1.73 m<sup>2</sup> /year for the sacubitril/valsartan group, compared with -2.4 (95% CI -2.5 to -2.2) ml/min/1.73 m<sup>2</sup> /year for the valsartan or enalapril group.",1179,1409
med:pmid:34989105:sec:results:sent:9,med:pmid:34989105,results,9,"The treatment effect on the composite renal endpoint was not modified by categories of baseline eGFR (p-interaction = 0.64), but was most pronounced in those with baseline EF between 30% and 60% (p-interaction = 0.001).",1410,1629
med:pmid:34989105:sec:conclusion:sent:10,med:pmid:34989105,conclusion,10,"In patients with heart failure, sacubitril/valsartan reduced the risk of serious adverse renal outcomes and slowed decline in eGFR, compared with valsartan or enalapril, independent of baseline renal function.",1630,1860
med:pmid:36128010:sec:title:sent:0,med:pmid:36128010,title,0,Impact of Digoxin Use on Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction.,0,122
med:pmid:36128010:sec:introduction:sent:1,med:pmid:36128010,introduction,1,Digoxin was one of the first agents used in the management of heart failure with reduced ejection fraction (HFrEF).,0,135
med:pmid:36128010:sec:introduction:sent:2,med:pmid:36128010,introduction,2,"Concerns over its safety, efficacy, and the introduction of guideline-directed medical therapy (GDMT) have relegated it to a secondary role.",136,276
med:pmid:36128010:sec:introduction:sent:3,med:pmid:36128010,introduction,3,"The efficacy of digoxin is still under debate, and its use in patients on GDMT remains unclear.",277,372
med:pmid:36128010:sec:introduction:sent:4,med:pmid:36128010,introduction,4,"We aim to evaluate whether patients with HFrEF on digoxin can tolerate higher doses of a β-blocker (BB), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blocker (ARB), mineralocorticoid receptor antagonists (MRAs), and angiotensin receptor-neprilysin inhibitor (ARNI).",373,664
med:pmid:36128010:sec:methods:sent:5,med:pmid:36128010,methods,5,"A retrospective chart review was performed on 233 patients with HFrEF managed at a tertiary care center in Cleveland, Ohio.",665,805
med:pmid:36128010:sec:methods:sent:6,med:pmid:36128010,methods,6,"A bivariate analysis was performed to compare patients on digoxin with patients not on digoxin in terms of ability to progress the dosing of BB, ACEI, MRA, ARB, or ARNI.",806,975
med:pmid:36128010:sec:results:sent:7,med:pmid:36128010,results,7,Thirty-four (14.6%) of our 233 patients were receiving digoxin at baseline visit.,976,1074
med:pmid:36128010:sec:results:sent:8,med:pmid:36128010,results,8,"The digoxin group was more likely to have lower initial and last systolic blood pressure, initial diastolic blood pressure, and left ventricular ejection fraction.",1075,1238
med:pmid:36128010:sec:results:sent:9,med:pmid:36128010,results,9,Mean follow-up duration and baseline sodium level were higher in the digoxin group.,1239,1322
med:pmid:36128010:sec:results:sent:10,med:pmid:36128010,results,10,"There was no significant difference between the two groups in terms of patients receiving higher doses of BB (P = 0.235), ACEI/ARB (P = 0.903), MRA (P = 0.331), or ARNI (P = 0.717).",1323,1504
med:pmid:36128010:sec:conclusion:sent:11,med:pmid:36128010,conclusion,11,"There was no significant difference between the doses of BB, ACEI, ARB, MRA, or ARNI among HFrEF patients on digoxin compared to those that were not.",1505,1675
med:pmid:36128010:sec:conclusion:sent:12,med:pmid:36128010,conclusion,12,Randomized control trials with a larger sample are needed to establish our findings of digoxin not significantly affecting the ability to up titrate GDMT in HFrEF patients.,1676,1848
med:pmid:35927632:sec:title:sent:0,med:pmid:35927632,title,0,Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort.,0,111
med:pmid:35927632:sec:introduction:sent:1,med:pmid:35927632,introduction,1,"National registries reveal significant gaps in medical therapy for patients with heart failure and reduced ejection fraction (HFrEF), but may not accurately (or fully) characterize the population eligible for therapy.",0,237
med:pmid:35927632:sec:introduction:sent:2,med:pmid:35927632,introduction,2,"We developed an automated, electronic health record-based algorithm to identify HFrEF patients eligible for evidence-based therapy, and extracted treatment data to assess gaps in therapy in a large, diverse health system.",238,478
med:pmid:35927632:sec:methods:sent:3,med:pmid:35927632,methods,3,"In this cross-sectional study of all NYU Langone Health outpatients with EF ≤ 40% on echocardiogram and an outpatient visit from 3/1/2019 to 2/29/2020, we assessed prescription of the following therapies: beta-blocker (BB), angiotensin converting enzyme inhibitor (ACE-I)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonist (MRA).",479,901
med:pmid:35927632:sec:methods:sent:4,med:pmid:35927632,methods,4,"Our algorithm accounted for contraindications such as medication allergy, bradycardia, hypotension, renal dysfunction, and hyperkalemia.",902,1038
med:pmid:35927632:sec:results:sent:5,med:pmid:35927632,results,5,We electronically identified 2732 patients meeting inclusion criteria.,1039,1126
med:pmid:35927632:sec:results:sent:6,med:pmid:35927632,results,6,"Among those eligible for each medication class, 84.8% and 79.7% were appropriately prescribed BB and ACE-I/ARB/ARNI, respectively, while only 23.9% and 22.7% were appropriately prescribed MRA and ARNI, respectively.",1127,1342
med:pmid:35927632:sec:results:sent:7,med:pmid:35927632,results,7,"In adjusted models, younger age, cardiology visit and lower EF were associated with increased prescribing of medications.",1343,1464
med:pmid:35927632:sec:results:sent:8,med:pmid:35927632,results,8,"Private insurance and Medicaid were associated with increased prescribing of ARNI (OR = 1.40, 95% CI = 1.02-2.00; and OR = 1.70, 95% CI = 1.07-2.67).",1465,1614
med:pmid:35927632:sec:conclusion:sent:9,med:pmid:35927632,conclusion,9,We observed substantial shortfalls in prescribing of MRA and ARNI therapy to ambulatory HFrEF patients.,1615,1739
med:pmid:35927632:sec:conclusion:sent:10,med:pmid:35927632,conclusion,10,"Subspecialty care setting, and Medicaid insurance were associated with higher rates of ARNI prescribing.",1740,1844
med:pmid:35927632:sec:conclusion:sent:11,med:pmid:35927632,conclusion,11,Further studies are warranted to prospectively evaluate provider- and policy-level interventions to improve prescribing of these evidence-based therapies.,1845,1999
med:pmid:35761118:sec:title:sent:0,med:pmid:35761118,title,0,The Prevalence of Adverse Drug Reactions and Adverse Drug Events from Heart Failure Medications in Frail Older Adults: A Systematic Review.,0,139
med:pmid:35761118:sec:introduction:sent:1,med:pmid:35761118,introduction,1,Frailty is highly prevalent in heart failure populations and a major risk factor for adverse drug reactions (ADRs) and adverse drug events (ADEs).,0,168
med:pmid:35761118:sec:introduction:sent:2,med:pmid:35761118,introduction,2,"This review aimed to describe the prevalence, causality and severity of ADRs or ADEs from heart failure medications among frail compared with non-frail older adults.",169,334
med:pmid:35761118:sec:methods:sent:3,med:pmid:35761118,methods,3,"A systematic search of CENTRAL, MEDLINE, Embase, Ageline, CINAHL, International Pharmaceutical Abstracts, PsychInfo, Scopus, registries and citations prior to 18 May 2021 was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist.",335,645
med:pmid:35761118:sec:methods:sent:4,med:pmid:35761118,methods,4,Risk of bias and quality of evidence were assessed.,646,697
med:pmid:35761118:sec:methods:sent:5,med:pmid:35761118,methods,5,"Eligible studies included randomised controlled trials (RCTs) and observational studies of people diagnosed with heart failure, aged ≥ 65 years, with frailty defined by an objective measurement, and reported ADRs/ADEs from/with heart failure medications.",698,952
med:pmid:35761118:sec:results:sent:6,med:pmid:35761118,results,6,Two reviewers screened 2419 articles; interrater reliability kappa = 0.88.,953,1044
med:pmid:35761118:sec:results:sent:7,med:pmid:35761118,results,7,"Three observational studies (n = 2596), a secondary analysis of two RCTs (n = 2098) and two cohort studies (n = 498) were included in a narrative synthesis.",1045,1201
med:pmid:35761118:sec:results:sent:8,med:pmid:35761118,results,8,"Frail patients in randomised trials of sacubitril/valsartan, aliskiren, or enalapril had twice the risk of mortality (hazard ratio [HR] 2.09, 1.62-2.71) and hospitalisations (HR 1.82, 1.37-2.41) compared with robust patients, which may reflect responsiveness to medications and/or factors unrelated to medication use.",1202,1519
med:pmid:35761118:sec:results:sent:9,med:pmid:35761118,results,9,"Hospitalisations from falls, tiredness and nausea were probably attributable to digoxin and possibly preventable according to the Naranjo and Hallas scales, respectively.",1520,1690
med:pmid:35761118:sec:conclusion:sent:10,med:pmid:35761118,conclusion,10,The potential harms from heart failure medications in frail older people are poorly studied and understood.,1691,1818
med:pmid:35761118:sec:conclusion:sent:11,med:pmid:35761118,conclusion,11,Clinical trials and pharmacovigilance studies should include frailty as a covariate to inform medication optimisation for this vulnerable and growing population.,1819,1980
med:pmid:35761118:sec:conclusion:sent:12,med:pmid:35761118,conclusion,12,<h4>Registration</h4> Prospero registration number: CRD 42021253762.,1981,2049
med:pmid:35709921:sec:title:sent:0,med:pmid:35709921,title,0,Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.,0,168
med:pmid:35709921:sec:abstract:sent:1,med:pmid:35709921,abstract,1,Patients with chronic kidney disease (CKD) are often complicated with heart failure with preserved ejection fraction (HFpEF).,0,125
med:pmid:35709921:sec:abstract:sent:2,med:pmid:35709921,abstract,2,"However, several drugs, including angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB), have not shown apparent benefits in terms of morbidity and mortality of HFpEF.",126,325
med:pmid:35709921:sec:abstract:sent:3,med:pmid:35709921,abstract,3,"PARAMOUNT and other studies have shown the potential benefits of Sacubitril/Valsartan on patients with HFpEF, but its effects on renal function and the effect of low-dose Sacubitril/Valsartan in actual clinical conditions have not been thoroughly evaluated.",326,583
med:pmid:35709921:sec:abstract:sent:4,med:pmid:35709921,abstract,4,"In our longitudinal and observational research, 353 patients were followed up for 12 weeks.",584,675
med:pmid:35709921:sec:abstract:sent:5,med:pmid:35709921,abstract,5,"We evaluated renal function [urinary protein, serum creatinine and estimated glomerular filtration rate (eGFR)] and cardiac function [NT-proBNP (brain natriuretic peptide), New York Heart Association (NYHA) classification, left ventricular ejection fraction (LVEF), left atrial width and left ventricular end-diastolic width] at baseline and during follow-up.",676,1035
med:pmid:35709921:sec:abstract:sent:6,med:pmid:35709921,abstract,6,Worsening renal function (WRF) was defined as an increased serum creatinine≥26.5umol/L or decreased eGFR≥20%.,1036,1145
med:pmid:35709921:sec:abstract:sent:7,med:pmid:35709921,abstract,7,The decline of eGFR in the Sacubitril/Valsartan group was slower than that in the control group (p = 0.021).,1146,1254
med:pmid:35709921:sec:abstract:sent:8,med:pmid:35709921,abstract,8,The outcome of proteinuria in the ACEI/ARB group was significantly better than that in the Sacubitril/Valsartan group (p = 0.001).,1255,1385
med:pmid:35709921:sec:abstract:sent:9,med:pmid:35709921,abstract,9,"In terms of echocardiogram, the average left atrial width in Sacubitril/Valsartan group decreased by 1.38 ± 3.02 mm, which was significantly lower than that in the ACEI/ARB group (p = 0.02).",1386,1576
med:pmid:35709921:sec:abstract:sent:10,med:pmid:35709921,abstract,10,"The increase of urine protein class in the ACEI/ARB group increased the risk of WRF with statistical significance (OR = 2.36, 95%CI 1.01-5.49, p = 0.047), but no statistical significance was found in all the patients or Sacubitril/Valsartan group.",1577,1824
med:pmid:35709921:sec:abstract:sent:11,med:pmid:35709921,abstract,11,"In conclusion, Sacubitril/Valsartan could more effectively slow down renal function decline and reverse myocardial remodeling in patients with CKD and HFpEF than ACEI/ARB, even at low doses, though its protective effect on urinary protein is not as good as that of ACEI/ARB.",1825,2099
med:pmid:35525261:sec:title:sent:0,med:pmid:35525261,title,0,Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.,0,173
med:pmid:35525261:sec:introduction:sent:1,med:pmid:35525261,introduction,1,"In clinical trials, sacubitril/valsartan has demonstrated significant survival benefits compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEi/ARB).",0,205
med:pmid:35525261:sec:introduction:sent:2,med:pmid:35525261,introduction,2,"Whether older patients with heart failure with reduced ejection fraction (HFrEF) benefit as much, due to higher rates of comorbidities, frailty and drug discontinuation, is unknown.",206,387
med:pmid:35525261:sec:results:sent:3,med:pmid:35525261,results,3,"Using a cohort of Medicare beneficiaries hospitalized with HFrEF between 2016 and 2018, we determined all-cause mortality and HF-readmission rates among patients not given ACEi/ARB or sacubitril/valsartan at hospital discharge, by age.",388,652
med:pmid:35525261:sec:results:sent:4,med:pmid:35525261,results,4,"We then used risk reductions from the SOLVD, PARADIGM-HF and PIONEER-HF trials to estimate the benefits of ACEi/ARB and sacubitril/valsartan.",653,794
med:pmid:35525261:sec:results:sent:5,med:pmid:35525261,results,5,We then incorporated age-specific estimates of drug discontinuation from Medicare.,795,877
med:pmid:35525261:sec:results:sent:6,med:pmid:35525261,results,6,"A Markov decision process model was used to simulate 5-year survival and estimate number needed to treat, comparing discharge on ACEi/ARB vs sacubitril/valsartan by age.",878,1047
med:pmid:35525261:sec:results:sent:7,med:pmid:35525261,results,7,"After accounting for drug discontinuation rates, which were surprisingly slightly higher among those discharged on ACEi/ARB (2.3%/month vs 1.9%/month), there was a small but significant survival advantage to discharge on sacubitril/valsartan over 5 years (+0.81 months [95% CI 0.80, 0.81]).",1048,1338
med:pmid:35525261:sec:results:sent:8,med:pmid:35525261,results,8,The benefit of sacubitril/valsartan over ACEi/ARB did not decrease with increasing age - the number needed to treat among 66 to 74-year-old patients was 84 and among 85+ year-old patients was 67.,1339,1534
med:pmid:35525261:sec:conclusion:sent:9,med:pmid:35525261,conclusion,9,"Even after accounting for ""real world"" rates of drug discontinuation, discharge on sacubitril/valsartan after conferred a small, but significant, survival advantage which does not appear to wane with increasing age.",1535,1771
med:pmid:35469709:sec:title:sent:0,med:pmid:35469709,title,0,"Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan.",0,159
med:pmid:35469709:sec:title:sent:1,med:pmid:35469709,title,1,Position Paper of the Italian Society of Cardiology.,160,212
med:pmid:35469709:sec:abstract:sent:2,med:pmid:35469709,abstract,2,Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the pharmacological treatment of heart failure with reduced ejection fraction (HFrEF).,0,158
med:pmid:35469709:sec:abstract:sent:3,med:pmid:35469709,abstract,3,"In the last years RAAS blockade has been improved by the introduction of the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) sacubitril/valsartan, that combines RAAS inhibition with the block of neprilysin, boosting the positive effects of natriuretic peptides.",159,421
med:pmid:35469709:sec:abstract:sent:4,med:pmid:35469709,abstract,4,The PARADIGM-HF trial demonstrated a significant advantage of sacubitril/valsartan over enalapril on the reduction of cardiovascular (CV) mortality and heart failure hospitalizations rates.,422,611
med:pmid:35469709:sec:abstract:sent:5,med:pmid:35469709,abstract,5,"Then, several randomized clinical trials and observational studies investigated its role in different clinical settings and its efficacy has been fully recognized in the most recent HFrEF European and USA guidelines.",612,828
med:pmid:35469709:sec:abstract:sent:6,med:pmid:35469709,abstract,6,"The effects of sacubitril/valsartan on major CV outcomes are associated with reduction of NT-proBNP levels and reverse cardiac remodeling and mitral regurgitation, recognized as one of the mechanistic effects of the drug explaining the favorable prognostic effects.",829,1094
med:pmid:35469709:sec:abstract:sent:7,med:pmid:35469709,abstract,7,A careful evaluation of patients' clinical profile is relevant to implement the use of ARNI in the clinical practice and to obtain the maximal treatment efficacy.,1095,1257
med:pmid:35469709:sec:abstract:sent:8,med:pmid:35469709,abstract,8,The present Position Paper reports the opinion of the Italian Society of Cardiology on the optimal blockade of the RAAS system in HF patients with the aim of fostering widespread implementation of scientific evidence and practice guidelines in the medical community.,1258,1524
med:pmid:35332595:sec:title:sent:0,med:pmid:35332595,title,0,"Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction.",0,128
med:pmid:35332595:sec:introduction:sent:1,med:pmid:35332595,introduction,1,"Following the availability of new drugs for chronic heart failure (HF) with reduced ejection fraction (HFrEF), we sought to provide an updated and comparative synthesis of the evidence on HFrEF pharmacotherapy efficacy.",0,239
med:pmid:35332595:sec:methods:sent:2,med:pmid:35332595,methods,2,We performed a Bayesian network meta-analysis of phase 2 and 3 randomized controlled trials (RCTs) of medical therapy in HFrEF patient cohorts with more than 90% of the participants with left ventricular ejection fraction less than 45% and all-cause mortality reported.,240,526
med:pmid:35332595:sec:results:sent:3,med:pmid:35332595,results,3,"Sixty-nine RCTs, accounting for 91,741 subjects, were evaluated.",527,608
med:pmid:35332595:sec:results:sent:4,med:pmid:35332595,results,4,"The step-wise introduction of new drugs progressively decreased the risk of all-cause death, up to reaching a random-effects hazard ratio (HR) of 0.43 (95% credible intervals [CrI] 0.27-0.63) with beta blockers (BB), angiotensin-converting enzyme inhibitors (ACEi), and mineralocorticoid receptor antagonist (MRA) versus placebo.",609,938
med:pmid:35332595:sec:results:sent:5,med:pmid:35332595,results,5,"The risk was further reduced by adding sodium-glucose cotransporter-2 inhibitors (SGLT2i; HR 0.38, 95% CrI 0.22-0.60), ivabradine (HR 0.39, 95% CrI 0.21-0.64), or vericiguat (HR 0.40, 95% CrI 0.22-0.65) to neurohormonal inhibitors, and by angiotensin receptor-neprilysin inhibitor (ARNI), BB, and MRA (HR 0.36, 95% CrI 0.20-0.60).",939,1269
med:pmid:35332595:sec:results:sent:6,med:pmid:35332595,results,6,"In a sensitivity analysis considering the ARNI and non-ARNI subgroups of SGLT2i RCTs, the combination SGLT2i + ARNI + BB + MRA was associated with the lowest HR (0.28, 95% CrI 0.16-0.45 vs. 0.40, 95% CrI 0.24-0.60 for SGLT2i + BB + ACEi + MRA).",1270,1514
med:pmid:35332595:sec:results:sent:7,med:pmid:35332595,results,7,"Consistent results were obtained in sensitivity analyses and by calculating surface under the cumulative ranking area, as well as for cardiovascular mortality (information available for 56 RCTs), HF hospitalization (45 RCTs), and all-cause hospitalization (26 RCTs).",1515,1781
med:pmid:35332595:sec:conclusion:sent:8,med:pmid:35332595,conclusion,8,"Combination medical therapy including neurohormonal inhibitors and newer drugs, especially ARNI and SGLT2i, confers the maximum benefit with regard to HFrEF prognosis.",1782,1970
med:pmid:35874853:sec:title:sent:0,med:pmid:35874853,title,0,The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.,0,145
med:pmid:35874853:sec:abstract:sent:1,med:pmid:35874853,abstract,1,The purpose of this study was to investigate the effects of sacubitril/valsartan on right ventricular (RV) function in patients with pulmonary hypertension (PH) due to heart failure with reduced ejection fraction (HFrEF).,0,221
med:pmid:35874853:sec:abstract:sent:2,med:pmid:35874853,abstract,2,We prospectively enrolled patients with HFrEF-induced PH admitted to the Department of Cardiology between August 2018 and December 2019.,222,358
med:pmid:35874853:sec:abstract:sent:3,med:pmid:35874853,abstract,3,Patients were randomized to receive oral treatment with sacubitril/valsartan or enalapril.,359,449
med:pmid:35874853:sec:abstract:sent:4,med:pmid:35874853,abstract,4,Epidemiological data were recorded before treatment.,450,502
med:pmid:35874853:sec:abstract:sent:5,med:pmid:35874853,abstract,5,"Echocardiography was performed at admission and 6 months of follow-up, and all parameters were compared.",503,607
med:pmid:35874853:sec:abstract:sent:6,med:pmid:35874853,abstract,6,Major adverse cardiac events (MACEs) were compared between baseline and 6 months follow-up.,608,699
med:pmid:35874853:sec:abstract:sent:7,med:pmid:35874853,abstract,7,There were no significant differences in the baseline characteristics between the two groups.,700,793
med:pmid:35874853:sec:abstract:sent:8,med:pmid:35874853,abstract,8,"After 6 months of treatment, both treatment groups improved the following parameters from baseline (mean ± SD): left atrium, left ventricle, the left ventricular ejection function (LVEF), RV systolic function (the tricuspid annular plane systolic excursion [TAPSE], the systolic pulmonary artery pressure [sPAP], and TAPSE/sPAP).",794,1123
med:pmid:35874853:sec:abstract:sent:9,med:pmid:35874853,abstract,9,"After 6 months, sacubitril/valsartan improved significantly the following parameters compared with enalapril (all <i>p</i> < 0.05): LVEF (47.07 ± 6.93% vs. 43.47 ± 7.95%); TAPSE (15.33 ± 1.31 vs. 14.78 ± 1.36 mm); sPAP (36.76 ± 14.32 vs. 42.26 ± 12.07 mmHg); and TAPSE/sPAP ratio (0.50 ± 0.23 vs. 0.39 ± 0.14), respectively.",1124,1448
med:pmid:35874853:sec:abstract:sent:10,med:pmid:35874853,abstract,10,There was no difference in readmissions due to recurrent heart failure.,1449,1520
med:pmid:35874853:sec:abstract:sent:11,med:pmid:35874853,abstract,11,"Sacubitril/valsartan seems to provide more beneficial effects among patients with HFrEF-induced PH to improve RV function, along with a decrease in pulmonary pressure.",1521,1688
med:pmid:35868319:sec:title:sent:0,med:pmid:35868319,title,0,[A practical approach to guideline-directed pharmacological treatment for heart failure with reduced ejection fraction].,0,120
med:pmid:35868319:sec:abstract:sent:1,med:pmid:35868319,abstract,1,"The 2021 guidelines of the European Society of Cardiology for the diagnosis and treatment of heart failure recommend the early implementation of all four mortality-lowering drug classes for heart failure with reduced ejection fraction (HFrEF), i. e. angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor II blocker-neprilysin inhibitor (ARNI), betablocker (BB), mineralocorticoid receptor-antagonists (MRA), and sodium-glucose linked transporter-2 inhibitors (SGLT2i).",0,485
med:pmid:35868319:sec:abstract:sent:2,med:pmid:35868319,abstract,2,This article aims to give a practical compendium supporting physicians to enable safe and efficacious treatment for patients with HFrEF.,486,622
med:pmid:35560696:sec:title:sent:0,med:pmid:35560696,title,0,"Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.",0,186
med:pmid:35560696:sec:introduction:sent:1,med:pmid:35560696,introduction,1,"N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin T (cTnT) and soluble ST2 (sST2) provide complementary prognostic information in heart failure with reduced ejection fraction (HFrEF).",0,219
med:pmid:35560696:sec:introduction:sent:2,med:pmid:35560696,introduction,2,"We aimed to assess the association between changes in these markers with changes in cardiac structure, function and health status.",220,350
med:pmid:35560696:sec:results:sent:3,med:pmid:35560696,results,3,"Patients in the EVALUATE-HF trial (n = 464) were randomized to sacubitril/valsartan or enalapril for 12 weeks, followed by 12-week open-label sacubitril/valsartan.",351,543
med:pmid:35560696:sec:results:sent:4,med:pmid:35560696,results,4,"Cardiac biomarkers, echocardiography, and Kansas City Cardiomyopathy Questionnaires (KCCQ) were completed at baseline, and after 12 and 24 weeks.",544,689
med:pmid:35560696:sec:results:sent:5,med:pmid:35560696,results,5,"A total of 410 patients (88%) had serial biomarker measurements available (mean age 67 ± 9 years, 75% male and 75% white).",690,812
med:pmid:35560696:sec:results:sent:6,med:pmid:35560696,results,6,"After 24 weeks of treatment, NT-proBNP, sST2 and cTnT decreased by median (Q1, Q3) -31% (-55%, +6%), -6% (-19%, +8%) and - 3% (-13%, +8%), respectively (all p < 0.001).",813,981
med:pmid:35560696:sec:results:sent:7,med:pmid:35560696,results,7,Decreases in NT-proBNP were associated with reductions in cardiac volumes and improvements in systolic and diastolic function and health status.,982,1126
med:pmid:35560696:sec:results:sent:8,med:pmid:35560696,results,8,"Decreases in cTnT were associated with reductions in left ventricular mass, but not with changes in left ventricular function or KCCQ.",1127,1261
med:pmid:35560696:sec:results:sent:9,med:pmid:35560696,results,9,"Decreases in sST2 were consistently associated with improvements in health status, but not with measures of cardiac structure or function.",1262,1400
med:pmid:35560696:sec:results:sent:10,med:pmid:35560696,results,10,"There was no effect modification from treatment on the associations investigated (p for interaction >0.05) CONCLUSION: In HFrEF, serial changes in NT-proBNP correlate with changes in several key measures of cardiac structure and health status.",1401,1644
med:pmid:35560696:sec:results:sent:11,med:pmid:35560696,results,11,cTnT changes correlate with changes in left ventricular mass and sST2 with changes in health status.,1645,1745
med:pmid:35560696:sec:results:sent:12,med:pmid:35560696,results,12,"These data highlight possible complementary pathophysiologic implications of changes in NT-proBNP, cTnT and sST2.",1746,1859
med:pmid:35560696:sec:results:sent:13,med:pmid:35560696,results,13,<h4>Clinical trial registration</h4> ClinicalTrials.gov Identifier: NCT02874794.,1860,1940
med:pmid:35301107:sec:title:sent:0,med:pmid:35301107,title,0,Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.,0,111
med:pmid:35301107:sec:introduction:sent:1,med:pmid:35301107,introduction,1,"For patients hospitalized for heart failure with reduced ejection fraction (HFrEF), guidelines recommend optimization of medical therapy prior to discharge.",0,176
med:pmid:35301107:sec:introduction:sent:2,med:pmid:35301107,introduction,2,The degree to which changes in medical therapy occur during hospitalizations for HFrEF in North American clinical practice is unclear.,177,311
med:pmid:35301107:sec:methods:sent:3,med:pmid:35301107,methods,3,The VICTORIA registry (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) enrolled patients hospitalized for worsening chronic HFrEF across 51 sites in the United States and Canada from February 2018-January 2019.,312,578
med:pmid:35301107:sec:methods:sent:4,med:pmid:35301107,methods,4,"In patients with complete medication data who were not receiving dialysis, use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor neprilysin inhibitor (ARNI), beta-blocker, mineralocorticoid receptor antagonist (MRA), and sodium glucose cotransporter-2 inhibitors (SGLT2i) were assessed at admission and discharge.",579,961
med:pmid:35301107:sec:results:sent:5,med:pmid:35301107,results,5,"Of 1695 patients, the median (IQR) age was 69 (59-79) years, and 33% were women.",962,1059
med:pmid:35301107:sec:results:sent:6,med:pmid:35301107,results,6,"Among eligible patients, 33%, 25% and 55% were not prescribed ACEI/ARB/ARNI, beta-blocker, and MRA at discharge, respectively; 99% were not prescribed SGLT2i.",1060,1218
med:pmid:35301107:sec:results:sent:7,med:pmid:35301107,results,7,"For each medication, > 50% of patients remained on stable subtarget doses or no medication during hospitalization.",1219,1333
med:pmid:35301107:sec:results:sent:8,med:pmid:35301107,results,8,"In-hospital rates of initiation/dose increase were 20% for ACEI/ARB, 4% for ARNI, 20% for beta-blocker, 22% for MRA, and < 1% for SGLT2i; corresponding rates of dose decrease/discontinuation were 11%, 2%, 9%, 5%, and < 1%, respectively.",1334,1570
med:pmid:35301107:sec:results:sent:9,med:pmid:35301107,results,9,"Overall, 17% and 28% of eligible patients were prescribed triple therapy prior to admission and at discharge, respectively.",1571,1694
med:pmid:35301107:sec:results:sent:10,med:pmid:35301107,results,10,"At both admission and discharge, 1% of patients were prescribed triple therapy at target doses.",1695,1790
med:pmid:35301107:sec:results:sent:11,med:pmid:35301107,results,11,"Across classes of medication, multiple factors were independently associated with higher likelihood of in-hospital initiation/dosing increase (eg, Canadian enrollment, white race, admission to intensive care units) and discontinuation/dosing decrease (eg, worse renal function, admission to intensive care units).",1791,2104
med:pmid:35301107:sec:conclusion:sent:12,med:pmid:35301107,conclusion,12,"In this contemporary North American registry of patients hospitalized for worsening chronic HFrEF, for each recommended medical therapy, the large majority of eligible patients remained on stable subtarget doses or without medication at admission and discharge.",2105,2387
med:pmid:35301107:sec:conclusion:sent:13,med:pmid:35301107,conclusion,13,"Although most patients had no alterations in medical therapy, hospitalization in Canada and multiple patient characteristics were associated with higher likelihood of favorable in-hospital medication changes.",2388,2596
med:pmid:36713022:sec:title:sent:0,med:pmid:36713022,title,0,Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study.,0,149
med:pmid:36713022:sec:introduction:sent:1,med:pmid:36713022,introduction,1,Underutilization of guideline-directed heart failure with reduced ejection fraction (HFrEF) medications contributes to poor outcomes.,0,147
med:pmid:36713022:sec:results:sent:2,med:pmid:36713022,results,2,A pilot study to evaluate the safety and efficacy of a home-based remote monitoring system for HFrEF management was performed.,148,303
med:pmid:36713022:sec:results:sent:3,med:pmid:36713022,results,3,The system included wearable armband monitors paired with the smartphone application.,304,389
med:pmid:36713022:sec:results:sent:4,med:pmid:36713022,results,4,An HFrEF medication titration algorithm was used to adjust medication daily.,390,466
med:pmid:36713022:sec:results:sent:5,med:pmid:36713022,results,5,The primary endpoint was HFrEF medication utilization at 120 days.,467,533
med:pmid:36713022:sec:results:sent:6,med:pmid:36713022,results,6,"Twenty patients (60.5 ± 8.2 years, men: 85%) with HFrEF were recruited.",534,605
med:pmid:36713022:sec:results:sent:7,med:pmid:36713022,results,7,All received angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI) at recruitment; 45% received ≥50% maximal targeted dose (MTD) with % MTD of 44.4 ± 31.7%.,606,839
med:pmid:36713022:sec:results:sent:8,med:pmid:36713022,results,8,"At baseline, 90 and 70% received beta-adrenergic blocker and mineralocorticoid receptor antagonist (MRA), 35% received ≥50% MTD beta-adrenergic blocker with % MTD of 34.1 ± 29.6%, and 25% received ≥50% MTD MRA with % MTD of 25.0 ± 19.9%.",840,1077
med:pmid:36713022:sec:results:sent:9,med:pmid:36713022,results,9,"At 120 days, 70% received ≥50% MTD ACEI/ARB/ARNI (<i>P</i> = 0.110) with % MTD increased to 64.4 ± 33.5% (<i>P</i> = 0.060).",1078,1202
med:pmid:36713022:sec:results:sent:10,med:pmid:36713022,results,10,The proportion receiving ≥50% MTD ARNI increased from 15 to 55% (<i>P</i> = 0.089) with % MTD ARNI increased from 20.6 ± 30.9 to 53.1 ± 39.5% (<i>P</i> = 0.006*).,1203,1365
med:pmid:36713022:sec:results:sent:11,med:pmid:36713022,results,11,"More patients received ≥50% MTD MRA (65 vs. 25%, <i>P</i> = 0.011*) with % MTD MRA increased from 25.0 ± 19.9 to 46.2 ± 28.8% (<i>P</i> = 0.009*).",1366,1512
med:pmid:36713022:sec:results:sent:12,med:pmid:36713022,results,12,Ninety-five per cent of patients had reduced NT-proBNP with the percentage reduction of 26.7 ± 19.7%.,1513,1614
med:pmid:36713022:sec:conclusion:sent:13,med:pmid:36713022,conclusion,13,Heart failure with reduced ejection fraction medication escalation with remote monitoring appeared feasible.,1615,1743
med:pmid:35717169:sec:title:sent:0,med:pmid:35717169,title,0,Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.,0,127
med:pmid:35717169:sec:introduction:sent:1,med:pmid:35717169,introduction,1,"Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.",0,220
med:pmid:35717169:sec:introduction:sent:2,med:pmid:35717169,introduction,2,"We sought to assess the glycemic effects of sacubitril/valsartan in heart failure with preserved ejection fraction (HFpEF) and diabetes, and across the spectrum of left ventricular ejection fraction (LVEF) in heart failure and diabetes.",221,457
med:pmid:35717169:sec:methods:sent:3,med:pmid:35717169,methods,3,"We compared the effect of sacubitril/valsartan, relative to valsartan, on HbA1c, new insulin therapy and hypoglycemia in the randomized controlled trial PARAGON-HF, and performed pooled analyses of PARAGON-HF and PARADIGM-HF.",458,700
med:pmid:35717169:sec:results:sent:4,med:pmid:35717169,results,4,"Among 2395 patients with HFpEF and diabetes in PARAGON-HF, sacubitril/valsartan compared with valsartan reduced HbA1c (baseline-adjusted between-group difference in HbA1c change at 48 weeks: - 0.24%, 95% CI - 0.33 to - 0.16%, P < 0.001).",701,955
med:pmid:35717169:sec:results:sent:5,med:pmid:35717169,results,5,"Numerically, new insulin treatment was initiated less often in the sacubitril/valsartan group than in the valsartan group, but the difference was not statistically significant (12.8% vs. 16.1%; HR: 0.80, 95% CI 0.62-1.02, P = 0.07).",956,1188
med:pmid:35717169:sec:results:sent:6,med:pmid:35717169,results,6,"Hypoglycemia adverse event reports were low, but more frequent in those receiving sacubitril/valsartan than in the valsartan group (4.2% vs. 2.6%; HR: 1.64, 95% CI 1.05-2.56, P = 0.030).",1189,1375
med:pmid:35717169:sec:results:sent:7,med:pmid:35717169,results,7,"In a pooled analysis of PARAGON-HF and PARADIGM-HF, the effect of sacubitril/valsartan on change in HbA1c was not significantly modified by LVEF (P<sub>interaction</sub> = 0.56).",1376,1554
med:pmid:35717169:sec:results:sent:8,med:pmid:35717169,results,8,"Across the spectrum of LVEF, sacubitril/valsartan reduced new insulin therapy (HR: 0.75, 95% CI 0.63-0.89, P = 0.001), compared with enalapril or valsartan.",1555,1711
med:pmid:35717169:sec:conclusion:sent:9,med:pmid:35717169,conclusion,9,Sacubitril/valsartan reduced HbA1c and new insulin therapy in patients with heart failure and diabetes across the spectrum of LVEF but may be associated with a slightly higher risk for hypoglycemia.,1712,1931
med:pmid:35717169:sec:conclusion:sent:10,med:pmid:35717169,conclusion,10,Trial registration ClinicalTrials.gov NCT01920711.,1932,1982
med:pmid:35690600:sec:title:sent:0,med:pmid:35690600,title,0,Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect.,0,98
med:pmid:35690600:sec:abstract:sent:1,med:pmid:35690600,abstract,1,We investigated the effect of angiotensin receptor neprilysin inhibitor (ARNI) on glycemic control in Korean patients.,0,118
med:pmid:35690600:sec:abstract:sent:2,med:pmid:35690600,abstract,2,This retrospective cohort study was conducted at a single tertiary hospital.,119,195
med:pmid:35690600:sec:abstract:sent:3,med:pmid:35690600,abstract,3,We compared the HbA<sub>1c</sub> level reduction between the ARNI and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in chronic heart failure patients with diabetes.,196,406
med:pmid:35690600:sec:abstract:sent:4,med:pmid:35690600,abstract,4,We also examined whether the target HbA<sub>1c</sub> level was reached and the time to start insulin between the two groups.,407,531
med:pmid:35690600:sec:abstract:sent:5,med:pmid:35690600,abstract,5,"Over the study period, ARNI did not significantly lower the HbA<sub>1c</sub> level after adjusting confounding factors compared to ACEIs or ARBs.",532,677
med:pmid:35690600:sec:abstract:sent:6,med:pmid:35690600,abstract,6,"However, as a result of a simple comparison using Mann-Whitney U test, ARNI group showed significant decrease in HbA<sub>1c</sub> at 6, 12, and 24 months compared to ACEIs or ARBs group (p = 0.003, 0.009, and 0.026, respectively).",678,908
med:pmid:35690600:sec:abstract:sent:7,med:pmid:35690600,abstract,7,"The initiation of insulin was delayed in the ARNI group, but this difference was not significant based on the result of hazard ratio, but cumulative incidence was significantly lower in the ARNI group.",909,1110
med:pmid:35690600:sec:abstract:sent:8,med:pmid:35690600,abstract,8,"In the real world, the blood glucose-control effects of ARNI were not superior to those of ACEIs or ARBs.",1111,1216
med:pmid:35690600:sec:abstract:sent:9,med:pmid:35690600,abstract,9,"However, long-term studies are needed as ARNI use increases to obtain more statistically significant results.",1217,1326
med:pmid:35654526:sec:title:sent:0,med:pmid:35654526,title,0,Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF.,0,104
med:pmid:35654526:sec:introduction:sent:1,med:pmid:35654526,introduction,1,"Up to 20% of patients in heart failure with reduced ejection fraction (HFrEF) trials are not taking diuretic agents at baseline, but little is known about them.",0,180
med:pmid:35654526:sec:introduction:sent:2,med:pmid:35654526,introduction,2,The aim of this study was to examine outcomes in patients with HFrEF not taking diuretic medications and after diuretic medications are started.,181,345
med:pmid:35654526:sec:methods:sent:3,med:pmid:35654526,methods,3,Patient characteristics and outcomes were compared between patients taking or not taking diuretic drugs at baseline in the ATMOSPHERE (Aliskiren Trial of Minimizing Outcomes for Patients With Heart Failure) and PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) trials combined.,346,722
med:pmid:35654526:sec:methods:sent:4,med:pmid:35654526,methods,4,Patients starting diuretic medications were also compared with those remaining off diuretic drugs during follow-up.,723,838
med:pmid:35654526:sec:methods:sent:5,med:pmid:35654526,methods,5,"Symptoms (Kansas City Cardiomyopathy Questionnaire Clinical Summary Score [KCCQ-CSS]), hospitalization for worsening heart failure (HF), mortality, and kidney function (estimated glomerular filtration rate slope) were examined.",839,1066
med:pmid:35654526:sec:results:sent:6,med:pmid:35654526,results,6,"At baseline, the 3,079 of 15,415 patients (20%) not taking diuretic medications had a less severe HF profile, less neurohumoral activation, and better kidney function.",1067,1251
med:pmid:35654526:sec:results:sent:7,med:pmid:35654526,results,7,They were less likely to experience the primary outcome (hospitalization for HF or cardiovascular death) than patients taking diuretic agents (adjusted HR: 0.77; 95% CI: 0.74-0.80; P < 0.001) and death of any cause.,1252,1467
med:pmid:35654526:sec:results:sent:8,med:pmid:35654526,results,8,Commencement of a diuretic drug was associated with higher subsequent risk for death (adjusted HR: 2.05; 95% CI: 1.99-2.11; P < 0.001) and greater decreases in KCCQ-CSS and estimated glomerular filtration rate.,1468,1678
med:pmid:35654526:sec:results:sent:9,med:pmid:35654526,results,9,"The 5 strongest predictors of initiation of diuretic medications were higher N-terminal pro-B-type natriuretic peptide, higher body mass index, older age, history of diabetes, and worse KCCQ-CSS.",1679,1874
med:pmid:35654526:sec:results:sent:10,med:pmid:35654526,results,10,"In PARADIGM-HF, fewer patients who were treated with sacubitril/valsartan commenced diuretic agents (OR: 0.72; 95% CI: 0.58-0.88; P = 0.002).",1875,2016
med:pmid:35654526:sec:conclusion:sent:11,med:pmid:35654526,conclusion,11,Patients with HFrEF not taking diuretic medications and those who remained off them had better outcomes than patients treated with diuretic agents or who commenced them.,2017,2207
med:pmid:33725113:sec:title:sent:0,med:pmid:33725113,title,0,Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.,0,141
med:pmid:33725113:sec:introduction:sent:1,med:pmid:33725113,introduction,1,To compare baseline characteristics of patients with heart failure with reduced ejection fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on conventional heart failure (HF)-treatment in a European out-patient setting.,0,266
med:pmid:33725113:sec:results:sent:2,med:pmid:33725113,results,2,"Between July 2016 and July 2019, ARIADNE enrolled 8787 outpatients aged ≥18 years with HFrEF from 17 European countries.",267,416
med:pmid:33725113:sec:results:sent:3,med:pmid:33725113,results,3,Choice of therapy was solely at the investigators' discretion.,417,479
med:pmid:33725113:sec:results:sent:4,med:pmid:33725113,results,4,"In total, 4173 patients were on conventional HF-treatment (non-S/V group), while 4614 patients were on sacubitril/valsartan either at enrolment or started sacubitril/valsartan within 1 month of enrolment (S/V group).",480,696
med:pmid:33725113:sec:results:sent:5,med:pmid:33725113,results,5,"Of these, 2108 patients started sacubitril/valsartan treatment ±1 month around enrolment [restricted S/V (rS/V) group].",697,816
med:pmid:33725113:sec:results:sent:6,med:pmid:33725113,results,6,The average age of the patients was 68 years.,817,862
med:pmid:33725113:sec:results:sent:7,med:pmid:33725113,results,7,"Patients on S/V were more likely to have New York Heart Association (NYHA) class III or IV symptoms (50.3%, 44.6%, 32.1% in rS/V, S/V, and non-S/V, respectively) and had lower left ventricular ejection fraction (LVEF; 32.3%, 32.7%, and 35.4% in rS/V, S/V, and non-S/V, respectively; P < 0.0001).",863,1158
med:pmid:33725113:sec:results:sent:8,med:pmid:33725113,results,8,"The most frequently received HF treatments were angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB; ∼84% in non-S/V), followed by β-blockers (∼80%) and mineralocorticoid receptor antagonists (MRAs; 53%).",1159,1390
med:pmid:33725113:sec:results:sent:9,med:pmid:33725113,results,9,"The use of triple HF therapy (ACEI/ARB/angiotensin receptor neprilysin inhibitor with β-blockers and MRA) was higher in the S/V groups than non-S/V group (48.2%, 48.2%, and 40.2% in rS/V, S/V, and non-S/V, respectively).",1391,1611
med:pmid:33725113:sec:conclusion:sent:10,med:pmid:33725113,conclusion,10,"In this large multinational HFrEF registry, patients receiving sacubitril/valsartan tended to be younger with lower LVEF and higher NYHA class.",1612,1775
med:pmid:33725113:sec:conclusion:sent:11,med:pmid:33725113,conclusion,11,Fewer than half of the patients received triple HF therapy.,1776,1835
med:pmid:35736368:sec:title:sent:0,med:pmid:35736368,title,0,[Angiotensine Receptor-Neprilysin Inhibitor combination is not the preferred medication for patients after acute myocardial infarction].,0,136
med:pmid:35736368:sec:abstract:sent:1,med:pmid:35736368,abstract,1,The PARADISE-MI study compared standard treatment with an ACE inhibitor (ramipril) after an acute myocardial infarction with the newer sacubitril/ valsartan combination (so-called ARNI) medication in 5661 patients.,0,214
med:pmid:35736368:sec:abstract:sent:2,med:pmid:35736368,abstract,2,Most patients had a reduced cardiac function (40% ejection fraction or less) and in about 50% of patients it was accompanied by complaints of congestion.,215,368
med:pmid:35736368:sec:abstract:sent:3,med:pmid:35736368,abstract,3,The expected 15% reduction in primary endpoint cardiovascular death or rehospitalization or extra visits for heart failure was not met after 22 months.,369,520
med:pmid:35736368:sec:abstract:sent:4,med:pmid:35736368,abstract,4,"The study is characterized by an increased incidence of symptomatic hypotension of 28,3% in the group treated with the ARNI, compared to an incidence of 21,9% in the group treated with the ACE inhibitor.",521,724
med:pmid:35736368:sec:abstract:sent:5,med:pmid:35736368,abstract,5,The interpretation of the trial is hampered by the mixed design of prevention and treatment trial for heart failure.,725,841
med:pmid:35736368:sec:abstract:sent:6,med:pmid:35736368,abstract,6,A continuing careful approach is advised with ACE inhibitors as first choice in the first week(s) after myocardial infarction.,842,968
med:pmid:35621872:sec:title:sent:0,med:pmid:35621872,title,0,Heart Failure-Do We Need New Drugs or Have Them Already?,0,56
med:pmid:35621872:sec:title:sent:1,med:pmid:35621872,title,1,A Case of Coenzyme Q10.,57,80
med:pmid:35621872:sec:abstract:sent:2,med:pmid:35621872,abstract,2,Heart failure (HF) is a global epidemic that contributes to the deterioration of quality of life and its shortening in 1-3% of adult people in the world.,0,153
med:pmid:35621872:sec:abstract:sent:3,med:pmid:35621872,abstract,3,Pharmacotherapy of HF should rely on highly effective drugs that improve prognosis and prolong life.,154,254
med:pmid:35621872:sec:abstract:sent:4,med:pmid:35621872,abstract,4,"Currently, the ESC guidelines from 2021 indicate that ACEI, ARNI, BB, and SGLT2 inhibitors are the first-line drugs in HF.",255,377
med:pmid:35621872:sec:abstract:sent:5,med:pmid:35621872,abstract,5,It is also worth remembering that the use of coenzyme Q10 brought many benefits in patients with HF.,378,478
med:pmid:35621872:sec:abstract:sent:6,med:pmid:35621872,abstract,6,Coenzyme Q10 is a very important compound that performs many functions in the human body.,479,568
med:pmid:35621872:sec:abstract:sent:7,med:pmid:35621872,abstract,7,"The most important function of coenzyme Q10 is participation in the production of energy in the mitochondria, which determines the proper functioning of all cells, tissues, and organs.",569,753
med:pmid:35621872:sec:abstract:sent:8,med:pmid:35621872,abstract,8,The highest concentration of coenzyme Q10 is found in the tissue of the heart muscle.,754,839
med:pmid:35621872:sec:abstract:sent:9,med:pmid:35621872,abstract,9,"As the body ages, the concentration of coenzyme Q10 in the tissue of the heart muscle decreases, which makes it more susceptible to damage by free radicals.",840,996
med:pmid:35621872:sec:abstract:sent:10,med:pmid:35621872,abstract,10,"It has been shown that in patients with HF, the aggravation of disease symptoms is inversely related to the concentration of coenzyme Q10.",997,1135
med:pmid:35621872:sec:abstract:sent:11,med:pmid:35621872,abstract,11,"Importantly, the concentration of coenzyme Q10 in patients with HF was an important predictor of the risk of death.",1136,1251
med:pmid:35621872:sec:abstract:sent:12,med:pmid:35621872,abstract,12,Long-term coenzyme Q10 supplementation at a dose of 300 mg/day (Q-SYMBIO study) has been shown to significantly improve heart function and prognosis in patients with HF.,1252,1421
med:pmid:35621872:sec:abstract:sent:13,med:pmid:35621872,abstract,13,This article summarizes the latest and most important data on CoQ10 in pathogenesis.,1422,1506
med:pmid:35483448:sec:title:sent:0,med:pmid:35483448,title,0,Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.,0,130
med:pmid:35483448:sec:introduction:sent:1,med:pmid:35483448,introduction,1,To compare the safety and efficacy of valsartan/sacubitril (angiotensin receptor neprilysin inhibitor [ARNI]) against enalapril (angiotensin-converting enzyme inhibitor [ACEI]) in patients with acute heart failure at 6-month follow-up.,0,254
med:pmid:35483448:sec:methods:sent:2,med:pmid:35483448,methods,2,"In this prospective, single centre, and observational study conducted between September 2017 and February 2020 in India, patients with acute decompensated heart failure with reduced ejection fraction (<40%) were included.",255,493
med:pmid:35483448:sec:methods:sent:3,med:pmid:35483448,methods,3,Patients were divided in two groups: valsartan/sacubitril (ARNI) group and enalapril (ACEI).,494,586
med:pmid:35483448:sec:methods:sent:4,med:pmid:35483448,methods,4,"Patients were followed up for at least 6 months after administration of first dose and were evaluated for safety, efficacy, and tolerability of target drug.",587,743
med:pmid:35483448:sec:methods:sent:5,med:pmid:35483448,methods,5,Student's independent t-test was employed for comparing continuous variables.,744,821
med:pmid:35483448:sec:methods:sent:6,med:pmid:35483448,methods,6,"Chi-square test or Fisher's exact test, whichever appropriate, was applied for comparing categorical variables.",822,933
med:pmid:35483448:sec:results:sent:7,med:pmid:35483448,results,7,"A total of 200 patients were included in the present study, 100 each in ARNI and ACEI group.",934,1043
med:pmid:35483448:sec:results:sent:8,med:pmid:35483448,results,8,"The mean age of the population was 61.2 ± 8.4 years and 62.6 ± 8.6 years in ARNI group and ACEI group, respectively.",1044,1160
med:pmid:35483448:sec:results:sent:9,med:pmid:35483448,results,9,The mean maximum tolerated dose by population in ARNI group was 203.6 mg and 8.9 mg in ACEI group.,1161,1259
med:pmid:35483448:sec:results:sent:10,med:pmid:35483448,results,10,Readmission for heart failure were seen significantly higher in ACEI group than ARNI group (p value = 0.001).,1260,1369
med:pmid:35483448:sec:results:sent:11,med:pmid:35483448,results,11,"Parameters like ejection fraction, left ventricular end diastolic and systolic dimensions, 6 min walk test and Kansas City Cardiomyopathy Questionnaires (KCCQ) showed p values < 0.05 between the groups.",1370,1572
med:pmid:35483448:sec:conclusion:sent:12,med:pmid:35483448,conclusion,12,The ARNI study group showed better safety and efficacy outcomes at the end of 6 months follow-up compared to ACEI group.,1573,1713
med:pmid:35257446:sec:title:sent:0,med:pmid:35257446,title,0,Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.,0,169
med:pmid:35257446:sec:introduction:sent:1,med:pmid:35257446,introduction,1,"To assess the association between combination, dose and use of current guideline-recommended target doses (TD) of renin-angiotensin system inhibitors (RASi), angiotensin receptor-neprilysin inhibitors (ARNi) and β-blockers, and outcomes in a large and unselected contemporary cohort of patients with heart failure (HF) and reduced ejection fraction.",0,363
med:pmid:35257446:sec:results:sent:2,med:pmid:35257446,results,2,"Overall, 17 809 outpatients registered in the Swedish Heart Failure Registry (SwedeHF) from May 2000 to December 2018, with ejection fraction <40% and duration of HF ≥90 days were selected.",364,582
med:pmid:35257446:sec:results:sent:3,med:pmid:35257446,results,3,Primary outcome was a composite of time to cardiovascular death and first HF hospitalization.,583,676
med:pmid:35257446:sec:results:sent:4,med:pmid:35257446,results,4,"Compared with no use of RASi or ARNi, the adjusted hazard ratio (HR) (95% confidence interval [CI]) was 0.83 (0.76-0.91) with <50% of TD, 0.78 (0.71-0.86) with 50%-99%, and 0.73 (0.67-0.80) with ≥100% of TD.",677,884
med:pmid:35257446:sec:results:sent:5,med:pmid:35257446,results,5,"Compared with no use of β-blockers, the adjusted HR (95% CI) was 0.86 (0.76-0.91), 0.81 (0.74-0.89) and 0.74 (0.68-0.82) with <50%, 50%-99% and ≥100% of TD, respectively.",885,1055
med:pmid:35257446:sec:results:sent:6,med:pmid:35257446,results,6,"Patients receiving both an angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB)/ARNi and a β-blocker at 50%-99% of TD had a lower adjusted risk of the primary outcome compared with patients only receiving one drug, i.e. ACEi/ARB/ARNi or β-blocker, even if this was at ≥100% of TD.",1056,1365
med:pmid:35257446:sec:conclusion:sent:7,med:pmid:35257446,conclusion,7,Heart failure with reduced ejection fraction patients using higher doses of RASi or ARNi and β-blockers had lower risk of cardiovascular death or HF hospitalization.,1366,1551
med:pmid:35257446:sec:conclusion:sent:8,med:pmid:35257446,conclusion,8,Use of two drug classes at 50%-99% of TD dose was associated with lower risk than one drug class at 100% of TD.,1552,1663
med:pmid:34993995:sec:title:sent:0,med:pmid:34993995,title,0,Cardiovascular therapeutics: A new potential for anxiety treatment?,0,67
med:pmid:34993995:sec:abstract:sent:1,med:pmid:34993995,abstract,1,"Besides the well-recognized risk factors, novel conditions increasing cardiovascular morbidity and mortality are emerging.",0,122
med:pmid:34993995:sec:abstract:sent:2,med:pmid:34993995,abstract,2,"Undesirable emotions and behavior such as anxiety and depression, appear to participate in worsening cardiovascular pathologies.",123,251
med:pmid:34993995:sec:abstract:sent:3,med:pmid:34993995,abstract,3,"On the other hand, deteriorating conditions of the heart and vasculature result in disturbed mental and emotional health.",252,373
med:pmid:34993995:sec:abstract:sent:4,med:pmid:34993995,abstract,4,The pathophysiological background of this bidirectional interplay could reside in an inappropriate activation of vegetative neurohormonal and other humoral systems in both cardiovascular and psychological disturbances.,374,592
med:pmid:34993995:sec:abstract:sent:5,med:pmid:34993995,abstract,5,This results in circulus vitiosus potentiating mental and circulatory disorders.,593,673
med:pmid:34993995:sec:abstract:sent:6,med:pmid:34993995,abstract,6,"Thus, it appears to be of utmost importance to examine the alteration of emotions, cognition, and behavior in cardiovascular patients.",674,808
med:pmid:34993995:sec:abstract:sent:7,med:pmid:34993995,abstract,7,"In terms of this consideration, recognizing the potential of principal cardiovascular drugs to interact with the mental state in patients with heart or vasculature disturbances is unavoidable, to optimize their therapeutic benefit.",809,1040
med:pmid:34993995:sec:abstract:sent:8,med:pmid:34993995,abstract,8,"In general, beta-blockers, central sympatholytics, ACE inhibitors, ARBs, aldosterone receptor blockers, sacubitril/valsartan, and fibrates are considered to exert anxiolytic effect in animal experiments and clinical settings.",1041,1266
med:pmid:34993995:sec:abstract:sent:9,med:pmid:34993995,abstract,9,Statins and some beta-blockers appear to have an equivocal impact on mood and anxiety and ivabradine expressed neutral psychological impact.,1267,1407
med:pmid:34993995:sec:abstract:sent:10,med:pmid:34993995,abstract,10,"It seems reasonable to suppose that the knowledge of a patient's mood, cognition, and behavior, along with applying careful consideration of the choice of the particular cardiovascular drug and respecting its potential psychological benefit or harm might improve the individualized approach to the treatment of cardiovascular disorders.",1408,1744
med:pmid:35919792:sec:title:sent:0,med:pmid:35919792,title,0,"Guideline-directed medical therapy in heart failure patients with reduced ejection fraction in Oman: utilization, reasons behind non-prescribing, and dose optimization.",0,168
med:pmid:35919792:sec:abstract:sent:1,med:pmid:35919792,abstract,1,"<h4>Background objective</h4> To determine the reasons behind guideline-directed medical therapy (GDMT) non-prescribing, drug utilization before and after excluding those intolerable to GDMT, as well as dose optimization in heart failure (HF) patients with reduced ejection fraction (<40%) (HFrEF) in Oman.",0,306
med:pmid:35919792:sec:methods:sent:2,med:pmid:35919792,methods,2,"The study included HF patients seen at the medical outpatient clinics at Sultan Qaboos University Hospital, Muscat, Oman, between January 2016 and December 2019 and followed up until the end of June 2021.",307,528
med:pmid:35919792:sec:methods:sent:3,med:pmid:35919792,methods,3,"The use of renin-angiotensin-system (RAS) blockers (angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitors (ARNIs)), beta blockers and mineralocorticoid receptor antagonists (MRAs) were evaluated as per the European, American, and Canadian HF guidelines.",529,866
med:pmid:35919792:sec:methods:sent:4,med:pmid:35919792,methods,4,Analyses were performed using univariate statistics.,867,919
med:pmid:35919792:sec:results:sent:5,med:pmid:35919792,results,5,"A total of 171 HFrEF patients were enrolled for this study, the overall mean age of the cohort was 63 ± 15 years old and 59% were male.",920,1072
med:pmid:35919792:sec:results:sent:6,med:pmid:35919792,results,6,Over 65% of the patients had chronic kidney disease.,1073,1125
med:pmid:35919792:sec:results:sent:7,med:pmid:35919792,results,7,Almost 55% of the patients were intolerable to GDMT.,1126,1178
med:pmid:35919792:sec:results:sent:8,med:pmid:35919792,results,8,"The proportion of patients on beta blockers, RAS blockers/ hydralazine-isosorbide dinitrate combination, and MRAs, before and after excluding those intolerable to GDMT, were 89%, 97%, and 77%, and, 94%, 47% and 85%, respectively, while the proportion of patients on the GDMT combination concomitantly was 41% and 83%, respectively.",1179,1510
med:pmid:35919792:sec:results:sent:9,med:pmid:35919792,results,9,"A total of 61%, 44% and 100% of the patients were prescribed ≥50% of the target dose for beta blockers, RAS blockers/ HYD-ISDN combination and MRAs respectively, while 19%, 8.2% and 94% of the patients attained 100% of the target dose for beta blockers, RAS blockers/ HYD-ISDN combination and MRAs respectively.",1511,1822
med:pmid:35919792:sec:conclusion:sent:10,med:pmid:35919792,conclusion,10,Reasons behind GDMT non-prescribing were frequent and not clearly obvious in patients' medical notes.,1823,1945
med:pmid:35919792:sec:conclusion:sent:11,med:pmid:35919792,conclusion,11,The majority of the patients were prescribed GDMT.,1946,1996
med:pmid:35919792:sec:conclusion:sent:12,med:pmid:35919792,conclusion,12,"However, dose optimization, specifically for beta blockers and RAS blockers/ HYD-ISDN combination, was still suboptimal.",1997,2117
med:pmid:35919792:sec:conclusion:sent:13,med:pmid:35919792,conclusion,13,"The findings should be interpreted in the context of low study power and that future studies, with larger sample sizes, are warranted to minimize this limitation.",2118,2280
med:pmid:35260016:sec:title:sent:0,med:pmid:35260016,title,0,Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.,0,98
med:pmid:35260016:sec:introduction:sent:1,med:pmid:35260016,introduction,1,"Despite considerable advances in the treatment of heart failure with reduced ejection fraction (HFrEF) over the last 60 years, mortality and morbidity remains high.",0,186
med:pmid:35260016:sec:introduction:sent:2,med:pmid:35260016,introduction,2,"Fortunately, in the last years, further developments expanded the toolbox for HF treatment.",187,278
med:pmid:35260016:sec:introduction:sent:3,med:pmid:35260016,introduction,3,<h4>Areas covered</h4> The authors provide an overview of recent developments in HF treatment and bring the recommendations in the HF guidelines of the European Society of Cardiology into perspective.,279,479
med:pmid:35260016:sec:introduction:sent:4,med:pmid:35260016,introduction,4,"<h4>Expert opinion</h4> Nowadays, basic pharmacological treatment of patients with HFrEF consists of a combination of angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA), and the SGLT2 inhibitors dapagliflozin or empagliflozin.",480,812
med:pmid:35260016:sec:introduction:sent:5,med:pmid:35260016,introduction,5,Treatment initiation of all four drug classes should be fast and simultaneous.,813,891
med:pmid:35260016:sec:introduction:sent:6,med:pmid:35260016,introduction,6,"In some cases, the ARNI sacubitril/valsartan may be initiated even in ACE inhibitor-naïve patients.",892,991
med:pmid:35260016:sec:introduction:sent:7,med:pmid:35260016,introduction,7,Further HF treatment has to be individualized.,992,1038
med:pmid:35260016:sec:introduction:sent:8,med:pmid:35260016,introduction,8,Another important point is that both SGLT2 inhibitors and vericiguat can be used in patients with severely reduced kidney function.,1039,1170
med:pmid:35260016:sec:introduction:sent:9,med:pmid:35260016,introduction,9,"Finally, an important piece in the HF management puzzle is the treatment of its comorbidities.",1171,1265
med:pmid:35260016:sec:introduction:sent:10,med:pmid:35260016,introduction,10,"For instance, patients hospitalized for acute HF decompensation should be systematically screened for iron deficiency, since HF patients with proven iron deficiency benefit from intravenous ferric carboxymaltose.",1266,1478
med:pmid:35253964:sec:title:sent:0,med:pmid:35253964,title,0,Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension.,0,101
med:pmid:35253964:sec:abstract:sent:1,med:pmid:35253964,abstract,1,"Sacubitril/valsartan, simultaneously inhibits neprilysin and angiotensin II receptor, showed an effect in reducing blood pressure (BP).",0,135
med:pmid:35253964:sec:abstract:sent:2,med:pmid:35253964,abstract,2,The authors aimed to study whether it can be used as an antihypertensive agent in patients with refractory hypertension who have already been treated.,136,286
med:pmid:35253964:sec:abstract:sent:3,med:pmid:35253964,abstract,3,A total of 66 Chinese patients with refractory hypertension were enrolled.,287,361
med:pmid:35253964:sec:abstract:sent:4,med:pmid:35253964,abstract,4,Patients received sacubitril/valsartan  200 instead of angiotensin II receptor blocker or angiotensin converting enzyme inhibitor while other agents continued.,362,521
med:pmid:35253964:sec:abstract:sent:5,med:pmid:35253964,abstract,5,"If BP was uncontrolled after 4 weeks, sacubitril/valsartan was increased to 400 mg.",522,605
med:pmid:35253964:sec:abstract:sent:6,med:pmid:35253964,abstract,6,The BP reduction was evaluated by office BP and ambulatory BP monitoring after 8-week treatment.,606,702
med:pmid:35253964:sec:abstract:sent:7,med:pmid:35253964,abstract,7,The baseline office BP and mean arterial pressure (MAP) were 150.0/95.0 mmHg and 113.3 mmHg.,703,795
med:pmid:35253964:sec:abstract:sent:8,med:pmid:35253964,abstract,8,BP and MAP reduced to 130.6/83.2 mmHg and 99.0 mmHg at week 8.,796,858
med:pmid:35253964:sec:abstract:sent:9,med:pmid:35253964,abstract,9,Office BP and MAP reductions were 19.4/11.8 mmHg and 14.3 mmHg at endpoint (all p < .001).,859,949
med:pmid:35253964:sec:abstract:sent:10,med:pmid:35253964,abstract,10,"The 24-h, daytime and nighttime ambulatory BP were 146.2/89.1, 148.1/90.3, and 137.5/83.7 mmHg, respectively at baseline, and BP reduced to 129.6/79.8, 130.6/81.1, and 121.7/75.8 mmHg, respectively at week 8.",950,1158
med:pmid:35253964:sec:abstract:sent:11,med:pmid:35253964,abstract,11,"The 24-h, daytime and nighttime ambulatory BP reductions were 16.6/9.3, 17.5/9.2, and 15.8/7.9 mmHg, respectively at endpoint (all p < .001).",1159,1300
med:pmid:35253964:sec:abstract:sent:12,med:pmid:35253964,abstract,12,Sacubitril/valsartan significantly reduced office and ambulatory BP in refractory hypertension patients.,1301,1405
med:pmid:35253964:sec:abstract:sent:13,med:pmid:35253964,abstract,13,Our study provided new evidence for sacubitril/valsartan in refractory hypertension.,1406,1490
med:pmid:35404555:sec:title:sent:0,med:pmid:35404555,title,0,Adverse drug effects across patients with heart failure: a systematic review.,0,77
med:pmid:35404555:sec:introduction:sent:1,med:pmid:35404555,introduction,1,To summarize published literature on the incidence of adverse drug effects (ADEs) associated with guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF).,0,231
med:pmid:35404555:sec:introduction:sent:2,med:pmid:35404555,introduction,2,<h4>Study design</h4> Systematic literature review.,232,283
med:pmid:35404555:sec:methods:sent:3,med:pmid:35404555,methods,3,"A systematic literature review was conducted in PubMed, Ovid MEDLINE, and Clinical Key covering January 1990 to December 2018.",284,427
med:pmid:35404555:sec:methods:sent:4,med:pmid:35404555,methods,4,"Key search terms were ADEs for β-blockers (BBs), ACE inhibitors (ACEis), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and/or angiotensin receptor-neprilysin inhibitors (ARNis) in adult patients (≥ 18 years) with HFrEF.",428,686
med:pmid:35404555:sec:results:sent:5,med:pmid:35404555,results,5,"A total of 279 eligible articles were identified, of which 29 reported drug-related adverse effects and were included in this review.",687,837
med:pmid:35404555:sec:results:sent:6,med:pmid:35404555,results,6,"Of the 29 studies, 11 examined BBs; 9, MRAs; 6, ARNis; 2, ACEis; and 1, ARBs.",838,915
med:pmid:35404555:sec:results:sent:7,med:pmid:35404555,results,7,"The most common reported ADEs across these therapeutic classes included bradycardia, dizziness, hypotension, hyperkalemia, cough, and renal impairment.",916,1067
med:pmid:35404555:sec:results:sent:8,med:pmid:35404555,results,8,"The incidence of BB-induced bradycardia was 1% to 52% based on 9 studies, and 6 studies described dizziness as a result of BBs and ARNis (15%-43%).",1068,1215
med:pmid:35404555:sec:results:sent:9,med:pmid:35404555,results,9,"Fourteen studies reported induced hypotension (1.4%-63%); 13 studies, hyperkalemia (0.6%-30.2%); 3 studies, cough (37%-50%); and 4 studies, renal impairment (0.6%-7.6%).",1216,1385
med:pmid:35404555:sec:conclusion:sent:10,med:pmid:35404555,conclusion,10,Findings show that drug-related adverse effects are commonly reported in clinical trials and highlight the sizable burden of ADEs with medical therapy across patients with HFrEF.,1386,1585
med:pmid:35404555:sec:conclusion:sent:11,med:pmid:35404555,conclusion,11,Additional real-world evidence and studies aiming to improve the tolerability of GDMT for patients with HFrEF are warranted.,1586,1710
med:pmid:35365031:sec:title:sent:0,med:pmid:35365031,title,0,Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis.,0,141
med:pmid:35365031:sec:introduction:sent:1,med:pmid:35365031,introduction,1,infarction (AMI) can be reduced by the use of sacubitril/valsartan.,0,87
med:pmid:35365031:sec:introduction:sent:2,med:pmid:35365031,introduction,2,"However, the therapeutic effects of sacubitril/valsartan in clinical settings are inconsistent.",88,183
med:pmid:35365031:sec:introduction:sent:3,med:pmid:35365031,introduction,3,"In this paper, the related research on the application of sacubitril/valsartan in AMI was comprehensively searched, in order to explore the clinical efficacy and safety of early application of sacubitril/valsartan after AMI.",184,408
med:pmid:35365031:sec:methods:sent:4,med:pmid:35365031,methods,4,"English databases, including American National Library of Medicine, Medline, and Embase, and Chinese databases, including Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI), Wanfang, and VIP, were searched using a combination of the following search terms: AMI, acute ST-segment elevation myocardial infarction (STEMI), acute non-ST-segment elevation myocardial infarction (NSTEMI), sacubitril/valsartan sodium tablets, and angiotensin receptor enkephalinase inhibitors.",409,934
med:pmid:35365031:sec:methods:sent:5,med:pmid:35365031,methods,5,"The experimental group was given Sacubitril/Valsartan sodium tablets, while the control group was given angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB).",935,1121
med:pmid:35365031:sec:methods:sent:6,med:pmid:35365031,methods,6,Cochrane Handbook 5.0 risk assessment table were used for quality assessment and bias risk assessment.,1122,1224
med:pmid:35365031:sec:results:sent:7,med:pmid:35365031,results,7,A total of 5 articles were included in the meta-analysis.,1225,1299
med:pmid:35365031:sec:results:sent:8,med:pmid:35365031,results,8,"The total incidence of adverse cardiovascular events in the sacubitril/valsartan group was significantly lower than that in the control group {relative risk (RR) =0.61 [95% confidence interval (CI): 0.46, 0.82], significance testing Z=3.36, and P=0.0008}.",1300,1555
med:pmid:35365031:sec:results:sent:9,med:pmid:35365031,results,9,"The difference between the rehospitalization rate of the sacubitril/valsartan group and control group was statistically significant [RR =0.67 (95% CI: 0.47, 0.95), significance testing Z=2.23, and P=0.03].",1556,1761
med:pmid:35365031:sec:results:sent:10,med:pmid:35365031,results,10,"The difference in low blood pressure between the sacubitril/valsartan group and the control group was statistically significant [RR =1.28 (95% CI: 1.18, 1.40), significance testing Z=5.58, and P<0.00001].",1762,1966
med:pmid:35365031:sec:results:sent:11,med:pmid:35365031,results,11,"The difference in left ventricular ejection fraction (LVEF) between the sacubitril/valsartan group and control group was statistically significant [mean difference (MD) =3.09 (95% CI: 1.69, 4.49), significance testing Z=4.33, and P<0.0001].",1967,2207
med:pmid:35365031:sec:discussion:sent:12,med:pmid:35365031,discussion,12,"Sacubitril/valsartan was found to inhibit ventricular remodeling after AMI, improve cardiac function, and reduce the incidence of adverse cardiovascular events after myocardial infarction, the rehospitalization rate, and the mortality rate.",2208,2468
med:pmid:35343504:sec:title:sent:0,med:pmid:35343504,title,0,[Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials].,0,192
med:pmid:35343504:sec:abstract:sent:1,med:pmid:35343504,abstract,1,"Renin-angiotensin-aldosterone (RAAS) system inhibition is a mainstay of the pharmacological treatment of heart failure with reduced ejection fraction and has been implemented by the introduction of angiotensin receptor-neprilysin inhibitors (ARNI), that combine RAAS inhibition with the inhibition of neprilysin, enhancing the favorable effects of natriuretic peptides.",0,369
med:pmid:35343504:sec:abstract:sent:2,med:pmid:35343504,abstract,2,The PARADIGM-HF trial demonstrated a favorable effect of sacubitril/valsartan over enalapril in terms of mortality and heart failure hospitalization rate reduction.,370,534
med:pmid:35343504:sec:abstract:sent:3,med:pmid:35343504,abstract,3,"Then several randomized clinical trials and observational studies confirmed the favorable role of ARNI in different clinical scenarios, supporting the guideline class I recommendation for the use of sacubitril/valsartan in patients with reduced systolic function.",535,798
med:pmid:35343504:sec:abstract:sent:4,med:pmid:35343504,abstract,4,The first part of this position paper summarizes the history of RAAS inhibition and reports the results of ARNI trials that support the recommendations of the most recent guidelines.,799,981
med:pmid:35094306:sec:title:sent:0,med:pmid:35094306,title,0,Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study.,0,219
med:pmid:35094306:sec:introduction:sent:1,med:pmid:35094306,introduction,1,"The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (SAC/VAL) has shown benefit in patients with symptomatic heart failure (HF), including those naïve to renin-angiotensin-aldosterone system inhibitor (RAASi) therapy, and is considered the preferred RAASi for chronic HF.",0,315
med:pmid:35094306:sec:introduction:sent:2,med:pmid:35094306,introduction,2,"Real-world data on ARNI, specifically in RAASi-naïve patients, are limited.",316,391
med:pmid:35094306:sec:introduction:sent:3,med:pmid:35094306,introduction,3,This study compared real-world outcomes of ARNI (SAC/VAL) vs. angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy in RAASi-naïve patients with HF and reduced ejection fraction (HFrEF).,392,617
med:pmid:35094306:sec:methods:sent:4,med:pmid:35094306,methods,4,"This retrospective cohort study included de-identified data on RAASi-naïve patients with HFrEF (left ventricular ejection fraction ≤ 40%) who had newly initiated SAC/VAL or ACEi/ARB between July 1, 2015, and March 31, 2019, from the Optum® Electronic Health Records database in the US.",618,920
med:pmid:35094306:sec:methods:sent:5,med:pmid:35094306,methods,5,New SAC/VAL users were propensity score matched 1:2 with new ACEi/ARB users by pre-selected characteristics.,921,1029
med:pmid:35094306:sec:methods:sent:6,med:pmid:35094306,methods,6,"One-year post-index rates of all-cause, HF, and cardiovascular hospitalizations and the composite of HF hospitalization or emergency room (ER) visits were measured using negative binomial regression.",1030,1229
med:pmid:35094306:sec:methods:sent:7,med:pmid:35094306,methods,7,"Time to first all-cause hospitalization, HF hospitalization, and composite of HF hospitalization or ER visits was measured using a subdistribution hazards model.",1230,1391
med:pmid:35094306:sec:results:sent:8,med:pmid:35094306,results,8,The matched sample included 3059 new SAC/VAL and 6118 new ACEi/ARB users.,1392,1482
med:pmid:35094306:sec:results:sent:9,med:pmid:35094306,results,9,"Rates of all-cause hospitalization and composite of HF hospitalization or ER visits were significantly lower with SAC/VAL compared with ACEi/ARB (incidence rate ratio [95% confidence interval]: 0.87 [0.81-0.93] and 0.87 [0.81-0.94], respectively), whereas rates of HF hospitalizations and cardiovascular hospitalizations were similar (1.00 [0.91-1.11] and 0.94 [0.87-1.02], respectively).",1483,1871
med:pmid:35094306:sec:results:sent:10,med:pmid:35094306,results,10,Time-to-event analyses also showed a similar trend.,1872,1923
med:pmid:35094306:sec:conclusion:sent:11,med:pmid:35094306,conclusion,11,"In real-world clinical practice, RAASi-naïve patients with HFrEF initiating SAC/VAL were less likely to be hospitalized than those initiating ACEi/ARB, suggesting a potential for a reduced clinical and economic burden in these patients.",1924,2181
med:pmid:34969175:sec:title:sent:0,med:pmid:34969175,title,0,Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.,0,95
med:pmid:34969175:sec:introduction:sent:1,med:pmid:34969175,introduction,1,Sudden death is a leading cause of mortality in heart failure with reduced ejection fraction (HFrEF).,0,115
med:pmid:34969175:sec:introduction:sent:2,med:pmid:34969175,introduction,2,"In PARADIGM-HF, sacubitril/valsartan reduced the incidence of sudden death.",116,191
med:pmid:34969175:sec:introduction:sent:3,med:pmid:34969175,introduction,3,"The purpose of this post hoc study was to analyse the effect of sacubitril/valsartan, compared to enalapril, on the incidence of ventricular arrhythmias.",192,345
med:pmid:34969175:sec:results:sent:4,med:pmid:34969175,results,4,Adverse event reports related to ventricular arrhythmias were examined in PARADIGM-HF.,346,461
med:pmid:34969175:sec:results:sent:5,med:pmid:34969175,results,5,"The effect of randomized treatment on two arrhythmia outcomes was analysed: ventricular arrhythmias and the composite of a ventricular arrhythmia, implantable cardioverter defibrillator (ICD) shock or resuscitated cardiac arrest.",462,691
med:pmid:34969175:sec:results:sent:6,med:pmid:34969175,results,6,The risk of death related to a ventricular arrhythmia was examined in time-updated models.,692,782
med:pmid:34969175:sec:results:sent:7,med:pmid:34969175,results,7,"The interaction between heart failure aetiology, or baseline ICD/cardiac resynchronization therapy-defibrillator (CRT-D) use, and the effect of sacubitril/valsartan was analysed.",783,961
med:pmid:34969175:sec:results:sent:8,med:pmid:34969175,results,8,"Of the 8399 participants, 333 (4.0%) reported a ventricular arrhythmia and 372 (4.4%) the composite arrhythmia outcome.",962,1081
med:pmid:34969175:sec:results:sent:9,med:pmid:34969175,results,9,Ventricular arrhythmias were associated with higher mortality.,1082,1144
med:pmid:34969175:sec:results:sent:10,med:pmid:34969175,results,10,"Compared with enalapril, sacubitril/valsartan reduced the risk of a ventricular arrhythmia (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.62-0.95; p = 0.015) and the composite arrhythmia outcome (HR 0.79, 95% CI 0.65-0.97; p = 0.025).",1145,1388
med:pmid:34969175:sec:results:sent:11,med:pmid:34969175,results,11,The treatment effect was maintained after adjustment and accounting for the competing risk of death.,1389,1489
med:pmid:34969175:sec:results:sent:12,med:pmid:34969175,results,12,"Baseline ICD/CRT-D use did not modify the effect of sacubitril/valsartan, but aetiology did: HR in patients with an ischaemic aetiology 0.93 (95% CI 0.71-1.21) versus 0.53 (95% CI 0.37-0.78) in those without an ischaemic aetiology (p for interaction = 0.020).",1490,1749
med:pmid:34969175:sec:conclusion:sent:13,med:pmid:34969175,conclusion,13,Sacubitril/valsartan reduced the incidence of investigator-reported ventricular arrhythmias in patients with HFrEF.,1750,1886
med:pmid:34969175:sec:conclusion:sent:14,med:pmid:34969175,conclusion,14,This effect may have been greater in patients with a non-ischaemic aetiology.,1887,1964
med:pmid:35282662:sec:title:sent:0,med:pmid:35282662,title,0,Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial.,0,196
med:pmid:35282662:sec:introduction:sent:1,med:pmid:35282662,introduction,1,"For patients with heart failure (HF), the effect of angiotensin receptor-neprilysin inhibitors (ARNIs, sacubitril/valsartan) on cardiac remodeling has been found to be superior to angiotensin-converting enzyme inhibitors (ACEI).",0,248
med:pmid:35282662:sec:introduction:sent:2,med:pmid:35282662,introduction,2,"However, little data have described the impact of early-initiation ARNI in patients with acute anterior ST-segment elevation myocardial infarction (STEMI).",249,404
med:pmid:35282662:sec:methods:sent:3,med:pmid:35282662,methods,3,"In this prospective, randomized, double-blind, parallel-group trial, we enrolled 131 anterior STEMI patients who were treated with primary percutaneous coronary intervention (PCI) between February 2019 and December 2019.",405,642
med:pmid:35282662:sec:methods:sent:4,med:pmid:35282662,methods,4,All patients received standard STEMI management and were divided into 2 groups (ARNI/enalapril).,643,739
med:pmid:35282662:sec:methods:sent:5,med:pmid:35282662,methods,5,"Primary efficacy outcomes were the between-group difference in change (from baseline to 4-, 12-, and 24-week) in N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration, left ventricular ejection fraction (LVEF), and left ventricular end-systolic volumes and end-diastolic volumes (LVESV and LVEDV).",740,1051
med:pmid:35282662:sec:methods:sent:6,med:pmid:35282662,methods,6,"Secondary outcomes were determined by a composite of death, reinfarction, outpatient HF or HF hospitalization, malignant arrhythmia, and stroke.",1052,1196
med:pmid:35282662:sec:methods:sent:7,med:pmid:35282662,methods,7,"Safety outcomes included worsening renal function, hypotension, hyperkalemia, angioedema and cough.",1197,1296
med:pmid:35282662:sec:results:sent:8,med:pmid:35282662,results,8,"We found that NT-proBNP concentration decreased more in the ARNI group than in the enalapril group [4 weeks: ratio of ARNI <i>vs.</i> enalapril 0.36, 95% confidence interval (CI): 0.24 to 0.52, P<0.001; 12 weeks: 0.54, 95% CI: 0.35 to 0.79, P<0.001; 24 weeks: 0.53, 95% CI: 0.32 to 0.83, P<0.001).",1297,1611
med:pmid:35282662:sec:results:sent:9,med:pmid:35282662,results,9,"When compared to the enalapril group, the ARNI group patients had a significant reduction in LVEDV (P<0.001) and LVESV (P<0.001), and an improvement in LVEF (P=0.011) at 24 weeks.",1612,1791
med:pmid:35282662:sec:results:sent:10,med:pmid:35282662,results,10,"Secondary outcomes occurred in 13 participants (20.3%) in the ARNI group and 22 participants (34.4%) in the enalapril group [hazard ratio (HR), 0.56; 95% CI: 0.28 to 1.12; P=0.102].",1792,1973
med:pmid:35282662:sec:results:sent:11,med:pmid:35282662,results,11,"The incidence of outpatient HF or HF hospitalization in the ARNI group was significantly lower than that in the enalapril group (HR, 0.36; 95% CI: 0.14 to 0.94; P=0.037).",1974,2144
med:pmid:35282662:sec:results:sent:12,med:pmid:35282662,results,12,There were no significant differences in the safety between the 2 groups.,2145,2218
med:pmid:35282662:sec:conclusion:sent:13,med:pmid:35282662,conclusion,13,"For patients with acute anterior STEMI undergoing primary PCI, early initiation of ARNI provided significant clinical benefits.",2219,2367
med:pmid:35282662:sec:conclusion:sent:14,med:pmid:35282662,conclusion,14,"<h4>Trial registration</h4> Chinese Clinical Trial Registry (ChiCTR2100042944) registered on February 1, 2021.",2368,2478
med:pmid:35268260:sec:title:sent:0,med:pmid:35268260,title,0,"Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics.",0,202
med:pmid:35268260:sec:abstract:sent:1,med:pmid:35268260,abstract,1,Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis.,0,216
med:pmid:35268260:sec:abstract:sent:2,med:pmid:35268260,abstract,2,The objective of the present study was to estimate the prevalence of hyperkalaemia in outpatients with HFrEF and its impact on achieving optimal medical treatment.,217,380
med:pmid:35268260:sec:abstract:sent:3,med:pmid:35268260,abstract,3,"For this purpose, a multicentre, prospective, and observational study was carried out on consecutive HFrEF patients who were monitored as outpatients in heart failure (HF) units and who, in the opinion of their doctor, received optimal medical treatment.",381,635
med:pmid:35268260:sec:abstract:sent:4,med:pmid:35268260,abstract,4,A total of 565 HFrEF patients were included from 16 specialised HF units.,636,709
med:pmid:35268260:sec:abstract:sent:5,med:pmid:35268260,abstract,5,"The mean age was 66 ± 12 years, 78% were male, 45% had an ischemic cause, 39% had atrial fibrillation, 43% were diabetic, 42% had a glomerular filtration rate < 60 mL/min/1.7 m2, and the mean left ventricular ejection fraction was 31 ± 7%.",710,949
med:pmid:35268260:sec:abstract:sent:6,med:pmid:35268260,abstract,6,"Treatment at the study entry included: 76% on diuretics, 13% on ivabradine, 7% on digoxin, 18.9% on angiotensin-conversing enzyme inhibitors (ACEi), 11.3% on angiotensin receptors blockers (ARBs), 63.8% on angiotensin-neprilysin inhibitors (ARNi), 78.5% on mineralocorticoid receptor antagonists (MRAs), and 92.9% on beta-blockers.",950,1281
med:pmid:35268260:sec:abstract:sent:7,med:pmid:35268260,abstract,7,"Potassium levels in the baseline analysis were: ≤5 mEq/L = 80.5%, 5.1−5.4 mEq/L = 13.8%, 5.5−5.9 mEq/L = 4.6%, and ≥6 mEq/L = 1.06%.",1282,1414
med:pmid:35268260:sec:abstract:sent:8,med:pmid:35268260,abstract,8,"Hyperkalaemia was the reason for not prescribing or reaching the target dose of an MRAs in 34.8% and 12.5% of patients, respectively.",1415,1548
med:pmid:35268260:sec:abstract:sent:9,med:pmid:35268260,abstract,9,"The impact of hyperkalaemia on not prescribing or dropping below the target dose in relation to ACEi, ARBs, and ARNi was significantly less.",1549,1689
med:pmid:35268260:sec:abstract:sent:10,med:pmid:35268260,abstract,10,"In conclusion, hyperkalaemia is a frequent problem in the management of patients with HFrEF and a limiting factor in the optimisation of medical treatment.",1690,1845
med:pmid:35200707:sec:title:sent:0,med:pmid:35200707,title,0,What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies.,0,88
med:pmid:35200707:sec:abstract:sent:1,med:pmid:35200707,abstract,1,"Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF study in 2014.",0,275
med:pmid:35200707:sec:abstract:sent:2,med:pmid:35200707,abstract,2,"Therefore, for patients with HFrEF, worldwide recommendations have been reformed to include sacubitril/valsartan.",276,389
med:pmid:35200707:sec:abstract:sent:3,med:pmid:35200707,abstract,3,"In addition, sacubitril/valsartan has been investigated in other cardiovascular disease states, such as patients with heart failure and preserved ejection fraction (HFpEF) and following myocardial infarction (MI) events.",390,610
med:pmid:35200707:sec:abstract:sent:4,med:pmid:35200707,abstract,4,"In February 2021, the FDA expanded the indication use of sacubitril/valsartan to include the HFpEF patient population based on the results of the PARAGON-HF trial.",611,774
med:pmid:35200707:sec:abstract:sent:5,med:pmid:35200707,abstract,5,"However, randomized clinical trials post-MI did not show promising results.",775,850
med:pmid:35200707:sec:abstract:sent:6,med:pmid:35200707,abstract,6,Sacubitril/valsartan is currently being investigated in many other cardiovascular and non-cardiovascular conditions.,851,967
med:pmid:35200707:sec:abstract:sent:7,med:pmid:35200707,abstract,7,This review aims to shed light and summarize the ongoing sacubitril/valsartan registered studies on the United States National Library of Medicine clinical trials registry.,968,1140
med:pmid:35115085:sec:title:sent:0,med:pmid:35115085,title,0,Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.,0,139
med:pmid:35115085:sec:introduction:sent:1,med:pmid:35115085,introduction,1,This study assessed changes in B-type natriuretic peptide (BNP) among patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (Sac/Val) according to standard prescribing information.,0,247
med:pmid:35115085:sec:introduction:sent:2,med:pmid:35115085,introduction,2,"Through inhibition of neprilysin, Sac/Val may increase BNP concentrations.",248,342
med:pmid:35115085:sec:methods:sent:3,med:pmid:35115085,methods,3,"In an individual patient analysis from the EVALUATE-HF (Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction) (n = 221) and the PROVE-HF (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes) (n = 146) studies, we examined changes in BNP, N-terminal pro-BNP (NT-proBNP), and urinary cyclic guanosine monophosphate (ucGMP) from baseline to week 4 and week 12.",343,845
med:pmid:35115085:sec:results:sent:4,med:pmid:35115085,results,4,"Median (IQRs) concentration of BNP at baseline, week 4, and week 12 were 145 [IQR: 55-329], 136 [IQR: 50-338], and 135 [IQR: 51-299] ng/L, respectively.",846,1015
med:pmid:35115085:sec:results:sent:5,med:pmid:35115085,results,5,There was no significant change from baseline to week 4 (0% [-30% to +41%]; P = 0.36) or week 12 (+1% [-36% to +50%]; P = 0.97).,1016,1144
med:pmid:35115085:sec:results:sent:6,med:pmid:35115085,results,6,"By week 12, one-half of the study participants had a BNP decline.",1145,1210
med:pmid:35115085:sec:results:sent:7,med:pmid:35115085,results,7,There was no association between Sac/Val dose and BNP changes.,1211,1273
med:pmid:35115085:sec:results:sent:8,med:pmid:35115085,results,8,"Change in BNP was directly associated with change in NT-proBNP (rho: = 0.81; P < 0.001), which decreased by -30% (-50% to -8%) and -32% (-54% to -1%) to weeks 4 and 12 (P < 0.001 for both).",1274,1463
med:pmid:35115085:sec:results:sent:9,med:pmid:35115085,results,9,"In contrast, change in BNP was only weakly associated with change in ucGMP (rho: = 0.19; P < 0.001).",1464,1564
med:pmid:35115085:sec:results:sent:10,med:pmid:35115085,results,10,"Increases in ucGMP were observed regardless of whether BNP was decreased (+11% [-34% to +115%]), unchanged (+34% [-15% to +205%]), or increased (+57% [-12% to +14%]).",1565,1731
med:pmid:35115085:sec:conclusion:sent:11,med:pmid:35115085,conclusion,11,"In this pooled analysis of patients with HFrEF with standard indications for Sac/Val treatment, there was no significant overall increase in BNP concentrations, and patients demonstrated increase in ucGMP regardless of the trajectory of BNP change. (",1732,2003
med:pmid:35115085:sec:conclusion:sent:12,med:pmid:35115085,conclusion,12,"Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction [EVALUATE-HF]; NCT02874794) (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183).",2003,2290
med:pmid:35115084:sec:title:sent:0,med:pmid:35115084,title,0,"Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.",0,86
med:pmid:35115084:sec:introduction:sent:1,med:pmid:35115084,introduction,1,The authors sought to examine the effect of dapagliflozin across the spectrum of risk in patients enrolled in DAPA-HF.,0,138
med:pmid:35115084:sec:introduction:sent:2,med:pmid:35115084,introduction,2,"In the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin decreased the risk of worsening HF events and cardiovascular death in patients with HF and reduced ejection fraction.",139,425
med:pmid:35115084:sec:methods:sent:3,med:pmid:35115084,methods,3,The MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) and the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) PREDICT-HF (Risk of Events and Death in the Contemporary Treatment of Heart Failure) risk models were used to categorize patients according to risk score quintiles.,426,806
med:pmid:35115084:sec:methods:sent:4,med:pmid:35115084,methods,4,"The authors analyzed rates of the primary composite outcome of a worsening HF event or cardiovascular death, its components, and all-cause mortality according to risk quintile and whether risk modified the effect of dapagliflozin.",807,1037
med:pmid:35115084:sec:results:sent:5,med:pmid:35115084,results,5,"The MAGGIC score was available for 4,740 of 4,744 patients in DAPA-HF (median score 22 [IQR: 18-25]).",1038,1156
med:pmid:35115084:sec:results:sent:6,med:pmid:35115084,results,6,A1-point increase was associated with an 8.2% (95% CI: 6.9%-9.4%) higher relative risk of the primary endpoint (P < 0.001).,1157,1280
med:pmid:35115084:sec:results:sent:7,med:pmid:35115084,results,7,The benefit of dapagliflozin over placebo for the primary endpoint was similar across the spectrum of MAGGIC risk score (interaction P = 0.71).,1281,1424
med:pmid:35115084:sec:results:sent:8,med:pmid:35115084,results,8,"Applying the overall relative risk reduction (26%) with dapagliflozin added to standard therapy resulted in 7 fewer patients in the highest MAGGIC risk quintile experiencing a primary outcome, compared with 2 in the lowest quintile, per 100 person-years of treatment.",1425,1692
med:pmid:35115084:sec:results:sent:9,med:pmid:35115084,results,9,"The findings with PREDICT-HF were similar, although this model led to better risk discrimination.",1693,1790
med:pmid:35115084:sec:conclusion:sent:10,med:pmid:35115084,conclusion,10,The benefits of dapagliflozin were consistent across the broad spectrum of baseline risk in DAPA-HF.,1791,1912
med:pmid:33119090:sec:title:sent:0,med:pmid:33119090,title,0,Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment.,0,185
med:pmid:33119090:sec:introduction:sent:1,med:pmid:33119090,introduction,1,"Although the beneficial effect of sacubitril/valsartan (SAC/VAL) compared to enalapril was consistent across ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy (NICM) groups, the PARADIGM-HF study did not analyse the effect of ventricular remodelling on patients with different aetiologies, which may affect clinical treatment outcomes.",0,363
med:pmid:33119090:sec:introduction:sent:2,med:pmid:33119090,introduction,2,This study aimed to compare left ventricular ejection fraction (LVEF) following SAC/VAL treatment and its association with clinical outcomes.,364,505
med:pmid:33119090:sec:results:sent:3,med:pmid:33119090,results,3,A total of 1576 patients were analysed.,506,574
med:pmid:33119090:sec:results:sent:4,med:pmid:33119090,results,4,Patients were grouped by LVEF changes following SAC/VAL treatment for 8-month period.,575,660
med:pmid:33119090:sec:results:sent:5,med:pmid:33119090,results,5,"LVEF improvement ≥15% was defined as 'significant improvement', and <5% or worse was classified as 'lack of improvement'.",661,782
med:pmid:33119090:sec:results:sent:6,med:pmid:33119090,results,6,The primary outcome was a composite of cardiovascular death and unplanned hospitalization for heart failure.,783,891
med:pmid:33119090:sec:results:sent:7,med:pmid:33119090,results,7,"Patients with NICM had lower baseline LVEF but improvement was significantly greater comparing to those with ICM (baseline 28.0 ± 7.7% vs. 30.1 ± 7.1%, P < 0.001, LVEF increase of 11.1 ± 12.6% vs. 6.7 ± 10.2%, P < 0.001).",892,1113
med:pmid:33119090:sec:results:sent:8,med:pmid:33119090,results,8,The effect of functional improvement of SAC/VAL on NICM patients showed bimodal distribution.,1114,1207
med:pmid:33119090:sec:results:sent:9,med:pmid:33119090,results,9,"Primary endpoints were inversely associated with LVEF changes in NICM patients: adjusted hazard ratio was 0.42 [95% confidence interval (CI) 0.31-0.58, P < 0.001] for NICM patients with significant improvement, and was 1.73 (95% CI 1.38-2.16, P < 0.001) for NICM patients but lack of improvement.",1208,1504
med:pmid:33119090:sec:results:sent:10,med:pmid:33119090,results,10,Primary endpoints of ICM patients did not demonstrate an association with LVEF changes.,1505,1592
med:pmid:33119090:sec:conclusion:sent:11,med:pmid:33119090,conclusion,11,"Patients with NICM had higher degree of LVEF improvement than those with ICM following SAC/VAL treatment, and significant improvement of LVEF in NICM patients indicates favourable outcome.",1593,1801
med:pmid:36818914:sec:title:sent:0,med:pmid:36818914,title,0,Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion.,0,81
med:pmid:36818914:sec:introduction:sent:1,med:pmid:36818914,introduction,1,"We investigated the pleiotropic effects of an angiotensin receptor-neprilysin inhibitor (ARNi) on collateral-dependent myocardial perfusion in a rat model of coronary arteriogenesis, and performed comprehensive analyses to uncover the underlying molecular mechanisms.",0,287
med:pmid:36818914:sec:methods:sent:2,med:pmid:36818914,methods,2,A rat model of coronary arteriogenesis was established by implanting an inflatable occluder on the left anterior descending coronary artery followed by a 7-day repetitive occlusion procedure (ROP).,288,502
med:pmid:36818914:sec:methods:sent:3,med:pmid:36818914,methods,3,Coronary collateral perfusion was measured by using a myocardial particle infusion technique.,503,596
med:pmid:36818914:sec:methods:sent:4,med:pmid:36818914,methods,4,The putative ARNi-induced pro-arteriogenic effects were further investigated and compared with an angiotensin-converting enzyme inhibitor (ACEi).,597,742
med:pmid:36818914:sec:methods:sent:5,med:pmid:36818914,methods,5,"Expression of the membrane receptors and key enzymes in the natriuretic peptide system (NPS), renin-angiotensin-aldosterone system (RAAS) and kallikrein-kinin system (KKS) were analyzed by quantitative polymerase chain reaction (qPCR) and immunoblot assay, respectively.",743,1013
med:pmid:36818914:sec:methods:sent:6,med:pmid:36818914,methods,6,"Protein levels of pro-arteriogenic cytokines were measured by enzyme-linked immunosorbent assay, and mitochondrial DNA copy number was assessed by qPCR due to their roles in arteriogenesis.",1014,1203
med:pmid:36818914:sec:methods:sent:7,med:pmid:36818914,methods,7,"Furthermore, murine heart endothelial cells (MHEC5-T) were treated with a neprilysin inhibitor (NEPi) alone, or in combination with bradykinin receptor antagonists.",1204,1368
med:pmid:36818914:sec:methods:sent:8,med:pmid:36818914,methods,8,MHEC5-T proliferation was analyzed by colorimetric assay.,1369,1426
med:pmid:36818914:sec:results:sent:9,med:pmid:36818914,results,9,"The <i>in vivo</i> study showed that ARNis markedly improved coronary collateral perfusion, regulated the gene expression of KKS, and increased the concentrations of relevant pro-arteriogenic cytokines.",1427,1646
med:pmid:36818914:sec:results:sent:10,med:pmid:36818914,results,10,"The <i>in vitro</i> study demonstrated that NEPis significantly promoted MHEC5-T proliferation, which was diminished by bradykinin receptor antagonists.",1647,1799
med:pmid:36818914:sec:conclusion:sent:11,med:pmid:36818914,conclusion,11,ARNis improve coronary collateral perfusion and exert pro-arteriogenic effects <i>via</i> the bradykinin receptor signaling pathway.,1800,1952
med:pmid:36712243:sec:title:sent:0,med:pmid:36712243,title,0,Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction.,0,137
med:pmid:36712243:sec:introduction:sent:1,med:pmid:36712243,introduction,1,"In 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from cardiovascular causes more effectively than enalapril (an ACEI) in heart failure patients with reduced ejection fraction (HFrEF).",0,386
med:pmid:36712243:sec:introduction:sent:2,med:pmid:36712243,introduction,2,"Similarly, the PARADIGM-HF trial (Comparison of Sacubitril-Valsartan vs. Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode) came to similar conclusions and extended the PARADIGM-HF trial results in 2019.",387,632
med:pmid:36712243:sec:introduction:sent:3,med:pmid:36712243,introduction,3,"Since then, numerous new studies have provided further insight in HFrEF, sacubitril/valsartan can reduce N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, increase left ventricular ejection fraction (LVEF), reverse ventricular remodeling, and reduce other non-fatal manifestations of clinical deterioration as compared to ACEI/ARB.",633,976
med:pmid:36712243:sec:introduction:sent:4,med:pmid:36712243,introduction,4,"However, few trials have compared the effects of these drugs in patients shortly after AMI.",977,1068
med:pmid:36712243:sec:introduction:sent:5,med:pmid:36712243,introduction,5,"Therefore, it is necessary to further explore the clinical efficacy and safety of sacubitril/valsartan vs. valsartan in patients with AMI.",1069,1207
med:pmid:36712243:sec:methods:sent:6,med:pmid:36712243,methods,6,"We conducted an open-label, prospective, randomized controlled trial to determine the superiority in ameliorating ventricular remodeling and preventing of heart failure in patients with AMI after percutaneous coronary intervention (PCI), 148 patients were randomly assigned (85 to sacubitril/valsartan and 63 to valsartan).",1208,1548
med:pmid:36712243:sec:results:sent:7,med:pmid:36712243,results,7,"LAV, LVDV, and LVSV were all decreased in the sacubitril/valsartan group when compared with before treatment, but there was no difference between the sacubitril/valsartan group and the valsartan group.",1549,1767
med:pmid:36712243:sec:results:sent:8,med:pmid:36712243,results,8,"In addition, compared with before treatment in the sacubitril/valsartan group, the heart global work index (GWI) and the global work efficiency (GWE) increased, while the heart global wasted work (GWW) decreased.",1768,1980
med:pmid:36712243:sec:results:sent:9,med:pmid:36712243,results,9,Patients in the sacubitril/valsartan group have similar MACE and adverse side effects to those in the valsartan group.,1981,2099
med:pmid:36712243:sec:conclusion:sent:10,med:pmid:36712243,conclusion,10,"Sacubitril/valsartan has the same performance as valsartan in inhibiting ventricular remodeling and preventing heart failure after PCI in patients with AMI, and its clinical application is safe.",2100,2314
med:pmid:36712243:sec:conclusion:sent:11,med:pmid:36712243,conclusion,11,It provides a clinical foundation for the application of sacubitril/valsartan in patients with AMI.,2315,2414
med:pmid:36440034:sec:title:sent:0,med:pmid:36440034,title,0,Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.,0,84
med:pmid:36440034:sec:introduction:sent:1,med:pmid:36440034,introduction,1,"Heart failure with preserved ejection fraction (HFpEF), which is a common co-morbidity in patients with maintenance hemodialysis (MHD), results in substantial mortality and morbidity.",0,205
med:pmid:36440034:sec:introduction:sent:2,med:pmid:36440034,introduction,2,"However, there are still no effective therapeutic drugs available for HFpEF currently.",206,292
med:pmid:36440034:sec:introduction:sent:3,med:pmid:36440034,introduction,3,Sacubitril/valsartan has been shown to significantly improve clinical outcomes and reverse myocardial remodeling among patients with heart failure with reduced ejection fraction (HFrEF).,293,479
med:pmid:36440034:sec:introduction:sent:4,med:pmid:36440034,introduction,4,The effect of sacubitril/valsartan in MHD patients with HFpEF remains unclear.,480,558
med:pmid:36440034:sec:introduction:sent:5,med:pmid:36440034,introduction,5,Our study was designed to assess the efficacy and safety of sacubitril/valsartan in MHD patients with HFpEF.,559,667
med:pmid:36440034:sec:methods:sent:6,med:pmid:36440034,methods,6,A total of 247 MHD patients with HFpEF treated with sacubitril/valsartan were included in this retrospective study.,668,800
med:pmid:36440034:sec:methods:sent:7,med:pmid:36440034,methods,7,Patients were followed up regularly after medication treatment.,801,864
med:pmid:36440034:sec:methods:sent:8,med:pmid:36440034,methods,8,"The alterations in clinical, biochemical, and echocardiographic parameters before and after taking sacubitril/valsartan were collected.",865,1000
med:pmid:36440034:sec:methods:sent:9,med:pmid:36440034,methods,9,"In addition, the safety of the sacubitril/valsartan treatment was also assessed.",1001,1081
med:pmid:36440034:sec:methods:sent:10,med:pmid:36440034,methods,10,"Among those 247 patients with MHD, 211 patients were already in treatment with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) before being treated with sacubitril/valsartan.",1082,1293
med:pmid:36440034:sec:methods:sent:11,med:pmid:36440034,methods,11,We also performed an analysis to compare the differences between the 211 patients who had previously received ACEi/ARB treatment and the 36 patients who were sacubitril/valsartan naive.,1294,1479
med:pmid:36440034:sec:results:sent:12,med:pmid:36440034,results,12,"Among those 247 patients with MHD, compared with baseline levels, systolic blood pressure (BP) (149.7 ± 23.6 vs. 137.2 ± 21.0 mmHg, <i>P</i> < 0.001), diastolic BP (90.2 ± 16.1 vs. 84.5 ± 14.1 mmHg, <i>P</i> < 0.001), heart rate (83.5 ± 12.5 vs. 80.0 ± 8.7 bpm, <i>P</i> < 0.001), N-terminal B-type natriuretic peptide precursor (NT-proBNP) [29125.0 (11474.5, 68532.0) vs. 12561.3 (4035.0, 37575.0) pg/ml, <i>P</i> < 0.001], and cardiac troponin I [0.044 (0.025, 0.078) vs. 0.0370 (0.020, 0.064) μg/L, <i>P</i> = 0.009] were markedly decreased after treatment with sacubitril/valsartan.",1480,2083
med:pmid:36440034:sec:results:sent:13,med:pmid:36440034,results,13,New York Heart Association (NYHA) functional class showed a notable trend of improvement after 3-12 months of follow-up.,2084,2204
med:pmid:36440034:sec:results:sent:14,med:pmid:36440034,results,14,"Echocardiographic parameters including left ventricular posterior wall thickness (LVPWT) (11.8 ± 2.0 vs. 10.8 ± 1.9 mm, <i>P</i> < 0.001), intraventricular septal thickness in diastole (11.8 ± 2.0 vs. 11.2 ± 2.0 mm, <i>P</i> < 0.001), left ventricular end-diastolic diameter (53.8 ± 6.9 vs. 51.2 ± 7.1 mm, <i>P</i> < 0.001), left atrial diameter (LAD) (40.5 ± 6.2 vs. 37.2 ± 7.2 mm, <i>P</i> < 0.001), left ventricular end-diastolic volume (LVEDV) [143.0 (111.5, 174.0) vs. 130.0 (105.0, 163.0) ml, <i>P</i> < 0.001], left ventricular end-systolic volume (LVESV) [57.0 (43.0, 82.5) vs. 48.0 (38.0, 74.0) ml, <i>P</i> < 0.001], and pulmonary arterial systolic pressure [39.0 (30.5, 50.0) vs. 28.0 (21.0, 37.5) mmHg, <i>P</i> < 0.001] were significantly reduced after initiating the treatment of sacubitril/valsartan.",2205,3020
med:pmid:36440034:sec:results:sent:15,med:pmid:36440034,results,15,"The parameters of left ventricular diastolic function including E/A ratio [0.8 (0.7, 1.3) vs. 0.9 (0.8, 1.3), <i>P</i> = 0.008], maximal tricuspid regurgitation velocity [2.7 (2.5, 3.2) vs. 2.4 (2.0, 2.8) m/s, <i>P</i> < 0.001], septal e'wave velocity (8.0 ± 0.6 vs. 8.2 ± 0.5 cm/s, <i>P</i> = 0.001), lateral e' wave velocity (9.9 ± 0.8 vs. 10.2 ± 0.7 cm/s, <i>P</i> < 0.001), E/e' [8.3 (6.4, 11.8) vs. 7.2 (6.1, 8.9), <i>P</i> < 0.001], and left atrial volume index (37.9 ± 4.2 vs. 36.4 ± 4.1 ml/m<sup>2</sup>, <i>P</i> < 0.001) were significantly improved by sacubitril/valsartan.",3021,3604
med:pmid:36440034:sec:results:sent:16,med:pmid:36440034,results,16,"Among 211 patients who were already in treatment with ACEi/ARB and 36 patients who were sacubitril/valsartan naive, the improvement of cardiac function demonstrated by clinical outcomes and echocardiographic parameters were similar to the previous one of the 247 MHD patients with HFpEF.",3605,3892
med:pmid:36440034:sec:results:sent:17,med:pmid:36440034,results,17,"During the follow-up, none of the patients showed severe adverse drug reactions.",3893,3973
med:pmid:36440034:sec:conclusion:sent:18,med:pmid:36440034,conclusion,18,Our study suggested that sacubitril/valsartan treatment in MHD patients with HFpEF was effective and safe.,3974,4100
med:pmid:36353496:sec:title:sent:0,med:pmid:36353496,title,0,Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis.,0,131
med:pmid:36353496:sec:abstract:sent:1,med:pmid:36353496,abstract,1,<b>Aim:</b> The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range ejection fractions (HFmrEF) remains unclear.,0,144
med:pmid:36353496:sec:abstract:sent:2,med:pmid:36353496,abstract,2,This study aimed to investigate the effects of ARNI in HFmrEF patients.,145,216
med:pmid:36353496:sec:abstract:sent:3,med:pmid:36353496,abstract,3,"<b>Methods:</b> From inception to 15 February 2022, articles were searched <i>via</i> PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Whip, and Wanfang databases.",217,422
med:pmid:36353496:sec:abstract:sent:4,med:pmid:36353496,abstract,4,"Left ventricular functions, indicators related to HF, quality of life score, 6-Minute Walk Test, total effective rate, mortality, readmission rate, and adverse events were the outcomes.",423,608
med:pmid:36353496:sec:abstract:sent:5,med:pmid:36353496,abstract,5,"Relative risk (RR), weighted mean difference (WMD), and 95% confidence interval (CI) were used to evaluate the outcomes.",609,729
med:pmid:36353496:sec:abstract:sent:6,med:pmid:36353496,abstract,6,The heterogeneity test was conducted for each indicator and measured by I<sup>2</sup> statistics.,730,827
med:pmid:36353496:sec:abstract:sent:7,med:pmid:36353496,abstract,7,Subgroup analysis was performed regarding the type of study and duration of treatment.,828,914
med:pmid:36353496:sec:abstract:sent:8,med:pmid:36353496,abstract,8,"<b>Results:</b> Sixteen studies involving 1,937 patients were included in this study.",915,1000
med:pmid:36353496:sec:abstract:sent:9,med:pmid:36353496,abstract,9,"Our results showed ARNI was likely to improve left ventricular function by increasing the left ventricular ejection fraction (LVEF) (WMD: 2.36, 95%CI: 1.09-3.62), stroke volume (WMD: 16.800, 95%CI: 11.385-22.215), and left ventricular short-axis shortening rate (WMD: 2.05, 95%CI: 0.25-3.86), decreasing left ventricular end-diastolic dimension (WMD: -2.48, 95%CI: -3.83 to -1.13), left atrial diameter (WMD: -2.23, 95%CI: -2.83 to -1.63), C-reactive protein level (WMD: -1.40, 95%CI: -2.62 to -0.18), and N-terminal-pro B-type natriuretic peptide level (WMD: -494.92, 95%CI: -641.34 to -348.50).",1001,1597
med:pmid:36353496:sec:abstract:sent:10,med:pmid:36353496,abstract,10,"ARNI has a higher total effective rate (RR: 1.15, 95%CI: 1.08-1.21), Kansas City cardiomyopathy questionnaire (WMD: 4.13, 95%CI: 3.46-4.81), and 6-Minute Walk Test (WMD: 51.35, 95%CI: 26.99-75.71) compared with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB).",1598,1897
med:pmid:36353496:sec:abstract:sent:11,med:pmid:36353496,abstract,11,"In addition, ARNI decreased the readmission rate (RR: 0.54, 95%CI: 0.43-0.68) (all <i>p</i> < 0.05).",1898,1998
med:pmid:36353496:sec:abstract:sent:12,med:pmid:36353496,abstract,12,"Nevertheless, there were no significant differences in the adverse outcomes.",1999,2075
med:pmid:36353496:sec:abstract:sent:13,med:pmid:36353496,abstract,13,"<b>Conclusion:</b> This meta-analysis suggests ARNI may be an effective strategy with which to improve the left ventricular function, and quality of life, and reduce the readmission rate in HFmrEF patients.",2076,2282
med:pmid:36353496:sec:abstract:sent:14,med:pmid:36353496,abstract,14,"However, long-term clinical studies with large samples are still needed to further explore the efficacy and safety of ARNI compared with ACEI or ARB in the HFmrEF population.",2283,2457
med:pmid:36304540:sec:title:sent:0,med:pmid:36304540,title,0,A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction.,0,170
med:pmid:36304540:sec:introduction:sent:1,med:pmid:36304540,introduction,1,"To systematically review the efficacy and safety of sacubitril and valsartan in treating acute myocardial infarction complicated with heart failure and to observe whether it can further improve patients' cardiac function, delay left ventricular remodeling, and reduce major adverse cardiovascular events (MACEs).",0,331
med:pmid:36304540:sec:methods:sent:2,med:pmid:36304540,methods,2,"Electronic databases including Pubmed, Embase, the Web of Science, Cochrane Library, Scopus, CNKI, Wanfang Data, and VIP were searched.",332,484
med:pmid:36304540:sec:methods:sent:3,med:pmid:36304540,methods,3,The search period was from the establishment of the database to March 2022 to search for relevant controlled trials.,485,601
med:pmid:36304540:sec:methods:sent:4,med:pmid:36304540,methods,4,"Two investigators independently screened the literature, extracted data, and assessed the risk of bias.",602,705
med:pmid:36304540:sec:methods:sent:5,med:pmid:36304540,methods,5,Revman5.3 and Stata14 software were used for statistical analysis.,706,772
med:pmid:36304540:sec:results:sent:6,med:pmid:36304540,results,6,"A total of 13 studies, with 6,968 patients were included.",773,847
med:pmid:36304540:sec:results:sent:7,med:pmid:36304540,results,7,"Meta-analysis results showed that sacubitril-valsartan increased left ventricular ejection fraction (LVEF) and decreased NT-proBNP level was better at 6 months and within 3 months of follow-up compared with the control group (<i>P</i> < 0.00001), but there was no significant difference at the 12-month follow-up (<i>P</i> > 0.05).",848,1179
med:pmid:36304540:sec:results:sent:8,med:pmid:36304540,results,8,"Sacubitril-valsartan reducing LVEDD [<i>MD</i> = -2.55, 95%CI(-3.21, -1.88), <i>P</i> < 0.00001], LVEDVI [<i>MD</i> = -3.61, 95%CI(-6.82, -0.39), <i>P</i> = 0.03], LVESVI [<i>MD</i> = -3.77, 95%CI(-6.05, -1.49), <i>P</i> = 0.001], and increasing the distance of the 6-min walk test [<i>MD</i> = 48.20, 95%CI(40.31, 56.09), <i>P</i> < 0.00001] were more effective.",1180,1543
med:pmid:36304540:sec:results:sent:9,med:pmid:36304540,results,9,"Compared with ACEI/ARB, the use of ARNI can further reduce the total incidence of adverse cardiovascular events [RR = 0.72, 95%CI(0.62, 0.84), <i>P</i><0.0001] and the rate of HF rehospitalization [RR = 0.73, 95%CI(0.61, 0.86), <i>P</i> = 0.0002] in patients with acute myocardial infarction and heart failure; there was no significant difference in the incidence of cardiac death, recurrence of myocardial infarction, and malignant arrhythmia between the experimental group and the control group (<i>P</i> > 0.05).",1544,2059
med:pmid:36304540:sec:results:sent:10,med:pmid:36304540,results,10,"In terms of the incidence of adverse reactions, the incidence of cough in ARNI was lower than that in ACEI/ARB group [RR = 0.69, 95%CI(0.60, 0.80), <i>P</i> < 0.00001], but the incidence of hypotension was higher [RR = 1.29, 95%CI(1.18, 1.41), <i>P</i> < 0.00001], and the adverse reactions of hyperkalemia, angioedema and renal insufficiency were not increased (<i>P</i> > 0.05).",2060,2440
med:pmid:36304540:sec:conclusion:sent:11,med:pmid:36304540,conclusion,11,"The use of sacubitril-valsartan sodium in patients with acute myocardial infarction complicated with heart failure can significantly improve cardiac function and reverse ventricular remodeling, reducing the risk of re-hospitalization for heart failure.",2441,2713
med:pmid:36304540:sec:conclusion:sent:12,med:pmid:36304540,conclusion,12,There is no apparent adverse reaction except easy cause hypotension.,2714,2782
med:pmid:36304540:sec:conclusion:sent:13,med:pmid:36304540,conclusion,13,<h4>Systematic trial registration</h4>[www.,2783,2826
med:pmid:36304540:sec:conclusion:sent:14,med:pmid:36304540,conclusion,14,"ClinicalTrials.gov], identifier [CRD42022322901].",2826,2875
med:pmid:36133814:sec:title:sent:0,med:pmid:36133814,title,0,Cost effectiveness analyses of pharmacological treatments in heart failure.,0,75
med:pmid:36133814:sec:abstract:sent:1,med:pmid:36133814,abstract,1,"In a rapidly growing and aging population, heart failure (HF) has become recognised as a public health concern that imposes high economic and societal costs worldwide.",0,167
med:pmid:36133814:sec:abstract:sent:2,med:pmid:36133814,abstract,2,"HF management stems from the use of highly cost-effective angiotensin converting enzyme inhibitors (ACEi) and β-blockers to the use of newer drugs such as sodium-glucose cotransporter-2 inhibitors (SGLT2i), ivabradine, and vericiguat.",168,402
med:pmid:36133814:sec:abstract:sent:3,med:pmid:36133814,abstract,3,Modelling studies of pharmacological treatments that report on cost effectiveness in HF is important in order to guide clinical decision making.,403,547
med:pmid:36133814:sec:abstract:sent:4,med:pmid:36133814,abstract,4,"Multiple cost-effectiveness analysis of dapagliflozin for heart failure with reduced ejection fraction (HFrEF) suggests that it is not only cost-effective and has the potential to improve long-term clinical outcomes, but is also likely to meet conventional cost-effectiveness thresholds in many countries.",548,853
med:pmid:36133814:sec:abstract:sent:5,med:pmid:36133814,abstract,5,Similar promising results have also been shown for vericiguat while a cost effectiveness analysis (CEA) of empagliflozin has shown cost effectiveness in HF patients with Type 2 diabetes.,854,1040
med:pmid:36133814:sec:abstract:sent:6,med:pmid:36133814,abstract,6,"Despite the recent FDA approval of dapagliflozin and empagliflozin in HF, it might take time for these SGLT2i to be widely used in real-world practice.",1041,1192
med:pmid:36133814:sec:abstract:sent:7,med:pmid:36133814,abstract,7,A recent economic evaluation of vericiguat found it to be cost effective at a higher cost per QALY threshold than SGLT2i.,1193,1314
med:pmid:36133814:sec:abstract:sent:8,med:pmid:36133814,abstract,8,"However, there is a lack of clinical or real-world data regarding whether vericiguat would be prescribed on top of newer treatments or in lieu of them.",1315,1466
med:pmid:36133814:sec:abstract:sent:9,med:pmid:36133814,abstract,9,Sacubitril/valsartan has been commonly compared to enalapril in cost effectiveness analysis and has been found to be similar to that of SGLT2i but was not considered a cost-effective treatment for heart failure with reduced ejection fraction in Thailand and Singapore with the current economic evaluation evidences.,1467,1782
med:pmid:36133814:sec:abstract:sent:10,med:pmid:36133814,abstract,10,"In order for more precise analysis on cost effectiveness analysis, it is necessary to take into account the income level of various countries as it is certainly easier to allocate more financial resources for the intervention, with greater effectiveness, in high- and middle-income countries than in low-income countries.",1783,2104
med:pmid:36133814:sec:abstract:sent:11,med:pmid:36133814,abstract,11,"This review aims to evaluate evidence and cost effectiveness studies in more recent HF drugs i.e., SGLT2i, ARNi, ivabradine, vericiguat and omecamtiv, and gaps in current literature on pharmacoeconomic studies in HF.",2105,2321
med:pmid:36132549:sec:title:sent:0,med:pmid:36132549,title,0,"The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure.",0,167
med:pmid:36132549:sec:introduction:sent:1,med:pmid:36132549,introduction,1,The valsartan-sacubitril therapy improved the outcomes of patients with acute decompensated heart failure (ADHF) of a reduced ejection fraction (HFrEF).,0,172
med:pmid:36132549:sec:introduction:sent:2,med:pmid:36132549,introduction,2,"In ADHF patients with preserved ejection fraction (HFpEF), it is not yet clear whether the same treatment regimen may be safely used to treat ADHF.",173,320
med:pmid:36132549:sec:methods:sent:3,med:pmid:36132549,methods,3,"For this study, HFpEF patients hospitalized due to ADHF were enrolled.",321,408
med:pmid:36132549:sec:methods:sent:4,med:pmid:36132549,methods,4,"Following hemodynamic stabilization, patients were randomized into two groups that were treated with enalapril or sacubitril-valsartan.",409,544
med:pmid:36132549:sec:methods:sent:5,med:pmid:36132549,methods,5,"In this trial, the primary efficacy outcomes were changes in echocardiographic parameters and NT-proBNP levels from baseline to 8 weeks treatment.",545,691
med:pmid:36132549:sec:results:sent:6,med:pmid:36132549,results,6,ARNI treatment resulted in a significant decrease in NT-proBNP levels and an increase in LVEF in patients with HFpEF.,692,826
med:pmid:36132549:sec:results:sent:7,med:pmid:36132549,results,7,"However, HFpEF patients that underwent ARNI treatment achieved better outcomes than did patients that underwent ACEI treatment.",827,954
med:pmid:36132549:sec:conclusion:sent:8,med:pmid:36132549,conclusion,8,"Sacubitril-valsartan treatment, which lowered NT-proBNP levels and improved cardiac function, was more effective in HFpEF patients with acute decompensated heart failure than enalapril.",955,1160
med:pmid:36051320:sec:title:sent:0,med:pmid:36051320,title,0,Characteristics and Outcomes of Heart Failure Patients from a Middle-Income Country: The RECOLFACA Registry.,0,108
med:pmid:36051320:sec:introduction:sent:1,med:pmid:36051320,introduction,1,There is a lack of epidemiological data around heart failure (HF) in Latin America; the potential impact description of this disease in middle-income countries is relevant.,0,192
med:pmid:36051320:sec:introduction:sent:2,med:pmid:36051320,introduction,2,This study aimed to describe the characteristics and healthcare resource utilization patterns of HF patients at baseline and six-month follow-up.,193,357
med:pmid:36051320:sec:methods:sent:3,med:pmid:36051320,methods,3,"This retrospective observational study used data from the RECOLFACA (<i>Registro Colombiano de Falla Cardíaca</i>) registry, which includes data obtained from the examination of clinical records from 2,528 patients in 60 Colombian healthcare institutions.",358,630
med:pmid:36051320:sec:methods:sent:4,med:pmid:36051320,methods,4,Baseline and six-month follow-up data were evaluated from patients with previous hospital admissions due to HF during the 12 months prior to enrollment.,631,783
med:pmid:36051320:sec:results:sent:5,med:pmid:36051320,results,5,"This study analyzed 2,045 patients (42.8% female) with a mean age of 67.71 ± 13.64 years.",784,890
med:pmid:36051320:sec:results:sent:6,med:pmid:36051320,results,6,The most common etiologies were ischemic (44.4%) and hypertensive heart disease (38.5%).,891,979
med:pmid:36051320:sec:results:sent:7,med:pmid:36051320,results,7,"At baseline, 53.4% of patients were classified with NYHA class II, and 73.6% had a reduced left ventricle ejection fraction (LVEF).",980,1111
med:pmid:36051320:sec:results:sent:8,med:pmid:36051320,results,8,"A year prior to entering the registry, patients were hospitalized an average of 1.4 ± 1.1 times due to HF.",1112,1218
med:pmid:36051320:sec:results:sent:9,med:pmid:36051320,results,9,"Prescription of evidence-based treatment at baseline included sacubitril/valsartan (10%), ACEI (33%), ARB (41%), beta-blocker (79%), diuretics (68%), and MRA (56%).",1219,1383
med:pmid:36051320:sec:results:sent:10,med:pmid:36051320,results,10,The average quality of life score measured using the EQ-5D-3L questionnaire was 78.7 ± 20.8 at baseline and 82.3 ± 20.1 at the six-month follow-up.,1384,1531
med:pmid:36051320:sec:results:sent:11,med:pmid:36051320,results,11,The mortality rate was 6.7%.,1532,1560
med:pmid:36051320:sec:conclusion:sent:12,med:pmid:36051320,conclusion,12,The use of information from the RECOLFACA registry allowed characterization as well as analyses of healthcare resource utilization of patients with heart failure in Colombia.,1561,1756
med:pmid:36051320:sec:conclusion:sent:13,med:pmid:36051320,conclusion,13,"The results of this study show that multiple evidence-based treatments for HF are being widely used in Colombia, but there seems to be room for improvement regarding some interventions for the treatment of patients with HF.",1757,1980
med:pmid:36016688:sec:title:sent:0,med:pmid:36016688,title,0,"Effect of Entresto on Clinical Symptoms, Ventricular Remodeling, Rehabilitation, and Hospitalization Rate in Patients with Both Acute Myocardial Infarction and Acute Heart Failure.",0,180
med:pmid:36016688:sec:introduction:sent:1,med:pmid:36016688,introduction,1,"To determine the influence of Entresto on clinical symptoms, ventricular remodeling (VR), and economic stress of patients with both acute myocardial infarction (AMI) and acute heart failure (AHF).",0,215
med:pmid:36016688:sec:methods:sent:2,med:pmid:36016688,methods,2,Totally 120 patients with AMI complicated with AHF admitted to our hospital between January 2017 and August 2019 were enrolled and randomly assigned to an observation group (obs group) and a control group (con group) (each <i>n</i> = 60).,216,471
med:pmid:36016688:sec:methods:sent:3,med:pmid:36016688,methods,3,"The obs group was treated with Entresto, while the other with angiotensin-converting enzyme inhibitors (ACEI).",472,582
med:pmid:36016688:sec:methods:sent:4,med:pmid:36016688,methods,4,"After treatment, the efficacy on both groups was evaluated, and their cardiac function-associated indexes (left ventricular end-systolic diameter (LVESd), left ventricular end-diastolic dimension (LVEDd), left ventricular ejection fraction (LVEF), VR-associated indexes (interventricular septal thickness (IVST), and left ventricular mass index (LVMI)) were determined and compared before treatment and after 1 month of treatment.",583,1013
med:pmid:36016688:sec:methods:sent:5,med:pmid:36016688,methods,5,"Additionally, their NT-pro-BNP, CRP, and TNF-<i>α</i> were tested and compared before and after treatment, and they were also compared in hospitalization time, treatment expense, readmission rate within one year after discharge, and adverse events.",1014,1262
med:pmid:36016688:sec:results:sent:6,med:pmid:36016688,results,6,"After treatment, the obs group showed notably higher efficacy than the con group (<i>P</i> < 0.05).",1263,1379
med:pmid:36016688:sec:results:sent:7,med:pmid:36016688,results,7,"Before treatment, the two groups were not greatly different in LVESd, LVEDd, LVEF, IVST, LVMI, NT-pro BNP, CRP, and TNF-<i>α</i> (all <i>P</i> > 0.05), while after treatment, these indexes of both groups were improved, but the improvement in the obs group was more notable (<i>P</i> < 0.05).",1380,1671
med:pmid:36016688:sec:results:sent:8,med:pmid:36016688,results,8,"Additionally, the hospitalization time, treatment expense, readmission rate one year after discharge, and incidence of adverse events in the obs group were notably lower (all <i>P</i> < 0.05).",1672,1864
med:pmid:36016688:sec:conclusion:sent:9,med:pmid:36016688,conclusion,9,"For patients with both AMI and AHF, Entresto can contribute to strong amelioration of their clinical symptoms and prognosis and ventricular reverse-remodeling, with a high safety, so it is worthy of clinical promotion.",1865,2103
med:pmid:35990986:sec:title:sent:0,med:pmid:35990986,title,0,Angiotensin receptor-neprilysin inhibitor therapy and recurrence of atrial fibrillation after radiofrequency catheter ablation: A propensity-matched cohort study.,0,162
med:pmid:35990986:sec:introduction:sent:1,med:pmid:35990986,introduction,1,"Compared with conventional medicines, angiotensin receptor-neprilysin inhibitor (ARNI) could further improve the prognosis for multiple cardiovascular diseases, such as heart failure, hypertension, and myocardial infarction.",0,244
med:pmid:35990986:sec:introduction:sent:2,med:pmid:35990986,introduction,2,"However, the relationship between ARNI therapy and the recurrence of atrial fibrillation (AF) after radiofrequency catheter ablation is currently unknown.",245,399
med:pmid:35990986:sec:methods:sent:3,med:pmid:35990986,methods,3,This study is a retrospective cohort study.,400,460
med:pmid:35990986:sec:methods:sent:4,med:pmid:35990986,methods,4,Patients with consecutive persistent or paroxysmal AF undergoing first-time radiofrequency ablation were enrolled from February 2018 to October 2021.,461,610
med:pmid:35990986:sec:methods:sent:5,med:pmid:35990986,methods,5,We compared the risk of AF recurrence in patients with catheter ablation who received ARNI with the risk of AF recurrence in those who received the angiotensin-converting enzyme inhibitor (ACEI).,611,806
med:pmid:35990986:sec:methods:sent:6,med:pmid:35990986,methods,6,The propensity-score matched analysis was conducted to examine the effectiveness of ARNI.,807,896
med:pmid:35990986:sec:methods:sent:7,med:pmid:35990986,methods,7,We used a Cox regression model to evaluate AF recurrence events.,897,961
med:pmid:35990986:sec:results:sent:8,med:pmid:35990986,results,8,"Among 679 eligible patients, 155 patients with ARNI treatment and 155 patients with ACEI treatment were included in the analyses.",962,1108
med:pmid:35990986:sec:results:sent:9,med:pmid:35990986,results,9,"At a median follow-up of 228 (196-322) days, ARNI as compared with ACEI was associated with a lower risk of AF recurrence [adjusted hazard ratio (HR), 0.39; 95% confidence interval (CI), 0.24-0.63; <i>p</i> < 0.001].",1109,1325
med:pmid:35990986:sec:results:sent:10,med:pmid:35990986,results,10,"In addition, no interaction was found in the subgroup analysis.",1326,1389
med:pmid:35990986:sec:conclusion:sent:11,med:pmid:35990986,conclusion,11,Angiotensin receptor-neprilysin inhibitor treatment was associated with a decreased risk of AF recurrence after first-time radiofrequency catheter ablation.,1390,1566
med:pmid:35990952:sec:title:sent:0,med:pmid:35990952,title,0,Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials.,0,144
med:pmid:35990952:sec:introduction:sent:1,med:pmid:35990952,introduction,1,Sacubitril/valsartan has been demonstrated to have cardiovascular benefits in patients with chronic heart failure (CHF).,0,134
med:pmid:35990952:sec:introduction:sent:2,med:pmid:35990952,introduction,2,"We aimed to conduct a meta-analysis of its effects on life quality in patients with CHF, in comparison with the angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB).",135,327
med:pmid:35990952:sec:methods:sent:3,med:pmid:35990952,methods,3,"PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched from inception through March 2022 for all relevant randomized controlled trials assessing the impact of sacubitril/valsartan and ACEI/ARB on health-related quality of life (HRQoL) in patients with CHF.",328,657
med:pmid:35990952:sec:methods:sent:4,med:pmid:35990952,methods,4,"Two reviewers independently conducted study selection, data extraction, and assessment of bias and quality of evidence.",658,777
med:pmid:35990952:sec:methods:sent:5,med:pmid:35990952,methods,5,Review Manager 5.3 software was used for meta-analysis.,778,833
med:pmid:35990952:sec:results:sent:6,med:pmid:35990952,results,6,"We included 10 clinical studies involving 10,426 patients with heart failure with reduced ejection fraction (HFrEF) and 7,689 patients with heart failure with preserved ejection fraction (HFpEF).",834,1046
med:pmid:35990952:sec:results:sent:7,med:pmid:35990952,results,7,"Meta-analysis results showed that, in terms of the primary outcome, the sacubitril/valsartan group was superior than the ACEI/ARB group in improving HRQoL of HFrEF, and the difference was statistically significant (SMD 1.26; 95% CI: 0.14, 2.37; <i>p</i> = 0.03), while there was no significant difference between the two groups in HFpEF (SMD 0.37; 95% CI: -0.35, 1.09; <i>p</i> = 0.32).",1047,1433
med:pmid:35990952:sec:results:sent:8,med:pmid:35990952,results,8,"The effect of sacubitril/valsartan on the secondary outcome of the minimal important improvement rate of HRQoL in HFrEF was consistent with the primary outcome, while the effect in HFpEF was not clear.",1434,1635
med:pmid:35990952:sec:results:sent:9,med:pmid:35990952,results,9,The descriptive analysis of individual studies indicated no significant difference in the improvement of 6-min walk distance between the two groups.,1636,1784
med:pmid:35990952:sec:conclusion:sent:10,med:pmid:35990952,conclusion,10,Sacubitril/valsartan is beneficial to improve HRQoL outcome in patients with HFrEF with high quality of evidence.,1785,1918
med:pmid:35990952:sec:conclusion:sent:11,med:pmid:35990952,conclusion,11,"Compared with ACEI/ARB, sacubitril/valsartan was more effective.",1919,1983
med:pmid:35990952:sec:conclusion:sent:12,med:pmid:35990952,conclusion,12,"While in patients with HFpEF, this improvement was similar between the two groups.",1984,2066
med:pmid:35859597:sec:title:sent:0,med:pmid:35859597,title,0,Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.,0,137
med:pmid:35859597:sec:abstract:sent:1,med:pmid:35859597,abstract,1,"<h4>Background and objective</h4> Relevant data of PARADIGM-HF reveals sacubitril/valsartan (SV) therapy led to a greater reduction in the risks of arrhythmia, and sudden cardiac death than angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor inhibitor (ARB) therapy in HFrEF, however, inconsistent results were reported in subsequent studies.",0,358
med:pmid:35859597:sec:abstract:sent:2,med:pmid:35859597,abstract,2,"Here, we conduct a meta-analysis of related randomized controlled trials (RCTs) to evaluate the protective effect of SV on reducing the risk of arrhythmias.",359,515
med:pmid:35859597:sec:results:sent:3,med:pmid:35859597,results,3,"RCTs focused on the difference in therapeutic outcomes between SV and ACEI/ARB were searched from PUBMED, EMBASE, ClinicalTrials.gov, and Cochrane Library.",516,700
med:pmid:35859597:sec:results:sent:4,med:pmid:35859597,results,4,"The results were extracted from each individual study, expressed as binary risk, 95% confidence interval (CI) and relative risk (RR).",701,834
med:pmid:35859597:sec:results:sent:5,med:pmid:35859597,results,5,"Sixteen RCTs including 22, 563 patients met the study criteria.",835,898
med:pmid:35859597:sec:results:sent:6,med:pmid:35859597,results,6,"Compared with ACEI/ARB therapy, SV therapy did significantly reduce in the risks of severe arrhythmias among patients with heart failure with reduced ejection fraction (HFrEF) (RR 0.83, 95% CI 0.73-0.95, <i>p</i> = 0.006), ventricular tachycardia (VT) among patients with HFrEF (RR 0.69, 95% CI 0.51-0.92, <i>p</i> = 0.01), cardiac arrest among patients with heart failure (HF) (RR 0.52, 95% CI 0.37-0.73, <i>p</i> = 0.0002), cardiac arrest among patients with HFrEF (RR 0.49, 95% CI 0.32-0.76, <i>p</i> = 0.001), cardiac arrest or ventricular fibrillation (VF) among patients with HF (RR 0.63, 95% CI 0.48-0.83, <i>p</i> = 0.001), and cardiac arrest or VF among patients with HFrEF (RR 0.65, 95% CI 0.47-0.89, <i>p</i> = 0.008), but reduced the risks of arrhythmias (RR 0.87, 95% CI 0.74-1.01, <i>p</i> = 0.07), atrial arrhythmias (RR 0.98, 95% CI 0.83-1.16, <i>p</i> = 0.85), and atrial fibrillation (RR 0.98, 95% CI 0.82-1.17, <i>p</i> = 0.82) among all patients with no significant between-group difference.",899,1910
med:pmid:35859597:sec:results:sent:7,med:pmid:35859597,results,7,"The merged result was robust after sensitivity analysis, and there was no publication bias.",1911,2002
med:pmid:35859597:sec:conclusion:sent:8,med:pmid:35859597,conclusion,8,"Our meta-analysis provides evidence that, compared with ACEI/ARB, SV can additionally reduce the risks of most arrhythmias, just the significant differences are revealed in reducing the risks of VT, severe arrhythmias, and cardiac arrest in patients with HFrEF.",2003,2284
med:pmid:35859597:sec:conclusion:sent:9,med:pmid:35859597,conclusion,9,"Besides, the positive effect of SV on VF according to statistical result of combining VF with cardiac arrest in patients with HFrEF is credibility.",2285,2432
med:pmid:35546745:sec:title:sent:0,med:pmid:35546745,title,0,An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.,0,147
med:pmid:35546745:sec:introduction:sent:1,med:pmid:35546745,introduction,1,"Hypertension is a leading cause of cardiovascular disease and chronic kidney disease, resulting in premature death and disability.",0,152
med:pmid:35546745:sec:introduction:sent:2,med:pmid:35546745,introduction,2,"The Renin-Angiotensin-Aldosterone System (RAAS) blockers, including Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin Receptor Blockers (ARBs), are used as first-line antihypertensive therapy to treat hypertensive patients with comorbidities, including diabetes, ischemic heart disease, heart failure, and chronic kidney disease.",153,494
med:pmid:35546745:sec:introduction:sent:3,med:pmid:35546745,introduction,3,"The use of RAS blockers is associated with the risks, such as hyperkalemia, angioedema, etc.",495,587
med:pmid:35546745:sec:introduction:sent:4,med:pmid:35546745,introduction,4,"The drugs potentiating them interact pharmacodynamically, resulting in adverse consequences.",588,680
med:pmid:35546745:sec:introduction:sent:5,med:pmid:35546745,introduction,5,This review article focuses on the clinically important drug interactions of RAAS blockers.,681,772
med:pmid:35546745:sec:methods:sent:6,med:pmid:35546745,methods,6,"The electronic databases, such as Medline/PubMed Central/PubMed, Google Scholar, ScienceDirect, Cochrane Library, Directory of Open Access Journals (DOAJ), Embase, and reference lists were searched to identify relevant articles.",773,1032
med:pmid:35546745:sec:results:sent:7,med:pmid:35546745,results,7,"The risk of hyperkalemia may be enhanced potentially in patients receiving a RAS blocker and potassium-sparing diuretics, potassium supplements, trimethoprim, adrenergic betablockers, antifungal agents, calcineurin inhibitors, pentamidine, heparins or an NSAID, concomitantly.",1033,1326
med:pmid:35546745:sec:results:sent:8,med:pmid:35546745,results,8,"The patients taking ACE inhibitors and mTOR inhibitors, DPP4 inhibitors, alteplase, or sacubitril/valsartan concurrently may be at increased risk of developing angioedema.",1327,1498
med:pmid:35546745:sec:conclusion:sent:9,med:pmid:35546745,conclusion,9,"Clinicians, pharmacists, and other healthcare practitioners should be accountable for medication safety.",1499,1623
med:pmid:35546745:sec:conclusion:sent:10,med:pmid:35546745,conclusion,10,"To avoid adverse implications, prescribers and pharmacists must be aware of the drugs that interact with RAAS blockers.",1624,1743
med:pmid:35400328:sec:title:sent:0,med:pmid:35400328,title,0,Effects of Sacubitril/Valsartan &lt;i&gt;Versus&lt;/i&gt; Telmisartan in Type 2 Diabetic or Pre-Diabetic Patients with Hypertension and Without Heart Failure: The Rationale and Design of A Randomized Clinical Trial.,0,215
med:pmid:35400328:sec:introduction:sent:1,med:pmid:35400328,introduction,1,Sacubitril/valsartan has revealed superior glycemic and blood pressure control compared with enalapril and irbesartan in patients with heart failure and type 2 diabetes and in individuals with chronic kidney disease.,0,236
med:pmid:35400328:sec:introduction:sent:2,med:pmid:35400328,introduction,2,"However, whether the effects of sacubitril/valsartan remain the same in those without heart failure is unknown.",237,348
med:pmid:35400328:sec:methods:sent:3,med:pmid:35400328,methods,3,A multicenter randomized double-blinded trial will be carried out in five military hospitals in Taiwan for a period of 1 year.,349,492
med:pmid:35400328:sec:methods:sent:4,med:pmid:35400328,methods,4,Participants with prior cardiovascular diseases and heart failure will be excluded.,493,576
med:pmid:35400328:sec:methods:sent:5,med:pmid:35400328,methods,5,"The purpose of the study is to compare the effects of sacubitril/valsartan (97/103 mg once or twice daily) on the temporal changes in fasting blood glucose, HbA1c, insulin resistance, and blood pressure levels with telmisartan (40 mg once or twice daily) in individuals with stage 1-3 hypertension and newly diagnosed type 2 diabetes or prediabetes who have an HbA1c ≥6.0% and a systolic blood pressure ≥130 mmHg or a diastolic blood pressure ≥85 mmHg.",577,1029
med:pmid:35400328:sec:methods:sent:6,med:pmid:35400328,methods,6,"The inclusion criteria include the age of 35-70 years, women who are not pregnant, estimated glomerular filtration rate ≥45 ml/min per 1.73m<sup>2</sup>, and B-type natriuretic peptide levels <400 pg/ml.",1030,1233
med:pmid:35400328:sec:results:sent:7,med:pmid:35400328,results,7,"The sample size is estimated to be 502 participants for randomization according to an assumption of between-person standard deviation in systolic blood pressure of 15 mmHg or in HbA1c of 1.5%, which provides ≥80% power (at p =0.05) to detect a difference in systolic blood pressure of 4 mmHg or in HbA1c of 0.3% at the final follow-up.",1234,1586
med:pmid:35400328:sec:results:sent:8,med:pmid:35400328,results,8,"All participants will receive a comprehensive physical examination and tests for blood cell counts, blood biochemistry, urine analysis, 12-lead electrocardiography, and an echocardiography every 3 months.",1587,1791
med:pmid:35400328:sec:conclusion:sent:9,med:pmid:35400328,conclusion,9,All analyses will be performed based on the intention-to-treat principle among all randomized participants.,1792,1919
med:pmid:35360037:sec:title:sent:0,med:pmid:35360037,title,0,Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.,0,184
med:pmid:35360037:sec:introduction:sent:1,med:pmid:35360037,introduction,1,Data regarding using angiotensin receptor-neprilysin inhibitor (ARNI) in patients with both heart failure with reduced ejection fraction (HFrEF) and advanced chronic kidney disease (CKD) are limited.,0,219
med:pmid:35360037:sec:results:sent:2,med:pmid:35360037,results,2,"Between January 2016 and December 2018, patients with HFrEF and advanced CKD (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min/1.73 m<sup>2</sup>) were identified from a multi-institutional database in Taiwan.",220,465
med:pmid:35360037:sec:results:sent:3,med:pmid:35360037,results,3,"Patients who had never been prescribed with an ARNI, angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB) were excluded.",466,619
med:pmid:35360037:sec:results:sent:4,med:pmid:35360037,results,4,"We used inverse probability of treatment weighting (IPTW) to balance baseline covariates, and compared outcomes between ARNI and ACEI/ARB users.",620,764
med:pmid:35360037:sec:results:sent:5,med:pmid:35360037,results,5,There were 206 patients in the ARNI group and 833 patients in the ACEI/ARB group.,765,846
med:pmid:35360037:sec:results:sent:6,med:pmid:35360037,results,6,"After IPTW adjustment, the mean ages (65.1 vs. 66.6 years), male patients (68.3 vs. 67.9%), left ventricular ejection fraction (30.5 vs.31.2%), eGFR (20.9 vs. 20.3 mL/min/1.73 m<sup>2</sup>) were comparable in the ARNI and ACEI/ARB groups.",847,1086
med:pmid:35360037:sec:results:sent:7,med:pmid:35360037,results,7,Over 85% of the patients had beta-blockers prescriptions in both groups (86.2 vs. 85.5%).,1087,1176
med:pmid:35360037:sec:results:sent:8,med:pmid:35360037,results,8,"After IPTW adjustment, the mean follow-up durations were 7.3 months and 6.6 months in the ARNI and ACEI/ARB groups, respectively.",1177,1306
med:pmid:35360037:sec:results:sent:9,med:pmid:35360037,results,9,"ARNI and ACEI/ARB users had a comparable risk of the composite clinical event (all-cause mortality or heart failure hospitalization) (hazard ratio [HR], 1.31; 95% confidence interval (CI) 0.91-1.88) and progression to dialysis (HR 1.04; 95% CI 0.54-2.03).",1307,1562
med:pmid:35360037:sec:results:sent:10,med:pmid:35360037,results,10,"In subgroup analysis, dialysis patients who used ARNIs were associated with higher incidence of heart failure hospitalization (subdistribution HR, 1.97; 95% CI 1.36-2.85).",1563,1734
med:pmid:35360037:sec:conclusion:sent:11,med:pmid:35360037,conclusion,11,"Compared with ACEIs or ARBs, ARNIs were associated with comparable clinical and renal outcomes in patients with HFrEF and advanced CKD (eGFR ≤ 30 mL/min/1.73 m<sup>2</sup>).",1735,1929
med:pmid:35360037:sec:conclusion:sent:12,med:pmid:35360037,conclusion,12,"In short-term, HF hospitalization may occur more frequently among ARNI users, especially in patients on dialysis.",1930,2043
med:pmid:35350535:sec:title:sent:0,med:pmid:35350535,title,0,Trends in Transcatheter Edge-to-Edge Mitral Valve Repair Over a Decade: Data From the MiTra ULM Registry.,0,105
med:pmid:35350535:sec:introduction:sent:1,med:pmid:35350535,introduction,1,This study sought to determine the potential change in trends in the baseline characteristics of patients with symptomatic severe mitral regurgitation who underwent transcatheter edge-to-edge mitral valve repair (M-TEER) over the last decade in a high-volume center.,0,285
med:pmid:35350535:sec:methods:sent:2,med:pmid:35350535,methods,2,The investigation included 942 symptomatic patients with moderate-to-severe and severe mitral regurgitation who underwent transcatheter edge-to-edge repair (TEER) at our institution between January 2010 and March 2021.,286,525
med:pmid:35350535:sec:methods:sent:3,med:pmid:35350535,methods,3,Patients were divided into quintiles and compared separately.,526,587
med:pmid:35350535:sec:results:sent:4,med:pmid:35350535,results,4,"Patients treated in the last quintile had significantly lower surgical risk (Euro Score 7.2 ± 6.8% in the last quintile vs. 10.9 ± 9.4% in the first quintile, <i>p</i> < 0.001), better New York Heart Association (NYHA) status (NYHA IV 14% in the last quintile vs. 40% in the first quintile, <i>p</i> < 0.001), lower NT-pro-BNP, and smaller left ventricle diameter than patients who were treated in the first quintile.",588,1022
med:pmid:35350535:sec:results:sent:5,med:pmid:35350535,results,5,There was no difference in age between quintiles.,1023,1072
med:pmid:35350535:sec:results:sent:6,med:pmid:35350535,results,6,"However, an invasive hemodynamic assessment did not show significant changes over the last decade (sPAP 51.35 ± 16.2 mmHg in the first quintile vs. 51.02 ± 14.5 mmHg in the last quintile, <i>p</i> = 0.90, pulmonary capillary wedge V wave 30.7 ± 14.8 mmHg in the first quintile vs. 27.4 ± 10.3 mmHg in the last quintile, <i>p</i> = 0.40).",1073,1410
med:pmid:35350535:sec:results:sent:7,med:pmid:35350535,results,7,There is a significant trend of a gradually increasing proportion of patients with degenerative mitral regurgitation (MR) over the last 10 years (<i>p</i> < 0.001).,1411,1575
med:pmid:35350535:sec:results:sent:8,med:pmid:35350535,results,8,The experience gained in the M-TEER procedure brought a significant reduction in fluoroscopy time and hospitalization duration.,1576,1703
med:pmid:35350535:sec:results:sent:9,med:pmid:35350535,results,9,"Medical therapy significantly changed over the last decade in terms of higher use of angiotensin receptor blockers (ARBs), lower use of angiotensin-converting enzyme inhibitors (ACEIs), and the introduction of angiotensin receptor-neprilysin inhibitors (ARNIs).",1704,1965
med:pmid:35350535:sec:conclusion:sent:10,med:pmid:35350535,conclusion,10,Patients undergoing the M-TEER procedure nowadays have lower surgical risk and are treated before they develop a significant left ventricular (LV) remodeling than before.,1966,2156
med:pmid:35350535:sec:conclusion:sent:11,med:pmid:35350535,conclusion,11,The increasing expertise on the procedure over the last decade led to a rising number of patients with complex degenerative pathology being treated.,2157,2305
med:pmid:35232346:sec:title:sent:0,med:pmid:35232346,title,0,Sex Differences in Therapies for Heart Failure.,0,47
med:pmid:35232346:sec:abstract:sent:1,med:pmid:35232346,abstract,1,Heart failure (HF) is a common cause of morbimortality with different etiopathogenesis and prognosis between men and women.,0,123
med:pmid:35232346:sec:abstract:sent:2,med:pmid:35232346,abstract,2,This review provides a brief overview of gender-based differences in response to pharmacological therapies of heart failure with or without reduced ejection fraction (EF).,124,295
med:pmid:35232346:sec:abstract:sent:3,med:pmid:35232346,abstract,3,"It focuses on the differences in therapy outcomes with angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), angiotensin neprilysin inhibitors (ARNI), beta-adrenergic blockers, mineralocorticoid/ aldosterone receptor antagonists, diuretics, ivabradine and digoxin.",296,593
med:pmid:35232346:sec:abstract:sent:4,med:pmid:35232346,abstract,4,The baseline data originate from randomised controlled trials (RCTs) and large registries.,594,684
med:pmid:35232346:sec:abstract:sent:5,med:pmid:35232346,abstract,5,"We conclude that current guidelines recommending similar therapeutic approaches for both men and women are appropriate, while additional consideration should be given to different approaches regarding the use of ARBs, ACEi, and digoxin.",685,921
med:pmid:35232346:sec:abstract:sent:6,med:pmid:35232346,abstract,6,"Based on the available data, the ARBs might be considered a first-line therapy of HR for women instead of ACEi.",922,1033
med:pmid:35232346:sec:abstract:sent:7,med:pmid:35232346,abstract,7,"Moreover, female patients should have stricter digoxin monitoring due to higher sensitivity and increased risk of complications.",1034,1162
med:pmid:35232346:sec:abstract:sent:8,med:pmid:35232346,abstract,8,"Finally, women are underrepresented in current clinical trials, and therefore future trials should aim to balance the gender recruitment disparity allowing sub-group analysis and comparisons between genders to guide individualised therapeutic strategies and appropriately targeted preventative steps.",1163,1463
med:pmid:35222898:sec:title:sent:0,med:pmid:35222898,title,0,"The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.",0,175
med:pmid:35222898:sec:introduction:sent:1,med:pmid:35222898,introduction,1,Sacubitril valsartan and valsartan are the first new drugs approved for angiotensin receptor neprilysin lysine inhibitors (ARNIs) in outpatients with chronic heart failure (CHF) and hypertension.,0,215
med:pmid:35222898:sec:introduction:sent:2,med:pmid:35222898,introduction,2,"Compared with enalapril, sacubitril valsartan and valsartan have been shown to reduce the mortality and morbidity of cardiovascular diseases.",216,357
med:pmid:35222898:sec:introduction:sent:3,med:pmid:35222898,introduction,3,"However, there is little actual evidence regarding the efficacy of ARNIs in hypertensive patients with CHF.",358,465
med:pmid:35222898:sec:methods:sent:4,med:pmid:35222898,methods,4,"From January 2019 to January 2021, 60 patients with hypertension and chronic heart failure were diagnosed and treated in our hospital.",466,617
med:pmid:35222898:sec:methods:sent:5,med:pmid:35222898,methods,5,"The patients were randomly divided into an observation group and a control group, with 30 cases in each group.",618,728
med:pmid:35222898:sec:methods:sent:6,med:pmid:35222898,methods,6,"The control group was given valsartan, the observation group was given sacubitril valsartan, and both groups were treated for six months.",729,866
med:pmid:35222898:sec:methods:sent:7,med:pmid:35222898,methods,7,"The endothelium-dependent vasodilation (EDD) function of the brachial artery and serum nitric oxide (NO), endothelin-1 (ET-1), carotid artery intima-media thickness, and glomerular filtration, excess rate (eGFR), and left ventricular ejection fraction (LVEF) were compared between the two groups of patients before and after treatment.",867,1202
med:pmid:35222898:sec:methods:sent:8,med:pmid:35222898,methods,8,"The serum adiponectin (APN), matrix metalloproteinase-9 (MMP-9), and brain natriuretic peptide (BNP) levels were compared before and after treatment.",1203,1352
med:pmid:35222898:sec:results:sent:9,med:pmid:35222898,results,9,The total effective rate of treatment in the research group was higher than that in the control group (<i>P</i> < 0.05).,1353,1490
med:pmid:35222898:sec:results:sent:10,med:pmid:35222898,results,10,"After treatment, the cardiac function indexes LVESD and LVEDD of the two groups of patients were lower than before treatment, and LVEF was higher than before treatment, and the improvement rate of the treatment group was better than that of the control group (<i>P</i> < 0.05).",1491,1768
med:pmid:35222898:sec:results:sent:11,med:pmid:35222898,results,11,"After treatment, the serum APN of the two groups was higher than before treatment, the levels of MMP-9 and BNP were lower than before treatment, and the improvement rate of patients in the treatment group was better than that of patients in the control group (<i>P</i> < 0.05).",1769,2046
med:pmid:35222898:sec:results:sent:12,med:pmid:35222898,results,12,"There was no statistically significant in the levels of EDD, NO, and ET-1 of the two groups of patients before treatment (<i>P</i> < 0.05).",2047,2186
med:pmid:35222898:sec:results:sent:13,med:pmid:35222898,results,13,"After treatment, compared with the control group, the EDD function and NO level of the research group were significantly increased (<i>P</i> < 0.05), and the level of ET-1 was significantly reduced (<i>P</i> < 0.05).",2187,2403
med:pmid:35222898:sec:results:sent:14,med:pmid:35222898,results,14,"There was no statistically significant difference in carotid artery intima-media thickness, glomerular filtration rate, and left ventricular ejection fraction before and after treatment in the two groups (<i>P</i> < 0.05).",2404,2626
med:pmid:35222898:sec:conclusion:sent:15,med:pmid:35222898,conclusion,15,"In the treatment of hypertension and chronic heart failure, sacubitril valsartan can improve the clinical symptoms of patients to the greatest extent and can significantly improve the levels of LVEF, LVEDD, NT-proBNP, heart function, and other indicators.",2627,2902
med:pmid:35222898:sec:conclusion:sent:16,med:pmid:35222898,conclusion,16,"Sacubitril valsartan can increase serum APN levels, reduce MMP-9 and BNP levels, and have good clinical effects.",2903,3015
med:pmid:35222898:sec:conclusion:sent:17,med:pmid:35222898,conclusion,17,Sacubitril valsartan has a protective effect on the vascular endothelial function of patients with hypertension and CHF.,3016,3136
med:pmid:35222898:sec:conclusion:sent:18,med:pmid:35222898,conclusion,18,"However, these results need to be confirmed in studies involving more subjects and require longer follow-up times.",3137,3251
med:pmid:35159990:sec:title:sent:0,med:pmid:35159990,title,0,Adaptive Servo-Ventilation as a Novel Therapeutic Strategy for Chronic Heart Failure.,0,85
med:pmid:35159990:sec:abstract:sent:1,med:pmid:35159990,abstract,1,"The introduction of new therapeutics for patients with chronic heart failure, including sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, and ivabradine, in addition to beta-blockers, angiotensin converting enzyme inhibitors, and mineralocorticoid receptor antagonists, lends an opportunity for significant clinical risk reduction compared to what was available just one decade ago.",0,397
med:pmid:35159990:sec:abstract:sent:2,med:pmid:35159990,abstract,2,"Further clinical options are needed, however, for patients with residual clinical congestion refractory to these therapies.",398,521
med:pmid:35159990:sec:abstract:sent:3,med:pmid:35159990,abstract,3,Adaptive servo-ventilation is a novel therapeutic option to address significant clinical volume in cases resistant to medical therapy.,522,656
med:pmid:35159990:sec:abstract:sent:4,med:pmid:35159990,abstract,4,The aggregate benefit of these additional therapeutic strategies in addition to foundational medical therapy may be a promising option in the selected candidates who do not achieve acceptable clinical and quality-of-life improvements with oral medical therapy alone.,657,923
med:pmid:35159990:sec:abstract:sent:5,med:pmid:35159990,abstract,5,Now is the era to reconsider the implication of an adaptive servo-ventilation-therapy-incorporated medical therapeutic strategy for patients with congestive heart failure.,924,1095
med:pmid:35081164:sec:title:sent:0,med:pmid:35081164,title,0,Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.,0,183
med:pmid:35081164:sec:introduction:sent:1,med:pmid:35081164,introduction,1,Heart failure (HF) and atrial fibrillation (AF) are often coexisting.,0,88
med:pmid:35081164:sec:introduction:sent:2,med:pmid:35081164,introduction,2,They have common risk factors and pathophysiologic mechanisms.,89,151
med:pmid:35081164:sec:introduction:sent:3,med:pmid:35081164,introduction,3,Sacubitril/valsartan has shown efficacy and tolerability in patients with HF.,152,229
med:pmid:35081164:sec:introduction:sent:4,med:pmid:35081164,introduction,4,"Thus, the study was performed to evaluate the impact of sacubitril/valsartan on AF occurrence in patients with HF.",230,344
med:pmid:35081164:sec:methods:sent:5,med:pmid:35081164,methods,5,The Embase and PubMed were searched from their inception date to June 2021 for all relevant randomized controlled trials (RCTs) evaluating the efficacy of sacubitril/valsartan in HF.,345,544
med:pmid:35081164:sec:methods:sent:6,med:pmid:35081164,methods,6,The outcome of interest was the AF occurrence during the follow-up.,545,612
med:pmid:35081164:sec:methods:sent:7,med:pmid:35081164,methods,7,Relative risks (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model.,613,711
med:pmid:35081164:sec:results:sent:8,med:pmid:35081164,results,8,"Six trials involving a total of 15,512 patients were included (7,750 randomized to sacubitril/valsartan and 7,762 to control).",712,855
med:pmid:35081164:sec:results:sent:9,med:pmid:35081164,results,9,"All trials were randomized, double-blind, and active-control.",856,917
med:pmid:35081164:sec:results:sent:10,med:pmid:35081164,results,10,"There was no significant difference in the prevention of AF occurrence between the sacubitril/valsartan group and the control group (enalapril or valsartan) in patients with HF (RR 1.07, 95%CI 0.95 to 1.19; I2 4%).",918,1132
med:pmid:35081164:sec:conclusion:sent:11,med:pmid:35081164,conclusion,11,Sacubitril/valsartan was similar to either enalapril or valsartan in preventing the occurrence of AF in patients with HF.,1133,1275
med:pmid:35035857:sec:title:sent:0,med:pmid:35035857,title,0,Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis.,0,122
med:pmid:35035857:sec:abstract:sent:1,med:pmid:35035857,abstract,1,Patients who develop heart failure (HF) after an acute myocardial infarction (AMI) are at higher risk of adverse fatal and nonfatal outcomes.,0,141
med:pmid:35035857:sec:abstract:sent:2,med:pmid:35035857,abstract,2,Studies have shown sacubitril/valsartan can further reduce the risk of cardiovascular death or hospitalization for heart failure by 20% compared with enalapril.,142,302
med:pmid:35035857:sec:abstract:sent:3,med:pmid:35035857,abstract,3,"At the same time, its tolerance and safety are better.",303,357
med:pmid:35035857:sec:abstract:sent:4,med:pmid:35035857,abstract,4,"However, the current evidence regarding the efficacy of sacubitril/valsartan in patients with heart failure after acute myocardial infarction is controversial.",358,517
med:pmid:35035857:sec:abstract:sent:5,med:pmid:35035857,abstract,5,"To assess the effect of sacubitril/valsartan on heart failure after acute myocardial infarction, we conducted a systematic review of the literature and a meta-analysis of existing randomized clinical trials.",518,725
med:pmid:35035857:sec:abstract:sent:6,med:pmid:35035857,abstract,6,"Meta-analysis of randomized controlled trails is used where data are collected from PubMed, the Cochrane library, Embase, and Web of Science.",726,867
med:pmid:35035857:sec:results:sent:7,med:pmid:35035857,results,7,about sacubitril/valsartan were available from 5 studies.,868,930
med:pmid:35035857:sec:results:sent:8,med:pmid:35035857,results,8,"Forest plots showed that the sacubitril/valsartan group had a 299% higher value of sacubitril/valsartan to the control group (MD = 2.99%, 95% CI: 2.01, 3.96, <i>I</i> <sup>2</sup> = 78%, <i>P</i> < 0.00001, Figure 2), and the difference was statistically significant.",931,1198
med:pmid:35035857:sec:results:sent:9,med:pmid:35035857,results,9,"Forest plots showed that the sacubitril/valsartan group had a 531% lower value of LVEF to the control group (MD = -5.31%, 95% CI: -7.36, -3.26, <i>I</i> <sup>2</sup> = 91%, <i>P</i> < 0.00001, Figure 2), and the difference was statistically significant.",1199,1452
med:pmid:35035857:sec:results:sent:10,med:pmid:35035857,results,10,"Forest plots showed that the sacubitril/valsartan group had a 133% lower value of NT-proBNP to the control group (MD = -1.33%, 95% CI: -1.54, -1.12, <i>I</i> <sup>2</sup> = 96%, <i>P</i> < 0.00001, Figure 3).",1453,1661
med:pmid:35035857:sec:results:sent:11,med:pmid:35035857,results,11,"Forest plots showed that the sacubitril/valsartan group had a 49% lower risk of heart failure to the control group (MD = 0.49, 95% CI: 0.27, 0.89, <i>I</i> <sup>2</sup> = 0%, <i>P</i>=0.02, Figure 3).",1662,1862
med:pmid:35035857:sec:results:sent:12,med:pmid:35035857,results,12,"The patients in experimental showed an obviously lower OR of MACE (OR = 0.47, 95% CI: 0.27, 0.82, <i>P</i>=0.007, Figure 3).",1863,1987
med:pmid:35035857:sec:results:sent:13,med:pmid:35035857,results,13,The data were statistically significant.,1988,2028
med:pmid:35035857:sec:results:sent:14,med:pmid:35035857,results,14,"We have observed that for patients with heart failure after acute myocardial infarction, early administration of sacubitril/valsartan can significantly reduce the incidence of heart rate, left ventricular ejection fraction, NT-proBNP, and MACE.",2029,2273
med:pmid:35035857:sec:results:sent:15,med:pmid:35035857,results,15,"Our meta-analysis suggests that taking sacubitril/valsartan is relatively safe and effective, especially if started early after acute myocardial infarction.",2274,2430
med:pmid:34994233:sec:title:sent:0,med:pmid:34994233,title,0,The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review.,0,84
med:pmid:34994233:sec:abstract:sent:1,med:pmid:34994233,abstract,1,Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.,0,85
med:pmid:34994233:sec:abstract:sent:2,med:pmid:34994233,abstract,2,"Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF.",86,196
med:pmid:34994233:sec:abstract:sent:3,med:pmid:34994233,abstract,3,"At present, there have been few systematic and detailed reviews discussing the efficacy and safety of sacubitril/valsartan in HF.",197,326
med:pmid:34994233:sec:abstract:sent:4,med:pmid:34994233,abstract,4,"In this review, we first introduced the pharmacological mechanisms of sacubitril/valsartan, including the reduction in the degradation of natriuretic peptides in the natriuretic peptide system and inhibition of the renin-angiotensin system.",327,567
med:pmid:34994233:sec:abstract:sent:5,med:pmid:34994233,abstract,5,"Then, we summarized the efficacy of sacubitril/valsartan in HF patients with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) including the reduction in risks of mortality and hospitalization, reversal of cardiac remodeling, regulation of biomarkers of HF, improvement of the quality of life, antiarrhythmia, improving renal dysfunction and regulation of metabolism.",568,958
med:pmid:34994233:sec:abstract:sent:6,med:pmid:34994233,abstract,6,"Finally, we discussed the safety and tolerability of sacubitril/valsartan in the treatment of HFrEF or HFpEF.",959,1068
med:pmid:34994233:sec:abstract:sent:7,med:pmid:34994233,abstract,7,"Compared with ACEIs/ARBs or placebo, sacubitril/valsartan showed good safety and tolerability, although the risk of hypotension might be high.",1069,1211
med:pmid:34994233:sec:abstract:sent:8,med:pmid:34994233,abstract,8,"In conclusion, the overwhelming majority of studies show that sacubitril/valsartan is effective and safe in the treatment of HFrEF patients but that it has little benefit in HFpEF patients.",1212,1401
med:pmid:34994233:sec:abstract:sent:9,med:pmid:34994233,abstract,9,Sacubitril/valsartan will probably be a promising anti-HF drug in the near future.,1402,1484
med:pmid:34986674:sec:title:sent:0,med:pmid:34986674,title,0,Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.,0,170
med:pmid:34986674:sec:abstract:sent:1,med:pmid:34986674,abstract,1,"Advances in cancer therapy have resulted in more cancer therapy-related cardiac dysfunction (CTRCD), which is the main cause of death in older female survivors of breast cancer.",0,177
med:pmid:34986674:sec:abstract:sent:2,med:pmid:34986674,abstract,2,"Traditionally, guideline-recommended medications for heart failure, such as beta-blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), are commonly used to prevent or attenuate CTRCD.",178,405
med:pmid:34986674:sec:abstract:sent:3,med:pmid:34986674,abstract,3,"However, sometimes their effectiveness is not satisfactory.",406,465
med:pmid:34986674:sec:abstract:sent:4,med:pmid:34986674,abstract,4,"Recently, the drug combination of sacubitril plus valsartan has been proven to be more beneficial for heart failure with reduced ejection fraction in the long term compared with an ACEI/ARB alone.",466,662
med:pmid:34986674:sec:abstract:sent:5,med:pmid:34986674,abstract,5,"However, there is a lack of evidence of the efficacy and safety of this drug combination in CTRCD.",663,761
med:pmid:34986674:sec:abstract:sent:6,med:pmid:34986674,abstract,6,"We report a case of worsening CTRCD, despite treatment with traditional medications, in which the patient improved after changing perindopril to sacubitril/valsartan.",762,928
med:pmid:34986674:sec:abstract:sent:7,med:pmid:34986674,abstract,7,The patient's heart function greatly improved after changing this ACEI to sacubitril/valsartan.,929,1024
med:pmid:34986674:sec:abstract:sent:8,med:pmid:34986674,abstract,8,Changing an ACEI/ARB to sacubitril/valsartan in patients with worsening chemotherapy-induced heart failure is appropriate.,1025,1147
med:pmid:34986674:sec:abstract:sent:9,med:pmid:34986674,abstract,9,Further studies with a high level of evidence are required to assess the efficacy and safety of sacubitril/valsartan for CTRCD.,1148,1275
med:pmid:34632983:sec:title:sent:0,med:pmid:34632983,title,0,Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan.,0,121
med:pmid:34632983:sec:introduction:sent:1,med:pmid:34632983,introduction,1,"The aim of this study was to determine the degree of short-term improvement in left ventricular ejection fraction (LVEF), haemodynamics, NT-proBNP and quality of life following initiation of sacubitril/valsartan in black patients when compared with white patients.",0,278
med:pmid:34632983:sec:methods:sent:2,med:pmid:34632983,methods,2,"This was a retrospective, observational, single-centre, hypothesis-generating study of patients with symptomatic heart failure and reduced ejection fraction (HFrEF) treated with guideline recommended therapy, who were transitioned from an ACE inhibitor (ACE-I) or angiotensin receptor blocker (ARB) to sacubitril/valsartan.",279,619
med:pmid:34632983:sec:results:sent:3,med:pmid:34632983,results,3,"Our analysis included 83 patients (mean age 57 years) with echocardiography performed before and after transition from ACE-I/ARB to sacubitril/valsartan, after excluding patients with concomitant Cardiac resynchronization therapy implantation.",620,880
med:pmid:34632983:sec:results:sent:4,med:pmid:34632983,results,4,"Overall, sacubitril/valsartan was associated with LVEF improvement from 28.8% ± 0.7 to 32.0% ± 1.1% (P = 0.0002), but no reverse remodelling was observed.",881,1035
med:pmid:34632983:sec:results:sent:5,med:pmid:34632983,results,5,"The association with LVEF improvement was only observed in white patients (n = 46, P = 0.0006), but not in black patients (n = 37, P = 0.1728), and appeared to be associated with reduced blood pressure (baseline vs. 2-week blood pressure 116.5 ± 13.9 vs. 109.4 ± 14.3 mmHg, respectively, in white patients, P = 0.0449).",1036,1355
med:pmid:34632983:sec:results:sent:6,med:pmid:34632983,results,6,Fifteen patients (18.1%) became ineligible for primary prevention Implantable cardioverter defibrillator implantation.,1356,1474
med:pmid:34632983:sec:conclusion:sent:7,med:pmid:34632983,conclusion,7,"Sacubitril/valsartan was associated with improved LVEF, NT-proBNP concentrations and quality of life in patients with symptomatic HFrEF on guideline recommended therapy.",1475,1664
med:pmid:34632983:sec:conclusion:sent:8,med:pmid:34632983,conclusion,8,"However, in our cohort, improvement of LVEF and quality of life might be attenuated in black patients, which warrants further investigation.",1665,1805
med:pmid:35097007:sec:title:sent:0,med:pmid:35097007,title,0,Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis.,0,94
med:pmid:35097007:sec:abstract:sent:1,med:pmid:35097007,abstract,1,<b>Background:</b> The medical treatments of chronic heart failure have made remarkable progress in recent years.,0,113
med:pmid:35097007:sec:abstract:sent:2,med:pmid:35097007,abstract,2,It is crucial to determine the optimal drug combination based on current evidence.,114,196
med:pmid:35097007:sec:abstract:sent:3,med:pmid:35097007,abstract,3,"<b>Methods:</b> A search of PubMed, EMBASE, and Cochrane CENTRAL databases was conducted for studies on angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter 2 inhibitors (SGLT2is), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and ivabradine (IVA) between 1987 and 2021.",197,605
med:pmid:35097007:sec:abstract:sent:4,med:pmid:35097007,abstract,4,The network meta-analysis was performed to compare the efficacy of drug therapies in heart failure with reduced ejection fraction (HFrEF).,606,744
med:pmid:35097007:sec:abstract:sent:5,med:pmid:35097007,abstract,5,"<b>Results:</b> Forty-eight randomized controlled trials (RCTs), which overall included 68,074 patients with HF and left ventricular ejection fraction (LVEF) ≤ 40%, were identified and included in the network meta-analysis.",745,968
med:pmid:35097007:sec:abstract:sent:6,med:pmid:35097007,abstract,6,"The efficacies of 13 intervention classes, including monotherapies or combinations of ACEI, ARB, ARNI, BB, MRA, SGLT2i, IVA, and placebo, on hospitalization for HF, cardiovascular mortality, and all-cause mortality were compared.",969,1198
med:pmid:35097007:sec:abstract:sent:7,med:pmid:35097007,abstract,7,"Among the 13 included interventions, ARNI+BB+MRA, SGLT2i+ACEI+BB+MRA, and IVA+ACEI+BB+MRA were found to be best in terms of all three outcomes.",1199,1342
med:pmid:35097007:sec:abstract:sent:8,med:pmid:35097007,abstract,8,"Compared with placebo, these three drug combinations were associated with significant reductions in the risk of all-cause death, cardiovascular mortality and hospitalization for HF.",1343,1524
med:pmid:35097007:sec:abstract:sent:9,med:pmid:35097007,abstract,9,"<b>Conclusions:</b> ARNI+BB+MRA, SGLT2i+ACEI+BB+MRA, and IVA+ACEI+BB+MRA were the top three therapies for patients with HFrEF.",1525,1651
med:pmid:35097007:sec:abstract:sent:10,med:pmid:35097007,abstract,10,The increasing use of combinations of conventional and novel drugs contributed to progressive reductions in hospitalization and mortality in patients with HFrEF.,1652,1813
med:pmid:41284794:sec:title:sent:0,med:pmid:41284794,title,0,Evidence review for medicines for heart failure with reduced ejection fraction: Chronic heart failure in adults: diagnosis and management: Evidence review A,0,156
med:pmid:41284794:sec:abstract:sent:1,med:pmid:41284794,abstract,1,"Overarching principles: In all types of heart failure, the specialist trained in heart failure and cardiac imaging should ascertains the phenotype of heart failure, looks for all potential causes of the patient’s syndrome beyond heart failure, and addresses the co-morbidities associated with heart failure.",0,307
med:pmid:41284794:sec:abstract:sent:2,med:pmid:41284794,abstract,2,It is important for the specialist in heart failure to look for the aetiology of heart failure and consider any required therapeutic interventions to treat the specific aetiology involved in the individual patient.,308,522
med:pmid:41284794:sec:abstract:sent:3,med:pmid:41284794,abstract,3,Chronic heart failure (CHF) with reduced ejection fraction (HFrEF) is defined by both the heart failure syndrome and a left ventricular ejection fraction <40%.,523,682
med:pmid:41284794:sec:abstract:sent:4,med:pmid:41284794,abstract,4,"The journey towards evidence-based pharmacological therapy for patients with HFrEF started in 1986, with the advent of combined hydralazine and nitrate therapy.",683,843
med:pmid:41284794:sec:abstract:sent:5,med:pmid:41284794,abstract,5,"Since then, evidence for treatment with angiotensin converting enzyme inhibitors (ACE inhibitor), beta-blockers (BB) and mineralocorticoid receptor antagonists (MRA) has emerged.",844,1022
med:pmid:41284794:sec:abstract:sent:6,med:pmid:41284794,abstract,6,"These last three comprised triple therapy for HFrEF, which was the first step of therapy in those with symptomatic HFrEF in the NICE guidelines of 2018.",1023,1175
med:pmid:41284794:sec:abstract:sent:7,med:pmid:41284794,abstract,7,"Traditionally, these patients are commenced on either an ACE inhibitor or a BB, which are up-titrated to the maximum tolerated doses, before they are commenced on an MRA if they remained symptomatic.",1176,1375
med:pmid:41284794:sec:abstract:sent:8,med:pmid:41284794,abstract,8,"The last NICE guidelines in 2018 proposed as a second stage one or more of the following interventions delivered by a specialist: angiotensin receptor/neprilysin antagonist (ARNI) instead of ACE inhibitor, ivabradine if in sinus rhythm with a heart rate >70 bpm, a combined hydralazine and nitrate if the patient is of Afro-Caribbean origin, and/or digoxin.",1376,1733
med:pmid:41284794:sec:abstract:sent:9,med:pmid:41284794,abstract,9,"Since these recommendations were implemented, sodium-glucose-co-transporter 2 inhibitors (SGLT2i) have become available.",1734,1854
med:pmid:41284794:sec:abstract:sent:10,med:pmid:41284794,abstract,10,NICE provided two health technology appraisals for this new intervention: TA679 and TA773.,1855,1945
med:pmid:41284794:sec:abstract:sent:11,med:pmid:41284794,abstract,11,"Beyond the need to integrate new evidence into the treatment pathway for patients with HFrEF, a new ethos in the treatment of patients with HFrEF has emerged.",1946,2104
med:pmid:41284794:sec:abstract:sent:12,med:pmid:41284794,abstract,12,"Many of the above-mentioned interventions reduce morbidity and mortality of patients with HFrEF by different pathways, and they tend to impact these outcomes at an early stage of commencing therapy.",2105,2303
med:pmid:41284794:sec:abstract:sent:13,med:pmid:41284794,abstract,13,"Thus, there is potential advantage of patients being commenced on no less than four agents.",2304,2395
med:pmid:41284794:sec:abstract:sent:14,med:pmid:41284794,abstract,14,"However, since these agents lower the patient’s blood pressure, a pragmatic approach into the plan of therapy may need to be considered.",2396,2532
med:pmid:41284794:sec:abstract:sent:15,med:pmid:41284794,abstract,15,"The step-wise approach hitherto adopted not infrequently leads to patients being on maximal doses of two or may be three agents and unable to tolerate the third agent, and certainly not able to tolerate the fourth.",2533,2747
med:pmid:41284794:sec:abstract:sent:16,med:pmid:41284794,abstract,16,"Therefore, using this pathway may have resulted in suboptimal treatment.",2748,2820
med:pmid:41284794:sec:abstract:sent:17,med:pmid:41284794,abstract,17,"Thus, the new approach that needs to be considered is the early introduction of all four modalities of therapy (ACEI+BB+MRA+SGLT2i) before up-titrating individual agents.",2821,2991
med:pmid:41284794:sec:abstract:sent:18,med:pmid:41284794,abstract,18,"For all these reasons, it was essential to re-consider the pharmacological therapy of patients with HFrEF in this iteration of the NICE guidelines.",2992,3139
ppr:doi:10.20944/preprints202509.0619.v1:sec:title:sent:0,ppr:doi:10.20944/preprints202509.0619.v1,title,0,Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis,0,188
ppr:doi:10.20944/preprints202509.0619.v1:sec:introduction:sent:1,ppr:doi:10.20944/preprints202509.0619.v1,introduction,1,"/Objectives: Angiotensin receptor-neprilysin inhibitor (AR-NI) has a well-established advantage over angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction the advantage of ARNI has not been clearly proven.",0,440
ppr:doi:10.20944/preprints202509.0619.v1:sec:introduction:sent:2,ppr:doi:10.20944/preprints202509.0619.v1,introduction,2,To com-pare of the efficacy of ARNI versus ACEI/ARB therapy in patients with the first AMI in terms of improvement of post-infarction LV systolic function.,441,596
ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:3,ppr:doi:10.20944/preprints202509.0619.v1,methods,3,"Overall 1473 pts (990M, median age 71 [64;77]) with AMI (the first AMI, complete coronary revascularization, no prior: coronary revas-cularization, history of HF) hospitalized in 2022-2024 were enrolled into retrospective cross-sectional analysis.",597,862
ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:4,ppr:doi:10.20944/preprints202509.0619.v1,methods,4,The study population was catego-rized into pts receiving ARNI and ACEI/ARB.,863,938
ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:5,ppr:doi:10.20944/preprints202509.0619.v1,methods,5,"Then based on ARNI subgroup included age, sex, and LV ejection fraction (LVEF) matching was performed by using the 1:1 nearest neighbour method without returning.",939,1101
ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:6,ppr:doi:10.20944/preprints202509.0619.v1,methods,6,Finally two groups (ARNI vs ACEI/ARB) of 30 pts were obtained and an-alysed at baseline and in 6-week follow-up.,1102,1214
ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:7,ppr:doi:10.20944/preprints202509.0619.v1,methods,7,"The improvement of post-infarction LV systolic function was obtained as LVEF value, ΔLVEF and relative ΔLVEF (ΔLVEF / baseline LVEF).",1215,1348
ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:8,ppr:doi:10.20944/preprints202509.0619.v1,results,8,"The comparison of baseline characteristics revealed borderline lower initial LVEF (30 vs 36%, p=0.076) and higher frequency of of SGLT-2 inhibitors use (70% vs 36.7%, p=0.01) in the ARNI subgroup.",1349,1563
ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:9,ppr:doi:10.20944/preprints202509.0619.v1,results,9,In 6-week follow-up in both subgroups a significant improvement in the median LVEF values was achieved: from median LVEF value 30% (27.3; 38) up to 37% (30; 43; p=0.0008) in ARNI and from median LVEF value 36% (33; 39) up to 45% (42; 52; p&amp;lt;0.0001) in ACEI/ARB subgroup.,1564,1840
ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:10,ppr:doi:10.20944/preprints202509.0619.v1,results,10,"Median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), p=0.018].",1841,1955
ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:11,ppr:doi:10.20944/preprints202509.0619.v1,results,11,"Similarly median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), p=0.047].",1956,2091
ppr:doi:10.20944/preprints202509.0619.v1:sec:conclusion:sent:12,ppr:doi:10.20944/preprints202509.0619.v1,conclusion,12,"Our current experience in ARNI therapy after AMI is promising, however, it is limited to a small group of patients with severe impairment of LV systolic function.",2092,2276
ppr:doi:10.20944/preprints202509.0619.v1:sec:conclusion:sent:13,ppr:doi:10.20944/preprints202509.0619.v1,conclusion,13,Regardless of significant improvement of baseline LVEF observed in patients receiving both ACEI/ARB and ARNI in 6 week follow-up the value of absolute and relative LVEF increase were higher in subjects treated with ACEI/ARB.,2277,2501
ppr:doi:10.20944/preprints202509.0619.v1:sec:conclusion:sent:14,ppr:doi:10.20944/preprints202509.0619.v1,conclusion,14,The clinical efficacy of early use of ARNI in the setting of AMI needs further evaluation.,2502,2592
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:title:sent:0,ppr:doi:10.21203/rs.3.rs-7118793/v1,title,0,Evaluation of Prescribing Adherence to Guideline-Directed Medical Therapy in Patients with Chronic Heart Failure.,0,113
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:title:sent:1,ppr:doi:10.21203/rs.3.rs-7118793/v1,title,1,A Retrospective Study at The National Heart Centre in Oman,114,172
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:title:sent:2,ppr:doi:10.21203/rs.3.rs-7118793/v1,title,2,<title>Abstract</title>  <p>Background  Guideline-directed medical therapy (GDMT) improves survival and quality of life in patients with heart failure with reduced ejection fraction (HFrEF).,0,190
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:title:sent:3,ppr:doi:10.21203/rs.3.rs-7118793/v1,title,3,"However, real-world adherence to these guidelines remains suboptimal.",191,260
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:title:sent:4,ppr:doi:10.21203/rs.3.rs-7118793/v1,title,4,This study aimed to evaluate prescribing adherence to GDMT in HFrEF patients using a global guideline adherence scoring tool.,261,386
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:methods:sent:5,ppr:doi:10.21203/rs.3.rs-7118793/v1,methods,5,This retrospective study included adult patients with HFrEF (left ventricular ejection fraction ≤ 40%) attending the Heart Failure Clinic at the National Heart Centre in Oman between January and June 2022.,387,600
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:methods:sent:6,ppr:doi:10.21203/rs.3.rs-7118793/v1,methods,6,GDMT adherence was assessed based on 2021 European Society of Cardiology guidelines.,601,685
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:methods:sent:7,ppr:doi:10.21203/rs.3.rs-7118793/v1,methods,7,"Adherence levels were categorized as good (all indicated GDMT at ≥ 50% of target dose), moderate (more than half at ≥ 50%), or poor (less than half or < 50%).",686,844
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:methods:sent:8,ppr:doi:10.21203/rs.3.rs-7118793/v1,methods,8,Descriptive statistics and chi-square tests were used to identify associations.,845,924
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:results:sent:9,ppr:doi:10.21203/rs.3.rs-7118793/v1,results,9,"Of the 259 patients included (mean age 57 ± 13.6 years, 70% male), 71% had good adherence, 22% moderate, and 7% poor.",925,1050
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:results:sent:10,ppr:doi:10.21203/rs.3.rs-7118793/v1,results,10,"Target dose attainment varied by drug class: 46% for beta-blockers, 41% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine.",1051,1180
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:results:sent:11,ppr:doi:10.21203/rs.3.rs-7118793/v1,results,11,"Suboptimal GDMT (< 50% target dose) was significantly associated with hypertension (P = 0.004), dilated cardiomyopathy (P = 0.015), chronic kidney disease (P = 0.001), and older age (P = 0.004).",1181,1375
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:conclusion:sent:12,ppr:doi:10.21203/rs.3.rs-7118793/v1,conclusion,12,Prescribing adherence to GDMT in Oman is consistent with international data.,1376,1463
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:conclusion:sent:13,ppr:doi:10.21203/rs.3.rs-7118793/v1,conclusion,13,"Suboptimal titration was significantly linked to older age and comorbidities, suggesting that perceived frailty and clinical complexity may influence physician prescribing patterns.",1464,1645
ppr:doi:10.21203/rs.3.rs-7118793/v1:sec:conclusion:sent:14,ppr:doi:10.21203/rs.3.rs-7118793/v1,conclusion,14,"Efforts to improve individualized, patient-centered GDMT titration are warranted.</p>",1646,1731
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:title:sent:0,ppr:doi:10.21203/rs.3.rs-6768681/v1,title,0,Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction – real world outcomes,0,125
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:title:sent:1,ppr:doi:10.21203/rs.3.rs-6768681/v1,title,1,"<title>Abstract</title>  <p><bold>Background</bold>: The evidence regarding the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with heart failure with reduced ejection fraction (HFrEF) is limited and conflicting, with some studies suggesting a favorable effect and some not.",0,302
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:title:sent:2,ppr:doi:10.21203/rs.3.rs-6768681/v1,title,2,The aim of the study was to examine the safety and efficacy of GLP-1 RA therapy in a large national database of patients with HFrEF.,303,435
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:title:sent:3,ppr:doi:10.21203/rs.3.rs-6768681/v1,title,3,"<bold>Methods</bold>: In this observational retrospective cohort, data was obtained from the electronic medical records of Clalit Health Services, the largest health care organization in Israel.",436,630
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:title:sent:4,ppr:doi:10.21203/rs.3.rs-6768681/v1,title,4,"Between the years 2014 -2024, using a 1:1 matching, patients with HFrEF who were treated with GLP-1 RA were compared with those who were not.",631,772
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:5,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,5,included heart failure (HF) hospitalization and death.,773,836
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:6,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,6,"A subgroup analysis by body mass index (BMI), age, sex, HbA1C level and concomitant medications was conducted as well.",837,955
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:7,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,7,"<bold>Results</bold>: Out of 22,411 patients with HFrEF, 3023 initiated GLP-1 RA therapy after the diagnosis of HF was made.",956,1080
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:8,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,8,"After a 1:1 nearest-neighbor matching, 3858 patients were matched and included in the study, with 1939 and 1919 patients in the GLP-1 RA group and the control group, respectively.",1081,1260
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:9,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,9,"Mean age of the cohort was 69, 33% female, and mean BMI was 29.9 kg/m<sup>2</sup>.",1261,1343
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:10,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,10,"While therapy with beta blockers and ACEI/ARB/ARNI was common within the cohort, only a third of the cohort was treated with SGLT2 inhibitors or mineralocorticoid receptor antagonists.",1344,1528
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:11,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,11,"Median follow-up time of the study was 30 months (17.06, 43.0).",1529,1592
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:12,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,12,"In a multivariable model which included multiple demographic and clinical variables, patients who were treated with GLP-1 RA were less likely to experience the primary outcome of death or HF hospitalization (HR 0.6, 0.53 – 0.68, p<0.001) compared with the control group.",1593,1863
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:13,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,13,The subgroup analysis revealed a robust favorable effect of GLP-1 RA across the entire spectrum of patients with HFrEF.,1864,1983
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:14,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,14,"<bold>Conclusion</bold>: In this large cohort study of patients with HFrEF, GLP-1 RA therapy in addition to standard guideline directed medical therapy was associated with a lower rate of death and HF hospitalization.",1984,2201
ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:15,ppr:doi:10.21203/rs.3.rs-6768681/v1,results,15,Future randomized trials are needed to confirm these results.</p>,2202,2267
ppr:doi:10.1101/2025.03.12.25323680:sec:title:sent:0,ppr:doi:10.1101/2025.03.12.25323680,title,0,A Network Meta-Analysis of Quality of Life in Heart Failure with Reduced Ejection Fraction,0,90
ppr:doi:10.1101/2025.03.12.25323680:sec:introduction:sent:1,ppr:doi:10.1101/2025.03.12.25323680,introduction,1,"While the effect of various combinations of treatments on mortality and morbidity outcomes in heart failure with reduced ejection fraction (HFrEF) have been evaluated, the impact on quality of life is unknown.",0,229
ppr:doi:10.1101/2025.03.12.25323680:sec:introduction:sent:2,ppr:doi:10.1101/2025.03.12.25323680,introduction,2,This study evaluated and compared the composite impact of pharmacological therapies on quality of life in HFrEF using a frequentist network meta analysis and systematic review methodology.,230,418
ppr:doi:10.1101/2025.03.12.25323680:sec:methods:sent:3,ppr:doi:10.1101/2025.03.12.25323680,methods,3,"We searched MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials for randomized controlled trials published between January 1987 - August 2024.",419,593
ppr:doi:10.1101/2025.03.12.25323680:sec:methods:sent:4,ppr:doi:10.1101/2025.03.12.25323680,methods,4,We included all contemporary and efficacious HFrEF therapies used in adults.,594,670
ppr:doi:10.1101/2025.03.12.25323680:sec:methods:sent:5,ppr:doi:10.1101/2025.03.12.25323680,methods,5,"The primary outcome was the mean change in QoL score measured through the Kansas City Cardiomyopathy Questionnaire and the Minnesota Living with Heart Failure Questionnaire, expressed as mean difference (MD).",671,879
ppr:doi:10.1101/2025.03.12.25323680:sec:results:sent:6,ppr:doi:10.1101/2025.03.12.25323680,results,6,"We identified 41 randomized controlled trials representing 41145 patients which had a median of 276 (IQR 105, 464) participants who were mostly male (76.5%) with a mean left ventricular ejection fraction of 28%, and a median follow up time of 5 months (IQR 3,8).",880,1159
ppr:doi:10.1101/2025.03.12.25323680:sec:results:sent:7,ppr:doi:10.1101/2025.03.12.25323680,results,7,"The combinations which resulted in the greatest improvement of quality of life were ARNi + BB + MRA + SGLT2i [MD 7.11 (95% CI -0.99-15.22)], which did not have a statistically significant effect, followed by ARNi + BB + SGLT2i [MD 5.33 (95% CI 0.40-10.25)], ACEi + BB + MRA+ SGLT2i [MD 5.32 (95% CI -2.63-13.26)], ACEi + BB + MRA + ivabradine [MD 5.24 (95% CI -3.07-13.55)].",1160,1534
ppr:doi:10.1101/2025.03.12.25323680:sec:results:sent:8,ppr:doi:10.1101/2025.03.12.25323680,results,8,"Individually, the treatments which led to the greatest improvement in quality of life were H-ISDN [MD 3.87 (95% CI, -0.73 to 8.47)], which did not have a statistically significant effect, followed by SGLT2i [MD 3.37 (95% CI 1.44-5.30)], ivabradine [MD 3.26 (95% CI 0.08-6.43)], ARNi [MD 2.62 (95% CI -3.24-8.47)] and vericiguat [MD 1.00 (95% CI -3.18-5.18)].",1535,1893
ppr:doi:10.1101/2025.03.12.25323680:sec:conclusion:sent:9,ppr:doi:10.1101/2025.03.12.25323680,conclusion,9,A composite of ARNi + BB + MRA + SGLT2i or ARNi + BB + SGLT2i was the most effective at improving quality of life in patients with HFrEF.,1894,2051
ppr:doi:10.1101/2025.01.10.25320367:sec:title:sent:0,ppr:doi:10.1101/2025.01.10.25320367,title,0,Ivabradine and Atrial Fibrillation Incidence: A Nested Matching Study,0,69
ppr:doi:10.1101/2025.01.10.25320367:sec:abstract:sent:1,ppr:doi:10.1101/2025.01.10.25320367,abstract,1,<h4>Objective</h4> The objective of this real-world study was to quantify and project the cumulative incidence of atrial fibrillation (AF) associated with exposure to ivabradine (IVB) in naïve-AF heart failure (HF) patients.,0,242
ppr:doi:10.1101/2025.01.10.25320367:sec:methods:sent:2,ppr:doi:10.1101/2025.01.10.25320367,methods,2,A retrospective observational comparative study was performed using a health plan claims database.,243,358
ppr:doi:10.1101/2025.01.10.25320367:sec:methods:sent:3,ppr:doi:10.1101/2025.01.10.25320367,methods,3,The new diagnosis of AF was compared between adult HF patients receiving IVB versus no IVB controls (CTRs) over 180-day follow-up period.,359,496
ppr:doi:10.1101/2025.01.10.25320367:sec:methods:sent:4,ppr:doi:10.1101/2025.01.10.25320367,methods,4,"Eligible IVB subjects were free from AF diagnosis before the IVB index date, which should be longer than 6 months.",497,611
ppr:doi:10.1101/2025.01.10.25320367:sec:methods:sent:5,ppr:doi:10.1101/2025.01.10.25320367,methods,5,"Incidence-density sampling was performed to select matched CTRs based on clinical characteristics, AF naïve status and time to be selected as a CTRs corresponding to the time to receive IVB from the initial HF diagnosis.",612,832
ppr:doi:10.1101/2025.01.10.25320367:sec:methods:sent:6,ppr:doi:10.1101/2025.01.10.25320367,methods,6,The measure of IVB-AF association was tested using Cox Proportional Hazards Regression model.,833,926
ppr:doi:10.1101/2025.01.10.25320367:sec:results:sent:7,ppr:doi:10.1101/2025.01.10.25320367,results,7,"Of the 153 IVB and 4,494,305 CTRs meeting the AF-naïve HF status, the analytic cohort of 107 IVB and 321 matched controls were created.",927,1079
ppr:doi:10.1101/2025.01.10.25320367:sec:results:sent:8,ppr:doi:10.1101/2025.01.10.25320367,results,8,"The groups were well matched for age: 52.9±11.3 (IVB) vs. 53.5±11.8, gender: 57% male, HFrEF diagnosis: 66.4%, co-morbidities: hypertension 81.3% and coronary artery disease event 38.3%, and goal-directed medical therapy: ß-adrenergic blockers 89.7%, ACEi/ARB/sacubitril/valsartan 79.4%, mineral corticoid antagonists 39.3%.",1080,1404
ppr:doi:10.1101/2025.01.10.25320367:sec:results:sent:9,ppr:doi:10.1101/2025.01.10.25320367,results,9,The adjusted HR [95% CI] estimates was 7.293 [4.985-10.668].,1405,1465
ppr:doi:10.1101/2025.01.10.25320367:sec:results:sent:10,ppr:doi:10.1101/2025.01.10.25320367,results,10,The only variable that predicted AF incidence was the IVB prescription.,1466,1537
ppr:doi:10.1101/2025.01.10.25320367:sec:conclusion:sent:11,ppr:doi:10.1101/2025.01.10.25320367,conclusion,11,"In HF AF-naive patients, analysis of healthcare claims point to a significant risk of AF receiving IVB.",1538,1662
ppr:doi:10.1101/2023.10.31.23297731:sec:title:sent:0,ppr:doi:10.1101/2023.10.31.23297731,title,0,PHYSICIANS’ ADHERENCE TO GUIDELINES ON MEDICAL THERAPY FOR HEART FAILURE AND PATIENTS’ OUTCOMES IN A KENYAN REFERRAL HOSPITAL,0,125
ppr:doi:10.1101/2023.10.31.23297731:sec:abstract:sent:1,ppr:doi:10.1101/2023.10.31.23297731,abstract,1,<h4>Background</h4> Adherence to guidelines on prescription and uptitration of GDMT for HFrEF is associated with reduced mortality and hospitalization.,0,169
ppr:doi:10.1101/2023.10.31.23297731:sec:abstract:sent:2,ppr:doi:10.1101/2023.10.31.23297731,abstract,2,Published data on physicians’ GDMT prescription in sub-Saharan Africa is scarce.,170,250
ppr:doi:10.1101/2023.10.31.23297731:sec:abstract:sent:3,ppr:doi:10.1101/2023.10.31.23297731,abstract,3,"In addition, there is a need for data on patients’ characteristics, treatment, and outcomes in this region.",251,358
ppr:doi:10.1101/2023.10.31.23297731:sec:introduction:sent:4,ppr:doi:10.1101/2023.10.31.23297731,introduction,4,"To determine physicians’ level of adherence to guidelines on prescription and uptitration of medical therapy for HFrEF at AKUHN, a referral hospital in Nairobi, Kenya.",359,545
ppr:doi:10.1101/2023.10.31.23297731:sec:methods:sent:5,ppr:doi:10.1101/2023.10.31.23297731,methods,5,We reviewed 280 files of all HFrEF patients admitted over a 3-year period.,546,637
ppr:doi:10.1101/2023.10.31.23297731:sec:methods:sent:6,ppr:doi:10.1101/2023.10.31.23297731,methods,6,Detailed patients’ characteristics and outcomes were analyzed.,638,700
ppr:doi:10.1101/2023.10.31.23297731:sec:methods:sent:7,ppr:doi:10.1101/2023.10.31.23297731,methods,7,We calculated the Guideline Adherence Index (GAI) and the QUality of Adherence to guideline recommendations for LIFe-saving treatment in heart failure (QUALIFY) scores.,701,869
ppr:doi:10.1101/2023.10.31.23297731:sec:methods:sent:8,ppr:doi:10.1101/2023.10.31.23297731,methods,8,"From worst to best, GAI ranges from 0 to 100%, while QUALIFY scores were categorized as poor, moderate, or good.",870,982
ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:9,ppr:doi:10.1101/2023.10.31.23297731,results,9,"The median age (IQR) was 63 years (53,74); 165(58.9%) were male; and 207(74.2%) were black; 98(35%) had ischemic heart disease; 153(54.6%) had hypertension, and 101(36.1%) had diabetes.",983,1185
ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:10,ppr:doi:10.1101/2023.10.31.23297731,results,10,"At six months follow-up, 43.8% of patients had been readmitted at least once and 8.8% had died.",1186,1281
ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:11,ppr:doi:10.1101/2023.10.31.23297731,results,11,"GAI at discharge were 66.2%, 71.7%, and 42.6% for ACEI/ARNI/ARBs, B-blockers, and MRAs, respectively.",1282,1383
ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:12,ppr:doi:10.1101/2023.10.31.23297731,results,12,"At 6 months, the scores were 86.3%, 84.4%, and 61.2%, respectively.",1384,1451
ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:13,ppr:doi:10.1101/2023.10.31.23297731,results,13,GAI for SGLT2is was 38.9% at 6 months.,1452,1490
ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:14,ppr:doi:10.1101/2023.10.31.23297731,results,14,"The proportions for good QUALIFY scores for ACEI/ARNI/ARBs, B- blockers, and MRAs were 35.8%, 38.5%, and 9.5%, respectively.",1491,1615
ppr:doi:10.1101/2023.10.31.23297731:sec:results:sent:15,ppr:doi:10.1101/2023.10.31.23297731,results,15,"Uptitration to ≥ 50% of target dose was done in 51.9%, 48.7%, and 7.9% of patients for ACEI/ARNI/ARBs, B- blockers, and MRAs, respectively.",1616,1755
ppr:doi:10.1101/2023.10.31.23297731:sec:conclusion:sent:16,ppr:doi:10.1101/2023.10.31.23297731,conclusion,16,"Physicians’ level of adherence to prescription and up-titration of GDMT was satisfactory for ACEI/ARNI/ARBs and B-blockers, however, it was poor for SGLT2is and MRAs.",1756,1942
ppr:doi:10.1101/2023.10.31.23297731:sec:conclusion:sent:17,ppr:doi:10.1101/2023.10.31.23297731,conclusion,17,There is a need for regular surveys on prescription and uptitration of GDMT with a special attention to MRAs and SGLT2is.,1943,2064
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:title:sent:0,ppr:doi:10.21203/rs.3.rs-2552934/v1,title,0,Comparative Efficacy of Angiotensin Converting Enzymes Inhibitors and Angiotensin Receptor Blockers in Patients with Heart Failure in Tanzania: A Prospective Cohort Study,0,170
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:introduction:sent:1,ppr:doi:10.21203/rs.3.rs-2552934/v1,introduction,1,Heart failure has been a rising concern in Tanzania.,0,74
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:introduction:sent:2,ppr:doi:10.21203/rs.3.rs-2552934/v1,introduction,2,"New drugs have been introduced, including the group of drugs called Angiotensin receptor Neprilysin inhibitors (ARNI), but due to their high cost, angiotensin-converting enzymes inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs) have been mostly used in Tanzania.",75,347
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:introduction:sent:3,ppr:doi:10.21203/rs.3.rs-2552934/v1,introduction,3,"However, according to our knowledge, the efficacy comparison of the two groups is yet to be studied in Tanzania.",348,460
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:introduction:sent:4,ppr:doi:10.21203/rs.3.rs-2552934/v1,introduction,4,The aim of this study was to compare the efficacy of ACEIs and ARBs among patients with heart failure.,461,563
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:methods:sent:5,ppr:doi:10.21203/rs.3.rs-2552934/v1,methods,5,"This was a hospital-based prospective cohort study done at Jakaya Kikwete Cardiac Institution (JKCI), Tanzania, from June to December 2020.",564,717
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:methods:sent:6,ppr:doi:10.21203/rs.3.rs-2552934/v1,methods,6,Consecutive enrollment was done until fulfilling the inclusion criteria.,718,790
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:methods:sent:7,ppr:doi:10.21203/rs.3.rs-2552934/v1,methods,7,Clinical details were measured at baseline.,791,834
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:methods:sent:8,ppr:doi:10.21203/rs.3.rs-2552934/v1,methods,8,We assessed the relationship between ARBs and ACEI users with N-terminal pro-Brain natriuretic peptide (NT pro-BNP) levels at admission and at 1-month follow-up using a chi-square test.,835,1020
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:methods:sent:9,ppr:doi:10.21203/rs.3.rs-2552934/v1,methods,9,A Kaplan-Meier curve was used to estimate the survival time of the two groups.,1021,1099
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:results:sent:10,ppr:doi:10.21203/rs.3.rs-2552934/v1,results,10,"155 HF patients were enrolled, with a mean age of 48 years, whereby 52.3% were male, and their mean left ventricular ejection fraction (LVEF) was 37.3%.",1100,1262
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:results:sent:11,ppr:doi:10.21203/rs.3.rs-2552934/v1,results,11,"52 (33.5%) heart failure patients were on ACEIs, 57 (36.8%) on ARBs, and 46 (29.7%) were neither using ACEIs nor ARBs.",1263,1381
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:results:sent:12,ppr:doi:10.21203/rs.3.rs-2552934/v1,results,12,"At least half of the patients did not receive a Guideline directed medical therapy (GDMT), with only 82 (52.9%) receiving a GDMT.",1382,1511
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:results:sent:13,ppr:doi:10.21203/rs.3.rs-2552934/v1,results,13,"A drop in NT pro-BNP levels was observed during admission and at 1-month follow-up on both groups, from 6389.2pg/ml to 4000.1pg/ml for ARB users and 5877.7pg/ml to 1328.2pg/ml for the ACEIs users.",1512,1708
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:results:sent:14,ppr:doi:10.21203/rs.3.rs-2552934/v1,results,14,"There was no statistical difference between the two groups when estimated by the Kaplan-Meier curve, though, more deaths were observed in those who were neither on ACEIs nor ARBs, with a calculated P value of 0.01.",1709,1923
ppr:doi:10.21203/rs.3.rs-2552934/v1:sec:conclusion:sent:15,ppr:doi:10.21203/rs.3.rs-2552934/v1,conclusion,15,"This study demonstrates that ACEIs have more efficacy and overall better clinical outcome than ARBs, but this should be taken under the patient-based case, considering the side effects of ACEIs and patients’ adherence.",1924,2155
ppr:doi:10.22541/au.166607824.44692296/v1:sec:title:sent:0,ppr:doi:10.22541/au.166607824.44692296/v1,title,0,Cancer treatment-related cardiotoxicity: A focus on sacubitril/valsartan,0,72
ppr:doi:10.22541/au.166607824.44692296/v1:sec:abstract:sent:1,ppr:doi:10.22541/au.166607824.44692296/v1,abstract,1,"Cardiotoxicity is the most dramatic complications of cancer therapies, leading to halt in potentially life-saving anti-tumor treatment regimens and a poor survival prognosis in a non-negligible percentage of patients.",0,217
ppr:doi:10.22541/au.166607824.44692296/v1:sec:abstract:sent:2,ppr:doi:10.22541/au.166607824.44692296/v1,abstract,2,"Angiotensin converting enzyme inhibitors (ACEIs) and β-blockers are effective in the treatment of the cancer therapy–related cardiac dysfunction (CTRCD), while their roles in the prevention of cardiotoxicity are unclear.",218,438
ppr:doi:10.22541/au.166607824.44692296/v1:sec:abstract:sent:3,ppr:doi:10.22541/au.166607824.44692296/v1,abstract,3,Sacubitril/valsartan was advantageous over ACEI in heart failure patients for further reduction of cardiovascular death or heart failure re-hospitalization.,439,595
ppr:doi:10.22541/au.166607824.44692296/v1:sec:abstract:sent:4,ppr:doi:10.22541/au.166607824.44692296/v1,abstract,4,"However, there is short of well-established testimony of its efficacy and safety in the prevention and treatment of CTRCD in the cardio-oncology setting.",596,749
ppr:doi:10.22541/au.166607824.44692296/v1:sec:abstract:sent:5,ppr:doi:10.22541/au.166607824.44692296/v1,abstract,5,"Although some small observational studies found a good performance of sacubitril/valsartan in patients with CTRCD, large-scale prospective clinical studies are required to confirm its excellent results.",750,952
ppr:doi:10.22541/au.166607824.44692296/v1:sec:abstract:sent:6,ppr:doi:10.22541/au.166607824.44692296/v1,abstract,6,"In this paper, we review the potential benefit of sacubitril/valsartan in human subjects with CTRCD.",953,1053
med:pmid:40954329:sec:title:sent:0,med:pmid:40954329,title,0,Membranous-like glomerulopathy with masked IgG-k deposits in a pediatric patient with juvenile idiopathic arthritis.,0,116
med:pmid:40954329:sec:abstract:sent:1,med:pmid:40954329,abstract,1,Membranous-like glomerulopathy with masked IgG-kappa deposits (MGMID) is a rare entity described primarily among young females with previously diagnosed autoimmune diseases.,0,173
med:pmid:40954329:sec:abstract:sent:2,med:pmid:40954329,abstract,2,We present a 12-year-old female with systemic juvenile idiopathic arthritis (sJIA) with persistent non-nephrotic range proteinuria despite normal kidney function.,174,336
med:pmid:40954329:sec:abstract:sent:3,med:pmid:40954329,abstract,3,She underwent two kidney biopsies with the second ultimately confirming her diagnosis.,337,423
med:pmid:40954329:sec:abstract:sent:4,med:pmid:40954329,abstract,4,The initial biopsy was suggestive of mild C3 glomerulonephritis (C3GN).,424,495
med:pmid:40954329:sec:abstract:sent:5,med:pmid:40954329,abstract,5,She was started on an angiotensin-converting enzyme inhibitor (ACE-I) without improvement.,496,586
med:pmid:40954329:sec:abstract:sent:6,med:pmid:40954329,abstract,6,"Proteinuria progressed to the nephrotic range, prompting initiation of high-dose steroids followed by a steroid taper.",587,705
med:pmid:40954329:sec:abstract:sent:7,med:pmid:40954329,abstract,7,Mycophenolate was added during steroid weaning due to ongoing proteinuria.,706,780
med:pmid:40954329:sec:abstract:sent:8,med:pmid:40954329,abstract,8,"Despite full-dose mycophenolate and ACE-I therapy, a repeat biopsy was performed due to lack of response and revealed MGMID.",781,905
med:pmid:40954329:sec:abstract:sent:9,med:pmid:40954329,abstract,9,She remains on full-dose mycophenolate and lisinopril with significant improvement in her proteinuria.,906,1008
med:pmid:41459384:sec:title:sent:0,med:pmid:41459384,title,0,"Assessment of prescriber adherence to guideline-directed medical therapy for heart failure at Jimma Medical Center, Ethiopia.",0,125
med:pmid:41459384:sec:introduction:sent:1,med:pmid:41459384,introduction,1,Heart failure with reduced ejection fraction (HFrEF) requires guideline-directed medical therapy (GDMT) to reduce morbidity and mortality.,0,158
med:pmid:41459384:sec:introduction:sent:2,med:pmid:41459384,introduction,2,"However, adherence to GDMT is often suboptimal in resource-limited settings, such as the Jimma Medical Center, Ethiopia.",159,279
med:pmid:41459384:sec:introduction:sent:3,med:pmid:41459384,introduction,3,"To assess prescriber adherence to guideline-based medical therapy in heart failure at Jimma Medical Center, Ethiopia.",280,417
med:pmid:41459384:sec:methods:sent:4,med:pmid:41459384,methods,4,"A convergent mixed-methods study was conducted from December 2023 to April 2024, enrolling 215 adult HFrEF patients.",418,551
med:pmid:41459384:sec:methods:sent:5,med:pmid:41459384,methods,5,Prescriber adherence was measured using the Guideline Adherence Index (GAI) and QUALIFY scores.,552,647
med:pmid:41459384:sec:methods:sent:6,med:pmid:41459384,methods,6,Semi-structured interviews with physicians explored the qualitative factors that affect adherence.,648,746
med:pmid:41459384:sec:methods:sent:7,med:pmid:41459384,methods,7,Multinomial logistic regression identified the factors associated with adherence.,747,828
med:pmid:41459384:sec:results:sent:8,med:pmid:41459384,results,8,"Only 13.5 % of patients were discharged on all four recommended GDMT classes (ACEI/ARB, beta-blockers, MRAs, and SGLT2 inhibitors).",829,977
med:pmid:41459384:sec:results:sent:9,med:pmid:41459384,results,9,"Moderate and poor prescriber adherence occurred in 70.1 % and 16.3 % of the cases, respectively.",978,1074
med:pmid:41459384:sec:results:sent:10,med:pmid:41459384,results,10,"Patient adherence was higher (74.9 % by MARS-5), yet 94 % were physically inactive, and 54.4 % regularly consumed salt.",1075,1194
med:pmid:41459384:sec:results:sent:11,med:pmid:41459384,results,11,"Insurance coverage (AOR: 4.81; p = 0.001), salt restriction (AOR: 6.62; p = 0.003), and shorter hospital stays (AOR: 0.90; p = 0.005) were linked to better adherence, whereas higher ejection fraction (AOR: 1.07; p = 0.005) and more comorbidities (AOR: 2.36; p = 0.037) predicted poorer adherence.",1195,1491
med:pmid:41459384:sec:results:sent:12,med:pmid:41459384,results,12,"The qualitative findings highlighted medication stock-outs, financial barriers, and clinical complexities as key challenges, with institutional support and multidisciplinary care as facilitators.",1492,1687
med:pmid:41459384:sec:conclusion:sent:13,med:pmid:41459384,conclusion,13,Prescriber and patient adherence to GDMT for HFrEF at Jimma Medical Center was suboptimal.,1688,1799
med:pmid:41459384:sec:methods:sent:14,med:pmid:41459384,methods,14,"targeting prescriber training, expansion of insurance coverage, patient education, and multidisciplinary care are needed to improve outcomes.",1800,1955
med:pmid:41425656:sec:title:sent:0,med:pmid:41425656,title,0,"Cardiorenal safety and efficacy of angiotensin receptor-neprilysin inhibitors in heart failure across the ejection fraction spectrum: A meta-analysis and meta-regression of RCTs with 28,001 patients.",0,199
med:pmid:41425656:sec:abstract:sent:1,med:pmid:41425656,abstract,1,"Angiotensin receptor-neprilysin inhibitors (ARNIs), including sacubitril/valsartan, exert blood pressure-lowering and organ-protective effects in patients with heart failure (HF).",0,179
med:pmid:41425656:sec:abstract:sent:2,med:pmid:41425656,abstract,2,"However, differences of these effects across HF phenotypes and their impact on renal outcomes remain unclear.",180,289
med:pmid:41425656:sec:abstract:sent:3,med:pmid:41425656,abstract,3,"The present systematic review aimed to evaluate the antihypertensive efficacy, safety and cardiorenal benefits of ARNIs vs. angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) in patients with HF with reduced, mildly reduced, and preserved ejection fractions.",290,587
med:pmid:41425656:sec:results:sent:4,med:pmid:41425656,results,4,"were extracted from PubMed, Scopus, Cochrane, ProQuest and Google Scholar up to July 2025.",588,683
med:pmid:41425656:sec:results:sent:5,med:pmid:41425656,results,5,Risk of bias was evaluated using the Cochrane Risk of Bias 2 tool.,684,750
med:pmid:41425656:sec:results:sent:6,med:pmid:41425656,results,6,Meta-analyses were performed using risk ratios (RRs) with 95% confidence intervals (CIs).,751,840
med:pmid:41425656:sec:results:sent:7,med:pmid:41425656,results,7,analyses were conducted using RevMan version 5.4 and STATA version 16.0.,841,918
med:pmid:41425656:sec:results:sent:8,med:pmid:41425656,results,8,"encompassed all-cause mortality, cardiovascular mortality, HF-related hospitalization, major adverse cardiovascular events (MACEs) and adverse events.",919,1078
med:pmid:41425656:sec:results:sent:9,med:pmid:41425656,results,9,"A total of 18 randomized control trials involving 28,001 patients were included.",1079,1159
med:pmid:41425656:sec:results:sent:10,med:pmid:41425656,results,10,"Compared with ACE-I/ARB, ARNI decreased all-cause (RR=0.67; 95% CI=0.83-0.97) and cardiovascular mortality (RR=0.84; 95% CI=0.77-0.92), HF hospitalization (RR=0.87; 95% CI=0.81-0.93) and MACE (RR=0.89; 95% CI=0.85-0.94), but increased symptomatic hypotension (RR=1.54; 95% CI=1.43-1.65).",1160,1447
med:pmid:41425656:sec:results:sent:11,med:pmid:41425656,results,11,Subgroup analysis by left ventricular ejection fraction category did not reveal any significant effect modification across outcomes.,1448,1580
med:pmid:41425656:sec:results:sent:12,med:pmid:41425656,results,12,Meta-regression identified N-terminal prohormone of brain natriuretic peptide (P=0.02) and body mass index (P<0.0001) as predictors of cardiovascular mortality.,1581,1741
med:pmid:41425656:sec:results:sent:13,med:pmid:41425656,results,13,"Estimated glomerular filtration rate was associated with all-cause mortality (P=0.001) and hypotension (P=0.03), while sex (P=0.001) predicted hospitalization.",1742,1901
med:pmid:41425656:sec:results:sent:14,med:pmid:41425656,results,14,Systolic blood pressure (P=0.001) was linked to renal outcomes.,1902,1965
med:pmid:41425656:sec:results:sent:15,med:pmid:41425656,results,15,"Overall, ARNIs confer consistent cardiorenal benefits across the HF spectrum, particularly in patients with elevated systolic blood pressure and decreased renal function, though hypotension requires careful monitoring.",1966,2184
med:pmid:41425656:sec:results:sent:16,med:pmid:41425656,results,16,The present study was registered in PROSPERO (registration no.,2185,2247
med:pmid:41425656:sec:results:sent:17,med:pmid:41425656,results,17,CRD42024569374).,2248,2264
med:pmid:41138763:sec:title:sent:0,med:pmid:41138763,title,0,The enhanced Wnt/β-catenin pathway upregulation by sacubitril/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model.,0,174
med:pmid:41138763:sec:abstract:sent:1,med:pmid:41138763,abstract,1,"Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by the progressive loss of dopaminergic neurons in the basal ganglia, particularly in the substantia nigra, and the accumulation of α-synuclein into Lewy bodies.",0,255
med:pmid:41138763:sec:abstract:sent:2,med:pmid:41138763,abstract,2,"Recently, the WNT/β-catenin signaling pathway has emerged as a potential neuroprotective mechanism in PD, activated by natriuretic peptides (NPs) such as ANP, BNP, and CNP.",256,428
med:pmid:41138763:sec:abstract:sent:3,med:pmid:41138763,abstract,3,Sacubitril/valsartan (SAC/VAL) is an FDA-approved medication for chronic heart failure.,429,516
med:pmid:41138763:sec:abstract:sent:4,med:pmid:41138763,abstract,4,"SAC contains neprilysin inhibition, while VAL is an angiotensin receptor blocker used to treat hypertension.",517,625
med:pmid:41138763:sec:abstract:sent:5,med:pmid:41138763,abstract,5,This study aimed to determine whether SAC/VAL could activate the WNT/β-catenin pathway by increasing NP levels.,626,737
med:pmid:41138763:sec:abstract:sent:6,med:pmid:41138763,abstract,6,"To isolate the effect of SAC, VAL was administered separately.",738,800
med:pmid:41138763:sec:abstract:sent:7,med:pmid:41138763,abstract,7,Male Wistar rats were injected with 2 mg/kg rotenone subcutaneously (S.C.) for 35 days to induce a PD-like model.,801,914
med:pmid:41138763:sec:abstract:sent:8,med:pmid:41138763,abstract,8,"VAL and SAC/VAL were administered orally at 20 mg/kg/day and 40 mg/kg/day, respectively, one week before rotenone treatment for six weeks.",915,1053
med:pmid:41138763:sec:abstract:sent:9,med:pmid:41138763,abstract,9,"SAC/VAL was more effective than VAL in reducing rotenone-induced behavioral deficits, mitigating dopaminergic injury, normalizing dopamine (DA), tyrosine hydroxylase (TH), and NP levels, and activating the WNT/β-catenin pathway.",1054,1282
med:pmid:41138763:sec:abstract:sent:10,med:pmid:41138763,abstract,10,SAC/VAL also suppressed oxidative stress and neuroinflammation.,1283,1346
med:pmid:41138763:sec:abstract:sent:11,med:pmid:41138763,abstract,11,"In conclusion, SAC/VAL exhibited greater neuroprotection against PD-induced neurodegeneration than VAL, likely due to neprilysin inhibition by the SAC component, which activates the WNT/β-catenin pathway.",1347,1551
med:pmid:40914997:sec:title:sent:0,med:pmid:40914997,title,0,Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights.,0,165
med:pmid:40914997:sec:abstract:sent:1,med:pmid:40914997,abstract,1,"This review meticulously examines the development, design, and pharmacological assessment of both well known antiviral and antihypertensive medications all time employing new chemical techniques and structure-based drug design to design and synthesize vital therapeutic entities such as aliskiren (renin inhibitor), captopril (a2-ACE-Inhibitor), dorzolamide (inhibitor of carbonic anhydrase) the review demonstrates initial steps regarding the significance of stereoselective synthesis, metal chelating pharmacophores, and rational molecular properties.",0,553
med:pmid:40914997:sec:abstract:sent:2,med:pmid:40914997,abstract,2,"More importantly, protease inhibitors (i.e., saquinavir, ritonavir, indinavir, amprenavir, etc.)",554,650
med:pmid:40914997:sec:abstract:sent:3,med:pmid:40914997,abstract,3,"and more contemporary agents (i.e., oseltamivir, nirmatrelvir/ritonavir (Paxlovid), etc.)",651,740
med:pmid:40914997:sec:abstract:sent:4,med:pmid:40914997,abstract,4,were identified in the review and form a basis of advancement in antiviral therapy.,741,824
med:pmid:40914997:sec:abstract:sent:5,med:pmid:40914997,abstract,5,"Using the above-mentioned computational applications (i.e., molecular dockings, structure-activity relationships (SAR)), quantitative structure-activity relationships (QSAR modeling), and ADMET profile information, selectivity, safety, and therapeutic reliability of compounds toward antiviral activity and antihypertensive activity have improved further as outcomes of drug discovery research.",825,1219
med:pmid:40914997:sec:abstract:sent:6,med:pmid:40914997,abstract,6,"Through the combinatorial application of computational drug design and experimental chemistry, researchers have significantly optimized the drug discovery process, minimized off-target effects, and expedited the pathway to develop therapeutically useful medications.",1220,1486
med:pmid:40914997:sec:abstract:sent:7,med:pmid:40914997,abstract,7,"In conclusion, this review highlights the transformative power of interdisciplinary approaches, including structure-based design, computational modeling, and the emerging approaches of drug repurposing and virtual screening.",1487,1711
med:pmid:40914997:sec:abstract:sent:8,med:pmid:40914997,abstract,8,"This hybrid approach provides a greater opportunity to improve drug therapy for cardiovascular disease and viral infections, and represents the rewards of collaboration.",1712,1881
med:pmid:40448468:sec:title:sent:0,med:pmid:40448468,title,0,Readmission Rates in Reduced Ejection Fraction Heart Failure Patients on Triple Guideline-Directed Medical Therapy at Hospital Discharge.,0,137
med:pmid:40448468:sec:introduction:sent:1,med:pmid:40448468,introduction,1,"Heart failure (HF) places a significant burden on the health care system, driven primarily by HF hospitalizations.",0,134
med:pmid:40448468:sec:introduction:sent:2,med:pmid:40448468,introduction,2,"While HF guidelines recommend initiation of quadruple guideline-directed medical therapy (GDMT) in patients with HF with reduced ejection fraction (HFrEF), in-hospital initiation of quadruple therapy remains a clinical challenge, particularly in patients with additional high-risk comorbidities.",135,430
med:pmid:40448468:sec:introduction:sent:3,med:pmid:40448468,introduction,3,The purpose of this study was to compare the efficacy and safety of triple GDMT with a sodium-glucose cotransporter inhibitor (SGLTi) vs mineralocorticoid receptor antagonist (MRA) added to beta blocker and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNi).,431,788
med:pmid:40448468:sec:methods:sent:4,med:pmid:40448468,methods,4,This retrospective cohort study was conducted in hospitalized patients with acute HFrEF.,789,894
med:pmid:40448468:sec:methods:sent:5,med:pmid:40448468,methods,5,Patients who received triple GDMT therapy with a SGLTi or MRA added to beta blocker and ACEi/ARB/ARNi therapy at discharge were compared.,895,1032
med:pmid:40448468:sec:methods:sent:6,med:pmid:40448468,methods,6,The primary outcome was 90-day readmission for HF with secondary outcomes of 30-day readmission for HF and 90-day readmission for GDMT-associated adverse events.,1033,1194
med:pmid:40448468:sec:results:sent:7,med:pmid:40448468,results,7,"A total of 210 patients were included (SGLTi group, n = 105; MRA group, n = 105).",1195,1293
med:pmid:40448468:sec:results:sent:8,med:pmid:40448468,results,8,Rates of 90-day readmission for HF between SGLTi and MRA groups were 23 (21.90%) vs 15 (14.29%); <i>P</i> = 0.1516.,1294,1409
med:pmid:40448468:sec:results:sent:9,med:pmid:40448468,results,9,"After adjusting for co-variables associated with 90-day readmission, 90-day readmission for HF was not significantly different in patients in the SGLTi vs MRA group (adjusted hazard ratio = 1.742, 95% confidence interval [CI] = 0.833 to 3.434; <i>P</i> = 0.1092).",1410,1673
med:pmid:40448468:sec:results:sent:10,med:pmid:40448468,results,10,Rates of 90-day readmission for GDMT-associated adverse events were similar between groups.,1674,1765
med:pmid:40448468:sec:conclusion:sent:11,med:pmid:40448468,conclusion,11,"In this cohort of patients receiving triple GDMT at discharge after hospitalization for acute HFrEF, triple therapy with an SGLTi vs MRA resulted in similar rates of 90-day HF hospitalization.",1766,1992
med:pmid:41501364:sec:title:sent:0,med:pmid:41501364,title,0,Early drop in blood pressure following angiotensin receptor-neprilysin inhibitor initiation in decompensated heart failure.,0,123
med:pmid:41501364:sec:abstract:sent:1,med:pmid:41501364,abstract,1,"In a large-scale randomized controlled study of heart failure (HF), angiotensin receptor-neprilysin inhibitors (ARNI) reduced cardiovascular events compared to enalapril, but resulted in more symptomatic hypotension.",0,216
med:pmid:41501364:sec:abstract:sent:2,med:pmid:41501364,abstract,2,"However, changes in blood pressure (BP) during hospitalization in patients with decompensated HF treated with ARNI remain unknown.",217,347
med:pmid:41501364:sec:abstract:sent:3,med:pmid:41501364,abstract,3,We retrospectively analyzed BP during hospitalization for decompensated HF in a multi-center registry.,348,450
med:pmid:41501364:sec:abstract:sent:4,med:pmid:41501364,abstract,4,"Among 166 patients treated with newly prescribed renin-angiotensin system inhibitor (75.7 ± 13.4 years, 57.2% men, and ejection fraction 39 ± 17%), 114 were treated with newly prescribed ARNI (ARNI group) and 52 were treated with newly prescribed angiotensin converting enzyme inhibitors or angiotensin receptor blockers but without ARNI (ACEi/ARB group).",451,806
med:pmid:41501364:sec:abstract:sent:5,med:pmid:41501364,abstract,5,The initial day of prescription was day 4 [2-6] for the ARNI group and day 3 [1-6] for the ACEi/ARB group.,807,913
med:pmid:41501364:sec:abstract:sent:6,med:pmid:41501364,abstract,6,"Three days after the initiation of each drug, systolic BP dropped from 132 ± 24 to 117 ± 19 mmHg (ARNI group, p < 0.001) and 131 ± 19 to 117 ± 21 mmHg (ACEi/ARB group, p < 0.001).",914,1093
med:pmid:41501364:sec:abstract:sent:7,med:pmid:41501364,abstract,7,A mixed-effects model showed similar BP reductions in both groups (p = 0.247).,1094,1172
med:pmid:41501364:sec:abstract:sent:8,med:pmid:41501364,abstract,8,Herein we showed a downward trend in BP following ARNI initiation in decompensated HF.,1173,1259
med:pmid:41501364:sec:abstract:sent:9,med:pmid:41501364,abstract,9,Early changes in BP after ARNI initiation were comparable with those in the ACEi/ARB group.,1260,1351
med:pmid:41499174:sec:title:sent:0,med:pmid:41499174,title,0,Angiotensin Receptor and Neprilysin Inhibitors in CKD: Opportunity or Concern?,0,78
med:pmid:41499174:sec:abstract:sent:1,med:pmid:41499174,abstract,1,Combined inhibition of neprilysin and the angiotensin II receptor through Angiotensin Receptor-Neprilysin inhibitors (ARNI) has transformed heart failure management and is garnering increasing attention in nephrology.,0,217
med:pmid:41499174:sec:abstract:sent:2,med:pmid:41499174,abstract,2,"This article explores the renal role of neprilysin and critically reviews preclinical and clinical evidence on the use of ARNIs in CKD, following a ""bench to bedside"" approach.",218,394
med:pmid:41499174:sec:abstract:sent:3,med:pmid:41499174,abstract,3,"Experimental data show that neprilysin inhibition improves proteinuria, fibrosis, and endothelial function, with enhanced benefits when combined with RAAS blockade.",395,559
med:pmid:41499174:sec:abstract:sent:4,med:pmid:41499174,abstract,4,"Randomized Clinical Trials (RCTs) in Heart Failure patients (PARADIGM-HF, PARAGON-HF, PARAGLIDE-HF) have demonstrated renal safety and potential benefit emerged in secondary endpoints and prespecified analysis.",560,770
med:pmid:41499174:sec:abstract:sent:5,med:pmid:41499174,abstract,5,"The only RCT performed with primary kidney outcome, the UK HARP-III trial, confirmed the tolerability of Sac/Val, and reported a significant reduction in proteinuria.",771,937
med:pmid:41499174:sec:abstract:sent:6,med:pmid:41499174,abstract,6,"No clear nephroprotective effect was observed; however, the trial design may not have been adequately structured to detect such an effect.",938,1076
med:pmid:41499174:sec:abstract:sent:7,med:pmid:41499174,abstract,7,"On the other hand, real-world data indicate that ARNIs have an acceptable risk profile when patients are appropriately monitored, as Renin-Angiotensin-Aldosterone System blockers.",1077,1256
med:pmid:41499174:sec:abstract:sent:8,med:pmid:41499174,abstract,8,"Moreover, the benefits of the treatment clearly outweigh the adverse effects.",1257,1334
med:pmid:41499174:sec:abstract:sent:9,med:pmid:41499174,abstract,9,"Therefore, Sac/Val may emerge as a promising therapeutic option in nephrology, especially in patients with cardiorenal disease, pending further trials to better define its role in CKD.",1335,1519
med:pmid:41498914:sec:title:sent:0,med:pmid:41498914,title,0,Triglyceride-glucose-based predictive model for in-hospital mortality in older acute myocardial infarction patients with multimorbidity.,0,136
med:pmid:41498914:sec:abstract:sent:1,med:pmid:41498914,abstract,1,This study aims to develop a predictive model based on the triglyceride-glucose (TyG) index to assess in-hospital mortality risk in older acute myocardial infarction (AMI) patients with multimorbidity.,0,201
med:pmid:41498914:sec:abstract:sent:2,med:pmid:41498914,abstract,2,"This retrospective study included 479 patients aged ≥ 65 years with AMI and multimorbidity, hospitalized at Qilu Hospital of Shandong University from September 2017 to March 2022.",202,381
med:pmid:41498914:sec:abstract:sent:3,med:pmid:41498914,abstract,3,Patients were randomly divided into a training set (n = 384) and an internal validation set (n = 95).,382,483
med:pmid:41498914:sec:abstract:sent:4,med:pmid:41498914,abstract,4,"In addition, 90 patients admitted after April 2022 were included as an external validation set.",484,579
med:pmid:41498914:sec:abstract:sent:5,med:pmid:41498914,abstract,5,"Univariate Cox regression and least absolute shrinkage and selection operator regression were employed to select potential predictive variables, and a predictive model was constructed using Cox regression.",580,785
med:pmid:41498914:sec:abstract:sent:6,med:pmid:41498914,abstract,6,"Model performance was assessed using receiver operating characteristic (ROC) curves, concordance (C)-index, time-dependent ROC curves, calibration plots, and decision curve analysis (DCA).",786,974
med:pmid:41498914:sec:abstract:sent:7,med:pmid:41498914,abstract,7,"The predictive performance of the TyG-incorporated model was compared with models excluding TyG, as well as the global registry of acute coronary events and thrombolysis in myocardial infarction risk scores.",975,1182
med:pmid:41498914:sec:abstract:sent:8,med:pmid:41498914,abstract,8,"During an average hospitalization of 9.8 days, 7.85% of patients experienced all-cause mortality.",1183,1280
med:pmid:41498914:sec:abstract:sent:9,med:pmid:41498914,abstract,9,"Key predictors included the TyG index, occupation, ≥ 2 Killip classification, hepatic insufficiency, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, Nicorandil and white blood cell.",1281,1487
med:pmid:41498914:sec:abstract:sent:10,med:pmid:41498914,abstract,10,"The TyG-incorporated model demonstrated superior predictive performance, with C-index values of 0.93 (95% CI 0.89, 0.97; P < 0.001) in the training set, 0.85 (95% CI 0.74, 0.96; P < 0.001) in the internal validation set, and 0.89 (95% CI 0.81, 0.97; P < 0.001) in the external validation set, indicating high predictive accuracy.",1488,1817
med:pmid:41498914:sec:abstract:sent:11,med:pmid:41498914,abstract,11,"Calibration plots demonstrated good model calibration, and DCA results indicated superior clinical applicability of the model.",1818,1944
med:pmid:41498914:sec:abstract:sent:12,med:pmid:41498914,abstract,12,"The predictive model based on the TyG index provides an effective tool for assessing in-hospital mortality risk in older AMI patients with multimorbidity, demonstrating strong predictive performance and significant clinical value.",1945,2175
med:pmid:41496625:sec:title:sent:0,med:pmid:41496625,title,0,"Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in heart failure with preserved ejection fraction patients with type 2 diabetes mellitus: A prospective and observational cohort study.",0,200
med:pmid:41496625:sec:introduction:sent:1,med:pmid:41496625,introduction,1,Treatments for heart failure with preserved ejection fraction (HFpEF) remain inconclusive.,0,110
med:pmid:41496625:sec:introduction:sent:2,med:pmid:41496625,introduction,2,"We aim to explore in this prospective and observational cohort study that how combined therapy with sodium-dependent glucose transporters 2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), angiotensin receptor-neprilysin inhibitor (ARNI) or mineralocorticoid receptor antagonists (MRA) impact clinical outcomes in HFpEF patients with type 2 diabetes mellitus (T2DM).",111,515
med:pmid:41496625:sec:introduction:sent:3,med:pmid:41496625,introduction,3,<h4>Material and methods</h4> We enrolled 1445 HFpEF patients with T2DM from a prospective cohort between October 2018 and October 2022.,516,652
med:pmid:41496625:sec:introduction:sent:4,med:pmid:41496625,introduction,4,"The patients were divided into five groups based on their medications at 3 months after discharge: defined as a combination of SGLT2i, GLP-1RA, ARNI and MRA.",653,810
med:pmid:41496625:sec:introduction:sent:5,med:pmid:41496625,introduction,5,"The primary outcome is the major adverse cardiovascular (CV) events (MACEs), corresponding to the CV mortality and/or HF rehospitalization.",811,950
med:pmid:41496625:sec:introduction:sent:6,med:pmid:41496625,introduction,6,The secondary outcome is the CV mortality as well as the left ventricular ejection fraction (LVEF) change or HF category transitions.,951,1084
med:pmid:41496625:sec:results:sent:7,med:pmid:41496625,results,7,"During a median follow-up period of 54 (27-75) months, participants with quadruple combination shows the most benefits, corresponding to MACEs (79/174; P <0.001), CV mortality (46/174; P = 0.03), LVEF change or HF transitions.",1085,1328
med:pmid:41496625:sec:results:sent:8,med:pmid:41496625,results,8,"Quadruple combination was a protective factor for MACEs, while higher N-terminal pro-B-type natriuretic peptide level was an independent risk factor.",1329,1478
med:pmid:41496625:sec:results:sent:9,med:pmid:41496625,results,9,"For participants with LVEF less than 60%, quadruple combination reduced incidence of composite endpoints events than those with LVEF over 60%.",1479,1621
med:pmid:41496625:sec:conclusion:sent:10,med:pmid:41496625,conclusion,10,"The quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in HFpEF patients with T2DM was associated with favorable clinical outcomes, especially in participants with LVEF less than 60%.",1622,1840
med:pmid:41487006:sec:title:sent:0,med:pmid:41487006,title,0,Severe Orolingual and Laryngeal Angioedema after Thrombolysis with Alteplase: Angiotensin II Receptor Blockers Should Not Be Underestimated.,0,140
med:pmid:41487006:sec:introduction:sent:1,med:pmid:41487006,introduction,1,"Alteplase is a recombinant tissue plasminogen activator (rt-PA), used for intravenous thrombolysis in ischaemic strokes.",0,142
med:pmid:41487006:sec:introduction:sent:2,med:pmid:41487006,introduction,2,Orolingual angioedema is a rare but potentially lifethreatening complication of alteplase.,143,233
med:pmid:41487006:sec:introduction:sent:3,med:pmid:41487006,introduction,3,Concomitant treatment with angiotensin-converting enzyme (ACE) inhibitors has been identified as a primary risk factor.,234,353
med:pmid:41487006:sec:introduction:sent:4,med:pmid:41487006,introduction,4,Angiotensin II receptor blockers (ARBs) have been rarely related to angioedema.,354,433
med:pmid:41487006:sec:introduction:sent:5,med:pmid:41487006,introduction,5,"<h4>Case presentation</h4> A 72-year-old woman with a personal history of type 1 diabetes mellitus, dyslipidemia, stage 3 CKD, and arterial hypertension, in treatment with valsartan/amlodipine, atorvastatin, acetylsalicylic acid, and metformin, visited the emergency room with a diagnosis of an ischemic stroke, affecting the right middle cerebral artery territory.",434,799
med:pmid:41487006:sec:introduction:sent:6,med:pmid:41487006,introduction,6,Intravenous alteplase (Actilyse™) was administered for thrombolysis.,800,868
med:pmid:41487006:sec:introduction:sent:7,med:pmid:41487006,introduction,7,"Twenty minutes later, the patient developed progressive lingual angioedema.",869,944
med:pmid:41487006:sec:introduction:sent:8,med:pmid:41487006,introduction,8,"She was initially treated with methylprednisolone, hydrocortisone, and intramuscular adrenaline.",945,1041
med:pmid:41487006:sec:introduction:sent:9,med:pmid:41487006,introduction,9,"Her angioedema worsened, leading to an acute hypoxemic respiratory failure.",1042,1117
med:pmid:41487006:sec:introduction:sent:10,med:pmid:41487006,introduction,10,A C1 esterase inhibitor (Berinert™) was administered with no improvement.,1118,1191
med:pmid:41487006:sec:introduction:sent:11,med:pmid:41487006,introduction,11,Sedation and orotracheal intubation were finally necessary.,1192,1251
med:pmid:41487006:sec:introduction:sent:12,med:pmid:41487006,introduction,12,No other symptoms were associated.,1252,1286
med:pmid:41487006:sec:introduction:sent:13,med:pmid:41487006,introduction,13,"Due to the suspicion of an interaction between alteplase and valsartan, the ARB was discontinued.",1287,1384
med:pmid:41487006:sec:introduction:sent:14,med:pmid:41487006,introduction,14,No history of previous episodes of angioedema was mentioned.,1385,1445
med:pmid:41487006:sec:introduction:sent:15,med:pmid:41487006,introduction,15,"After 3 days, extubation failed due to respiratory distress and severe stridor, probably secondary to laryngeal edema.",1446,1564
med:pmid:41487006:sec:introduction:sent:16,med:pmid:41487006,introduction,16,"Successful extubation was achieved 7 days later, and the patient was discharged from the ICU after 9 days of admission.",1565,1684
med:pmid:41487006:sec:introduction:sent:17,med:pmid:41487006,introduction,17,"She was later referred, and an allergy workup was carried out.",1685,1747
med:pmid:41487006:sec:introduction:sent:18,med:pmid:41487006,introduction,18,"A blood analysis with a basal tryptase, an ACE, a total immunoglobulin E (IgE) profile, and complement proteins (C3, C4, C1q, C1 inhibitor) showed normal serum levels.",1748,1915
med:pmid:41487006:sec:introduction:sent:19,med:pmid:41487006,introduction,19,"Skin prick and intradermal tests with alteplase were performed, which showed negative results.",1916,2010
med:pmid:41487006:sec:introduction:sent:20,med:pmid:41487006,introduction,20,The increased production of bradykinin due to alteplase and the decreased degradation of bradykinin due to ACE inhibition explained the development of angioedema.,2011,2173
med:pmid:41487006:sec:introduction:sent:21,med:pmid:41487006,introduction,21,"ARBs, such as valsartan, have a different pathway.",2174,2224
med:pmid:41487006:sec:introduction:sent:22,med:pmid:41487006,introduction,22,"They directly block the angiotensin II receptors (AT1 receptors), preventing angiotensin II (ATII) from exerting its vasoconstrictive effect.",2225,2366
med:pmid:41487006:sec:introduction:sent:23,med:pmid:41487006,introduction,23,"By blocking the effect of ATII, the negative feedback that normally regulates bradykinin is deactivated, potentially leading to higher concentrations of bradykinin.",2367,2531
med:pmid:41487006:sec:introduction:sent:24,med:pmid:41487006,introduction,24,"The main suspicion in our patient was a solitary rt-PA-induced bradykininmediated angioedema, secondary to an increase of bradykinin promoted by alteplase and likely amplified by valsartan.",2532,2721
med:pmid:41487006:sec:conclusion:sent:25,med:pmid:41487006,conclusion,25,We have presented the case of a patient with severe and life-threatening nonimmunologic angioedema secondary to a combination of IV alteplase and valsartan.,2722,2898
med:pmid:41487006:sec:conclusion:sent:26,med:pmid:41487006,conclusion,26,We emphasize the importance of being aware of this potentially severe complication in patients with ischaemic stroke treated with an rt-PA and in patients on treatment with ACEi and ARB.,2899,3085
med:pmid:41487006:sec:conclusion:sent:27,med:pmid:41487006,conclusion,27,"Alteplase and tenecteplase are recombinant tPA, with a potential risk of producing angioedema.",3086,3180
med:pmid:41487006:sec:conclusion:sent:28,med:pmid:41487006,conclusion,28,There are no solid treatment recommendations for angioedema caused by rt-PA.,3181,3257
med:pmid:41487006:sec:conclusion:sent:29,med:pmid:41487006,conclusion,29,"Still, an early treatment with icatibant seems to be a consistent option in a bradykinin-mediated angioedema independent of the pathway responsible for bradykinin formation.",3258,3431
med:pmid:41487006:sec:conclusion:sent:30,med:pmid:41487006,conclusion,30,Specific and revised protocols to manage this solitary angioedema based on severity are crucial and urgent.,3432,3539
med:pmid:41487006:sec:conclusion:sent:31,med:pmid:41487006,conclusion,31,Finding an alternative IV thrombolytic treatment to improve the patients' safety should become an objective of research.,3540,3660
med:pmid:41485680:sec:title:sent:0,med:pmid:41485680,title,0,Design and Rationale of the WARRIOR Ancillary Study for Coronary CT Angiographic Analysis.,0,90
med:pmid:41485680:sec:introduction:sent:1,med:pmid:41485680,introduction,1,Over 50% of women evaluated for suspected ischemia have no obstructive coronary artery disease (INOCA).,0,123
med:pmid:41485680:sec:introduction:sent:2,med:pmid:41485680,introduction,2,"Statins, angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are effective in intermediate outcome trials; however, impact on coronary plaque has not been well characterized.",124,333
med:pmid:41485680:sec:introduction:sent:3,med:pmid:41485680,introduction,3,"The Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR NCT03417388) trial testing intensive medical therapy (IMT)(high intensity statin, ACEI or ARB and low dose aspirin) vs usual care (UC) in women with suspected INOCA offers the opportunity to evaluate the impact of IMT vs UC on plaque composition, and chest pain symptoms by coronary CT angiography (CCTA).",334,735
med:pmid:41485680:sec:introduction:sent:4,med:pmid:41485680,introduction,4,We hypothesize that IMT provides beneficial data on plaque composition impacting flow reserve and trial outcomes.,736,849
med:pmid:41485680:sec:methods:sent:5,med:pmid:41485680,methods,5,This WARRIOR ancillary study will consecutively enroll 200 eligible participants randomized to IMT vs UC by baseline and exit CCTA.,850,998
med:pmid:41485680:sec:methods:sent:6,med:pmid:41485680,methods,6,Changes in plaque and peri-coronary artery adipose tissue attenuation (PCAT) characteristics will be quantified.,999,1111
med:pmid:41485680:sec:results:sent:7,med:pmid:41485680,results,7,"Results will address: (1) Changes in coronary plaque characteristics and their hemodynamic significance using AI-enabled quantification of CCTA; (2) Changes in plaque inflammatory characteristics through pericoronary adipose tissue (PCAT) density analysis; (3) Plaque burden, composition and PCAT density changes related to angina score (Seattle Angina Questionnaire [SAQ]), (4) Derive a quantitative machine learning risk score (MLRS) using CCTA-derived variables for prediction of change in angina.",1112,1629
med:pmid:41485680:sec:conclusion:sent:8,med:pmid:41485680,conclusion,8,"The ancillary study will be the first to quantify the impact of IMT vs UC on plaque composition, and outcomes in women with suspected INOCA.",1630,1791
med:pmid:41485680:sec:conclusion:sent:9,med:pmid:41485680,conclusion,9,"<h4>Trial registration</h4> WARRIOR Ancillary Study for CCTA Analysis, NCT05035056.",1792,1875
med:pmid:41485231:sec:title:sent:0,med:pmid:41485231,title,0,Effective Management of a Rare Case of Pediatric ANCA-Associated Vasculitis With Rituximab and Mycophenolate Mofetil.,0,117
med:pmid:41485231:sec:introduction:sent:1,med:pmid:41485231,introduction,1,Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare pediatric condition that can present with rapidly progressive glomerulonephritis and is characterized by necrotizing crescentic glomerulonephritis.,0,239
med:pmid:41485231:sec:introduction:sent:2,med:pmid:41485231,introduction,2,"While there are no specific pediatric treatment guidelines, rituximab has shown promising benefits in the management of pediatric AAV.",240,374
med:pmid:41485231:sec:introduction:sent:3,med:pmid:41485231,introduction,3,"This report presents a case of AAV in a 6-year-old girl treated with rituximab and mycophenolate mofetil, resulting in remission that was maintained at 5-year follow-up.",375,544
med:pmid:41485231:sec:introduction:sent:4,med:pmid:41485231,introduction,4,"CASE REPORT A 6-year-old girl with eczema herpeticum presented with progressive bilateral lower extremity pain, weakness, and intermittent fever and later developed microscopic hematuria.",545,732
med:pmid:41485231:sec:introduction:sent:5,med:pmid:41485231,introduction,5,"Initial workup revealed proteinuria, elevated inflammatory markers, and renal biopsy findings of pauci-immune crescentic glomerulonephritis, with positive perinuclear ANCA and myeloperoxidase antibodies, confirming AAV.",733,952
med:pmid:41485231:sec:introduction:sent:6,med:pmid:41485231,introduction,6,"She was initially treated with corticosteroids without improvement, but subsequent rituximab induction followed by mycophenolate mofetil maintenance resulted in clinical improvement.",953,1135
med:pmid:41485231:sec:introduction:sent:7,med:pmid:41485231,introduction,7,"At 5-year follow-up, she remained in remission while receiving enalapril and annual rituximab therapy.",1136,1238
med:pmid:41485231:sec:conclusion:sent:8,med:pmid:41485231,conclusion,8,S This report presents a rare occurrence of AAV in a pediatric patient and demonstrates the challenges in treating this condition given the lack of pediatric-specific treatment protocols.,1239,1436
med:pmid:41485231:sec:conclusion:sent:9,med:pmid:41485231,conclusion,9,Further research and case reports are essential in the development of standardized and evidence-based treatment strategies tailored to the pediatric population.,1437,1597
med:pmid:41485231:sec:conclusion:sent:10,med:pmid:41485231,conclusion,10,"This case highlights that AAV, while rare in children, can be effectively managed with rituximab and mycophenolate mofetil to achieve long-term remission.",1598,1752
med:pmid:41476813:sec:title:sent:0,med:pmid:41476813,title,0,Delayed Onset Unilateral Tongue Edema From ACE Inhibitor-Induced Angioedema.,0,76
med:pmid:41476813:sec:abstract:sent:1,med:pmid:41476813,abstract,1,Recognize that angioedema induced by ACE inhibitors can present in atypical forms and may occur years after initiating therapy.,0,127
med:pmid:41445545:sec:title:sent:0,med:pmid:41445545,title,0,Clinical profiling and prognosis of out-of-hospital cardiac arrest in ST-segment elevation myocardial infarction in an Asian population.,0,136
med:pmid:41445545:sec:introduction:sent:1,med:pmid:41445545,introduction,1,Out-of-hospital cardiac arrest (OHCA) is a major cause of mortality in patients with ST-segment elevation myocardial infarction (STEMI).,0,156
med:pmid:41445545:sec:introduction:sent:2,med:pmid:41445545,introduction,2,"However, the clinical characteristics and prognostic outcomes of STEMI patients who experience OHCA remain poorly understood.",157,282
med:pmid:41445545:sec:methods:sent:3,med:pmid:41445545,methods,3,"Using data from the CCC-ACS (Improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome) project, we analyzed data from 70,901 patients with STEMI.",283,465
med:pmid:41445545:sec:methods:sent:4,med:pmid:41445545,methods,4,Multivariable regression models were used to evaluate the associations between patient characteristics and the occurrence of OHCA as well as subsequent in-hospital cardiac arrest (IHCA).,466,652
med:pmid:41445545:sec:results:sent:5,med:pmid:41445545,results,5,"Among the 70,901 STEMI patients included in this national retrospective cohort study, 1.9 % experienced OHCA, of whom 35.1 % subsequently developed IHCA.",653,823
med:pmid:41445545:sec:results:sent:6,med:pmid:41445545,results,6,"Ten independent predictors of OHCA were identified, including a history of atrial fibrillation, chronic heart failure, chronic renal failure, diabetes mellitus, ischemic stroke, culprit lesions in the left main coronary artery (LMCA), left circumflex artery (LCX), or right coronary artery (RCA), and the use of antiplatelet agents or angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB).",824,1244
med:pmid:41445545:sec:results:sent:7,med:pmid:41445545,results,7,"IHCA was the strongest predictor of in-hospital mortality among OHCA patients, with four factors independently associated with IHCA: advanced age, female gender, Killip class IV, and absence of standard modifiable cardiovascular risk factors (SMuRF-less).",1245,1500
med:pmid:41445545:sec:results:sent:8,med:pmid:41445545,results,8,"Percutaneous coronary intervention (PCI) and timely medical treatment (statins, ACEI/ARB, and mineralocorticoid receptor antagonists [MRA]) are critical for preventing IHCA.",1501,1674
med:pmid:41445545:sec:conclusion:sent:9,med:pmid:41445545,conclusion,9,OHCA is a rare but highly fatal complication in STEMI patients.,1675,1759
med:pmid:41445545:sec:conclusion:sent:10,med:pmid:41445545,conclusion,10,"A multitude of factors are associated with OHCA and subsequent IHCA, laying the groundwork for early risk stratification and optimized treatment strategies to enhance patient outcomes.",1760,1944
med:pmid:41335448:sec:title:sent:0,med:pmid:41335448,title,0,"Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.",0,127
med:pmid:41335448:sec:abstract:sent:1,med:pmid:41335448,abstract,1,<h4>Importance</h4> The efficacy and safety of guideline-recommended treatments for heart failure (HF) are uncertain in patients with Chagas disease.,0,149
med:pmid:41335448:sec:introduction:sent:2,med:pmid:41335448,introduction,2,To evaluate the efficacy and safety of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan in patients with HF with reduced ejection fraction due to Chagas disease.,150,348
med:pmid:41335448:sec:introduction:sent:3,med:pmid:41335448,introduction,3,"<h4>Design, setting, and participants</h4> From December 10, 2019, through September 13, 2023, patients with HF, confirmed diagnosis of Chagas disease, left ventricular ejection fraction of 40% or less, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) of 600 pg/mL or greater (or B-type natriuretic peptide [BNP] ≥150 pg/mL) or 400 pg/mL or greater (or BNP ≥100 pg/mL) if hospitalized for HF within the previous 12 months were screened at 83 sites in Argentina, Brazil, Colombia, and Mexico.",349,849
med:pmid:41335448:sec:methods:sent:4,med:pmid:41335448,methods,4,was conducted between May and July 2025.,850,911
med:pmid:41335448:sec:methods:sent:5,med:pmid:41335448,methods,5,"Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or enalapril (target dose, 10 mg twice daily), in addition to standard therapy.",912,1105
med:pmid:41335448:sec:methods:sent:6,med:pmid:41335448,methods,6,"<h4>Main outcomes and measures</h4> The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks.",1106,1338
med:pmid:41335448:sec:methods:sent:7,med:pmid:41335448,methods,7,The primary analysis was done using a win ratio approach.,1339,1396
med:pmid:41335448:sec:results:sent:8,med:pmid:41335448,results,8,"Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).",1397,1577
med:pmid:41335448:sec:results:sent:9,med:pmid:41335448,results,9,"Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group.",1578,1829
med:pmid:41335448:sec:results:sent:10,med:pmid:41335448,results,10,A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF.,1830,2002
med:pmid:41335448:sec:results:sent:11,med:pmid:41335448,results,11,"Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (-54.3% to -0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (-31.9% to 37.5%) decrease (7.2% wins).",2003,2235
med:pmid:41335448:sec:results:sent:12,med:pmid:41335448,results,12,"The resulting stratified win ratio was 1.52 (95% CI, 1.28-1.82; P < .001) for sacubitril/valsartan compared with enalapril.",2236,2359
med:pmid:41335448:sec:conclusion:sent:13,med:pmid:41335448,conclusion,13,"In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group.",2360,2675
med:pmid:41335448:sec:conclusion:sent:14,med:pmid:41335448,conclusion,14,<h4>Trial registration</h4> ClinicalTrials.gov Identifier: NCT04023227.,2676,2747
med:pmid:41267358:sec:title:sent:0,med:pmid:41267358,title,0,"Incidence and risk factors for chronic kidney disease in individuals with type 1 diabetes: A population-based study in Salford, Manchester.",0,139
med:pmid:41267358:sec:introduction:sent:1,med:pmid:41267358,introduction,1,Chronic kidney disease (CKD) is a serious and common complication of type 1 diabetes (T1D).,0,105
med:pmid:41267358:sec:introduction:sent:2,med:pmid:41267358,introduction,2,"Despite improvements in diabetes management, the prevalence of CKD in people with T1D remains high.",106,205
med:pmid:41267358:sec:introduction:sent:3,med:pmid:41267358,introduction,3,"However, large-scale, real-world data from the UK are limited.",206,268
med:pmid:41267358:sec:introduction:sent:4,med:pmid:41267358,introduction,4,"This study aimed to provide contemporary estimates of CKD incidence and its associated risk factors in a population with T1D in Salford, Greater Manchester.",269,425
med:pmid:41267358:sec:methods:sent:5,med:pmid:41267358,methods,5,We conducted a retrospective cohort study using anonymised electronic health records from the Salford Integrated Record Research Database between 2010 and 2023.,426,603
med:pmid:41267358:sec:methods:sent:6,med:pmid:41267358,methods,6,"Adults with T1D were assessed for CKD, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m<sup>2</sup> and/or albuminuria (urine albumin-to-creatinine ratio ≥3 mg/mmol), confirmed by two readings at least 90 days apart.",604,847
med:pmid:41267358:sec:methods:sent:7,med:pmid:41267358,methods,7,"Competing risk regression models (accounting for death as a competing event) were used to identify associations with demographic and clinical risk factors, including age, sex, ethnicity, deprivation, smoking, body mass index (BMI), HbA1c and use of ACE inhibitors or ARBs.",848,1120
med:pmid:41267358:sec:results:sent:8,med:pmid:41267358,results,8,"Among 1106 adults with T1D, 38.5% developed reduced eGFR, 47.2% had albuminuria, and 23.8% met both criteria for CKD.",1121,1255
med:pmid:41267358:sec:results:sent:9,med:pmid:41267358,results,9,"Older age was strongly associated with reduced eGFR: compared to those aged 18-28 years, the sub-distribution hazard ratio (sHR) was 3.1 (95% CI: 2.0-5.0) for ages 42-54 and 8.6 (95% CI: 5.4-13.9) for ≥55 years.",1256,1467
med:pmid:41267358:sec:results:sent:10,med:pmid:41267358,results,10,"Other significant predictors included missing ethnicity data (sHR 1.5), higher BMI (sHR 1.1 per kg/m<sup>2</sup>), higher HbA1c (sHR 1.1 per mmol/mol) and not being prescribed an ACE inhibitor or ARB (sHR 1.4).",1468,1678
med:pmid:41267358:sec:results:sent:11,med:pmid:41267358,results,11,"For albuminuria, increased risk was associated with female sex (sHR 1.3), missing ethnicity (sHR 1.4), higher HbA1c (sHR 1.1), current smoking (sHR 1.5), living in the second most deprived quintile (sHR 1.9) and being prescribed ACE inhibitors or ARBs (sHR 2.1).",1679,1941
med:pmid:41267358:sec:conclusion:sent:12,med:pmid:41267358,conclusion,12,"This large UK cohort study highlights a high burden of CKD among adults with T1D. Key risk factors included older age, higher BMI, poor glycaemic control, smoking and deprivation.",1942,2141
med:pmid:41267358:sec:conclusion:sent:13,med:pmid:41267358,conclusion,13,"Although ACE inhibitors and ARBs were commonly prescribed, the uptake of newer reno-protective treatments was low.",2142,2256
med:pmid:41267358:sec:conclusion:sent:14,med:pmid:41267358,conclusion,14,"These findings point to a need for earlier detection, targeted interventions and broader implementation of effective therapies to reduce kidney disease burden in this population.",2257,2435
med:pmid:41216848:sec:title:sent:0,med:pmid:41216848,title,0,Optimizing blood pressure control in multimorbid hypertensive patients: insights from a real-world taiwanese cohort.,0,116
med:pmid:41216848:sec:introduction:sent:1,med:pmid:41216848,introduction,1,"Guidelines from ACC/AHA, ESC/ESH, and JNC 8 recommend ACE inhibitors (ACEi), ARBs, calcium channel blockers (CCBs), and diuretics for hypertension in patients with cardiometabolic multimorbidity (CMM).",0,220
med:pmid:41216848:sec:introduction:sent:2,med:pmid:41216848,introduction,2,Their effectiveness in Asians is underexplored.,221,268
med:pmid:41216848:sec:introduction:sent:3,med:pmid:41216848,introduction,3,This study evaluates their association with mortality in Taiwanese patients with hypertension and CMM.,269,371
med:pmid:41216848:sec:methods:sent:4,med:pmid:41216848,methods,4,A population-based cohort study was conducted using Taiwan's administrative health databases (2004-2014).,372,494
med:pmid:41216848:sec:methods:sent:5,med:pmid:41216848,methods,5,Patients aged ≥20 years with hypertension and ≥8 outpatient blood pressure measurements were included.,495,597
med:pmid:41216848:sec:methods:sent:6,med:pmid:41216848,methods,6,"All-cause mortality was assessed using inverse probability weighted Cox models, evaluating medication classes, adherence, and systolic blood pressure (SBP) control.",598,762
med:pmid:41216848:sec:results:sent:7,med:pmid:41216848,results,7,"Of 80 748 patients (mean age 60 years, 56.3% male), 41.7% had one CMM, and 9.4% had multiple CMMs.",763,878
med:pmid:41216848:sec:results:sent:8,med:pmid:41216848,results,8,"ARBs reduced mortality in multimorbid patients [hazard ratio (HR) = 0.80, 95% confidence interval (CI) 0.67-0.95], while diuretics (HR = 1.63, 95% CI 1.33-1.99) and vasodilators (HR = 1.22, 95% CI 1.03-1.45) increased risk.",879,1102
med:pmid:41216848:sec:results:sent:9,med:pmid:41216848,results,9,ACEi and CCBs were neutral.,1103,1130
med:pmid:41216848:sec:results:sent:10,med:pmid:41216848,results,10,"Optimal SBP control (120-139 mmHg) benefited multimorbid patients, but intensive control (<120 mmHg) increased risk in those with ≤1 CMM (HR = 1.37, 95% CI 1.20-1.55).",1131,1298
med:pmid:41216848:sec:results:sent:11,med:pmid:41216848,results,11,"High SBP variability (SD >18 mmHg) raised mortality risk (HR = 1.62, 95% CI 1.07-2.44).",1299,1386
med:pmid:41216848:sec:conclusion:sent:12,med:pmid:41216848,conclusion,12,Antihypertensive effectiveness varies by CMM burden.,1387,1460
med:pmid:41216848:sec:conclusion:sent:13,med:pmid:41216848,conclusion,13,"ARBs reduce mortality in multimorbid patients, while diuretics and vasodilators may increase risk.",1461,1559
med:pmid:41216848:sec:conclusion:sent:14,med:pmid:41216848,conclusion,14,"Optimal SBP control (120-139 mmHg) benefits multimorbid patients, but intensive control may harm less complex cases.",1560,1676
med:pmid:41216848:sec:conclusion:sent:15,med:pmid:41216848,conclusion,15,Further research is needed.,1677,1704
med:pmid:41161546:sec:title:sent:0,med:pmid:41161546,title,0,Stimulator of interferon genes: A potential target for treating type 2 diabetes mellitus.,0,89
med:pmid:41161546:sec:abstract:sent:1,med:pmid:41161546,abstract,1,Type 2 diabetes mellitus (T2DM) has emerged as a major global public health challenge.,0,86
med:pmid:41161546:sec:abstract:sent:2,med:pmid:41161546,abstract,2,"Its core pathological features, including insulin resistance and disorders of glucose and lipid metabolism, can induce multi-organ damage and substantiall reduce the quality of life of patients.",87,281
med:pmid:41161546:sec:abstract:sent:3,med:pmid:41161546,abstract,3,"The stimulator of interferon genes (STING), which is a critical signaling hub of innate immunity, plays a crucial role in the pathogenesis of T2DM.",282,429
med:pmid:41161546:sec:abstract:sent:4,med:pmid:41161546,abstract,4,"The structure and function of STING, its signal transduction, and the research progress in T2DM are summarized in this review.",430,556
med:pmid:41161546:sec:abstract:sent:5,med:pmid:41161546,abstract,5,The findings indicate that STING is highly expressed in patients with T2DM.,557,632
med:pmid:41161546:sec:abstract:sent:6,med:pmid:41161546,abstract,6,"The activation of STING promotes the progression of T2DM by inducing mitochondrial damage, oxidative stress, autophagy disorders, inflammatory responses, macrophage polarization, imbalance of synaptic plasticity, apoptosis, and pyroptosis.",633,872
med:pmid:41161546:sec:abstract:sent:7,med:pmid:41161546,abstract,7,"A variety of inhibitors, including small-molecule compounds (fenofibrate and nicotinamide riboside), proteins (proprotein convertase subtilisin/kexin type 9 monoclonal antibody, Metrnl, Brahma-related gene 1, and irsin, interferon-stimulated gene 15), natural products (rosavin and spermidine), probiotics (ZBiotics and garlic-derived exosomes-like nanoparticles), compound drugs (sacubitril/valsartan), and nanoparticles (Mito-G and Jumonji domain-containing protein 3 inhibitory nanoparticles), can inhibit STING signal transduction, alleviate glucose dysregulation, improve lipid metabolism in T2DM, and reduce organ damage.",873,1500
med:pmid:41161546:sec:abstract:sent:8,med:pmid:41161546,abstract,8,"This review provides a theoretical foundation for the development of targeted drugs, clarifies the molecular basis of STING as a novel therapeutic target for T2DM, and has important translational value for the prevention and treatment of diabetes and its complications.",1501,1770
med:pmid:41067687:sec:title:sent:0,med:pmid:41067687,title,0,Antiobesogenic effect of hydrolysates and peptide fractions of porcine collagen after in vitro gastrointestinal digestion.,0,122
med:pmid:41067687:sec:abstract:sent:1,med:pmid:41067687,abstract,1,The present study evaluated the angiotensin-converting enzyme inhibitory activity (ACEi) of a porcine skin collagen hydrolysate (PSCH) and its peptide fractions before and after a simulation of gastrointestinal digestion and their ability to reduce lipid accumulation in adipocytes (LAA).,0,288
med:pmid:41067687:sec:abstract:sent:2,med:pmid:41067687,abstract,2,"Before digestion, peptide fractions <1 kDa (PF4) had the highest (p < 0.05) ACEia (85.45 %), followed by PSCH (53.54 %).",289,409
med:pmid:41067687:sec:abstract:sent:3,med:pmid:41067687,abstract,3,"Post-digestion, PF4 (IC<sub>50</sub>: 124.49 μg/mL) decreased its activity; thus, DPF4 (digested PF4) had an ACE IC<sub>50</sub> of 204.56 μg/mL, while fraction <1 kDa from digested hydrolysate (FDH) showed the lowest activity (IC<sub>50</sub>: 313.81 μg/mL).",410,669
med:pmid:41067687:sec:abstract:sent:4,med:pmid:41067687,abstract,4,Peptides were identified by LC-MS/MS and homology database search and aligned to peptides widely recognized as ACE inhibitors.,670,796
med:pmid:41067687:sec:abstract:sent:5,med:pmid:41067687,abstract,5,"Nine peptides were identified as potential ACE inhibitors through docking with the active site cavity of this enzyme (mainly GAXGPXGPQ and GPPGPA), and interaction with Zn (II).",797,974
med:pmid:41067687:sec:abstract:sent:6,med:pmid:41067687,abstract,6,"Subsequently, adding 600 μg/mL of FDH in preadipocytes reduced 71 % LAA, while DPF4 was less effective (45.5 % reduction).",975,1097
med:pmid:41067687:sec:abstract:sent:7,med:pmid:41067687,abstract,7,The addition of digested peptide fractions into differentiated adipocytes had a similar (p > 0.05) reduction of LAA of 22-39 %.,1098,1225
med:pmid:41067687:sec:abstract:sent:8,med:pmid:41067687,abstract,8,"Therefore, regardless of their differences as ACE inhibitors, digested FDH and DPF4 have a similar potential as anti-obesogenic adjuvants.",1226,1364
med:pmid:41067687:sec:abstract:sent:9,med:pmid:41067687,abstract,9,"SIGNIFICANCE: In this study, we evaluated the angiotensin-converting enzyme inhibitory activity of a porcine skin collagen hydrolysate and its peptide fractions before and after a simulation of gastrointestinal digestion and their ability to reduce lipid accumulation in adipocytes.",1365,1647
med:pmid:41067687:sec:abstract:sent:10,med:pmid:41067687,abstract,10,Peptides were identified by LC-MS/MS and homology database search and aligned to peptides widely recognized as ACE inhibitors.,1648,1774
med:pmid:41067687:sec:abstract:sent:11,med:pmid:41067687,abstract,11,"Nine peptides were identified as potential ACE inhibitors through docking with the active site cavity of this enzyme (mainly GAXGPXGPQ and GPPGPA), and interaction with Zn (II).",1775,1952
med:pmid:41067687:sec:abstract:sent:12,med:pmid:41067687,abstract,12,"Subsequently, adding digested peptide fractions into differentiated adipocytes resulted in a reduction of lipid accumulation in adipocytes.",1953,2092
med:pmid:40999916:sec:title:sent:0,med:pmid:40999916,title,0,"Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial.",0,151
med:pmid:40999916:sec:abstract:sent:1,med:pmid:40999916,abstract,1,"Antiangiogenic therapy with bevacizumab improves outcomes in ovarian cancer but induces hypertension, leading to major adverse cardiovascular events (MACE).",0,156
med:pmid:40999916:sec:abstract:sent:2,med:pmid:40999916,abstract,2,"While calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEi) are recommended for managing bevacizumab-associated hypertension, their impacts on cancer progression and cardiovascular outcomes are unclear.",157,389
med:pmid:40999916:sec:abstract:sent:3,med:pmid:40999916,abstract,3,This study compared the effects of CCBs and ACEi on progression-free survival (PFS) in ovarian cancer patients treated with adjuvant bevacizumab.,390,535
med:pmid:40999916:sec:abstract:sent:4,med:pmid:40999916,abstract,4,The incidence of MACE and overall survival (OS) were also evaluated.,536,604
med:pmid:40999916:sec:abstract:sent:5,med:pmid:40999916,abstract,5,"We conducted an emulated clinical trial using data from January 1, 2011, to January 1, 2021, from the French National Health Data System (SNDS), covering 98.8% of the French population.",605,790
med:pmid:40999916:sec:abstract:sent:6,med:pmid:40999916,abstract,6,"Patients with FIGO stage III to IV ovarian cancer who underwent cytoreductive surgery and adjuvant chemotherapy with bevacizumab, treated with CCBs or ACEi monotherapy within 6 months after surgery, were included.",791,1004
med:pmid:40999916:sec:abstract:sent:7,med:pmid:40999916,abstract,7,"Out of 4,165 patients treated with bevacizumab, 454 met inclusion criteria for the main analysis: 273 in the CCBs group and 181 in the ACEi group.",1005,1151
med:pmid:40999916:sec:abstract:sent:8,med:pmid:40999916,abstract,8,"CCBs use was associated with a longer median PFS compared to ACEi (21.8 vs. 18.2 months) and a higher 3-year PFS rate (difference of 8.2 percentage points, 95% CI: 2.0%; 14.8%).",1152,1329
med:pmid:40999916:sec:abstract:sent:9,med:pmid:40999916,abstract,9,No significant difference in OS was observed between groups.,1330,1390
med:pmid:40999916:sec:abstract:sent:10,med:pmid:40999916,abstract,10,"Cardiovascular complications were more frequent with CCBs compared to ACEi, particularly congestive heart failure (difference in 3-year incidence of MACE: -4.5 percentage points; 95% CI: -8.2%; -1.1%).",1391,1592
med:pmid:40999916:sec:abstract:sent:11,med:pmid:40999916,abstract,11,"These findings emphasize the need for a balanced approach to managing hypertension in cancer patients, considering both oncologic and cardiologic outcomes.",1593,1748
med:pmid:40986251:sec:title:sent:0,med:pmid:40986251,title,0,Prioritizing Antihypertensive Agents in Secondary Prevention of Ischemic Stroke: A Retrospective Population-Based Study.,0,120
med:pmid:40986251:sec:introduction:sent:1,med:pmid:40986251,introduction,1,"Although recurrent ischemic stroke (IS) is associated with higher rates of mortality and comorbidities as well as an increased economic burden than the first attack, the choice of first-line antihypertensive agent for secondary prevention remains controversial.",0,281
med:pmid:40986251:sec:introduction:sent:2,med:pmid:40986251,introduction,2,This study examined the efficacy of various antihypertensive agents for the secondary prevention of recurrent ischemic stroke in a real-world context.,281,432
med:pmid:40986251:sec:methods:sent:3,med:pmid:40986251,methods,3,"Using the National Health Insurance Research Database, patients with first acute IS from 1 January 2000 to 31 December 2020 were enrolled.",433,588
med:pmid:40986251:sec:methods:sent:4,med:pmid:40986251,methods,4,"Using propensity score-based probability of treatment weighting, all participants were divided into other antihypertensive drugs (OHTND), angiotensin-converting-enzyme-inhibitors/angiotensin II-receptor-blockers (ACEI/ARB), and calcium-channel-blockers (CCB) cohorts.",589,856
med:pmid:40986251:sec:methods:sent:5,med:pmid:40986251,methods,5,"Primary outcome was difference in risk of recurrent IS, and secondary outcomes were all-cause mortality, stroke-related death, and major adverse cardiac and cerebrovascular events (MACCEs).",857,1046
med:pmid:40986251:sec:methods:sent:6,med:pmid:40986251,methods,6,Cox proportional hazards models were used to estimate the adjusted hazard ratio and 95% confidence intervals.,1047,1156
med:pmid:40986251:sec:results:sent:7,med:pmid:40986251,results,7,"Compared with the OHTND cohort, individuals in the ACEI/ARB and CCB cohorts had a 14% (p < 0.001) and 15% (p < 0.001) lower risk of recurrent IS, respectively.",1157,1333
med:pmid:40986251:sec:results:sent:8,med:pmid:40986251,results,8,Individuals in the CCB cohort had a 37% (p = 0.006) higher risk of acute myocardial infarction compared with the OHTND cohort.,1334,1460
med:pmid:40986251:sec:results:sent:9,med:pmid:40986251,results,9,"Compared with ACEI users, ARB users experienced a 22% lower risk of recurrent IS, while ARB users had a 46% lower risk of stroke-related death.",1461,1604
med:pmid:40986251:sec:conclusion:sent:10,med:pmid:40986251,conclusion,10,The use of ACEI/ARB following acute IS was associated with a lower risk of recurrent IS.,1605,1714
med:pmid:40986251:sec:conclusion:sent:11,med:pmid:40986251,conclusion,11,Our results not only corresponded to pre-existing randomized controlled trials (RCTs) but also addressed the knowledge gap regarding the choice of first-line antihypertensive agents following acute IS.,1715,1916
med:pmid:40914445:sec:introduction:sent:0,med:pmid:40914445,introduction,0,and design of the comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMP-ICD) trial.,0,174
med:pmid:40914445:sec:introduction:sent:1,med:pmid:40914445,introduction,1,Current recommendations for a prophylactic (primary prevention) implantable cardioverter defibrillator (ICD) in patients with both ischemic and nonischemic heart failure with reduced ejection fraction (HFrEF) originate from clinical trials conducted in selected patients over 20 years ago that showed an overall statistically significant survival benefit associated with a primary prevention ICD in the range of 23%-34%.,0,440
med:pmid:40914445:sec:introduction:sent:2,med:pmid:40914445,introduction,2,The recent introduction of angiotensin receptor-neprilysin inhibitors [ARNI] and sodium glucose co-transporter 2 inhibitors [SGLT2i]) was shown to further reduce the risk of sudden cardiac death (SCD) in patients with HFrEF.,441,665
med:pmid:40914445:sec:introduction:sent:3,med:pmid:40914445,introduction,3,"Thus, there is an unmet need appropriately designed comparative effectiveness clinical trials aimed to reassess the survival benefit of a primary prevention ICD in contemporary patients with HFrEF.",666,863
med:pmid:40914445:sec:methods:sent:4,med:pmid:40914445,methods,4,"The comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMP-ICD) trial is a prospective, multicenter, open-label, randomized-controlled trial; enrolling 3,290 participants with HFrEF who are treated with optimal stable GDMT and are eligible for a primary prevention ICD, but have a lower predicted risk of life-threatening ventricular tachyarrhythmia (VTA) than nonarrhythmic mortality.",864,1346
med:pmid:40914445:sec:methods:sent:5,med:pmid:40914445,methods,5,Enrolled participants will be randomized to non-ICD vs ICD treatment arms and will be followed over an average period of 3.5 years.,1347,1478
med:pmid:40914445:sec:methods:sent:6,med:pmid:40914445,methods,6,The specific aims of the proposed clinical trial are to: (1) Compare the risk of all-cause mortality of non-ICD vs ICD in HFrEF patients who have a lower predicted risk of VTA than nonarrhythmic mortality per the MADIT-ICD Benefit Score; (2) Evaluate whether non-ICD vs ICD is associated with improved survival free of major CV events in patients with HFrEF who are at a lower predicted arrhythmic risk; (3) Assess healthcare utilization and quality of life implications of non-ICD vs ICD management approaches in HFrEF patients who are at a lower predicted arrhythmic risk; and (4) Determine the effect of non-ICD vs ICD management on all-cause mortality in prespecified subgroups.,1479,2161
med:pmid:40914445:sec:conclusion:sent:7,med:pmid:40914445,conclusion,7,"We hypothesize that, in patients with HFrEF who are at a lower predicted arrhythmic risk, non-ICD vs ICD is noninferior with respect to the primary endpoint of all-cause mortality and superior with respect to the secondary endpoint of survival free of major CV events.",2162,2451
med:pmid:40914445:sec:conclusion:sent:8,med:pmid:40914445,conclusion,8,NCT06543446; https://contemp-icd.org.,2452,2489
med:pmid:40907856:sec:title:sent:0,med:pmid:40907856,title,0,Angiotensin Receptor-Neprilysin Inhibitors and Mortality Among Patients With HFrEF.,0,83
med:pmid:40907856:sec:abstract:sent:1,med:pmid:40907856,abstract,1,"While trial evidence supports the benefit of angiotensin receptor-neprilysin inhibitor (ARNI) therapy in heart failure with reduced ejection fraction (HFrEF), its effectiveness in routine clinical practice is less explored.",0,223
med:pmid:40907856:sec:abstract:sent:2,med:pmid:40907856,abstract,2,This study investigated the relative and absolute effectiveness of ARNI in patients with HFrEF.,224,319
med:pmid:40907856:sec:abstract:sent:3,med:pmid:40907856,abstract,3,"This nationwide Danish database study included patients with left ventricular ejection fraction (LVEF) ≤40%, 2018 to 2023.",320,442
med:pmid:40907856:sec:abstract:sent:4,med:pmid:40907856,abstract,4,"Using a prevalent new user design, 2,446 ARNI initiators were matched 1:2 to 4,892 users of angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) based on propensity scores, age, LVEF, and NT-proBNP.",443,676
med:pmid:40907856:sec:abstract:sent:5,med:pmid:40907856,abstract,5,The primary outcome was all-cause mortality; secondary outcomes were cardiovascular mortality and hospitalization.,677,791
med:pmid:40907856:sec:abstract:sent:6,med:pmid:40907856,abstract,6,"There were 279 deaths among ARNI initiators (5.6/100 person-years) and 533 among ACE-I/ARB users (6.7/100 person-years), yielding a hazard ratio (HR) of 0.85 (95% CI, 0.74 to 0.98) for all-cause mortality.",792,997
med:pmid:40907856:sec:abstract:sent:7,med:pmid:40907856,abstract,7,"A significant interaction was observed for recent hospitalization (p = 0.04), with ARNI yielding a lower HR in this group.",998,1120
med:pmid:40907856:sec:abstract:sent:8,med:pmid:40907856,abstract,8,"HRs were otherwise consistent across age, sex, LVEF, NT-proBNP, NYHA class, ischemic heart disease, chronic kidney disease, and type 2 diabetes.",1121,1265
med:pmid:40907856:sec:abstract:sent:9,med:pmid:40907856,abstract,9,"The largest absolute mortality reductions were seen in subgroups with recent hospitalization, NYHA class III to IV, and severely elevated NT-proBNP.",1266,1414
med:pmid:40907856:sec:abstract:sent:10,med:pmid:40907856,abstract,10,"ARNI was also associated with a lower risk of cardiovascular death (HR, 0.81; 95% CI, 0.65 to 0.99), but not with other secondary outcomes.",1415,1554
med:pmid:40907856:sec:abstract:sent:11,med:pmid:40907856,abstract,11,"In this study, ARNI was associated with a 15% reduction in all-cause mortality vs ACE-I/ARB.",1555,1647
med:pmid:40907856:sec:abstract:sent:12,med:pmid:40907856,abstract,12,Patients with advanced or symptomatic heart failure appeared to experience the greatest absolute benefit.,1648,1753
med:pmid:40879458:sec:title:sent:0,med:pmid:40879458,title,0,Design and experimental verification of novel angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitory peptides from Ziziphus jujuba peptide KALVAP.,0,160
med:pmid:40879458:sec:introduction:sent:1,med:pmid:40879458,introduction,1,"KALVAP is an angiotensin-converting enzyme inhibitor derived from Ziziphus jujuba, but shows poor dipeptidyl peptidase (DPP)-IV inhibitory activity.",0,168
med:pmid:40879458:sec:introduction:sent:2,med:pmid:40879458,introduction,2,"To remedy this shortcoming, KALVAP was modified according to the distinctive features of DPP-IV inhibitory peptides, yielding nine novel peptides.",169,315
med:pmid:40879458:sec:introduction:sent:3,med:pmid:40879458,introduction,3,The DPP-IV inhibitory activity of the peptides was further verified in vitro and in vivo.,316,405
med:pmid:40879458:sec:results:sent:4,med:pmid:40879458,results,4,The in vitro DPP-IV inhibitory activities of WALVAP and WPLVAP were respectively 6.25- and 3.52-fold higher than that of KALVAP (360.39 ± 14.39 μmol L<sup>-1</sup>) after screening through molecular docking.,406,630
med:pmid:40879458:sec:results:sent:5,med:pmid:40879458,results,5,"Moreover, WALVAP (201.88 ± 8.27 μmol L<sup>-1</sup>) and WPLVAP (450.61 ± 16.83 μmol L<sup>-1</sup>) displayed superior DPP-IV inhibitory activity to KALVAP (1372.57 ± 49.52 μmol L<sup>-1</sup>) in Caco-2 cells.",631,842
med:pmid:40879458:sec:results:sent:6,med:pmid:40879458,results,6,"On the basis of in vitro and cellular experiments, oral glucose tolerance tests indicated that WALVAP and WPLVAP significantly improved glucose metabolism in C57BL/6 mice by promoting the secretion of insulin (11.13 ± 0.89% and 11.61 ± 0.44%), GLP-1 (11.12 ± 0.89% and 11.61 ± 0.44%) and GIP (7.58 ± 0.78% and 7.66 ± 0.11%).",843,1167
med:pmid:40879458:sec:results:sent:7,med:pmid:40879458,results,7,"Molecular dynamics simulations revealed that WALVAP and WPLVAP mainly inhibited DPP-IV through Glu205, Trp629, Glu206, Arg125 and Arg429.",1168,1305
med:pmid:40879458:sec:conclusion:sent:8,med:pmid:40879458,conclusion,8,"In summary, two new peptides, WALVAP and WPLVAP, were screened and exhibited excellent DPP-IV inhibitory activity.",1306,1440
med:pmid:40879458:sec:conclusion:sent:9,med:pmid:40879458,conclusion,9,The results implied that the optimization strategy is feasible and can provide a reference for drug design.,1441,1548
med:pmid:40879458:sec:conclusion:sent:10,med:pmid:40879458,conclusion,10,Thus WALVAP and WPLVAP could serve as potential drug candidates for patients with hypertension and diabetes mellitus.,1549,1666
med:pmid:40879458:sec:conclusion:sent:11,med:pmid:40879458,conclusion,11,© 2025 Society of Chemical Industry.,1667,1703
